<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40715595</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2731-4383</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>27</Day></PubDate></JournalIssue><Title>Discover mental health</Title><ISOAbbreviation>Discov Ment Health</ISOAbbreviation></Journal><ArticleTitle>From physical activity to sedentary behavior: the COVID-19 lockdown and mental health in high-performance athletes.</ArticleTitle><Pagination><StartPage>112</StartPage><MedlinePgn>112</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s44192-025-00251-0</ELocationID><Abstract><AbstractText Label="BACKGROUND AND AIMS" NlmCategory="OBJECTIVE">The COVID-19 pandemic significantly impacted high-performance athletes (HPAs) by affecting their training and participation in competitions due to cancellations. The aim of this study is to analyze HPAs' physical activity, sedentary behavior, and mental health during and after the COVID-19 lockdown while considering sex and type of sport.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">A repeated-measures observational study with a census sampling approach (N&#x2009;=&#x2009;556) HPAs from a public university in Mexico. Informed consent was obtained, and a survey was administered in person and online. Physical activity and sedentary behavior were measured using the International Physical Activity Questionnaire (IPAQ), and mental health was assessed using the Profile of Mood States (POMS). Percentages, means, standard deviations, Student's t-test, and Kruskal-Wallis tests were analyzed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Participants were an average age of 19.5&#xa0;years; 50.2% were male, 55.9% practiced ball sports, 28.5% engaged in athletic sports, and 15.6% participated in combat sports. During confinement, 63.1% reported a high level of physical activity, which increased to 89.4% after confinement (X<sup>2</sup>&#x2009;=&#x2009;20.37, p&#x2009;&lt;&#x2009;0.0001). Moreover, 86% exhibited sedentary behavior during confinement, which decreased to 57.9% afterward (p&#x2009;&lt;&#x2009;0.00001). No significant differences were found considering sex or type of sport. Regarding mental health, significant improvements were observed in all dimensions by sex and type of sport (p&#x2009;&lt;&#x2009;0.05), except for the vigor dimension.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The lockdown impacted HPAs' physical activity levels and mental health. After confinement, athletes increased their levels of vigorous physical activity and reduced sedentary behavior, reflecting adaptation to the new circumstances. Mental health indicators improved post-lockdown, although differences by sex and type of sport persisted in certain aspects.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>N&#xfa;&#xf1;ez-Rocha</LastName><ForeName>Georgina Mayela</ForeName><Initials>GM</Initials><Identifier Source="ORCID">0000-0002-5789-774X</Identifier><AffiliationInfo><Affiliation>Universidad Aut&#xf3;noma de Nuevo Le&#xf3;n, Facultad de Salud P&#xfa;blica y Nutrici&#xf3;n, Calle Dr. Eduardo Aguirre Peque&#xf1;o No. 905, Col. Mitras Centro, CP. 64460, Monterrey, Nuevo Le&#xf3;n, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Platas-Valadez</LastName><ForeName>Wendy Jakeline</ForeName><Initials>WJ</Initials><Identifier Source="ORCID">0000-0003-1762-8817</Identifier><AffiliationInfo><Affiliation>Universidad Aut&#xf3;noma de Nuevo Le&#xf3;n, Facultad de Enfermer&#xed;a, Av. Dr. Jos&#xe9; Eleuterio Gonz&#xe1;lez No. 1500, Col. Mitras Centro, CP. 64460, Monterrey, Nuevo Le&#xf3;n, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cano-Verdugo</LastName><ForeName>Guillermo</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-4905-1939</Identifier><AffiliationInfo><Affiliation>Universidad Aut&#xf3;noma de Nuevo Le&#xf3;n, Facultad de Salud P&#xfa;blica y Nutrici&#xf3;n, Calle Dr. Eduardo Aguirre Peque&#xf1;o No. 905, Col. Mitras Centro, CP. 64460, Monterrey, Nuevo Le&#xf3;n, Mexico. cavgod0002@uanl.edu.mx.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#xc1;vila-Ortiz</LastName><ForeName>Mar&#xed;a Natividad</ForeName><Initials>MN</Initials><Identifier Source="ORCID">0000-0001-6164-4000</Identifier><AffiliationInfo><Affiliation>Universidad Aut&#xf3;noma de Nuevo Le&#xf3;n, Facultad de Salud P&#xfa;blica y Nutrici&#xf3;n, Calle Dr. Eduardo Aguirre Peque&#xf1;o No. 905, Col. Mitras Centro, CP. 64460, Monterrey, Nuevo Le&#xf3;n, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paz-Morales</LastName><ForeName>Mar&#xed;a de Los &#xc1;ngeles</ForeName><Initials>ML&#xc1;</Initials><Identifier Source="ORCID">0000-0002-4111-8449</Identifier><AffiliationInfo><Affiliation>Universidad Aut&#xf3;noma de Nuevo Le&#xf3;n, Facultad de Enfermer&#xed;a, Av. Dr. Jos&#xe9; Eleuterio Gonz&#xe1;lez No. 1500, Col. Mitras Centro, CP. 64460, Monterrey, Nuevo Le&#xf3;n, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hern&#xe1;ndez-Ruiz</LastName><ForeName>Karina Janett</ForeName><Initials>KJ</Initials><AffiliationInfo><Affiliation>Universidad Aut&#xf3;noma de Nuevo Le&#xf3;n, Facultad de Salud P&#xfa;blica y Nutrici&#xf3;n, Calle Dr. Eduardo Aguirre Peque&#xf1;o No. 905, Col. Mitras Centro, CP. 64460, Monterrey, Nuevo Le&#xf3;n, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mart&#xed;nez-Hern&#xe1;ndez</LastName><ForeName>Roc&#xed;o</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-0288-6960</Identifier><AffiliationInfo><Affiliation>Universidad Aut&#xf3;noma de Nuevo Le&#xf3;n, Facultad de Organizaci&#xf3;n Deportiva, Monterrey, Mexico.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Discov Ment Health</MedlineTA><NlmUniqueID>9918350483906676</NlmUniqueID><ISSNLinking>2731-4383</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Athlete</Keyword><Keyword MajorTopicYN="N">High performance</Keyword><Keyword MajorTopicYN="N">Mental health</Keyword><Keyword MajorTopicYN="N">Physical activity</Keyword><Keyword MajorTopicYN="N">Sedentary behavior</Keyword></KeywordList><CoiStatement>Declarations. Ethics approval and consent to participate: This study was approved by the Research Ethics Committee of the Facultad de Salud P&#xfa;blica y Nutrici&#xf3;n of the Universidad Aut&#xf3;noma de Nuevo Le&#xf3;n with registry number FaSPyN-4-1292/2022 and was conducted following the 1964 Declaration of Helsinki. Written consent was obtained from all the participants prior to participation. Consent for publication: Not applicable. Competing interest: The authors declare they have no competing interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>27</Day><Hour>11</Hour><Minute>51</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40715595</ArticleId><ArticleId IdType="doi">10.1007/s44192-025-00251-0</ArticleId><ArticleId IdType="pii">10.1007/s44192-025-00251-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Comit&#xe9; Ol&#xed;mpico Internacional. Gu&#xed;a para el desarrollo del deportista de alto rendimiento [Internet]. 2015 [citado 2025 may 30]. Disponible en: https://www.olympic.org</Citation></Reference><Reference><Citation>Organizaci&#xf3;n Mundial de la Salud. Informaci&#xf3;n b&#xe1;sica sobre la COVID-19 [Internet]. 2020 [citado 2025 may 30]. Disponible en: https://www.who.int/es/emergencies/diseases/novel-coronavirus-2019/question-and-answers-hub/q-a-detail/coronavirus-disease-covid-19</Citation></Reference><Reference><Citation>Tsolakis C, Cherouveim ED, Viliotis A, Simeonidis T, Skouras A, Koulouvaris P. Effect of a home-based exercise training program on anthropometric characteristics and exercise performance during Covid-19 quarantine in young high-level kayak athletes. Sport Sci Health. 2023;19(1):339&#x2013;47. https://doi.org/10.1007/s11332-022-00979-0 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11332-022-00979-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Waddington GS. Covid-19, mental health and physical activity. J Sci Med Sport. 2021;24(4):319. https://doi.org/10.1016/j.jsams.2021.02.009 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsams.2021.02.009</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#xed;az-Castrill&#xf3;n FJ, Toro-Montoya AI. SARS-CoV-2/COVID-19: el virus, la enfermedad y la pandemia. Med Lab [Internet]. 2020;24(3):183&#x2013;205 [citado 2025 may 30]. Disponible en: https://medicinaylaboratorio.com/index.php/myl/article/view/268</Citation></Reference><Reference><Citation>Solano Mora A, Solano Castillo A, Gamboa Ellis C. SARS-CoV-2: la nueva pandemia. Rev M&#xe9;d Sinergia [Internet]. 2020;5(7):e538 [citado 2025 may 30]. Disponible en: https://revistamedicasinergia.com/index.php/rms/article/view/538</Citation></Reference><Reference><Citation>di Cagno A, Buonsenso A, Baralla F, Grazioli E, Di Martino G, Lecce E, et al. Psychological impact of the quarantine-induced stress during the Coronavirus (COVID-19) outbreak among Italian athletes. Int J Environ Res Public Health. 2020;17(23): 8867. https://doi.org/10.3390/ijerph17238867 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph17238867</ArticleId></ArticleIdList></Reference><Reference><Citation>Secretar&#xed;a de Salud. Consejo de Salubridad General declara emergencia sanitaria nacional a epidemia por coronavirus COVID-19 [Internet]. 2020 [citado 2025 may 30]. Disponible en: https://www.gob.mx/salud/prensa/consejo-de-salubridad-general-declara-emergencia-sanitaria-nacional-a-epidemia-por-coronavirus-covid-19-239301</Citation></Reference><Reference><Citation>W Radio. As&#xed; sufrieron los atletas mexicanos durante la pandemia [Internet]. 2021 [citado 2025 may 30]. Disponible en: https://wradio.com.mx/radio/2021/03/17/deportes/1616003335_213020.html</Citation></Reference><Reference><Citation>UNAM. Impacto de la pandemia de COVID-19 en la educaci&#xf3;n superior en M&#xe9;xico y el mundo [Internet]. 2020 [citado 2025 may 30]. Disponible en: http://www.dgei.unam.mx/hwp/impacto-de-la-pandemia-de-covid-19-en-la-educacion-superior-en-mexico-y-el-mundo/</Citation></Reference><Reference><Citation>Coronado N. Cancelan Universiada Nacional 2020 por rebrote de COVID-19 [Internet]. 2020 [citado 2025 may 30]. Disponible en: https://puntou.uanl.mx/noti-u/cancelan-universiada-nacional-2020-por-rebrote-de-covid-19/</Citation></Reference><Reference><Citation>Organizaci&#xf3;n Mundial de la Salud. Directrices de la OMS sobre actividad f&#xed;sica y h&#xe1;bitos sedentarios: de un vistazo [Internet]. Ginebra: OMS; 2020 [citado 2025 may 30]. Disponible en: https://apps.who.int/iris/bitstream/handle/10665/337004/9789240014817-spa.pdf</Citation></Reference><Reference><Citation>National Collegiate Athletic Association. Playing and Practice Seasons [Internet]. Divisi&#xf3;n I. 2000 [citado 2025 may 30]. Disponible en: https://web3.ncaa.org/lsdbi/search/bylawView?id=8823#result</Citation></Reference><Reference><Citation>Hermassi S, Bouhafs EG, Bragazzi NL, Ichimura S, Alsharji KE, Hayes LD, et al. Effects of home confinement on the intensity of physical activity during the COVID-19 outbreak in team handball according to country, gender, competition level, and playing position: a worldwide study. Int J Environ Res Public Health. 2021;18(8): 4050. https://doi.org/10.3390/ijerph18084050 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph18084050</ArticleId></ArticleIdList></Reference><Reference><Citation>McKay AK, Stellingwerff T, Smith ES, Martin DT, Mujika I, Goosey-Tolfrey VL, et al. Defining training and performance caliber: a participant classification framework. Int J Sports Physiol Perform. 2022;17(2):317&#x2013;31. https://doi.org/10.1123/ijspp.2021-0451 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1123/ijspp.2021-0451</ArticleId></ArticleIdList></Reference><Reference><Citation>Prabhu SS, Thakur AM. Reliability and validity of the Hindi version of international physical activity questionnaire-long-form (IPAQ-LF). Hong Kong Physiother J. 2023;43(1):33&#x2013;41. https://doi.org/10.1142/S1013702523500026 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1142/S1013702523500026</ArticleId></ArticleIdList></Reference><Reference><Citation>Shea C, Khawaja AR, Sofi K, Nabi G. Association of metabolic equivalent of task (MET) score in length of stay in hospital following radical cystectomy with urinary diversion: a multi-institutional study. Int Urol Nephrol. 2021;53(7):1305&#x2013;10. https://doi.org/10.1007/s11255-021-02813-x .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11255-021-02813-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrade E, Arce C, De Francisco C, Torrado J, Garrido J. Versi&#xf3;n breve en espa&#xf1;ol del cuestionario POMS para deportistas adultos y poblaci&#xf3;n general. Rev Psicol Deport. 2013;22(1):95&#x2013;102.</Citation></Reference><Reference><Citation>Alarc&#xf3;n Meza EI, Hall-L&#xf3;pez JA. Physical activity in university student athletes, prior and in confinement due to pandemic associated with COVID-19. Retos. 2020;39:572&#x2013;5.</Citation></Reference><Reference><Citation>Pillay L, Janse van Rensburg DCC, Jansen van Rensburg A, Ramagole DA, Holtzhausen L, Dijkstra HP, et al. Nowhere to hide: the significant impact of coronavirus disease 2019 (COVID-19) measures on elite and semi-elite South African athletes. J Sci Med Sport. 2020;23(7):670&#x2013;9. https://doi.org/10.1016/j.jsams.2020.05.016 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsams.2020.05.016</ArticleId></ArticleIdList></Reference><Reference><Citation>da Silva Santos AM, Rossi FE, dos Santos Nunes de Moura HP, de Sousa Junior AVM, Machado DCD, Neves LM, et al. COVID-19 pandemic impacts physical activity levels and sedentary time but not sleep quality in young badminton athletes. Sport Sci Health. 2021;17(4):969&#x2013;77. https://doi.org/10.1007/s11332-021-00799-0 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11332-021-00799-0</ArticleId></ArticleIdList></Reference><Reference><Citation>FIFPRO. Confinamiento por coronavirus: notable aumento de futbolistas con s&#xed;ntomas de depresi&#xf3;n [Internet]. 2020 [citado 2025 may 30]. Disponible en: https://www.fifpro.org/es/salud/coronavirus-covid-19/coronavirus-shutdown-sharp-rise-in-players-reporting-depression-symptoms</Citation></Reference><Reference><Citation>FIFPRO. Toda la informaci&#xf3;n que debe de saber sobre salud y bienestar mental [Internet]. 2021 [citado 2025 may 30]. Disponible en: https://www.fifpro.org/es/salud/salud-mental/toda-la-informacion-que-debe-saber-sobre-salud-y-bienestar-mental</Citation></Reference><Reference><Citation>Roberts RJ, Lane AM. Mood responses and regulation strategies used during COVID-19 among boxers and coaches. Front Psychol. 2021;12: 622710. https://doi.org/10.3389/fpsyg.2021.622710 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpsyg.2021.622710</ArticleId></ArticleIdList></Reference><Reference><Citation>Guszkowska M, W&#xf3;jcik K. Effect of mental toughness on sporting performance: review of studies. Balt J Health Phys Act. 2021;1(2):1&#x2013;12.</Citation></Reference><Reference><Citation>Vargas Olarte CE. Ciencias del Deporte: evoluci&#xf3;n de aspectos te&#xf3;rico-cient&#xed;ficos. Entramado. 2012;8(1):140&#x2013;65.</Citation></Reference><Reference><Citation>Robles J, Abad M, Gim&#xe9;nez F. Concepto, caracter&#xed;sticas, orientaciones y clasificaciones del deporte actual. EFDeportes [Internet]. 2009 nov [citado 2025 may 30];14(138). Disponible en: https://www.efdeportes.com/efd138/concepto-y-clasificaciones-del-deporte-actual.htm</Citation></Reference><Reference><Citation>Sperlich B, Becker M, Hotho A, Wallmann-Sperlich B, Sareban M, Winkert K, et al. Sedentary behavior among national elite rowers during off-training&#x2014;a pilot study. Front Physiol. 2017;8: 655. https://doi.org/10.3389/fphys.2017.00655 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphys.2017.00655</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehrsafar AH, Moghadam Zadeh A, Gazerani P, Jaenes Sanchez JC, Nejat M, Rajabian Tabesh M, Abolhasani M. Mental health status, life satisfaction, and mood state of elite athletes during the COVID-19 pandemic: a follow-up study in the phases of home confinement, reopening, and semi-lockdown condition. Front Psychol. 2021;12: 630414.</Citation></Reference><Reference><Citation>Carnevale Pellino V, Lovecchio N, Puci MV, Marin L, Gatti A, Pirazzi A, Negri F, Ferraro OE, Vandoni M. Effects of the lockdown period on the mental health of elite athletes during the COVID-19 pandemic: a narrative review. Sport Sci Health. 2022;18(4):1187&#x2013;99.</Citation></Reference><Reference><Citation>Shukla A, Dogra DK, Bhattacharya D, Gulia S, Sharma R. Impact of COVID-19 outbreak on the mental health in sports: a review. Sport Sci Health. 2023;19(4):1043&#x2013;57.</Citation></Reference><Reference><Citation>Taheri M, Saad HB, Washif JA, Reynoso-S&#xe1;nchez LF, Mirmoezzi M, Youzbashi L, Trabelsi K, Moshtagh M, Mu&#xf1;oz-Hel&#xfa; H, Mataruna-Dos-Santos LJ, Seghatoleslami A, Torabi F, Soylu Y, Kurt C, Vancini RL, Delkash S, Rezaei MS, Ashouri M, Tahira S, Sayyah M, Chtourou H, Dergaa I, Strahler J, Guimar&#xe3;es-Mataruna AF, Lebaron TW, Ezdini ES, Alizade A, Zouhal H, Tarnava AT, Clark C, Bigdeli N, Ammar A, Eken &#xd6;, Ayed KB, Bragazzi NL, Nobari H, Thuany M, Weiss K, Knechtle B, Irandoust K. Comparative study of the long-term impact of the COVID-19 pandemic on mental health and nutritional practices among international elite and sub-elite athletes: a sample of 1420 participants from 14 countries. Sports Med-Open. 2023;9(1): 104.</Citation></Reference><Reference><Citation>Le&#xf3;n-Zarce&#xf1;o E, Moreno-Tenas A, Boix Vilella S, Garc&#xed;a-Naveira A, Serrano-Rosa MA. Habits and psychological factors associated with changes in physical activity due to COVID-19 confinement. Front Psychol. 2021;12: 620745.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40715548</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>26</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Longitudinal dynamics of clinical and neurophysiological changes in parkinson's disease over four and a half years.</ArticleTitle><Pagination><StartPage>27284</StartPage><MedlinePgn>27284</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-025-13558-3</ELocationID><Abstract><AbstractText>Parkinson's disease (PD) is a clinically heterogeneous neurodegenerative disorder whose trajectory is shaped by progressive motor impairment and cortical dysfunction. However, longitudinal studies integrating clinical scales with direct neurophysiological assessments remain scarce. In this 4.5-year cohort study, we conducted one of the longest clinical-electrophysiological follow-ups in PD to date, evaluating 22 patients across early and advanced stages using both Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) scores and transcranial magnetic stimulation (TMS). We demonstrate that the cortical silent period (CSP), a marker of GABAergic inhibition, progressively lengthens over time and is associated with motor decline, suggesting its potential as a dynamic biomarker of disease progression. Resting motor threshold (rMT) and motor asymmetry also deteriorated longitudinally, with changes most pronounced following the COVID-19 pandemic-suggesting that environmental stressors may accelerate PD pathophysiology. Unlike prior short-term studies, our findings reveal persistent cortical reorganization over several years, independent of sex, and underscore the clinical relevance of TMS-derived metrics in tracking disease progression. These findings suggest that CSP may serve as a non-invasive and scalable biomarker for monitoring Parkinson's disease progression and informing neurophysiological endpoints in future therapeutic studies.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Santana-Rom&#xe1;n</LastName><ForeName>Estefan&#xed;a</ForeName><Initials>E</Initials><Identifier Source="ORCID">0009-0000-7901-0444</Identifier><AffiliationInfo><Affiliation>Unidad de Trastornos del Movimiento y Sue&#xf1;o (TMS), Hospital General Dr. Manuel Gea Gonz&#xe1;lez, Ciudad de M&#xe9;xico, 14080, M&#xe9;xico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Programa de Doctorado en Ciencias Biom&#xe9;dicas, Universidad Nacional Aut&#xf3;noma de M&#xe9;xico, Ciudad de M&#xe9;xico, 04510, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Ortega-Robles</LastName><ForeName>Emmanuel</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-1667-2253</Identifier><AffiliationInfo><Affiliation>Unidad de Trastornos del Movimiento y Sue&#xf1;o (TMS), Hospital General Dr. Manuel Gea Gonz&#xe1;lez, Ciudad de M&#xe9;xico, 14080, M&#xe9;xico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Divisi&#xf3;n de Neurociencias, Instituto Nacional de Rehabilitaci&#xf3;n Luis Guillermo Ibarra Ibarra, Cl&#xed;nica, Ciudad de M&#xe9;xico, 14389, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arias-Carri&#xf3;n</LastName><ForeName>Oscar</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0002-9982-7571</Identifier><AffiliationInfo><Affiliation>Unidad de Trastornos del Movimiento y Sue&#xf1;o (TMS), Hospital General Dr. Manuel Gea Gonz&#xe1;lez, Ciudad de M&#xe9;xico, 14080, M&#xe9;xico. ariasemc2@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Divisi&#xf3;n de Neurociencias, Instituto Nacional de Rehabilitaci&#xf3;n Luis Guillermo Ibarra Ibarra, Cl&#xed;nica, Ciudad de M&#xe9;xico, 14389, M&#xe9;xico. ariasemc2@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Escuela de Medicina y Ciencias de la Salud, Tecnologico de Monterrey, Mexico City, 14380, Mexico. ariasemc2@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Disease progression</Keyword><Keyword MajorTopicYN="N">Longitudinal study</Keyword><Keyword MajorTopicYN="N">Motor asymmetry</Keyword><Keyword MajorTopicYN="N">Parkinson&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Transcranial magnetic stimulation</Keyword></KeywordList><CoiStatement>Declarations. Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>27</Day><Hour>11</Hour><Minute>48</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40715548</ArticleId><ArticleId IdType="doi">10.1038/s41598-025-13558-3</ArticleId><ArticleId IdType="pii">10.1038/s41598-025-13558-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Moustafa, A. A. et al. Motor symptoms in parkinson&#x2019;s disease: A unified framework. Neurosci. Biobehav Rev. 68, 727&#x2013;740. https://doi.org/10.1016/j.neubiorev.2016.07.010 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neubiorev.2016.07.010</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaudhuri, K. R., Healy, D. G. &amp; Schapira, A. H. Non-motor symptoms of parkinson&#x2019;s disease: diagnosis and management. Lancet Neurol. 5, 235&#x2013;245. https://doi.org/10.1016/s1474-4422(06)70373-8 (2006).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1474-4422(06)70373-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacy, B., Piotrowski, H. J., Dewey, R. B. Jr. &amp; Husain, M. M. Severity of depressive and motor symptoms impacts quality of life in parkinson&#x2019;s disease patients at an academic movement clinic: A cross-sectional study. Clin. Park Relat. Disord. 8, 100180. https://doi.org/10.1016/j.prdoa.2022.100180 (2023).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.prdoa.2022.100180</ArticleId></ArticleIdList></Reference><Reference><Citation>Holden, S. K., Finseth, T., Sillau, S. H. &amp; Berman, B. D. Progression of MDS-UPDRS scores over five years in de Novo Parkinson disease from the parkinson&#x2019;s progression markers initiative cohort. Mov. Disord Clin. Pract. 5, 47&#x2013;53. https://doi.org/10.1002/mdc3.12553 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mdc3.12553</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartl, M. et al. Longitudinal change and progression indicators using the movement disorder Society-Unified parkinson&#x2019;s disease rating scale in two independent cohorts with early parkinson&#x2019;s disease. J. Parkinsons Dis. 12, 437&#x2013;452. https://doi.org/10.3233/jpd-212860 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/jpd-212860</ArticleId></ArticleIdList></Reference><Reference><Citation>Furukawa, K. et al. Motor progression and nigrostriatal neurodegeneration in Parkinson disease. Ann. Neurol. 92, 110&#x2013;121. https://doi.org/10.1002/ana.26373 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.26373</ArticleId></ArticleIdList></Reference><Reference><Citation>Surmeier, D. J., Zhai, S., Cui, Q. &amp; Simmons, D. V. Rethinking the network determinants of motor disability in parkinson&#x2019;s disease. Front. Synaptic Neurosci. 15, 1186484. https://doi.org/10.3389/fnsyn.2023.1186484 (2023).</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnsyn.2023.1186484</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindenbach, D. &amp; Bishop, C. Critical involvement of the motor cortex in the pathophysiology and treatment of parkinson&#x2019;s disease. Neurosci. Biobehav Rev. 37, 2737&#x2013;2750. https://doi.org/10.1016/j.neubiorev.2013.09.008 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neubiorev.2013.09.008</ArticleId></ArticleIdList></Reference><Reference><Citation>Underwood, C. F. &amp; Parr-Brownlie, L. C. Primary motor cortex in parkinson&#x2019;s disease: functional changes and opportunities for neurostimulation. Neurobiol. Dis. 147, 105159. https://doi.org/10.1016/j.nbd.2020.105159 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2020.105159</ArticleId></ArticleIdList></Reference><Reference><Citation>de la Fuente-Fern&#xe1;ndez, R. Frontostriatal cognitive staging in Parkinson&#x2019;s disease. Parkinsons Dis. 561046, (2012). https://doi.org/10.1155/2012/561046 (2012).</Citation></Reference><Reference><Citation>Boon, L. I. et al. Cortical and subcortical changes in MEG activity reflect parkinson&#x2019;s progression over a period of 7 years. Brain Topogr. 36, 566&#x2013;580. https://doi.org/10.1007/s10548-023-00965-w (2023).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10548-023-00965-w</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye, Z. Mapping neuromodulatory systems in parkinson&#x2019;s disease: lessons learned beyond dopamine. Curr. Med. 1, 15. https://doi.org/10.1007/s44194-022-00015-w (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s44194-022-00015-w</ArticleId></ArticleIdList></Reference><Reference><Citation>Barker, A. T., Jalinous, R. &amp; Freeston, I. L. Non-invasive magnetic stimulation of human motor cortex. Lancet 325, 1106&#x2013;1107. https://doi.org/10.1016/S0140-6736(85)92413-4 (1985).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(85)92413-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothwell, J. C. Transcranial magnetic stimulation: Twenty years of stimulating the human motor cortex in health and disease. Biocybern Biomed. Eng. 31, 81&#x2013;91. https://doi.org/10.1016/S0208-5216(11)70013-4 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0208-5216(11)70013-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossini, P. M. et al. Non-invasive electrical and magnetic stimulation of the brain, spinal cord, roots and peripheral nerves: basic principles and procedures for routine clinical and research application. An updated report from an IFCN committee. Clin. Neurophysiol. 126, 1071&#x2013;1107. https://doi.org/10.1016/j.clinph.2015.02.001 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2015.02.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Cantello, R., Tarletti, R. &amp; Civardi, C. Transcranial magnetic stimulation and parkinson&#x2019;s disease. Brain Res. Brain Res. Rev. 38, 309&#x2013;327. https://doi.org/10.1016/s0165-0173(01)00158-8 (2002).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0165-0173(01)00158-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Ni, Z. &amp; Chen, R. Transcranial magnetic stimulation to understand pathophysiology and as potential treatment for neurodegenerative diseases. Transl Neurodegener. 4, 22. https://doi.org/10.1186/s40035-015-0045-x (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40035-015-0045-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Spagnolo, F. et al. Interhemispheric balance in parkinson&#x2019;s disease: a transcranial magnetic stimulation study. Brain Stimul. 6, 892&#x2013;897. https://doi.org/10.1016/j.brs.2013.05.004 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brs.2013.05.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Priori, A., Berardelli, A., Inghilleri, M., Accornero, N. &amp; Manfredi, M. Motor cortical Inhibition and the dopaminergic system. Pharmacological changes in the silent period after transcranial brain stimulation in normal subjects, patients with parkinson&#x2019;s disease and drug-induced parkinsonism. Brain 117 (Pt 2), 317&#x2013;323. https://doi.org/10.1093/brain/117.2.317 (1994).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/117.2.317</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimamoto, H. et al. [Motor evoked potentials of transcranial magnetic stimulation for parkinson&#x2019;s disease]. No Shinkei. 48, 825&#x2013;829 (1996).</Citation></Reference><Reference><Citation>Ni, Z., Bahl, N., Gunraj, C. A., Mazzella, F. &amp; Chen, R. Increased motor cortical facilitation and decreased Inhibition in Parkinson disease. Neurology 80, 1746&#x2013;1753. https://doi.org/10.1212/WNL.0b013e3182919029 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3182919029</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic, S. et al. Clinical diagnostic utility of transcranial magnetic stimulation in neurological disorders. Updated report of an IFCN committee. Clin. Neurophysiol. 150, 131&#x2013;175. https://doi.org/10.1016/j.clinph.2023.03.010 (2023). https://doi.org/https://doi.org/</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2023.03.010</ArticleId></ArticleIdList></Reference><Reference><Citation>Birreci, D. et al. The role of Non-Invasive brain modulation in identifying disease biomarkers for diagnostic and therapeutic purposes in parkinsonism. Brain Sci. 14 https://doi.org/10.3390/brainsci14070695 (2024).</Citation></Reference><Reference><Citation>Strafella, A. P. et al. Effects of chronic Levodopa and Pergolide treatment on cortical excitability in patients with parkinson&#x2019;s disease: a transcranial magnetic stimulation study. Clin. Neurophysiol. 111, 1198&#x2013;1202. https://doi.org/10.1016/S1388-2457(00)00316-3 (2000).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1388-2457(00)00316-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Kojovic, M. et al. Transcranial magnetic stimulation follow-up study in early parkinson&#x2019;s disease: A decline in compensation with disease progression? Mov. Disord. 30, 1098&#x2013;1106. https://doi.org/10.1002/mds.26167 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.26167</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerra, A. et al. Long-term changes in short-interval intracortical facilitation modulate motor cortex plasticity and L-dopa-induced dyskinesia in parkinson&#x2019;s disease. Brain Stimul. 15, 99&#x2013;108. https://doi.org/10.1016/j.brs.2021.11.016 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brs.2021.11.016</ArticleId></ArticleIdList></Reference><Reference><Citation>Poewe, W. &amp; Mahlknecht, P. The clinical progression of parkinson&#x2019;s disease. Parkinsonism Relat. Disord. 15 (Suppl 4), 28&#x2013;32. https://doi.org/10.1016/s1353-8020(09)70831-4 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1353-8020(09)70831-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Arya, R. et al. Parkinson&#x2019;s Disease: Biomarkers for Diagnosis and Disease Progression. Int. J. Mol. Sci. 25 https://doi.org/10.3390/ijms252212379 (2024).</Citation></Reference><Reference><Citation>Alves, G., Wentzel-Larsen, T., Aarsland, D. &amp; Larsen, J. P. Progression of motor impairment and disability in Parkinson disease: a population-based study. Neurology 65, 1436&#x2013;1441. https://doi.org/10.1212/01.wnl.0000183359.50822.f2 (2005).</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000183359.50822.f2</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;nez-Mart&#xed;n, P. et al. Parkinson&#x2019;s disease severity levels and MDS-Unified parkinson&#x2019;s disease rating scale. Parkinsonism Relat. Disord. 21, 50&#x2013;54. https://doi.org/10.1016/j.parkreldis.2014.10.026 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.parkreldis.2014.10.026</ArticleId></ArticleIdList></Reference><Reference><Citation>Aslam, S., Manfredsson, F., Stokes, A. &amp; Shill, H. Advanced parkinson&#x2019;s disease: A review. Parkinsonism Relat. Disord. 123, 106065. https://doi.org/10.1016/j.parkreldis.2024.106065 (2024).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.parkreldis.2024.106065</ArticleId></ArticleIdList></Reference><Reference><Citation>Regnault, A. et al. Does the MDS-UPDRS provide the precision to assess progression in early parkinson&#x2019;s disease? Learnings from the parkinson&#x2019;s progression marker initiative cohort. J. Neurol. 266, 1927&#x2013;1936. https://doi.org/10.1007/s00415-019-09348-3 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-019-09348-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Goetz, C. G. et al. Movement disorder Society-sponsored revision of the unified parkinson&#x2019;s disease rating scale (MDS-UPDRS): process, format, and clinimetric testing plan. Mov. Disord. 22, 41&#x2013;47. https://doi.org/10.1002/mds.21198 (2007).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.21198</ArticleId></ArticleIdList></Reference><Reference><Citation>Uitti, R. J., Baba, Y., Whaley, N. R., Wszolek, Z. K. &amp; Putzke, J. D. Parkinson disease: handedness predicts asymmetry. Neurology 64, 1925&#x2013;1930. https://doi.org/10.1212/01.Wnl.0000163993.82388.C8 (2005).</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.Wnl.0000163993.82388.C8</ArticleId></ArticleIdList></Reference><Reference><Citation>Marinus, J. &amp; van Hilten, J. J. The significance of motor (a)symmetry in parkinson&#x2019;s disease. Mov. Disord. 30, 379&#x2013;385. https://doi.org/10.1002/mds.26107 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.26107</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller-Patterson, C. et al. Motor asymmetry over time in parkinson&#x2019;s disease. J. Neurol. Sci. 393, 14&#x2013;17. https://doi.org/10.1016/j.jns.2018.08.001 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2018.08.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiorenzato, E., Antonini, A., Bisiacchi, P., Weis, L. &amp; Biundo, R. Asymmetric dopamine transporter loss affects cognitive and motor progression in parkinson&#x2019;s disease. Mov. Disord. 36, 2303&#x2013;2313. https://doi.org/10.1002/mds.28682 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.28682</ArticleId></ArticleIdList></Reference><Reference><Citation>Falla, M. et al. Lockdown effects on parkinson&#x2019;s disease during COVID-19 pandemic: a pilot study. Acta Neurol. Belg. 121, 1191&#x2013;1198. https://doi.org/10.1007/s13760-021-01732-z (2021).</Citation></Reference><Reference><Citation>Shalash, A. et al. A 6-month longitudinal study on worsening of parkinson&#x2019;s disease during the COVID-19 pandemic. NPJ Parkinsons Dis. 8, 111. https://doi.org/10.1038/s41531-022-00376-x (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41531-022-00376-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Ineichen, C., Baumann-Vogel, H., Sitzler, M., Waldvogel, D. &amp; Baumann, C. R. Worsened parkinson&#x2019;s disease progression: impact of the COVID-19 pandemic. J. Parkinson Dis. 11, 1579&#x2013;1583. https://doi.org/10.3233/JPD-212779 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JPD-212779</ArticleId></ArticleIdList></Reference><Reference><Citation>Ineichen, C., Vogel-Baumann, H., Sitzler, M., Deuschl, G. &amp; Baumann, C. R. Worsening of parkinson&#x2019;s disease after termination of COVID-19 quarantine cannot be reversed despite resumption of physiotherapy. J. Parkinsons Dis. 13, 845&#x2013;848. https://doi.org/10.3233/jpd-230061 (2023).</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/jpd-230061</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonini, A. et al. The progression of non-motor symptoms in parkinson&#x2019;s disease and their contribution to motor disability and quality of life. J. Neurol. 259, 2621&#x2013;2631. https://doi.org/10.1007/s00415-012-6557-8 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-012-6557-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, Y. C. et al. The severity progression of non-motor symptoms in parkinson&#x2019;s disease: a 6-year longitudinal study in Taiwanese patients. Sci. Rep. 11, 14781. https://doi.org/10.1038/s41598-021-94255-9 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-94255-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Ou, R. et al. Longitudinal evolution of non-motor symptoms in early parkinson&#x2019;s disease: a 3-year prospective cohort study. NPJ Parkinsons Dis. 7, 58. https://doi.org/10.1038/s41531-021-00207-5 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41531-021-00207-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Bugalho, P. et al. Progression in parkinson&#x2019;s disease: variation in motor and non-motor symptoms severity and predictors of decline in cognition, motor function, disability, and health&#x2010;related quality of life as assessed by two different methods. Mov. Disord Clin. Pract. 8, 885&#x2013;895. https://doi.org/10.1002/mdc3.13262 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mdc3.13262</ArticleId></ArticleIdList></Reference><Reference><Citation>Evers, L. J. W., Krijthe, J. H., Meinders, M. J., Bloem, B. R. &amp; Heskes, T. M. Measuring parkinson&#x2019;s disease over time: the real-world within-subject reliability of the MDS-UPDRS. Mov. Disord. 34, 1480&#x2013;1487. https://doi.org/10.1002/mds.27790 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.27790</ArticleId></ArticleIdList></Reference><Reference><Citation>Khedr, E. M., Lefaucheur, J. P., Hasan, A. M. &amp; Osama, K. Are there differences in cortical excitability between akinetic-rigid and tremor-dominant subtypes of parkinson&#x2019;s disease? Neurophysiol. Clin. 51, 443&#x2013;453. https://doi.org/10.1016/j.neucli.2021.08.002 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neucli.2021.08.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Lefaucheur, J. P. Motor cortex dysfunction revealed by cortical excitability studies in parkinson&#x2019;s disease: influence of antiparkinsonian treatment and cortical stimulation. Clin. Neurophysiol. 116, 244&#x2013;253. https://doi.org/10.1016/j.clinph.2004.11.017 (2005).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2004.11.017</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolmancic, K. et al. Sex differences in parkinson&#x2019;s disease: A transcranial magnetic stimulation study. Mov. Disord. 34, 1873&#x2013;1881. https://doi.org/10.1002/mds.27870 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.27870</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, R. et al. Clinical neurophysiology of parkinson&#x2019;s disease and parkinsonism. Clin. Neurophysiol. Pract. 7, 201&#x2013;227. https://doi.org/10.1016/j.cnp.2022.06.002 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cnp.2022.06.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerri, S., Mus, L. &amp; Blandini, F. Parkinson&#x2019;s disease in women and men: what&#x2019;s the difference?? J. Parkinsons Dis. 9, 501&#x2013;515. https://doi.org/10.3233/jpd-191683 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/jpd-191683</ArticleId></ArticleIdList></Reference><Reference><Citation>Moisan, F. et al. Parkinson disease male-to-female ratios increase with age: French nationwide study and meta-analysis. J. Neurol. Neurosurg. Psychiatry. 87, 952&#x2013;957. https://doi.org/10.1136/jnnp-2015-312283 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2015-312283</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwaki, H. et al. Differences in the presentation and progression of parkinson&#x2019;s disease by sex. Mov. Disord. 36, 106&#x2013;117. https://doi.org/10.1002/mds.28312 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.28312</ArticleId></ArticleIdList></Reference><Reference><Citation>Abraham, D. S. et al. Sex differences in parkinson&#x2019;s disease presentation and progression. Parkinsonism Relat. Disord. 69, 48&#x2013;54. https://doi.org/10.1016/j.parkreldis.2019.10.019 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.parkreldis.2019.10.019</ArticleId></ArticleIdList></Reference><Reference><Citation>Dahodwala, N., Pei, Q. &amp; Schmidt, P. Sex differences in the clinical progression of parkinson&#x2019;s disease. J. Obstet. Gynecol. Neonatal Nurs. 45, 749&#x2013;756. https://doi.org/10.1016/j.jogn.2016.05.002 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jogn.2016.05.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Choudhury, S. et al. Short-Latency afferent Inhibition correlates with stage of disease in parkinson&#x2019;s patients. Can. J. Neurol. Sci. 50, 579&#x2013;583. https://doi.org/10.1017/cjn.2022.83 (2023).</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/cjn.2022.83</ArticleId></ArticleIdList></Reference><Reference><Citation>Paparella, G. et al. Interhemispheric imbalance and bradykinesia features in parkinson&#x2019;s disease. Brain Commun. 6, fcae020. https://doi.org/10.1093/braincomms/fcae020 (2024).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcae020</ArticleId></ArticleIdList></Reference><Reference><Citation>Janssen Daalen, J. M., Schootemeijer, S., Richard, E., Darweesh, S. K. L. &amp; Bloem, B. R. Lifestyle interventions for the prevention of Parkinson disease: A recipe for action. Neurology 99, 42&#x2013;51. https://doi.org/10.1212/wnl.0000000000200787 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.0000000000200787</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan, P. L. &amp; Holford, N. H. Drug treatment effects on disease progression. Annu. Rev. Pharmacol. Toxicol. 41, 625&#x2013;659. https://doi.org/10.1146/annurev.pharmtox.41.1.625 (2001).</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.pharmtox.41.1.625</ArticleId></ArticleIdList></Reference><Reference><Citation>Hilker, R. et al. Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. Arch. Neurol. 62, 378&#x2013;382. https://doi.org/10.1001/archneur.62.3.378 (2005).</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.62.3.378</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin, R., Yoshioka, H., Sato, H. &amp; Hisaka, A. Data-driven disease progression model of parkinson&#x2019;s disease and effect of sex and genetic variants. CPT Pharmacometrics Syst. Pharmacol. 13, 649&#x2013;659. https://doi.org/10.1002/psp4.13112 (2024).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/psp4.13112</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, J. et al. Akinetic-rigid and tremor-dominant parkinson&#x2019;s disease patients show different patterns of intrinsic brain activity. Parkinsonism Relat. Disord. 21, 23&#x2013;30. https://doi.org/10.1016/j.parkreldis.2014.10.017 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.parkreldis.2014.10.017</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamble, N. et al. Cortical excitability changes as a marker of cognitive impairment in parkinson&#x2019;s disease. Behav. Brain Res. 422, 113733. https://doi.org/10.1016/j.bbr.2022.113733 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbr.2022.113733</ArticleId></ArticleIdList></Reference><Reference><Citation>Ly, J. Q. M. et al. Circadian regulation of human cortical excitability. Nat. Commun. 7, 11828. https://doi.org/10.1038/ncomms11828 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms11828</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerra, A. et al. Abnormal cortical facilitation and L-dopa-induced dyskinesia in parkinson&#x2019;s disease. Brain Stimul. 12, 1517&#x2013;1525. https://doi.org/10.1016/j.brs.2019.06.012 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brs.2019.06.012</ArticleId></ArticleIdList></Reference><Reference><Citation>Postuma, R. B. et al. MDS clinical diagnostic criteria for parkinson&#x2019;s disease. Mov. Disord. 30, 1591&#x2013;1601. https://doi.org/10.1002/mds.26424 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.26424</ArticleId></ArticleIdList></Reference><Reference><Citation>Vonloh, M., Chen, R. &amp; Kluger, B. Safety of transcranial magnetic stimulation in parkinson&#x2019;s disease: a review of the literature. Parkinsonism Relat. Disord. 19, 573&#x2013;585. https://doi.org/10.1016/j.parkreldis.2013.01.007 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.parkreldis.2013.01.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi, S. et al. Safety and recommendations for TMS use in healthy subjects and patient populations, with updates on training, ethical and regulatory issues: expert guidelines. Clin. Neurophysiol. 132, 269&#x2013;306. https://doi.org/10.1016/j.clinph.2020.10.003 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2020.10.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Edwards, D. J. et al. in In A Practical Manual for Transcranial Magnetic Stimulation. Edwards15&#x2013;33 (eds Dylan, J.) (Springer Nature Switzerland, 2024).</Citation></Reference><Reference><Citation>Espay, A. J., Li, J. Y., Johnston, L., Chen, R. &amp; Lang, A. E. Mirror movements in parkinsonism: evaluation of a new clinical sign. J. Neurol. Neurosurg. Psychiatry. 76, 1355&#x2013;1358. https://doi.org/10.1136/jnnp.2005.062950 (2005).</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2005.062950</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortega-Robles, E., Cantillo-Negrete, J. &amp; Carino-Escobar, R. I. Arias-Carri&#xf3;n, O. Methodological approach for assessing motor cortical excitability changes with single-pulse transcranial magnetic stimulation. MethodsX 11, 102451. https://doi.org/10.1016/j.mex.2023.102451 (2023).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mex.2023.102451</ArticleId></ArticleIdList></Reference><Reference><Citation>Julkunen, P. Mobile application for adaptive threshold hunting in transcranial magnetic stimulation. IEEE Trans. Neural Syst. Rehabil Eng. 27, 1504&#x2013;1510. https://doi.org/10.1109/TNSRE.2019.2925904 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/TNSRE.2019.2925904</ArticleId></ArticleIdList></Reference><Reference><Citation>Devanne, H., Lavoie, B. A. &amp; Capaday, C. Input-output properties and gain changes in the human corticospinal pathway. Exp. Brain Res. 114, 329&#x2013;338. https://doi.org/10.1007/PL00005641 (1997).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/PL00005641</ArticleId></ArticleIdList></Reference><Reference><Citation>Milardovich, D. et al. DELMEP: a deep learning algorithm for automated annotation of motor evoked potential latencies. Sci. Rep. 13, 8225. https://doi.org/10.1038/s41598-023-34801-9 (2023).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-023-34801-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Carson, R. G. et al. Characterizing changes in the excitability of corticospinal projections to proximal muscles of the upper limb. Brain Stimul. 6, 760&#x2013;768. https://doi.org/10.1016/j.brs.2013.01.016 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brs.2013.01.016</ArticleId></ArticleIdList></Reference><Reference><Citation>Geniole, S. N. et al. Testosterone reduces the threat premium in competitive resource division. Proc. Biol. Sci. 286, 20190720. https://doi.org/10.1098/rspb.2019.0720 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rspb.2019.0720</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf3;mez, Y. et al. Similarity in Temporal movement patterns in laying hens increases with time and social association. Anim. (Basel). 12 https://doi.org/10.3390/ani12050555 (2022).</Citation></Reference><Reference><Citation>Bland, J. M. &amp; Altman, D. G. Calculating correlation coefficients with repeated observations: part 1&#x2014;Correlation within subjects. Bmj 310, 446. https://doi.org/10.1136/bmj.310.6977.446 (1995).</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.310.6977.446</ArticleId></ArticleIdList></Reference><Reference><Citation>Bland, J. M. &amp; Altman, D. G. Calculating correlation coefficients with repeated observations: part 2&#x2014;Correlation between subjects. Bmj 310, 633. https://doi.org/10.1136/bmj.310.6980.633 (1995).</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.310.6980.633</ArticleId></ArticleIdList></Reference><Reference><Citation>R Core Team. R: A Language and Environment for Statistical Computing. (4.4.1). (2024). https://www.R-project.org/</Citation></Reference><Reference><Citation>Posit team. RStudio: Integrated Development Environment for R. (2023.06.1). (2023). http://www.posit.co/</Citation></Reference><Reference><Citation>Kassambara, A. ggpubr: &#x2018;ggplot2&#x2019; Based Publication Ready Plots. (0.6.0). (2023). https://CRAN.R-project.org/package=ggpubr</Citation></Reference><Reference><Citation>Kassambara, A. Pipe-Friendly Framework for Basic Statistical Tests. (0.7.2). (2023). https://CRAN.R-project.org/package=rstatix</Citation></Reference><Reference><Citation>Wickham, H., Vaughan, D. &amp; Girlich, M. Tidy Messy Data. (1.3.1). (2024). https://CRAN.R-project.org/package=tidyr</Citation></Reference><Reference><Citation>Dawson, C. ggprism: A &#x2018;ggplot2&#x2019; Extension Inspired by &#x2018;GraphPad Prism&#x2019;. (1.0.5). (2024). https://CRAN.R-project.org/package=ggprism</Citation></Reference><Reference><Citation>Wilke, C. O. &amp; cowplot Streamlined Plot Theme and Plot Annotations for &#x2018;ggplot2&#x2019;. (1.1.1). (2020). https://CRAN.R-project.org/package=cowplot</Citation></Reference><Reference><Citation>Fox, J., Weisberg, S. &amp; Third An {R} Companion to Applied Regression. (). (2019). https://socialsciences.mcmaster.ca/jfox/Books/Companion/</Citation></Reference><Reference><Citation>Bates, D., M&#xe4;chler, M., Bolker, B. &amp; Walker, S. Fitting linear Mixed-Effects models using lme4. J. Stat. Softw. 67, 1&#x2013;48. https://doi.org/10.18637/jss.v067.i01 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.18637/jss.v067.i01</ArticleId></ArticleIdList></Reference><Reference><Citation>Koller, M. &amp; robustlmm An R package for robust Estimation of linear Mixed-Effects models. J. Stat. Softw. 75, 1&#x2013;24. https://doi.org/10.18637/jss.v075.i06 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.18637/jss.v075.i06</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenth, R. V. &amp; emmeans Estimated Marginal Means, aka Least-Squares Means. (1.10.3). (2024). https://CRAN.R-project.org/package=emmeans</Citation></Reference><Reference><Citation>Kuznetsova, A., Brockhoff, P. B. &amp; Christensen, R. H. B. LmerTest package: tests in linear mixed effects models. J. Stat. Softw. 82, 1&#x2013;26. https://doi.org/10.18637/jss.v082.i13 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.18637/jss.v082.i13</ArticleId></ArticleIdList></Reference><Reference><Citation>Elzhov, T. V., Mullen, K. M., Spiess, A. N. &amp; Bolker, B. minpack.lm: R interface to the Levenberg-Marquardt nonlinear Least-Squares algorithm found in MINPACK, plus support for bounds. (1.2.4). (2023). https://CRAN.R-project.org/package=minpack.lm</Citation></Reference><Reference><Citation>Bakdash, J. Z., Marusich, L. R. &amp; rmcorr Repeated Measures Correlation (0.7.0). (2024). https://CRAN.R-project.org/package=rmcorr</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40715455</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1696</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Jul</Month><Day>25</Day></PubDate></JournalIssue><Title>Nature biotechnology</Title><ISOAbbreviation>Nat Biotechnol</ISOAbbreviation></Journal><ArticleTitle>Single-cell polygenic risk scores dissect cellular and molecular heterogeneity of complex human diseases.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41587-025-02725-6</ELocationID><Abstract><AbstractText>Polygenic risk scores (PRSs) predict an individual's genetic risk for complex diseases, yet their utility in elucidating disease biology remains limited. We introduce scPRS, a graph neural network-based framework that computes single-cell-resolved PRSs by integrating reference single-cell chromatin accessibility profiles. scPRS outperforms traditional PRS approaches in genetic risk prediction, as demonstrated across multiple diseases including type 2 diabetes, hypertrophic cardiomyopathy, Alzheimer disease and severe COVID-19. Beyond risk prediction, scPRS prioritizes disease-critical cells and, when combined with a layered multiomic analysis, links risk variants to gene regulation in a cell-type-specific manner. Applied to these diseases, scPRS fine-maps causal cell types and cell-type-specific variants and genes, demonstrating its ability to bridge genetic risk with cell-specific biology. scPRS provides a unified framework for genetic risk prediction and mechanistic dissection of complex diseases, laying a methodological foundation for single-cell genetics.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhang</LastName><ForeName>Sai</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-5996-6086</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology, University of Florida, Gainesville, FL, USA. sai.zhang@ufl.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departments of Biostatistics &amp; Biomedical Engineering, UF Genetics Institute, University of Florida, Gainesville, FL, USA. sai.zhang@ufl.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics, Center for Genomics and Personalized Medicine, Stanford University School of Medicine, Stanford, CA, USA. sai.zhang@ufl.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>VA Palo Alto Healthcare System, Palo Alto, CA, USA. sai.zhang@ufl.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Shu</LastName><ForeName>Hantao</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-7306-5644</Identifier><AffiliationInfo><Affiliation>Institute for Interdisciplinary Information Sciences, Tsinghua University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhou</LastName><ForeName>Jingtian</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Arc Institute, Palo Alto, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Genomic Analysis Laboratory, The Salk Institute for Biological Studies, La Jolla, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Bioinformatics and Systems Biology Program, University of California, San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rubin-Sigler</LastName><ForeName>Jasper</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Stem Cell Biology and Regenerative Medicine, Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Xiaoyu</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Institute for Human Genetics, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yuxi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Institute for Human Genetics, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cooper-Knock</LastName><ForeName>Johnathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Monte</LastName><ForeName>Emma</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Genetics, Center for Genomics and Personalized Medicine, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Chenchen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Genetics, Center for Genomics and Personalized Medicine, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tu</LastName><ForeName>Sharon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Stem Cell Biology and Regenerative Medicine, Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Han</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-7380-6174</Identifier><AffiliationInfo><Affiliation>Institute for Interdisciplinary Information Sciences, Tsinghua University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tong</LastName><ForeName>Mingming</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-8422-5108</Identifier><AffiliationInfo><Affiliation>Department of Genetics, Center for Genomics and Personalized Medicine, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ecker</LastName><ForeName>Joseph R</ForeName><Initials>JR</Initials><Identifier Source="ORCID">0000-0001-5799-5895</Identifier><AffiliationInfo><Affiliation>Genomic Analysis Laboratory, The Salk Institute for Biological Studies, La Jolla, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, The Salk Institute for Biological Studies, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ichida</LastName><ForeName>Justin K</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>Department of Stem Cell Biology and Regenerative Medicine, Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research, University of Southern California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Yin</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-9901-5613</Identifier><AffiliationInfo><Affiliation>Institute for Human Genetics, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeng</LastName><ForeName>Jianyang</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-0950-7716</Identifier><AffiliationInfo><Affiliation>School of Engineering, Research Center for Industries of the Future, Westlake University, Hangzhou, China. zengjy@westlake.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsao</LastName><ForeName>Philip S</ForeName><Initials>PS</Initials><Identifier Source="ORCID">0000-0001-7274-9318</Identifier><AffiliationInfo><Affiliation>VA Palo Alto Healthcare System, Palo Alto, CA, USA. ptsao@stanford.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA. ptsao@stanford.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Snyder</LastName><ForeName>Michael P</ForeName><Initials>MP</Initials><Identifier Source="ORCID">0000-0003-0784-7987</Identifier><AffiliationInfo><Affiliation>Department of Genetics, Center for Genomics and Personalized Medicine, Stanford University School of Medicine, Stanford, CA, USA. mpsnyder@stanford.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>5P50HG007735</GrantID><Agency>U.S. Department of Health &amp; Human Services | National Institutes of Health (NIH)</Agency><Country/></Grant><Grant><GrantID>2R01NS097850</GrantID><Agency>U.S. Department of Health &amp; Human Services | National Institutes of Health (NIH)</Agency><Country/></Grant><Grant><GrantID>1R01NS131409</GrantID><Agency>U.S. Department of Health &amp; Human Services | National Institutes of Health (NIH)</Agency><Country/></Grant><Grant><GrantID>RF1AG079557</GrantID><Agency>U.S. Department of Health &amp; Human Services | National Institutes of Health (NIH)</Agency><Country/></Grant><Grant><GrantID>R01AG079291</GrantID><Agency>U.S. Department of Health &amp; Human Services | National Institutes of Health (NIH)</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Biotechnol</MedlineTA><NlmUniqueID>9604648</NlmUniqueID><ISSNLinking>1087-0156</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement>Competing interests: M.P.S. is a cofounder and the scientific advisory board member of Personalis, SensOmics, Qbio, January AI, Fodsel, Filtricine, Protos, RTHM, Iollo, Marble Therapeutics, Crosshair Therapeutics, NextThought and Mirvie. He is a scientific advisor of Jupiter, Neuvivo, Swaza, Mitrix, Yuvan, TranscribeGlass and Applied Cognition. J.K.I. is a cofounder and a scientific advisory board member of AcuraStem and Modulo Bio and a scientific advisory board member of Synapticure and Vesalius Therapeutics. J.K.I. is also an employee of BioMarin Pharmaceutical. The remaining authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>5</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>27</Day><Hour>11</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40715455</ArticleId><ArticleId IdType="doi">10.1038/s41587-025-02725-6</ArticleId><ArticleId IdType="pii">10.1038/s41587-025-02725-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ding, Y. et al. Polygenic scoring accuracy varies across the genetic ancestry continuum. Nature 618, 774&#x2013;781 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37198491</ArticleId><ArticleId IdType="pmc">10284707</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi, S. W., Mak, T. S.-H. &amp; O&#x2019;Reilly, P. F. Tutorial: a guide to performing polygenic risk score analyses. Nat. Protoc. 15, 2759&#x2013;2772 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32709988</ArticleId><ArticleId IdType="pmc">7612115</ArticleId></ArticleIdList></Reference><Reference><Citation>Torkamani, A., Wineinger, N. E. &amp; Topol, E. J. The personal and clinical utility of polygenic risk scores. Nat. Rev. Genet. 19, 581&#x2013;590 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29789686</ArticleId></ArticleIdList></Reference><Reference><Citation>Uffelmann, E. et al. Genome-wide association studies. Nat. Rev. Methods Primers 1, 59 (2021).</Citation></Reference><Reference><Citation>Priv&#xe9;, F., Arbel, J. &amp; Vilhj&#xe1;lmsson, B. J. LDpred2: better, faster, stronger. Bioinformatics 36, 5424&#x2013;5431 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">8016455</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi, S. W. &amp; O&#x2019;Reilly, P. F. PRSice-2: polygenic risk score software for biobank-scale data. Gigascience 8, giz082 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31307061</ArticleId><ArticleId IdType="pmc">6629542</ArticleId></ArticleIdList></Reference><Reference><Citation>Mak, T. S. H., Porsch, R. M., Choi, S. W., Zhou, X. &amp; Sham, P. C. Polygenic scores via penalized regression on summary statistics. Genet. Epidemiol. 41, 469&#x2013;480 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28480976</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson, D. J. et al. A systematic evaluation of the performance and properties of the UK Biobank Polygenic Risk Score (PRS) Release. PLoS ONE 19, e0307270 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">39292644</ArticleId><ArticleId IdType="pmc">11410272</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi, Y. H. &amp; Kim, J. K. Dissecting cellular heterogeneity using single-cell RNA sequencing. Mol. Cells 42, 189&#x2013;199 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30764602</ArticleId><ArticleId IdType="pmc">6449718</ArticleId></ArticleIdList></Reference><Reference><Citation>Westra, H.-J. &amp; Franke, L. From genome to function by studying eQTLs. Biochim. Biophys. Acta 1842, 1896&#x2013;1902 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24798236</ArticleId></ArticleIdList></Reference><Reference><Citation>Maurano, M. T. et al. Systematic localization of common disease-associated variation in regulatory DNA. Science 337, 1190&#x2013;1195 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22955828</ArticleId><ArticleId IdType="pmc">3771521</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasser, J. et al. Genome-wide enhancer maps link risk variants to disease genes. Nature 593, 238&#x2013;243 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33828297</ArticleId><ArticleId IdType="pmc">9153265</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, Y., Tsuo, K., Kanai, M., Neale, B. M. &amp; Martin, A. R. Challenges and opportunities for developing more generalizable polygenic risk scores. Annu. Rev. Biomed. Data Sci. 5, 293&#x2013;320 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35576555</ArticleId><ArticleId IdType="pmc">9828290</ArticleId></ArticleIdList></Reference><Reference><Citation>Piwecka, M., Rajewsky, N. &amp; Rybak-Wolf, A. Single-cell and spatial transcriptomics: deciphering brain complexity in health and disease. Nat. Rev. Neurol. 19, 346&#x2013;362 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37198436</ArticleId><ArticleId IdType="pmc">10191412</ArticleId></ArticleIdList></Reference><Reference><Citation>Amariuta, T. et al. Improving the trans-ancestry portability of polygenic risk scores by prioritizing variants in predicted cell-type-specific regulatory elements. Nat. Genet. 52, 1346&#x2013;1354 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33257898</ArticleId><ArticleId IdType="pmc">8049522</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, H., Zeng, J., Snyder, M. P. &amp; Zhang, S. Modeling gene interactions in polygenic prediction via geometric deep learning. Genome Res 35, 178&#x2013;187 (2025).</Citation><ArticleIdList><ArticleId IdType="pubmed">39562137</ArticleId><ArticleId IdType="pmc">11789630</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuomo, A. S. E., Nathan, A., Raychaudhuri, S., MacArthur, D. G. &amp; Powell, J. E. Single-cell genomics meets human genetics. Nat. Rev. Genet. 24, 535&#x2013;549 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37085594</ArticleId><ArticleId IdType="pmc">10784789</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamilton, W. L., Ying, R. &amp; Leskovec, J. Representation learning on graphs: methods and applications. IEEE Data Eng. Bull. 40, 52&#x2013;74 (2017).</Citation></Reference><Reference><Citation>Buenrostro, J. D. et al. Single-cell chromatin accessibility reveals principles of regulatory variation. Nature 523, 486&#x2013;490 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26083756</ArticleId><ArticleId IdType="pmc">4685948</ArticleId></ArticleIdList></Reference><Reference><Citation>The ENCODE Project Consortiumet al.Expanded encyclopaedias of DNA elements in the human and mouse genomes. Nature 583, 699&#x2013;710 (2020).</Citation></Reference><Reference><Citation>Kipf, T. N. &amp; Welling, M. Semi-supervised classification with graph convolutional networks. Preprint at https://doi.org/10.48550/arxiv.1609.02907 (2016)</Citation></Reference><Reference><Citation>Vuckovic, D. et al. The polygenic and monogenic basis of blood traits and diseases. Cell 182, 1214&#x2013;1231 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32888494</ArticleId><ArticleId IdType="pmc">7482360</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, J. et al. Decoding the genomics of abdominal aortic aneurysm. Cell 174, 1361&#x2013;1372 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30193110</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler, A., Hoffman, P., Smibert, P., Papalexi, E. &amp; Satija, R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 36, 411&#x2013;420 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29608179</ArticleId><ArticleId IdType="pmc">6700744</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, J., Li, X., Zhang, S. &amp; Snyder, M.Gene&#x2013;environment interaction in the era of precision medicine. Cell 177, 38&#x2013;44 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30901546</ArticleId><ArticleId IdType="pmc">8108774</ArticleId></ArticleIdList></Reference><Reference><Citation>Bycroft, C. et al. The UK Biobank resource with deep phenotyping and genomic data. Nature 562, 203&#x2013;209 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30305743</ArticleId><ArticleId IdType="pmc">6786975</ArticleId></ArticleIdList></Reference><Reference><Citation>Monte, E. et al. Personalized transcriptome signatures in a cardiomyopathy stem cell biobank. Preprint at bioRxiv https://doi.org/10.1101/2024.05.10.593618 (2024).</Citation></Reference><Reference><Citation>Gaziano, J. M. et al. Million Veteran Program: a mega-biobank to study genetic influences on health and disease. J. Clin. Epidemiol. 70, 214&#x2013;223 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26441289</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunkle, B. W. et al. Genetic meta-analysis of diagnosed Alzheimer&#x2019;s disease identifies new risk loci and implicates A&#x3b2;, tau, immunity and lipid processing. Nat. Genet. 51, 414&#x2013;430 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30820047</ArticleId><ArticleId IdType="pmc">6463297</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakaue, S. et al. A cross-population atlas of genetic associations for 220 human phenotypes. Nat. Genet. 53, 1415&#x2013;1424 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34594039</ArticleId><ArticleId IdType="pmc">12208603</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott, R. A. et al. An expanded genome-wide association study of type 2 diabetes in Europeans. Diabetes 66, 2888&#x2013;2902 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28566273</ArticleId><ArticleId IdType="pmc">5652602</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19 Host Genetics Initiative Mapping the human genetic architecture of COVID-19. Nature 600, 472&#x2013;477 (2021).</Citation></Reference><Reference><Citation>Chiou, J. et al. Interpreting type 1 diabetes risk with genetics and single-cell epigenomics. Nature 594, 398&#x2013;402 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34012112</ArticleId><ArticleId IdType="pmc">10560508</ArticleId></ArticleIdList></Reference><Reference><Citation>ENCODE Project Consortiumet al. Perspectives on ENCODE. Nature 583, 693&#x2013;698 (2020).</Citation></Reference><Reference><Citation>Corces, M. R. et al. Single-cell epigenomic analyses implicate candidate causal variants at inherited risk loci for Alzheimer&#x2019;s and Parkinson&#x2019;s diseases. Nat. Genet. 52, 1158&#x2013;1168 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33106633</ArticleId><ArticleId IdType="pmc">7606627</ArticleId></ArticleIdList></Reference><Reference><Citation>Purcell, S. et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 81, 559&#x2013;575 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17701901</ArticleId><ArticleId IdType="pmc">1950838</ArticleId></ArticleIdList></Reference><Reference><Citation>Weissbrod, O. et al. Leveraging fine-mapping and multipopulation training data to improve cross-population polygenic risk scores. Nat. Genet. 54, 450&#x2013;458 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35393596</ArticleId><ArticleId IdType="pmc">9009299</ArticleId></ArticleIdList></Reference><Reference><Citation>Weissbrod, O. et al. Functionally informed fine-mapping and polygenic localization of complex trait heritability. Nat. Genet. 52, 1355&#x2013;1363 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33199916</ArticleId><ArticleId IdType="pmc">7710571</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuchsberger, C. et al. The genetic architecture of type 2 diabetes. Nature 536, 41&#x2013;47 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27398621</ArticleId><ArticleId IdType="pmc">5034897</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou, B. et al. Identification of a splicing variant that regulates type 2 diabetes risk factor CDKAL1 level by a coding-independent mechanism in human. Hum. Mol. Genet. 23, 4639&#x2013;4650 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24760768</ArticleId></ArticleIdList></Reference><Reference><Citation>Diamanti, K. et al. Organ-specific metabolic pathways distinguish prediabetes, type 2 diabetes, and normal tissues. Cell Rep. Med. 3, 100763 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36198307</ArticleId><ArticleId IdType="pmc">9589007</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, K. et al. A single-cell atlas of chromatin accessibility in the human genome. Cell 184, 5985&#x2013;6001 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34774128</ArticleId><ArticleId IdType="pmc">8664161</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen, R. C. et al. Alzheimer&#x2019;s Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology 74, 201&#x2013;209 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20042704</ArticleId><ArticleId IdType="pmc">2809036</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiou, J. et al. Single-cell chromatin accessibility identifies pancreatic islet cell type- and state-specific regulatory programs of diabetes risk. Nat. Genet. 53, 455&#x2013;466 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33795864</ArticleId><ArticleId IdType="pmc">9037575</ArticleId></ArticleIdList></Reference><Reference><Citation>Finucane, H. K. et al. Partitioning heritability by functional annotation using genome-wide association summary statistics. Nat. Genet. 47, 1228&#x2013;1235 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26414678</ArticleId><ArticleId IdType="pmc">4626285</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu, F. et al. Variant to function mapping at single-cell resolution through network propagation. Nat. Biotechnol. 40, 1644&#x2013;1653 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35668323</ArticleId><ArticleId IdType="pmc">9646486</ArticleId></ArticleIdList></Reference><Reference><Citation>Eizirik, D. L., Pasquali, L. &amp; Cnop, M. Pancreatic &#x3b2;-cells in type 1 and type 2 diabetes mellitus: different pathways to failure. Nat. Rev. Endocrinol. 16, 349&#x2013;362 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32398822</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki, K. et al. Genetic drivers of heterogeneity in type 2 diabetes pathophysiology. Nature 627, 347&#x2013;357 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38374256</ArticleId><ArticleId IdType="pmc">10937372</ArticleId></ArticleIdList></Reference><Reference><Citation>Tellez, K. et al. In vivo studies of glucagon secretion by human islets transplanted in mice. Nat. Metab. 2, 547&#x2013;557 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32694729</ArticleId><ArticleId IdType="pmc">7739959</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai, X.-Q. et al. Heterogenous impairment of &#x3b1; cell function in type 2 diabetes is linked to cell maturation state. Cell Metab. 34, 256&#x2013;268 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35108513</ArticleId><ArticleId IdType="pmc">8852281</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilon, P. The role of &#x3b1;-cells in islet function and glucose homeostasis in health and type 2 diabetes. J. Mol. Biol. 432, 1367&#x2013;1394 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31954131</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, G. et al. Integrating genetics with single-cell multiomic measurements across disease states identifies mechanisms of beta cell dysfunction in type 2 diabetes. Nat. Genet. 55, 984&#x2013;994 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37231096</ArticleId><ArticleId IdType="pmc">10550816</ArticleId></ArticleIdList></Reference><Reference><Citation>Marian, A. J. &amp; Braunwald, E. Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circ. Res. 121, 749&#x2013;770 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28912181</ArticleId><ArticleId IdType="pmc">5654557</ArticleId></ArticleIdList></Reference><Reference><Citation>Avolio, E., Campagnolo, P., Katare, R. &amp; Madeddu, P.The role of cardiac pericytes in health and disease: therapeutic targets for myocardial infarction. Nat. Rev. Cardiol. 21, 106&#x2013;118 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">37542118</ArticleId></ArticleIdList></Reference><Reference><Citation>Cattaneo, M. et al. The longevity-associated BPIFB4 gene supports cardiac function and vascularization in ageing cardiomyopathy. Cardiovasc. Res. 119, 1583&#x2013;1595 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36635236</ArticleId><ArticleId IdType="pmc">10318395</ArticleId></ArticleIdList></Reference><Reference><Citation>Rolle, I. G. et al. Heart failure impairs the mechanotransduction properties of human cardiac pericytes. J. Mol. Cell. Cardiol. 151, 15&#x2013;30 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33159916</ArticleId></ArticleIdList></Reference><Reference><Citation>Chintalgattu, V. et al. Coronary microvascular pericytes are the cellular target of sunitinib malate-induced cardiotoxicity. Sci. Transl. Med. 5, 187ra69 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23720580</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen, D. V., Hanson, J. E. &amp; Sheng, M. Microglia in Alzheimer&#x2019;s disease. J. Cell Biol. 217, 459&#x2013;472 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29196460</ArticleId><ArticleId IdType="pmc">5800817</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopes, K. et al. Genetic analysis of the human microglial transcriptome across brain regions, aging and disease pathologies. Nat. Genet. 54, 4&#x2013;17 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34992268</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosoy, R. et al. Genetics of the human microglia regulome refines Alzheimer&#x2019;s disease risk loci. Nat. Genet. 54, 1145&#x2013;1154 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35931864</ArticleId><ArticleId IdType="pmc">9388367</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellaver, B. et al. Astrocyte reactivity influences amyloid-&#x3b2; effects on tau pathology in preclinical Alzheimer&#x2019;s disease. Nat. Med. 29, 1775&#x2013;1781 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37248300</ArticleId><ArticleId IdType="pmc">10353939</ArticleId></ArticleIdList></Reference><Reference><Citation>Price, B. R., Johnson, L. A. &amp; Norris, C. M.Reactive astrocytes: the nexus of pathological and clinical hallmarks of Alzheimer&#x2019;s disease. Ageing Res. Rev. 68, 101335 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33812051</ArticleId><ArticleId IdType="pmc">8168445</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchanan, J., da Costa, N. M. &amp; Cheadle, L. Emerging roles of oligodendrocyte precursor cells in neural circuit development and remodeling. Trends Neurosci. 46, 628&#x2013;639 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37286422</ArticleId><ArticleId IdType="pmc">10524797</ArticleId></ArticleIdList></Reference><Reference><Citation>Sefik, E. et al. Inflammasome activation in infected macrophages drives COVID-19 pathology. Nature 606, 585&#x2013;593 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35483404</ArticleId><ArticleId IdType="pmc">9288243</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, S. T. et al. A shift in lung macrophage composition is associated with COVID-19 severity and recovery. Sci. Transl. Med. 14, eabn5168 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36103512</ArticleId><ArticleId IdType="pmc">10117220</ArticleId></ArticleIdList></Reference><Reference><Citation>Lian, Q. et al. Differential effects of macrophage subtypes on SARS-CoV-2 infection in a human pluripotent stem cell-derived model. Nat. Commun. 13, 2028 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35440562</ArticleId><ArticleId IdType="pmc">9018716</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, S. et al. Multiomic analysis reveals cell-type-specific molecular determinants of COVID-19 severity. Cell Syst. 13, 598&#x2013;614 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35690068</ArticleId><ArticleId IdType="pmc">9163145</ArticleId></ArticleIdList></Reference><Reference><Citation>Miorin, L. et al. SARS-CoV-2 Orf6 hijacks Nup98 to block STAT nuclear import and antagonize interferon signaling. Proc. Natl Acad. Sci. USA 117, 28344&#x2013;28354 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33097660</ArticleId><ArticleId IdType="pmc">7668094</ArticleId></ArticleIdList></Reference><Reference><Citation>Vietzen, H. et al. Deletion of the NKG2C receptor encoding KLRC2 gene and HLA-E variants are risk factors for severe COVID-19. Genet. Med. 23, 963&#x2013;967 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33500568</ArticleId><ArticleId IdType="pmc">7835668</ArticleId></ArticleIdList></Reference><Reference><Citation>Maucourant, C. et al. Natural killer cell immunotypes related to COVID-19 disease severity. Sci. Immunol. 5, eabd6832 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32826343</ArticleId><ArticleId IdType="pmc">7665314</ArticleId></ArticleIdList></Reference><Reference><Citation>Wack, A. Monocyte and dendritic cell defects in COVID-19. Nat. Cell Biol. 23, 445&#x2013;447 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33972732</ArticleId></ArticleIdList></Reference><Reference><Citation>Saichi, M. et al. Single-cell RNA sequencing of blood antigen-presenting cells in severe COVID-19 reveals multi-process defects in antiviral immunity. Nat. Cell Biol. 23, 538&#x2013;551 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33972731</ArticleId></ArticleIdList></Reference><Reference><Citation>Arunachalam, P. S. et al. Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans. Science 369, 1210&#x2013;1220 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32788292</ArticleId><ArticleId IdType="pmc">7665312</ArticleId></ArticleIdList></Reference><Reference><Citation>de Leeuw, C. A., Mooij, J. M. &amp; Heskes, T. MAGMA: generalized gene-set analysis of GWAS data. PLoS Comput. Biol. 11, e1004219 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25885710</ArticleId><ArticleId IdType="pmc">4401657</ArticleId></ArticleIdList></Reference><Reference><Citation>Pliner, H. A. et al. Cicero predicts cis-regulatory DNA interactions from single-cell chromatin accessibility data. Mol. Cell 71, 858&#x2013;871 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30078726</ArticleId><ArticleId IdType="pmc">6582963</ArticleId></ArticleIdList></Reference><Reference><Citation>Gazal, S. et al. Combining SNP-to-gene linking strategies to identify disease genes and assess disease omnigenicity. Nat. Genet. 54, 827&#x2013;836 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35668300</ArticleId><ArticleId IdType="pmc">9894581</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou, J. &amp; Troyanskaya, O. G. Predicting effects of noncoding variants with deep learning-based sequence model. Nat. Methods 12, 931&#x2013;934 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26301843</ArticleId><ArticleId IdType="pmc">4768299</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou, J. et al. Deep learning sequence-based ab initio prediction of variant effects on expression and disease risk. Nat. Genet. 50, 1171&#x2013;1179 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30013180</ArticleId><ArticleId IdType="pmc">6094955</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, K. M., Cofer, E. M., Zhou, J. &amp; Troyanskaya, O. G. Selene: a PyTorch-based deep learning library for sequence data. Nat. Methods 16, 315&#x2013;318 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30923381</ArticleId><ArticleId IdType="pmc">7148117</ArticleId></ArticleIdList></Reference><Reference><Citation>De Bortoli, M. et al. Novel missense variant in MYL2 gene associated with hypertrophic cardiomyopathy showing high incidence of restrictive physiology. Circ. Genom. Precis. Med. 13, e002824 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32004434</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee, J. et al. Tead1 reciprocally regulates adult &#x3b2;-cell proliferation and function. eLife 13, RP95603 (2024).</Citation></Reference><Reference><Citation>Katoh, M. C. et al. MafB is critical for glucagon production and secretion in mouse pancreatic &#x3b1; cells in vivo. Mol. Cell Biol. 38, e00504-17 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29378833</ArticleId><ArticleId IdType="pmc">5879460</ArticleId></ArticleIdList></Reference><Reference><Citation>Artner, I. et al. MafB is required for islet beta cell maturation. Proc. Natl. Acad. Sci. USA. 104, 3853&#x2013;3858 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17360442</ArticleId><ArticleId IdType="pmc">1803762</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee, K. et al. XBP1 maintains beta cell identity, represses beta-to-alpha cell transdifferentiation and protects against diabetic beta cell failure during metabolic stress in mice. Diabetologia 65, 984&#x2013;996 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35316840</ArticleId><ArticleId IdType="pmc">9076738</ArticleId></ArticleIdList></Reference><Reference><Citation>V&#xf5;sa, U. et al. Large-scale cis- and trans-eQTL analyses identify thousands of genetic loci and polygenic scores that regulate blood gene expression. Nat. Genet. 53, 1300&#x2013;1310 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34475573</ArticleId><ArticleId IdType="pmc">8432599</ArticleId></ArticleIdList></Reference><Reference><Citation>GTEx Consortium The GTEx Consortium atlas of genetic regulatory effects across human tissues. Science 369, 1318&#x2013;1330 (2020).</Citation></Reference><Reference><Citation>Kerimov, N. et al. A compendium of uniformly processed human gene expression and splicing quantitative trait loci. Nat. Genet. 53, 1290&#x2013;1299 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34493866</ArticleId><ArticleId IdType="pmc">8423625</ArticleId></ArticleIdList></Reference><Reference><Citation>Alonso, L. et al. TIGER: the gene expression regulatory variation landscape of human pancreatic islets. Cell Rep. 37, 109807 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34644572</ArticleId><ArticleId IdType="pmc">8864863</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar, S., Ambrosini, G. &amp; Bucher, P. SNP2TFBS&#x2014;a database of regulatory SNPs affecting predicted transcription factor binding site affinity. Nucleic Acids Res. 45, D139&#x2013;D144 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">27899579</ArticleId></ArticleIdList></Reference><Reference><Citation>Kong, Y., Sharma, R. B., Nwosu, B. U. &amp; Alonso, L. C. Islet biology, the CDKN2A/B locus and type 2 diabetes risk. Diabetologia 59, 1579&#x2013;1593 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27155872</ArticleId><ArticleId IdType="pmc">4930689</ArticleId></ArticleIdList></Reference><Reference><Citation>Coetzee, S. G., Coetzee, G. A. &amp; Hazelett, D. J. motifbreakR: an R/Bioconductor package for predicting variant effects at transcription factor binding sites. Bioinformatics 31, 3847&#x2013;3849 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26272984</ArticleId><ArticleId IdType="pmc">4653394</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang, J., Chirikjian, M., Pajvani, U. B. &amp; Bartolom&#xe9;, A. MafA regulation in &#x3b2;-cells: from transcriptional to post-translational mechanisms. Biomolecules 12, 535 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35454124</ArticleId><ArticleId IdType="pmc">9033020</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, R. et al. Tead1 is required for maintaining adult cardiomyocyte function, and its loss results in lethal dilated cardiomyopathy. JCI Insight 2, e93343 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28878117</ArticleId><ArticleId IdType="pmc">5621883</ArticleId></ArticleIdList></Reference><Reference><Citation>Pikkarainen, S., Tokola, H., Kerkel&#xe4;, R. &amp; Ruskoaho, H. GATA transcription factors in the developing and adult heart. Cardiovasc. Res. 63, 196&#x2013;207 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15249177</ArticleId></ArticleIdList></Reference><Reference><Citation>Pashmforoush, M. et al. Nkx2-5 pathways and congenital heart disease; loss of ventricular myocyte lineage specification leads to progressive cardiomyopathy and complete heart block. Cell 117, 373&#x2013;386 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15109497</ArticleId></ArticleIdList></Reference><Reference><Citation>Di&#xe9;guez-Hurtado, R. et al. Loss of the transcription factor RBPJ induces disease-promoting properties in brain pericytes. Nat. Commun. 10, 1&#x2013;19 (2019).</Citation></Reference><Reference><Citation>Haghikia, A., Ricke-Hoch, M., Stapel, B., Gorst, I. &amp; Hilfiker-Kleiner, D. STAT3, a key regulator of cell-to-cell communication in the heart. Cardiovasc. Res. 102, 281&#x2013;289 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24518140</ArticleId></ArticleIdList></Reference><Reference><Citation>Szklarczyk, D. et al. The STRING database in 2023: protein&#x2013;protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res. 51, D638&#x2013;D646 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36370105</ArticleId></ArticleIdList></Reference><Reference><Citation>Nag, S., Gollapudi, S. K., Del Rio, C. L., Spudich, J. A. &amp; McDowell, R. Mavacamten, a precision medicine for hypertrophic cardiomyopathy: from a motor protein to patients. Sci Adv 9, eabo7622 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37506209</ArticleId></ArticleIdList></Reference><Reference><Citation>Teerlink, J. R. et al. Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure. N. Engl. J. Med. 384, 105&#x2013;116 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33185990</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaffin, M. et al. Single-nucleus profiling of human dilated and hypertrophic cardiomyopathy. Nature 608, 174&#x2013;180 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35732739</ArticleId></ArticleIdList></Reference><Reference><Citation>GTEx Consortium Genetic effects on gene expression across human tissues. Nature 550, 204&#x2013;213 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">5776756</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma, L. et al. ZNF382 controls mouse neuropathic pain via silencer-based epigenetic inhibition of Cxcl13 in DRG neurons. J. Exp. Med. 218, e20210920 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34762123</ArticleId><ArticleId IdType="pmc">8590274</ArticleId></ArticleIdList></Reference><Reference><Citation>Agnihotri, S., Wolf, A., Picard, D., Hawkins, C. &amp; Guha, A. GATA4 is a regulator of astrocyte cell proliferation and apoptosis in the human and murine central nervous system. Oncogene 28, 3033&#x2013;3046 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19543315</ArticleId></ArticleIdList></Reference><Reference><Citation>Crotti, A. &amp; Ransohoff, R. M. Microglial Physiology and pathophysiology: insights from genome-wide transcriptional profiling. Immunity 44, 505&#x2013;515 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26982357</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujimoto, M. et al. RBP-J promotes neuronal differentiation and inhibits oligodendroglial development in adult neurogenesis. Dev. Biol. 332, 339&#x2013;350 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19501584</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, Z. et al. Astrocytic response mediated by the CLU risk allele inhibits OPC proliferation and myelination in a human iPSC model. Cell Rep. 42, 112841 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37494190</ArticleId><ArticleId IdType="pmc">10510531</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang, X. et al. Functional characterization of Alzheimer&#x2019;s disease genetic variants in microglia. Nat. Genet. 55, 1735&#x2013;1744 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37735198</ArticleId><ArticleId IdType="pmc">10939305</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin, C. et al. Crucial role of the transcription factors family activator protein 2 in cancer: current clue and views. J. Transl. Med. 21, 371 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37291585</ArticleId><ArticleId IdType="pmc">10249218</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi, Y. et al. Identification and therapeutic rescue of autophagosome and glutamate receptor defects in C9ORF72 and sporadic ALS neurons. JCI Insight 5, e127736 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31310593</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi, Y. et al. Haploinsufficiency leads to neurodegeneration in C9ORF72 ALS/FTD human induced motor neurons. Nat. Med. 24, 313&#x2013;325 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29400714</ArticleId><ArticleId IdType="pmc">6112156</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdellaoui, A., Yengo, L., Verweij, K. J. H. &amp; Visscher, P. M. 15 years of GWAS discovery: realizing the promise. Am. J. Hum. Genet. 110, 179&#x2013;194 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36634672</ArticleId><ArticleId IdType="pmc">9943775</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, Y. et al. Global Biobank analyses provide lessons for developing polygenic risk scores across diverse cohorts. Cell Genom. 3, 100241 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36777179</ArticleId><ArticleId IdType="pmc">9903818</ArticleId></ArticleIdList></Reference><Reference><Citation>Manolio, T. A. et al. Finding the missing heritability of complex diseases. Nature 461, 747&#x2013;753 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19812666</ArticleId><ArticleId IdType="pmc">2831613</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou, W. et al. Global Biobank Meta-analysis Initiative: powering genetic discovery across human disease. Cell Genom. 2, 100192 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36777996</ArticleId><ArticleId IdType="pmc">9903716</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, S. et al. Genome-wide identification of the genetic basis of amyotrophic lateral sclerosis. Neuron 110, 992&#x2013;1008 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35045337</ArticleId><ArticleId IdType="pmc">9017397</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, X. et al. Interpretable deep learning: interpretation, interpretability, trustworthiness and beyond. Knowl. Inf. Syst. 64, 3197&#x2013;3234 (2022).</Citation></Reference><Reference><Citation>Zhang, F. &amp; Lupski, J. R. Non-coding genetic variants in human disease. Hum. Mol. Genet. 24, R102&#x2013;R110 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26152199</ArticleId><ArticleId IdType="pmc">4572001</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, M. J. et al. Polygenic enrichment distinguishes disease associations of individual cells in single-cell RNA-seq data. Nat. Genet. 54, 1572&#x2013;1580 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36050550</ArticleId><ArticleId IdType="pmc">9891382</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma, Y. et al. Polygenic regression uncovers trait-relevant cellular contexts through pathway activation transformation of single-cell RNA sequencing data. Cell Genom. 3, 100383 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37719150</ArticleId><ArticleId IdType="pmc">10504677</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, Y. E. et al. A comparative atlas of single-cell chromatin accessibility in the human brain. Science 382, eadf7044 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37824643</ArticleId><ArticleId IdType="pmc">10852054</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith, B. N. et al. Mutations in the vesicular trafficking protein annexin A11 are associated with amyotrophic lateral sclerosis. Sci. Transl. Med. 9, eaad9157 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28469040</ArticleId><ArticleId IdType="pmc">6599403</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder, A. et al. An ANXA11 P93S variant dysregulates TDP-43 and causes corticobasal syndrome. Alzheimers. Dement. 20, 5220&#x2013;5235 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38923692</ArticleId><ArticleId IdType="pmc">11350008</ArticleId></ArticleIdList></Reference><Reference><Citation>Arseni, D. et al. Heteromeric amyloid filaments of ANXA11 and TDP-43 in FTLD-TDP type C. Nature 634, 662&#x2013;668 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">39260416</ArticleId><ArticleId IdType="pmc">11485244</ArticleId></ArticleIdList></Reference><Reference><Citation>Leoni, T. B. et al. A novel multisystem proteinopathy caused by a missense ANXA11 variant. Ann. Neurol. 90, 239&#x2013;252 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34048612</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao, Y.-C. et al. RNA granules hitchhike on lysosomes for long-distance transport, using annexin A11 as a molecular tether. Cell 179, 147&#x2013;164 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31539493</ArticleId><ArticleId IdType="pmc">6890474</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerbino, V. et al. The loss of TBK1 kinase activity in motor neurons or in all cell types differentially impacts ALS disease progression in SOD1 mice. Neuron 106, 789&#x2013;805 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32220666</ArticleId></ArticleIdList></Reference><Reference><Citation>Tadros, R. et al. Shared genetic pathways contribute to risk of hypertrophic and dilated cardiomyopathies with opposite directions of effect. Nat. Genet. 53, 128&#x2013;134 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33495596</ArticleId><ArticleId IdType="pmc">7611259</ArticleId></ArticleIdList></Reference><Reference><Citation>Harper, A. R. et al. Common genetic variants and modifiable risk factors underpin hypertrophic cardiomyopathy susceptibility and expressivity. Nat. Genet. 53, 135&#x2013;142 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33495597</ArticleId><ArticleId IdType="pmc">8240954</ArticleId></ArticleIdList></Reference><Reference><Citation>Yazar, S. et al. Single-cell eQTL mapping identifies cell type-specific genetic control of autoimmune disease. Science 376, eabf3041 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35389779</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Wijst, M. G. P. et al. Single-cell RNA sequencing identifies celltype-specific cis-eQTLs and co-expression QTLs. Nat. Genet. 50, 493&#x2013;497 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29610479</ArticleId><ArticleId IdType="pmc">5905669</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang, J. B., Raveane, A., Nathan, A., Soranzo, N. &amp; Raychaudhuri, S. Methods and insights from single-cell expression quantitative trait loci. Annu. Rev. Genomics Hum. Genet. 24, 277&#x2013;303 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37196361</ArticleId><ArticleId IdType="pmc">10784788</ArticleId></ArticleIdList></Reference><Reference><Citation>Eraslan, G. et al. Single-nucleus cross-tissue molecular reference maps toward understanding disease gene function. Science 376, eabl4290 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35549429</ArticleId><ArticleId IdType="pmc">9383269</ArticleId></ArticleIdList></Reference><Reference><Citation>Siletti, K. et al. Transcriptomic diversity of cell types across the adult human brain. Science 382, eadd7046 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37824663</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo, C. et al. Single-cell methylomes identify neuronal subtypes and regulatory elements in mammalian cortex. Science 357, 600&#x2013;604 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28798132</ArticleId><ArticleId IdType="pmc">5570439</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian, W. et al. Single-cell DNA methylation and 3D genome architecture in the human brain. Science 382, eadf5357 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37824674</ArticleId><ArticleId IdType="pmc">10572106</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf, F. A., Angerer, P. &amp; Theis, F. J. SCANPY: large-scale single-cell gene expression data analysis. Genome Biol. 19, 15 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29409532</ArticleId><ArticleId IdType="pmc">5802054</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolock, S. L., Lopez, R. &amp; Klein, A. M. Scrublet: computational identification of cell doublets in single-cell transcriptomic data. Cell Syst 8, 281&#x2013;291 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30954476</ArticleId><ArticleId IdType="pmc">6625319</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, H. et al. Single-cell DNA methylome and 3D multi-omic atlas of the adult mouse brain. Nature 624, 366&#x2013;377 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">38092913</ArticleId><ArticleId IdType="pmc">10719113</ArticleId></ArticleIdList></Reference><Reference><Citation>Litvi&#x148;ukov&#xe1;, M. et al. Cells of the adult human heart. Nature 588, 466&#x2013;472 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32971526</ArticleId><ArticleId IdType="pmc">7681775</ArticleId></ArticleIdList></Reference><Reference><Citation>Tucker, N. R. et al. Transcriptional and cellular diversity of the human heart. Circulation 142, 466&#x2013;482 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32403949</ArticleId><ArticleId IdType="pmc">7666104</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, K., Zemke, N. R., Armand, E. J. &amp; Ren, B. A fast, scalable and versatile tool for analysis of single-cell omics data. Nat. Methods 21, 217&#x2013;227 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38191932</ArticleId><ArticleId IdType="pmc">10864184</ArticleId></ArticleIdList></Reference><Reference><Citation>Korsunsky, I. et al. Fast, sensitive and accurate integration of single-cell data with Harmony. Nat. Methods 16, 1289&#x2013;1296 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31740819</ArticleId><ArticleId IdType="pmc">6884693</ArticleId></ArticleIdList></Reference><Reference><Citation>Kendig, K. I. et al. Sentieon DNASeq variant calling workflow demonstrates strong computational performance and accuracy. Front. Genet. 10, 736 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31481971</ArticleId><ArticleId IdType="pmc">6710408</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, H. &amp; Durbin, R. Fast and accurate short read alignment with Burrows&#x2013;Wheeler transform. Bioinformatics 25, 1754&#x2013;1760 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19451168</ArticleId><ArticleId IdType="pmc">2705234</ArticleId></ArticleIdList></Reference><Reference><Citation>DePristo, M. A. et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat. Genet. 43, 491&#x2013;498 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21478889</ArticleId><ArticleId IdType="pmc">3083463</ArticleId></ArticleIdList></Reference><Reference><Citation>Song, R. J. et al. Phenome-wide association of 1809 phenotypes and COVID-19 disease progression in the Veterans Health Administration Million Veteran Program. PLoS ONE 16, e0251651 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33984066</ArticleId><ArticleId IdType="pmc">8118298</ArticleId></ArticleIdList></Reference><Reference><Citation>Regier, A. A. et al. Functional equivalence of genome sequencing analysis pipelines enables harmonized variant calling across human genetics projects. Nat. Commun. 9, 4038 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30279509</ArticleId><ArticleId IdType="pmc">6168605</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilmer, J., Schoenholz, S. S., Riley, P. F., Vinyals, O. &amp; Dahl, G. E. Neural message passing for quantum chemistry. Preprint at https://doi.org/10.48550/arXiv.1704.01212 (2017).</Citation></Reference><Reference><Citation>Kingma, D. P. &amp; Ba, J. Adam: a method for stochastic optimization. Preprint at https://doi.org/10.48550/arXiv.1412.6980 (2014).</Citation></Reference><Reference><Citation>Karczewski, K. J. et al. Pan-UK Biobank GWAS improves discovery, analysis of genetic architecture, and resolution into ancestry-enriched effects. Preprint at medRxiv https://doi.org/10.1101/2024.03.13.24303864 (2024).</Citation></Reference><Reference><Citation>Ulirsch, J. C. et al. Interrogation of human hematopoiesis at single-cell and single-variant resolution. Nat. Genet. 51, 683&#x2013;693 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30858613</ArticleId><ArticleId IdType="pmc">6441389</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahajan, A. et al. Fine-mapping type 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome maps. Nat Genet 50, 1505&#x2013;1513 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30297969</ArticleId><ArticleId IdType="pmc">6287706</ArticleId></ArticleIdList></Reference><Reference><Citation>Stuart, T., Srivastava, A., Madad, S., Lareau, C. A. &amp; Satija, R. Single-cell chromatin state analysis with Signac. Nat. Methods 18, 1333&#x2013;1341 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34725479</ArticleId><ArticleId IdType="pmc">9255697</ArticleId></ArticleIdList></Reference><Reference><Citation>Fulco, C. P. et al. Activity-by-contact model of enhancer&#x2013;promoter regulation from thousands of CRISPR perturbations. Nat. Genet. 51, 1664&#x2013;1669 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31784727</ArticleId><ArticleId IdType="pmc">6886585</ArticleId></ArticleIdList></Reference><Reference><Citation>van Heeringen, S. J. &amp; Veenstra, G. J. C. GimmeMotifs: a de novo motif prediction pipeline for ChIP-sequencing experiments. Bioinformatics 27, 270&#x2013;271 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21081511</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishnan, A. et al. Genome-wide prediction and functional characterization of the genetic basis of autism spectrum disorder. Nat. Neurosci. 19, 1454&#x2013;1462 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27479844</ArticleId><ArticleId IdType="pmc">5803797</ArticleId></ArticleIdList></Reference><Reference><Citation>Blondel, V. D., Guillaume, J.-L., Lambiotte, R. &amp; Lefebvre, E. Fast unfolding of communities in large networks. J. Stat. Mech. 2008, P10008 (2008).</Citation></Reference><Reference><Citation>Amemiya, H. M., Kundaje, A. &amp; Boyle, A. P. The ENCODE blacklist: identification of problematic regions of the genome. Sci. Rep. 9, 9354 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31249361</ArticleId><ArticleId IdType="pmc">6597582</ArticleId></ArticleIdList></Reference><Reference><Citation>Gruber, J. J. et al. Chromatin remodeling in response to BRCA2-Crisis. Cell Rep. 28, 2182&#x2013;2193 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31433991</ArticleId><ArticleId IdType="pmc">6754178</ArticleId></ArticleIdList></Reference><Reference><Citation>Burridge, P. W. et al. Chemically defined generation of human cardiomyocytes. Nat. Methods 11, 855&#x2013;860 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24930130</ArticleId><ArticleId IdType="pmc">4169698</ArticleId></ArticleIdList></Reference><Reference><Citation>Love, M. I., Huber, W. &amp; Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25516281</ArticleId><ArticleId IdType="pmc">4302049</ArticleId></ArticleIdList></Reference><Reference><Citation>Song, M. et al. Mapping cis-regulatory chromatin contacts in neural cells links neuropsychiatric disorder risk variants to target genes. Nat. Genet. 51, 1252&#x2013;1262 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31367015</ArticleId><ArticleId IdType="pmc">6677164</ArticleId></ArticleIdList></Reference><Reference><Citation>Bryois, J. et al. Cell-type-specific cis-eQTLs in eight human brain cell types identify novel risk genes for psychiatric and neurological disorders. Nat. Neurosci. 25, 1104&#x2013;1112 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35915177</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40715278</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>26</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Corticosteroids in immunocompromised ICU patients with severe COVID-19: a multicenter retrospective study.</ArticleTitle><Pagination><StartPage>27252</StartPage><MedlinePgn>27252</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-025-10864-8</ELocationID><Abstract><AbstractText>Immunocompromised patients were excluded most of the time from trials testing corticosteroids in COVID-19. This study aimed to assess the associations between early corticosteroid use and (1) mortality at day 60, and (2) the occurrence of nosocomial infections in immunocompromised patients with severe COVID-19 admitted to the ICU. It was a multicentre retrospective study, achieved in French ICUs of the Outcomerea&#x2122; network and medical ICUs of 4 other hospitals in France. This study included immunocompromised patients admitted to an ICU between January 1, 2020, and August 31, 2022, for severe COVID-19, with an ICU stay of more than 2 days. Patients were classified as receiving early corticosteroid therapy if they were given steroids within the first 5 days following ICU admission. Each patient was categorized into one of four immunosuppression subgroups: 'corticosteroid therapy,' 'monocytic alteration,' 'cellular immunosuppression,' or 'humoral immunosuppression.' Survival analyses were performed, and confounding by indication was addressed using propensity score weighting with overlap. 383 patients were included, 50 were into the no-early-corticosteroids group and 333 in the early-corticosteroids group. In the overlap cohort, 118 were included (46 in the non-early-corticosteroids and 72 in the early-corticosteroids group). There was no association with day-60 mortality (<sub>IPTWoverlap</sub>HR&#x2009;=&#x2009;0.97, 95% CI [0.51; 1.85], p&#x2009;=&#x2009;0.92). There was also no association with the occurrence of nosocomial infections (<sub>IPTWoverlap</sub>SubHR&#x2009;=&#x2009;2.59, CI 95% [0.77; 8.7], p&#x2009;=&#x2009;0.13). We report that steroids had no benefit on mortality in immunocompromised patients admitted to ICU for severe COVID-19.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dupuis</LastName><ForeName>Claire</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Medical Intensive Care Unit, University Hospital Gabriel Montpied, 63000, Clermont-Ferrand, France. cdupuis1@chu-clermontferrand.fr.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unit&#xe9; de Nutrition Humaine, INRAe, CRNH Auvergne, Universit&#xe9; Clermont Auvergne, 63000, Clermont-Ferrand, France. cdupuis1@chu-clermontferrand.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Timsit</LastName><ForeName>Jean-Fran&#xe7;ois</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>OUTCOMEREA Network, 93700, Drancy, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical and Infectious Diseases ICU (MI2), AP-HP, Bichat Hospital, 75018, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IAME, INSERM, University Paris-Cit&#xe9;, 75018, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Domitile</LastName><ForeName>Julien</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Medical Intensive Care Unit, University Hospital Gabriel Montpied, 63000, Clermont-Ferrand, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klouche</LastName><ForeName>Kada</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Intensive Care Medicine, Lapeyronie University Hospital, PhyMedExp, INSERM, CNRS, University of Montpellier, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calvet</LastName><ForeName>Laure</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Medical Intensive Care Unit, University Hospital Gabriel Montpied, 63000, Clermont-Ferrand, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neuville</LastName><ForeName>Mathilde</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Polyvalent Intensive Care Unit, H&#xf4;pital Foch, 92150, Suresnes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siami</LastName><ForeName>Shidasp</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>General Intensive Care Unit, Sud Essonne Hospital, 91150, Etampes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>Yves</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Intensive Care Unit, University Hospital Avicenne, AP-HP, 93000, Bobigny, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laurent</LastName><ForeName>Virginie</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Polyvalent Intensive Care Unit, Andr&#xe9; Mignot Hospital, 78150, Le Chesnay, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mourvillier</LastName><ForeName>Bruno</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Medical Intensive Care Unit, University Hospital of Reims, 51100, Reims, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CardioVir - Infections Cardiovasculaires Virales et Inflammation en Pathologie Humaine (CardioVir) UMR-S 1320, Universit&#xe9; de Reims Champagne-Ardenne, 51100, Reims, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldgran-Toledano</LastName><ForeName>Dany</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Medical and Surgical Intensive Care, Montfermeil Hospital, 93370, Montfermeil, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schwebel</LastName><ForeName>Carole</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Medical Intensive Care Unit, University Hospital Grenoble-Alpes, 38000, Grenoble, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruckly</LastName><ForeName>St&#xe9;phane</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>OUTCOMEREA Network, 93700, Drancy, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IAME, INSERM, University Paris-Cit&#xe9;, 75018, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meziani</LastName><ForeName>Ferhat</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Facult&#xe9; de M&#xe9;decine, H&#xf4;pitaux Universitaires de Strasbourg, Service de M&#xe9;decine Intensive-R&#xe9;animation, Nouvel H&#xf4;pital Civil, Universit&#xe9; de Strasbourg (UNISTRA), 1, Place de l'H&#xf4;pital, 67091, Strasbourg Cedex, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raymond</LastName><ForeName>Matthieu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Medical Intensive Care Unit, University Hospital of Nantes, 44000, Nantes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dessap</LastName><ForeName>Armand Mekontso</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Service de R&#xe9;animation M&#xe9;dicale, DHU A-TVB, H&#xf4;pitaux Universitaires Henri Mondor, Assistance Publique-H&#xf4;pitaux de Paris, Groupe de Recherche Clinique CARMAS, Facult&#xe9; de M&#xe9;decine de Cr&#xe9;teil, Universit&#xe9; Paris Est Cr&#xe9;teil, 94010, Cr&#xe9;teil Cedex, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Souweine</LastName><ForeName>Bertrand</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Medical Intensive Care Unit, University Hospital Gabriel Montpied, 63000, Clermont-Ferrand, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CNRS, LMGE, Universit&#xe9; Clermont Auvergne, Clermont-Ferrand, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">ICU</Keyword><Keyword MajorTopicYN="N">Immunosuppression</Keyword><Keyword MajorTopicYN="N">Nosocomial infections</Keyword><Keyword MajorTopicYN="N">Outcomes</Keyword><Keyword MajorTopicYN="N">Steroids</Keyword></KeywordList><CoiStatement>Declarations. Competing interests: The authors declare no competing interests. Ethics approval and consent to participate: The study was approved by the ethics committee of the Soci&#xe9;t&#xe9; de R&#xe9;animation de Langue Fran&#xe7;aise (SRLF) (Institutional Review Board (IRB)&#xa0;00014135) (Project number: 22-060) (Project number: 22-060) and complied with the Declaration of Helsinki and good clinical practice. Due to the retrospective nature of the study, the need for approval was waived by the IRB.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>27</Day><Hour>11</Hour><Minute>30</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40715278</ArticleId><ArticleId IdType="doi">10.1038/s41598-025-10864-8</ArticleId><ArticleId IdType="pii">10.1038/s41598-025-10864-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rhen, T. &amp; Cidlowski, J. A. Antiinflammatory action of glucocorticoids&#x2013;new mechanisms for old drugs. N. Engl. J. Med. 353, 1711&#x2013;1723 (2005).</Citation></Reference><Reference><Citation>ECOVERY Collaborative Group et al. Dexamethasone in hospitalized patients with Covid-19. N. Engl. J. Med. 384, 693&#x2013;704 (2021).</Citation></Reference><Reference><Citation>The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: A meta-analysis. JAMA 324, 1330 (2020).</Citation></Reference><Reference><Citation>Bruse, N. et al. Clinical phenotyping uncovers heterogeneous associations between corticosteroid treatment and survival in critically ill COVID-19 patients. Intensive Care Med. 50, 1884&#x2013;1896 (2024).</Citation></Reference><Reference><Citation>Wicky, P.-H. et al. Ventilator-associated pneumonia in COVID-19 patients admitted in intensive care units: relapse, therapeutic failure and attributable mortality-A multicentric observational study from the OutcomeRea network. J. Clin. Med. 12, 1298 (2023).</Citation></Reference><Reference><Citation>Laurichesse, G. et al. Mortality, incidence, and microbiological documentation of ventilated acquired pneumonia (VAP) in critically ill patients with COVID-19 or influenza. Ann. Intensive Care 13, 108 (2023).</Citation></Reference><Reference><Citation>Buetti, N. et al. COVID-19 increased the risk of ICU-acquired bloodstream infections: A case-cohort study from the multicentric OUTCOMEREA network. Intensive Care Med. 47, 180&#x2013;187 (2021).</Citation></Reference><Reference><Citation>Rouz&#xe9;, A. et al. Relationship between SARS-CoV-2 infection and the incidence of ventilator-associated lower respiratory tract infections: A European multicenter cohort study. Intensive Care Med. 47, 188&#x2013;198 (2021).</Citation></Reference><Reference><Citation>Azoulay, E. et al. Diagnosis of severe respiratory infections in immunocompromised patients. Intensive Care Med. 46, 298&#x2013;314 (2020).</Citation></Reference><Reference><Citation>Siempos, I. I. et al. Immunomodulators for immunocompromised patients hospitalized for COVID-19: A meta-analysis of randomized controlled trials. eClinicalMedicine 69, 102472 (2024).</Citation></Reference><Reference><Citation>Chaudhuri, D. et al. 2024 focused update: Guidelines on use of corticosteroids in sepsis, acute respiratory distress syndrome, and community-acquired pneumonia. Crit. Care Med. 52, e219&#x2013;e233 (2024).</Citation></Reference><Reference><Citation>Agarwal, A. et al. A living WHO guideline on drugs for covid-19. BMJ 370, m3379 (2020).</Citation></Reference><Reference><Citation>Pereira, M. R. et al. COVID-19 in solid organ transplant recipients: Initial report from the US epicenter. Am. J. Transplant. 20, 1800&#x2013;1808 (2020).</Citation></Reference><Reference><Citation>Passamonti, F. et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: A retrospective, multicentre, cohort study. Lancet Haematol. 7, e737&#x2013;e745 (2020).</Citation></Reference><Reference><Citation>Turtle, L. et al. Outcome of COVID-19 in hospitalised immunocompromised patients: An analysis of the WHO ISARIC CCP-UK prospective cohort study. PLoS Med 20, e1004086 (2023).</Citation></Reference><Reference><Citation>Dul&#xe9;ry, R. et al. Prolonged in-hospital stay and higher mortality after Covid-19 among patients with non-Hodgkin lymphoma treated with B-cell depleting immunotherapy. Am. J. Hematol. 96, 934&#x2013;944 (2021).</Citation></Reference><Reference><Citation>Nakajima, Y. et al. Prolonged viral shedding of SARS-CoV-2 in an immunocompromised patient. J. Infect. Chemother. 27, 387&#x2013;389 (2021).</Citation></Reference><Reference><Citation>Kim, C. S. et al. Nosocomial outbreak of COVID-19 from a Kidney transplant patient: Necessity of a longer isolation period in immunocompromised patients. Infect. Chemother. 55, 42&#x2013;49 (2023).</Citation></Reference><Reference><Citation>Planquette, B. et al. Pseudomonas aeruginosa ventilator-associated pneumonia. Predictive factors of treatment failure. Am. J. Respir. Crit. Care Med. 188, 69&#x2013;76 (2013).</Citation></Reference><Reference><Citation>Calandra, T., Cohen, J., International Sepsis Forum Definition of Infection in the ICU Consensus Conference. The international sepsis forum consensus conference on definitions of infection in the intensive care unit. Crit. Care Med. 33, 1538&#x2013;1548 (2005).</Citation></Reference><Reference><Citation>Vacheron, C.-H. et al. Increased incidence of ventilator-acquired pneumonia in coronavirus disease 2019 patients: A multicentric cohort study. Crit. Care Med. 50, 449&#x2013;459 (2022).</Citation></Reference><Reference><Citation>Boers, L. S. et al. Pulmonary herpes simplex virus and cytomegalovirus in patients with acute respiratory distress syndrome related to COVID-19. Intensive Care Med. 50, 1251&#x2013;1264 (2024).</Citation></Reference><Reference><Citation>Koehler, P. et al. Defining and managing COVID-19-associated pulmonary aspergillosis: The 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. Lancet Infect. Dis. 21, e149&#x2013;e162 (2021).</Citation></Reference><Reference><Citation>Knaus, W. A. et al. The APACHE III prognostic system. Chest 100, 1619&#x2013;1636 (1991).</Citation></Reference><Reference><Citation>A New Simplified Acute Physiology Score (SAPS II) Based on a European/North American Multicenter Study |JAMA| JAMA Network. https://jamanetwork-com.ezproxy.u-paris.fr/journals/jama/article-abstract/409979 .</Citation></Reference><Reference><Citation>Vincent, J.-L., de Mendonca, A., Cantraine, F., Moreno, R., Takala, J., Suter, P. M., Sprung, C. L., Colardyn, F., Blecher, S. Ovid: Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: Results of a multicenter, prospective study. https://ovidsp-dc1-ovid-com.ezproxy.u-paris.fr/ovid-b/ovidweb.cgi?&amp;S=OKIAFPDKLAACMGAGKPMJJHPMBIPFAA00&amp;Link+Set=S.sh.22.23.27.39%7c16%7csl_10 .</Citation></Reference><Reference><Citation>Li, F., Thomas, L. E. &amp; Li, F. Addressing Extreme propensity scores via the overlap weights. Am. J. Epidemiol. 188, 250&#x2013;257 (2019).</Citation></Reference><Reference><Citation>Thomas, L. E., Li, F. &amp; Pencina, M. J. Overlap weighting: A propensity score method that mimics attributes of a randomized clinical trial. JAMA 323, 2417&#x2013;2418 (2020).</Citation></Reference><Reference><Citation>Austin, P. C. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav. Res. 46, 399&#x2013;424 (2011).</Citation></Reference><Reference><Citation>Austin, P. C. &amp; Stuart, E. A. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat. Med. 34, 3661&#x2013;3679 (2015).</Citation></Reference><Reference><Citation>Moore, K. L., Neugebauer, R., Laan, M. J. &amp; Tager, I. B. Causal inference in epidemiological studies with strong confounding. Stat. Med. 31, 1380&#x2013;1404 (2012).</Citation></Reference><Reference><Citation>Austin, P. C., Grootendorst, P. &amp; Anderson, G. M. A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: A Monte Carlo study. Stat. Med. 26, 734&#x2013;753 (2007).</Citation></Reference><Reference><Citation>Hern&#xe1;n, M. A. &amp; Robins, J. M. Causal Inference. (2016).</Citation></Reference><Reference><Citation>Fine, J. P. &amp; Gray, R. J. A Proportional hazards model for the subdistribution of a competing risk. J. Am. Stat. Assoc. 94, 496&#x2013;509 (1999).</Citation></Reference><Reference><Citation>Wolkewitz, M., Cooper, B. S., Bonten, M. J. M., Barnett, A. G. &amp; Schumacher, M. Interpreting and comparing risks in the presence of competing events. BMJ 349, g5060 (2014).</Citation></Reference><Reference><Citation>Garc&#xed;a-Su&#xe1;rez, J. et al. Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: Lessons from a large population-based registry study. J. Hematol. Oncol. 13, 133 (2020).</Citation></Reference><Reference><Citation>Baek, M. S., Lee, M.-T., Kim, W.-Y., Choi, J. C. &amp; Jung, S.-Y. COVID-19-related outcomes in immunocompromised patients: A nationwide study in Korea. PLoS ONE 16, e0257641 (2021).</Citation></Reference><Reference><Citation>Hueso, T. et al. Convalescent plasma improves overall survival in patients with B-cell lymphoid malignancy and COVID-19: A longitudinal cohort and propensity score analysis. Leukemia 36, 1025&#x2013;1034 (2022).</Citation></Reference><Reference><Citation>Lacombe, K. et al. Use of covid-19 convalescent plasma to treat patients admitted to hospital for covid-19 with or without underlying immunodeficiency: Open label, randomised clinical trial. BMJ Med. 2, e000427 (2023).</Citation></Reference><Reference><Citation>Gottlieb, R. L. et al. Early remdesivir to prevent progression to severe Covid-19 in outpatients. N. Engl. J. Med. 386, 305&#x2013;315 (2022).</Citation></Reference><Reference><Citation>Mozaffari, E. et al. Remdesivir reduced mortality in immunocompromised patients hospitalized for COVID-19 across variant waves: findings from routine clinical practice. Clin. Infect. Dis. 77, 1626&#x2013;1634 (2023).</Citation></Reference><Reference><Citation>Wu, M. Y. et al. WHO&#x2019;s therapeutics and COVID-19 living guideline on mAbs needs to be reassessed. The Lancet 400, 2193&#x2013;2196 (2022).</Citation></Reference><Reference><Citation>Immunocompromised. COVID-19 Treatment Guidelines https://www.covid19treatmentguidelines.nih.gov/special-populations/immunocompromised/ .</Citation></Reference><Reference><Citation>Shoham, S. et al. Vaccines and therapeutics for immunocompromised patients with COVID-19. EClinicalMedicine 59, 101965 (2023).</Citation></Reference><Reference><Citation>Yamani, A. H. et al. Early use of tocilizumab in solid organ transplant recipients with COVID-19: A retrospective cohort study in Saudi Arabia. Immun. Inflamm. Dis. 10, e587 (2022).</Citation></Reference><Reference><Citation>Bodro, M. et al. Use of anti-cytokine therapy in kidney transplant recipients with COVID-19. J. Clin. Med. 10, 1551 (2021).</Citation></Reference><Reference><Citation>Pereira, M. R. et al. Tocilizumab for severe COVID-19 in solid organ transplant recipients: A matched cohort study. Am. J. Transplant. 20, 3198&#x2013;3205 (2020).</Citation></Reference><Reference><Citation>Gudiol, C. et al. Co-infections and superinfections complicating COVID-19 in cancer patients: A multicentre, international study. J. Infect. 83, 306&#x2013;313 (2021).</Citation></Reference><Reference><Citation>Bansal, S. B. et al. Risk factors and outcomes of COVID associated mucormycosis in kidney transplant recipients. Transpl. Infect. Dis. 24, e13777 (2022).</Citation></Reference><Reference><Citation>Meshram, H. S., Kumar, D. &amp; Kute, V. B. Rare and unusual follow-up sequelae of coronavirus disease 2019: Splenic Mucormycosis in a renal transplant recipient. Transplant. Proc. 54, 1554&#x2013;1556 (2022).</Citation></Reference><Reference><Citation>Antinori, A. &amp; Bausch-Jurken, M. The burden of COVID-19 in the immunocompromised patient: Implications for vaccination and needs for the future. J. Infect. Dis. 228, S4&#x2013;S12 (2023).</Citation></Reference><Reference><Citation>Fung, M. &amp; Babik, J. M. COVID-19 in immunocompromised hosts: What we know so far. Clin. Infect. Dis. 72, 340&#x2013;350 (2021).</Citation></Reference><Reference><Citation>Galmiche, S. et al. Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: A systematic review. Clin. Microbiol. Infect. 28, 163&#x2013;177 (2022).</Citation></Reference><Reference><Citation>Goldman, J. D., Robinson, P. C., Uldrick, T. S. &amp; Ljungman, P. COVID-19 in immunocompromised populations: Implications for prognosis and repurposing of immunotherapies. J. Immunother. Cancer 9, e002630 (2021).</Citation></Reference><Reference><Citation>Dequin, P.-F. et al. Hydrocortisone in severe community-acquired pneumonia. N. Engl. J. Med. 388, 1931&#x2013;1941 (2023).</Citation></Reference><Reference><Citation>Pirracchio, R., Venkatesh, B. &amp; Legrand, M. Low-dose corticosteroids for critically ill adults with severe pulmonary infections: A review. JAMA 332, 318&#x2013;328 (2024).</Citation></Reference><Reference><Citation>Meduri, G. U. et al. Low-dose methylprednisolone treatment in critically ill patients with severe community-acquired pneumonia. Intensive Care Med. 48, 1009&#x2013;1023 (2022).</Citation></Reference><Reference><Citation>Torres, A. et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: A randomized clinical trial. JAMA 313, 677&#x2013;686 (2015).</Citation></Reference><Reference><Citation>Blum, C. A. et al. Adjunct prednisone therapy for patients with community-acquired pneumonia: a Multicentre, double-blind, randomised, placebo-controlled trial. Lancet 385, 1511&#x2013;1518 (2015).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40715266</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>26</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>SARS-CoV-2 mRNA vaccines confer protection in diet-induced obese mice despite altered immune cell profiles in the lung.</ArticleTitle><Pagination><StartPage>27209</StartPage><MedlinePgn>27209</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-025-12320-z</ELocationID><Abstract><AbstractText>Hypertension, diabetes, and obesity are comorbidities that influence severe cases of COVID-19 and are associated with weak humoral immunity after vaccination. We hypothesized that the diet-induced obese (DIO) K18-hACE2 mouse model could be utilized to reveal sex and DIO- specific differences in responses to COVID-19 immunization. To test this hypothesis, we immunized male and female DIO mice with a COVID-19 mRNA vaccine. Female DIO mice after immunization showed higher neutralizing antibody levels that recognized both SARS-CoV-2 variant RBD than male DIO mice. After Omicron SARS-CoV-2 challenge, single cell RNA sequencing analysis of lung tissue suggested decreased na&#xef;ve B cell populations in immunized DIO mice in addition to an increase in macrophages in vaccinated female DIO mice. Analysis of viral burden revealed that the DIO variable did not impact immunity in immunized mice. Overall, this study underscores the ability of COVID-19 mRNA vaccines to confer protection in the comorbid SARS-CoV-2 murine challenge model.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Katherine S</ForeName><Initials>KS</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Immunology, and Cell Biology, West Virginia University, Morgantown, WV, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Vaccine Development Center , West Virginia University Health Sciences Center, Morgantown, WV, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boehm</LastName><ForeName>Dylan T</ForeName><Initials>DT</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Immunology, and Cell Biology, West Virginia University, Morgantown, WV, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Vaccine Development Center , West Virginia University Health Sciences Center, Morgantown, WV, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller-Stump</LastName><ForeName>Olivia A</ForeName><Initials>OA</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Immunology, and Cell Biology, West Virginia University, Morgantown, WV, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Vaccine Development Center , West Virginia University Health Sciences Center, Morgantown, WV, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rader</LastName><ForeName>Nathaniel A</ForeName><Initials>NA</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Immunology, and Cell Biology, West Virginia University, Morgantown, WV, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Vaccine Development Center , West Virginia University Health Sciences Center, Morgantown, WV, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cooper</LastName><ForeName>Melissa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Immunology, and Cell Biology, West Virginia University, Morgantown, WV, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Vaccine Development Center , West Virginia University Health Sciences Center, Morgantown, WV, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cyphert</LastName><ForeName>Holly A</ForeName><Initials>HA</Initials><AffiliationInfo><Affiliation>Department of Biological Sciences, Marshall University, Huntington, WV, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sen-Kilic</LastName><ForeName>Emel</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Immunology, and Cell Biology, West Virginia University, Morgantown, WV, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Vaccine Development Center , West Virginia University Health Sciences Center, Morgantown, WV, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barbier</LastName><ForeName>Mariette</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Immunology, and Cell Biology, West Virginia University, Morgantown, WV, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Vaccine Development Center , West Virginia University Health Sciences Center, Morgantown, WV, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Damron</LastName><ForeName>F Heath</ForeName><Initials>FH</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Immunology, and Cell Biology, West Virginia University, Morgantown, WV, USA. fdamron@hsc.wvu.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Vaccine Development Center , West Virginia University Health Sciences Center, Morgantown, WV, USA. fdamron@hsc.wvu.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Diabetes</Keyword><Keyword MajorTopicYN="N">K18-hACE2 transgenic mouse</Keyword><Keyword MajorTopicYN="N">Obesity</Keyword><Keyword MajorTopicYN="N">Omicron variant</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">mRNA COVID-19 vaccines</Keyword><Keyword MajorTopicYN="N">scRNAseq</Keyword></KeywordList><CoiStatement>Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>27</Day><Hour>11</Hour><Minute>29</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40715266</ArticleId><ArticleId IdType="doi">10.1038/s41598-025-12320-z</ArticleId><ArticleId IdType="pii">10.1038/s41598-025-12320-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fischinger, S. et al. Sex differences in vaccine-induced humoral immunity. Semin. Immunopathol. 41 (2), 239&#x2013;249 (2019).</Citation></Reference><Reference><Citation>Flanagan, K. L. et al. Sex and gender differences in the outcomes of vaccination over the life course. Annu. Rev. Cell Dev. Biol. 33 (1), 577&#x2013;599 (2017).</Citation></Reference><Reference><Citation>Liu, C. et al. Risk factors associated with SARS-CoV-2 breakthrough infections in fully mRNA-Vaccinated individuals: retrospective analysis. JMIR Public. Health Surveillance. 8 (5), e35311 (2022).</Citation></Reference><Reference><Citation>Sanchis-Gomar, F. et al. Obesity and outcomes in COVID-19: when an epidemic and pandemic collide. Mayo Clin. Proc. 95 (7), 1445&#x2013;1453 (2020).</Citation></Reference><Reference><Citation>Carvalho, T., Krammer, F. &amp; Iwasaki, A. The first 12 months of COVID-19: A timeline of immunological insights.&#xa0;Nat Rev Immunol&#xa0;21(4) 245&#x2013;256. (2021).&#xa0;</Citation></Reference><Reference><Citation>Anderson, E. J. et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N. Engl. J. Med. 383 (25), 2427&#x2013;2438 (2020).</Citation></Reference><Reference><Citation>Milane, L. &amp; Amiji, M. Clinical approval of nanotechnology-based SARS-CoV-2 mRNA vaccines: impact on translational nanomedicine. Drug Delivery Translational Res. 11 (4), 1309&#x2013;1315 (2021).</Citation></Reference><Reference><Citation>Zhou, H. et al. A review of SARS-CoV2: compared with SARS-CoV and MERS-CoV. Front. Med., 8. (2021).</Citation></Reference><Reference><Citation>Mohammad, S. et al. Obesity and COVID-19: What Makes Obese Host so Vulnerable??18 (Immunity &amp; Ageing, 2021). 1.</Citation></Reference><Reference><Citation>Zheng, K. I. et al. Letter to the editor: obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease. Metabolism 108, 154244 (2020).</Citation></Reference><Reference><Citation>Caussy, C. et al. Obesity is associated with severe forms of COVID-19. Obesity 28 (7), 1175&#x2013;1175 (2020).</Citation></Reference><Reference><Citation>Zhang, J. J. et al. Risk and protective factors for COVID-19 morbidity, severity, and mortality. Clin. Rev. Allergy Immunol. 64 (1), 90&#x2013;107 (2022).</Citation></Reference><Reference><Citation>Singh, R. et al. Association of Obesity With COVID-19 Severity and Mortality: An Updated Systemic Review, Meta-Analysis, and Meta-Regression. Front. Endocrinol. 13, (2022).</Citation></Reference><Reference><Citation>Ray, A. et al. Infections and immunity: associations with obesity and related metabolic disorders. J. Pathol. Translational Med. 57 (1), 28&#x2013;42 (2023).</Citation></Reference><Reference><Citation>Huttunen, R. &amp; Syrj&#xe4;nen, J. Obesity and the risk and outcome of infection. Int. J. Obes. 37 (3), 333&#x2013;340 (2013).</Citation></Reference><Reference><Citation>Dicker, D. et al. Vaccinating people with obesity for COVID-19: EASO call for action. Obes. Facts. 14 (3), 334&#x2013;335 (2021).</Citation></Reference><Reference><Citation>Watanabe, M. et al. Central obesity, smoking habit, and hypertension are associated with lower antibody titres in response to COVID-19 mRNA vaccine.&#xa0;Diabetes Metab Res Rev 38(1) (2022)</Citation></Reference><Reference><Citation>Frasca, D. et al. The majority of SARS-CoV-2-specific antibodies in COVID-19 patients with obesity are autoimmune and not neutralizing. Int. J. Obes. 46 (2), 427&#x2013;432 (2022).</Citation></Reference><Reference><Citation>Nutsubidze, T., Uchava, L. &amp; Giorgadze, E. Correlation of obesity with diminished neutralizing antibody count. Endocr. Abstracts, (2022).</Citation></Reference><Reference><Citation>Yamamoto, S. et al. Sex-associated differences between BMI and SARS&#x2010;CoV&#x2010;2 antibody titers following the BNT162b2 vaccine. Obesity 30 (5), 999&#x2013;1003 (2022).</Citation></Reference><Reference><Citation>Chauvin, C., Retnakumar, S. V. &amp; Bayry, J. Obesity negatively impacts maintenance of antibody response to COVID-19 vaccines. Cell. Rep. Med. 4 (7), 101117 (2023).</Citation></Reference><Reference><Citation>Van Der Klaauw, A. A. et al. Accelerated waning of the humoral response to COVID-19 vaccines in obesity. Nat. Med. 29 (5), 1146&#x2013;1154 (2023).</Citation></Reference><Reference><Citation>Lee, K. S. et al. Obesity and metabolic dysfunction drive sex-associated differential disease profiles in hACE2-mice challenged with SARS-CoV-2. iScience 25 (10), 105038 (2022).</Citation></Reference><Reference><Citation>Fan, Y. et al. SARS-CoV-2 Omicron variant: Recent progress and future perspectives. Signal. Transduct. Target. Therapy, 7(1). (2022).</Citation></Reference><Reference><Citation>Lee, K. S. et al. Intranasal VLP-RBD vaccine adjuvanted with BECC470 confers immunity against Delta SARS-CoV-2 challenge in K18-hACE2-mice. Vaccine 41 (34), 5003&#x2013;5017 (2023).</Citation></Reference><Reference><Citation>Rader, N. A. et al.&#xa0;Influenza virus strains expressing SARS-CoV-2 receptor binding domain protein confer immunity in K18-hACE2 mice. Vaccine X 20 100543 (2024)&#xa0;</Citation></Reference><Reference><Citation>Chen, L. et al. Potential immune evasion of the severe acute respiratory syndrome coronavirus 2 Omicron variants. Front. Immunol., 15. (2024).</Citation></Reference><Reference><Citation>Willett, B. J. et al. SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway. Nat. Microbiol. 7 (8), 1161&#x2013;1179 (2022).</Citation></Reference><Reference><Citation>Halfmann, P. J. et al. SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters. Nature 603 (7902), 687&#x2013;692 (2022).</Citation></Reference><Reference><Citation>Tarr&#xe9;s-Freixas, F. et al. Heterogeneous infectivity and pathogenesis of Sars-Cov-2 variants beta, delta and omicron in transgenic K18-hace2 and wildtype mice. Front. Microbiol., 13. (2022).</Citation></Reference><Reference><Citation>Rizvi, Z. A. et al. Omicron sub-lineage BA.5 infection results in attenuated pathology in hACE2 Transgenic mice. Commun. Biology, 6(1). (2023).</Citation></Reference><Reference><Citation>Lee, K. S. et al. SARS-CoV-2 Delta variant induces enhanced pathology and inflammatory responses in K18-hACE2 mice. PLOS ONE. 17 (8), e0273430 (2022).</Citation></Reference><Reference><Citation>Wong, T. Y. et al. Intranasal administration of BReC-CoV-2 COVID-19 vaccine protects K18-hACE2 mice against lethal SARS-CoV-2 challenge. Npj Vaccines, 7(1). (2022).</Citation></Reference><Reference><Citation>Wong, T. Y. et al. Evaluating antibody mediated protection against alpha, beta, and Delta SARS-CoV-2 variants of concern in K18-hACE2 Transgenic mice. J. Virol., 96(6). (2022).</Citation></Reference><Reference><Citation>Cai, Z., Huang, Y. &amp; He, B. New insights into adipose tissue macrophages in obesity and insulin resistance. Cells 11 (9), 1424 (2022).</Citation></Reference><Reference><Citation>Weisberg, S. P. et al. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. 112 (12), 1796&#x2013;1808 (2003).</Citation></Reference><Reference><Citation>Oh, D. Y. et al. Increased macrophage migration into adipose tissue in obese mice. Diabetes 61 (2), 346&#x2013;354 (2012).</Citation></Reference><Reference><Citation>Goldblatt, D. et al. Correlates of protection against SARS-CoV&#x2010;2 infection and COVID&#x2010;19 disease. Immunol. Rev. 310 (1), 6&#x2013;26 (2022).</Citation></Reference><Reference><Citation>Fong, Y. et al. Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial. Nat. Commun., 14(1). (2023).</Citation></Reference><Reference><Citation>Menni, C. et al. COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID study. Lancet. Infect. Dis. 22 (7), 1002&#x2013;1010 (2022).</Citation></Reference><Reference><Citation>Chemaitelly, H. et al. Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: a retrospective population-based cohort study. Lancet. Infect. Dis. 23 (7), 816&#x2013;827 (2023).</Citation></Reference><Reference><Citation>Matsumoto, N. et al. Longitudinal antibody dynamics after COVID-19 vaccine boosters based on prior infection status and booster doses. Sci. Rep., 14(1). (2024).</Citation></Reference><Reference><Citation>Ou, X., et al., Antibody responses to COVID-19 vaccination in people with obesity: A systematic review and meta&#x2010;analysis. Influenza and Other Respiratory Viruses . 17(1).(&#xa0;2023)</Citation></Reference><Reference><Citation>Piernas, C., et al., Associations of BMI with COVID-19 vaccine uptake, vaccine effectiveness, and risk of severe COVID-19 outcomes after vaccination in England: a population-based cohort study. The Lancet Diabetes &amp; Endocrinology,&#xa0;10(8) 571&#x2013;580. (2022)&#xa0;</Citation></Reference><Reference><Citation>Chen, Y. et al. COVID-19 mRNA vaccine protects against SARS-CoV-2 Omicron BA.1 infection in diet-induced obese mice through boosting host innate antiviral responses. eBioMedicine 89, 104485 (2023).</Citation></Reference><Reference><Citation>O&#x2019;Meara, T. R. et al. Reduced SARS-CoV-2 mRNA vaccine immunogenicity and protection in mice with diet-induced obesity and insulin resistance. J. Allergy Clin. Immunol. 152 (5), 1107&#x2013;1120e6 (2023).</Citation></Reference><Reference><Citation>Demetrius, L. Of mice and men. EMBO Rep. 6 (S1), S39&#x2013;S44 (2005).</Citation></Reference><Reference><Citation>Kleinert, M. et al. Animal models of obesity and diabetes mellitus. Nat. Reviews Endocrinol. 14 (3), 140&#x2013;162 (2018).</Citation></Reference><Reference><Citation>Suleiman, J., Mohamed, M. &amp; Bakar, A. A systematic review on different models of inducing obesity in animals: advantages and limitations. J. Adv. Veterinary Anim. Res. 7 (1), 103 (2020).</Citation></Reference><Reference><Citation>Kovacs, E. J. et al. Aging and innate immunity in the mouse: impact of intrinsic and extrinsic factors. Trends Immunol. 30 (7), 319&#x2013;324 (2009).</Citation></Reference><Reference><Citation>Chen, Y. et al. Age-associated SARS-CoV-2 breakthrough infection and changes in immune response in a mouse model. Emerg. Microbes Infections. 11 (1), 368&#x2013;383 (2022).</Citation></Reference><Reference><Citation>Casimiro, I. et al. Phenotypic sexual dimorphism in response to dietary fat manipulation in C57BL/6J mice. J. Diabetes Complicat. 35 (2), 107795 (2021).</Citation></Reference><Reference><Citation>Ianevski, A., Giri, A. K. &amp; Aittokallio, T. Fully-automated and ultra-fast cell-type identification using specific marker combinations from single-cell transcriptomic data. Nat. Commun., 13(1). (2022).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40715253</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>25</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Development of a time-resolved fluorescence-based lateral flow immunoassay for rapid and sensitive diagnosis of Middle East respiratory syndrome.</ArticleTitle><Pagination><StartPage>27036</StartPage><MedlinePgn>27036</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-025-09832-z</ELocationID><Abstract><AbstractText>Middle East respiratory syndrome (MERS) is a viral respiratory infection caused by the MERS-coronavirus (MERS-CoV). Due to its high mortality and lack of a vaccine or treatment, MERS has remained on the WHO's priority list of diseases with the highest public health risk since 2012. Although rapid diagnosis is essential for interrupting transmission, initiating timely treatment, and maintaining public health systems, no rapid diagnostic method currently exists for MERS. In this study, a sensitive and specific lateral flow immunoassay (LFIA)-based rapid antigen diagnostic test for MERS was developed using time-resolved fluorescence (TRF) technology. Monoclonal antibodies specific for the MERS-CoV N protein were generated, and optimal pairs were selected through affinity measurement. A TRF-LFIA using Europium nanoparticles was then constructed based on these pairs. The TRF-LFIA showed a detection limit of 0.1&#xa0;ng/ml MERS-CoV N protein and 5&#x2009;&#xd7;&#x2009;10<sup>4</sup> copies/ml of MERS-CoV, demonstrating a 25-fold sensitivity increase relative to the cellulose nanobeads (CNB)-LFIA. Furthermore, it displayed high specificity without cross-reactivity to the N proteins of SARS-CoV, SARS-CoV-2, or influenza virus. Consequently, these findings indicate that the TRF-LFIA platform is a promising approach for rapid diagnosis of MERS-CoV infection, with potential for broader application through enhanced sensitivity.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Kim</LastName><ForeName>Mi Jeong</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Digital Omics Research Center, Korea Basic Science Institute, Cheongju, 28119, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Immunotherapy Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, 34141, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Kim</LastName><ForeName>Hye-Yeon</ForeName><Initials>HY</Initials><AffiliationInfo><Affiliation>Biopharmaceutical Research Center, Korea Basic Science Institute, Cheongju, 28119, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Minhye</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Digital Omics Research Center, Korea Basic Science Institute, Cheongju, 28119, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Critical Diseases Diagnostics Convergence Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, 34141, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shin</LastName><ForeName>Eun-Young</ForeName><Initials>EY</Initials><AffiliationInfo><Affiliation>Digital Omics Research Center, Korea Basic Science Institute, Cheongju, 28119, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Wooyoung</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Digital Omics Research Center, Korea Basic Science Institute, Cheongju, 28119, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Critical Diseases Diagnostics Convergence Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, 34141, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Hyunghoon</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Precision Biosensor, Inc., Daejeon, 34036, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ku</LastName><ForeName>Keun Bon</ForeName><Initials>KB</Initials><AffiliationInfo><Affiliation>Center for Infectious Disease Vaccine and Diagnosis Innovation, Korea Research Institute of Chemical Technology, Daejeon, 34114, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Jong-Hwan</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Center for Infectious Disease Vaccine and Diagnosis Innovation, Korea Research Institute of Chemical Technology, Daejeon, 34114, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>College of Advanced Technology and Convergence, Major in Bionano Engineering, Hanyang University, Ansan, 15588, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Seung Il</ForeName><Initials>SI</Initials><AffiliationInfo><Affiliation>Digital Omics Research Center, Korea Basic Science Institute, Cheongju, 28119, Republic of Korea. ksi@kbsi.re.kr.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Bio-Analysis Science, University of Science and Technology, Daejeon, 34113, Republic of Korea. ksi@kbsi.re.kr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Edmond Changkyun</ForeName><Initials>EC</Initials><AffiliationInfo><Affiliation>Digital Omics Research Center, Korea Basic Science Institute, Cheongju, 28119, Republic of Korea. edpark@kbsi.re.kr.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Critical Diseases Diagnostics Convergence Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, 34141, Republic of Korea. edpark@kbsi.re.kr.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Bio-Analysis Science, University of Science and Technology, Daejeon, 34113, Republic of Korea. edpark@kbsi.re.kr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>HI20C0363</GrantID><Agency>Ministry of Health and Welfare, Republic of Korea</Agency><Country/></Grant><Grant><GrantID>C523400</GrantID><Agency>Korea Basic Science Institute</Agency><Country/></Grant><Grant><GrantID>CRC22021-100</GrantID><Agency>National Research Council of Science and Technology, Republic of Korea</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Europium</Keyword><Keyword MajorTopicYN="N">MERS</Keyword><Keyword MajorTopicYN="N">Nucleocapsid protein</Keyword><Keyword MajorTopicYN="N">Rapid diagnostic test</Keyword><Keyword MajorTopicYN="N">Time-resolved fluorescence</Keyword></KeywordList><CoiStatement>Declarations. Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>4</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>27</Day><Hour>11</Hour><Minute>28</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40715253</ArticleId><ArticleId IdType="doi">10.1038/s41598-025-09832-z</ArticleId><ArticleId IdType="pii">10.1038/s41598-025-09832-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Groot, R. J. D. et al. Commentary: Middle East respiratory syndrome coronavirus (MERS-CoV): Announcement of the coronavirus study group. J. Virol. 87, 7790&#x2013;7792. https://doi.org/10.1128/jvi.01244-13 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.01244-13</ArticleId><ArticleId IdType="pubmed">23678167</ArticleId><ArticleId IdType="pmc">3700179</ArticleId></ArticleIdList></Reference><Reference><Citation>Durai, P., Batool, M., Shah, M. &amp; Choi, S. Middle East respiratory syndrome coronavirus: Transmission, virology and therapeutic targeting to aid in outbreak control. Exp. Mol. Med. 47, e181&#x2013;e181. https://doi.org/10.1038/emm.2015.76 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emm.2015.76</ArticleId><ArticleId IdType="pubmed">26315600</ArticleId><ArticleId IdType="pmc">4558490</ArticleId></ArticleIdList></Reference><Reference><Citation>Assiri, A. et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: A descriptive study. Lancet. Infect. Dis. 13, 752&#x2013;761. https://doi.org/10.1016/S1473-3099(13)70204-4 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(13)70204-4</ArticleId><ArticleId IdType="pubmed">23891402</ArticleId><ArticleId IdType="pmc">7185445</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeung, M.-L. et al. MERS coronavirus induces apoptosis in kidney and lung by upregulating Smad7 and FGF2. Nat. Microbiol. 1, 16004. https://doi.org/10.1038/nmicrobiol.2016.4 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmicrobiol.2016.4</ArticleId><ArticleId IdType="pubmed">27572168</ArticleId><ArticleId IdType="pmc">7097571</ArticleId></ArticleIdList></Reference><Reference><Citation>Alsaad, K. O. et al. Histopathology of Middle East respiratory syndrome coronovirus (MERS-CoV) infection: Clinicopathological and ultrastructural study. Histopathology 72, 516&#x2013;524. https://doi.org/10.1111/his.13379 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/his.13379</ArticleId><ArticleId IdType="pubmed">28858401</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO. Middle East respiratory syndrome coronavirus (MERS-CoV): Symptoms, https://www.who.int/health-topics/middle-east-respiratory-syndrome-coronavirus-mers#tab=tab_2 (2024).</Citation></Reference><Reference><Citation>WHO. Middle East respiratory syndrome coronavirus - Kingdom of Saudi Arabia, https://www.who.int/emergencies/disease-outbreak-news/item/2025-DON560 (2025).</Citation></Reference><Reference><Citation>Kelly-Cirino, C., Mazzola, L. T., Chua, A., Oxenford, C. J. &amp; Kerkhove, M. D. V. An updated roadmap for MERS-CoV research and product development: focus on diagnostics. BMJ Glob. Health 4, e001105. https://doi.org/10.1136/bmjgh-2018-001105 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjgh-2018-001105</ArticleId><ArticleId IdType="pubmed">30815285</ArticleId><ArticleId IdType="pmc">6361340</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandes, R. S. et al. Recent advances in point of care testing for COVID-19 detection. Biomed. Pharmacother. 153, 113538. https://doi.org/10.1016/j.biopha.2022.113538 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2022.113538</ArticleId><ArticleId IdType="pubmed">36076617</ArticleId><ArticleId IdType="pmc">9371983</ArticleId></ArticleIdList></Reference><Reference><Citation>Budd, J. et al. Lateral flow test engineering and lessons learned from COVID-19. Nat. Rev. Bioeng. 1, 13&#x2013;31. https://doi.org/10.1038/s44222-022-00007-3 (2023).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s44222-022-00007-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim, J. et al. A two-colour multiplexed lateral flow immunoassay system to differentially detect human malaria species on a single test line. Malar. J. 18, 313. https://doi.org/10.1186/s12936-019-2957-x (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12936-019-2957-x</ArticleId><ArticleId IdType="pubmed">31533756</ArticleId><ArticleId IdType="pmc">6749696</ArticleId></ArticleIdList></Reference><Reference><Citation>Agarwal, S. et al. Lateral flow&#x2013;based nucleic acid detection of SARS-CoV-2 using enzymatic incorporation of biotin-labeled dUTP for POCT use. Anal. Bioanal. Chem. 414, 3177&#x2013;3186. https://doi.org/10.1007/s00216-022-03880-4 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00216-022-03880-4</ArticleId><ArticleId IdType="pubmed">35044487</ArticleId><ArticleId IdType="pmc">8766626</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma, L. et al. Comparison between gold nanoparticles and FITC as the labelling in lateral flow immunoassays for rapid detection of Ralstonia solanacearum. Food Hydrocolloids 29, 1074&#x2013;1085. https://doi.org/10.1080/09540105.2018.1510474 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/09540105.2018.1510474</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, J. et al. Quantum dot-based lateral flow test strips for highly sensitive detection of the tetanus antibody. ACS Omega 4, 6789&#x2013;6795. https://doi.org/10.1021/acsomega.9b00657 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsomega.9b00657</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang, Z.-Y., Deng, Y.-Q. &amp; Tao, Z.-Z. A quantum dot-based lateral flow immunoassay for the rapid, quantitative, and sensitive detection of specific IgE for mite allergens in sera from patients with allergic rhinitis. Anal. Bioanal. Chem. 412, 1785&#x2013;1794. https://doi.org/10.1007/s00216-020-02422-0 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00216-020-02422-0</ArticleId><ArticleId IdType="pubmed">32052065</ArticleId><ArticleId IdType="pmc">7048869</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeo, S.-J. et al. Improvement of a rapid diagnostic application of monoclonal antibodies against avian influenza H7 subtype virus using Europium nanoparticles. Sci. Rep. 7, 7933. https://doi.org/10.1038/s41598-017-08328-9 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-08328-9</ArticleId><ArticleId IdType="pubmed">28801679</ArticleId><ArticleId IdType="pmc">5554140</ArticleId></ArticleIdList></Reference><Reference><Citation>Ou, X. et al. AIEgens assisted label free DNA supersandwich immunoassay for ultrasensitive &#x3b1;-fetoprotein detection. Giant 11, 100110. https://doi.org/10.1016/j.giant.2022.100110 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.giant.2022.100110</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu, J. et al. A time-resolved fluorescence lateral flow immunoassay for rapid and quantitative serodiagnosis of Brucella infection in humans. J. Pharm. Biomed. Anal. 200, 114071. https://doi.org/10.1016/j.jpba.2021.114071 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpba.2021.114071</ArticleId><ArticleId IdType="pubmed">33866295</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee, M. et al. A comprehensive Exdia TRF-LFIA for simultaneous quantification of GFAP and NT-proBNP in distinguishing ischemic and hemorrhagic stroke. Clin. Chim. Acta 557, 117872. https://doi.org/10.1016/j.cca.2024.117872 (2024).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2024.117872</ArticleId><ArticleId IdType="pubmed">38471630</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiao, X. et al. Lateral flow immunoassay based on time-resolved fluorescence microspheres for rapid and quantitative screening CA199 in human serum. Int. J. Mol. Sci. 23, 9991. https://doi.org/10.3390/ijms23179991 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23179991</ArticleId><ArticleId IdType="pubmed">36077387</ArticleId><ArticleId IdType="pmc">9456114</ArticleId></ArticleIdList></Reference><Reference><Citation>Natarajan, S., Saat&#xe7;i, E. &amp; Joseph, J. Development and evaluation of europium-based quantitative lateral flow immunoassay for the chronic kidney disease marker cystatin-C. J. Fluoresc. 32, 419&#x2013;426. https://doi.org/10.1007/s10895-021-02886-y (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10895-021-02886-y</ArticleId><ArticleId IdType="pubmed">35025016</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang, C. K., Hou, M. H., Chang, C. F., Hsiao, C. D. &amp; Huang, T. H. The SARS coronavirus nucleocapsid protein&#x2013;forms and functions. Antiviral. Res. 103, 39&#x2013;50. https://doi.org/10.1016/j.antiviral.2013.12.009 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2013.12.009</ArticleId><ArticleId IdType="pubmed">24418573</ArticleId><ArticleId IdType="pmc">7113676</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee, J. H. et al. Rapid biosensor of SARS-CoV-2 using specific monoclonal antibodies recognizing conserved nucleocapsid protein epitopes. Viruses 14, 255. https://doi.org/10.3390/v14020255 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14020255</ArticleId><ArticleId IdType="pubmed">35215848</ArticleId><ArticleId IdType="pmc">8879994</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40715218</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>26</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Decadal (2012-2023) account of spatio-temporal variability in satellite-detected biomass fires on Indian landmass and their fire radiative power.</ArticleTitle><Pagination><StartPage>27233</StartPage><MedlinePgn>27233</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-025-11200-w</ELocationID><Abstract><AbstractText>Worldwide escalation in wildfire incidences calls for continuous monitoring and early detection of fires to strengthen regional fire combating strategies. Inter-annual variability in fire count and Fire Radiative Power (FRP), spatial spread of fires in the most active seasons during 2012&#x2012;2023 on Indian landmass are reported. Fire data is extracted from 375&#xa0;m active fire detection product of Visible Infrared Imaging Radiometer Suite (VIIRS) hosted by Suomi National Polar-orbiting Partnership. In every fire-year (March-February), constructed from the month of remarkable escalation in fires, fires were most populated in March or April in summer and November in winter. The yearly sum of fire spots ranged from 492,282 (2013) to 731,154 (2021). Inter-annual fire count trend grew at a rate of 10,794 per year, excluding COVID years of 2020 and 2021. Many cities with&#x2009;&gt;&#x2009;0.1 million population are located within or adjacent to the fire hot spots (20&#xa0;km&#x2009;&#xd7;&#x2009;20&#xa0;km grids), implying possibility of some impacts of seasonal fires both within and outside Wildfire Urban Interphases (WUIs). The study highlights the urgency of streamlining interventions to minimize wildfire incidences in order to protect forests, habitats, biodiversity, ecosystem services, human lives and property and minimize carbon loss, air pollution, perturbations in regional meteorology and radiative forcing.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Majumdar</LastName><ForeName>Deepanjan</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-8063-7623</Identifier><AffiliationInfo><Affiliation>Kolkata Zonal Centre, CSIR-National Environmental Engineering Research Institute (CSIR-NEERI), i-8, Sector C, EKADP, E.M. Bypass, Kolkata, India. d_majumdar@neeri.res.in.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Crop residue burning</Keyword><Keyword MajorTopicYN="N">Fire count</Keyword><Keyword MajorTopicYN="N">Fire spot</Keyword><Keyword MajorTopicYN="N">Remote sensing</Keyword><Keyword MajorTopicYN="N">Sen&#x2019;s slope</Keyword><Keyword MajorTopicYN="N">VIIRS</Keyword></KeywordList><CoiStatement>Declarations. Competing interests: The author declares no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>27</Day><Hour>11</Hour><Minute>26</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40715218</ArticleId><ArticleId IdType="doi">10.1038/s41598-025-11200-w</ArticleId><ArticleId IdType="pii">10.1038/s41598-025-11200-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Crutzen, P. J. &amp; Andreae, M. O. Biomass burning in the tropics: Impact on atmospheric chemistry and biogeochemical cycles. Science 250(4988), 1669&#x2013;1678. https://doi.org/10.1126/science.250.4988.1669 (1990).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.250.4988.1669</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain, N., Bhatia, A. &amp; Pathak, H. Emission of air pollutants from crop residue burning in India. Aerosol Air Qual. Res. 14, 422&#x2013;430. https://doi.org/10.4209/aaqr.2013.01.0031 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.4209/aaqr.2013.01.0031</ArticleId></ArticleIdList></Reference><Reference><Citation>Csiszar, I. et al. Active fires from the Suomi NPP visible infrared imaging radiometer suite: Product status and first evaluation results. J. Geophys. Res. Atmos. 119(2), 2013JD020453. https://doi.org/10.1002/2013JD020453 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/2013JD020453</ArticleId></ArticleIdList></Reference><Reference><Citation>Hao, W. M. &amp; Liu, M. H. Spatial and temporal distribution of tropical biomass burning. Glob. Biogeochem. Cycles 8, 495&#x2013;503. https://doi.org/10.1029/94GB02086 (1994).</Citation><ArticleIdList><ArticleId IdType="doi">10.1029/94GB02086</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunningham, C. X., Williamson, G. J. &amp; Bowman, D. M. J. S. Increasing frequency and intensity of the most extreme wildfires on Earth. Nat. Ecol. Evol. 8, 1420&#x2013;1425. https://doi.org/10.1038/s41559-024-02452-2 (2024).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41559-024-02452-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones, M. W. et al. State of wildfires 2023&#x2013;2024. Earth Syst. Sci. Data 16, 3601&#x2013;3685. https://doi.org/10.5194/essd-16-3601-2024 (2024).</Citation><ArticleIdList><ArticleId IdType="doi">10.5194/essd-16-3601-2024</ArticleId></ArticleIdList></Reference><Reference><Citation>UNEP (United Nations Environment Programme). Global Peatlands Assessment: The State of the World&#x2019;s Peatlands, Nairobi, Kenya, accessed 12 September 2024; https://www.unep.org/resources/global-peatlands-assessment-2022 (2022).</Citation></Reference><Reference><Citation>Ponomarev, E. I., Zabrodin, A. N., Shvetsov, E. G. &amp; Ponomareva, T. V. Wildfire intensity and fire emissions in Siberia. Fire 6, 246. https://doi.org/10.3390/fire6070246 (2023).</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/fire6070246</ArticleId></ArticleIdList></Reference><Reference><Citation>Ell, K. Moody&#x2019;s Analytics research, weekly market outlook, accessed 14 September 2020; https://www.moodysanalytics.com/-/media/article/2020/weekly-market-outlook-overvalued-equities-increase-corporate-credits-downside-risk.pdf (2020).</Citation></Reference><Reference><Citation>Corpuz, J. C. G. Heatwaves, wildfires and global warming: A call to public health action. J. Public Health 46(2), e326&#x2013;e327. https://doi.org/10.1093/pubmed/fdad242 (2024).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/pubmed/fdad242</ArticleId></ArticleIdList></Reference><Reference><Citation>Streets, D. G., Yarber, K. F., Woo, J. H. &amp; Carmichael, G. R. An inventory of gaseous and primary aerosol emissions in Asia in the year 2000. J. Geophys. Res. 108, 8809&#x2013;8823. https://doi.org/10.1029/2002JD003093 (2003).</Citation><ArticleIdList><ArticleId IdType="doi">10.1029/2002JD003093</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, L., Liu, Y. &amp; Lu, H. Contributions of open crop straw burning emissions to PM<sub>2.5</sub> concentrations in China. Environ. Res. Lett. 11(1), 014014. https://doi.org/10.1088/1748-9326/11/1/014014 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1088/1748-9326/11/1/014014</ArticleId></ArticleIdList></Reference><Reference><Citation>Yadav, I. C. &amp; Devi, N. L. Biomass burning, regional air quality, and climate change. In Earth Systems and Environmental Sciences. Edition: Encyclopedia of Environmental Health 2nd edn (ed Nriagu, J. J.) (Elsevier, 2018). https://doi.org/10.1016/B978-0-12-409548-9.11022-X .</Citation></Reference><Reference><Citation>Ravindra, K., Singh, T. &amp; Mor, S. Emissions of air pollutants from primary crop residue burning in India and their mitigation strategies for cleaner emissions. J. Clean. Prod. 208, 261&#x2013;273. https://doi.org/10.1016/j.jclepro.2018.10.031 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclepro.2018.10.031</ArticleId></ArticleIdList></Reference><Reference><Citation>IARI. Crop Residues Management with Conservation Agriculture: Potential, Constraints and Policy Needs 7&#x2013;32 (Indian Agricultural Research Institute, 2012).</Citation></Reference><Reference><Citation>Vadrevu, K. P., Ellicott, E., Badarinath, K. V. S. &amp; Vermote, E. MODIS derived fire characteristics and aerosol optical depth variations during the agricultural residue burning season, north India. Environ. Poll. 159, 1560&#x2013;1569. https://doi.org/10.1016/j.envpol.2011.03.001 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.envpol.2011.03.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Jitendra, S. V. et al. India&#x2019;s burning issues of crop burning takes a new turn. Down to Earth, accessed on 7 December 2021; https://www.downtoearth.org.in/coverage/river-of-fire-57924 (2017).</Citation></Reference><Reference><Citation>Gadde, B., Bonnet, S., Menke, C. &amp; Garivait, S. Air pollutant emissions from rice straw open field burning in India Thailand and the Philippines. Environ. Poll. 157, 1554&#x2013;1558. https://doi.org/10.1016/j.envpol.2009.01.004 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.envpol.2009.01.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Forest Survey of India. India State of Forest Report. Forest Survey of India (Ministry of Environment &amp; Forests, 2015).</Citation></Reference><Reference><Citation>Forest Survey of India. India State of Forest Report. Forest Survey of India (Ministry of Environment &amp; Forests, 2019).</Citation></Reference><Reference><Citation>Forest Survey of India. Accessed on 9 January 2024; https://fsi.nic.in/forest-fire-activities?pgID=forest-fire-activities .</Citation></Reference><Reference><Citation>Sahu, L. K. et al. Regional biomass burning trends in India: Analysis of satellite fire data. J. Earth Syst. Sci. 124, 1377&#x2013;1387. https://doi.org/10.1007/s12040-015-0616-3 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12040-015-0616-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmad, F. &amp; Goparaju, L. Forest fire trend and influence of climate variability in India: A geospatial analysis at national and local scale. Ekol&#xf3;gia 38(1), 49&#x2013;68. https://doi.org/10.2478/eko-2019-0005 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.2478/eko-2019-0005</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain, M., Saxena, P., Sharma, S. &amp; Sonwani, S. Investigation of forest fire activity changes over the central India domain using satellite observations during 2001&#x2013;2020. Geo Health 5, e2021GH000528. https://doi.org/10.1029/2021GH000528 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1029/2021GH000528</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohanty, A. &amp; Mithal, V. Managing Forest Fires in a Changing Climate (Council on Energy, Environment and Water, 2022). https://www.ceew.in/publications/states-vulnerable-to-forest-fire-events-india-and-mitigation-measures .</Citation></Reference><Reference><Citation>Li, F., Zhang, X. &amp; Kondragunta, S. Biomass burning in Africa: An investigation of fire radiative power missed by MODIS using the 375 m VIIRS active fire product. Remote Sens. 12, 1561. https://doi.org/10.3390/rs12101561 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/rs12101561</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasslop, G. &amp; Kloster, S. Human impact on wildfires varies between regions and with vegetation productivity. Environ. Res. Lett. 12, 115011. https://doi.org/10.1088/1748-9326/aa8c82 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1088/1748-9326/aa8c82</ArticleId></ArticleIdList></Reference><Reference><Citation>Seitinthang, L. Cropping pattern of north east India: An appraisal. Am. Res. Thoughts 1(1), 488&#x2013;498 (2014).</Citation></Reference><Reference><Citation>Banerjee, P. MODIS-FIRMS and ground-truthing-based wildfire likelihood mapping of Sikkim Himalaya using machine learning algorithms. Nat. Haz. 110, 899&#x2013;935. https://doi.org/10.1007/s11069-021-04973-6 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11069-021-04973-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Shikhov, A. N., Perminova, E. S. &amp; Perminov, S. I. Satellite-based analysis of the spatial patterns of fire and storm-related forest disturbances in the Ural region, Russia. Nat. Haz. 97, 283&#x2013;308. https://doi.org/10.1007/s11069-019-03642-z (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11069-019-03642-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Wooster, M., Roberts, G., Perry, G. L. W. &amp; Kaufman, Y. J. Retrieval of biomass combustion rates and totals from fire radiative power observations: FRP derivation and calibration relationships between biomass consumption and fire radiative energy release. J. Geophys. Res.-Atmos. 110(24), D24311. https://doi.org/10.1029/2005JD006318 (2005).</Citation><ArticleIdList><ArticleId IdType="doi">10.1029/2005JD006318</ArticleId></ArticleIdList></Reference><Reference><Citation>Roy, D. P. &amp; Kumar, S. S. Multi-year MODIS active fire type classification over the Brazilian tropical moist forest biome. Int. J. Digital Earth 10(1), 54&#x2013;84. https://doi.org/10.1080/17538947.2016.1208686 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17538947.2016.1208686</ArticleId></ArticleIdList></Reference><Reference><Citation>Schroeder, W., Csiszar, I., Giglio, L. &amp; Schmidt, C. C. On the use of fire radiative power, area, and temperature estimates to characterize biomass burning via moderate to coarse spatial resolution remote sensing data in the Brazilian Amazon. J. Geophys. Res. 115, D21121. https://doi.org/10.1029/2009JD013769 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.1029/2009JD013769</ArticleId></ArticleIdList></Reference><Reference><Citation>Schroeder, W., Oliva, P., Giglio, L. &amp; Csiszar, I. A. The new VIIRS 375m active fire detection data product: Algorithm description and initial assessment. Remote Sens. Environ. 143, 85&#x2013;96. https://doi.org/10.1016/j.rse.2013.12.008 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rse.2013.12.008</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, T., Wooster, M. J. &amp; Xu, W. Approaches for synergistically exploiting VIIRS I- and M-Band data in regional active fire detection and FRP assessment: A demonstration with respect to agricultural residue burning in Eastern China. Remote Sens. Environ. 198, 407&#x2013;424. https://doi.org/10.1016/j.rse.2017.06.028 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rse.2017.06.028</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurjar, B. R., Ravindra, K. &amp; Nagpure, A. S. Air pollution trends over Indian megacities and their local-to-global implications. Atmos. Environ. 142, 475&#x2013;495. https://doi.org/10.1016/j.atmosenv.2016.06.030 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.atmosenv.2016.06.030</ArticleId></ArticleIdList></Reference><Reference><Citation>Bond, T. C. et al. Bounding the role of black carbon in the climate system: A scientific assessment. J. Geophys. Res. 118, 5380&#x2013;5552. https://doi.org/10.1002/jgrd.50171 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jgrd.50171</ArticleId></ArticleIdList></Reference><Reference><Citation>Srivastava, S. &amp; Senthil Kumar, A. Implications of intense biomass burning over Uttarakhand in April&#x2013;May 2016. Nat. Haz. 101, 367&#x2013;383. https://doi.org/10.1007/s11069-020-03877-1 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11069-020-03877-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Santi, P., Cannon, S. &amp; DeGraff, J. Wildfire and landscape change. In Treatise on Geomorphology Vol. 13 262&#x2013;287 (Academic Press, 2013). https://doi.org/10.1016/B978-0-12-818234-5.00017-1 .</Citation></Reference><Reference><Citation>Rengers, F. K. Wildfire as a catalyst for hydrologic and geomorphic change. Environ. Sci. Oxf. https://doi.org/10.1093/OBO/9780199363445-0112 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/OBO/9780199363445-0112</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, Z., Ballantyne, A. P. &amp; Cooper, L. A. Biophysical feedback of global forest fires on surface temperature. Nat. Commun. 10, 214. https://doi.org/10.1038/s41467-018-08237-z (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-08237-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang, R., Huang, X., Zhou, D. &amp; Ding, A. Biomass-burning-induced surface darkening and its impact on regional meteorology in eastern China. Atmos. Chem. Phys. 20, 6177&#x2013;6191. https://doi.org/10.5194/acp-20-6177-2020 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.5194/acp-20-6177-2020</ArticleId></ArticleIdList></Reference><Reference><Citation>Pellegrini, A. F. A., Reich, P. B., Hobbie, S. E. &amp; Coetsee, C. Soil carbon storage capacity of drylands under altered fire regimes. Nat. Clim. Change 13(10), 1&#x2013;6. https://doi.org/10.1038/s41558-023-01800-7 (2023).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41558-023-01800-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Martins, F. S. R. V., Xaud, H. A. M., dos Santos, J. R. &amp; Galv&#xe3;o, L. S. Effects of fire on above-ground forest biomass in the northern Brazilian Amazon. J. Trop. Ecol. 28(6), 591&#x2013;601. https://doi.org/10.1017/S0266467412000636 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0266467412000636</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith, J. K. In Wildland fire in ecosystems: Effects of fire on fauna. General Technical Report, RMRS-GTR-42-Volume 1 (ed Kapler, S. J.) 83 (U.S. Department of Agriculture, Forest Service, Rocky Mountain Research Station, 2000).</Citation></Reference><Reference><Citation>Huang, L., Lin, W., Li, F., Wang, Y. &amp; Jiang, B. Climate impacts of the biomass burning in Indochina on atmospheric conditions over Southern China. Aerosol Air Qual. Res. 19, 2707&#x2013;2720. https://doi.org/10.4209/aaqr.2019.01.0028 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.4209/aaqr.2019.01.0028</ArticleId></ArticleIdList></Reference><Reference><Citation>Ad&#xe1;mek, M., Hadincov&#xe1;, V. &amp; Wild, J. Long-term effect of wildfires on temperate Pinus sylvestris forests: Vegetation dynamics and ecosystem resilience. For. Ecol. Manag. 380, 285&#x2013;295. https://doi.org/10.1016/j.foreco.2016.08.051 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.foreco.2016.08.051</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulido-Chavez, M. F. et al. Rapid bacterial and fungal successional dynamics in first year after chaparral wildfire. Mol. Ecol. 32(7), 1685&#x2013;1707. https://doi.org/10.1111/mec.16835 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/mec.16835</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrenberg, S. et al. Changes in assembly processes in soil bacterial communities following a wildfire disturbance. ISME J. 7(6), 1102&#x2013;1111. https://doi.org/10.1038/ismej.2013.11 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ismej.2013.11</ArticleId></ArticleIdList></Reference><Reference><Citation>Taboada, A., Garc&#xed;a-Llamas, P., Fern&#xe1;ndez-Guisuraga, J. M. &amp; Calvo, L. Wildfires impact on ecosystem service delivery in fire-prone maritime pine-dominated forests. Ecos. Serv. 50, 101334. https://doi.org/10.1016/j.ecoser.2021.101334 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ecoser.2021.101334</ArticleId></ArticleIdList></Reference><Reference><Citation>Lecina-Diaz, J., Mart&#xed;nez-Vilalta, J., Alvarez, A., Vayreda, J. &amp; Retana, J. Assessing the risk of losing forest ecosystem services due to wildfires. Ecosys. 24, 1687&#x2013;1701. https://doi.org/10.1007/s10021-021-00611-1 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10021-021-00611-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Vukomanovic, J. &amp; Steelman, T. A systematic review of relationships between mountain wildfire and ecosystem Services. Landsc. Ecol. 34, 1179&#x2013;1194. https://doi.org/10.1007/s10980-019-00832-9 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10980-019-00832-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens-Rumann, C. &amp; Morgan, P. Repeated wildfires alter forest recovery of mixed-conifer ecosystems. Ecol. Appl. 26(6), 1842&#x2013;1853. https://doi.org/10.1890/15-1521.1 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1890/15-1521.1</ArticleId></ArticleIdList></Reference><Reference><Citation>Govt. of India. Accessed on 3 May 2024; https://rajyasabha.nic.in/rsnew/official_sites/statelegis.asp .</Citation></Reference><Reference><Citation>Govt. of India. Accessed on 2 June 2024; https://www.india.gov.in/india-glance/profile .</Citation></Reference><Reference><Citation>NASA. Accessed on 25 September 2024. https://www.earthdata.nasa.gov/faq/firms-faq#:~:text=For%20MODIS%2C%20the%20confidence%20value,fire)%20to%20all%20fire%20pixels .</Citation></Reference><Reference><Citation>Wolfe, R., Nishihama, M. &amp; Kuyper, J. MODIS Geolocation status. MODIS Science Team meeting Calibration Breakout Session, NASA GSFC Code 619, accessed on 2 February 2024; https://modis.gsfc.nasa.gov/sci_team/meetings/201304/presentations/calibration/wolfe.pdf (2013).</Citation></Reference><Reference><Citation>Csiszar, I. &amp; Schroeder, W. Short-term observations of the temporal development of active fires from consecutive same-day ETM+ and ASTER imagery in the Amazon: Implications for active fire product validation. IEEE J. Sel. Top. Appl. Earth Obs. Remote Sens. 1(4), 248&#x2013;253 (2008).</Citation></Reference><Reference><Citation>Cooperative Institute for Research in the Atmosphere. https://rammb2.cira.colostate.edu/wp-content/uploads/2020/01/VIIRS_Active_Fire_Quick_Guide_v1-2022.pdf .</Citation></Reference><Reference><Citation>Dickinson, M. B. et al. Measuring radiant emissions from entire prescribed fires with ground, airborne and satellite sensors&#x2013;RxCADRE 2012. Int. J. Wildland Fire 25, 48&#x2013;61. https://doi.org/10.1071/WF15090 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1071/WF15090</ArticleId></ArticleIdList></Reference><Reference><Citation>Boschetti, L. &amp; Roy, D. P. Defining a fire year for reporting and analysis of global interannual fire variability. J. Geophys. Res. 113, G03020. https://doi.org/10.1029/2008JG000686 (2008).</Citation><ArticleIdList><ArticleId IdType="doi">10.1029/2008JG000686</ArticleId></ArticleIdList></Reference><Reference><Citation>Sen, P. K. Estimates of the regression coefficient based on Kendall&#x2019;s. J. Am. Stat. Assoc. 63, 1379&#x2013;1389 (1968).</Citation></Reference><Reference><Citation>Helsel, D. R. &amp; Hirsch, R. M. Statistical methods in water resources. U.S. Geological survey technique of water resources investigations. Book 4, chapter A3, p 524 (2002).</Citation></Reference><Reference><Citation>Salmi, T., M&#xe4;&#xe4;tt&#xe4;, A., Anttila, P., Ruoho-Airola, T. &amp; Amnell, T. Detecting trends of annual values of atmospheric pollutants by the Mann-Kendall test and Sen&#x2019;s slope estimates-the excel template application MakeSens (Finnish Meteorological Institute, 2002).</Citation></Reference><Reference><Citation>Ward, J. H. Jr. Hierarchical grouping to optimize an objective function. J. Am. Stat. Assoc. 58, 236&#x2013;244 (1963).</Citation></Reference><Reference><Citation>Global Forest Watch. Accessed on 18 September 2024, https://www.globalforestwatch.org/dashboards/country/IND/?category=fires .</Citation></Reference><Reference><Citation>Indian Institute of Remote Sensing. Accessed on 10 May 2025. https://www.iirs.gov.in/iirs_slide_page?s=121 .</Citation></Reference><Reference><Citation>Roberts, G., Wooster, M. J. &amp; Lagoudakis, E. Annual and diurnal African biomass burning temporal dynamics. Biogeosciences 6, 849&#x2013;866. https://doi.org/10.5194/bg-6-849-2009 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.5194/bg-6-849-2009</ArticleId></ArticleIdList></Reference><Reference><Citation>Vadrevu, K. &amp; Lasko, K. Intercomparison of MODIS AQUA and VIIRS I-band fires and emissions in an agricultural landscape-implications for air pollution research. Remote Sens. 10, 978. https://doi.org/10.3390/rs10070978 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/rs10070978</ArticleId></ArticleIdList></Reference><Reference><Citation>Department of Agriculture and Framers Welfare. Accessed on 23 May 2024. https://agriwelfare.gov.in/Documents/CropSituation/crops_13012023.pdf .</Citation></Reference><Reference><Citation>Directorate of Rice Development. Accessed on 1 May 2024. https://drdpat.bih.nic.in/Status%20Paper%20-%2002.htm .</Citation></Reference><Reference><Citation>Forest Survey of India. Accessed on 3 April 2024. http://vanagniportal.fsiforestfire.gov.in/fsi_fire/fire.html .</Citation></Reference><Reference><Citation>Balasubramanian, A. Major Forest Areas in India. Technical Report, University of Mysore, India (2017). https://doi.org/10.13140/RG.2.2.17863.70563 .</Citation></Reference><Reference><Citation>Reddy, C. S. et al. Nationwide assessment of forest burnt area in India using Resourcesat-2 AWiFS data. Curr. Sci. 112(7), 1521&#x2013;1532. https://doi.org/10.18520/cs/v112/i07/1521-1532 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.18520/cs/v112/i07/1521-1532</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahuguna, V. K. &amp; Upadhay, A. Forest fires in India: Policy initiatives for community participation. Int. For. Rev. 4(2), 122&#x2013;127. https://doi.org/10.1505/IFOR.4.2.122.17446 (2002).</Citation><ArticleIdList><ArticleId IdType="doi">10.1505/IFOR.4.2.122.17446</ArticleId></ArticleIdList></Reference><Reference><Citation>North Eastern Space Applications Centre (NESAC). Forest Fire Assessment in Northeast India. North Eastern Space Applications Centre, Dept. of Space, Govt. of India, Meghalaya, India (2014).</Citation></Reference><Reference><Citation>Forest Survey of India. Accessed on 1 February 2024. http://vanagniportal.fsiforestfire.gov.in/fsi_fire/fire.html .</Citation></Reference><Reference><Citation>Yadav, K., Escobedo, F. J., Thomas, A. S. &amp; Johnson, N. G. Increasing wildfires and changing sociodemographics in communities across California, USA. Int. J. Disaster Risk Reduct. 98, 104065. https://doi.org/10.1016/j.ijdrr.2023.104065 (2023).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijdrr.2023.104065</ArticleId></ArticleIdList></Reference><Reference><Citation>Radeloff, V. C. et al. Rapid growth of the US wildland-urban interface raises wildfire risk. PNAS 115(13), 3314&#x2013;3319. https://doi.org/10.1073/pnas.1718850115 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1718850115</ArticleId></ArticleIdList></Reference><Reference><Citation>Kramer, H. A., Mockrin, M. H., Alexandre, P. M. &amp; Radeloff, V. C. High wildfire damage in interface communities in California. Int. J. Wildland Fire 28(9), 641&#x2013;650. https://doi.org/10.1071/WF18108 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1071/WF18108</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, B. et al. Wildfire risk for global wildland&#x2013;urban interface areas. Nat. Sust. 7, 474&#x2013;484. https://doi.org/10.1038/s41893-024-01291-0 (2024).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41893-024-01291-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Bikkina, S. et al. Air quality in megacity Delhi affected by countryside biomass burning. Nat. Sust. 2, 200&#x2013;205. https://doi.org/10.1038/s41893-019-0219-0 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41893-019-0219-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Majumdar, D. Spatial distribution and temporal variation of biomass burning and surface black carbon concentrations during summer (2015&#x2013;2021) in India. Air Qual. Atmos. Health 16, 459&#x2013;476. https://doi.org/10.1007/s11869-022-01284-y (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11869-022-01284-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang, X., Zhao, C., Yang, Y., Yan, X. &amp; Fan, H. Statistical aerosol properties associated with fire events from 2002 to 2019 and a case analysis in 2019 over Australia. Atmos. Chem. Phys. 21, 3833&#x2013;3853. https://doi.org/10.5194/acp-21-3833-2021 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.5194/acp-21-3833-2021</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan, H. et al. The role of primary emission and transboundary transport in the air quality changes during and after the COVID-19 lockdown in China. Geophys. Res. Lett. 48(7), e2020GL091065. https://doi.org/10.1029/2020GL091065 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1029/2020GL091065</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang, X., Zhao, C., Yang, Y. &amp; Fan, H. Long-term multi-source data analysis about the characteristics of aerosol optical properties and types over Australia. Atmos. Chem. Phys. 21, 3803&#x2013;3825. https://doi.org/10.5194/acp-21-3803-2021 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.5194/acp-21-3803-2021</ArticleId></ArticleIdList></Reference><Reference><Citation>Tonini, M. M., Pereira, M. G., Parente, J. &amp; Orozco, C. V. Evolution of forest fires in Portugal: From spatiotemporal point events to smoothed density maps. Nat. Haz. 85, 1489&#x2013;1510. https://doi.org/10.1007/s11069-016-2637-x (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11069-016-2637-x</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40715151</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>25</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Vasoprotective effects of lysophosphatidic acid inhibit vascular injury caused by SARS-CoV-2 infection.</ArticleTitle><Pagination><StartPage>24622</StartPage><MedlinePgn>24622</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-025-06569-7</ELocationID><Abstract><AbstractText>Vasculitis and vascular injury are induced in coronavirus disease 2019 (COVID-19) patients, suggesting an association between multi-organ failure and sequelae. Vascular endothelial dysfunction induced by severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) disrupts vascular barrier function, activates coagulation pathways, and induces extravasation of inflammatory cells. In addition to employing standard anti-inflammatory and antiviral agents, using treatments that stabilize and protect blood vessels following SARS-CoV-2 infection is a potentially effective strategy to relieve COVID-19 severity. Here, we focused on the vasoprotective effects of lysophosphatidic acid (LPA), a lipid mediator with diverse activities, and investigated whether it could be a novel therapeutic for COVID-19. Three-dimensional cultures of various human vascular endothelial cells that form luminal structures showed increased expression of LPA4 and entry receptors for SARS-CoV-2 infection, mimicking blood vessels in vivo. Validation using this culture system showed that LPA attenuated SARS-CoV-2 infection-induced vascular destruction and the activation of inflammatory signaling. In experiments with infected animals, LPA administration protected blood vessels and suppressed inflammation and vascular damage in lung tissue. The activation of LPA signaling in vascular endothelial cells may be an effective therapeutic approach for mitigating vascular injury in COVID-19.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Muramatsu</LastName><ForeName>Fumitaka</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Signal Transduction, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, 565-0871, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives, Osaka University, Suita, Osaka, 565-0871, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hosoe</LastName><ForeName>Naoi</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Integrative Vascular Biology, Faculty of Medical Sciences, University of Fukui, 23-&#x2009;3 Matsuoka-Shimoaizuki, Eiheiji, Yoshida, Fukui, 910-1193, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suzuki</LastName><ForeName>Tatsuya</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Juntendo University School of Medicine, Tokyo, 113- 8421, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shimamura</LastName><ForeName>Teppei</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Computational and Systems Biology, Medical Research Institute, Institute of Science Tokyo, Bunkyo-ku, Tokyo, 113-8510, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hayashi</LastName><ForeName>Yumiko</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Integrative Vascular Biology, Faculty of Medical Sciences, University of Fukui, 23-&#x2009;3 Matsuoka-Shimoaizuki, Eiheiji, Yoshida, Fukui, 910-1193, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takara</LastName><ForeName>Kazuhiro</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Integrative Vascular Biology, Faculty of Medical Sciences, University of Fukui, 23-&#x2009;3 Matsuoka-Shimoaizuki, Eiheiji, Yoshida, Fukui, 910-1193, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lynda</LastName><ForeName>Lamri</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Integrative Vascular Biology, Faculty of Medical Sciences, University of Fukui, 23-&#x2009;3 Matsuoka-Shimoaizuki, Eiheiji, Yoshida, Fukui, 910-1193, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shimizu</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Integrative Vascular Biology, Faculty of Medical Sciences, University of Fukui, 23-&#x2009;3 Matsuoka-Shimoaizuki, Eiheiji, Yoshida, Fukui, 910-1193, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jia</LastName><ForeName>Weizhen</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Signal Transduction, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, 565-0871, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Noda</LastName><ForeName>Yoshimi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Signal Transduction, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, 565-0871, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takakura</LastName><ForeName>Nobuyuki</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Signal Transduction, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, 565-0871, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives, Osaka University, Suita, Osaka, 565-0871, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okamoto</LastName><ForeName>Toru</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Juntendo University School of Medicine, Tokyo, 113- 8421, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kidoya</LastName><ForeName>Hiroyasu</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Integrative Vascular Biology, Faculty of Medical Sciences, University of Fukui, 23-&#x2009;3 Matsuoka-Shimoaizuki, Eiheiji, Yoshida, Fukui, 910-1193, Japan. kidoya@u-fukui.ac.jp.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Signal Transduction, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, 565-0871, Japan. kidoya@u-fukui.ac.jp.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives, Osaka University, Suita, Osaka, 565-0871, Japan. kidoya@u-fukui.ac.jp.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>20fk0108303h0001</GrantID><Agency>Japan Agency for Medical Research and Development</Agency><Country/></Grant><Grant><GrantID>20fk0108303h0001</GrantID><Agency>Japan Agency for Medical Research and Development</Agency><Country/></Grant><Grant><GrantID>20fk0108303h0001</GrantID><Agency>Japan Agency for Medical Research and Development</Agency><Country/></Grant><Grant><GrantID>JPMJPR1944</GrantID><Agency>PRESTO-JST</Agency><Country/></Grant><Grant><GrantID>JPMJFR2160</GrantID><Agency>JST FOREST Program</Agency><Country/></Grant><Grant><GrantID>23H04931</GrantID><Agency>JSPS Grant-in-Aid for Transformative Research Areas (A)</Agency><Country/></Grant><Grant><GrantID>22K19453</GrantID><Agency>JSPS Grant-in-Aid for Challenging Research (Exploratory)</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Lysophosphatidic acid (LPA)</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Vascular endothelial cell</Keyword><Keyword MajorTopicYN="N">Vascular injury</Keyword></KeywordList><CoiStatement>Declarations. Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>27</Day><Hour>11</Hour><Minute>19</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40715151</ArticleId><ArticleId IdType="doi">10.1038/s41598-025-06569-7</ArticleId><ArticleId IdType="pii">10.1038/s41598-025-06569-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ackermann, M. et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl. J. Med. 383, 120&#x2013;128. https://doi.org/10.1056/NEJMoa2015432 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2015432</ArticleId><ArticleId IdType="pubmed">32437596</ArticleId><ArticleId IdType="pmc">7412750</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker, R. C. COVID-19-associated vasculitis and vasculopathy. J. Thromb. Thrombolysis. 50, 499&#x2013;511. https://doi.org/10.1007/s11239-020-02230-4 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-020-02230-4</ArticleId><ArticleId IdType="pubmed">32700024</ArticleId><ArticleId IdType="pmc">7373848</ArticleId></ArticleIdList></Reference><Reference><Citation>Varga, Z. et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet 395, 1417&#x2013;1418. https://doi.org/10.1016/S0140-6736(20)30937-5 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30937-5</ArticleId><ArticleId IdType="pubmed">32325026</ArticleId><ArticleId IdType="pmc">7172722</ArticleId></ArticleIdList></Reference><Reference><Citation>Jose, R. J. &amp; Manuel, A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir Med. 8, e46&#x2013;e47. https://doi.org/10.1016/S2213-2600(20)30216-2 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30216-2</ArticleId><ArticleId IdType="pubmed">32353251</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy, J. H. et al. COVID-19: thrombosis, thromboinflammation, and anticoagulation considerations. Int. J. Lab. Hematol. 43 (Suppl 1), 29&#x2013;35. https://doi.org/10.1111/ijlh.13500 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ijlh.13500</ArticleId><ArticleId IdType="pubmed">34288441</ArticleId><ArticleId IdType="pmc">8444926</ArticleId></ArticleIdList></Reference><Reference><Citation>Teuwen, L. A., Geldhof, V., Pasut, A. &amp; Carmeliet, P. COVID-19: the vasculature unleashed. Nat. Rev. Immunol. 20, 389&#x2013;391. https://doi.org/10.1038/s41577-020-0343-0 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-0343-0</ArticleId><ArticleId IdType="pubmed">32439870</ArticleId><ArticleId IdType="pmc">7240244</ArticleId></ArticleIdList></Reference><Reference><Citation>McCracken, I. R. et al. Lack of evidence of Angiotensin-Converting enzyme 2 expression and replicative infection by SARS-CoV-2 in human endothelial cells. Circulation 143, 865&#x2013;868. https://doi.org/10.1161/CIRCULATIONAHA.120.052824 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.120.052824</ArticleId><ArticleId IdType="pubmed">33405941</ArticleId><ArticleId IdType="pmc">7899720</ArticleId></ArticleIdList></Reference><Reference><Citation>Cantuti-Castelvetri, L. et al. Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity. Science 370, 856&#x2013;860. https://doi.org/10.1126/science.abd2985 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd2985</ArticleId><ArticleId IdType="pubmed">33082293</ArticleId><ArticleId IdType="pmc">7857391</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei, Y. et al. SARS-CoV-2 Spike Protein Impairs Endothelial Function via Downregulation of ACE2. bioRxiv, (2020). https://doi.org/10.1101/2020.12.04.409144</Citation></Reference><Reference><Citation>Evans, P. C. et al. Endothelial dysfunction in COVID-19: a position paper of the ESC working group for atherosclerosis and vascular biology, and the ESC Council of basic cardiovascular science. Cardiovasc. Res. 116, 2177&#x2013;2184. https://doi.org/10.1093/cvr/cvaa230 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cvr/cvaa230</ArticleId><ArticleId IdType="pubmed">32750108</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannotta, M., Trani, M. &amp; Dejana, E. VE-cadherin and endothelial adherens junctions: active guardians of vascular integrity. Dev. Cell. 26, 441&#x2013;454. https://doi.org/10.1016/j.devcel.2013.08.020 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.devcel.2013.08.020</ArticleId><ArticleId IdType="pubmed">24044891</ArticleId></ArticleIdList></Reference><Reference><Citation>Pober, J. S. &amp; Sessa, W. C. Evolving functions of endothelial cells in inflammation. Nat. Rev. Immunol. 7, 803&#x2013;815. https://doi.org/10.1038/nri2171 (2007).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri2171</ArticleId><ArticleId IdType="pubmed">17893694</ArticleId></ArticleIdList></Reference><Reference><Citation>Moolenaar, W. H., van Meeteren, L. A. &amp; Giepmans, B. N. The Ins and outs of lysophosphatidic acid signaling. Bioessays 26, 870&#x2013;881. https://doi.org/10.1002/bies.20081 (2004).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bies.20081</ArticleId><ArticleId IdType="pubmed">15273989</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka, M. et al. Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid. J. Biol. Chem. 281, 25822&#x2013;25830. https://doi.org/10.1074/jbc.M605142200 (2006).</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M605142200</ArticleId><ArticleId IdType="pubmed">16829511</ArticleId></ArticleIdList></Reference><Reference><Citation>van Meeteren, L. A. et al. Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. Mol. Cell. Biol. 26, 5015&#x2013;5022. https://doi.org/10.1128/MCB.02419-05 (2006).</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.02419-05</ArticleId><ArticleId IdType="pubmed">16782887</ArticleId><ArticleId IdType="pmc">1489177</ArticleId></ArticleIdList></Reference><Reference><Citation>Noguchi, K., Herr, D., Mutoh, T. &amp; Chun, J. Lysophosphatidic acid (LPA) and its receptors. Curr. Opin. Pharmacol. 9, 15&#x2013;23. https://doi.org/10.1016/j.coph.2008.11.010 (2009).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coph.2008.11.010</ArticleId><ArticleId IdType="pubmed">19119080</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasuda, D. et al. Lysophosphatidic acid-induced YAP/TAZ activation promotes developmental angiogenesis by repressing Notch ligand Dll4. J. Clin. Invest. 129, 4332&#x2013;4349. https://doi.org/10.1172/JCI121955 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI121955</ArticleId><ArticleId IdType="pubmed">31335323</ArticleId><ArticleId IdType="pmc">6763231</ArticleId></ArticleIdList></Reference><Reference><Citation>Takara, K. et al. Lysophosphatidic acid receptor 4 activation augments drug delivery in tumors by tightening endothelial Cell-Cell contact. Cell. Rep. 20, 2072&#x2013;2086. https://doi.org/10.1016/j.celrep.2017.07.080 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2017.07.080</ArticleId><ArticleId IdType="pubmed">28854359</ArticleId></ArticleIdList></Reference><Reference><Citation>Eino, D. et al. LPA4-Mediated vascular network formation increases the efficacy of Anti-PD-1 therapy against brain tumors. Cancer Res. 78, 6607&#x2013;6620. https://doi.org/10.1158/0008-5472.CAN-18-0498 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-18-0498</ArticleId><ArticleId IdType="pubmed">30301839</ArticleId></ArticleIdList></Reference><Reference><Citation>Higuchi, Y. et al. Engineered ACE2 receptor therapy overcomes mutational escape of SARS-CoV-2. Nat. Commun. 12, 3802. https://doi.org/10.1038/s41467-021-24013-y (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-24013-y</ArticleId><ArticleId IdType="pubmed">34155214</ArticleId><ArticleId IdType="pmc">8217473</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikemura, N. et al. An engineered ACE2 decoy neutralizes the SARS-CoV-2 Omicron variant and confers protection against infection in vivo. Sci. Transl Med. 14, eabn7737. https://doi.org/10.1126/scitranslmed.abn7737 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abn7737</ArticleId><ArticleId IdType="pubmed">35471044</ArticleId></ArticleIdList></Reference><Reference><Citation>Yanagida, K. &amp; Shimizu, T. Lysophosphatidic acid, a simple phospholipid with myriad functions. Pharmacol. Ther. 246, 108421. https://doi.org/10.1016/j.pharmthera.2023.108421 (2023).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pharmthera.2023.108421</ArticleId><ArticleId IdType="pubmed">37080433</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang, S. et al. IL-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome. Proc. Natl. Acad. Sci. U S A. 117, 22351&#x2013;22356. https://doi.org/10.1073/pnas.2010229117 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2010229117</ArticleId><ArticleId IdType="pubmed">32826331</ArticleId><ArticleId IdType="pmc">7486751</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez-Parra, G. &amp; Dobrovolny, H. M. The rate of viral transfer between upper and lower respiratory tracts determines RSV illness duration. J. Math. Biol. 79, 467&#x2013;483. https://doi.org/10.1007/s00285-019-01364-1 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00285-019-01364-1</ArticleId><ArticleId IdType="pubmed">31011792</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellanti, J. A. The long COVID syndrome: A conundrum for the allergist/immunologist. Allergy Asthma Proc. 43, 368&#x2013;374. https://doi.org/10.2500/aap.2022.43.220059 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.2500/aap.2022.43.220059</ArticleId><ArticleId IdType="pubmed">36065103</ArticleId><ArticleId IdType="pmc">9465643</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiao, H. et al. SARS-CoV-2 induces blood-brain barrier and choroid plexus barrier impairments and vascular inflammation in mice. J. Med. Virol. 96, e29671. https://doi.org/10.1002/jmv.29671 (2024).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.29671</ArticleId><ArticleId IdType="pubmed">38747003</ArticleId><ArticleId IdType="pmc">11446308</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas, D. et al. CCL2-mediated endothelial injury drives cardiac dysfunction in long COVID. Nat. Cardiovasc. Res. 3, 1249&#x2013;1265. https://doi.org/10.1038/s44161-024-00543-8 (2024).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s44161-024-00543-8</ArticleId><ArticleId IdType="pubmed">39402206</ArticleId></ArticleIdList></Reference><Reference><Citation>Murikipudi, S., Methe, H. &amp; Edelman, E. R. The effect of substrate modulus on the growth and function of matrix-embedded endothelial cells. Biomaterials 34, 677&#x2013;684. https://doi.org/10.1016/j.biomaterials.2012.09.079 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biomaterials.2012.09.079</ArticleId><ArticleId IdType="pubmed">23102623</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng, H. et al. Endothelial dysfunction and SARS-CoV-2 infection: association and therapeutic strategies. Pathogens 10 https://doi.org/10.3390/pathogens10050582 (2021).</Citation></Reference><Reference><Citation>Colmenero, I. et al. SARS-CoV-2 endothelial infection causes COVID-19 chilblains: histopathological, immunohistochemical and ultrastructural study of seven paediatric cases. Br. J. Dermatol. 183, 729&#x2013;737. https://doi.org/10.1111/bjd.19327 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjd.19327</ArticleId><ArticleId IdType="pubmed">32562567</ArticleId><ArticleId IdType="pmc">7323219</ArticleId></ArticleIdList></Reference><Reference><Citation>Thacker, V. V. et al. Rapid endotheliitis and vascular damage characterize SARS-CoV-2 infection in a human lung-on-chip model. EMBO Rep. 22, e52744. https://doi.org/10.15252/embr.202152744 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embr.202152744</ArticleId><ArticleId IdType="pubmed">33908688</ArticleId><ArticleId IdType="pmc">8183417</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin, Y. et al. Endothelial activation and dysfunction in COVID-19: from basic mechanisms to potential therapeutic approaches. Signal. Transduct. Target. Ther. 5, 293. https://doi.org/10.1038/s41392-020-00454-7 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-020-00454-7</ArticleId><ArticleId IdType="pubmed">33361764</ArticleId><ArticleId IdType="pmc">7758411</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwasaki, M. et al. Inflammation triggered by SARS-CoV-2 and ACE2 augment drives multiple organ failure of severe COVID-19: molecular mechanisms and implications. Inflammation 44, 13&#x2013;34. https://doi.org/10.1007/s10753-020-01337-3 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10753-020-01337-3</ArticleId><ArticleId IdType="pubmed">33029758</ArticleId></ArticleIdList></Reference><Reference><Citation>Pelle, M. C. et al. Endothelial dysfunction in COVID-19: potential mechanisms and possible therapeutic options. Life (Basel). 12 https://doi.org/10.3390/life12101605 (2022).</Citation></Reference><Reference><Citation>Manzur-Pineda, K. et al. COVID-19-related thrombotic complications experience before and during delta wave. J Vasc Surg 76, 1374&#x2013;1382 e1371, (2022). https://doi.org/10.1016/j.jvs.2022.04.053</Citation></Reference><Reference><Citation>Matute-Bello, G. et al. An official American thoracic society workshop report: features and measurements of experimental acute lung injury in animals. Am. J. Respir Cell. Mol. Biol. 44, 725&#x2013;738. https://doi.org/10.1165/rcmb.2009-0210ST (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1165/rcmb.2009-0210ST</ArticleId><ArticleId IdType="pubmed">21531958</ArticleId><ArticleId IdType="pmc">7328339</ArticleId></ArticleIdList></Reference><Reference><Citation>Kidoya, H. et al. APJ regulates parallel alignment of arteries and veins in the skin. Dev. Cell. 33, 247&#x2013;259. https://doi.org/10.1016/j.devcel.2015.02.024 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.devcel.2015.02.024</ArticleId><ArticleId IdType="pubmed">25920569</ArticleId></ArticleIdList></Reference><Reference><Citation>Ge, S. X., Son, E. W. &amp; Yao, R. iDEP: an integrated web application for differential expression and pathway analysis of RNA-Seq data. BMC Bioinform. 19, 534. https://doi.org/10.1186/s12859-018-2486-6 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12859-018-2486-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Ge, X. iDEP web application for RNA-Seq data analysis. Methods Mol. Biol. 2284, 417&#x2013;443. https://doi.org/10.1007/978-1-0716-1307-8_22 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-0716-1307-8_22</ArticleId><ArticleId IdType="pubmed">33835455</ArticleId></ArticleIdList></Reference><Reference><Citation>Love, M. I., Huber, W. &amp; Anders, S. Moderated Estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550. https://doi.org/10.1186/s13059-014-0550-8 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-014-0550-8</ArticleId><ArticleId IdType="pubmed">25516281</ArticleId><ArticleId IdType="pmc">4302049</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashburner, M. et al. Gene ontology: tool for the unification of biology. The gene ontology consortium. Nat. Genet. 25, 25&#x2013;29. https://doi.org/10.1038/75556 (2000).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/75556</ArticleId><ArticleId IdType="pubmed">10802651</ArticleId><ArticleId IdType="pmc">3037419</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanehisa, M. &amp; Goto, S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27&#x2013;30. https://doi.org/10.1093/nar/28.1.27 (2000).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/28.1.27</ArticleId><ArticleId IdType="pubmed">10592173</ArticleId><ArticleId IdType="pmc">102409</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40714940</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>27</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1099-1654</ISSN><JournalIssue CitedMedium="Internet"><Volume>35</Volume><Issue>4</Issue><PubDate><Year>2025</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Reviews in medical virology</Title><ISOAbbreviation>Rev Med Virol</ISOAbbreviation></Journal><ArticleTitle>The Role of Emerging/Re-Emerging RNA Viruses in Bone-Related Diseases With a Focus on DENV, CHIKV, and SARS-CoV-2.</ArticleTitle><Pagination><StartPage>e70053</StartPage><MedlinePgn>e70053</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/rmv.70053</ELocationID><Abstract><AbstractText>Emerging and re-emerging RNA viruses represent a persistent and evolving global health threat. While primarily recognized for their acute systemic or respiratory illnesses, a growing body of evidence implicates several of these pathogens in the development or exacerbation of bone-related diseases. This review critically describes the multifaceted roles of selected major RNA viruses-Dengue Virus (DENV), Chikungunya Virus (CHIKV), and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)- in bone-related diseases. It discusses the current understanding of the clinical manifestations, ranging from arthralgia and arthritis to more severe outcomes such as osteopenia, osteoporosis, and bone erosions. The review describes the potential pathogenic mechanisms, including direct viral infection of bone cells (osteoblasts, osteoclasts, and osteocytes), as well as virus-induced dysregulation of host immune responses that lead to pro-inflammatory cytokine storms and altered signalling pathways, collectively driving aberrant bone remodelling. By discussing current knowledge, this review aims to highlight the significant, yet often underappreciated, impact of these RNA viruses on bone health, identify existing knowledge gaps, and underscore the need for further mechanistic research to inform targeted therapeutic and preventive strategies that reduce bone morbidity in affected populations.</AbstractText><CopyrightInformation>&#xa9; 2025 John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jinxi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Orthopaedics, Hangzhou Ninth People's Hospital, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Jiandong</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Orthopaedics, Hangzhou Ninth People's Hospital, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jian</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Orthopaedics, Hangzhou Ninth People's Hospital, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Jiawei</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Orthopaedics, Hangzhou Ninth People's Hospital, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Orthopaedics, Hangzhou Ninth People's Hospital, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Shuying</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery, Sir Run Run Shaw Hospital, Medical College of Zhejiang University, Hangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Musculoskeletal System Degeneration and Regeneration Translational Research of Zhejiang Province, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Jianglong</ForeName><Initials>J</Initials><Identifier Source="ORCID">0009-0001-0335-8927</Identifier><AffiliationInfo><Affiliation>Department of Orthopaedics, Hangzhou Ninth People's Hospital, Hangzhou, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>20222A146</GrantID><Agency>Zhejiang Traditional Chinese Medicine Science and Technology Project</Agency><Country/></Grant><Grant><GrantID>LGF22H060032</GrantID><Agency>Zhejiang Provincial Basic Public Welfare Research Program</Agency><Country/></Grant><Grant><GrantID>A20210086</GrantID><Agency>Hangzhou Health and Family Planning Science and Technology Program</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Rev Med Virol</MedlineTA><NlmUniqueID>9112448</NlmUniqueID><ISSNLinking>1052-9276</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">bone diseases</Keyword><Keyword MajorTopicYN="N">chikungunya virus (CHIKV)</Keyword><Keyword MajorTopicYN="N">dengue virus (DENV)</Keyword><Keyword MajorTopicYN="N">severe acute respiratory syndrome coronavirus 2 (SARS&#x2010;CoV&#x2010;2)</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>6</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>27</Day><Hour>8</Hour><Minute>12</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40714940</ArticleId><ArticleId IdType="doi">10.1002/rmv.70053</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>M. B. Sannathimmappa, V. Nambiar, and R. Patil, &#x201c;Emerging and Re&#x2010;emerging Viral Infections in the 21st Century: Microbiological and Public Health Perspectives,&#x201d; Journal of Krishna Institute of Medical Sciences 10, no. 2 (2021).</Citation></Reference><Reference><Citation>S. Onuora, &#x201c;A Direct Link Between SARS&#x2010;CoV&#x2010;2 and Bone Loss,&#x201d; Nature Reviews Rheumatology 21, no. 3 (2025): 1, https://doi.org/10.1038/s41584&#x2010;025&#x2010;01224&#x2010;x.</Citation></Reference><Reference><Citation>S. Noisakran, N. Onlamoon, H.&#x2010;M. Hsiao, et&#xa0;al., &#x201c;Infection of Bone Marrow Cells by Dengue Virus In Vivo,&#x201d; Experimental Hematology 40, no. 3 (2012): 250&#x2013;259.e4, https://doi.org/10.1016/j.exphem.2011.11.011.</Citation></Reference><Reference><Citation>A. M. Avila&#x2010;Trejo, L. I. Rodr&#xed;guez&#x2010;P&#xe1;ez, V. Alc&#xe1;ntara&#x2010;Farf&#xe1;n, and J. L. Aguilar&#x2010;Faisal, &#x201c;Multiple Factors Involved in Bone Damage Caused by Chikungunya Virus Infection,&#x201d; International Journal of Molecular Sciences 24, no. 17 (2023): 13087, https://doi.org/10.3390/ijms241713087.</Citation></Reference><Reference><Citation>L. Drago, C. L. Roman&#xf2;, I. Morelli, and T. Benzakour, Viral Bone Infection: A Neglected Disease? (MDPI, 2020), 797.</Citation></Reference><Reference><Citation>T. Nakashima, M. Hayashi, T. Fukunaga, et&#xa0;al., &#x201c;Evidence for Osteocyte Regulation of Bone Homeostasis Through RANKL Expression,&#x201d; Nature Medicine 17, no. 10 (2011): 1231&#x2013;1234, https://doi.org/10.1038/nm.2452.</Citation></Reference><Reference><Citation>S. M. A. Toloza and S. E. Ag&#xfc;ero, &#x201c;Arthritis Associated With Alphavirus Infections: Dengue and Zika,&#x201d; in Infections and the Rheumatic Diseases. L. R. Espinoza, ed. (Springer International Publishing, 2019), 125&#x2013;142.</Citation></Reference><Reference><Citation>B. A. Goupil and C. N. Mores, &#x201c;A Review of Chikungunya Virus&#x2010;Induced Arthralgia: Clinical Manifestations, Therapeutics, and Pathogenesis,&#x201d; Open Rheumatology Journal 10, no. 1 (2016): 129&#x2013;140, https://doi.org/10.2174/1874312901610010129.</Citation></Reference><Reference><Citation>M. Tsukasaki and H. Takayanagi, &#x201c;Osteoimmunology: Evolving Concepts in Bone&#x2013;Immune Interactions in Health and Disease,&#x201d; Nature Reviews Immunology 19, no. 10 (2019): 626&#x2013;642, https://doi.org/10.1038/s41577&#x2010;019&#x2010;0178&#x2010;8.</Citation></Reference><Reference><Citation>C. S.&#x2010;P. Terrier and P. Gasque, &#x201c;Bone Responses in Health and Infectious Diseases: A Focus on Osteoblasts,&#x201d; Journal of Infection 75, no. 4 (2017): 281&#x2013;292, https://doi.org/10.1016/j.jinf.2017.07.007.</Citation></Reference><Reference><Citation>C. C. Caetano, T. Azamor, N. M. Meyer, et&#xa0;al., &#x201c;Mechanistic Insights Into Bone Remodelling Dysregulation by Human Viral Pathogens,&#x201d; Nature Microbiology 9, no. 2 (2024): 322&#x2013;335, https://doi.org/10.1038/s41564&#x2010;023&#x2010;01586&#x2010;6.</Citation></Reference><Reference><Citation>S. R. Goldring, &#x201c;Bone and Joint Destruction in Rheumatoid Arthritis: What is Really Happening?,&#x201d; Journal of Rheumatology. Supplement 65 (2002): 44&#x2013;48.</Citation></Reference><Reference><Citation>N. Mumtaz, M. Koedam, P. B. van den Doel, et&#xa0;al., &#x201c;Zika Virus Infection Perturbs Osteoblast Function,&#x201d; Scientific Reports 8, no. 1 (2018): 16975, https://doi.org/10.1038/s41598&#x2010;018&#x2010;35422&#x2010;3.</Citation></Reference><Reference><Citation>A. Anoopkumar and E. M. Aneesh, &#x201c;Environmental Epidemiology and Neurological Manifestations of Dengue Serotypes With Special Inference on Molecular Trends, Virus Detection, and Pathogenicity,&#x201d; Environment, Development and Sustainability 23, no. 8 (2021): 11217&#x2013;11239, https://doi.org/10.1007/s10668&#x2010;020&#x2010;01161&#x2010;7.</Citation></Reference><Reference><Citation>S. Bhatt, P. W. Gething, O. J. Brady, et&#xa0;al., &#x201c;The Global Distribution and Burden of Dengue,&#x201d; Nature 496, no. 7446 (2013): 504&#x2013;507, https://doi.org/10.1038/nature12060.</Citation></Reference><Reference><Citation>Z. Mardashti, S. Fatollahi Arani, and M. Shoushtari, &#x201c;Dengue Fever Disease: Diagnosis, Treatment and Control Strategies,&#x201d; Modares Journal of Biotechnology 16, no. 1 (2024): 123&#x2013;140.</Citation></Reference><Reference><Citation>R. Aguas, I. Dorigatti, L. Coudeville, C. Luxemburger, and N. Ferguson, &#x201c;Cross&#x2010;Serotype Interactions and Disease Outcome Prediction of Dengue Infections in Vietnam,&#x201d; Scientific Reports 9, no. 1 (2019): 9395, https://doi.org/10.1038/s41598&#x2010;019&#x2010;45816&#x2010;6.</Citation></Reference><Reference><Citation>D. Shamala, &#x201c;Dengue: Breakbone Fever, Hemorrhagia or Shock,&#x201d; Journal of Health and Translational Medicine 11, no. 2 (2008): 39&#x2013;52, https://doi.org/10.22452/jummec.vol11no2.2.</Citation></Reference><Reference><Citation>T. H. Mallhi, Y. H. Khan, A. S. Adnan, et&#xa0;al., Dengue&#x2010;Induced Musculoskeletal Complications (Expanded Dengue Syndrome, 2021), 97&#x2013;114.</Citation></Reference><Reference><Citation>L. I. Zambrano, I. C. Fuentes&#x2010;Barahona, R. Portillo&#x2010;Pineda, et&#xa0;al., &#x201c;Assessment of Post&#x2010;Dengue Rheumatic Symptoms Using the WOMAC and DAS&#x2010;28 Questionnaires in a Honduran Population After a Four&#x2010;Month Follow&#x2010;Up,&#x201d; Tropical Medicine and Infectious Disease 7, no. 12 (2022): 394, https://doi.org/10.3390/tropicalmed7120394.</Citation></Reference><Reference><Citation>Y.&#x2010;W. Chen, T.&#x2010;Y. Hsieh, C.&#x2010;H. Lin, H.&#x2010;M. Chen, C.&#x2010;C. Lin, and H.&#x2010;H. Chen, &#x201c;Association Between a History of Dengue Fever and the Risk of Systemic Autoimmune Rheumatic Diseases: A Nationwide, Population&#x2010;Based Case&#x2010;Control Study,&#x201d; Frontiers of Medicine 8 (2021): 738291, https://doi.org/10.3389/fmed.2021.738291.</Citation></Reference><Reference><Citation>A. C. Outhred, J. Kok, and D. E. Dwyer, &#x201c;Viral Arthritides,&#x201d; Expert Review of Anti&#x2010;infective Therapy 9, no. 5 (2011): 545&#x2013;554, https://doi.org/10.1586/eri.11.34.</Citation></Reference><Reference><Citation>M. Indurkar and R. Sethi, &#x201c;An Unusual Case of Osteonecrosis of the Jaw Associated With Dengue Fever and Periodontitis,&#x201d; Australian Dental Journal 61, no. 1 (2016): 113&#x2013;119, https://doi.org/10.1111/adj.12308.</Citation></Reference><Reference><Citation>S. R. Prakash, A. Nasim, N. Kamarthi, and S. Gupta, &#x201c;Osteonecrosis of Jaw Bones: A Complication of Severe Dengue,&#x201d; Journal of Indian Academy of Oral Medicine and Radiology 30, no. 2 (2018): 173&#x2013;176, https://doi.org/10.4103/jiaomr.jiaomr_59_18.</Citation></Reference><Reference><Citation>N. Al&#x2010;Namnam, P. Nambiar, P. Shanmuhasuntharam, and M. Harris, &#x201c;A Case of Dengue&#x2010;Related Osteonecrosis of the Maxillary Dentoalveolar Bone,&#x201d; Australian Dental Journal 62, no. 2 (2017): 228&#x2013;232, https://doi.org/10.1111/adj.12472.</Citation></Reference><Reference><Citation>A. L. Rothman, &#x201c;Immunity to Dengue Virus: A Tale of Original Antigenic Sin and Tropical Cytokine Storms,&#x201d; Nature Reviews Immunology 11, no. 8 (2011): 532&#x2013;543, https://doi.org/10.1038/nri3014.</Citation></Reference><Reference><Citation>S. Balaiya, J. Edwards, T. Tillis, V. Khetpal, and K. V. Chalam, &#x201c;Tumor Necrosis Factor&#x2010;Alpha (TNF&#x2010;&#x3b1;) Levels in Aqueous Humor of Primary Open Angle Glaucoma,&#x201d; Clinical Ophthalmology (2011): 553&#x2013;556, https://doi.org/10.2147/opth.s19453.</Citation></Reference><Reference><Citation>G. Luo, F. Li, X. Li, Z. G. Wang, and B. Zhang, &#x201c;TNF&#x2010;&#x391; and RANKL Promote Osteoclastogenesis by Upregulating RANK via the NF&#x2010;&#x39a;b Pathway,&#x201d; Molecular Medicine Reports 17, no. 5 (2018): 6605&#x2013;6611, https://doi.org/10.3892/mmr.2018.8698.</Citation></Reference><Reference><Citation>L. Gilbert, X. He, P. Farmer, et&#xa0;al., &#x201c;Inhibition of Osteoblast Differentiation by Tumor Necrosis Factor&#x2010;&#x3b1;,&#x201d; Endocrinology 141, no. 11 (2000): 3956&#x2013;3964, https://doi.org/10.1210/en.141.11.3956.</Citation></Reference><Reference><Citation>A. Liacini, J. Sylvester, W. Q. Li, et&#xa0;al., &#x201c;Induction of Matrix Metalloproteinase&#x2010;13 Gene Expression by TNF&#x2010;&#x3b1; Is Mediated by MAP Kinases, AP&#x2010;1, and NF&#x2010;&#x39a;b Transcription Factors in Articular Chondrocytes,&#x201d; Experimental Cell Research 288, no. 1 (2003): 208&#x2013;217, https://doi.org/10.1016/s0014&#x2010;4827(03)00180&#x2010;0.</Citation></Reference><Reference><Citation>P. Pan, Q. Zhang, W. Liu, et&#xa0;al., &#x201c;Dengue Virus Infection Activates Interleukin&#x2010;1&#x3b2; to Induce Tissue Injury and Vascular Leakage,&#x201d; Frontiers in Microbiology 10 (2019): 2637, https://doi.org/10.3389/fmicb.2019.02637.</Citation></Reference><Reference><Citation>P. Ruscitti, P. Cipriani, F. Carubbi, et&#xa0;al., &#x201c;The Role of IL&#x2010;1&#x3b2; in the Bone Loss During Rheumatic Diseases,&#x201d; Mediators of Inflammation 2015, no. 1 (2015): 782382, https://doi.org/10.1155/2015/782382.</Citation></Reference><Reference><Citation>Y.&#x2010;L. Huang, S.&#x2010;T. Chen, R.&#x2010;S. Liu, et&#xa0;al., &#x201c;CLEC5A Is Critical for Dengue Virus&#x2010;Induced Osteoclast Activation and Bone Homeostasis,&#x201d; Journal of Molecular Medicine 94, no. 9 (2016): 1025&#x2013;1037, https://doi.org/10.1007/s00109&#x2010;016&#x2010;1409&#x2010;0.</Citation></Reference><Reference><Citation>P. R. Beatty, H. Puerta&#x2010;Guardo, S. S. Killingbeck, D. R. Glasner, K. Hopkins, and E. Harris, &#x201c;Dengue Virus NS1 Triggers Endothelial Permeability and Vascular Leak That is Prevented by NS1 Vaccination,&#x201d; Science Translational Medicine 7, no. 304 (2015): 304ra141, https://doi.org/10.1126/scitranslmed.aaa3787.</Citation></Reference><Reference><Citation>S. W. Metz and G. P. Pijlman, &#x201c;Function of Chikungunya Virus Structural Proteins,&#x201d; in Chikungunya Virus: Advances in Biology, Pathogenesis, and Treatment C. M. Okeoma, ed. (Springer International Publishing, 2016), 63&#x2013;74.</Citation></Reference><Reference><Citation>L. P. de G&#xf3;es Cavalcanti, A. M. Siqueira, J. A. de Sousa Moreira, and A. R. R. Freitas, &#x201c;Chikungunya,&#x201d; in Infectious Tropical Diseases and One Health in Latin America H. Mehlhorn and J. Heukelbach, eds. (Springer International Publishing, 2022), 19&#x2013;36.</Citation></Reference><Reference><Citation>R. S. Mani, V. Ravi, A. Desai, and S. N. Madhusudana, &#x201c;Emerging Viral Infections in India,&#x201d; Proceedings of the National Academy of Sciences, India &#x2010; Section B: Biological Sciences 82, no. 1 (2012): 5&#x2013;21, https://doi.org/10.1007/s40011&#x2010;011&#x2010;0001&#x2010;1.</Citation></Reference><Reference><Citation>M. Krutikov and J. Manson, &#x201c;Chikungunya Virus Infection: An Update on Joint Manifestations and Management,&#x201d; Rambam Maimonides Medical Journal 7, no. 4 (2016): e0033, https://doi.org/10.5041/rmmj.10260.</Citation></Reference><Reference><Citation>W. H. Ng, K. Amaral, E. Javelle, and S. Mahalingam, &#x201c;Chronic Chikungunya Disease (CCD): Clinical Insights, Immunopathogenesis and Therapeutic Perspectives,&#x201d; QJM: International Journal of Medicine 117, no. 7 (2024): 489&#x2013;494, https://doi.org/10.1093/qjmed/hcae028.</Citation></Reference><Reference><Citation>M. C. Jaffar&#x2010;Bandjee, T. Das, J. J. Hoarau, et&#xa0;al., &#x201c;Chikungunya Virus Takes Centre Stage in Virally Induced Arthritis: Possible Cellular and Molecular Mechanisms to Pathogenesis,&#x201d; Microbes and Infection 11, no. 14 (2009): 1206&#x2013;1218, https://doi.org/10.1016/j.micinf.2009.10.001.</Citation></Reference><Reference><Citation>J. B. Bilsborrow, J. K. Amaral, and R. T. Schoen, &#x201c;Chikungunya: An Emerging Rheumatological Pandemic?,&#x201d; Current Rheumatology Research 2, no. 1 (2021): 12&#x2013;17.</Citation></Reference><Reference><Citation>R. Huits, &#x201c;Challenges in Diagnosis and Management of Chikungunya and Zika Virus Infections.&#x201d; (2019).</Citation></Reference><Reference><Citation>D. Srinivasulu, A Clinical Study of Chikungunya Fever with Special Reference to Acute Complications (Rajiv Gandhi University of Health Sciences, 2012).</Citation></Reference><Reference><Citation>S. K. Singh and S. K. Unni, &#x201c;Chikungunya Virus: Host Pathogen Interaction,&#x201d; Reviews in Medical Virology 21, no. 2 (2011): 78&#x2013;88, https://doi.org/10.1002/rmv.681.</Citation></Reference><Reference><Citation>H. A. Imad, W. Matsee, S. Kludkleeb, et&#xa0;al., &#x201c;Post&#x2013;Chikungunya Virus Infection Musculoskeletal Disorders: Syndromic Sequelae After an Outbreak,&#x201d; Tropical Medicine and Infectious Disease 6, no. 2 (2021): 52, https://doi.org/10.3390/tropicalmed6020052.</Citation></Reference><Reference><Citation>R. V. da Cunha and K. S. Trinta, &#x201c;Chikungunya Virus: Clinical Aspects and Treatment&#x2010;A Review,&#x201d; Mem&#xf3;rias do Instituto Oswaldo Cruz 112, no. 8 (2017): 523&#x2013;531, https://doi.org/10.1590/0074&#x2010;02760170044.</Citation></Reference><Reference><Citation>J. K. Amaral, J. B. Bilsborrow, and R. T. Schoen, &#x201c;Chronic Chikungunya Arthritis and Rheumatoid Arthritis: What They Have in Common,&#x201d; American Journal of Medicine 133, no. 3 (2020): e91&#x2013;e97, https://doi.org/10.1016/j.amjmed.2019.10.005.</Citation></Reference><Reference><Citation>&#xc9; Bouquillard and B. Combe, &#x201c;A Report of 21 Cases of Rheumatoid Arthritis Following Chikungunya Fever. A Mean Follow&#x2010;Up of Two Years,&#x201d; Joint Bone Spine 76, no. 6 (2009): 654&#x2013;657, https://doi.org/10.1016/j.jbspin.2009.08.005.</Citation></Reference><Reference><Citation>S. Amdekar, D. Parashar, and K. Alagarasu, &#x201c;Chikungunya Virus&#x2010;Induced Arthritis: Role of Host and Viral Factors in the Pathogenesis,&#x201d; Viral Immunology 30, no. 10 (2017): 691&#x2013;702, https://doi.org/10.1089/vim.2017.0052.</Citation></Reference><Reference><Citation>V. Kril, O. A&#xef;qui&#x2010;Reboul&#x2010;Paviet, L. Briant, and A. Amara, &#x201c;New Insights into Chikungunya Virus Infection and Pathogenesis,&#x201d; Annual Review of Virology 8, no. 1 (2021): 327&#x2013;347, https://doi.org/10.1146/annurev&#x2010;virology&#x2010;091919&#x2010;102021.</Citation></Reference><Reference><Citation>S. P. Selvamani, R. Mishra, and S. K. Singh, &#x201c;Chikungunya Virus Exploits miR&#x2010;146a to Regulate NF&#x2010;&#x39a;b Pathway in Human Synovial Fibroblasts,&#x201d; PLoS One 9, no. 8 (2014): e103624, https://doi.org/10.1371/journal.pone.0103624.</Citation></Reference><Reference><Citation>W. Chen, S.&#x2010;S. Foo, A. Taylor, et&#xa0;al., &#x201c;Bindarit, an Inhibitor of Monocyte Chemotactic Protein Synthesis, Protects Against Bone Loss Induced by Chikungunya Virus Infection,&#x201d; Journal of Virology 89, no. 1 (2015): 581&#x2013;593, https://doi.org/10.1128/jvi.02034&#x2010;14.</Citation></Reference><Reference><Citation>P. Srivastava, A. Kumar, A. Hasan, et&#xa0;al., &#x201c;Disease Resolution in Chikungunya&#x2014;What Decides the Outcome?,&#x201d; Frontiers in Immunology 11 (2020): 695, https://doi.org/10.3389/fimmu.2020.00695.</Citation></Reference><Reference><Citation>A. Y. Chang, K. A. Martins, L. Encinales, et&#xa0;al., &#x201c;Chikungunya Arthritis Mechanisms in the Americas: A Cross&#x2010;sectional Analysis of Chikungunya Arthritis Patients Twenty&#x2010;Two Months After Infection Demonstrating No Detectable Viral Persistence in Synovial Fluid,&#x201d; Arthritis &amp; Rheumatology 70, no. 4 (2018): 585&#x2013;593, https://doi.org/10.1002/art.40383.</Citation></Reference><Reference><Citation>W. Phuklia, J. Kasisith, N. Modhiran, et&#xa0;al., &#x201c;Osteoclastogenesis Induced by CHIKV&#x2010;Infected Fibroblast&#x2010;Like Synoviocytes: A Possible Interplay Between Synoviocytes and Monocytes/Macrophages in CHIKV&#x2010;Induced Arthralgia/arthritis,&#x201d; Virus Research 177, no. 2 (2013): 179&#x2013;188, https://doi.org/10.1016/j.virusres.2013.08.011.</Citation></Reference><Reference><Citation>Y. Bedoui, C. Giry, M.&#x2010;C. Jaffar&#x2010;Bandjee, J. Selambarom, P. Guiraud, and P. Gasque, &#x201c;Immunomodulatory Drug Methotrexate Used to Treat Patients With Chronic Inflammatory Rheumatisms Post&#x2010;Chikungunya Does Not Impair the Synovial Antiviral and Bone Repair Responses,&#x201d; PLoS Neglected Tropical Diseases 12, no. 8 (2018): e0006634, https://doi.org/10.1371/journal.pntd.0006634.</Citation></Reference><Reference><Citation>Y. H. Zhang, A. Heulsmann, M. M. Tondravi, A. Mukherjee, and Y. Abu&#x2010;Amer, &#x201c;Tumor Necrosis Factor&#x2010;Alpha (TNF) Stimulates RANKL&#x2010;Induced Osteoclastogenesis via Coupling of TNF Type 1 Receptor and RANK Signaling Pathways,&#x201d; Journal of Biological Chemistry 276, no. 1 (2001): 563&#x2013;568, https://doi.org/10.1074/jbc.m008198200.</Citation></Reference><Reference><Citation>C. G. Di, E. Marzano, A. Mastrostefano, et&#xa0;al., &#x201c;The Pathogenetic Role of RANK/RANKL/OPG Signaling in Osteoarthritis and Related Targeted Therapies,&#x201d; Biomedicines 12, no. 10 (2024): 2292, https://doi.org/10.3390/biomedicines12102292.</Citation></Reference><Reference><Citation>J.&#x2010;J. Hoarau, M.&#x2010;C. Jaffar Bandjee, P. Krejbich Trotot, et&#xa0;al., &#x201c;Persistent Chronic Inflammation and Infection by Chikungunya Arthritogenic Alphavirus in Spite of a Robust Host Immune Response,&#x201d; Journal of Immunology 184, no. 10 (2010): 5914&#x2013;5927, https://doi.org/10.4049/jimmunol.0900255.</Citation></Reference><Reference><Citation>I. K. Chaaithanya, N. Muruganandam, S. G. Sundaram, et&#xa0;al., &#x201c;Role of Proinflammatory Cytokines and Chemokines in Chronic Arthropathy in CHIKV Infection,&#x201d; Viral Immunology 24, no. 4 (2011): 265&#x2013;271, https://doi.org/10.1089/vim.2010.0123.</Citation></Reference><Reference><Citation>V. Reddy, A. Desai, S. S. Krishna, and R. Vasanthapuram, &#x201c;Molecular Mimicry Between Chikungunya Virus and Host Components: A Possible Mechanism for the Arthritic Manifestations,&#x201d; PLoS Neglected Tropical Diseases 11, no. 1 (2017): e0005238, https://doi.org/10.1371/journal.pntd.0005238.</Citation></Reference><Reference><Citation>M. Marks, G. O&#x2019;Hara, C. Houlihan, L. Bell, M. Heightman, and N. Hart, &#x201c;Severe Acute Respiratory Syndrome Coronavirus 2,&#x201d; Encyclopedia of Respiratory Medicine (2021): 231&#x2013;242, https://doi.org/10.1016/b978&#x2010;0&#x2010;08&#x2010;102723&#x2010;3.00139&#x2010;6.</Citation></Reference><Reference><Citation>S. Shah, D. Danda, C. Kavadichanda, S. Das, M. Adarsh, and V. S. Negi, &#x201c;Autoimmune and Rheumatic Musculoskeletal Diseases as a Consequence of SARS&#x2010;CoV&#x2010;2 Infection and Its Treatment,&#x201d; Rheumatology International 40, no. 10 (2020): 1539&#x2013;1554, https://doi.org/10.1007/s00296&#x2010;020&#x2010;04639&#x2010;9.</Citation></Reference><Reference><Citation>N. P. Disser, A. J. De Micheli, M. M. Schonk, et&#xa0;al., &#x201c;Musculoskeletal Consequences of COVID&#x2010;19,&#x201d; Journal of Bone and Joint Surgery 102, no. 14 (2020): 1197&#x2013;1204, https://doi.org/10.2106/jbjs.20.00847.</Citation></Reference><Reference><Citation>H. Li, S. Zhuang, Y. Lin, et&#xa0;al., &#x201c;The Impact of COVID&#x2010;19 Infection on Musculoskeletal Pain and its Associating Factors: A Cross&#x2010;Sectional Study,&#x201d; Frontiers in Public Health 12 (2024): 1422659, https://doi.org/10.3389/fpubh.2024.1422659.</Citation></Reference><Reference><Citation>R. Swarnakar, S. Jenifa, and S. Wadhwa, &#x201c;Musculoskeletal Complications in Long COVID&#x2010;19: A Systematic Review,&#x201d; World Journal of Virology 11, no. 6 (2022): 485&#x2013;495, https://doi.org/10.5501/wjv.v11.i6.485.</Citation></Reference><Reference><Citation>F. Migliorini, A. Bell, R. Vaishya, J. Eschweiler, F. Hildebrand, and N. Maffulli, &#x201c;Reactive Arthritis Following COVID&#x2010;19 Current Evidence, Diagnosis, and Management Strategies,&#x201d; Journal of Orthopaedic Surgery and Research 18, no. 1 (2023): 205, https://doi.org/10.1186/s13018&#x2010;023&#x2010;03651&#x2010;6.</Citation></Reference><Reference><Citation>J. M. Torres, N. P. Juarez, D. P. Ju&#xe1;rez, and I. B. Amoros, &#x201c;Ultrasound Findings in Reactive Arthritis After COVID&#x2010;19: Case Report,&#x201d; International Journal of Clinical Rheumatology (2021).</Citation></Reference><Reference><Citation>S. Ahmed, O. Zimba, and A. Y. Gasparyan, &#x201c;COVID&#x2010;19 and the Clinical Course of Rheumatic Manifestations,&#x201d; Clinical Rheumatology 40, no. 7 (2021): 2611&#x2013;2619, https://doi.org/10.1007/s10067&#x2010;021&#x2010;05691&#x2010;x.</Citation></Reference><Reference><Citation>K. Akhtar Ali, L. He, J. Li, W. Zhang, B. Tasiken, and H. Huang, &#x201c;MRI Spectrum of Avascular Necrosis of Femoral Head in Patients Treated for COVID&#x2010;19,&#x201d; Hip International 34, no. 4 (2024): 510&#x2013;515, https://doi.org/10.1177/11207000241233906.</Citation></Reference><Reference><Citation>F. Alghamdi, K. Mokbel, R. Meertens, et&#xa0;al., &#x201c;Bone Mineral Density, Bone Biomarkers, and Joints in Acute, Post, and Long COVID&#x2010;19: A Systematic Review,&#x201d; Viruses 16, no. 11 (2024): 1694, https://doi.org/10.3390/v16111694.</Citation></Reference><Reference><Citation>T. J. Louis, A. Qasem, L. S. Abdelli, and S. A. Naser, &#x201c;Extra&#x2010;Pulmonary Complications in SARS&#x2010;CoV&#x2010;2 Infection: A Comprehensive Multi Organ&#x2010;System Review,&#x201d; Microorganisms 10, no. 1 (2022): 153, https://doi.org/10.3390/microorganisms10010153.</Citation></Reference><Reference><Citation>S. Mokuda, T. Tokunaga, J. Masumoto, and E. Sugiyama, &#x201c;Angiotensin&#x2010;Converting Enzyme 2, a SARS&#x2010;CoV&#x2010;2 Receptor, is Upregulated by Interleukin 6 Through STAT3 Signaling in Synovial Tissues,&#x201d; Journal of Rheumatology 47, no. 10 (2020): 1593&#x2013;1595, https://doi.org/10.3899/jrheum.200547.</Citation></Reference><Reference><Citation>C. M. Queiroz&#x2010;Junior, A. C. P. M. Santos, I. Galv&#xe3;o, et&#xa0;al., &#x201c;The Angiotensin Converting Enzyme 2/Angiotensin&#x2010;(1&#x2010;7)/Mas Receptor axis as a Key Player in Alveolar Bone Remodeling,&#x201d; Bone 128 (2019): 115041, https://doi.org/10.1016/j.bone.2019.115041.</Citation></Reference><Reference><Citation>A. Harris, A. Creecy, O. D. Awosanya, et&#xa0;al., &#x201c;SARS&#x2010;CoV&#x2010;2 and Its Multifaceted Impact on Bone Health: Mechanisms and Clinical Evidence,&#x201d; Current Osteoporosis Reports 22, no. 1 (2024): 135&#x2013;145, https://doi.org/10.1007/s11914&#x2010;023&#x2010;00843&#x2010;1.</Citation></Reference><Reference><Citation>W. Qiao, H. E. Lau, H. Xie, et&#xa0;al., &#x201c;SARS&#x2010;CoV&#x2010;2 Infection Induces Inflammatory Bone Loss in Golden Syrian Hamsters,&#x201d; Nature Communications 13, no. 1 (2022): 2539, https://doi.org/10.1038/s41467&#x2010;022&#x2010;30195&#x2010;w.</Citation></Reference><Reference><Citation>A. Fara, Z. Mitrev, R. A. Rosalia, and B. M. Assas, &#x201c;Cytokine Storm and COVID&#x2010;19: A Chronicle of Pro&#x2010;Inflammatory Cytokines,&#x201d; Open Biology 10, no. 9 (2020): 200160, https://doi.org/10.1098/rsob.200160.</Citation></Reference><Reference><Citation>K. T. Steeve, P. Marc, T. Sandrine, H. Dominique, and F. Yannick, &#x201c;IL&#x2010;6, RANKL, TNF&#x2010;alpha/IL&#x2010;1: Interrelations in Bone Resorption Pathophysiology,&#x201d; Cytokine &amp; Growth Factor Reviews 15, no. 1 (2004): 49&#x2013;60, https://doi.org/10.1016/j.cytogfr.2003.10.005.</Citation></Reference><Reference><Citation>Z. Yao, S. J. Getting, and I. C. Locke, &#x201c;Regulation of TNF&#x2010;Induced Osteoclast Differentiation,&#x201d; Cells 11, no. 1 (2021): 132, https://doi.org/10.3390/cells11010132.</Citation></Reference><Reference><Citation>M. Vahabi, T. Ghazanfari, and S. Sepehrnia, &#x201c;Molecular Mimicry, Hyperactive Immune System, and SARS&#x2010;COV&#x2010;2 Are Three Prerequisites of the Autoimmune Disease Triangle Following COVID&#x2010;19 Infection,&#x201d; International Immunopharmacology 112 (2022): 109183, https://doi.org/10.1016/j.intimp.2022.109183.</Citation></Reference><Reference><Citation>A. Dotan, S. Muller, D. Kanduc, P. David, G. Halpert, and Y. Shoenfeld, &#x201c;The SARS&#x2010;CoV&#x2010;2 as an Instrumental Trigger of Autoimmunity,&#x201d; Autoimmunity Reviews 20, no. 4 (2021): 102792, https://doi.org/10.1016/j.autrev.2021.102792.</Citation></Reference><Reference><Citation>I. M. Omar, J. S. Weaver, J. D. Samet, A. M. Serhal, W. A. Mar, and M. S. Taljanovic, &#x201c;Musculoskeletal Manifestations of COVID&#x2010;19: Currently Described Clinical Symptoms and Multimodality Imaging Findings,&#x201d; RadioGraphics 42, no. 5 (2022): 1415&#x2013;1432, https://doi.org/10.1148/rg.220036.</Citation></Reference><Reference><Citation>M. Cutolo, V. Smith, S. Paolino, and E. Gotelli, &#x201c;Involvement of the Secosteroid Vitamin D in Autoimmune Rheumatic Diseases and COVID&#x2010;19,&#x201d; Nature Reviews Rheumatology 19, no. 5 (2023): 265&#x2013;287, https://doi.org/10.1038/s41584&#x2010;023&#x2010;00944&#x2010;2.</Citation></Reference><Reference><Citation>M. Pereira, A. Dantas Damascena, L. M. Galv&#xe3;o Azevedo, T. de Almeida Oliveira, M. da, and J. Santana, &#x201c;Vitamin D Deficiency Aggravates COVID&#x2010;19: Systematic Review and Meta&#x2010;Analysis,&#x201d; Critical Reviews in Food Science and Nutrition 62, no. 5 (2022): 1308&#x2013;1316, https://doi.org/10.1080/10408398.2020.1841090.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40714935</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>27</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1099-1611</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>7</Issue><PubDate><Year>2025</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Psycho-oncology</Title><ISOAbbreviation>Psychooncology</ISOAbbreviation></Journal><ArticleTitle>Bereavement Support for Spouses: An Evaluation of a 6-Session Group Program.</ArticleTitle><Pagination><StartPage>e70221</StartPage><MedlinePgn>e70221</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/pon.70221</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Within oncology, bereavement outreach to families varies greatly following the death of a patient, depending upon the institution and its resources, the discipline of the provider, and the types of bereavement support offered. Bereavement support groups are commonplace, though little attention has been paid to understanding the impact on family members and what aspects of a group they find beneficial.</AbstractText><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">This study sought feedback from participants about the support group curriculum used at Dana-Farber Cancer Institute (DFCI) with recently bereaved spouses and partners.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Adopting a quality improvement framework, bereaved spouses who participated in a 6-session structured CBT-based bereavement support group between April 2020 and December 2022 were invited to complete an evaluation of the group program. Due to the COVID-19 pandemic, all groups were offered virtually.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In total, 138 spouses participated in one of 18, 6-session support groups at DFCI with 86 (62.32%) completing the evaluation. 67.44% were female and 74.42% were aged between 60 and 79&#xa0;years. The participants evaluated the program highly, reporting that they felt less isolated in their grief (4.26/5 on a 5-point Likert Scale); many of their concerns were similar to others (4.42/5); and the session discussion topics were relevant to their experience (4.40/5). 81.40% of participants said that they either liked or strongly liked the virtual format and if given a choice, 56.47% expressed a preference for a hybrid delivery model.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The CBT-based bereavement support group curriculum was highly evaluated with a hybrid model endorsed as the preferred method for future groups.</AbstractText><CopyrightInformation>&#xa9; 2025 John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>Sue E</ForeName><Initials>SE</Initials><Identifier Source="ORCID">0000-0002-3022-5951</Identifier><AffiliationInfo><Affiliation>Department of Supportive Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Psychooncology</MedlineTA><NlmUniqueID>9214524</NlmUniqueID><ISSNLinking>1057-9249</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">bereavement</Keyword><Keyword MajorTopicYN="N">bereavement support group</Keyword><Keyword MajorTopicYN="N">oncology</Keyword><Keyword MajorTopicYN="N">partner loss</Keyword><Keyword MajorTopicYN="N">spouse loss</Keyword><Keyword MajorTopicYN="N">virtual support group</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>6</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>27</Day><Hour>7</Hour><Minute>52</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40714935</ArticleId><ArticleId IdType="doi">10.1002/pon.70221</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>M. Stroebe, H. Schut, and W. Stroebe, &#x201c;Health Outcomes of Bereavement,&#x201d; Lancet 370, no. 9603 (2007): 1960&#x2013;1973, https://doi.org/10.1016/s0140&#x2010;6736(07)61816&#x2010;9.</Citation></Reference><Reference><Citation>K. M. Bennett, &#x201c;Widowhood in Elderly Women: The Medium and Long&#x2010;Term Effects on Mental and Physical Health,&#x201d; Mortality 2 (1997): 137&#x2013;148, https://doi.org/10.1080/713685857.</Citation></Reference><Reference><Citation>H. G. Prigerson, M. J. Horowitz, S. C. Jacobs, et&#xa0;al., &#x201c;Prolonged Grief Disorder: Psychometric Validation of Criteria Proposed for DSM&#x2010;5 and ICD&#x2010;11,&#x201d; PLoS Medicine 6 (2009): e10000121.</Citation></Reference><Reference><Citation>National Consensus Project for Quality Palliative Care. Clinical Practice Guidelines for Quality Palliative Care, 4th ed. (National Coalition for Hospice and Palliative Care, 2018).</Citation></Reference><Reference><Citation>Medicare Hospice Conditions of Participation &#x2010; Bereavement [Cited December 29, 2024]. Available from, https://www.nhpco.org/wp&#x2010;content/uploads/Bereavement_CoP_Tip_Sheet.pdf.</Citation></Reference><Reference><Citation>S. E. Morris and S. D. Block, &#x201c;Adding Value to Palliative Care Services: The Development of an Institutional Bereavement Program,&#x201d; Journal of Palliative Medicine 18, no. 11 (2015): 915&#x2013;922, https://doi.org/10.1089/jpm.2015.0080.</Citation></Reference><Reference><Citation>E. Harrop, F. Morgan, M. Longo, et&#xa0;al., &#x201c;The Impacts and Effectiveness of Support for People Bereaved Through Advanced Illness: A Systematic Review and Thematic Synthesis,&#x201d; Palliative Medicine 34, no. 7 (2020): 871&#x2013;888, https://doi.org/10.1177/0269216320920533.</Citation></Reference><Reference><Citation>S. M. Aoun, L. J. Breen, D. A. Howting, B. Rumbold, B. McNamara, and D. Hegney, &#x201c;Who Needs Bereavement Support? A Population Based Survey of Bereavement Risk and Support Need,&#x201d; PLoS One 10, no. 3 (2015): e0121101, https://doi.org/10.1371/journal.pone.0121101.</Citation></Reference><Reference><Citation>J. M. Yopp and D. L. Rosenstein, &#x201c;A Support Group for Fathers Whose Partners Died From Cancer,&#x201d; Clinical Journal of Oncology Nursing 17, no. 2 (2013): 169&#x2013;173, https://doi.org/10.1188/13.cjon.169&#x2010;173.</Citation></Reference><Reference><Citation>S. E. Morris, P. M. Souza, and K. M. Fasciano, &#x201c;The Development of a Bereavement Support Group Curriculum for Young Adults Dealing With the Death of a Partner: A Quality Improvement Project,&#x201d; Journal of Adolescent and Young Adult Oncology 10, no. 3 (2021): 260&#x2013;265, https://doi.org/10.1089/jayao.2020.0131.</Citation></Reference><Reference><Citation>K. Law and S. Kirk, &#x201c;Examining the Experiences and Support Needs of Bereaved Parents After the Death of a Child During Early Adulthood From Cancer,&#x201d; Cancer Nursing 45, no. 4 (2022): E719&#x2013;E727, https://doi.org/10.1097/ncc.0000000000000998.</Citation></Reference><Reference><Citation>S. E. Morris and A. K. Ryan, &#x201c;Bereavement via Zoom During COVID&#x2010;19,&#x201d; Journal of Psychosocial Oncology 39, no. 3 (2021): 316&#x2013;319, https://doi.org/10.1080/07347332.2021.1899355.</Citation></Reference><Reference><Citation>S. K. Rao, V. Carballo, B. M. Cummings, F. Millham, and J. O. Jacobson, &#x201c;Developing an Interdisciplinary, Team&#x2010;Based Quality Improvement Leadership Training Program for Clinicians: The Partners Clinical Process Improvement Leadership Program,&#x201d; American Journal of Medical Quality 32, no. 3 (2017): 271&#x2013;277, https://doi.org/10.1177/1062860616648773.</Citation></Reference><Reference><Citation>G. J. Langley, R. D. Moen, K. M. Nolan, T. W. Nolan, C. L. Norman, and L. P. Provost, The Improvement Guide: A Practical Approach to Enhancing Organizational Performance (Wiley, 2009).</Citation></Reference><Reference><Citation>J. S. Beck and A. T. Beck, Cognitive Behavior Therapy, Second Edition: Basics and beyond (Guilford Publications, 2011).</Citation></Reference><Reference><Citation>S. Morris, Overcoming Grief : A Self&#x2010;Help Guide Using Cognitive Behavioural Techniques, 2nd ed. (Little, Brown Book Group, 2018).</Citation></Reference><Reference><Citation>S. Morris, An Introduction to Coping with Grief, 2nd ed. (Little, Brown Book Group, 2017).</Citation></Reference><Reference><Citation>D. J. Kavanagh, &#x201c;Towards a Cognitive&#x2010;Behavioural Intervention for Adult Grief Reactions,&#x201d; British Journal of Psychiatry 157, no. 3 (1990): 373&#x2013;383, https://doi.org/10.1192/bjp.157.3.373.</Citation></Reference><Reference><Citation>B. T. Litz, Y. Schorr, E. Delaney, et&#xa0;al., &#x201c;A Randomized Controlled Trial of an Internet&#x2010;Based Therapist&#x2010;Assisted Indicated Preventive Intervention for Prolonged Grief Disorder,&#x201d; Behaviour Research and Therapy 61 (2014): 23&#x2013;34, https://doi.org/10.1016/j.brat.2014.07.005.</Citation></Reference><Reference><Citation>E. Cole and J. Johnson, Six Simple Weeks: A Caring Manual for Support Group Leaders (Centering Corporation, 2004).</Citation></Reference><Reference><Citation>K. Dyregrov, A. Dyregrov, and I. Johnsen, &#x201c;Participants' Recommendations for the Ideal Grief Group: A Qualitative Study,&#x201d; Omega 67, no. 4 (2013): 363&#x2013;377, https://doi.org/10.2190/om.67.4.b.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40714926</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2770</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Jul</Month><Day>27</Day></PubDate></JournalIssue><Title>American journal of community psychology</Title><ISOAbbreviation>Am J Community Psychol</ISOAbbreviation></Journal><ArticleTitle>Mental health of urban Black women experiencing intimate partner violence since the start of the COVID-19 pandemic.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/ajcp.12822</ELocationID><Abstract><AbstractText>Black women are disproportionally impacted by intimate partner violence (IPV), which influences women's mental health. The COVID-19 pandemic caused significant mental health strain on women experiencing IPV while also affecting their ability to seek mental health services. This study was conducted to qualitatively investigate the impact of IPV on urban Black women's mental health since the start of the COVID-19 pandemic. This analysis is part of an ongoing mixed-methods study in the Upper Midwest of the United States. We used purposive and snowball sampling to engage 28 women in in-depth individual interviews. Using content analysis, four themes were identified, including (1) anxious feelings, (2) feeling depressed, (3) posttraumatic stress disorder feelings, and (4) substance use. There is an urgent need to consider mental health interventions in times of national or global crises. Mental health interventions are especially of consideration for populations experiencing deep vulnerability, like women who experience IPV. This is more so the case in crises where there is a need to enact restrictive policies to contain public health epidemics or pandemics.</AbstractText><CopyrightInformation>&#xa9; 2025 Society for Community Research and Action.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Abusbaitan</LastName><ForeName>Hanan A</ForeName><Initials>HA</Initials><Identifier Source="ORCID">0000-0002-6388-7214</Identifier><AffiliationInfo><Affiliation>University of Wisconsin-Milwaukee, School of Nursing, Milwaukee, Wisconsin, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopez</LastName><ForeName>Alexa A</ForeName><Initials>AA</Initials><Identifier Source="ORCID">0000-0002-6451-1630</Identifier><AffiliationInfo><Affiliation>University of Wisconsin-Milwaukee, School of Nursing, Milwaukee, Wisconsin, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eyadat</LastName><ForeName>Anwar</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Irbid National University, College of Nursing, Irbid, Jordan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pirsch</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Augsburg University, Nursing program, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luebke</LastName><ForeName>Jeneile</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>University of Wisconsin-Madison, School of Nursing, Madison, Wisconsin, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yip</LastName><ForeName>Winnie</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>University of Minnesota, School of Nursing, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>Amanda</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>University of Minnesota, School of Nursing, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Norton</LastName><ForeName>Antonia Drew</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>The ASHA Project, Milwaukee, Wisconsin, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rice</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Lac Courte Oreilles Women's Shelter &amp; Tribal Governments TTA at Red Wind Consulting, Inc, Wisconsin, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kako</LastName><ForeName>Peninnah M</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>University of Wisconsin-Milwaukee, School of Nursing, Milwaukee, Wisconsin, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dressel</LastName><ForeName>Anne</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-2254-1815</Identifier><AffiliationInfo><Affiliation>University of Wisconsin-Milwaukee, School of Nursing, Milwaukee, Wisconsin, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schadewald</LastName><ForeName>Diane M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>University of Wisconsin-Milwaukee, School of Nursing, Milwaukee, Wisconsin, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hawkins</LastName><ForeName>Maren</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Carroll University, Public Health Department, College of Health Sciences, Waukesha, Wisconsin, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>W Kibicho</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>University of Wisconsin-Milwaukee, School of Nursing, Milwaukee, Wisconsin, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mkandawire-Valhmu</LastName><ForeName>Lucy</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>University of Minnesota, School of Nursing, Minneapolis, Minnesota, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>National Institute on Minority Health and Health Disparities (R01MD016388)</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Am J Community Psychol</MedlineTA><NlmUniqueID>0364535</NlmUniqueID><ISSNLinking>0091-0562</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Black women</Keyword><Keyword MajorTopicYN="N">COVID&#x2010;19 pandemic</Keyword><Keyword MajorTopicYN="N">United States</Keyword><Keyword MajorTopicYN="N">help&#x2010;seeking</Keyword><Keyword MajorTopicYN="N">intimate partner violence</Keyword><Keyword MajorTopicYN="N">mental health</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>5</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>11</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>5</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>27</Day><Hour>7</Hour><Minute>12</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40714926</ArticleId><ArticleId IdType="doi">10.1002/ajcp.12822</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Alhomaizi, A., Alhomaizi, D., Willis, S., &amp; Verdeli, H. (2021). Social distancing in the era of COVID&#x2010;19: A call for maintaining social support for the maternal population. Global Health, Science and Practice, 9(2), 229&#x2013;237. https://doi.org/10.9745/GHSP-D-20-00398</Citation></Reference><Reference><Citation>American Psychiatric Association. (n.d.). Intimate partner violence. https://www.psychiatry.org/psychiatrists/diversity/education/intimate-partner-violence</Citation></Reference><Reference><Citation>Assari, S. (2018). Health disparities due to diminished return among black Americans: Public policy solutions. Social Issues and Policy Review, 12(1), 112&#x2013;145. https://doi.org/10.1111/sipr.12042</Citation></Reference><Reference><Citation>Bent&#x2010;Goodley, T. B. (2007). Health disparities and violence against women. Trauma, Violence, &amp; Abuse, 8(2), 90&#x2013;104. https://doi.org/10.1177/1524838007301160</Citation></Reference><Reference><Citation>Bibi, D. E. M. E. (2021). Exploring the impacts of COVID&#x2010;19 pandemic on the domestic violence victim&#x2010;serving agencies and professionals (Master's thesis, North Dakota State University).</Citation></Reference><Reference><Citation>Byrne, A., Barber, R., &amp; Lim, C. H. (2021). Impact of the COVID&#x2010;19 pandemic&#x2013;A mental health service perspective. Progress in Neurology and Psychiatry, 25(2), 27&#x2013;33b. https://doi.org/10.1002/pnp.708</Citation></Reference><Reference><Citation>Campbell, J. C., Webster, D., Koziol&#x2010;McLain, J., Block, C., Campbell, D., Curry, M. A., Gary, F., Glass, N., McFarlane, J., Sachs, C., Sharps, P., Ulrich, Y., Wilt, S. A., Manganello, J., Xu, X., Schollenberger, J., Frye, V., &amp; Laughon, K. (2003). Risk factors for femicide in abusive relationships: Results from a multisite case control study. American Journal of Public Health, 93(7), 1089&#x2013;1097. https://doi.org/10.2105/ajph.93.7.1089</Citation></Reference><Reference><Citation>Cannon, C., Ferreira, R. J., &amp; Buttell, F. (2018). Critical race theory, parenting, and intimate partner violence: Analyzing race and gender. Research on Social Work Practice, 29(5), 590&#x2013;602. https://doi.org/10.1177/1049731518784181</Citation></Reference><Reference><Citation>Cattaneo, L. B., &amp; Chapman, A. R. (2010). The process of empowerment: A model for use in research and practice. American Psychologist, 65(7), 646&#x2013;659. https://doi.org/10.1037/a0018854</Citation></Reference><Reference><Citation>Cheng, T. C., &amp; Lo, C. C. (2015). Racial disparities in intimate partner violence and in seeking help with mental health. Journal of Interpersonal Violence, 30(18), 3283&#x2013;3307. https://doi.org/10.1177/0886260514555011</Citation></Reference><Reference><Citation>City of Philadelphia. (n.d.). Populations of Special Interest African American Communities. https://www.phila.gov/media/20190701131600/RCHNA_PopsSpecial.pdf</Citation></Reference><Reference><Citation>Collins, P. H. (1990). Black feminist thought: Knowledge, consciousness, and the politics of empowerment. Routledge.</Citation></Reference><Reference><Citation>Evans, M. L., Lindauer, M., &amp; Farrell, M. E. (2020). A pandemic within a pandemic&#x2014;Intimate partner violence during COVID&#x2010;19. New England Journal of Medicine, 383(24), 2302&#x2013;2304. https://doi.org/10.1056/NEJMp2024046</Citation></Reference><Reference><Citation>Geyen, D. J., &amp; Bailey, R. K. (2021). Substance abuse and intimate partner violence, Intimate partner violence: An evidence&#x2010;based approach (pp. 127&#x2013;135). https://doi.org/10.1007/978-3-030-55864-2_17</Citation></Reference><Reference><Citation>Gilchrist, G., Dennis, F., Radcliffe, P., Henderson, J., Howard, L. M., &amp; Gadd, D. (2019). The interplay between substance use and intimate partner violence perpetration: A meta&#x2010;ethnography. International Journal of Drug Policy, 65, 8&#x2013;23. https://doi.org/10.1016/j.drugpo.2018.12.009</Citation></Reference><Reference><Citation>Gosangi, B., Park, H., Thomas, R., Gujrathi, R., Bay, C. P., Raja, A. S., Seltzer, S. E., Balcom, M. C., McDonald, M. L., Orgill, D. P., Harris, M. B., Boland, G. W., Rexrode, K., &amp; Khurana, B. (2021). Exacerbation of physical intimate partner violence during COVID&#x2010;19 pandemic. Radiology, 298(1), E38&#x2013;E45. https://doi.org/10.1148/radiol.2020202866</Citation></Reference><Reference><Citation>Hawkins, M. M., Lopez, A. A., Schmitt, M. E., Tamkin, V. L., Dressel, A. E., Kako, P., Mkandawire&#x2010;Valhmu, L., &amp; Weinhardt, L. S. (2022). A qualitative analysis of perceptions of and reactions to COVID&#x2010;19. Public Health Nursing, 39(4), 719&#x2013;727.</Citation></Reference><Reference><Citation>Holden, K. B., Hernandez, N. D., Wrenn, G. L., &amp; Belton, A. S. (2017). Resilience: Protective 'factors for depression and post traumatic stress disorder among African American women? Health, Culture and Society, 9, 12&#x2013;29. https://doi.org/10.5195/hcs.2017.222</Citation></Reference><Reference><Citation>Joseph, N. P. (2021). Racial and ethnic disparities in COVID&#x2010;19 care among Black women in the United States. Journal of Racial and Ethnic Health Disparities, 8(5), 1114&#x2013;1121. https://doi.org/10.1016/j.annepidem.2021.03.006</Citation></Reference><Reference><Citation>Lacey, K. K., Parnell, R., Mouzon, D. M., Matusko, N., Head, D., Abelson, J. M., &amp; Jackson, J. S. (2015). The mental health of US Black women: The roles of social context and severe intimate partner violence. BMJ Open, 5(10), e008415. https://doi.org/10.1136/bmjopen-2015-008415</Citation></Reference><Reference><Citation>Lincoln, Y. S., &amp; Guba, E. G. (1985). Naturalistic inquiry. SAGE Publications.</Citation></Reference><Reference><Citation>Lokhmatkina, N. V., Agnew&#x2010;Davies, R., Costelloe, C., Kuznetsova, O. Y., Nikolskaya, I. M., &amp; Feder, G. S. (2015). Intimate partner violence and ways of coping with stress: Cross&#x2010;sectional survey of female patients in Russian general practice. Family Practice, 32(2), 141&#x2013;146. https://doi.org/10.1093/fampra/cmu086</Citation></Reference><Reference><Citation>Lopez, A. A., Dressel, A., Luebke, J., Williams, J., Campbell, J., Miller, J., Kibicho, J., Schadewald, D., Abusbaitan, H., Pirsch, A., Gondwe, K. W., Schubert, E., Ruiz, A., Kako, P., Mkandawire&#x2010;Valhmu, L., &amp; Egede, L. E. (2024). Intimate partner violence in the lives of indigenous and Black women in the upper Midwest of the United States during the COVID&#x2010;19 pandemic: A mixed&#x2010;methods protocol examining help&#x2010;seeking behaviours and experiences. International journal of mental health nursing, 33, 1003&#x2013;1012. https://doi.org/10.1111/inm.13294</Citation></Reference><Reference><Citation>Luo, A. (2023). Content analysis | Guide, methods &amp; examples. Scribbr. https://www.scribbr.com/methodology/content-analysis/</Citation></Reference><Reference><Citation>Lyons, M., &amp; Brewer, G. (2022). Experiences of intimate partner violence during lockdown and the COVID&#x2010;19 pandemic. Journal of Family Violence, 37(6), 969&#x2013;977. https://doi.org/10.1007/s10896-021-00260-x</Citation></Reference><Reference><Citation>McGarry, J., Ali, P., &amp; Hinchliff, S. (2017). Older women, intimate partner violence and mental health: A consideration of the particular issues for health and healthcare practice. Journal of Clinical Nursing, 26(15&#x2013;16), 2177&#x2013;2191. https://doi.org/10.1111/jocn.13490</Citation></Reference><Reference><Citation>McNeil, A., Hicks, L., Yalcinoz&#x2010;Ucan, B., &amp; Browne, D. T. (2023). Prevalence &amp; correlates of intimate partner violence during COVID&#x2010;19: A rapid review. Journal of Family Violence, 38(2), 241&#x2013;261. https://doi.org/10.1007/s10896-022-00386-6</Citation></Reference><Reference><Citation>Mkandawire&#x2010;Valhmu, L., Callari&#x2010;Robinson, J., Schadewald, D., Abusbaitan, H., Pirsch, A., Luebke, J., Marquardt, L., Schubert, E., Kibicho, J., Lopez, A., Gondwe, K., Rice, E., Bement, K., Morgan, M., McClain, R., Kako, P., Raghe, F., Hunter, C. F., Ayad, C., &amp; Dressel, A. (2024). A protocol for the safe recruitment of indigenous and Black women experiencing intimate partner violence during the COVID&#x2010;19 pandemic into a large mixed methods study: The sisters by choice study. Global Public Health, 19(1), 2290122. https://doi.org/10.1080/17441692.2023.2290122</Citation></Reference><Reference><Citation>Modeste&#x2010;James, A., McClain, T., &amp; Hanna, M. (2024). The system isn't set up for us&#x201d;: Stories of young Black women's mental health journey. Women's Health, 20, 17455057241297106. https://doi.org/10.1177/17455057241297106</Citation></Reference><Reference><Citation>Moradi, B., &amp; Grzanka, P. R. (2017). Using intersectionality responsibly: Toward critical epistemology, structural analysis, and social justice activism. Journal of Counseling Psychology, 64(5), 500&#x2013;513. https://doi.org/10.1037/cou0000203</Citation></Reference><Reference><Citation>Moreno, C., Wykes, T., Galderisi, S., Nordentoft, M., Crossley, N., Jones, N., Cannon, M., Correll, C. U., Byrne, L., Carr, S., Chen, E. Y. H., Gorwood, P., Johnson, S., K&#xe4;rkk&#xe4;inen, H., Krystal, J. H., Lee, J., Lieberman, J., L&#xf3;pez&#x2010;Jaramillo, C., M&#xe4;nnikk&#xf6;, M., &#x2026; Arango, C. (2020). How mental health care should change as a consequence of the COVID&#x2010;19 pandemic. The Lancet Psychiatry, 7(9), 813&#x2013;824. https://doi.org/10.1016/S2215-0366(20)30307-2</Citation></Reference><Reference><Citation>Moyer, C. A., Compton, S. D., Kaselitz, E., &amp; Muzik, M. (2020). Pregnancy&#x2010;related anxiety during COVID&#x2010;19: A nationwide survey of 2740 pregnant women. Archives of Women's Mental Health, 23, 757&#x2013;765. https://doi.org/10.1007/s00737-020-01073-5</Citation></Reference><Reference><Citation>National Coalition Against Domestic Violence. (n.d.). Statistics. https://ncadv.org/STATISTICS</Citation></Reference><Reference><Citation>National Institutes of Health. (n.d.). COVID&#x2010;19 Research. COVID&#x2010;19 Mental Health Information and Resources. https://covid19.nih.gov/covid-19-topics/mental-health</Citation></Reference><Reference><Citation>O'Connor, C., &amp; Joffe, H. (2020). Intercoder reliability in qualitative research: Debates and practical guidelines. International Journal of Qualitative Methods, 19, 0. https://doi.org/10.1177/1609406919899220</Citation></Reference><Reference><Citation>Ogden, S. N., Dichter, M. E., &amp; Bazzi, A. R. (2022). Intimate partner violence as a predictor of substance use outcomes among women: A systematic review. Addictive Behaviors, 127, 107214. https://doi.org/10.1016/j.addbeh.2021.107214</Citation></Reference><Reference><Citation>Peitzmeier, S. M., Fedina, L., Ashwell, L., Herrenkohl, T. I., &amp; Tolman, R. (2022). Increases in intimate partner violence during COVID&#x2010;19: Prevalence and correlates. Journal of Interpersonal Violence, 37(21&#x2013;22), NP20482&#x2013;NP20512. https://doi.org/10.1177/08862605211052586</Citation></Reference><Reference><Citation>Pew Research Center. (2023). Key facts about the nation's 47.2 million Black Americans. https://www.pewresearch.org/short-reads/2023/02/10/key-facts-about-black-americans/</Citation></Reference><Reference><Citation>Pieh, C., Budimir, S., Delgadillo, J., Barkham, M., Fontaine, J. R. J., &amp; Probst, T. (2021). Mental health during COVID&#x2010;19 lockdown in the United Kingdom. Psychosomatic Medicine, 83(4), 328&#x2013;337. https://doi.org/10.1097/PSY.0000000000000871</Citation></Reference><Reference><Citation>Puri, M. C., Maharjan, D. C., Dahal, M., Raifman, S., &amp; Diamond&#x2010;Smith, N. (2023). Intimate partner violence, food insecurity and COVID&#x2010;19 among newly married women in Nawalparasi district of Nepal: A longitudinal study. Sexual and Reproductive Health Matters, 31(1), 2181282. https://doi.org/10.1080/26410397.2023.2181282</Citation></Reference><Reference><Citation>Rappaport, J. (1987). Terms of empowerment/exemplars of prevention: Toward a theory for community psychology. American Journal of Community Psychology, 15(2), 121&#x2013;148. https://doi.org/10.1007/bf00919275</Citation></Reference><Reference><Citation>Rice, J., West, C. M., Cottman, K., &amp; Gardner, G. (2021). The intersectionality of intimate partner violence in the Black community, Handbook of interpersonal violence and abuse across the lifespan (pp. 2705&#x2013;2733). https://doi.org/10.1007/978-3-319-89999-2_240</Citation></Reference><Reference><Citation>Ritchie, J., Lewis, J., Nicholls, C. M., &amp; Ormston, R. (Eds.) (2013). Qualitative research practice: A guide for social science students and researchers. Sage.</Citation></Reference><Reference><Citation>Rowh, A., &amp; Jack, S. (2024). Notes from the field: Intimate partner homicide among women &#x2014; United States, 2018&#x2013;2021. MMWR. Morbidity and Mortality Weekly Report, 73(34), 754&#x2013;756. https://doi.org/10.15585/mmwr.mm7334a4</Citation></Reference><Reference><Citation>Scoglio, A., Zhu, Y., Lawn, R. B., Murchland, A. R., Sampson, L., Rich&#x2010;Edwards, J. W., Jha, S. C., Kang, J. H., &amp; Koenen, K. C. (2023). Intimate partner violence, mental health symptoms, and modifiable health factors in women during the COVID&#x2010;19 pandemic in the US. JAMA Network Open, 6(3), e232977. https://doi.org/10.1001/jamanetworkopen.2023.2977</Citation></Reference><Reference><Citation>Smith, S. G., Chen, J., Basile, K. C., Gilbert, L. K., Merrick, M. T., Patel, N., Walling, M., &amp; Jain, A. (2017). The National Intimate Partner and Sexual Violence Survey (NISVS): 2010&#x2013;2012 State Report. Center for Injury Prevention and Control Centers for Disease. https://www.cdc.gov/violenceprevention/pdf/nisvs-statereportbook.pdf</Citation></Reference><Reference><Citation>Smyth, C., Cullen, P., Breckenridge, J., Cortis, N., &amp; Valentine, K (2021). COVID&#x2010;19 lockdowns, intimate partner violence and coercive control. Australian Journal of Social Issues, 56(3), 359&#x2013;373. https://doi.org/10.1002/ajs4.162</Citation></Reference><Reference><Citation>Talevi, D., Socci, V., Carai, M., Carnaghi, G., Faleri, S., Trebbi, E., di Bernardo, A., Capelli, F., &amp; Pacitti, F. (2020). Mental health outcomes of the COVID&#x2010;19 pandemic. Rivista di psichiatria, 55(3), 137&#x2013;144. https://doi.org/10.1708/3382.33569</Citation></Reference><Reference><Citation>Tennakoon, L., Hakes, N. A., Knowlton, L. M., &amp; Spain, D. A. (2020). Traumatic injuries due to interpersonal and domestic violence in the United States. Journal of Surgical Research, 254, 206&#x2013;216. https://doi.org/10.1016/j.jss.2020.03.062</Citation></Reference><Reference><Citation>Toccalino, D., Haag, H., Estrella, M. J., Cowle, S., Fuselli, P., Ellis, M. J., Gargaro, J., &amp; Colantonio, A. (2022). Addressing the shadow pandemic: COVID&#x2010;19 related impacts, barriers, needs, and priorities to health care and support for women survivors of intimate partner violence and brain injury. Archives of Physical Medicine and Rehabilitation, 103(7), 1466&#x2013;1476. https://doi.org/10.1016/j.apmr.2021.12.012</Citation></Reference><Reference><Citation>UCDAVIS Health. (2022). Unemployment associated with increase in violence early in COVID&#x2010;19 pandemic. https://health.ucdavis.edu/news/headlines/unemployment-associated-with-increase-in-violence-early-in-covid-19-pandemic/2022/01</Citation></Reference><Reference><Citation>Uzoho, I. C., Baptiste&#x2010;Roberts, K., Animasahun, A., &amp; Bronner, Y. (2023). The impact of COVID&#x2010;19 pandemic on intimate partner violence (IPV) against women. International Journal of Social Determinants of Health and Health Services, 53(4), 494&#x2013;507. https://doi.org/10.1177/27551938231185968</Citation></Reference><Reference><Citation>Vance, M. M., Wade, J. M., Brandy, M., &amp; Webster, A. R. (2023). Contextualizing Black women's mental health in the twenty&#x2010;first century: Gendered racism and suicide&#x2010;related behavior. Journal of Racial and Ethnic Health Disparities, 10(1), 83&#x2013;92. https://doi.org/10.1007/s40615-021-01198-y</Citation></Reference><Reference><Citation>Vann, A. (2003). Developing Culturally&#x2010;Relevant Responses to Domestic Abuse: Asha Family Services, Inc. National Resource Center on Domestic Violence (NRCDV). https://vawnet.org/material/developing-culturally-relevant-responses-domestic-abuse-asha-family-services-inc</Citation></Reference><Reference><Citation>Vann, A. (2020). Black Women Victims of Domestic Violence: Challenge and Supports. University of Wisconsin &#x2013; Platteville. https://orcid.org/0009-0003-8209-6658 https://minds.wisconsin.edu/bitstream/handle/1793/80667/Vann,%20Antonia.pdf?sequence=1</Citation></Reference><Reference><Citation>Waller, B. Y., Harris, J., &amp; Quinn, C. R. (2022). Caught in the crossroad: An intersectional examination of African American women intimate partner violence survivors' help seeking. Trauma, Violence &amp; Abuse, 23(4), 1235&#x2013;1248. https://doi.org/10.1177/1524838021991303</Citation></Reference><Reference><Citation>West, C. M. (2015). African immigrant women and intimate partner violence: A systematic review. Journal of Aggression, Maltreatment &amp; Trauma, 25(1), 4&#x2013;17. https://doi.org/10.1080/10926771.2016.1116479</Citation></Reference><Reference><Citation>Willie, T. C., Sharpless, L., Katague, M., &amp; Kershaw, T. (2025). A mixed&#x2010;methods analysis of coercive control and COVID&#x2010;19 stress among Black women experiencing intimate partner violence during the COVID&#x2010;19 pandemic. Public Health Reports, 140, 40. https://doi.org/10.1177/00333549241238895</Citation></Reference><Reference><Citation>World Health Organization. (2021). Violence against women prevalence estimates, 2018: Global, regional and national prevalence estimates for intimate partner violence against women and global and regional prevalence estimates for non&#x2010;partner sexual violence against women. Executive summary. https://iris.who.int/bitstream/handle/10665/341338/9789240026681-eng.pdf</Citation></Reference><Reference><Citation>World Health Organization. (2022a). Preventing intimate partner violence improves mental health. https://www.who.int/news/item/06-10-2022-preventing-intimate&#x2010;</Citation></Reference><Reference><Citation>World Health Organization. (2022b). Intimate partner violence. https://apps.who.int/violence-info/intimate-partner-violence/</Citation></Reference><Reference><Citation>Zimmerman, M. A. (1995). Psychological empowerment: Issues and illustrations. American Journal of Community Psychology, 23(5), 581&#x2013;599. https://doi.org/10.1007/bf02506983</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40714824</PMID><DateCompleted><Year>2025</Year><Month>07</Month><Day>27</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1643-3750</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><PubDate><Year>2025</Year><Month>Jul</Month><Day>27</Day></PubDate></JournalIssue><Title>Medical science monitor : international medical journal of experimental and clinical research</Title><ISOAbbreviation>Med Sci Monit</ISOAbbreviation></Journal><ArticleTitle>Psychological Well-Being of Nurses and Influencing Factors During Normalization of Epidemic Prevention and Control in China.</ArticleTitle><Pagination><StartPage>e948503</StartPage><MedlinePgn>e948503</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.12659/MSM.948503</ELocationID><Abstract><AbstractText>BACKGROUND The mental health of nurses has been significantly affected by the prolonged stress and high-intensity work environments resulting from the COVID-19 pandemic. By the end of 2022, China's national epidemic prevention policy was optimized and adjusted, and all cities no longer had strict lockdown measures. The management of COVID-19 in China has transitioned to a normalization phase since this stage. This study aimed to examine the psychological status and its related factors among nurses in 4 tertiary hospitals in Dalian during the normalization phase of epidemic prevention and control. MATERIAL AND METHODS A total of 778 nurses from 4 tertiary hospitals in Dalian were surveyed through electronic web-based questionnaires between September 1, 2023, and September 30, 2023. The psychological status and work stress of the nurses were evaluated utilizing the Symptom Check List 90 (SCL-90) and the Chinese Nurses' Work Stressors Scale. Statistical analyses, comprising rank-sum tests and logistic regression models, were performed using SPSS 26.0 software. RESULTS Marital status, alcohol consumption, frontline work experience, weekly working hours, age, professional title, and years of work were found to impact the psychological well-being of nurses. Being a senior nursing staff and consuming alcohol were significant independent risk factors for nurses' psychological symptoms (P&lt;0.05). Conversely, age 20-29 years and working &#x2264;40 hours per week were identified as independent protective factors for nurses' psychological well-being during the epidemic. CONCLUSIONS The mental well-being of nurses is greatly influenced by work-related stress, which is heightened by specific demographic and occupational factors. To promote the mental health of nurses amidst ongoing epidemic control endeavors, hospitals should introduce specific interventions, such as adequate staffing, psychological support services, and customized stress management initiatives. These actions can reduce the psychological strain on nurses, enhancing overall well-being and job effectiveness.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Lu</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Neurology Department 2, The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiao</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Lin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jingdan</ForeName><Initials>J</Initials><Identifier Source="ORCID">0009-0004-4812-9564</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology, The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Med Sci Monit</MedlineTA><NlmUniqueID>9609063</NlmUniqueID><ISSNLinking>1234-1010</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008603" MajorTopicYN="Y">Mental Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009726" MajorTopicYN="Y">Nurses</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073397" MajorTopicYN="N">Occupational Stress</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009741" MajorTopicYN="Y">Nursing Staff, Hospital</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013315" MajorTopicYN="N">Stress, Psychological</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000092862" MajorTopicYN="N">Psychological Well-Being</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>27</Day><Hour>1</Hour><Minute>45</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40714824</ArticleId><ArticleId IdType="doi">10.12659/MSM.948503</ArticleId><ArticleId IdType="pii">948503</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40714792</PMID><DateCompleted><Year>2025</Year><Month>07</Month><Day>27</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">0869-866X</ISSN><JournalIssue CitedMedium="Print"><Volume>33</Volume><Issue>3</Issue><PubDate><Year>2025</Year><Month>Dec</Month><Day>15</Day></PubDate></JournalIssue><Title>Problemy sotsial'noi gigieny, zdravookhraneniia i istorii meditsiny</Title><ISOAbbreviation>Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med</ISOAbbreviation></Journal><ArticleTitle>[THE REGIONAL TRENDS IN NATALITY AND MORBIDITY OF POPULATION: CHARACTERISTICS OF PRE- AND POST-COVID PERIODS].</ArticleTitle><Pagination><StartPage>333</StartPage><EndPage>338</EndPage><MedlinePgn>333-338</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.32687/0869-866X-2025-33-3-333-338</ELocationID><Abstract><AbstractText>The issue of national demographic well-being of population is the most actual task in the national state programs of social economic development and security. The tools implementing these tasks at state level are the current Concept of Demographic Policy of the Russian Federation for the period up to 2025, the Decree of the President of the Russian Federation "On the National Development Goals of the Russian Federation for the period up to 2030 and in perspective up to 2036" and also a number of other normative legal acts. The study of regional characteristics permits to identify specifics of demographic problems and to develop targeted measures considering local conditions and needs of population. The presented results can be used as basis for assessing demographic trends at level of the Regions of Russian Federation and can be considered as development of theoretical propositions in the field of demographic process management at Federal and Regional levels. Besides, the results of analysis and modeling make it possible to assume that demographic processes in the Regions are determined not only by the level of morbidity of population, but by a number of other factors of social, economic and institutional nature that can be assumed as basis for subsequent studies of this issue.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Khabriev</LastName><ForeName>R U</ForeName><Initials>RU</Initials><AffiliationInfo><Affiliation>N. A. Semashko National Research Institute of Public Health, 105064, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gasajnieva</LastName><ForeName>M M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>N. A. Semashko National Research Institute of Public Health, 105064, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mingazova</LastName><ForeName>E N</ForeName><Initials>EN</Initials><AffiliationInfo><Affiliation>N. A. Semashko National Research Institute of Public Health, 105064, Moscow, Russia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Federal State Budget Institution "The Kazan State Medical University", 420012, Kazan, Russia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Federal State Budget Educational Institution of Additional Professional Education "The Russian Medical Academy of Continuous Professional Education" of Minzdrav of Russia, 125445, Moscow, Russia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>rus</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>12</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Russia (Federation)</Country><MedlineTA>Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med</MedlineTA><NlmUniqueID>101270373</NlmUniqueID><ISSNLinking>0869-866X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012426" MajorTopicYN="N" Type="Geographic">Russia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009017" MajorTopicYN="N">Morbidity</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011157" MajorTopicYN="Y">Population Dynamics</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003710" MajorTopicYN="Y">Demography</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="rus"><AbstractText>&#x41e;&#x431;&#x435;&#x441;&#x43f;&#x435;&#x447;&#x435;&#x43d;&#x438;&#x435; &#x434;&#x435;&#x43c;&#x43e;&#x433;&#x440;&#x430;&#x444;&#x438;&#x447;&#x435;&#x441;&#x43a;&#x43e;&#x433;&#x43e; &#x431;&#x43b;&#x430;&#x433;&#x43e;&#x43f;&#x43e;&#x43b;&#x443;&#x447;&#x438;&#x44f; &#x441;&#x442;&#x440;&#x430;&#x43d;&#x44b; &#x44f;&#x432;&#x43b;&#x44f;&#x435;&#x442;&#x441;&#x44f; &#x43d;&#x430;&#x438;&#x431;&#x43e;&#x43b;&#x435;&#x435; &#x430;&#x43a;&#x442;&#x443;&#x430;&#x43b;&#x44c;&#x43d;&#x43e;&#x439; &#x437;&#x430;&#x434;&#x430;&#x447;&#x435;&#x439; &#x432; &#x433;&#x43e;&#x441;&#x443;&#x434;&#x430;&#x440;&#x441;&#x442;&#x432;&#x435;&#x43d;&#x43d;&#x44b;&#x445; &#x43f;&#x440;&#x43e;&#x433;&#x440;&#x430;&#x43c;&#x43c;&#x430;&#x445; &#x441;&#x43e;&#x446;&#x438;&#x430;&#x43b;&#x44c;&#x43d;&#x43e;-&#x44d;&#x43a;&#x43e;&#x43d;&#x43e;&#x43c;&#x438;&#x447;&#x435;&#x441;&#x43a;&#x43e;&#x433;&#x43e; &#x440;&#x430;&#x437;&#x432;&#x438;&#x442;&#x438;&#x44f;, &#x431;&#x435;&#x437;&#x43e;&#x43f;&#x430;&#x441;&#x43d;&#x43e;&#x441;&#x442;&#x438; &#x441;&#x442;&#x440;&#x430;&#x43d;&#x44b;. &#x418;&#x43d;&#x441;&#x442;&#x440;&#x443;&#x43c;&#x435;&#x43d;&#x442;&#x430;&#x43c;&#x438; &#x440;&#x435;&#x430;&#x43b;&#x438;&#x437;&#x430;&#x446;&#x438;&#x438; &#x43e;&#x431;&#x43e;&#x437;&#x43d;&#x430;&#x447;&#x435;&#x43d;&#x43d;&#x44b;&#x445; &#x437;&#x430;&#x434;&#x430;&#x447; &#x43d;&#x430; &#x433;&#x43e;&#x441;&#x443;&#x434;&#x430;&#x440;&#x441;&#x442;&#x432;&#x435;&#x43d;&#x43d;&#x43e;&#x43c; &#x443;&#x440;&#x43e;&#x432;&#x43d;&#x435; &#x44f;&#x432;&#x43b;&#x44f;&#x44e;&#x442;&#x441;&#x44f; &#x434;&#x435;&#x439;&#x441;&#x442;&#x432;&#x443;&#x44e;&#x449;&#x430;&#x44f; &#x41a;&#x43e;&#x43d;&#x446;&#x435;&#x43f;&#x446;&#x438;&#x44f; &#x434;&#x435;&#x43c;&#x43e;&#x433;&#x440;&#x430;&#x444;&#x438;&#x447;&#x435;&#x441;&#x43a;&#x43e;&#x439; &#x43f;&#x43e;&#x43b;&#x438;&#x442;&#x438;&#x43a;&#x438; &#x420;&#x43e;&#x441;&#x441;&#x438;&#x439;&#x441;&#x43a;&#x43e;&#x439; &#x424;&#x435;&#x434;&#x435;&#x440;&#x430;&#x446;&#x438;&#x438; &#x43d;&#x430; &#x43f;&#x435;&#x440;&#x438;&#x43e;&#x434; &#x434;&#x43e; 2025 &#x433;&#x43e;&#x434;&#x430;, &#x423;&#x43a;&#x430;&#x437; &#x41f;&#x440;&#x435;&#x437;&#x438;&#x434;&#x435;&#x43d;&#x442;&#x430; &#x420;&#x43e;&#x441;&#x441;&#x438;&#x439;&#x441;&#x43a;&#x43e;&#x439; &#x424;&#x435;&#x434;&#x435;&#x440;&#x430;&#x446;&#x438;&#x438; &#xab;&#x41e; &#x43d;&#x430;&#x446;&#x438;&#x43e;&#x43d;&#x430;&#x43b;&#x44c;&#x43d;&#x44b;&#x445; &#x446;&#x435;&#x43b;&#x44f;&#x445; &#x440;&#x430;&#x437;&#x432;&#x438;&#x442;&#x438;&#x44f; &#x420;&#x43e;&#x441;&#x441;&#x438;&#x439;&#x441;&#x43a;&#x43e;&#x439; &#x424;&#x435;&#x434;&#x435;&#x440;&#x430;&#x446;&#x438;&#x438; &#x43d;&#x430; &#x43f;&#x435;&#x440;&#x438;&#x43e;&#x434; &#x434;&#x43e; 2030 &#x433;&#x43e;&#x434;&#x430; &#x438; &#x43d;&#x430; &#x43f;&#x435;&#x440;&#x441;&#x43f;&#x435;&#x43a;&#x442;&#x438;&#x432;&#x443; &#x434;&#x43e; 2036 &#x433;&#x43e;&#x434;&#x430;&#xbb;, &#x430; &#x442;&#x430;&#x43a;&#x436;&#x435; &#x440;&#x44f;&#x434; &#x434;&#x440;&#x443;&#x433;&#x438;&#x445; &#x43d;&#x43e;&#x440;&#x43c;&#x430;&#x442;&#x438;&#x432;&#x43d;&#x43e;-&#x43f;&#x440;&#x430;&#x432;&#x43e;&#x432;&#x44b;&#x445; &#x430;&#x43a;&#x442;&#x43e;&#x432;. &#x418;&#x437;&#x443;&#x447;&#x435;&#x43d;&#x438;&#x435; &#x440;&#x435;&#x433;&#x438;&#x43e;&#x43d;&#x430;&#x43b;&#x44c;&#x43d;&#x44b;&#x445; &#x43e;&#x441;&#x43e;&#x431;&#x435;&#x43d;&#x43d;&#x43e;&#x441;&#x442;&#x435;&#x439; &#x43f;&#x43e;&#x437;&#x432;&#x43e;&#x43b;&#x44f;&#x435;&#x442; &#x432;&#x44b;&#x44f;&#x432;&#x438;&#x442;&#x44c; &#x441;&#x43f;&#x435;&#x446;&#x438;&#x444;&#x438;&#x43a;&#x443; &#x434;&#x435;&#x43c;&#x43e;&#x433;&#x440;&#x430;&#x444;&#x438;&#x447;&#x435;&#x441;&#x43a;&#x438;&#x445; &#x43f;&#x440;&#x43e;&#x431;&#x43b;&#x435;&#x43c; &#x438; &#x440;&#x430;&#x437;&#x440;&#x430;&#x431;&#x43e;&#x442;&#x430;&#x442;&#x44c; &#x430;&#x434;&#x440;&#x435;&#x441;&#x43d;&#x44b;&#x435; &#x43c;&#x435;&#x440;&#x44b;, &#x443;&#x447;&#x438;&#x442;&#x44b;&#x432;&#x430;&#x44e;&#x449;&#x438;&#x435; &#x43b;&#x43e;&#x43a;&#x430;&#x43b;&#x44c;&#x43d;&#x44b;&#x435; &#x443;&#x441;&#x43b;&#x43e;&#x432;&#x438;&#x44f; &#x438; &#x43f;&#x43e;&#x442;&#x440;&#x435;&#x431;&#x43d;&#x43e;&#x441;&#x442;&#x438; &#x43d;&#x430;&#x441;&#x435;&#x43b;&#x435;&#x43d;&#x438;&#x44f;. &#x41f;&#x440;&#x435;&#x434;&#x441;&#x442;&#x430;&#x432;&#x43b;&#x435;&#x43d;&#x43d;&#x44b;&#x435; &#x432; &#x441;&#x442;&#x430;&#x442;&#x44c;&#x435; &#x440;&#x435;&#x437;&#x443;&#x43b;&#x44c;&#x442;&#x430;&#x442;&#x44b; &#x43c;&#x43e;&#x433;&#x443;&#x442; &#x431;&#x44b;&#x442;&#x44c; &#x43f;&#x43e;&#x43b;&#x43e;&#x436;&#x435;&#x43d;&#x44b; &#x432; &#x43e;&#x441;&#x43d;&#x43e;&#x432;&#x443; &#x43e;&#x446;&#x435;&#x43d;&#x43a;&#x438; &#x434;&#x435;&#x43c;&#x43e;&#x433;&#x440;&#x430;&#x444;&#x438;&#x447;&#x435;&#x441;&#x43a;&#x438;&#x445; &#x442;&#x440;&#x435;&#x43d;&#x434;&#x43e;&#x432; &#x43d;&#x430; &#x443;&#x440;&#x43e;&#x432;&#x43d;&#x435; &#x440;&#x435;&#x433;&#x438;&#x43e;&#x43d;&#x43e;&#x432; &#x420;&#x43e;&#x441;&#x441;&#x438;&#x439;&#x441;&#x43a;&#x43e;&#x439; &#x424;&#x435;&#x434;&#x435;&#x440;&#x430;&#x446;&#x438;&#x438; &#x438; &#x43c;&#x43e;&#x433;&#x443;&#x442; &#x440;&#x430;&#x441;&#x441;&#x43c;&#x430;&#x442;&#x440;&#x438;&#x432;&#x430;&#x442;&#x44c;&#x441;&#x44f; &#x43a;&#x430;&#x43a; &#x440;&#x430;&#x437;&#x432;&#x438;&#x442;&#x438;&#x435; &#x442;&#x435;&#x43e;&#x440;&#x435;&#x442;&#x438;&#x447;&#x435;&#x441;&#x43a;&#x438;&#x445; &#x43f;&#x43e;&#x43b;&#x43e;&#x436;&#x435;&#x43d;&#x438;&#x439; &#x432; &#x43e;&#x431;&#x43b;&#x430;&#x441;&#x442;&#x438; &#x443;&#x43f;&#x440;&#x430;&#x432;&#x43b;&#x435;&#x43d;&#x438;&#x44f; &#x434;&#x435;&#x43c;&#x43e;&#x433;&#x440;&#x430;&#x444;&#x438;&#x447;&#x435;&#x441;&#x43a;&#x438;&#x43c;&#x438; &#x43f;&#x440;&#x43e;&#x446;&#x435;&#x441;&#x441;&#x430;&#x43c;&#x438; &#x43d;&#x430; &#x444;&#x435;&#x434;&#x435;&#x440;&#x430;&#x43b;&#x44c;&#x43d;&#x43e;&#x43c; &#x438; &#x440;&#x435;&#x433;&#x438;&#x43e;&#x43d;&#x430;&#x43b;&#x44c;&#x43d;&#x43e;&#x43c; &#x443;&#x440;&#x43e;&#x432;&#x43d;&#x44f;&#x445;. &#x41a;&#x440;&#x43e;&#x43c;&#x435; &#x442;&#x43e;&#x433;&#x43e;, &#x440;&#x435;&#x437;&#x443;&#x43b;&#x44c;&#x442;&#x430;&#x442;&#x44b; &#x430;&#x43d;&#x430;&#x43b;&#x438;&#x437;&#x430; &#x438; &#x43c;&#x43e;&#x434;&#x435;&#x43b;&#x438;&#x440;&#x43e;&#x432;&#x430;&#x43d;&#x438;&#x44f; &#x434;&#x430;&#x44e;&#x442; &#x432;&#x43e;&#x437;&#x43c;&#x43e;&#x436;&#x43d;&#x43e;&#x441;&#x442;&#x44c; &#x43f;&#x440;&#x435;&#x434;&#x43f;&#x43e;&#x43b;&#x43e;&#x436;&#x438;&#x442;&#x44c;, &#x447;&#x442;&#x43e; &#x434;&#x435;&#x43c;&#x43e;&#x433;&#x440;&#x430;&#x444;&#x438;&#x447;&#x435;&#x441;&#x43a;&#x438;&#x435; &#x43f;&#x440;&#x43e;&#x446;&#x435;&#x441;&#x441;&#x44b; &#x432; &#x440;&#x435;&#x433;&#x438;&#x43e;&#x43d;&#x430;&#x445; &#x434;&#x435;&#x442;&#x435;&#x440;&#x43c;&#x438;&#x43d;&#x438;&#x440;&#x443;&#x44e;&#x442;&#x441;&#x44f; &#x43d;&#x435; &#x442;&#x43e;&#x43b;&#x44c;&#x43a;&#x43e; &#x443;&#x440;&#x43e;&#x432;&#x43d;&#x435;&#x43c; &#x437;&#x430;&#x431;&#x43e;&#x43b;&#x435;&#x432;&#x430;&#x435;&#x43c;&#x43e;&#x441;&#x442;&#x438; &#x43d;&#x430;&#x441;&#x435;&#x43b;&#x435;&#x43d;&#x438;&#x44f;, &#x43d;&#x43e; &#x438; &#x440;&#x44f;&#x434;&#x43e;&#x43c; &#x434;&#x440;&#x443;&#x433;&#x438;&#x445; &#x444;&#x430;&#x43a;&#x442;&#x43e;&#x440;&#x43e;&#x432; &#x441;&#x43e;&#x446;&#x438;&#x430;&#x43b;&#x44c;&#x43d;&#x43e;&#x433;&#x43e;, &#x44d;&#x43a;&#x43e;&#x43d;&#x43e;&#x43c;&#x438;&#x447;&#x435;&#x441;&#x43a;&#x43e;&#x433;&#x43e;, &#x438;&#x43d;&#x441;&#x442;&#x438;&#x442;&#x443;&#x446;&#x438;&#x43e;&#x43d;&#x430;&#x43b;&#x44c;&#x43d;&#x43e;&#x433;&#x43e; &#x445;&#x430;&#x440;&#x430;&#x43a;&#x442;&#x435;&#x440;&#x430;, &#x447;&#x442;&#x43e; &#x43c;&#x43e;&#x436;&#x435;&#x442; &#x431;&#x44b;&#x442;&#x44c; &#x43f;&#x43e;&#x43b;&#x43e;&#x436;&#x435;&#x43d;&#x43e; &#x432; &#x43e;&#x441;&#x43d;&#x43e;&#x432;&#x443; &#x434;&#x430;&#x43b;&#x44c;&#x43d;&#x435;&#x439;&#x448;&#x438;&#x445; &#x438;&#x441;&#x441;&#x43b;&#x435;&#x434;&#x43e;&#x432;&#x430;&#x43d;&#x438;&#x439; &#x43f;&#x43e; &#x434;&#x430;&#x43d;&#x43d;&#x43e;&#x43c;&#x443; &#x432;&#x43e;&#x43f;&#x440;&#x43e;&#x441;&#x443;.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Region</Keyword><Keyword MajorTopicYN="N">Regional policy</Keyword><Keyword MajorTopicYN="N">demography</Keyword><Keyword MajorTopicYN="N">fertility</Keyword><Keyword MajorTopicYN="N">forecast</Keyword><Keyword MajorTopicYN="N">morbidity</Keyword><Keyword MajorTopicYN="N">population</Keyword><Keyword MajorTopicYN="N">the Russian Federation</Keyword><Keyword MajorTopicYN="N">trends</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>6</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>27</Day><Hour>1</Hour><Minute>44</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40714792</ArticleId><ArticleId IdType="doi">10.32687/0869-866X-2025-33-3-333-338</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40714774</PMID><DateCompleted><Year>2025</Year><Month>07</Month><Day>27</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">0869-866X</ISSN><JournalIssue CitedMedium="Print"><Volume>33</Volume><Issue>3</Issue><PubDate><Year>2025</Year><Month>Dec</Month><Day>15</Day></PubDate></JournalIssue><Title>Problemy sotsial'noi gigieny, zdravookhraneniia i istorii meditsiny</Title><ISOAbbreviation>Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med</ISOAbbreviation></Journal><ArticleTitle>[THE COMPARATIVE ANALYSIS OF MORTALITY FROM MALIGNANT NEOPLASMS IN MOSCOW AND THE MOSCOW OBLAST].</ArticleTitle><Pagination><StartPage>339</StartPage><EndPage>344</EndPage><MedlinePgn>339-344</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.32687/0869-866X-2025-33-3-339-344</ELocationID><Abstract><AbstractText>The City of Moscow and the Moscow Oblast form the Moscow agglomeration, but urban residents have advantages over rural ones. The contribution of deaths from malignant neoplasms (MNP) into mortality from all causes in higher in Moscow (23.3&#xb1;0.5% and 18.3&#xb1;2.8%) than in the Moscow Oblast (15.0&#xb1;0.3% and 12.3&#xb1;2.2%). The standardized mortality rate from MNP in Moscow made up to 146.82&#xb1;2.05 per 100,000 of population in 2017-2019 and 131.35&#xb1;8.92 in 2020-2022. In the Moscow Oblast the mentioned indicator made up to 138.54&#xb1;0.12 and 131.84&#xb1;4.10, respectively. In both City of Moscow and the Moscow Oblast 80% of deaths from all MNP in 2017-2019 and 2020-2022 were caused by 14 out of 33 groups with MNP and 13 of them coincided in both Subjects of the Russian Federation. The percentage of MNP of five localizations (trachea/bronchi/lungs, colorectal cancer, stomach, breast and pancreas) in Moscow made up to 50.6% and 51.7%, and in the Moscow Oblast up to 55.1% and 55.2% in both time periods accordingly. The COVID-19 pandemic resulted not in increasing of standardized mortality rate from MNP, but in decreasing of its percentage in the structure of total mortality. Despite differences between Moscow and the Moscow Oblast, the mortality from MNP in both Subjects of the Russian Federation differs insignificantly, and structure of causes of mortality from MNP is factually the same. The obtained data is an additional basis to confirm sufficient efficiency of the system of organization of medical care of patients with MNP in the studied Subjects of the Russian Federation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Semenov</LastName><ForeName>V Y</ForeName><Initials>VY</Initials><AffiliationInfo><Affiliation>The Federal State Budget Scientific Institution "A. N. Bakulev Research Center of Cardiovascular Surgery" of Minzdrav of Russia, 119049, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Samorodskaya</LastName><ForeName>I V</ForeName><Initials>IV</Initials><AffiliationInfo><Affiliation>The Federal State Budget Institution "The National Medical Research Center of Therapy and Preventive Medicine" of Minzdrav of Russia, 101000, Moscow, Russia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>rus</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D004740">English Abstract</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>12</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Russia (Federation)</Country><MedlineTA>Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med</MedlineTA><NlmUniqueID>101270373</NlmUniqueID><ISSNLinking>0869-866X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009031" MajorTopicYN="N" Type="Geographic">Moscow</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014505" MajorTopicYN="Y">Urban Population</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002423" MajorTopicYN="N">Cause of Death</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="rus"><AbstractText>&#x41c;&#x43e;&#x441;&#x43a;&#x432;&#x430; &#x438; &#x41c;&#x43e;&#x441;&#x43a;&#x43e;&#x432;&#x441;&#x43a;&#x430;&#x44f; &#x43e;&#x431;&#x43b;&#x430;&#x441;&#x442;&#x44c; &#x43e;&#x431;&#x440;&#x430;&#x437;&#x443;&#x44e;&#x442; &#x41c;&#x43e;&#x441;&#x43a;&#x43e;&#x432;&#x441;&#x43a;&#x443;&#x44e; &#x430;&#x433;&#x43b;&#x43e;&#x43c;&#x435;&#x440;&#x430;&#x446;&#x438;&#x44e;, &#x43e;&#x434;&#x43d;&#x430;&#x43a;&#x43e; &#x433;&#x43e;&#x440;&#x43e;&#x434;&#x441;&#x43a;&#x438;&#x435; &#x436;&#x438;&#x442;&#x435;&#x43b;&#x438; &#x438;&#x43c;&#x435;&#x44e;&#x442; &#x43f;&#x440;&#x435;&#x438;&#x43c;&#x443;&#x449;&#x435;&#x441;&#x442;&#x432;&#x430; &#x43f;&#x435;&#x440;&#x435;&#x434; &#x441;&#x435;&#x43b;&#x44c;&#x441;&#x43a;&#x438;&#x43c;&#x438;. &#x412;&#x43a;&#x43b;&#x430;&#x434; &#x441;&#x43c;&#x435;&#x440;&#x442;&#x435;&#x439; &#x43e;&#x442; &#x437;&#x43b;&#x43e;&#x43a;&#x430;&#x447;&#x435;&#x441;&#x442;&#x432;&#x435;&#x43d;&#x43d;&#x44b;&#x445; &#x43d;&#x43e;&#x432;&#x43e;&#x43e;&#x431;&#x440;&#x430;&#x437;&#x43e;&#x432;&#x430;&#x43d;&#x438;&#x439; &#x432; &#x441;&#x43c;&#x435;&#x440;&#x442;&#x43d;&#x43e;&#x441;&#x442;&#x44c; &#x43e;&#x442; &#x432;&#x441;&#x435;&#x445; &#x43f;&#x440;&#x438;&#x447;&#x438;&#x43d; &#x432; &#x41c;&#x43e;&#x441;&#x43a;&#x432;&#x435; &#x432;&#x44b;&#x448;&#x435; (23,3&#xb1;0,5 &#x438; 18,3&#xb1;2,8% &#x441;&#x43e;&#x43e;&#x442;&#x432;&#x435;&#x442;&#x441;&#x442;&#x432;&#x435;&#x43d;&#x43d;&#x43e;), &#x447;&#x435;&#x43c; &#x432; &#x41c;&#x43e;&#x441;&#x43a;&#x43e;&#x432;&#x441;&#x43a;&#x43e;&#x439; &#x43e;&#x431;&#x43b;&#x430;&#x441;&#x442;&#x438; (15,0&#xb1;0,3 &#x438; 12,3&#xb1;2,2%). &#x421;&#x442;&#x430;&#x43d;&#x434;&#x430;&#x440;&#x442;&#x438;&#x437;&#x43e;&#x432;&#x430;&#x43d;&#x43d;&#x44b;&#x439; &#x43a;&#x43e;&#x44d;&#x444;&#x444;&#x438;&#x446;&#x438;&#x435;&#x43d;&#x442; &#x441;&#x43c;&#x435;&#x440;&#x442;&#x43d;&#x43e;&#x441;&#x442;&#x438; &#x43e;&#x442; &#x437;&#x43b;&#x43e;&#x43a;&#x430;&#x447;&#x435;&#x441;&#x442;&#x432;&#x435;&#x43d;&#x43d;&#x44b;&#x445; &#x43d;&#x43e;&#x432;&#x43e;&#x43e;&#x431;&#x440;&#x430;&#x437;&#x43e;&#x432;&#x430;&#x43d;&#x438;&#x439; &#x441;&#x43e;&#x441;&#x442;&#x430;&#x432;&#x438;&#x43b; &#x432; &#x41c;&#x43e;&#x441;&#x43a;&#x432;&#x435; 146,82&#xb1;2,05 &#x43d;&#x430; 100 &#x442;&#x44b;&#x441;. &#x43d;&#x430;&#x441;&#x435;&#x43b;&#x435;&#x43d;&#x438;&#x44f; &#x432; 2017&#x2014;2019 &#x433;&#x433;. &#x438; 131,35&#xb1;8,92 &#x432; 2020&#x2014;2022 &#x433;&#x433;., &#x430; &#x432; &#x41c;&#x43e;&#x441;&#x43a;&#x43e;&#x432;&#x441;&#x43a;&#x43e;&#x439; &#x43e;&#x431;&#x43b;&#x430;&#x441;&#x442;&#x438;&#x2014;138,54&#xb1;0,12 &#x438; 131,84&#xb1;4,10 &#x441;&#x43e;&#x43e;&#x442;&#x432;&#x435;&#x442;&#x441;&#x442;&#x432;&#x435;&#x43d;&#x43d;&#x43e;. &#x418; &#x432; &#x41c;&#x43e;&#x441;&#x43a;&#x432;&#x435;, &#x438; &#x432; &#x41c;&#x43e;&#x441;&#x43a;&#x43e;&#x432;&#x441;&#x43a;&#x43e;&#x439; &#x43e;&#x431;&#x43b;&#x430;&#x441;&#x442;&#x438; &#x432; &#x43e;&#x431;&#x430; &#x43f;&#x435;&#x440;&#x438;&#x43e;&#x434;&#x430; 80% &#x441;&#x43c;&#x435;&#x440;&#x442;&#x435;&#x439; &#x43e;&#x442; &#x432;&#x441;&#x435;&#x445; &#x437;&#x43b;&#x43e;&#x43a;&#x430;&#x447;&#x435;&#x441;&#x442;&#x432;&#x435;&#x43d;&#x43d;&#x44b;&#x445; &#x43d;&#x43e;&#x432;&#x43e;&#x43e;&#x431;&#x440;&#x430;&#x437;&#x43e;&#x432;&#x430;&#x43d;&#x438;&#x439; &#x43e;&#x431;&#x443;&#x441;&#x43b;&#x43e;&#x432;&#x43b;&#x438;&#x432;&#x430;&#x43b;&#x438; 14 &#x438;&#x437; 33 &#x433;&#x440;&#x443;&#x43f;&#x43f; &#x437;&#x43b;&#x43e;&#x43a;&#x430;&#x447;&#x435;&#x441;&#x442;&#x432;&#x435;&#x43d;&#x43d;&#x44b;&#x445; &#x43d;&#x43e;&#x432;&#x43e;&#x43e;&#x431;&#x440;&#x430;&#x437;&#x43e;&#x432;&#x430;&#x43d;&#x438;&#x439;, 13 &#x438;&#x437; &#x43d;&#x438;&#x445; &#x441;&#x43e;&#x432;&#x43f;&#x430;&#x434;&#x430;&#x43b;&#x438; &#x432; &#x43e;&#x431;&#x43e;&#x438;&#x445; &#x441;&#x443;&#x431;&#x44a;&#x435;&#x43a;&#x442;&#x430;&#x445; &#x420;&#x424;. &#x414;&#x43e;&#x43b;&#x44f; &#x437;&#x43b;&#x43e;&#x43a;&#x430;&#x447;&#x435;&#x441;&#x442;&#x432;&#x435;&#x43d;&#x43d;&#x44b;&#x445; &#x43d;&#x43e;&#x432;&#x43e;&#x43e;&#x431;&#x440;&#x430;&#x437;&#x43e;&#x432;&#x430;&#x43d;&#x438;&#x439; &#x43f;&#x44f;&#x442;&#x438; &#x43b;&#x43e;&#x43a;&#x430;&#x43b;&#x438;&#x437;&#x430;&#x446;&#x438;&#x439; (&#x442;&#x440;&#x430;&#x445;&#x435;&#x44f;/&#x431;&#x440;&#x43e;&#x43d;&#x445;&#x438;/&#x43b;&#x435;&#x433;&#x43a;&#x438;&#x435;, &#x43a;&#x43e;&#x43b;&#x43e;&#x440;&#x435;&#x43a;&#x442;&#x430;&#x43b;&#x44c;&#x43d;&#x44b;&#x439; &#x440;&#x430;&#x43a;, &#x436;&#x435;&#x43b;&#x443;&#x434;&#x43e;&#x43a;, &#x43c;&#x43e;&#x43b;&#x43e;&#x447;&#x43d;&#x430;&#x44f; &#x436;&#x435;&#x43b;&#x435;&#x437;&#x430;, &#x43f;&#x43e;&#x434;&#x436;&#x435;&#x43b;&#x443;&#x434;&#x43e;&#x447;&#x43d;&#x430;&#x44f; &#x436;&#x435;&#x43b;&#x435;&#x437;&#x430;) &#x441;&#x43e;&#x441;&#x442;&#x430;&#x432;&#x438;&#x43b;&#x430; &#x432; &#x41c;&#x43e;&#x441;&#x43a;&#x432;&#x435; 50,6 &#x438; 51,7%, &#x432; &#x41c;&#x43e;&#x441;&#x43a;&#x43e;&#x432;&#x441;&#x43a;&#x43e;&#x439; &#x43e;&#x431;&#x43b;&#x430;&#x441;&#x442;&#x438; &#x2014; 55,1 &#x438; 55,2% &#x432; &#x434;&#x432;&#x430; &#x43f;&#x435;&#x440;&#x438;&#x43e;&#x434;&#x430; &#x441;&#x43e;&#x43e;&#x442;&#x432;&#x435;&#x442;&#x441;&#x442;&#x432;&#x435;&#x43d;&#x43d;&#x43e;. &#x41f;&#x430;&#x43d;&#x434;&#x435;&#x43c;&#x438;&#x44f; COVID-19 &#x43d;&#x435; &#x43f;&#x440;&#x438;&#x432;&#x435;&#x43b;&#x430; &#x43a; &#x443;&#x432;&#x435;&#x43b;&#x438;&#x447;&#x435;&#x43d;&#x438;&#x44e; &#x441;&#x442;&#x430;&#x43d;&#x434;&#x430;&#x440;&#x442;&#x438;&#x437;&#x43e;&#x432;&#x430;&#x43d;&#x43d;&#x43e;&#x433;&#x43e; &#x43a;&#x43e;&#x44d;&#x444;&#x444;&#x438;&#x446;&#x438;&#x435;&#x43d;&#x442;&#x430; &#x441;&#x43c;&#x435;&#x440;&#x442;&#x43d;&#x43e;&#x441;&#x442;&#x438; &#x43e;&#x442; &#x437;&#x43b;&#x43e;&#x43a;&#x430;&#x447;&#x435;&#x441;&#x442;&#x432;&#x435;&#x43d;&#x43d;&#x44b;&#x445; &#x43d;&#x43e;&#x432;&#x43e;&#x43e;&#x431;&#x440;&#x430;&#x437;&#x43e;&#x432;&#x430;&#x43d;&#x438;&#x439;, &#x43d;&#x43e; &#x43f;&#x440;&#x438;&#x432;&#x435;&#x43b;&#x430; &#x43a; &#x443;&#x43c;&#x435;&#x43d;&#x44c;&#x448;&#x435;&#x43d;&#x438;&#x44e; &#x435;&#x435; &#x434;&#x43e;&#x43b;&#x438; &#x432; &#x441;&#x442;&#x440;&#x443;&#x43a;&#x442;&#x443;&#x440;&#x435; &#x43e;&#x431;&#x449;&#x435;&#x439; &#x441;&#x43c;&#x435;&#x440;&#x442;&#x43d;&#x43e;&#x441;&#x442;&#x438;. &#x41d;&#x435;&#x441;&#x43c;&#x43e;&#x442;&#x440;&#x44f; &#x43d;&#x430; &#x438;&#x43c;&#x435;&#x44e;&#x449;&#x438;&#x435;&#x441;&#x44f; &#x440;&#x430;&#x437;&#x43b;&#x438;&#x447;&#x438;&#x44f; &#x43c;&#x435;&#x436;&#x434;&#x443; &#x41c;&#x43e;&#x441;&#x43a;&#x432;&#x43e;&#x439; &#x438; &#x41c;&#x43e;&#x441;&#x43a;&#x43e;&#x432;&#x441;&#x43a;&#x43e;&#x439; &#x43e;&#x431;&#x43b;&#x430;&#x441;&#x442;&#x44c;&#x44e;, &#x441;&#x43c;&#x435;&#x440;&#x442;&#x43d;&#x43e;&#x441;&#x442;&#x44c; &#x43e;&#x442; &#x437;&#x43b;&#x43e;&#x43a;&#x430;&#x447;&#x435;&#x441;&#x442;&#x432;&#x435;&#x43d;&#x43d;&#x44b;&#x445; &#x43d;&#x43e;&#x432;&#x43e;&#x43e;&#x431;&#x440;&#x430;&#x437;&#x43e;&#x432;&#x430;&#x43d;&#x438;&#x439; &#x432; &#x43e;&#x431;&#x43e;&#x438;&#x445; &#x441;&#x443;&#x431;&#x44a;&#x435;&#x43a;&#x442;&#x430;&#x445; &#x420;&#x424; &#x440;&#x430;&#x437;&#x43b;&#x438;&#x447;&#x430;&#x435;&#x442;&#x441;&#x44f; &#x43d;&#x435;&#x441;&#x443;&#x449;&#x435;&#x441;&#x442;&#x432;&#x435;&#x43d;&#x43d;&#x43e;, &#x430; &#x441;&#x442;&#x440;&#x443;&#x43a;&#x442;&#x443;&#x440;&#x430; &#x43f;&#x440;&#x438;&#x447;&#x438;&#x43d; &#x441;&#x43c;&#x435;&#x440;&#x442;&#x43d;&#x43e;&#x441;&#x442;&#x438; &#x43e;&#x442; &#x437;&#x43b;&#x43e;&#x43a;&#x430;&#x447;&#x435;&#x441;&#x442;&#x432;&#x435;&#x43d;&#x43d;&#x44b;&#x445; &#x43d;&#x43e;&#x432;&#x43e;&#x43e;&#x431;&#x440;&#x430;&#x437;&#x43e;&#x432;&#x430;&#x43d;&#x438;&#x439; &#x43f;&#x440;&#x430;&#x43a;&#x442;&#x438;&#x447;&#x435;&#x441;&#x43a;&#x438; &#x43e;&#x434;&#x438;&#x43d;&#x430;&#x43a;&#x43e;&#x432;&#x430;. &#x41f;&#x43e;&#x43b;&#x443;&#x447;&#x435;&#x43d;&#x43d;&#x44b;&#x435; &#x434;&#x430;&#x43d;&#x43d;&#x44b;&#x435; &#x44f;&#x432;&#x43b;&#x44f;&#x44e;&#x442;&#x441;&#x44f; &#x434;&#x43e;&#x43f;&#x43e;&#x43b;&#x43d;&#x438;&#x442;&#x435;&#x43b;&#x44c;&#x43d;&#x44b;&#x43c; &#x43e;&#x441;&#x43d;&#x43e;&#x432;&#x430;&#x43d;&#x438;&#x435;&#x43c; &#x434;&#x43b;&#x44f; &#x43f;&#x43e;&#x434;&#x442;&#x432;&#x435;&#x440;&#x436;&#x434;&#x435;&#x43d;&#x438;&#x44f; &#x434;&#x43e;&#x441;&#x442;&#x430;&#x442;&#x43e;&#x447;&#x43d;&#x43e;&#x439; &#x44d;&#x444;&#x444;&#x435;&#x43a;&#x442;&#x438;&#x432;&#x43d;&#x43e;&#x441;&#x442;&#x438; &#x441;&#x438;&#x441;&#x442;&#x435;&#x43c;&#x44b; &#x43e;&#x440;&#x433;&#x430;&#x43d;&#x438;&#x437;&#x430;&#x446;&#x438;&#x438; &#x43c;&#x435;&#x434;&#x438;&#x446;&#x438;&#x43d;&#x441;&#x43a;&#x43e;&#x439; &#x43f;&#x43e;&#x43c;&#x43e;&#x449;&#x438; &#x431;&#x43e;&#x43b;&#x44c;&#x43d;&#x44b;&#x43c; &#x441;&#x43e; &#x437;&#x43b;&#x43e;&#x43a;&#x430;&#x447;&#x435;&#x441;&#x442;&#x432;&#x435;&#x43d;&#x43d;&#x44b;&#x43c;&#x438; &#x43d;&#x43e;&#x432;&#x43e;&#x43e;&#x431;&#x440;&#x430;&#x437;&#x43e;&#x432;&#x430;&#x43d;&#x438;&#x44f;&#x43c;&#x438; &#x432; &#x438;&#x437;&#x443;&#x447;&#x430;&#x435;&#x43c;&#x44b;&#x445; &#x441;&#x443;&#x431;&#x44a;&#x435;&#x43a;&#x442;&#x430;&#x445; &#x420;&#x424;.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">causes of death</Keyword><Keyword MajorTopicYN="N">malignant neoplasm</Keyword><Keyword MajorTopicYN="N">mortality</Keyword><Keyword MajorTopicYN="N">oncological mortality</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>6</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>27</Day><Hour>1</Hour><Minute>44</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40714774</ArticleId><ArticleId IdType="doi">10.32687/0869-866X-2025-33-3-339-344</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40714772</PMID><DateCompleted><Year>2025</Year><Month>07</Month><Day>27</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">0869-866X</ISSN><JournalIssue CitedMedium="Print"><Volume>33</Volume><Issue>3</Issue><PubDate><Year>2025</Year><Month>Dec</Month><Day>15</Day></PubDate></JournalIssue><Title>Problemy sotsial'noi gigieny, zdravookhraneniia i istorii meditsiny</Title><ISOAbbreviation>Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med</ISOAbbreviation></Journal><ArticleTitle>[THE RISK AND PROTECTIVE FACTORS FOR NONCOMMUNICABLE DISEASES].</ArticleTitle><Pagination><StartPage>445</StartPage><EndPage>447</EndPage><MedlinePgn>445-447</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.32687/0869-866X-2025-33-3-445-447</ELocationID><Abstract><AbstractText>The article presents modern data on non-communicable diseases (NCDs) and their risk factors. The tendency of increasing mortality from NCDs due to increase in the number and aging of the population is noted. The data is presented testifying that, in addition to biological risk factors, influence of environmental factors is increasing, including atmospheric and household air pollution, the levels of which are high in a significant number of countries. It is emphasized that green spaces (e.g., trees, grass, forests and parks) and blue spaces (e.g., lakes, rivers, ponds, etc.) provide beneficial effect on human health, being in fact protective factors for NCDs. The NCD risk factors are found to interact closely with each other: air pollution, depression, tobacco smoking, high blood pressure and obesity have been linked to all NCDs. The evidence is provided that presence of behavioral risk factors for NCDs exacerbates severity of infectious pathology, particularly COVID-19 and other infectious diseases (influenza, HIV, tuberculosis, hepatitis, etc.). Given that NCD risk factors can occur in early childhood, promoting healthy lifestyles among expectant mothers and adolescents should be a priority to reduce NCD risks, especially in low- and middle-income countries.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Amlaev</LastName><ForeName>K R</ForeName><Initials>KR</Initials><AffiliationInfo><Affiliation>The Abu Ali ibn Sino Bukhara State Medical Institute, Ministry of Health of Uzbekistan, Bukhara, Uzbekistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdullah</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>The Sana Klinikum Berlin, Board Certified in Preventive Medicine, 10711 Berlin, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>rus</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D004740">English Abstract</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>12</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Russia (Federation)</Country><MedlineTA>Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med</MedlineTA><NlmUniqueID>101270373</NlmUniqueID><ISSNLinking>0869-866X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073296" MajorTopicYN="Y">Noncommunicable Diseases</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065840" MajorTopicYN="N">Protective Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000397" MajorTopicYN="N">Air Pollution</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="rus"><AbstractText>The article presents modern data on non-communicable diseases (NCDs) and their risk factors. The tendency of increasing mortality from NCDs due to increase in the number and aging of the population is noted. The data is presented testifying that, in addition to biological risk factors, influence of environmental factors is increasing, including atmospheric and household air pollution, the levels of which are high in a significant number of countries. It is emphasized that green spaces (e.g., trees, grass, forests and parks) and blue spaces (e.g., lakes, rivers, ponds, etc.) provide beneficial effect on human health, being in fact protective factors for NCDs. The NCD risk factors are found to interact closely with each other: air pollution, depression, tobacco smoking, high blood pressure and obesity have been linked to all NCDs. The evidence is provided that presence of behavioral risk factors for NCDs exacerbates severity of infectious pathology, particularly COVID-19 and other infectious diseases (influenza, HIV, tuberculosis, hepatitis, etc.). Given that NCD risk factors can occur in early childhood, promoting healthy lifestyles among expectant mothers and adolescents should be a priority to reduce NCD risks, especially in low- and middle-income countries.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">NCD risk factors</Keyword><Keyword MajorTopicYN="N">behavioral factors</Keyword><Keyword MajorTopicYN="N">infectious diseases</Keyword><Keyword MajorTopicYN="N">non-communicable diseases</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>6</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>27</Day><Hour>1</Hour><Minute>44</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40714772</ArticleId><ArticleId IdType="doi">10.32687/0869-866X-2025-33-3-445-447</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40714729</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2352-3964</ISSN><JournalIssue CitedMedium="Internet"><Volume>118</Volume><PubDate><Year>2025</Year><Month>Jul</Month><Day>25</Day></PubDate></JournalIssue><Title>EBioMedicine</Title><ISOAbbreviation>EBioMedicine</ISOAbbreviation></Journal><ArticleTitle>Post COVID 19 resurgence of diphtheria in Kano, Nigeria: analysis of 18,320 cases.</ArticleTitle><Pagination><StartPage>105877</StartPage><MedlinePgn>105877</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ebiom.2025.105877</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2352-3964(25)00321-4</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The COVID 19 pandemic led to significant disruptions in health services, including immunisation programs, which contributed to a major post-pandemic diphtheria outbreak in Kano State, Nigeria. This region accounted for 85% of the nation's documented diphtheria cases.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This study examined the epidemiology, clinical characteristics, and mortality outcomes of cases diagnosed between February 2022 and April 2024. Data were collected through the Surveillance Outbreak Response Management and Analysis System (SORMAS), and case definitions followed WHO guidelines. Case fatality rate (CFR) was calculated, and a logistic regression model was used to assess mortality-related risk factors, reporting adjusted odds ratios (AOR).</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">A total of 18,320 cases were analysed, with the outbreak showing a bimodal distribution. The primary peak occurred in August 2023, followed by a smaller secondary peak in early 2024. The case fatality rate (CFR) was 4.5%. Patients who were not vaccinated had more than double the likelihood of death compared to fully vaccinated individuals (AOR 2.45; 95% CI: 2.05, 2.94, p &lt; 0.0001; logistic regression). Similarly, patients without vaccination documentation also had greater odds, with more than 87% increase likelihood of mortality compared to fully vaccinated individuals (AOR 1.87, 95% CI: 1.27, 2.68, p &lt; 0.0001; logistic regression).</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">Our study reinforces previous reports of the weakening preventive health delivery systems in resource constrained settings, particularly after the disruptions caused by the COVID 19 pandemic leading to the resurgence of vaccine preventable diseases, such as diphtheria. These highlight the need for improved vaccination coverage and surveillance systems.</AbstractText><AbstractText Label="FUNDINGS" NlmCategory="RESULTS">This research did not receive any external funding.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 The Authors. Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Abbas</LastName><ForeName>Muhammad Adamu</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Kano Center for Disease Control and Prevention, Nigeria; Department of Community Medicine, Bayero University Kano, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yusuf</LastName><ForeName>Abubakar Labaran</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Office of the Commissioner for Health, Kano State Ministry of Health, Kano, Nigeria; Department of Medicine, Federal University Dutse, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murtala</LastName><ForeName>Hassan Adam</ForeName><Initials>HA</Initials><AffiliationInfo><Affiliation>Department of Epidemiology &amp; Population Health, Kano Independent Research Centre Trust, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdullahi</LastName><ForeName>Aisha Adam</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Department of Epidemiology &amp; Population Health, Kano Independent Research Centre Trust, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murtala</LastName><ForeName>Adam Muhammad</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Epidemiology &amp; Population Health, Kano Independent Research Centre Trust, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torrelles</LastName><ForeName>Jordi Bertran</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>I-CARE, Texas Biomedical Research Institute, San Antonio, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aliyu</LastName><ForeName>Muktar Hassan</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>Vanderbilt Institute for Global Health, Vanderbilt University Medical Centre, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salihu</LastName><ForeName>Hamisu Mohammed</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Department of Epidemiology &amp; Population Health, Kano Independent Research Centre Trust, Nigeria. Electronic address: Hamisu.salihu@kirct.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>EBioMedicine</MedlineTA><NlmUniqueID>101647039</NlmUniqueID><ISSNLinking>2352-3964</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Diphtheria</Keyword><Keyword MajorTopicYN="N">Epidemiology</Keyword><Keyword MajorTopicYN="N">Nigeria</Keyword><Keyword MajorTopicYN="N">Outbreak</Keyword><Keyword MajorTopicYN="N">Vaccine preventable diseases</Keyword></KeywordList><CoiStatement>Declaration of interests The authors declare no conflicts of interest. This research was conducted independently, with no commercial or financial ties that could have influenced the study's outcomes. M.A.A. and A.L.Y. were affiliated with the Kano State government during the submission process, but this had no bearing on the peer review or final decision.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>11</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>6</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>27</Day><Hour>1</Hour><Minute>42</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40714729</ArticleId><ArticleId IdType="doi">10.1016/j.ebiom.2025.105877</ArticleId><ArticleId IdType="pii">S2352-3964(25)00321-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40714693</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0070</ISSN><JournalIssue CitedMedium="Internet"><Volume>113</Volume><Issue>3</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>18</Day></PubDate></JournalIssue><Title>Diagnostic microbiology and infectious disease</Title><ISOAbbreviation>Diagn Microbiol Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Impact of COVID-19 pandemic on toxinogenic Clostridioides difficile infections and correlation with multidrug-resistant bacterial infections.</ArticleTitle><Pagination><StartPage>117014</StartPage><MedlinePgn>117014</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.diagmicrobio.2025.117014</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0732-8893(25)00337-2</ELocationID><Abstract><AbstractText>Clostridioides difficile infection (CDI) is one of the most common healthcare-associated infections, contributing to significant morbidity and mortality, particularly in hospitalized patients. Its incidence is influenced by infection control measures, antimicrobial stewardship, and hospital hygiene protocols. The Coronavirus disease 2019 (COVID-19) pandemic led to the widespread adoption of stringent infection prevention strategies. These measures may have influenced the incidence of CDI. At the university hospital Policlinico Umberto I in Rome, we conducted a retrospective analysis of CDI cases across three periods: preCOVID-19, COVID-19 and postCOVID-19. Our findings revealed a statistically significant decrease in CDI cases during the COVID-19 period compared to the preCOVID-19 period, as well as in the postCOVID-19 period compared to the COVID-19 period. Additionally, we explored the potential association between CDI and multidrug-resistant organisms (MDRO). Our findings indicate a reduction in MDRO infections among patients with CDI in the COVID-19 and postCOVID-19 periods compared to the preCOVID-19 period. These results highlight the potential impact of infection control strategies on CDI incidence and suggest a possible relationship between CDI and MDRO infection. Further research is needed to assess the long-term effects of these measures and their implications for future infection prevention strategies.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 The Author(s). Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Torrini</LastName><ForeName>Luisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine, Sapienza University of Rome, Italy. Electronic address: luisa.torrini@uniroma1.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diaco</LastName><ForeName>Fabiana</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine, Sapienza University of Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Viscido</LastName><ForeName>Agnese</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Clinical Microbiology Laboratory, University Hospital Policlinico Umberto I of Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sacco</LastName><ForeName>Federica</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Clinical Microbiology Laboratory, University Hospital Policlinico Umberto I of Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sfara</LastName><ForeName>Germana</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine, Sapienza University of Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Compagnino</LastName><ForeName>Daniele Emanuele</ForeName><Initials>DE</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine, Sapienza University of Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Puggioni</LastName><ForeName>Gianluca</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Clinical Microbiology Laboratory, University Hospital Policlinico Umberto I of Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coletti</LastName><ForeName>Monica</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Clinical Microbiology Laboratory, University Hospital Policlinico Umberto I of Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Antonelli</LastName><ForeName>Guido</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine, Sapienza University of Rome, Italy; Clinical Microbiology Laboratory, University Hospital Policlinico Umberto I of Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raponi</LastName><ForeName>Giammarco</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Clinical Microbiology Laboratory, University Hospital Policlinico Umberto I of Rome, Italy; Department of Public Health and Infectious Disease, Sapienza University of Rome, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Diagn Microbiol Infect Dis</MedlineTA><NlmUniqueID>8305899</NlmUniqueID><ISSNLinking>0732-8893</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Clostridioides difficile infection</Keyword><Keyword MajorTopicYN="N">Coronavirus disease 2019 (COVID-19) pandemic</Keyword><Keyword MajorTopicYN="N">Healthcare-associated infections</Keyword><Keyword MajorTopicYN="N">Infection control</Keyword><Keyword MajorTopicYN="N">Multidrug-resistant organisms</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>6</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>27</Day><Hour>1</Hour><Minute>41</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40714693</ArticleId><ArticleId IdType="doi">10.1016/j.diagmicrobio.2025.117014</ArticleId><ArticleId IdType="pii">S0732-8893(25)00337-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40714585</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-3336</ISSN><JournalIssue CitedMedium="Internet"><Volume>496</Volume><PubDate><Year>2025</Year><Month>Jul</Month><Day>23</Day></PubDate></JournalIssue><Title>Journal of hazardous materials</Title><ISOAbbreviation>J Hazard Mater</ISOAbbreviation></Journal><ArticleTitle>Gentle collection of bacteria aerosols using ferrofluid-bovine serum albumin coating and electromagnetic air sampling for rapid bioaerosol monitoring.</ArticleTitle><Pagination><StartPage>139348</StartPage><MedlinePgn>139348</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jhazmat.2025.139348</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0304-3894(25)02264-2</ELocationID><Abstract><AbstractText>To monitor infectious airborne microorganisms (bioaerosols) such as SARS-CoV-2 (the COVID-19-causing agent), they should first be transferred to a liquid. Rapid bioaerosol monitoring should minimize mechanical damage to the samples and maintain high collection efficiency. This study presents a gentle airborne bacterial collection method. First, airborne bacteria were subjected to an aerosol coating of ferrofluid for magnetization and bovine serum albumin to reduce damage to the bacteria during coating. Second, the coated bacteria were collected using an electromagnetic air sampler. Finally, the highly enriched bacterial samples were flushed with a liquid. Our aerosol-coating electromagnetic air sampling system (ACEMASS) showed considerably higher bacterial recovery (8389&#x202f;%) than the SKC BioSampler (1925&#x202f;%, one of the most widely used commercial bioaerosol samplers). ACEMASS maintained high bacterial collection efficiencies (8294&#x202f;%) for all air sampling flow rates (610&#x202f;L/min) in the laboratory, providing highly enriched samples for qPCR detection (240-fold higher concentrations than collected using the SKC BioSampler). ACEMASS also provided colony-countable samples (4.0 CFU/mL) even in low-bioaerosol environments (20 CFU/m<sup>3</sup> air), where the SKC BioSampler failed to produce colonies.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025. Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Hyeong Rae</ForeName><Initials>HR</Initials><AffiliationInfo><Affiliation>Gas Metrology Group, Korea Research Institute of Standards and Science (KRISS), Daejeon 34113, Republic of Korea. Electronic address: hrkim@kriss.re.kr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hwang</LastName><ForeName>Jungho</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>School of Mechanical Engineering, Yonsei University, Seoul 03722, Republic of Korea. Electronic address: hwangjh@yonsei.ac.kr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Hazard Mater</MedlineTA><NlmUniqueID>9422688</NlmUniqueID><ISSNLinking>0304-3894</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Aerosol coating</Keyword><Keyword MajorTopicYN="N">Electromagnetic air sampler</Keyword><Keyword MajorTopicYN="N">Gentle sampling</Keyword><Keyword MajorTopicYN="N">High collection efficiency</Keyword><Keyword MajorTopicYN="N">Rapid bioaerosol monitoring</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>27</Day><Hour>1</Hour><Minute>39</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40714585</ArticleId><ArticleId IdType="doi">10.1016/j.jhazmat.2025.139348</ArticleId><ArticleId IdType="pii">S0304-3894(25)02264-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40714527</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN><JournalIssue CitedMedium="Internet"><Volume>62</Volume><PubDate><Year>2025</Year><Month>Jul</Month><Day>25</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>Long-term efficacy and immune response of CoronaVac in Brazilian health care workers: Insights from PROFISCOV unblinded trial.</ArticleTitle><Pagination><StartPage>127527</StartPage><MedlinePgn>127527</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2025.127527</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0264-410X(25)00824-2</ELocationID><Abstract><AbstractText>Covid-19 remains a global threat due to vaccine-waning immune responses, and the need to update to emerging variants. This study presents the post-unblinding analysis of the PROFISCOV trial (NCT04456595), a double-blind, randomized, placebo-controlled phase 3, among adult healthcare workers (HCWs&#x2265;18y). A cohort (N&#xa0;=&#xa0;12,688) was randomized to receive a two-dose regimen of the inactivated COVID-19 vaccine (CoronaVac) or placebo (1:1), 14&#xa0;days apart. ANVISA granted emergency use authorization for CoronaVac in January 2021, prompting the study's unblinding. Outcomes included incidence of symptomatic confirmed COVID-19 cases (RT-PCR), immune response over one year, and effects of boosters among the vaccinees. Population (N&#xa0;=&#xa0;1554) exhibited a reduction in confirmed cases from November 2021, peaking from December 2021 to February 2022, when the Omicron wave prevailed. Mean IgG-RBD titres increased from baseline to the 52nd week. IgG-N titres peaked in the 13th week and declined. The homologous booster enhanced significantly the immune response compared to the heterologous one (Pfizer).</AbstractText><CopyrightInformation>Copyright &#xa9; 2025. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Salom&#xe3;o</LastName><ForeName>Maria da Gra&#xe7;a</ForeName><Initials>MDG</Initials><AffiliationInfo><Affiliation>Centro de Ensaios Cl&#xed;nicos e Farmacovigil&#xe2;ncia, Instituto Butantan, Av. Vital Brasil, 1500, Butant&#xe3;, S&#xe3;o Paulo, SP 05503-900, Brazil. Electronic address: maria.salomao@fundacaobutantan.org.br.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Almeida Leit&#xe3;o Curimbaba</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Centro de Ensaios Cl&#xed;nicos e Farmacovigil&#xe2;ncia, Instituto Butantan, Av. Vital Brasil, 1500, Butant&#xe3;, S&#xe3;o Paulo, SP 05503-900, Brazil. Electronic address: caroline.curimbaba@fundacaobutantan.org.br.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Braga</LastName><ForeName>Patr&#xed;cia Em&#xed;lia</ForeName><Initials>PE</Initials><AffiliationInfo><Affiliation>Centro de Ensaios Cl&#xed;nicos e Farmacovigil&#xe2;ncia, Instituto Butantan, Av. Vital Brasil, 1500, Butant&#xe3;, S&#xe3;o Paulo, SP 05503-900, Brazil. Electronic address: patricia.braga@fundacaobutantan.org.br.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fran&#xe7;a</LastName><ForeName>Jo&#xe3;o Italo Dias</ForeName><Initials>JID</Initials><AffiliationInfo><Affiliation>Centro de Ensaios Cl&#xed;nicos e Farmacovigil&#xe2;ncia, Instituto Butantan, Av. Vital Brasil, 1500, Butant&#xe3;, S&#xe3;o Paulo, SP 05503-900, Brazil. Electronic address: joao.franca@fundacaobutantan.org.br.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patino</LastName><ForeName>Elizabeth Gonzalez</ForeName><Initials>EG</Initials><AffiliationInfo><Affiliation>Centro de Ensaios Cl&#xed;nicos e Farmacovigil&#xe2;ncia, Instituto Butantan, Av. Vital Brasil, 1500, Butant&#xe3;, S&#xe3;o Paulo, SP 05503-900, Brazil. Electronic address: Elizabeth.patino@fundacaobutantan.org.br.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boulos</LastName><ForeName>Fernanda Castro</ForeName><Initials>FC</Initials><AffiliationInfo><Affiliation>Centro de Ensaios Cl&#xed;nicos e Farmacovigil&#xe2;ncia, Instituto Butantan, Av. Vital Brasil, 1500, Butant&#xe3;, S&#xe3;o Paulo, SP 05503-900, Brazil. Electronic address: fernanda.boulos@fundacaobutantan.org.br.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Sousa Moreira</LastName><ForeName>Jos&#xe9; Alfredo</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Centro de Ensaios Cl&#xed;nicos e Farmacovigil&#xe2;ncia, Instituto Butantan, Av. Vital Brasil, 1500, Butant&#xe3;, S&#xe3;o Paulo, SP 05503-900, Brazil. Electronic address: jose.amoreira@fundacaobutantan.org.br.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>PROFISCOV Study Group</CollectiveName><AffiliationInfo><Affiliation>Centro de Ensaios Cl&#xed;nicos e Farmacovigil&#xe2;ncia, Instituto Butantan, Av. Vital Brasil, 1500, Butant&#xe3;, S&#xe3;o Paulo, SP 05503-900, Brazil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CoronaVac</Keyword><Keyword MajorTopicYN="N">Healthcare workers</Keyword><Keyword MajorTopicYN="N">Homologous booster</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2 incidence</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: The authors (MGS, JASM, PEB, JIDF, EGP, CALC, FCB) are current employees of Funda&#xe7;&#xe3;o Butantan. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>3</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>27</Day><Hour>1</Hour><Minute>35</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40714527</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2025.127527</ArticleId><ArticleId IdType="pii">S0264-410X(25)00824-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40714526</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN><JournalIssue CitedMedium="Internet"><Volume>62</Volume><PubDate><Year>2025</Year><Month>Jul</Month><Day>25</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>Strengthening spontaneous reporting-based signal detection during a pandemic with cases from electronic health records using a natural language processing tool.</ArticleTitle><Pagination><StartPage>127549</StartPage><MedlinePgn>127549</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2025.127549</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0264-410X(25)00846-1</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">During the COVID-19 pandemic, vaccines were rapidly developed, but some potential adverse drug reactions (ADRs) were still undetected at the time of market authorization. The analysis of ADR reports received through the spontaneous reporting system (SRS) remains the cornerstone for safety signal detection. A limitation is that reporting ADRs is voluntary. In this study the added value of electronic health records (EHRs) was explored as an additional source to spontaneous reports, to strengthen safety signal detection concerning COVID-19 vaccines.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The electronic health record adverse event (EHR-AE) search method was developed to enable targeted searches in EHRs using a natural language processing (NLP) tool with text-mining functionalities to identify additional potential cases. Searches were performed in EHRs of two Dutch hospitals concerning several established and non-established (potential) ADRs associated with COVID-19 vaccines. Identified cases were reported to Lareb and analyzed in addition to spontaneous reports for safety signal detection.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Thirteen searches were conducted between January 1, 2023, and December 1, 2023, concerning different (potential) ADRs associated with COVID-19 vaccines. For 6 associations at least 1 case was identified, resulting in a total of 41 additional cases reported to Lareb. These cases contributed to the detection of two safety signals concerning COVID-19 vaccines. Two safety signals could have been detected approximately 18 and 2&#xa0;months earlier, if the EHR-AE method had been implemented during the COVID-19 pandemic.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The EHR-AE search method can strengthen and accelerate the signal detection process for potential ADRs associated with COVID-19 vaccination. Future studies should expand to more hospitals, aiming to further evaluate the added value of the method, including for which drug-ADR associations the EHR-AE search method is most beneficial.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 The Authors. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>van der Weg</LastName><ForeName>W</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>The Netherlands Pharmacovigilance Centre Lareb, 's-Hertogenbosch, the Netherlands; Department of Clinical Pharmacology and Toxicology, Leiden University Medical Centre, Leiden, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>von Kreijfelt</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>The Netherlands Pharmacovigilance Centre Lareb, 's-Hertogenbosch, the Netherlands; Department of Clinical Pharmacology and Toxicology, Leiden University Medical Centre, Leiden, the Netherlands. Electronic address: g.j.von_kreijfelt@lumc.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davidson</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>The Netherlands Pharmacovigilance Centre Lareb, 's-Hertogenbosch, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zwaveling</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacology and Toxicology, Leiden University Medical Centre, Leiden, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Visser</LastName><ForeName>L E</ForeName><Initials>LE</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Haga Teaching Hospital, The Hague, the Netherlands; Department of Hospital Pharmacy, Erasmus Medical Centre, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Hunsel</LastName><ForeName>F P A M</ForeName><Initials>FPAM</Initials><AffiliationInfo><Affiliation>The Netherlands Pharmacovigilance Centre Lareb, 's-Hertogenbosch, the Netherlands; Department of Pharmacotherapy, Epidemiology and Economics, Groningen Research Institute of Pharmacy (GRIP), University of Groningen, Groningen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kant</LastName><ForeName>A C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>The Netherlands Pharmacovigilance Centre Lareb, 's-Hertogenbosch, the Netherlands; Department of Clinical Pharmacology and Toxicology, Leiden University Medical Centre, Leiden, the Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19 vaccine safety surveillance</Keyword><Keyword MajorTopicYN="N">Electronic health records</Keyword><Keyword MajorTopicYN="N">Natural language processing</Keyword><Keyword MajorTopicYN="N">Pharmacovigilance</Keyword><Keyword MajorTopicYN="N">Safety signal detection</Keyword><Keyword MajorTopicYN="N">Spontaneous report system</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Agnes C. Kant reports financial support was provided by Zorg Onderzoek Nederland Medische Wetenschappen (ZonMw). If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>27</Day><Hour>1</Hour><Minute>34</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40714526</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2025.127549</ArticleId><ArticleId IdType="pii">S0264-410X(25)00846-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40714385</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-7714</ISSN><JournalIssue CitedMedium="Internet"><Volume>96</Volume><PubDate><Year>2025</Year><Month>Jul</Month><Day>23</Day></PubDate></JournalIssue><Title>General hospital psychiatry</Title><ISOAbbreviation>Gen Hosp Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Economic stimulus for households during the COVID-19 pandemic may have mitigated rise in overdose deaths.</ArticleTitle><Pagination><StartPage>193</StartPage><EndPage>194</EndPage><MedlinePgn>193-194</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.genhosppsych.2025.07.019</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0163-8343(25)00155-0</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ghertner</LastName><ForeName>Robin</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Emory University, Department of Health Policy and Management, Rollins School of Public Health, 1518 Clifton Rd N E, Atlanta, GA 30322, United States of America. Electronic address: robinghertner@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ali</LastName><ForeName>Mir M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Department of Health Policy and Management, University of Maryland, 4200 Valley Drive, College Park, MD 20742, United States of America. Electronic address: ali.mir.m@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Gen Hosp Psychiatry</MedlineTA><NlmUniqueID>7905527</NlmUniqueID><ISSNLinking>0163-8343</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Mortality</Keyword><Keyword MajorTopicYN="N">Opioid</Keyword><Keyword MajorTopicYN="N">Overdose</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>6</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>27</Day><Hour>1</Hour><Minute>28</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40714385</ArticleId><ArticleId IdType="doi">10.1016/j.genhosppsych.2025.07.019</ArticleId><ArticleId IdType="pii">S0163-8343(25)00155-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40714326</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-3573</ISSN><JournalIssue CitedMedium="Internet"><Volume>297</Volume><Issue>Pt A</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>23</Day></PubDate></JournalIssue><Title>Talanta</Title><ISOAbbreviation>Talanta</ISOAbbreviation></Journal><ArticleTitle>Extracting the SERS characteristic features of SARS-CoV-2 and using machine learning to quickly screen positive specimens among hospitalized patients.</ArticleTitle><Pagination><StartPage>128621</StartPage><MedlinePgn>128621</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.talanta.2025.128621</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0039-9140(25)01111-7</ELocationID><Abstract><AbstractText>The emergence of widespread viral transmission has prompted further development of early diagnostic methods, especially in situations where rapid and accurate testing is urgently needed. Label-free surface enhanced Raman spectroscopy (SERS) specimen classification through analytical chemistry combined with machine learning (ML) was shown to address such issue. However, the complexity of clinical specimens limit the qualitative interpretation, posing a challenge to the fast screening of clinical specimens. SERS-active substrates consisting of Au NPs/pZrO2 or Au NPs/fZrO2 were used to screen for SARS CoV-2 BA.2 variant among hospitalized inpatients. Nasopharyngeal and throat swabs were used, and their SERS spectra were distinguished. Full SERS spectra were extracted to distinguish CoV (+) and CoV (-) specimens to investigate the differences between ML of full SERS spectra and that of extracted spectral features. Nasopharyngeal specimens have shown to provide identifiable distinct features. Au NPs/fZrO2 exhibited better signal detection than Au NPs/pZrO2 owing to the filtering capability of the fibers, retaining only the virus particles on the surface. Full SERS spectra as input data in ML resulted in a sensitivity and specificity of 60&#xa0;%; on the other hand, when extracted spectral features were used, a sensitivity of 100&#xa0;% was exhibited by both substrates and specificities of 43&#xa0;% and 57&#xa0;% with Au NPs/pZrO2 and Au NPs/fZrO2, respectively. This study can quickly screen CoV (+) inpatients but is limited by the complexity of spectral profile affected by comorbidities, the number and diversity of inpatient specimens, and the need to further distinguish spectral profiles of CoV (-).</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sitjar</LastName><ForeName>Jaya</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Engineered Materials for Biomedical Applications Laboratory, Department of Materials Science and Engineering, National Cheng Kung University, Tainan, 701, Taiwan. Electronic address: jaya.sitjar@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Huey-Pin</ForeName><Initials>HP</Initials><AffiliationInfo><Affiliation>Department of Medical Laboratory Science and Biotechnology, College of Medicine, National Cheng Kung University, Tainan, 701, Taiwan; Department of Pathology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, 704, Taiwan. Electronic address: tsaihp@mail.ncku.edu.tw.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Han</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Engineered Materials for Biomedical Applications Laboratory, Department of Materials Science and Engineering, National Cheng Kung University, Tainan, 701, Taiwan. Electronic address: 10608102@gs.ncku.edu.tw.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Chun-Wei</ForeName><Initials>CW</Initials><AffiliationInfo><Affiliation>Engineered Materials for Biomedical Applications Laboratory, Department of Materials Science and Engineering, National Cheng Kung University, Tainan, 701, Taiwan. Electronic address: wayne60803@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Xin-Ni</ForeName><Initials>XN</Initials><AffiliationInfo><Affiliation>Engineered Materials for Biomedical Applications Laboratory, Department of Materials Science and Engineering, National Cheng Kung University, Tainan, 701, Taiwan. Electronic address: poal1031623@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>Jiunn-Der</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Engineered Materials for Biomedical Applications Laboratory, Department of Materials Science and Engineering, National Cheng Kung University, Tainan, 701, Taiwan. Electronic address: jdliao@mail.ncku.edu.tw.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Talanta</MedlineTA><NlmUniqueID>2984816R</NlmUniqueID><ISSNLinking>0039-9140</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Analytical chemistry</Keyword><Keyword MajorTopicYN="N">Extracted SERS spectral feature</Keyword><Keyword MajorTopicYN="N">False positive</Keyword><Keyword MajorTopicYN="N">Hospitalized patients</Keyword><Keyword MajorTopicYN="N">Label-free surface enhanced Raman spectroscopy</Keyword><Keyword MajorTopicYN="N">Machine learning</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:Jiunn-Der Liao reports financial support was provided by National Science and Technology Council of Taiwan. Jiunn-Der Liao reports financial support was provided by Center for Drug Evaluation (CDE) of Taiwan. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>27</Day><Hour>1</Hour><Minute>26</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40714326</ArticleId><ArticleId IdType="doi">10.1016/j.talanta.2025.128621</ArticleId><ArticleId IdType="pii">S0039-9140(25)01111-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40714149</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1527-3296</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Jul</Month><Day>24</Day></PubDate></JournalIssue><Title>American journal of infection control</Title><ISOAbbreviation>Am J Infect Control</ISOAbbreviation></Journal><ArticleTitle>Enhancing Infection Prevention and Control Practices Among Nurses: The Mediating Role of Resilience and the Moderating Effect of Training Participation.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S0196-6553(25)00495-X</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ajic.2025.07.009</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Infection prevention and control (IPC) practices are essential for pandemic preparedness. This study examined the individual-level cognitive and psychological factors influencing IPC practices among nurses during the COVID-19 pandemic.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A cross-sectional survey was conducted with 120 nurses in Korea from July 7 to August 31, 2022. Partial least squares-based path analysis was performed to assess the relationships among knowledge, nursing attitude, resilience, IPC practices, and training participation, as well as the mediation and moderation effects.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Knowledge (&#x3b2; = 0.216, p = 0.007) and resilience (&#x3b2; = 0.211, p = 0.014) significantly influenced IPC practices. Resilience significantly mediated the relationship between nursing attitude and IPC practices. Training participation significantly moderated the effects of knowledge on resilience (&#x3b2; = 0.184, p = 0.004) and nursing attitude on IPC practices (&#x3b2; = 0.158, p = 0.025). The adjusted R<sup>2</sup> value of resilience was 13.3%, whereas that of IPC practice was 18.6%.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Nurses' knowledge and attitude enhance IPC practices through the mediating effect of resilience and the moderating role of training participation. Prioritizing practical reinforcement training and resilience-building programs can strengthen IPC compliance and improve infection prevention in future outbreaks.</AbstractText><AbstractText Label="DATA AVAILABILITY STATEMENT" NlmCategory="UNASSIGNED">The datasets generated and analyzed during the current study are available from the corresponding author on reasonable request.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025. Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Yeongmi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Nursing, Wonju College of Nursing, Yonsei University, Wonju, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Jihea</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Nursing, Wonju College of Nursing, Yonsei University, Wonju, Republic of Korea. Electronic address: jiheachoi@yonsei.ac.kr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Infect Control</MedlineTA><NlmUniqueID>8004854</NlmUniqueID><ISSNLinking>0196-6553</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Education</Keyword><Keyword MajorTopicYN="N">Infection control</Keyword><Keyword MajorTopicYN="N">Knowledge</Keyword><Keyword MajorTopicYN="N">Nursing attitude</Keyword><Keyword MajorTopicYN="N">Resilience</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>2</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>27</Day><Hour>1</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40714149</ArticleId><ArticleId IdType="doi">10.1016/j.ajic.2025.07.009</ArticleId><ArticleId IdType="pii">S0196-6553(25)00495-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40714117</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-2742</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Jul</Month><Day>24</Day></PubDate></JournalIssue><Title>The Journal of infection</Title><ISOAbbreviation>J Infect</ISOAbbreviation></Journal><ArticleTitle>Surveillance of invasive beta-haemolytic streptococci in Denmark, 2012 to 2023: A nationwide study.</ArticleTitle><Pagination><StartPage>106559</StartPage><MedlinePgn>106559</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jinf.2025.106559</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0163-4453(25)00153-7</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To analyse trends in incidence, seasonality, and antimicrobial resistance of invasive beta-haemolytic streptococci (iBHS) in Denmark from 2012 to 2023.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Nationwide laboratory surveillance included submission of invasive isolates of Lancefield group A, B, C, and G streptococci from blood, cerebrospinal fluid, and other sterile sites to the National Reference Laboratory. Incidence rates (IRs) per 100,000 were calculated. Seasonality was analysed using Poisson regression, and antimicrobial susceptibility was determined by EUCAST disc diffusion.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In total, 9,470 iBHS cases were identified. Annual IRs increased from 2.6 to 9.4 for iGAS, 2.5 to 4.9 for iGBS, 1.4 to 4.8 for iGCS, and 3.1 to 8.5 for iGGS. iGAS exhibited marked seasonality, peaking in February and troughing in September (peak-to-trough ratio 3.2). Incidence declined during the COVID-19 pandemic but rebounded in 2023. No seasonality was observed for iGBS, iGCS, or iGGS. Incidences were highest in males and older adults, except iGBS, which showed a bimodal distribution. Recurrent infections occurred in 5.4% of cases, predominantly with iGGS and iGCS. All isolates were penicillin susceptible, but erythromycin and clindamycin resistance increased in iGBS and iGGS.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The rising incidence of iBHS, particularly iGAS resurgence and increasing resistance, highlights the need for continued surveillance.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 The Author(s). Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Christiansen</LastName><ForeName>Cecilie Hviid</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Department of Clinical Microbiology, Aarhus University Hospital, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#xf8;gaard</LastName><ForeName>Kirstine Kobber&#xf8;e</ForeName><Initials>KK</Initials><AffiliationInfo><Affiliation>Department of Clinical Microbiology, Aalborg University Hospital, Denmark; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dam-Dalgeir</LastName><ForeName>Gertrud</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>FORSA, Forskningens Hus, Region Nordjylland, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dessau</LastName><ForeName>Ram B</ForeName><Initials>RB</Initials><AffiliationInfo><Affiliation>Department of Clinical Microbiology, Zealand University Hospital, Slagelse, Denmark; Institute of regional health research, University of Southern Denmark, Odense, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dzajic</LastName><ForeName>Esad</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Clinical Microbiology, Esbjerg and Grinsted Hospital, Esbjerg, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jensen</LastName><ForeName>Christian Salg&#xe5;rd</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>Department of Clinical Microbiology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xfc;tzen</LastName><ForeName>Lisbeth</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Clinical Microbiology, Sygehus Lilleb&#xe6;lt, Vejle, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pedersen</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Clinical Microbiology, Copenhagen University Hospital - Amager and Hvidovre, Copenhagen; Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Skovgaard</LastName><ForeName>Sissel</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Clinical Microbiology, Copenhagen University Hospital - Herlev and Gentofte Hospital, Herlev, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sydenham</LastName><ForeName>Thomas Vognbjerg</ForeName><Initials>TV</Initials><AffiliationInfo><Affiliation>Department of Clinical Microbiology, Odense University Hospital, Denmark; Research unit of Clinical Microbiology (Odense), Department of Health, University of Southern Denmark, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoffmann</LastName><ForeName>Steen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Neisseria and Streptococcus Reference Laboratory, Statens Serum Institut, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nielsen</LastName><ForeName>Hans Linde</ForeName><Initials>HL</Initials><AffiliationInfo><Affiliation>Department of Clinical Microbiology, Aalborg University Hospital, Denmark; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. Electronic address: halin@rn.dk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Infect</MedlineTA><NlmUniqueID>7908424</NlmUniqueID><ISSNLinking>0163-4453</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Beta-haemolytic streptococci</Keyword><Keyword MajorTopicYN="N">Denmark</Keyword><Keyword MajorTopicYN="N">epidemiology</Keyword><Keyword MajorTopicYN="N">invasive</Keyword><Keyword MajorTopicYN="N">surveillance</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>27</Day><Hour>1</Hour><Minute>22</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40714117</ArticleId><ArticleId IdType="doi">10.1016/j.jinf.2025.106559</ArticleId><ArticleId IdType="pii">S0163-4453(25)00153-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40714114</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-3150</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Jul</Month><Day>24</Day></PubDate></JournalIssue><Title>Toxicon : official journal of the International Society on Toxinology</Title><ISOAbbreviation>Toxicon</ISOAbbreviation></Journal><ArticleTitle>The Impact of the COVID-19 Pandemic and Post-Pandemic Economic Crisis on Snakebite Patterns in Rural Sri Lanka.</ArticleTitle><Pagination><StartPage>108502</StartPage><MedlinePgn>108502</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.toxicon.2025.108502</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0041-0101(25)00277-6</ELocationID><Abstract><AbstractText Label="AIM" NlmCategory="OBJECTIVE">We aimed to compare the pattern of snakebites and the pre-hospital practices of snakebite victims during, before, and after the COVID-19 period in a region of Sri Lanka with a high snakebite incidence.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Data were extracted from the Anuradhapura snakebite cohort from March 2018 to October 2023. The cohort recruits all snakebite patients (&gt;16 years) admitted to the Teaching Hospital, Anuradhapura. For this study, data from pre-COVID (March 2018 - October 2019), COVID (March 2020 - October 2021), and post-COVID (March 2022 - October 2023) periods were analysed RESULTS: There were 1141, 1312, and 1375 patients in the Pre-COVID, COVID and Post-COVID groups. Authenticated Hypnale hypnale bites increased during COVID (454/784, 58%) and post-COVID (501/849,59%) compared to pre-COVID (234/658, 36%), while Daboia russelii bites decreased during COVID (210/784, 27%) and post-COVID (205/849, 24%) compared to pre-COVID (259/658, 39%). The proportion of home garden bites increased during post-COVID (560/1375, 41%) compared to pre-COVID (378/1141, 33%) and COVID (416/1312, 32%). The percentage of patients who intentionally delayed hospital admission was greater in post-COVID (26%) compared to groups pre-COVID (18%) and COVID (16%). The percentage who sought native treatment before hospital admission was greater post-COVID (15%) compared to pre-COVID (6%) and during COVID (7%), as was the application of tourniquets as first aid post-COVID (37%) compared to pre-COVID (22%) and COVID (22%). During the COVID-19 pandemic, the rate of patients leaving the hospital against medical advice rose to 4%, up from 3% in the pre-COVID period. This trend continued to increase after the pandemic.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">During and after the COVID-19 pandemic, H. hypnale cases increased and D. russelii bites decreased, coinciding with shift of snakebites from farmlands to home gardens. More patients delayed hospital treatment, used harmful first aid, or left against medical advice during and after the COVID-19 pandemic.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Waiddyanatha</LastName><ForeName>Subodha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Parasitology, Faculty of Medicine and Allied Sciences, Rajarata University of Sri Lanka.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silva</LastName><ForeName>Anjana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Parasitology, Faculty of Medicine and Allied Sciences, Rajarata University of Sri Lanka; South Asian Clinical Toxicology Research Collaboration, Faculty of Medicine, University of Peradeniya, Sri Lanka.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wijayasekara</LastName><ForeName>Asela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Parasitology, Faculty of Medicine and Allied Sciences, Rajarata University of Sri Lanka; Department of Parasitology, Faculty of Medicine, Wayamba University of Sri Lanka, Sri Lanka.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wedasingha</LastName><ForeName>Supun</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Faculty of Medicine and Allied Sciences, Rajarata University of Sri Lanka.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siribaddana</LastName><ForeName>Sisira</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medicine, Faculty of Medicine and Allied Sciences, Rajarata University of Sri Lanka.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Isbister</LastName><ForeName>Geoffrey K</ForeName><Initials>GK</Initials><AffiliationInfo><Affiliation>South Asian Clinical Toxicology Research Collaboration, Faculty of Medicine, University of Peradeniya, Sri Lanka; Clinical Toxicology Research Group, University of Newcastle, Newcastle, Australia. Electronic address: geoff.isbister@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Toxicon</MedlineTA><NlmUniqueID>1307333</NlmUniqueID><ISSNLinking>0041-0101</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Daboia russelii</Keyword><Keyword MajorTopicYN="N">Hypnale hypnale</Keyword><Keyword MajorTopicYN="N">exposure</Keyword><Keyword MajorTopicYN="N">snakebite</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest &#x2612; The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Geoffrey K. Isbister reports financial support was provided by National Health and Medical Research Council. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>27</Day><Hour>1</Hour><Minute>22</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40714114</ArticleId><ArticleId IdType="doi">10.1016/j.toxicon.2025.108502</ArticleId><ArticleId IdType="pii">S0041-0101(25)00277-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40714040</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2468-1253</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Jul</Month><Day>22</Day></PubDate></JournalIssue><Title>The lancet. Gastroenterology &amp; hepatology</Title><ISOAbbreviation>Lancet Gastroenterol Hepatol</ISOAbbreviation></Journal><ArticleTitle>Scientific and medical evidence informing expansion of hepatitis B treatment guidelines.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S2468-1253(25)00053-6</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/S2468-1253(25)00053-6</ELocationID><Abstract><AbstractText>Chronic hepatitis B treatment relies on nucleoside or nucleotide analogue drugs that suppress hepatitis B virus (HBV) replication, normalise liver enzymes, and slow disease progression with excellent safety profiles. Treatment is not curative, and patients remain at risk of cirrhosis and hepatocellular carcinoma. Treatment guidelines have generally restricted antiviral therapy to individuals with high HBV DNA and elevated ALT or hepatic fibrosis, often requiring longitudinal testing that can be scarcely available in resource-limited settings. Consequently, fewer than 3% of people living with HBV infection are receiving antiviral therapy. Guidelines from China and WHO recently broadened access criteria to antiviral therapy, but there are people who fall outside these guidelines who could still benefit from treatment initiation. The pathological processes induced by HBV infection are still active in these patients. We present the benefits and risks of expanding treatment eligibility. We believe that the benefits of reduced hepatic damage and carcinogenic stimuli greatly outweigh the risks.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kennedy</LastName><ForeName>Patrick T</ForeName><Initials>PT</Initials><AffiliationInfo><Affiliation>Immunobiology, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK. Electronic address: p.kennedy@qmul.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Allweiss</LastName><ForeName>Lena</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Medical Clinic and Polyclinic, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; German Center for Infection Research, Hamburg-L&#xfc;beck-Borstel-Riems Site, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bertoletti</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cornberg</LastName><ForeName>Markus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany; German Center for Infection Research, Partner Site Hannover-Braunschweig, Hannover, Germany; Centre for Individualised Infection Medicine, Hannover, Germany; Cluster of Excellence RESIST, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gehring</LastName><ForeName>Adam J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Schwartz Reisman Liver Research Centre, Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada; Toronto Centre for Liver Disease, Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada; Department of Immunology, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guidotti</LastName><ForeName>Luca G</ForeName><Initials>LG</Initials><AffiliationInfo><Affiliation>Division of Immunology, Transplantation, and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kerth</LastName><ForeName>H&#xe9;l&#xe8;ne A</ForeName><Initials>HA</Initials><AffiliationInfo><Affiliation>Institute of Virology, Technical University of Munich/Helmholtz Center Munich, Munich, Germany; German Center for Infectious Research, Munich Partner Site, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lemoine</LastName><ForeName>Maud</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Metabolism Digestion and Reproduction-Liver Unit, St Mary's Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levrero</LastName><ForeName>Massimo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>INSERM U1052, CNRS UMR-5286, Cancer Research Center of Lyon, Lyon, France; University of Lyon, UMR_S1052, Cancer Research Center of Lyon, Lyon, France; The Lyon Hepatology Institute EVEREST, Lyon, France; Department of Hepatology, Croix Rousse Hospital, Hospices Civils de Lyon, Lyon, France; Department of Internal Medicine, Sapienza University, Rome, Italy; IIT Center for Life Nanoscience, Sapienza University, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Seng Gee</ForeName><Initials>SG</Initials><AffiliationInfo><Affiliation>Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Division of Gastroenterology and Hepatology, National University Health System, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tavis</LastName><ForeName>John E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Department of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, Saint Louis, MO, USA; Institute for Drug and Biotherapeutic Development, Saint Louis University, Saint Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Testoni</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Universit&#xe9; Claude-Bernard Lyon 1, INSERM, UMR 1350 PaThLiv, Lyon, France; The Lyon Hepatology Institute, IHU EVEREST, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tu</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Westmead Institute for Medical Research, University of Sydney School of Medicine and Health, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>International Coalition to Eliminate HBV</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Lancet Gastroenterol Hepatol</MedlineTA><NlmUniqueID>101690683</NlmUniqueID></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement>Declaration of Interests PTK receives grants and/or contracts from Aligos and Vir Biotechnology; consulting fees from AssemblyBio, Bluejay Therapeutics, GlaxoSmithKline (GSK), and Gilead Sciences; honoraria from GSK and Gilead Sciences; and has a leadership role in the British Viral Hepatitis Group (Chair). MC receives funding from the Deutsche Zentrum f&#xfc;r Infektionsforshung and the German Research Foundation; consulting fees from AbbVie (consulting; advisory board [hepatitis C]), AiCuris (consulting; advisory board [hepatitis B]), GSK (consulting; advisory board [hepatitis B]), Merck Sharpe and Dohme (consulting; advisory board [Covid and hepatitis B]), Roche (consulting; advisory board [hepatitis B]), AstraZeneca (consulting; advisory board [Covid]), and Gilead Sciences (consulting; advisory board [hepatitis B]); and honoraria from Abbvie (hepatitis C), Gilead Sciences (hepatitis D), and Falk (hepatitis); participates on an advisory board for Novartis; and has stock options in Biontech, unrelated to HBV. AJG receives support from Aligos Therapeutics, Bluejay Therapeutics, GSK, Roche, Vir Biotechnology, and EVOQ Therapeutics; and has participated in data safety monitoring boards or advisory boards to Aligos Therapeutics, Arbutus Biopharma, Assembly Biosciences, Bluejay Therapeutics, Gilead Sciences, GSK, Roche, Vir Biotechnology, and Virion therapeutics. LGG receives research funding from the Italian Ministry for University and Research (PE00000007 [INF-ACT], PRIN 20224NMLXK, and PRIN P2022Z8HNC), the Fondazione SAME Italy donation to support HBV research, and the Fondazione Prossimo Mio Italy donation to support HBV research; Sponsored Research Agreement (SRA) support from Gilead Sciences, Takis Biotechnology, and Avalia Immunotherapies; royalties from Scripps Research (payments to LGG as the creator of HBV transgenic mice) and license fees from Antios Therapeutics (for the selling of intellectual property related to CAMs; no longer active); consulting fees from Aligos Therapeutics, Ananda Immunotherapies, Antios Therapeutics, Arbutus Biopharma, Avalia Immunotherapies Chroma Medicine, Epsilen Bio, Genenta Science, and Gilead Sciences; has patents or planned patents UK 2018657.3 (Agents and methods for increasing liver immune response) and WO2021/160617 (Spirocyclic inhibitors of hepatitis B virus; at present the intellectual property is back to the investors [San Raffaele Hospital, LGG, and the Italian institutions Istituto Nazionale Genetica Molecolare and Istituto di Ricerca Biomedica]; the assets are no longer in development and not being marketed, and in the case of any future remuneration from it, including license fees and royalties, those would be shared between the inventors and the institutions they belong to); and stock or options from Genenta Science and Ananda Immunotherapies unrelated to HBV. HAK is Director of Operations for the International Coalition to Eliminate HBV. MLem has received consulting fees from Abbott Laboratories, Cepheid, and Gilead Sciences. MLev has received honoraria from AbbVie and Gilead Sciences, and travel support from AbbVie and Gilead Sciences. SGL receives research funding from Gilead Sciences, Abbott, and Sysmex through his institution; consulting fees from Gilead Sciences, Abbott, Roche, GSK, Janssen, Sysmex, Arbutus Biopharma, Assembly Biosciences, Grifols, AusperBio, and Aligos; honoraria from Gilead Sciences, Janssen, Roche, Sysmex, and GSK; travel support from GSK and Abbott; serves on a data safety monitoring board for Roche; and has unpaid leadership roles in ICE-HBV, AASLD, and Agence Nationale de Recherche sur le Sida et les h&#xe9;patites&#x2013;Maladies Infectieuses Emergentes. JET has unpaid roles on the Executive Committee of ICE-HBV and the Scientific and Medical Advisory Board to the Hepatitis B Foundation. BT receives research funding from Assembly Biosciences, Bluejay Therapeutics, Aligos, and Beam Therapeutics; has received fees for expert testimony from the International Hepatology Education Program; and has a patent pending with Beam Therapeutics for gRNA sequences targeting the HBV genome (not yet on the market; if the product reaches the market, remunerations would be split between Beam, INSERM, and the inventors [of note, the entire HBV programme including the development of this therapeutic strategy was stopped by Beam in 2023]). TT receives support through a Paul &amp; Valeria Ainsworth Fellowship; research funding from Gilead Biosciences, ACH4, GESA, NSW Ministry of Health, National Health and Medical Research Council, and the Stephan Urban Foundation; consulting fees from Excision BioTherapeutics, Kerna Ventures, Gilead Sciences, and GSK; has received honoraria from GSK, ASHM, and the Science of HBV Cure Meeting 2024 in Singapore; has received travel support from GSK and the Science of HBV Cure Meeting; and has leadership roles in the Australian Centre for Hepatitis Virology, HepB Voices Australia, HepBcommunity.org, Hepatitis B Forum for Collaborative Research, Australian WHO Collaborating Centre, NSW Hepatitis B Strategy Implementation Program, the Hepatitis B Foundation, Australian National Hepatitis B Strategy Targets Workshop, the Australian Centre for HIV and Hepatitis Virology Research, ICE-HBV, ASHM, and Parramatta District Men's Shed. LA and AB declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>11</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>2</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>2</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>27</Day><Hour>1</Hour><Minute>21</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40714040</ArticleId><ArticleId IdType="doi">10.1016/S2468-1253(25)00053-6</ArticleId><ArticleId IdType="pii">S2468-1253(25)00053-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40713968</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-4186</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Jul</Month><Day>23</Day></PubDate></JournalIssue><Title>Structure (London, England : 1993)</Title><ISOAbbreviation>Structure</ISOAbbreviation></Journal><ArticleTitle>EnsembleFlex: Protein structure ensemble analysis made easy.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S0969-2126(25)00249-7</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.str.2025.07.001</ELocationID><Abstract><AbstractText>Proteins exhibit conformational dynamics that underpin function and inform drug design. EnsembleFlex is a computational suite to extract, quantify, and visualize conformational heterogeneity from experimentally determined structure ensembles, thereby enabling both computational and experimental scientists to gain actionable insights into protein dynamics, ligand interactions, and drug-design applications. It performs dual-scale flexibility analysis (backbone and side-chain) via optimized superposition, dimension reduction (principal-component analysis [PCA] and uniform manifold approximation and projection [UMAP]), clustering, automated binding-site frequency mapping, and conserved water detection. Accessible through a no-code graphical interface or scriptable pipelines, EnsembleFlex accepts heterogeneous PDB sets (X-ray, NMR, and cryoelectron microscopy [cryo-EM]) and optionally integrates elastic network-model predictions (anisotropic network model [ANM]/Gaussian network model [GNM]) to complement experimental data. Case studies-including adenylate kinase, hexokinase-1, interleukin-1&#x3b2; (IL-1&#x3b2;) fragment screens, and SARS-CoV-2 main protease ensembles-demonstrate its scalability and utility for high-throughput structural analysis.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Melanie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridgeshire CB10 1SD, UK; European Molecular Biology Laboratory, EMBL Grenoble, 71 avenue des Martyrs, 9018 38042 Grenoble, France. Electronic address: melanie@ebi.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marquez</LastName><ForeName>Jos&#xe9; Antonio</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>European Molecular Biology Laboratory, EMBL Grenoble, 71 avenue des Martyrs, 9018 38042 Grenoble, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leach</LastName><ForeName>Andrew R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridgeshire CB10 1SD, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Structure</MedlineTA><NlmUniqueID>101087697</NlmUniqueID><ISSNLinking>0969-2126</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CADD</Keyword><Keyword MajorTopicYN="N">analysis of dynamics</Keyword><Keyword MajorTopicYN="N">computational structural biology</Keyword><Keyword MajorTopicYN="N">conserved water identification</Keyword><Keyword MajorTopicYN="N">drug discovery</Keyword><Keyword MajorTopicYN="N">high-throughput screening</Keyword><Keyword MajorTopicYN="N">ligand-binding site analysis</Keyword><Keyword MajorTopicYN="N">protein flexibility</Keyword><Keyword MajorTopicYN="N">structural ensembles</Keyword><Keyword MajorTopicYN="N">superposition methods</Keyword></KeywordList><CoiStatement>Declaration of interests The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>2</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>6</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>27</Day><Hour>1</Hour><Minute>18</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40713968</ArticleId><ArticleId IdType="doi">10.1016/j.str.2025.07.001</ArticleId><ArticleId IdType="pii">S0969-2126(25)00249-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40713966</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-4186</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Jul</Month><Day>22</Day></PubDate></JournalIssue><Title>Structure (London, England : 1993)</Title><ISOAbbreviation>Structure</ISOAbbreviation></Journal><ArticleTitle>Cross-species recognition of squirrel ACE2 by the receptor binding domains of SARS-CoV-2, RaTG13, PCoV-GD and PCoV-GX.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S0969-2126(25)00251-5</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.str.2025.07.003</ELocationID><Abstract><AbstractText>SARS-CoV-2 has a broad animal host range, but its origin and intermediate hosts are still debated. Arctic ground squirrel is proved to be a susceptible animal host of SARS-CoV-2 and RaTG13, as the Arctic ground squirrel ACE2 (sACE2) could bind to the RBDs of SARS-CoV-2 and RaTG13, and support transduction of the SARS-CoV-2 and RaTG13 pseudovirions. Here, we determined crystal structures of sACE2 bound to the RBDs of RaTG13, PCoV-GD, PCoV-GX, SARS-CoV-2 A372T and SARS-CoV-2 JN.1 variant. SPR assay indicated that RBD residues 493, 498 and 501 might be important for sACE2 recognition. Notably, N322-linked glycans of sACE2 were found to be in contact with S375 of the RaTG13 RBD. Moreover, the recent SARS-CoV-2 KP.2 and KP.3 variant RBDs could also bind to the sACE2. Our results provide further insights into interactions between coronavirus RBD and cell receptor ACE2, which may promote our understanding of SARS-CoV-2 evolution.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Chenghai</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>School of Biomedical Sciences, Hunan University, Changsha, Hunan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nan</LastName><ForeName>Xiaoyan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>School of Biomedical Sciences, Hunan University, Changsha, Hunan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Hunan Provincial Key Laboratory of Anti-Resistance Microbial Drugs, The Third Hospital of Changsha, Changsha, Hunan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>Shilong</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Beijing Advanced Innovation Center for Structural Biology, School of Life Sciences, Tsinghua University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lan</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>School of Biomedical Sciences, Hunan University, Changsha, Hunan, China; Hunan Provincial Key Laboratory of Anti-Resistance Microbial Drugs, The Third Hospital of Changsha, Changsha, Hunan, China. Electronic address: lanjun2022@hnu.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Structure</MedlineTA><NlmUniqueID>101087697</NlmUniqueID><ISSNLinking>0969-2126</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Arctic ground squirrel ACE2</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2 evolution</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2 variants</Keyword><Keyword MajorTopicYN="N">coronavirus RBDs</Keyword><Keyword MajorTopicYN="N">crystal structures</Keyword></KeywordList><CoiStatement>Declaration of interests The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>1</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>3</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>27</Day><Hour>1</Hour><Minute>18</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40713966</ArticleId><ArticleId IdType="doi">10.1016/j.str.2025.07.003</ArticleId><ArticleId IdType="pii">S0969-2126(25)00251-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40713926</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1460-2393</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Jul</Month><Day>26</Day></PubDate></JournalIssue><Title>QJM : monthly journal of the Association of Physicians</Title><ISOAbbreviation>QJM</ISOAbbreviation></Journal><ArticleTitle>Correction to: A case of anti-LGI1 encephalitis after mRNA COVID-19 vaccination.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">hcaf162</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/qjmed/hcaf162</ELocationID><Language>eng</Language><PublicationTypeList><PublicationType UI="D016425">Published Erratum</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>QJM</MedlineTA><NlmUniqueID>9438285</NlmUniqueID><ISSNLinking>1460-2393</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumFor"><RefSource>QJM. 2023 Jul 28;116(7):582-583. doi: 10.1093/qjmed/hcad060.</RefSource><PMID Version="1">37067518</PMID></CommentsCorrections></CommentsCorrectionsList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>27</Day><Hour>1</Hour><Minute>16</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40713926</ArticleId><ArticleId IdType="doi">10.1093/qjmed/hcaf162</ArticleId><ArticleId IdType="pii">8213975</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40713897</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1475-6773</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Jul</Month><Day>26</Day></PubDate></JournalIssue><Title>Health services research</Title><ISOAbbreviation>Health Serv Res</ISOAbbreviation></Journal><ArticleTitle>Predicting Risk of Long-Term Institutionalization Among Community Dwelling Veterans Before the COVID-19 Pandemic.</ArticleTitle><Pagination><StartPage>e70016</StartPage><MedlinePgn>e70016</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/1475-6773.70016</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To identify risk of long-term institutionalization (LTI) among Veterans receiving care in the Veterans Health Administration (VA).</AbstractText><AbstractText Label="STUDY SETTING AND DESIGN" NlmCategory="METHODS">We developed the "Predicted Long-term Institutionalization" (PLI) risk model for Veterans alive in the community at the end of fiscal-year (FY) 2017 followed for LTI in nursing home (cumulative NH days allowing any acute care and up to 7&#x2009;days in community &gt;&#x2009;90&#x2009;days) during FY2018-FY2019.</AbstractText><AbstractText Label="DATA SOURCES AND ANALYTIC SAMPLE" NlmCategory="UNASSIGNED">PLI used demographics, diagnoses, prior hospital and nursing home (NH) use, and risk indices for death and frailty from VA and Medicare claims and Minimum Data Set data. Development of PLI used multiple iterations to maximize sensitivity, constrained by achieving a number needed to screen (&#x2264;&#x2009;8), including age normalization to minimize algorithmic bias. We combined the elevated risk (ER) and common risk (CR) strata-specific predictions from the logistic regression models to identify three tiers of PLI: low risk, moderate risk, and high risk. We describe Veterans' outcomes in FY2018/2019 (LTI, death, hospitalization and VA cost) across the three PLI tiers.</AbstractText><AbstractText Label="PRINCIPAL FINDINGS" NlmCategory="RESULTS">For identifying Veterans in LTI, compared to a baseline model that used only VA data as predictors (sensitivity 23%, specificity 98%), calibrating separate ER and CR strata increased sensitivity to 30%, the addition of Medicare data increased sensitivity to 33%, and age-normalization with differential risk strata thresholds increased sensitivity to 41% (specificity 96.6%). The final PLI model (c-statistic&#x2009;=&#x2009;0.87) identified 3.5% of Veterans in PLI-high risk (13% LTI rate), who accounted for 41% of new LTI, 22% of decedents, 19% of VA cost, and 11% of hospitalizations in FY2018-2019.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The PLI score identifies Veterans at high risk of LTI for further assessment and targeting of resources to support continued community residence.</AbstractText><CopyrightInformation>Published 2025. This article is a U.S. Government work and is in the public domain in the USA. Health Services Research published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kinosian</LastName><ForeName>Bruce</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0003-2098-6340</Identifier><AffiliationInfo><Affiliation>Geriatrics and Extended Care Data Analysis Center (GECDAC), Bronx, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cpl Michael J Crescenz VA Medical Center, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Leonard Davis Institute for Health Economics, University of Pennsylvania, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Division of Geriatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmitt</LastName><ForeName>Susan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Geriatrics and Extended Care Data Analysis Center (GECDAC), Bronx, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>VA Palo Alto Health Care System, Palo Alto, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Stanford University, Palo Alto, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Augustine</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Geriatrics and Extended Care Data Analysis Center (GECDAC), Bronx, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>James J Peters VAMC, Bronx, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Geriatrics &amp; Palliative Care, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hartronft</LastName><ForeName>Scotte</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Veterans Affairs, Geriatrics and Extended Care, Washington, DC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Makineni</LastName><ForeName>Rajesh</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Geriatrics and Extended Care Data Analysis Center (GECDAC), Bronx, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Public Health Sciences, University of Rochester, Rochester, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Judon</LastName><ForeName>Kimberly</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Geriatrics and Extended Care Data Analysis Center (GECDAC), Bronx, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>James J Peters VAMC, Bronx, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krautner</LastName><ForeName>Gregory</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Veterans Affairs, Geriatrics and Extended Care, Washington, DC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmitz</LastName><ForeName>Cheryl</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Veterans Affairs, Geriatrics and Extended Care, Washington, DC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldstein</LastName><ForeName>Mary K</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Department of Veterans Affairs, Geriatrics and Extended Care, Washington, DC, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Health Policy, Stanford University, Palo Alto, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>VA Health Systems Research Center for Innovation to Implementation (Ci2i), VA Palo Alto Health Care System, Palo Alto, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Phibbs</LastName><ForeName>Ciaran S</ForeName><Initials>CS</Initials><Identifier Source="ORCID">0000-0002-4353-3507</Identifier><AffiliationInfo><Affiliation>Geriatrics and Extended Care Data Analysis Center (GECDAC), Bronx, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>VA Palo Alto Health Care System, Palo Alto, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Stanford University, Palo Alto, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Health Policy, Stanford University, Palo Alto, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Intrator</LastName><ForeName>Orna</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Geriatrics and Extended Care Data Analysis Center (GECDAC), Bronx, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>James J Peters VAMC, Bronx, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Geriatrics &amp; Palliative Care, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Health Serv Res</MedlineTA><NlmUniqueID>0053006</NlmUniqueID><ISSNLinking>0017-9124</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">HCBS veterans</Keyword><Keyword MajorTopicYN="N">VA</Keyword><Keyword MajorTopicYN="N">cost</Keyword><Keyword MajorTopicYN="N">hospitalization</Keyword><Keyword MajorTopicYN="N">mortality</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>1</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>27</Day><Hour>1</Hour><Minute>14</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40713897</ArticleId><ArticleId IdType="doi">10.1111/1475-6773.70016</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>US Government Accountability Office, &#x201c;Veterans' use of long&#x2010;term care is increasing, and VA faces challenges in meeting the demand (Report to Congressional Committees GAO&#x2010;20&#x2010;284).&#x201d; (2020) https://www.gao.gov/assets/gao&#x2010;20&#x2010;284.pdf.</Citation></Reference><Reference><Citation>C. Madrigal, C. W. Halladay, K. McConeghy, et&#xa0;al., &#x201c;Derivation and Validation of a Predictive Algorithm for Long&#x2010;Term Care Admission or Death,&#x201d; Journal of the American Medical Directors Association 22, no. 8 (2021): 1658&#x2013;1663.e6, https://doi.org/10.1016/j.jamda.2021.03.034.</Citation></Reference><Reference><Citation>H. S. Kaye, M. P. LaPlante, and C. Harrington, &#x201c;Do Noninstitutional Long&#x2010;Term Care Services Reduce Medicaid Spending?,&#x201d; Health Aff (Millwood) 28, no. 1 (2009): 262&#x2013;272, https://doi.org/10.1377/hlthaff.28.1.262.</Citation></Reference><Reference><Citation>H. S. Kaye, &#x201c;Gradual Rebalancing of Medicaid Long&#x2010;Term Services and Supports Saves Money and Serves More People, Statistical Model Shows,&#x201d; Health Aff (Millwood) 31, no. 6 (2012): 1195&#x2013;1203, https://doi.org/10.1377/hlthaff.2011.1237.</Citation></Reference><Reference><Citation>G. Valluru, J. Yudin, C. L. Patterson, et&#xa0;al., &#x201c;Integrated Home&#x2010; and Community&#x2010;Based Services Improve Community Survival Among Independence at Home Medicare Beneficiaries Without Increasing Medicaid Costs,&#x201d; Journal of the American Geriatrics Society 67, no. 7 (2019): 1495&#x2013;1501, https://doi.org/10.1111/jgs.15968.</Citation></Reference><Reference><Citation>R. Campos, How the VA Plans to Keep Up With an Aging Veteran Population (MOAA, 2022).</Citation></Reference><Reference><Citation>M. A. Greiner, L. G. Qualls, I. Iwata, et&#xa0;al., &#x201c;Predicting Nursing Home Placement Among Home&#x2010; and Community&#x2010;Based Services Program Participants,&#x201d; American Journal of Managed Care 20, no. 12 (2014): e535&#x2013;e536.</Citation></Reference><Reference><Citation>M. Luppa, T. Luck, S. Weyerer, et&#xa0;al., &#x201c;Prediction of Institutionalization in the Elderly. A Systematic Review,&#x201d; Age and Ageing 39, no. 1 (2010): 31&#x2013;38, https://doi.org/10.1093/ageing/afp202.</Citation></Reference><Reference><Citation>J. C. Jacobs, M. L. Maciejewski, T. H. Wagner, et&#xa0;al., &#x201c;Improving Prediction of Long&#x2010;Term Care Utilization Through Patient&#x2010;Reported Measures: Cross&#x2010;Sectional Analysis of High&#x2010;Need U.S. Veterans Affairs Patients,&#x201d; Medical Care Research and Review 14 (2021): 10775587211062403, https://doi.org/10.1177/10775587211062403.</Citation></Reference><Reference><Citation>J. L. Wolff, J. Mulcahy, D. L. Roth, et&#xa0;al., &#x201c;Long&#x2010;Term Nursing Home Entry: A Prognostic Model for Older Adults With a Family or Unpaid Caregiver,&#x201d; Journal of the American Geriatrics Society 66, no. 10 (2018): 1887&#x2013;1894, https://doi.org/10.1111/jgs.15447.</Citation></Reference><Reference><Citation>D. H. Kim, S. Schneeweiss, R. J. Glynn, L. A. Lipsitz, K. Rockwood, and J. Avorn, &#x201c;Measuring Frailty in Medicare Data: Development and Validation of a Claims&#x2010;Based Frailty Index,&#x201d; Journals of Gerontology. Series A, Biological Sciences and Medical Sciences 73, no. 7 (2018): 980&#x2013;987, https://doi.org/10.1093/gerona/glx229.</Citation></Reference><Reference><Citation>A. R. Orkaby, T. Huan, O. Intrator, et&#xa0;al., &#x201c;Comparison of Claims Based Frailty Indices in US Veterans 65 and Older for Prediction of Long&#x2010;Term Institutionalization and Mortality,&#x201d; Journals of Gerontology. Series A, Biological Sciences and Medical Sciences 78 (2023): glad157, https://doi.org/10.1093/gerona/glad157.</Citation></Reference><Reference><Citation>D. H. Kim, E. Patorno, A. Pawar, H. Lee, S. Schneeweiss, and R. J. Glynn, &#x201c;Measuring Frailty in Administrative Claims Data: Comparative Performance of Four Claims&#x2010;Based Frailty Measures in the U.S. Medicare Data,&#x201d; Journals of Gerontology. Series A, Biological Sciences and Medical Sciences 75, no. 6 (2020): 1120&#x2013;1125, https://doi.org/10.1093/gerona/glz224.</Citation></Reference><Reference><Citation>A. D. Haimovich and W. J. Deardorff, &#x201c;From Bedside&#x2010;To&#x2010;Model: Designing Clinical Prediction Rules for Implementation,&#x201d; Journal of the American Geriatrics Society 72 (2024): 1654&#x2013;1657, https://doi.org/10.1111/jgs.18921.</Citation></Reference><Reference><Citation>B. Kinosian, D. Wieland, X. Gu, E. Stallard, C. S. Phibbs, and O. Intrator, &#x201c;Validation of the JEN Frailty Index in the National Long&#x2010;Term Care Survey Community Population: Identifying Functionally Impaired Older Adults From Claims Data,&#x201d; BMC Health Services Research 18, no. 1 (2018): 908, https://doi.org/10.1186/s12913&#x2010;018&#x2010;3689&#x2010;2.</Citation></Reference><Reference><Citation>L. Wang, B. Porter, C. Maynard, et&#xa0;al., &#x201c;Predicting Risk of Hospitalization or Death Among Patients Receiving Primary Care in the Veterans Health Administration,&#x201d; Medical Care 51, no. 4 (2013): 368&#x2013;373.</Citation></Reference><Reference><Citation>&#x201c;Minimum Data Set 3.0 Public Reports.&#x201d; https://www.cms.gov/Research&#x2010;Statistics&#x2010;Data&#x2010;and&#x2010;Systems/Computer&#x2010;Data&#x2010;and&#x2010;Systems/Minimum&#x2010;Data&#x2010;Set&#x2010;3&#x2010;0&#x2010;Public&#x2010;Reports.</Citation></Reference><Reference><Citation>O. Intrator, J. Hiris, K. Berg, S. C. Miller, and V. Mor, &#x201c;The Residential History File: Studying Nursing Home Residents' Long&#x2010;Term Care Histories,&#x201d; Health Services Research 46, no. 1 (2011): 120&#x2013;137, https://doi.org/10.1111/j.1475&#x2010;6773.2010.01194.x.</Citation></Reference><Reference><Citation>J. Yoon, &#x201c;VA costs: HERC vs. MCA.&#x201d; accessed September 4, 2025, https://www.hsrd.research.va.gov/for_researchers/cyber_seminars/archives/video_archive.cfm?SessionID=4103&amp;Seriesid=42.</Citation></Reference><Reference><Citation>S. Dally, S. Wesgate, C. Phibbs, et&#xa0;al., Guidebook for Use of the GECDAC Core Files (Geriatrics and Extended Care Data Analysis Center (GECDAC), 2018) accessed September 4, 2025, https://www.va.gov/GERIATRICS/GECDAC/Products.asp.</Citation></Reference><Reference><Citation>G. Taler, P. Boling, K. E. Deligiannidis, J. Kubisiak, A. Lee, and B. Kinosian, &#x201c;High Needs Criteria in High Need Accountable Care Organization Realizing Equity, Access, and Community Health Inequitably Limits Access to Equally High&#x2010;Need Medicare Beneficiaries,&#x201d; Journal of the American Geriatrics Society 72 (2023): 620&#x2013;623, https://doi.org/10.1111/jgs.18651.</Citation></Reference><Reference><Citation>J. M. List, P. Palevsky, S. Tamang, et&#xa0;al., &#x201c;Eliminating Algorithmic Racial Bias in Clinical Decision Support Algorithms: Use Cases From the Veterans Health Administration,&#x201d; Health Equity 7, no. 1 (2023): 809&#x2013;816, https://doi.org/10.1089/heq.2023.0037.</Citation></Reference><Reference><Citation>A. S. Navathe, S. H. Park, C. M. Hearn, et&#xa0;al., &#x201c;(In)equity in Risk Prediction: Examining and Mitigating Racial Bias in the Veterans Affairs Care Assessment Needs (CAN) Risk Model.&#x201d; https://www.hsrd.research.va.gov/meetings/2023/abstract&#x2010;display.cfm?AbsNum=1004.</Citation></Reference><Reference><Citation>L. Breiman, &#x201c;Random Forests,&#x201d; Machine Learning 45 (2001): 5&#x2013;32, https://doi.org/10.1023/A:1010933404324.</Citation></Reference><Reference><Citation>C. M. Rembold, &#x201c;Number Needed to Screen: Development of a Statistic for Disease Screening,&#x201d; BMJ 317, no. 7154 (1998): 307&#x2013;312, https://doi.org/10.1136/bmj.317.7154.307.</Citation></Reference><Reference><Citation>S. L. Salzberg, &#x201c;On Comparing Classifiers: Pitfalls to Avoid and a Recommended Approach,&#x201d; Data Mining and Knowledge Discovery 1 (1997): 317&#x2013;328.</Citation></Reference><Reference><Citation>G. S. Collins, J. B. Reitsma, D. G. Altman, and K. G. Moons, &#x201c;Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD): The TRIPOD Statement,&#x201d; BMJ 7, no. 350 (2015): g7594, https://doi.org/10.1136/bmj.g7594.</Citation></Reference><Reference><Citation>W. J. Deardorff, L. G. Diaz&#x2010;Ramirez, W. J. Boscardin, A. K. Smith, and S. J. Lee, &#x201c;Around the EQUATOR With Clin&#x2010;STAR: Prediction Modeling Opportunities and Challenges in Aging Research,&#x201d; Journal of the American Geriatrics Society 72, no. 6 (2024): 1658&#x2013;1668, https://doi.org/10.1111/jgs.18704.</Citation></Reference><Reference><Citation>E. C. Norton, B. E. Dowd, M. M. Garrido, and M. L. Maciejewski, &#x201c;Requiem for Odds Ratios,&#x201d; Health Services Research 59, no. 4 (2024): e14337, https://doi.org/10.1111/1475&#x2010;6773.14337.</Citation></Reference><Reference><Citation>C. S. Chan, D. Davis, D. Cooper, et&#xa0;al., &#x201c;VA Home&#x2010;Based Primary Care Interdisciplinary Team Structure Varies With Veterans' Needs, Aligns With PACE Regulation,&#x201d; Journal of the American Geriatrics Society 69, no. 7 (2021): 1729&#x2013;1737, https://doi.org/10.1111/jgs.17174.</Citation></Reference><Reference><Citation>J. C. Jacobs, T. H. Wagner, R. Trivedi, K. Lorenz, and C. H. van Houtven, &#x201c;Long&#x2010;Term Care Service Mix in the Veterans Health Administration After Home Care Expansion,&#x201d; Health Services Research 56, no. 6 (2021): 1126&#x2013;1136, https://doi.org/10.1111/1475&#x2010;6773.13687.</Citation></Reference><Reference><Citation>T. H. Wagner, A. Upadhyay, E. Cowgill, et&#xa0;al., &#x201c;Risk Adjustment Tools for Learning Health Systems: A Comparison of DxCG and CMS&#x2010;HCC V21,&#x201d; Health Services Research 51, no. 5 (2016): 2002&#x2013;2019, https://doi.org/10.1111/1475&#x2010;6773.12454.</Citation></Reference><Reference><Citation>L. Lei, S. Cooley, C. Phibbs, et&#xa0;al., &#x201c;Attributable Cost of Dementia: Demonstrating Pitfalls of Ignoring Multiple Healthcare System Utilization. Special Issue: Linking VA and Non&#x2010;VA Data to Conduct Health Services Research,&#x201d; Health Services Research 53, no. Suppl 3 (2018): 5331&#x2013;5351.</Citation></Reference><Reference><Citation>Y. Ma, J. Phelan, K. Y. Jeong, et&#xa0;al., &#x201c;Medicare Advantage Plans With High Numbers of Veterans: Enrollment, Utilization, and Potential Wasteful Spending,&#x201d; Health Aff (Millwood) 43, no. 11 (2024): 1508&#x2013;1517, https://doi.org/10.1377/hlthaff.2024.00302.</Citation></Reference><Reference><Citation>R. M. Werner and E. Bressman, &#x201c;Trends in Post&#x2010;Acute Care Utilization During the COVID&#x2010;19 Pandemic,&#x201d; Journal of the American Medical Directors Association 22, no. 12 (2021): 2496&#x2013;2499.</Citation></Reference><Reference><Citation>P. Y. Cornell, K. H. Magid, E. Corneau, L. M. Haverhals, and C. Levy, &#x201c;Decline in Veterans' Admissions to Nursing Homes During COVID&#x2010;19: Fewer Beds, More Fear, and Finding Alternative Care Settings,&#x201d; Journal of the American Medical Directors Association 24, no. 4 (2023): 447&#x2013;450, https://doi.org/10.1016/j.jamda.2022.12.021.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40713890</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1943-7730</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Jul</Month><Day>26</Day></PubDate></JournalIssue><Title>Laboratory medicine</Title><ISOAbbreviation>Lab Med</ISOAbbreviation></Journal><ArticleTitle>Prolonged COVID-19 infection in a patient with B-cell acute lymphoblastic leukemia maintained on convalescent plasma until recovery with monoclonal antibodies.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">lmaf047</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/labmed/lmaf047</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Patients with hematologic malignancies who undergo immunosuppressive therapies such as chimeric antigen receptor T-cell (CAR-T) therapy are at high risk of prolonged SARS-CoV-2 infection due to impaired humoral immunity. Treatment options remain limited, with variable efficacy, in such settings.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We describe a 21-year-old man with Down syndrome and B-cell acute lymphoblastic leukemia complicated by B-cell aplasia following CD19-directed CAR-T therapy. The patient developed COVID-19 and experienced persistent symptomatic infection, with high viral load and prolonged reverse transcriptase-polymerase chain reaction (RT-PCR) positivity for more than 7 months.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Despite multiple courses of remdesivir and extended weekly infusions of COVID-19 convalescent plasma (CCP), the patient remained viremic and intermittently symptomatic. Anti-SARS-CoV-2 immunoglobulin G titers were detectable only toward the latter time frame of treatment, and passive antibody therapy with CCP was insufficient for viral clearance. Ultimately, compassionate use of monoclonal antibody (mAb) therapy (casirivimab and imdevimab) was granted. Following administration, the patient achieved viral clearance for the first time, with resolution of symptoms and persistently negative RT-PCR findings for 8 months of available follow-up thereafter.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">This case illustrates the limitations of CCP in patients with prolonged SARS-CoV-2 infection and highlights the effectiveness of mAbs in achieving viral clearance in severely immunocompromised hosts. It supports targeted use of mAb therapy in select high-risk populations and reinforces the importance of specific passive immunotherapy strategies (when available) for the management of viremia in immunodeficient patients.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2025. Published by Oxford University Press on behalf of American Society for Clinical Pathology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mathur</LastName><ForeName>Gagan</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-7885-635X</Identifier><AffiliationInfo><Affiliation>University of California, Irvine, Orange, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qiao</LastName><ForeName>Jesse</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-8348-4893</Identifier><AffiliationInfo><Affiliation>University of California, Irvine, Orange, CA, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lab Med</MedlineTA><NlmUniqueID>0250641</NlmUniqueID><ISSNLinking>0007-5027</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">B-cell aplasia</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">convalescent plasma</Keyword><Keyword MajorTopicYN="N">immunocompromised host</Keyword><Keyword MajorTopicYN="N">monoclonal antibodies</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>27</Day><Hour>1</Hour><Minute>14</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40713890</ArticleId><ArticleId IdType="doi">10.1093/labmed/lmaf047</ArticleId><ArticleId IdType="pii">8213976</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40713880</PMID><DateCompleted><Year>2025</Year><Month>07</Month><Day>27</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1752-1947</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>25</Day></PubDate></JournalIssue><Title>Journal of medical case reports</Title><ISOAbbreviation>J Med Case Rep</ISOAbbreviation></Journal><ArticleTitle>Diagnostic challenges for severe infection with severe acute respiratory syndrome coronavirus 2 in pregnancy: a case report.</ArticleTitle><Pagination><StartPage>365</StartPage><MedlinePgn>365</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13256-025-05410-z</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Diagnosis of severe acute respiratory syndrome coronavirus 2 (coronavirus disease 2019) proved challenging during the initial waves of the pandemic owing to false-negative diagnostic tests. Maternal patients with conditions such as preeclampsia and thromboembolism presented with overlapping symptoms with coronavirus disease 2019.</AbstractText><AbstractText Label="CASE PRESENTATION" NlmCategory="METHODS">A 44-year-old South Asian mother in the third trimester presented with respiratory symptoms and preeclampsia. Two successive rapid antigen tests for coronavirus disease 2019 were negative. Treatment was started for lower respiratory tract infection and suspected thromboembolism (with a therapeutic dose of enoxaparin). With worsening respiratory distress, a chest X-ray was performed, which suggested severe coronavirus disease 2019. A repeated rapid antigen test was found to be positive. She was started on intravenous dexamethasone. She underwent an emergency caesarean section following reversal of enoxaparin with protamine and delivered a healthy baby. The mother was transferred to a tertiary care center for advanced intensive care. She was intubated 24&#xa0;hours later and received a single dose of intravenous tocilizumab owing to increasing ventilatory supports. A computed tomography pulmonary angiogram excluded pulmonary embolism. She was extubated on day 5 and discharged home on day 15. On follow-up, she was found to be devoid of long-term sequelae coronavirus disease 2019 at 1&#xa0;year. The false-negative rapid antigen test for coronavirus disease 2019 presented a diagnostic challenge to clinicians, especially when further supportive radiological investigations were unavailable in a low-resource setting. Maternal coronavirus disease 2019 bore nonspecific symptoms of other pregnancy-related conditions, further complicating the diagnostic and therapeutic process.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Pandemics pose significant challenges to clinicians, particularly in the initial stages, owing to diagnostic difficulties. A high index of suspicion and early involvement of multidisciplinary teams may prove to be adjunctive to surrogate investigations.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Munasinghe</LastName><ForeName>B M</ForeName><Initials>BM</Initials><Identifier Source="ORCID">0000-0001-8373-4752</Identifier><AffiliationInfo><Affiliation>Department of Anaesthesiology, District General Hospital, Mannar, Sri Lanka. mannaranaesthesia@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Med Case Rep</MedlineTA><NlmUniqueID>101293382</NlmUniqueID><ISSNLinking>1752-1947</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>I031V2H011</RegistryNumber><NameOfSubstance UI="C502936">tocilizumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017984">Enoxaparin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011251" MajorTopicYN="Y">Pregnancy Complications, Infectious</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002585" MajorTopicYN="N">Cesarean Section</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011225" MajorTopicYN="Y">Pre-Eclampsia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017984" MajorTopicYN="N">Enoxaparin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Case report</Keyword><Keyword MajorTopicYN="N">Maternal</Keyword><Keyword MajorTopicYN="N">RAT</Keyword><Keyword MajorTopicYN="N">Rapid antigen testing</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList><CoiStatement>Declarations. Ethics approval and consent to participate: Our institution does not require ethical approval to report individual cases or case series. Consent for publication: Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal. Competing interests: The author declared no potential competing interests concerning the research, authorship, and/or publication of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>27</Day><Hour>1</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40713880</ArticleId><ArticleId IdType="doi">10.1186/s13256-025-05410-z</ArticleId><ArticleId IdType="pii">10.1186/s13256-025-05410-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organisation. Strategic preparedness, readiness, and response plan to end the global COVID-19 emergency in 2022. Geneva: World Health Organisation; 2022.</Citation></Reference><Reference><Citation>Allotey J, Fernandez S, Bonet M, Stallings E, Yap M, Kew T, et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. Bmj. 2020. https://doi.org/10.1136/bmj.m3320 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m3320</ArticleId><ArticleId IdType="pubmed">32873575</ArticleId></ArticleIdList></Reference><Reference><Citation>Marchand G, Patil AS, Masoud AT, Ware K, King A, Ruther S, et al. Systematic review and meta-analysis of COVID-19 maternal and neonatal clinical features and pregnancy outcomes up to June 3, 2021. AJOG Glob Rep. 2022;2(1):100049.</Citation><ArticleIdList><ArticleId IdType="pubmed">35005663</ArticleId><ArticleId IdType="pmc">8720679</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotlar B, Gerson E, Petrillo S, Langer A, Tiemeier H. The impact of the COVID-19 pandemic on maternal and perinatal health: a scoping review. Reprod Health. 2021;18:1&#x2013;39.</Citation></Reference><Reference><Citation>Peeling RW, Olliaro PL, Boeras DI, Fongwen N. Scaling up COVID-19 rapid antigen tests: promises and challenges. Lancet Infect Dis. 2021;21(9):e290&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">33636148</ArticleId><ArticleId IdType="pmc">7906660</ArticleId></ArticleIdList></Reference><Reference><Citation>Rochwerg B, Brochard L, Elliott MW, Hess D, Hill NS, Nava S, et al. Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure. Eur Respir J. 2017;50(2):1602426.</Citation><ArticleIdList><ArticleId IdType="pubmed">28860265</ArticleId></ArticleIdList></Reference><Reference><Citation>Servante J, Swallow G, Thornton JG, Myers B, Munireddy S, Malinowski AK, et al. Haemostatic and thrombo-embolic complications in pregnant women with COVID-19: a systematic review and critical analysis. BMC Pregnancy Childbirth. 2021;21:1&#x2013;14.</Citation></Reference><Reference><Citation>Group RC. Dexamethasone in hospitalised patients with COVID-19. N Engl J Med. 2021;384(8):693&#x2013;704.</Citation></Reference><Reference><Citation>Salama C, Han J, Yau L, Reiss WG, Kramer B, Neidhart JD, et al. Tocilizumab in patients hospitalised with COVID-19 pneumonia. N Engl J Med. 2021;384(1):20&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">33332779</ArticleId></ArticleIdList></Reference><Reference><Citation>Soleimani R, Khourssaji M, Gruson D, Rodriguez-Villalobos H, Berghmans M, Belkhir L, et al. Clinical usefulness of fully automated chemiluminescent immunoassay for quantitative antibody measurements in COVID-19 patients. J Med Virol. 2021;93(3):1465&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">32797641</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamayoshi S, Sakai-Tagawa Y, Koga M, Akasaka O, Nakachi I, Koh H, et al. Comparison of rapid antigen tests for COVID-19. Viruses. 2020;12(12):1420.</Citation><ArticleIdList><ArticleId IdType="pubmed">33322035</ArticleId><ArticleId IdType="pmc">7764512</ArticleId></ArticleIdList></Reference><Reference><Citation>Arshadi M, Fardsanei F, Deihim B, Farshadzadeh Z, Nikkhahi F, Khalili F, et al. Diagnostic accuracy of rapid antigen tests for COVID-19 detection: a systematic review with meta-analysis. Front Med. 2022;9:870738.</Citation></Reference><Reference><Citation>Dinnes J, Deeks J, Berhane S. Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection. Cochrane Database Syst Rev. 2021. https://doi.org/10.1002/14651858.CD013705.pub2 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD013705.pub2</ArticleId><ArticleId IdType="pubmed">33760236</ArticleId><ArticleId IdType="pmc">8447485</ArticleId></ArticleIdList></Reference><Reference><Citation>Routsias JG, Mavrouli M, Tsoplou P, Dioikitopoulou K, Tsakris A. Diagnostic performance of rapid antigen tests (RATs) for SARS-CoV-2 and their efficacy in monitoring the infectiousness of COVID-19 patients. Sci Rep. 2021;11(1):22863.</Citation><ArticleIdList><ArticleId IdType="pubmed">34819567</ArticleId><ArticleId IdType="pmc">8613285</ArticleId></ArticleIdList></Reference><Reference><Citation>Knight M, Bunch K, Vousden N, Morris E, Simpson N, Gale C, et al. Characteristics and outcomes of pregnant women admitted to hospital with confirmed SARS-CoV-2 infection in the UK: national population-based cohort study. Bmj. 2020. https://doi.org/10.1136/bmj.m2107 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m2107</ArticleId><ArticleId IdType="pubmed">33127603</ArticleId><ArticleId IdType="pmc">7527835</ArticleId></ArticleIdList></Reference><Reference><Citation>Thakur V, Ratho RK, Kumar P, Bhatia SK, Bora I, Mohi GK, et al. Multi-organ involvement in COVID-19: beyond pulmonary manifestations. J Clin Med. 2021;10(3):446.</Citation><ArticleIdList><ArticleId IdType="pubmed">33498861</ArticleId><ArticleId IdType="pmc">7866189</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xfc;rb&#xfc;z T, G&#xf6;kmen O, G&#xfc;ng&#xf6;r ND. COVID-19 infection mimicking postpartum pulmonary embolism: a case report. J Exp Clin Med. 2022;39(2):577&#x2013;8.</Citation></Reference><Reference><Citation>Boettcher LB, Metz TD. Maternal and neonatal outcomes following SARS-CoV-2 infection. In: Lakshminrusimha S, Hedriana H, editors. Seminars in fetal and neonatal medicine. Amsterdam: Elsevier; 2023.</Citation></Reference><Reference><Citation>Xu L, Yang Q, Shi H, Lei S, Liu X, Zhu Y, et al. Clinical presentations and outcomes of SARS-CoV-2-infected pneumonia in pregnant women and health status of their neonates. Sci Bull. 2020;65(18):1537.</Citation></Reference><Reference><Citation>Mullins E, Evans D, Viner R, O&#x2019;Brien P, Morris E. Coronavirus in pregnancy and delivery: rapid review. Ultrasound Obstet Gynaecol. 2020;55(5):586&#x2013;92.</Citation></Reference><Reference><Citation>Harrop-Griffiths W, Cook T, Gill H, Hill D, Ingram M, Party: MotW, et al. Regional anaesthesia and patients with abnormalities of coagulation: the association of anaesthetists of Great Britain &amp; Ireland, the Obstetric Anaesthetists&#x2019; Association, Regional Anaesthesia UK. Anaesthesia. 2013;68(9):966&#x2013;72.</Citation></Reference><Reference><Citation>Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing G-J, Harjola V-P, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). Eur Heart J. 2020;41(4):543&#x2013;603.</Citation><ArticleIdList><ArticleId IdType="pubmed">31504429</ArticleId></ArticleIdList></Reference><Reference><Citation>Zotzmann V, Lang CN, Wengenmayer T, Bemtgen X, Schmid B, Mueller-Peltzer K, et al. Combining lung ultrasound and Wells score for diagnosing pulmonary embolism in critically ill COVID-19 patients. J Thromb Thrombolysis. 2021;52:76&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">33145663</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziert Y, Abou-Dakn M, Backes C, Banz-Jansen C, Bock N, Bohlmann M, et al. Maternal and neonatal outcomes of pregnancies with COVID-19 after medically assisted reproduction: results from the prospective COVID-19-related obstetrical and neonatal outcome study. Am J Obstet Gynaecol. 2022;227(3):495.</Citation></Reference><Reference><Citation>Riera J, Barbeta E, Tormos A, Mellado-Artigas R, Ceccato A, Motos A, et al. Effects of intubation timing in patients with COVID-19 throughout the four waves of the pandemic: a matched analysis. Eur Respir J. 2023;61(3):2201426.</Citation><ArticleIdList><ArticleId IdType="pubmed">36396142</ArticleId><ArticleId IdType="pmc">9686319</ArticleId></ArticleIdList></Reference><Reference><Citation>Magnus MC, &#xd6;rtqvist AK, Dahlqwist E, Ljung R, Sk&#xe5;r F, Oakley L, Macsali F, Pasternak B, Gjessing HK, H&#xe5;berg SE, Stephansson O. Association of SARS-CoV-2 vaccination during pregnancy with pregnancy outcomes. JAMA. 2022;327(15):1469&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">35323851</ArticleId><ArticleId IdType="pmc">8949721</ArticleId></ArticleIdList></Reference><Reference><Citation>Favilli A, Mattei Gentili M, De Paola F, Lagan&#xe0; AS, Vitagliano A, Bosco M, Cicinelli E, Chiantera V, Uccella S, Parazzini F, Gerli S. COVID-19 and pregnancy: an updated review about evidence-based therapeutic strategies. J Pers Med. 2023;13(7):1035.</Citation><ArticleIdList><ArticleId IdType="pubmed">37511648</ArticleId><ArticleId IdType="pmc">10381390</ArticleId></ArticleIdList></Reference><Reference><Citation>Greer O, Saeed Z, Woon EV, Singh N, Johnson M, Shah N. COVID-19 in pregnancy. Obstet Gynaecol. 2025;27(1):43&#x2013;56.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40713834</PMID><DateCompleted><Year>2025</Year><Month>07</Month><Day>27</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1745-6215</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>25</Day></PubDate></JournalIssue><Title>Trials</Title><ISOAbbreviation>Trials</ISOAbbreviation></Journal><ArticleTitle>Bringing optimised COVID-19 vaccine schedules to immunocompromised populations: statistical elements and design.</ArticleTitle><Pagination><StartPage>256</StartPage><MedlinePgn>256</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13063-025-08965-w</ELocationID><Abstract><AbstractText>Bringing optimised coronavirus disease 2019 (COVID-19) vaccine schedules to immunocompromised populations (BOOST-IC) is a multi-site, adaptive platform trial designed to assess the effect of different booster vaccination schedules in the Australian immunocompromised population on the immunogenicity, safety and cross-protection against COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its variants. Participants from one of three immunocompromised subpopulations (people living with human immunodeficiency virus, solid organ transplants or haematological malignancies) are randomised to receive a one- or two-dose booster vaccination schedule using one of three COVID-19 vaccine brands (Pfizer, Moderna or Novavax) available in Australia. The primary endpoint is the SARS-CoV-2 anti-spike immunoglobulin G concentration at 28 days after the final dose of study vaccine and is modelled using a Bayesian hierarchical two-part model, anticipating that a significant proportion of responses may be below the limit of assay detection. We describe the structure and objectives of the BOOST-IC trial and how these are mathematically represented, modelled and reported, including specification of the estimands, statistical models and decision criteria for trial adaptations. This paper should be read in conjunction with the BOOST-IC study protocol. BOOST-IC was registered on 27 September 2022 with the Australian and New Zealand Clinical Trials Registry NCT05556720.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dymock</LastName><ForeName>Michael</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-4881-2860</Identifier><AffiliationInfo><Affiliation>Wesfarmers Centre of Vaccines and Infectious Diseases, The Kids Research Institute Australia, 15 Hospital Avenue, Nedlands, 6009, Perth, Australia. michael.dymock@thekids.org.au.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Population and Global Health, The University of Western Australia, 35 Stirling Highway, Crawley, 6009, Perth, Australia. michael.dymock@thekids.org.au.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McMahon</LastName><ForeName>James H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Alfred Hospital, 85 Commercial Road, 3004, Melbourne, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases, Monash Medical Centre, 246 Clayton Road, 3168, Melbourne, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Translational Medicine, Monash University, 99 Commercial Road, 3004, Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Griffin</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Alfred Hospital, 85 Commercial Road, 3004, Melbourne, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Translational Medicine, Monash University, 99 Commercial Road, 3004, Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hagenauer</LastName><ForeName>Michelle</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Alfred Hospital, 85 Commercial Road, 3004, Melbourne, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Translational Medicine, Monash University, 99 Commercial Road, 3004, Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Snelling</LastName><ForeName>Tom L</ForeName><Initials>TL</Initials><AffiliationInfo><Affiliation>Sydney School of Public Health, Faculty of Medicine and Health, University of Sydney, Camperdown, 2006, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marsh</LastName><ForeName>Julie A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Wesfarmers Centre of Vaccines and Infectious Diseases, The Kids Research Institute Australia, 15 Hospital Avenue, Nedlands, 6009, Perth, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Child Health Research, The University of Western Australia, 35 Stirling Highway, Crawley, 6009, Perth, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>On&#xa0;behalf&#xa0;of&#xa0;the&#xa0;BOOST-IC&#xa0;Investigator Team</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT05556720</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>MRF2014921</GrantID><Agency>Medical Research Future Fund</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078325">Clinical Trial Protocol</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Trials</MedlineTA><NlmUniqueID>101263253</NlmUniqueID><ISSNLinking>1745-6215</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016867" MajorTopicYN="Y">Immunocompromised Host</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001315" MajorTopicYN="N" Type="Geographic">Australia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007115" MajorTopicYN="Y">Immunization Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007117" MajorTopicYN="N">Immunization, Secondary</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015337" MajorTopicYN="N">Multicenter Studies as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071497" MajorTopicYN="N">Immunogenicity, Vaccine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001499" MajorTopicYN="N">Bayes Theorem</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adaptive trial</Keyword><Keyword MajorTopicYN="N">Bayesian</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Immunocompromised</Keyword><Keyword MajorTopicYN="N">Immunogenicity</Keyword><Keyword MajorTopicYN="N">Statistical model</Keyword><Keyword MajorTopicYN="N">Vaccine</Keyword></KeywordList><CoiStatement>Declarations. Ethics approval and consent to participate: Ethics approval for the conduct of this study has been provided by the Alfred Ethics Committee (122/22). Informed consent to participate will be obtained from all participants in either written or electronic form. Consent for publication: No identifying images or other personal or clinical details of participants are presented here or will be presented in reports of the trial results. The participant information materials and informed consent form are available from the corresponding author on request and will be available on the trial website. Competing interests: The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>27</Day><Hour>1</Hour><Minute>10</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40713834</ArticleId><ArticleId IdType="doi">10.1186/s13063-025-08965-w</ArticleId><ArticleId IdType="pii">10.1186/s13063-025-08965-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Weerasuria M, Ko C, Ehm A, O&#x2019;Bryan J, et al. The impact of the COVID-19 pandemic on people living with HIV in Victoria, Australia. AIDS Res Hum Retrovir. 2021;37(4):322&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">33586997</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohamed K, Rzymski P, Islam MS, Makuku R, Mushtaq A, Khan A, et al. COVID-19 vaccinations: The unknowns, challenges, and hopes. J Med Virol. 2022;94(4):1336&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">34845731</ArticleId></ArticleIdList></Reference><Reference><Citation>Vijenthira A, Gong IY, Fox TA, Booth S, Cook G, et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020;136(25):2881&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">33113551</ArticleId><ArticleId IdType="pmc">7746126</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhaskaran K, Rentsch CT, MacKenna B, Schultze A, Mehrkar A, et al. HIV infection and COVID-19 death: a population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform. Lancet HIV. 2021;8(1):24&#x2013;32.</Citation></Reference><Reference><Citation>Yamanaga S, Shimata K, Ohfuji S, Yoshikawa M, Natori Y, Hibi T, et al. Excess mortality in COVID-19-affected solid organ transplant recipients across the pandemic. Am J Transplant. 2024. https://doi.org/10.1016/j.ajt.2024.03.016 .</Citation></Reference><Reference><Citation>Slaoui M, Hepburn M. Developing Safe and Effective Covid Vaccines &#x2013; Operation Warp Speed&#x2019;s Strategy and Approach. N Eng J Med. 2020;383(18):1701&#x2013;3.</Citation></Reference><Reference><Citation>McLeod C, Ramsay J, Flanagan KL, Plebanski M, Marshall H, Dymock M, et&#xa0;al. Core protocol for the adaptive Platform Trial In COVID-19 Vaccine priming and BOOsting (PICOBOO). Trials. 2023;24(202). https://doi.org/10.1186/s13063-023-07225-z .</Citation></Reference><Reference><Citation>Berry SM, Connor JT, Lewis RJ. The Platform Trial: An Efficient Strategy for Evaluating Multiple Treatments. JAMA. 2015;313(16):1619&#x2013;20. https://doi.org/10.1001/jama.2015.2316 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2015.2316</ArticleId><ArticleId IdType="pubmed">25799162</ArticleId></ArticleIdList></Reference><Reference><Citation>Saville BR, Berry SM. Efficiencies of platform clinical trials: A vision of the future. Clin Trials. 2016;13(3):358&#x2013;66. https://doi.org/10.1177/1740774515626362 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1740774515626362</ArticleId><ArticleId IdType="pubmed">26908536</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer EL, Mesenbrink P, Dunger-Baldauf C, Li Y, Posch M, K&#xf6;nig F. The Evolution of Master Protocol Clinical Trial Designs: A Systematic Literature Review. Clin Ther. 2020;42(7):1330&#x2013;60. https://doi.org/10.1016/j.clinthera.2020.05.010 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinthera.2020.05.010</ArticleId><ArticleId IdType="pubmed">32622783</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin DWJ, Dymock M, Wong G, Morrissey CO, Lewin SR, et al. Bringing optimised COVID-19 vaccine schedules to immunocompromised populations (BOOST-IC): study protocol for an adaptive randomised controlled clinical trial. Trials. 2024;25(485). https://doi.org/10.1186/s13063-024-08315-2 .</Citation></Reference><Reference><Citation>Dymock M, McLeod C, Richmond P, Snelling T, Marsh JA. Statistical considerations for the platform trial in COVID-19 vaccine priming and boosting. Trials. 2024;25(507). https://doi.org/10.1186/s13063-024-08343-y .</Citation></Reference><Reference><Citation>Gelman A, Carlin JB, Stern HS, Dunson DB, Vehtari A, Rubin DB. Bayesian Data Analysis (3rd Edition). United States: Chapman and Hall/CRC; 2013. https://doi.org/10.1201/b16018 .</Citation></Reference><Reference><Citation>McGlothlin AE, Viele K. Bayesian Hierarchical Models. JAMA. 2018;320(22):2365&#x2013;6. https://doi.org/10.1001/jama.2018.17977 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2018.17977</ArticleId><ArticleId IdType="pubmed">30535206</ArticleId></ArticleIdList></Reference><Reference><Citation>Berry SM, Carlin BP, Lee JJ, Muller P. Bayesian Adaptive Methods for Clinical Trials (1st Edition). United States: CRC Press; 2010. https://doi.org/10.1201/EBK1439825488 .</Citation></Reference><Reference><Citation>E9(R1) Statistical principles for clinical trials: addendum: estimands and sensitivity analysis in clinical trials. https://www.fda.gov/media/108698/download . Accessed 20 Feb 2023.</Citation></Reference><Reference><Citation>Saville BR, Berry DA, Berry NS, Viele K, Berry SM. The Bayesian Time Machine: Accounting for temporal drift in multi-arm platform trials. Clin Trials. 2022;19(5):490&#x2013;501. https://doi.org/10.1177/17407745221112013 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/17407745221112013</ArticleId><ArticleId IdType="pubmed">35993547</ArticleId></ArticleIdList></Reference><Reference><Citation>Bofill&#xa0;Roig M, Krotka P, Burman CF, Glimm E, Gold SM, et al. On model-based time trend adjustments in platform trials with non-concurrent controls. BMC Med Res Methodol. 2022;22(228). https://doi.org/10.1186/s12874-022-01683-w .</Citation></Reference><Reference><Citation>Mahar RK, McGlothlin A, Dymock M, Lee TC, Lewis RJ, et al. A blueprint for a multi-disease, multi-domain Bayesian adaptive platform trial incorporating adult and paediatric subgroups: the Staphylococcus aureus Network Adaptive Platform trial. Trials. 2023;24(795). https://doi.org/10.1186/s13063-023-07718-x .</Citation></Reference><Reference><Citation>Lewis RJ, Wears RL. An introduction to the Bayesian analysis of clinical trials. Ann Emerg Med. 1993;22(8):1328&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">8333640</ArticleId></ArticleIdList></Reference><Reference><Citation>Munro APS, Janani L, Cornelius V, Aley PK, Babbage G, Baxter D, et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet. 2021;298(10318):2258&#x2013;76. https://doi.org/10.1016/S0140-6736(21)02717-3 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)02717-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Carpenter B, Gelman A, Hoffman MD, Lee D, Goodrich B, Betancourt M, et al. Stan: A probabilistic programming language. J Stat Softw. 2017;76(1):1-32.</Citation></Reference><Reference><Citation>Gabry J, &#x10c;e&#x161;novar R, Johnson A. cmdstanr: R Interface to &#x2018;CmdStan&#x2019;; 2022. https://mc-stan.org/cmdstanr/ , https://discourse.mc-stan.org . Accessed 31 Jan 2025.</Citation></Reference><Reference><Citation>Team RC. R: A Language and Environment for Statistical Computing. Vienna, Austria; 2022. https://www.R-project.org/ . Accessed 31 Jan 2025.</Citation></Reference><Reference><Citation>Denholm JT, Venkatesh B, Davis J, Bowen AC, Hammond NE, Jha V, et&#xa0;al. ASCOT ADAPT study of COVID-19 therapeutics in hospitalised patients: an international multicentre adaptive platform trial. Trials. 2022;75(1014). https://doi.org/10.1186/s13063-022-06929-y .</Citation></Reference><Reference><Citation>Angus DC, Berry S, Lewis R, Al-Beidh F, Arabi Y, et al. The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) Study Rationale and Design. Ann Am Thorac Soc. 2020;17(7). https://doi.org/10.1513/AnnalsATS.202003-192SD .</Citation></Reference><Reference><Citation>Tong SYC, Mora J, Bowen AC, Cheng MP, Daneman N, Goodman AL, et al. The Staphylococcus aureus Network Adaptive Platform Trial Protocol: New Tools for an Old Foe. Clin Infect Dis. 2022;75(11):2027&#x2013;34. https://doi.org/10.1093/cid/ciac476 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac476</ArticleId><ArticleId IdType="pubmed">35717634</ArticleId><ArticleId IdType="pmc">9710697</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40713780</PMID><DateCompleted><Year>2025</Year><Month>07</Month><Day>27</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2072-1315</ISSN><JournalIssue CitedMedium="Internet"><Volume>44</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>26</Day></PubDate></JournalIssue><Title>Journal of health, population, and nutrition</Title><ISOAbbreviation>J Health Popul Nutr</ISOAbbreviation></Journal><ArticleTitle>Dietary intakes in relation to nutrition recommendations and dietary quality in an Iranian adult population: the results of the Food and Nutrition Surveillance (FNS).</ArticleTitle><Pagination><StartPage>268</StartPage><MedlinePgn>268</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s41043-025-01022-x</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The Iranian population faces a dual burden of overconsumption and nutrient insufficiency. Considering recent socioeconomic changes due to severe sanctions and the impact of the COVID-19 crisis, this research aimed to assess the energy, macronutrient, and micronutrient intakes of Iranian adults (19-60 years) and elderly individuals (&gt;&#x2009;60 years), based on the Food and Drug Administration dietary intake recommendations, through a survey.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This was a cross-sectional survey conducted from 2021 to 2022. The study included 1697 adults aged over18 years, selected from 11 geographical zones of Iran based on socio-economic and geographic similarities. All participants underwent dietary assessment using a validated 65-item Food Frequency Questionnaire (FFQ). Macronutrient and micronutrient intakes were compared with Dietary Reference Intakes (DRI). The Dietary Quality Index- International (DQI-I) was also calculated.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In the adults aged 19-60 years, the mean usual energy intake was 2,321.64&#x2009;&#xb1;&#x2009;33.16&#xa0;kcal/day. Carbohydrates, fat, and protein constituted 50.4%, 38.3%, and 13.45% of total energy intake, respectively. About 64.0% of women and 78.0% of men consumed fiber in amounts lower than recommended. The percentage of insufficiency was approximately 100% for retinol and vitamin D in both genders. Insufficient folate intake was 90.1% in women and 89.9% in men (p&#x2009;=&#x2009;0.038). Excess sodium intake was more prevalent in men (p&#x2009;=&#x2009;0.003). In the elderly (&gt;&#x2009;60 years), the mean usual energy intake was 1,987&#xa0;kcal/day. Carbohydrates, fat, and protein constituted 52.98%, 35.88%, and 13.9% of total energy intake, respectively. The percentage of insufficiency for vitamin D, retinol, folate, selenium, and potassium intake was high (more than 80%) in both genders. Zinc insufficiency and excess sodium intake were significantly more prevalent in men.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study indicated that carbohydrate and protein intakes were within the recommended ranges, while fat consumption was elevated in both adults and the elderly. Widespread micronutrient insufficiencies- especially in retinol, folate, vitamin D, potassium, and selenium- were evident across both genders and age groups. Excessive sodium consumption was more prevalent in men, along with a higher prevalence of zinc deficiency. These findings highlight the need for targeted dietary interventions to address nutritional gaps and promote healthier eating habits.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Seifi</LastName><ForeName>Najmeh</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>International UNESCO Center for Health-Related Basic Sciences and Human Nutrition, Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, 99199-91766, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Talkhi</LastName><ForeName>Nasrin</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, School of Health, Mashhad University of Medical Sciences, Mashhad, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khorasanchi</LastName><ForeName>Zahra</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Nutrition, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soflaei</LastName><ForeName>Sara Saffar</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>International UNESCO Center for Health-Related Basic Sciences and Human Nutrition, Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, 99199-91766, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sobhani</LastName><ForeName>Seyyed Reza</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Department of Nutrition, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdollahi</LastName><ForeName>Zahra</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Office of Nutrition Department Society, Health Ministry, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mottaghi Moghaddam Shahri</LastName><ForeName>Ali</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>International UNESCO Center for Health-Related Basic Sciences and Human Nutrition, Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, 99199-91766, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohammadi-BajgIran</LastName><ForeName>Maryam</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>International UNESCO Center for Health-Related Basic Sciences and Human Nutrition, Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, 99199-91766, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>A Ferns</LastName><ForeName>Gordon</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Medical Education, Brighton and Sussex Medical School, Brighton, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Esmaily</LastName><ForeName>Habibollah</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, School of Health, Mashhad University of Medical Sciences, Mashhad, Iran. EsmailyH@mums.ac.ir.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Social Determinants of Health Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. EsmailyH@mums.ac.ir.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghayour-Mobarhan</LastName><ForeName>Majid</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>International UNESCO Center for Health-Related Basic Sciences and Human Nutrition, Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, 99199-91766, Iran. ghayourmobarhan@yahoo.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Bangladesh</Country><MedlineTA>J Health Popul Nutr</MedlineTA><NlmUniqueID>100959228</NlmUniqueID><ISSNLinking>1606-0997</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018977">Micronutrients</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007492" MajorTopicYN="N" Type="Geographic">Iran</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009749" MajorTopicYN="N">Nutrition Surveys</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004032" MajorTopicYN="Y">Diet</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002149" MajorTopicYN="N">Energy Intake</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018977" MajorTopicYN="N">Micronutrients</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064167" MajorTopicYN="Y">Recommended Dietary Allowances</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018673" MajorTopicYN="N">Nutrition Policy</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">DRI</Keyword><Keyword MajorTopicYN="N">Dietary habits</Keyword><Keyword MajorTopicYN="N">Dietary reference intakes</Keyword><Keyword MajorTopicYN="N">Nutrition survey</Keyword><Keyword MajorTopicYN="N">Nutritional status</Keyword></KeywordList><CoiStatement>Declarations. Ethics approval and consent to participate: All experiments were performed in accordance with the declaration of Helsinki and Mashhad University of Medical Sciences ethical guidelines and regulations. The research protocol was approved by the School of Medicine, Mashhad University of Medical Sciences, Biomedical Research Ethics Committee (IR.MUMS.MEDICAL.REC.1400.489). Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>27</Day><Hour>1</Hour><Minute>7</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40713780</ArticleId><ArticleId IdType="doi">10.1186/s41043-025-01022-x</ArticleId><ArticleId IdType="pii">10.1186/s41043-025-01022-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Forouhi NG, Unwin N. Global diet and health: old questions, fresh evidence, and new horizons. Lancet. 2019;393(10184):1916&#x2013;8.</Citation></Reference><Reference><Citation>Lange KW. Movement and nutrition in health and disease. J Disease Prev Health Promotion. 2017;1.</Citation></Reference><Reference><Citation>Diani YH. The epidemiological impact of diet and nutrition on non-communicable diseases: insights into over nutrition and undernutrition. Asian J Adv Res Rep. 2024;18(12):180&#x2013;8.</Citation></Reference><Reference><Citation>Dehghani A, Molani-Gol R, Mohammadi-Narab M, Norouzy A, Abolhassani MH, Tabatabaee Jabali SM, et al. The prevalence of obesity and overweight among Iranian population: an umbrella systematic review and meta-analysis. BMC Public Health. 2024;24(1):1&#x2013;27.</Citation></Reference><Reference><Citation>Djalalinia S, Mehdipour P, Mohajer B, Mohebi F, Larijani B, Sepanlou SG, et al. Levels and trends of BMI, obesity, and overweight at national and sub-national levels in Iran from 1990 to 2016; a comprehensive pooled analysis of half a million individuals. Arch Iran Med. 2021;24(5):344&#x2013;53.</Citation></Reference><Reference><Citation>Vaisi-Raygani A, Mohammadi M, Jalali R, Ghobadi A, Salari N. The prevalence of obesity in older adults in Iran: a systematic review and meta-analysis. BMC Geriatr. 2019;19(1):1&#x2013;9.</Citation></Reference><Reference><Citation>Mensink G, Fletcher R, Gurinovic M, Huybrechts I, Lafay L, Serra-Majem L, et al. Mapping low intake of micronutrients across Europe. Br J Nutr. 2013;110(4):755&#x2013;73.</Citation></Reference><Reference><Citation>Pouraram H, Djazayery A, Mohammad K, Parsaeian M, Abdollahi Z, Motlagh AD, et al. Second national integrated micronutrient survey in Iran: study design and preliminary findings. Arch Iran Med. 2018;21(4):137&#x2013;44.</Citation></Reference><Reference><Citation>Babaali E, Rahmdel S, Berizi E, Akhlaghi M, G&#xf6;tz F, Mazloomi SM. Dietary intakes of zinc, copper, magnesium, calcium, phosphorus, and sodium by the general adult population aged 20&#x2013;50 years in shiraz, Iran: a total diet study approach. Nutrients. 2020;12(11):3370.</Citation></Reference><Reference><Citation>Olyaei HP, Bahadoran Z, MirmIran P, Azizi F. Repeated cross-sectional and longitudinal study of dietary mineral intake status in Iranian adults: Tehran lipid and glucose study. J Health Popul Nutr. 2025;44(1):1&#x2013;12.</Citation></Reference><Reference><Citation>Eslamloueyan K, Kahromi H. The effects of the Covid-19 pandemic, economic sanctions, and institutional quality on the poverty gap: the case of Iran. Economic Sanctions, and Institutional Quality on the Poverty Gap: The Case of Iran. 2022.</Citation></Reference><Reference><Citation>Hejazi J, Emamgholipour S. The effects of the re-imposition of US sanctions on food security in Iran. Int J Health Policy Manage. 2022;11(5):651.</Citation></Reference><Reference><Citation>Ghassemi H, Harrison G, Mohammad K. An accelerated nutrition transition in Iran. Public Health Nutr. 2002;5(1a):149&#x2013;55.</Citation></Reference><Reference><Citation>Abbasalizad-Farhangi M, Barzegari M. Nutrition transition in Iran: an analytical study of the factors related to life-style regarding non-communicable diseases in recent decades. J Nutr Food Secur. 2023;8(4):553&#x2013;64.</Citation></Reference><Reference><Citation>Shiri MS, Karami H, Ghanbarnezhad A, Bordbar N, Mouseli A, Emamgholipour S. National and subnational trends in obesity prevalence in Iran: a spatiotemporal study with future predictions. Sci Rep. 2025;15(1):1&#x2013;13.</Citation></Reference><Reference><Citation>Kim S, Haines PS, Siega-Riz AM, Popkin BM. The diet quality index-international (DQI-I) provides an effective tool for cross-national comparison of diet quality as illustrated by China and the United States. J Nutr. 2003;133(11):3476&#x2013;84.</Citation></Reference><Reference><Citation>Ebrahimi S, McNaughton SA, Leech RM, Abdollahi M, Houshiarrad A, Livingstone KM. A comparison of diet quality indices in a nationally representative cross-sectional study of Iranian households. Nutr J. 2020;19:1&#x2013;11.</Citation></Reference><Reference><Citation>Ghayour-Mobarhan M, Moohebati M, Esmaily H, Ebrahimi M, Parizadeh SMR, Heidari-Bakavoli AR, et al. Mashhad stroke and heart atherosclerotic disorder (MASHAD) study: design, baseline characteristics and 10-year cardiovascular risk estimation. Int J Public Health. 2015;60(5):561&#x2013;72.</Citation></Reference><Reference><Citation>Ahmadnezhad M, Asadi Z, Miri HH, Ebrahimi-Mamaghani M, Ghayour-Mobarhan M, Ferns GA. Validation of a short semi-quantitative food frequency questionnaire for adults: a pilot study. J Nutritional Sci Dietetics. 2017;3(2):49&#x2013;55.</Citation></Reference><Reference><Citation>Allowances RD. Recommended dietary allowances. Washington, DC, USA: National Research Council-National Academy; 1989.</Citation></Reference><Reference><Citation>Inc S. PASW statistics for windows, version 18.0. USA: SPSS Inc Illinois; 2009.</Citation></Reference><Reference><Citation>Salehi FMK, Siasi F, Abdollahi Z, Abdollahi M, Rad AH, Sadeghian-Sarif S. Optimum food basket for Iraninas. Tehran, Iran: Community Nutrition Office and National Nutrition and Food Technology Research Center, Ministry of Health and MedicalEducation; 2013.</Citation></Reference><Reference><Citation>Doggui R, Al-Jawaldeh H, El Ati J, Barham R, Nasreddine L, Alqaoud N, et al. Meta-analysis and systematic review of micro-and macro-nutrient intakes and trajectories of macro-nutrient supply in the Eastern Mediterranean region. Nutrients. 2021;13(5):1515.</Citation></Reference><Reference><Citation>Najafipour H, Bagheri M, Saberi S, Farokhi M, Amirzadeh R, Mirzazadeh A. Epidemiological update on prevalence and incidence of overweight and obesity in adults in the south-east of the Islamic Republic of Iran: findings from the Kerman coronary artery diseases risk factors study (KERCADRS). East Mediterr Health J. 2021;27(9):874&#x2013;83.</Citation></Reference><Reference><Citation>Heidari Z, Feizi A, Azadbakht L, Mohammadifard N, Maghroun M, Sarrafzadegan N. Usual energy and macronutrient intakes in a large sample of Iranian middle-aged and elderly populations. Nutr Dietetics. 2019;76(2):174&#x2013;83.</Citation></Reference><Reference><Citation>Dehghan M, Mente A, Zhang X, Swaminathan S, Li W, Mohan V, et al. Associations of fats and carbohydrate intake with cardiovascular disease and mortality in 18 countries from five continents (PURE): a prospective cohort study. Lancet. 2017;390(10107):2050&#x2013;62.</Citation></Reference><Reference><Citation>Bahreynian M, Esmaillzadeh A. Opinion: quantity and quality of carbohydrate intake in Iran: a target for nutritional intervention. Arch Iran Med. 2012;15(10):648&#x2013;9.</Citation></Reference><Reference><Citation>Tavassoli AA, Gharipour M, Khosravi A, Kelishadi R, Siadat ZD, Bahonar A, et al. Gender differences in obesogenic behaviour, socioeconomic and metabolic factors in a population-based sample of Iranians: the IHHP study. J Health Popul Nutr. 2010;28(6):602.</Citation></Reference><Reference><Citation>Lombardo M, Feraco A, Armani A, Camajani E, Gorini S, Strollo R, et al. Gender differences in body composition, dietary patterns, and physical activity: insights from a cross-sectional study. Front Nutr. 2024;11:1414217.</Citation></Reference><Reference><Citation>Seidelmann SB, Claggett B, Cheng S, Henglin M, Shah A, Steffen LM, et al. Dietary carbohydrate intake and mortality: a prospective cohort study and meta-analysis. Lancet Public Health. 2018;3(9):e419&#x2013;28.</Citation></Reference><Reference><Citation>Azadbakht L, Esmaillzadeh A. Macro and micro-nutrients intake, food groups consumption and dietary habits among female students in Isfahan university of medical sciences. Iran Red Crescent Med J. 2012;14(4):204.</Citation></Reference><Reference><Citation>Rashidi AA, Bakavoli ARH, Avan A, Aghasizade M, Ghazizadeh H, Tayefi M, et al. Dietary intake and its relationship to different body mass index categories: a population-based study. J Res Health Sci. 2018;18(4):e00426.</Citation></Reference><Reference><Citation>Aghayan M, Asghari G, Yuzbashian E, Mahdavi M, MirmIran P, Azizi F. Secular trend in dietary patterns of Iranian adults from 2006 to 2017: Tehran lipid and glucose study. Nutr J. 2020;19(1):1&#x2013;8.</Citation></Reference><Reference><Citation>McCartney DM, Younger KM, Walsh J, O&#x2019;Neill M, Sheridan C, Kearney JM. Socio-economic differences in food group and nutrient intakes among young women in Ireland. Br J Nutr. 2013;110(11):2084&#x2013;97.</Citation></Reference><Reference><Citation>Mishra G, Ball K, Arbuckle J, Crawford D. Dietary patterns of Australian adults and their association with socioeconomic status: results from the 1995 National Nutrition Survey. Eur J Clin Nutr. 2002;56(7):687&#x2013;93.</Citation></Reference><Reference><Citation>Nikooyeh B, Rabiei S, Amini M, Ghodsi D, Rasekhi H, Doustmohammadian A, et al. COVID-19 epidemic lockdown-induced changes of cereals and animal protein foods consumption of Iran population: the first nationwide survey. J Health Popul Nutr. 2022;41(1):1&#x2013;9.</Citation></Reference><Reference><Citation>Ghanbari Movahed R, Maleki Fard F, Gholamrezai S, Pakravan-Charvadeh M. The impact of COVID-19 pandemic on food security and food diversity of Iranian rural households. Front Public Health. 2022;10:862043.</Citation></Reference><Reference><Citation>Asghari S, Mohammadzadegan-Tabrizi R, Rafraf M, Sarbakhsh P, Babaie J. Prevalence and predictors of iron-deficiency anemia: women&#x2019;s health perspective at reproductive age in the suburb of dried Urmia Lake, Northwest of Iran. J Educ Health Promotion. 2020;9.</Citation></Reference><Reference><Citation>Eftekharzadeh MI, Hedayati MMR, Fathimoghadam F, Bidkhori HR, Shamsian SK. Anemia as a public health issue in mashhad, Iran: evidence from the first population-based study. Acta Medica Iranica. 2015;53(3).</Citation></Reference><Reference><Citation>Sadeghian M, Fatourechi A, Lesanpezeshki M, Ahmadnezhad E. Prevalence of anemia and correlated factors in the reproductive age women in rural areas of Tabas. J Family Reproductive Health. 2013;7(3):139.</Citation></Reference><Reference><Citation>Sheikholeslam R, Jamshidbeygi E, Salehian P, Malekafzali H. Prevalence of iron deficiency, anemia and iron deficiency anemia in reproductive age women (49&#x2013;15 years) in urban and rural areas of Iran. Teb Va Tazkiyeh. 2001;47:37&#x2013;44.</Citation></Reference><Reference><Citation>Bathla S, Arora S. Prevalence and approaches to manage iron deficiency anemia (IDA). Crit Rev Food Sci Nutr. 2022;62(32):8815&#x2013;28.</Citation></Reference><Reference><Citation>Organization WH. Global nutrition targets 2025: anaemia policy brief. 2014. Available from: Google Scholar [Accessed 2021].</Citation></Reference><Reference><Citation>Eshak ES, Iso H, Yamagishi K, Maruyama K, Umesawa M, Tamakoshi A. Associations between copper and zinc intakes from diet and mortality from cardiovascular disease in a large population-based prospective cohort study. J Nutr Biochem. 2018;56:126&#x2013;32.</Citation></Reference><Reference><Citation>Manios Y, Moschonis G, Mavrogianni C, Bos R, Singh-Povel C. Micronutrient intakes among children and adults in greece: the role of age, sex and socio-economic status. Nutrients. 2014;6(10):4073&#x2013;92.</Citation></Reference><Reference><Citation>Cowan AE, Jun S, Tooze JA, Eicher-Miller HA, Dodd KW, Gahche JJ, et al. Total usual micronutrient intakes compared to the dietary reference intakes among US adults by food security status. Nutrients. 2019;12(1):38.</Citation></Reference><Reference><Citation>Schmid A, Walther B. Natural vitamin D content in animal products. Adv Nutr. 2013;4(4):453&#x2013;62.</Citation></Reference><Reference><Citation>Esmaeili M, Yekta R, Abedi A-S, Ghanati K, Derav RZ, Houshyarrad A, et al. Encapsulating vitamin D: a feasible and promising approach to combat its deficiency. Pharm Sci. 2021;28(2):194&#x2013;207.</Citation></Reference><Reference><Citation>Saini A, Habib M, Jan S, Jan K, Chauhan K. Vitamin D fortification. Food fortification. Boca Rayton: CRC; 2024. pp. 57&#x2013;71.</Citation></Reference><Reference><Citation>J&#xe4;&#xe4;skel&#xe4;inen T, Itkonen ST, Lundqvist A, Erkkola M, Koskela T, Lakkala K, et al. The positive impact of general vitamin D food fortification policy on vitamin D status in a representative adult Finnish population: evidence from an 11-y follow-up based on standardized 25-hydroxyvitamin D data. Am J Clin Nutr. 2017;105(6):1512&#x2013;20.</Citation></Reference><Reference><Citation>Rezaei S, Mahmoudi Z, Sheidaei A, Aryan Z, Mahmoudi N, Gohari K, et al. Salt intake among Iranian population: the first national report on salt intake in Iran. J Hypertens. 2018;36(12):2380&#x2013;9.</Citation></Reference><Reference><Citation>Mohammadifard N, Mahdavi A, Khosravi A, Esmaillzadeh A, Feizi A, Sarrafzadegan N. Salt intake and its sources in children, adolescents and adults in the Islamic Republic of Iran. East Mediterr Health J. 2021;27(3):279&#x2013;86.</Citation></Reference><Reference><Citation>Jayedi A, Ghomashi F, Zargar MS, Shab-Bidar S. Dietary sodium, sodium-to-potassium ratio, and risk of stroke: a systematic review and nonlinear dose-response meta-analysis. Clin Nutr. 2019;38(3):1092&#x2013;100.</Citation></Reference><Reference><Citation>Yang Q, Liu T, Kuklina EV, Flanders WD, Hong Y, Gillespie C, et al. Sodium and potassium intake and mortality among US adults: prospective data from the Third National Health and Nutrition Examination Survey. Arch Intern Med. 2011;171(13):1183&#x2013;91.</Citation></Reference><Reference><Citation>Abdurahman A, Bule M, Fallahyekt M, Abshirini M, Azadbakht L, Qorbani M, Dorosty A. Association of diet quality and food insecurity with metabolic syndrome in obese adults. Int J Prev Med. 2021;12.</Citation></Reference><Reference><Citation>Cho IY, Lee KM, Lee Y, Paek CM, Kim HJ, Kim JY, et al. Assessment of dietary habits using the diet quality index&#x2014;international in cerebrovascular and cardiovascular disease patients. Nutrients. 2021;13(2):542.</Citation></Reference><Reference><Citation>Zhang Y, Fan S, Hui H, Zhang N, Li J, Liao L, et al. Privacy protection for open sharing of psychiatric and behavioral research data: ethical considerations and recommendations. Alpha Psychiatry. 2025;26(1):38759.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">40713767</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2050-7283</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>26</Day></PubDate></JournalIssue><Title>BMC psychology</Title><ISOAbbreviation>BMC Psychol</ISOAbbreviation></Journal><ArticleTitle>Network analysis of comorbid depression and anxiety and their associations with academic engagement among medical students in the Post-Peak COVID-19 period in China.</ArticleTitle><Pagination><StartPage>838</StartPage><MedlinePgn>838</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s40359-025-03181-2</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Changqing</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>School of Nursing and Health, Zhengzhou University, 101 Kexue Avenue, Zhengzhou, Henan, 450001, PR China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>College of Public Health, Zhengzhou University, Zhengzhou, Henan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Jiale</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>School of Nursing and Health, Zhengzhou University, 101 Kexue Avenue, Zhengzhou, Henan, 450001, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Zhengqi</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>School of Nursing and Health, Zhengzhou University, 101 Kexue Avenue, Zhengzhou, Henan, 450001, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Qiang</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>School of Nursing and Health, Zhengzhou University, 101 Kexue Avenue, Zhengzhou, Henan, 450001, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Panpan</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>School of Nursing and Health, Zhengzhou University, 101 Kexue Avenue, Zhengzhou, Henan, 450001, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Peijia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Nursing, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Zhengzhou, Henan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qin</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>School of Nursing and Health, Zhengzhou University, 101 Kexue Avenue, Zhengzhou, Henan, 450001, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>School of Nursing and Health, Zhengzhou University, 101 Kexue Avenue, Zhengzhou, Henan, 450001, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xue</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>School of Nursing and Health, Zhengzhou University, 101 Kexue Avenue, Zhengzhou, Henan, 450001, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Dequan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>School of Nursing and Health, Zhengzhou University, 101 Kexue Avenue, Zhengzhou, Henan, 450001, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Zizheng</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>School of Nursing and Health, Zhengzhou University, 101 Kexue Avenue, Zhengzhou, Henan, 450001, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Lianke</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>School of Nursing and Health, Zhengzhou University, 101 Kexue Avenue, Zhengzhou, Henan, 450001, PR China. lianke0109@163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>242102311135</GrantID><Agency>Henan Provincial Science and Technology Research Project</Agency><Country/></Grant><Grant><GrantID>232102311023</GrantID><Agency>Henan Provincial Science and Technology Research Project</Agency><Country/></Grant><Grant><GrantID>242102310234</GrantID><Agency>Henan Province Science and Technology Research Project</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Psychol</MedlineTA><NlmUniqueID>101627676</NlmUniqueID><ISSNLinking>2050-7283</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Academic engagement</Keyword><Keyword MajorTopicYN="N">Anxiety</Keyword><Keyword MajorTopicYN="N">Depression</Keyword><Keyword MajorTopicYN="N">Network analysis</Keyword></KeywordList><CoiStatement>Declarations. Ethics approval and consent to participate: Our study adheres to the ethical principles set forth in the Declaration of Helsinki and has received approval from the Ethics Review Board of Zhengzhou University (ZZUIRB2022-06), including the approval of electronic consent procedures. Informed consent was obtained from all subjects participating in the study. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>10</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>27</Day><Hour>1</Hour><Minute>6</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40713767</ArticleId><ArticleId IdType="doi">10.1186/s40359-025-03181-2</ArticleId><ArticleId IdType="pii">10.1186/s40359-025-03181-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mao Y, Zhang N, Liu J, Zhu B, He R, Wang X. A systematic review of depression and anxiety in medical students in China. Bmc Med Educ. 2019;19(1):327.</Citation></Reference><Reference><Citation>Li W, Zhao Z, Chen D, Peng Y, Lu Z. Prevalence and associated factors of depression and anxiety symptoms among college students: a systematic review and meta-analysis. J Child Psychol Psychiatry. 2022;63(11):1222&#x2013;1230.</Citation></Reference><Reference><Citation>Alshamrani KM, Ghulam EM, Alattas M, Aljaddani H, Alhakami M, Nufaiei ZFA, et al. Transition to remote/hybrid learning during the covid-19 pandemic among Saudi students of the college of applied medical sciences: a cross-sectional study. Front Med (Lausanne). 2023;10:1257589.</Citation></Reference><Reference><Citation>Mansueto G, Palmieri S, Marino C, Caselli G, Sassaroli S, Ruggiero GM, et al. The Italian covid-19 anxiety syndrome scale: investigation of the covid-19 anxiety syndrome and its association with psychological symptoms in an Italian population. Clin Psychol Psychother. 2022;29:1972&#x2013;1990.</Citation></Reference><Reference><Citation>Grossman ES, Hoffman YSG, Palgi Y, Shrira A. Covid-19 related loneliness and sleep problems in older adults: worries and resilience as potential moderators. Pers Individ Dif. 2021;168:110371.</Citation></Reference><Reference><Citation>Mansueto G, Lopes FL, Grassi L, Cosci F. Impact of covid-19 outbreak on Italian healthcare workers versus general population: results from an online survey. Clin Psychol Psychother. 2021;28:1334&#x2013;1345.</Citation></Reference><Reference><Citation>Pivec T, Kozina A. Anxiety and covid-19 anxiety in positive youth development: a latent profile analysis study. J Youth Adolesc. 2023;52:2328&#x2013;2343.</Citation></Reference><Reference><Citation>Brailovskaia J, Cosci F, Mansueto G, Miragall M, Herrero R, Banos RM, et al. The association between depression symptoms, psychological burden caused by covid-19 and physical activity: an investigation in germany, italy, russia, and Spain. Psychiatry Res. 2021;295:113596.</Citation></Reference><Reference><Citation>Mansueto G, Ruggiero GM, Palmieri S. The relationship between covid-19 fear, affective symptoms and well-being: the mediating role of psychological flexibility. J Ration Emot Cogn Behav Ther. 2024;42:681.</Citation></Reference><Reference><Citation>Ma Z, Zhao J, Li Y, Chen D, Wang T, Zhang Z, et al. Mental health problems and correlates among 746 217 college students during the coronavirus disease 2019 outbreak in China. Epidemiol Psychiatr Sci. 2020;29:e181.</Citation></Reference><Reference><Citation>Monroe SM, Harkness KL. Major depression and its recurrences: life course matters. Annu Rev Clin Psychol. 2022;18:329&#x2013;357.</Citation></Reference><Reference><Citation>Groen RN, Ryan O, Wigman JTW, Riese H, Penninx BWJH, Giltay EJ, et al. Comorbidity between depression and anxiety: assessing the role of Bridge mental States in dynamic psychological networks. Bmc Med. 2020;18(1):308.</Citation></Reference><Reference><Citation>Jang H, Reeve J, Deci EL. Engaging students in learning activities: it is not autonomy support or structure but autonomy support and structure. J Educ Psychol. 2010;102:588&#x2013;600.</Citation></Reference><Reference><Citation>Chen S, Cardenas D, Zhou H, Reynolds KJ. Positive school climate and strong school identification as protective factors of adolescent mental health and learning engagement: a longitudinal investigation before and during covid-19. Soc Sci Med. 2024;348:116795.</Citation></Reference><Reference><Citation>Krifa I, Hallez Q, van Zyl LE, Braham A, Sahli J, Nasr SB, et al. Effectiveness of an online positive psychology intervention among Tunisian healthcare students on mental health and study engagement during the covid-19 pandemic. Appl Psychol Health Well Being. 2022;14:1228&#x2013;1254.</Citation></Reference><Reference><Citation>Borsboom D. A network theory of mental disorders. World Psychiatry. 2017;16:5&#x2013;13.</Citation></Reference><Reference><Citation>Bringmann LF, Lemmens LHJM, Huibers MJH, Borsboom D, Tuerlinckx F. Revealing the dynamic network structure of the Beck depression inventory-ii. Psychol Med. 2015;45:747&#x2013;757.</Citation></Reference><Reference><Citation>Borsboom D, Cramer AOJ. Network analysis: an integrative approach to the structure of psychopathology. Ann Rev Clin Psychol. 2013;9:9:91&#x2013;121.</Citation></Reference><Reference><Citation>Zhang P, Wang L, Zhou Q, Dong X, Guo Y, Wang P, et al. A network analysis of anxiety and depression symptoms in Chinese disabled elderly. J Affect Disord. 2023;333:535&#x2013;542.</Citation></Reference><Reference><Citation>Lee CS, Chu SH, Dunne J, Spintzyk E, Locatelli G, Babicheva V, et al. Body listening in the link between symptoms and self-care management in cardiovascular disease: a cross-sectional correlational descriptive study. Int J Nurs Stud. 2024;156:104809.</Citation></Reference><Reference><Citation>Sun C, Zhu Z, Zhang P, Wang L, Zhang Q, Guo Y, et al. Exploring the interconnections of anxiety, depression, sleep problems and health-promoting lifestyles among Chinese university students: a comprehensive network approach. Front Psychiatry. 2024;15:1402680.</Citation></Reference><Reference><Citation>Abdolkarimi M, Masoomi M, Lotfipur SS, Zakeri MA. The relationship between spiritual health and happiness in medical students during the covid-19 outbreak: a survey in southeastern Iran. Front Psychol. 2022;13:974697.</Citation></Reference><Reference><Citation>Regli J, Sadeghi-Bahmani D, Rigotti V, Stanga Z, Ulguer II, Fichter C, et al. Psychiatric characteristics, symptoms of insomnia and depression, emotion regulation, and social activity among Swiss medical students. J Clin Med. 2024;13(15):4372.</Citation></Reference><Reference><Citation>Milasauskiene E, Burkauskas J, Podlipskyte A, Kiraly O, Demetrovics Z, Ambrasas L, et al. Compulsive internet use scale: psychometric properties and associations with sleeping patterns, mental health, and well-being in Lithuanian medical students during the coronavirus disease 2019 pandemic. Front Psychol. 2021;12:685137.</Citation></Reference><Reference><Citation>Sergi MR, Picconi L, Saggino A, Fermani A, Bongelli R, Tommasi M. Psychometric properties of a new instrument for the measurement of the perceived quality of distance learning during the coronavirus disease 2019 (covid-19) pandemic. Front Psychol. 2023;14:1169957.</Citation></Reference><Reference><Citation>Castro Pecci Maddalena N, Lamas Granero Lucchetti A, da Silva Ezequiel O, Lucchetti G. Factors associated with mental health and quality of life among Brazilian medical students: a three-year longitudinal study. J Ment Health. 2025;34(1):38&#x2013;45.</Citation></Reference><Reference><Citation>Cen S, Zhao M, Wang F, Tang L. Gender differences in the relationship between mental health and academic performance among undergraduate students at a medical school in shanghai: a cross-sectional study. BMC Public Health. 2025;25(1):731.</Citation></Reference><Reference><Citation>Wang W, Wang J, Zhang X, Pei Y, Tang J, Zhu Y, et al. Network connectivity between anxiety, depressive symptoms and psychological capital in Chinese university students during the covid-19 campus closure. J Affect Disord. 2023;329:11&#x2013;18.</Citation></Reference><Reference><Citation>Luo J, Xu J, Lin Y, Chen Q. Understanding the complex network of anxiety, depression, sleep problems, and smartphone addiction among college Art students using network analysis. Front Psychiatry. 2025;16:1533757.</Citation></Reference><Reference><Citation>Mi Y, Ahn S, Ren L. Exploring the interconnections of loneliness, anxiety, and depression among nursing students: a network analysis approach. Front Psychiatry. 2025;16:1537935.</Citation></Reference><Reference><Citation>Kroenke K, Spitzer RL, Williams J. The phq-9 - validity of a brief depression severity measure. J Gen Intern Med. 2001;16:606&#x2013;613.</Citation></Reference><Reference><Citation>Huang L, Li X, Gu X, Zhang H, Ren L, Guo L, et al. Health outcomes in people 2 years after surviving hospitalisation with covid-19: a longitudinal cohort study. Lancet Respir Med. 2022;10:863&#x2013;876.</Citation></Reference><Reference><Citation>Spitzer RL, Kroenke K, Williams JBW, Loewe B. A brief measure for assessing generalized anxiety disorder -: the gad-7. Arch Intern Med. 2006;166:1092&#x2013;1097.</Citation></Reference><Reference><Citation>Huang X, Ma H, Wang X, Zhong J, Sheng D, Xu M. Equating the phq-9 and gad-7 to the Hads depression and anxiety subscales in patients with major depressive disorder. J Affect Disord. 2022;311:327&#x2013;335.</Citation></Reference><Reference><Citation>Schaufeli WB, Mart&#xed;nez IM, Pinto AM, Salanova M, Bakker AB. Burnout and engagement in university students -: a cross-national study. J Cross Cult Psychol. 2002;33:464&#x2013;481.</Citation></Reference><Reference><Citation>Meng L, Jin Y. A confirmatory factor analysis of the Utrecht work engagement scale for students in a Chinese sample. Nurse Educ Today. 2017;49:129&#x2013;134.</Citation></Reference><Reference><Citation>Epskamp S, Cramer AOJ, Waldorp LJ, Schmittmann VD, Borsboom D. Qgraph: network visualizations of relationships in psychometric data. J Stat Softw. 2012;48:1&#x2013;18.</Citation></Reference><Reference><Citation>Epskamp S, Borsboom D, Fried EI. Estimating psychological networks and their accuracy: a tutorial paper. Behav Res Methods. 2018;50:195&#x2013;212.</Citation></Reference><Reference><Citation>Tibshirani R. Regression shrinkage and selection via the Lasso. J R Stat Soc Ser B Stat Methodol. 1996;58:267&#x2013;288.</Citation></Reference><Reference><Citation>Chen J, Chen Z. Extended bayesian information criteria for model selection with large model spaces. Biometrika. 2008;95:759&#x2013;771.</Citation></Reference><Reference><Citation>Haslbeck JMB, Waldorp LJ. Mgm: estimating time-varying mixed graphical models in high-dimensional data. J Stat Softw. 2020;93(8):1&#x2013;46.</Citation></Reference><Reference><Citation>Robinaugh DJ, Millner AJ, Mcnally RJ. Identifying highly influential nodes in the complicated grief network. J Abnorm Psychol. 2016;125:747&#x2013;757.</Citation></Reference><Reference><Citation>Jones PJ, Ma R, Mcnally RJ. Bridge centrality: a network approach to Understanding comorbidity. Multivar Behav Res. 2021;56:353&#x2013;367.</Citation></Reference><Reference><Citation>Gao WJ, Ping SQ, Liu XQ. Gender differences in depression, anxiety, and stress among college students: a longitudinal study from China. J Affect Disord. 2020;263:292&#x2013;300.</Citation></Reference><Reference><Citation>Bu F, Steptoe A, Fancourt D. Loneliness during a strict lockdown: trajectories and predictors during the covid-19 pandemic in 38,217 united Kingdom adults. Soc Sci Med. 2020;265:113521.</Citation></Reference><Reference><Citation>van Borkulo CD, van Bork R, Boschloo L, Kossakowski JJ, Tio P, Schoevers RA, et al. Comparing network structures on three aspects: a permutation test. Psychol Methods. 2023;28:1273&#x2013;1285.</Citation></Reference><Reference><Citation>Huang J, Liu X. Anxiety, depression, and their comorbidity among Chinese college students during the covid-19 lockdown in the post-epidemic era: an online cross-sectional survey. BMC Psychiatry. 2023;23(1):923.</Citation></Reference><Reference><Citation>Hu Z, Li W, Ye Y, Zhang F, Liu H, Chen X, et al. Alterations of functional connectivity in young people with depression mediate the relationship between sleep quality and cognitive function. J Affect Disord. 2023;340:160&#x2013;166.</Citation></Reference><Reference><Citation>Cheng W, Rolls ET, Ruan H, Feng J. Functional connectivities in the brain that mediate the association between depressive problems and sleep quality. Jama Psychiatry. 2018;75:1052&#x2013;1061.</Citation></Reference><Reference><Citation>Bekkevold O, Damas JK, Brumpton BM, Asvold BO. The causal role of c-reactive protein and interleukin-6 on anxiety and depression symptoms and life satisfaction: Mendelian randomisation analyses in the Hunt study. Psychol Med. 2023;53:7561&#x2013;7568.</Citation></Reference><Reference><Citation>Nguyen M, Chaudhry S, Desai MM, Chen C, Mason HRC, Mcdade WA, et al. Association of sociodemographic characteristics with Us medical student attrition. Jama Intern Med. 2022;182:917&#x2013;924.</Citation></Reference><Reference><Citation>Sun H, Zhao Y, Sha S, Li X, Si TL, Liu Y, et al. Depression and anxiety among caregivers of psychiatric patients during the late stage of the covid-19 pandemic: a perspective from network analysis. J Affect Disord. 2024;344:33&#x2013;40.</Citation></Reference><Reference><Citation>Ren L, Wang Y, Wu L, Wei Z, Cui L, Wei X, et al. Network structure of depression and anxiety symptoms in Chinese female nursing students. BMC Psychiatry. 2021;21(1):279.</Citation></Reference><Reference><Citation>Park S, Kim D. The centrality of depression and anxiety symptoms in major depressive disorder determined using a network analysis. J Affect Disord. 2020;271:19&#x2013;26.</Citation></Reference><Reference><Citation>Zhang Y, Luo M, Ouyang J, Chen Y, Xia H, Yang F, et al. The influence of changes in the Chinese covid-19 prevention and control policies on mental health of medical staff: a network analysis. J Affect Disord. 2023;335:10&#x2013;17.</Citation></Reference><Reference><Citation>Badenoch JB, Rengasamy ER, Watson C, Jansen K, Chakraborty S, Sundaram RD, et al. Persistent neuropsychiatric symptoms after covid-19: a systematic review and meta-analysis. Brain Commun. 2022;4(1):fcab297.</Citation></Reference><Reference><Citation>Mack DL, Dasilva AW, Rogers C, Hedlund E, Murphy E, Vojdanovski V, et al. Mental health and behavior of college students during the covid-19 pandemic: longitudinal mobile smartphone and ecological momentary assessment study, part Ii. J Med Internet Res. 2021;23(6):e28892.</Citation></Reference><Reference><Citation>Zhang C, Huang J, Xu W. Longitudinal relationships between depressive symptoms and generalized anxiety symptoms in adolescents: a cross-lagged network analysis. J Youth Adolesc. 2024;53(8):1918&#x2013;1927.</Citation></Reference><Reference><Citation>Zhang K, Peng Y, Zhang X, Li L. Psychological burden and experiences following exposure to covid-19: a qualitative and quantitative study of Chinese medical student volunteers. Int J Environ Res Public Health. 2021;18(8):4089.</Citation></Reference><Reference><Citation>Passemard S, Faye A, Dubertret C, Peyre H, Vorms C, Boimare V, et al. Covid-19 crisis impact on the next generation of physicians: a survey of 800 medical students. Bmc Med Educ. 2021;21:529.</Citation></Reference><Reference><Citation>Harries AJ, Lee C, Jones L, Rodriguez RM, Davis JA, Boysen-Osborn M, et al. Effects of the covid-19 pandemic on medical students: a multicenter quantitative study. Bmc Med Educ. 2021;21:529.</Citation></Reference><Reference><Citation>Bai W, Xi H, Zhu Q, Ji M, Zhang H, Xiang B, et al. Network analysis of anxiety and depressive symptoms among nursing students during the covid-19 pandemic (294, Pg 753, 2021). J Affect Disord. 2023;328:355.</Citation></Reference><Reference><Citation>Li J, Jin Y, Xu S, Wilson A, Chen C, Luo X, et al. Effects of bullying on anxiety, depression, and posttraumatic stress disorder among sexual minority youths: network analysis. Jmir Public Health Surveill. 2023;9:e47233.</Citation></Reference><Reference><Citation>Reyes-Rodriguez ML, Riyera-Medina CL, Camara-Fuentes L, Suarez-Torres A, Bernal G. Depression symptoms and stressful life events among college students in Puerto Rico. J Affect Disord. 2013;145:324&#x2013;330.</Citation></Reference><Reference><Citation>Almarri FK, Alaseem AM, Alanazi MS, Alyahya S, Alsanad NH, Alswayed KE, et al. Prevalence of Pharmacological and non - Pharmacological coping mechanisms for anxiety management during the covid-19 pandemic: investigating the transition to online learning among medical students. BMC Psychiatry. 2022;22(1):704.</Citation></Reference><Reference><Citation>Dolcos F, Katsumi Y, Moore M, Berggren N, de Gelder B, Derakshan N, et al. Neural correlates of emotion-attention interactions: from perception, learning, and memory to social cognition, individual differences, and training interventions. Neurosci Biobehav Rev. 2020;108:559&#x2013;601.</Citation></Reference><Reference><Citation>Sanchez J, Lesmes M, Rubio M, Gal B, Tutor AS. Enhancing academic performance and student engagement in health education: insights from work station learning activities (wsla). Bmc Med Educ. 2024;24(1):496.</Citation></Reference><Reference><Citation>Hu Y, Fang C, Wu J, Mi L, Dai P. Investigating the interrelationship among academic emotions, classroom engagement, and self-efficacy in the context of Efl learning in smart classrooms in China. Aust J Psychol. 2024; 76(1):2300460.</Citation></Reference><Reference><Citation>Sinval J, Oliveira P, Novais F, Almeida CM, Telles-Correia D. Exploring the impact of depression, anxiety, stress, academic engagement, and dropout intention on medical students&#x2019; academic performance: a prospective study. J Affect Disord. 2025;368:665&#x2013;673.</Citation></Reference><Reference><Citation>Cao S, Geok SK, Roslan S, Qian S, Sun H, Lam SK, et al. Mindfulness-based interventions for the recovery of mental fatigue: a systematic review. Int J Environ Res Public Health. 2022;19(13):7825.</Citation></Reference><Reference><Citation>Cosci F, Guidi J, Mansueto G, Fava GA. Psychotherapy in recurrent depression: efficacy, pitfalls, and recommendations. Expert Rev Neurother. 2020;20:1169&#x2013;1175.</Citation></Reference><Reference><Citation>Cuijpers P, Sijbrandij M, Koole SL, Andersson G, Beekman AT, Reynolds CF. The efficacy of psychotherapy and pharmacotherapy in treating depressive and anxiety disorders: a meta-analysis of direct comparisons. World Psychiatry. 2013;12:137&#x2013;148.</Citation></Reference><Reference><Citation>Cuijpers P, Sijbrandij M, Koole SL, Andersson G, Beekman AT, Reynolds CF. Adding psychotherapy to antidepressant medication in depression and anxiety disorders: a meta-analysis. World Psychiatry. 2014;13:56&#x2013;67.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40713726</PMID><DateCompleted><Year>2025</Year><Month>07</Month><Day>27</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1472-6939</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>26</Day></PubDate></JournalIssue><Title>BMC medical ethics</Title><ISOAbbreviation>BMC Med Ethics</ISOAbbreviation></Journal><ArticleTitle>Family satisfaction with the end-of-life discussions and resuscitation orders for patients with severe COVID-19: a multicenter study in Saudi Arabia.</ArticleTitle><Pagination><StartPage>107</StartPage><MedlinePgn>107</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12910-025-01248-8</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Despite the significant mortality, data on end-of-life (EoL) discussions during COVID-19 pandemic are scarce. Health care providers had to cope with significant challenges, particularly overcoming barriers to effective communication with patients and their families, and lack of information on therapy and prognosis. This study was undertaken to assess the satisfaction of close family members (CFMs) with EoL discussions for patients hospitalized with severe COVID-19 infection.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The study was conducted in five major hospitals in Saudi Arabia. Medical charts of consecutive patients who died from COVID-19 complications were retrospectively reviewed. Demographic and clinical data were collected, and communication with close family members (CFMs) about clinical decisions were evaluated. A follow-up telephone interview was conducted using a validated Arabic questionnaire to evaluate satisfaction of CFMs with the EoL discussions prior death.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">EoL discussions were documented in less than half (67, 49.28%) and were often delayed (the median time 19.75 days [range 1-119] after admission. However, in the interviews of the CFMs, 109 of 136 (80.15%) acknowledged that physicians had shared with them information regarding the medical condition of the patient. Most of these discussions were conducted with the CFMs rather than the patients. Do Not Attempt Resuscitation orders were implemented in half of the patients, and most CFMs (70%) felt they were appropriate. Satisfaction levels for physicians, were as follows: 61.68% for the adequacy of information provided, 60.00% for time spent, and 61.49% for empathy from physicians. A strong correlation existed between the time spent and both the adequacy of information (rs&#x2009;=&#x2009;0.89, p&#x2009;&lt;&#x2009;0.001) and empathy (rs&#x2009;=&#x2009;0.82, p&#x2009;&lt;&#x2009;0.001). As for nursing performance, satisfaction was 47.83% for information, 48.06% for time, and 55.81% for empathy. Physicians' scores were significantly higher than nurses on information sharing (P = 0.022) and time spent (P = 0.05), but there was not significant difference with regards to empathy.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Despite the challenges associated with the pandemic, there is room for improvement in EoL discussions, particularly the early introduction of personalized goal-oriented care plans. Defining roles and fostering interdisciplinary collaboration between healthcare professionals may enhance satisfaction of patients and their families.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>A</LastName><ForeName>Mobeireek</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-0880-206X</Identifier><AffiliationInfo><Affiliation>Department of Medicine (MBC 46), King Faisal Specialist Hospital &amp; Research Centre, PO Box 5534, Riyadh, 11211, Saudi Arabia. mobeireek@yahoo.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>College of Medicine, Alfaisal University, Riyadh, Saudi Arabia. mobeireek@yahoo.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>H</LastName><ForeName>Al-Jahdali</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>King Saud University for Health Sciences and King Abdulaziz Medical City, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>A</LastName><ForeName>AlJohaney</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>N</LastName><ForeName>Al-Rajhi</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>King Khalid University Hospital, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S</LastName><ForeName>Al-Fadhli</ForeName><Initials>AF</Initials><AffiliationInfo><Affiliation>King Fahad Medical City, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>H</LastName><ForeName>Lababidi</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>King Fahad Medical City, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>A</LastName><ForeName>Al-Firm</ForeName><Initials>AF</Initials><AffiliationInfo><Affiliation>Department of Medicine (MBC 46), King Faisal Specialist Hospital &amp; Research Centre, PO Box 5534, Riyadh, 11211, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>A</LastName><ForeName>AlFattani</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine (MBC 46), King Faisal Specialist Hospital &amp; Research Centre, PO Box 5534, Riyadh, 11211, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L</LastName><ForeName>Ahmed</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>King Faisal Specialist Hospital &amp; Research Centre, Al-Madinah, Saudi Arabia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Med Ethics</MedlineTA><NlmUniqueID>101088680</NlmUniqueID><ISSNLinking>1472-6939</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012529" MajorTopicYN="N" Type="Geographic">Saudi Arabia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005190" MajorTopicYN="Y">Family</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013727" MajorTopicYN="Y">Terminal Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016414" MajorTopicYN="Y">Resuscitation Orders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003142" MajorTopicYN="N">Communication</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011368" MajorTopicYN="Y">Professional-Family Relations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010549" MajorTopicYN="Y">Personal Satisfaction</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Autonomy</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Healthcare professionals</Keyword><Keyword MajorTopicYN="N">Nurses</Keyword><Keyword MajorTopicYN="N">Pandemic</Keyword><Keyword MajorTopicYN="N">Physician-patient communication</Keyword><Keyword MajorTopicYN="N">Physicians</Keyword></KeywordList><CoiStatement>Declarations. Ethics approval and consent to participate: This study was approved by the Institutional Review Boards (IRB) of King Faisal Specialist Hospital Research Centre (Project No. 2201251), King Abdullah International Medical Research Centre, King Fahad Medical City and King Khalid University Hospital all located in Riyadh, Saudi Arabia, and King Abdulaziz University Hospital in Jeddah, Saudi Arabia. Informed consent was obtained from all participants in the phone survey, and participation was voluntary (please refer to Supplementary information, the Arabic section). Due to the retrospective nature of study without collecting any identifiable personal details of both patient data collection and interviews of the family members, a consent waiver was requested by the study team and approved by the IRB. National and international ethical standards and policies for conducting research on human subjects, such as the Declaration of Helsinki, were upheld throughout the study. Competing interests: The authors declare no competing interests. Clinical trial number: Not applicable.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>27</Day><Hour>1</Hour><Minute>5</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40713726</ArticleId><ArticleId IdType="doi">10.1186/s12910-025-01248-8</ArticleId><ArticleId IdType="pii">10.1186/s12910-025-01248-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Institute of Medicine. Dying in America: improving quality and honoring individual preferences near the end of life. Washington DC: National Academies; 2014.</Citation></Reference><Reference><Citation>Zwakman M, Jabbarian LJ, Van Delden J, et al. Advance care planning: a systematic review about experiences of patients with a life-threatening or life-limiting illness. Palliat Med. 2018;32(8):1305&#x2013;21.</Citation></Reference><Reference><Citation>Albashayreh A, Gilbertson-White S, Al Nashash D, et al. A qualitative exploration of goals-of-care discussions with seriously ill patients in Jordan. Palliat Support Care. 2023;24:1&#x2013;8.</Citation></Reference><Reference><Citation>Bokhour BG, Fix GM, Mueller NM, et al. How can healthcare organizations implement patient-centered care? Examining a large-scale cultural transformation. BMC Health Serv Res. 2018;18(1):168.</Citation></Reference><Reference><Citation>Schreiner MN, Gee PM, Hopkins RO, et al. Patient- and family-centered outcomes after intensive care unit admission. Am J Crit Care. 2025;34(1):12&#x2013;20. PMID: 39740976. https://doi.org/10.4037/ajcc2025684 .</Citation></Reference><Reference><Citation>Lightbody CJ, Campbell JN, Herbison GP, et al. Impact of a treatment escalation/limitation plan on non-beneficial interventions and harms in patients during their last admission before in-hospital death, using the structured judgment review method. BMJ Open. 2018;8(10):e024264.</Citation></Reference><Reference><Citation>Wright AA, Zhang B, Ray A, et al. Associations between end-of-life discussions, patient mental health, medical care near death, and caregiver bereavement adjustment. JAMA. 2008;300(14):1665&#x2013;73. PMID: 18840840; PMCID: PMC2853806. https://doi.org/10.1001/jama.300.14.1665 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.300.14.1665</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurlow A, Wyld L, Breen A. An evaluation of advance care planning during the COVID-19 pandemic: a retrospective review of patient involvement in decision making using routinely collected data from digital ReSPECT records. Clin Med. 2021;21(4):e395&#x2013;8.</Citation></Reference><Reference><Citation>Yen YF, Huang LY, Hu HY, et al. Association of advance directives completion with the utilization of life-sustaining treatments during the end-of-life care in older patients. J Pain Symptom Manag. 2017;55(2):265&#x2013;71.</Citation></Reference><Reference><Citation>Canavan ME, Wang X, Ascha MS, et al. Systemic anticancer therapy and overall survival in patients with very advanced solid tumors. JAMA Oncol. 2024;10(7):887&#x2013;95. PMID: 38753341; PMCID: PMC11099840. https://doi.org/10.1001/jamaoncol.2024.1129 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoncol.2024.1129</ArticleId></ArticleIdList></Reference><Reference><Citation>Desai A, Schneiderman H. Bolstering outpatient advanced care planning and palliative care in oncology: why and how. J Oncol Pract. 2019;15(7):360&#x2013;2.</Citation></Reference><Reference><Citation>Arruda LMD, Abreu KPB, Santana LBC, Santana LBC. Variables that influence the medical decision regarding advance directives and their impact on end-of-life care. Einstein (S&#xe3;o Paulo). 2019;18:eRW4852.</Citation></Reference><Reference><Citation>Robinson L, Lawrie I, Hard J, et al. Preparing for end-of-life: learning from do not attempt cardiopulmonary resuscitation decision-making during COVID-19. Postgrad Med J. 2023;99(1172):516&#x2013;9.</Citation></Reference><Reference><Citation>Curtis JR, Kross EK, Stapleton RD. The importance of addressing advance care planning and decisions about do-not-resuscitate orders during novel coronavirus 2019 (COVID-19). JAMA. 2020;323(18):1771&#x2013;2.</Citation></Reference><Reference><Citation>Nolan JP, Monsieurs KG, Bossaert L, et al. European resuscitation council COVID-19 guidelines executive summary. Resuscitation. 2020;153:45&#x2013;55.</Citation></Reference><Reference><Citation>Kiker WA, Cheng S, Pollack LR, et al. Admission code status and end-of-life care for hospitalized patients with COVID-19. J Pain Symptom Manag. 2022;64(4):359&#x2013;69.</Citation></Reference><Reference><Citation>Moin EE, Okin D, Jesudasen SJ, et al. Code status orders in patients admitted to the intensive care unit with COVID-19: a retrospective cohort study. Resusc Plus. 2022;10:100219.</Citation></Reference><Reference><Citation>Reja M, Naik J, Parikh P. COVID-19: implications for advanced care planning and end-of-life care. West J Emerg Med. 2020;21(5):1046&#x2013;7.</Citation></Reference><Reference><Citation>Tietzova I, Buzgova R, Kopecky O. Decision-making and ethical dilemmas experienced by hospital physicians during the COVID-19 pandemic in the Czech Republic. BMC Med Ethics. 2024;25(1):144. PMID: 39633385; PMCID: PMC11619269. https://doi.org/10.1186/s12910-024-01133-w .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12910-024-01133-w</ArticleId></ArticleIdList></Reference><Reference><Citation>Younan S, Cardona M, Sahay A, et al. Advanced care planning in the early phase of COVID-19: a rapid review of the practice and policy lessons learned. Front Health Serv. 2023;3:1242413.</Citation></Reference><Reference><Citation>Coleman JJ, Botkai A, Marson EJ, et al. Bringing into focus treatment limitation and DNACPR decisions: how COVID-19 has changed practice. Resuscitation. 2020;155:172&#x2013;9.</Citation></Reference><Reference><Citation>Piscitello GM, Fukushima CM, Saulitis AK, Tian KT, et al. Family meetings in the intensive care unit during the coronavirus disease 2019 pandemic. Am J Hosp Palliat Care. 2021;38(3):305&#x2013;12. Epub 2020 Nov 19. PMID: 33207937; PMCID: PMC7859662. https://doi.org/10.1177/1049909120973431 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1049909120973431</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnato AE, Johnson GR, Birkmeyer JD, et al. Advance care planning and treatment intensity before death among black, hispanic, and white patients hospitalized with COVID-19. J Gen Intern Med. 2022;37(8):1996&#x2013;2002.</Citation></Reference><Reference><Citation>Olds PK, Musinguzi N, Geisler BP, et al. Evaluating disparities in code status designation among patients admitted with COVID-19 at a quaternary care center early in the pandemic. Medicine. 2023;102(30):e34447.</Citation></Reference><Reference><Citation>Alfayyad IN, Al-Tannir MA, Alessa WA, et al. Physicians and nurses&#x2019; knowledge and attitudes towards advance directives for cancer patients in Saudi Arabia. PLoS ONE. 2019;14(4):e0213938.</Citation></Reference><Reference><Citation>Baharoon S, Alzahrani M, Alsafi E, et al. Advance directive preferences of patients with chronic and terminal illness towards end of life decisions: a sample from Saudi Arabia. East Mediterr Health J. 2019;25(11):791&#x2013;7.</Citation></Reference><Reference><Citation>Mobeireek AF, Al-Kassimi FA, Al-Majid SA, et al. Communication with the seriously ill: physicians&#x2019; attitudes in Saudi Arabia. J Med Ethics. 1996;22(5):282&#x2013;5.</Citation></Reference><Reference><Citation>Williams BA, Jones CH, Welch V, et al. Outlook of pandemic preparedness in a post-COVID-19 world. NPJ Vaccines. 2023;8(1):178.</Citation></Reference><Reference><Citation>Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inf. 2009;42(2):377&#x2013;81. Epub 2008 Sep 30. PMID: 18929686; PMCID: PMC2700030. https://doi.org/10.1016/j.jbi.2008.08.010 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2008.08.010</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inf. 2019;95:103208. Epub 2019 May 9. PMID: 31078660; PMCID: PMC7254481. https://doi.org/10.1016/j.jbi.2019.103208 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2019.103208</ArticleId></ArticleIdList></Reference><Reference><Citation>Paladino J, Sanders JJ, Fromme EK, et al. Improving serious illness communication: a qualitative study of clinical culture. BMC Palliat Care. 2023;22(1):104. PMID: 37481530; PMCID: PMC10362669. https://doi.org/10.1186/s12904-023-01229-x .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12904-023-01229-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Forbes TH 3rd, Evans S. From anticipation to confidence: a descriptive qualitative study of new graduate nurse communication with physicians. J Nurs Manag. 2022;30(6):2039&#x2013;45. Epub 2022 May 19. PMID: 35506538; PMCID: PMC9790247. https://doi.org/10.1111/jonm.13656 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jonm.13656</ArticleId></ArticleIdList></Reference><Reference><Citation>Strachan PH, Kryworuchko J, Nouvet E, et al. Canadian hospital nurses&#x2019; roles in communication and decision-making about goals of care: an interpretive description of critical incidents. Appl Nurs Res. 2018;40:26&#x2013;33. Epub 2017 Dec 18. PMID: 29579495. https://doi.org/10.1016/j.apnr.2017.12.014 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.apnr.2017.12.014</ArticleId></ArticleIdList></Reference><Reference><Citation>Woldring JM, Gans ROB, Paans W, et al. Physicians and nurses view on their roles in communication and collaboration with families: a qualitative study. Scand J Caring Sci. 2023;37(4):1109&#x2013;22. Epub 2023 May 29. PMID: 37248644. https://doi.org/10.1111/scs.13185 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/scs.13185</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuguero O, Ramon Marsal J, Esquerda M, et al. Association between low empathy and high burnout among primary care physicians and nurses in Lleida, Spain. Eur J Gen Pract. 2017;23(1):4&#x2013;10. Epub 2016 Oct 10. PMID: 27723375; PMCID: PMC5774288Spanish. https://doi.org/10.1080/13814788.2016.1233173 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13814788.2016.1233173</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy NR, Steinberg A, Arnold RM, et al. Perspectives on telephone and video communication in the intensive care unit during COVID-19. Ann Am Thorac Soc. 2021;18(5):838&#x2013;47.</Citation></Reference><Reference><Citation>Paladino J, Mitchell S, Mohta N, et al. Communication tools to support advance care planning and hospital care during the COVID-19 pandemic: a design process. Jt Comm J Qual Patient Saf. 2020;47(2):127&#x2013;36.</Citation></Reference><Reference><Citation>Crook RL, Iftikhar H, Moore S et al. A comparison of in-person versus telephone consultations for outpatient hospital care. Future Healthc J. 2022;9(2):154&#x2013;160. PMID: PMC9345241. https://doi.org/10.7861/fhj.2022-0006 .</Citation></Reference><Reference><Citation>Filindassi V, Pedrini C, Sabadini C, et al. Impact of COVID-19 first wave on psychological and psychosocial dimensions: a systematic review. COVID. 2022;2(3):273&#x2013;340. https://doi.org/10.3390/covid2030022 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/covid2030022</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardona M, Anstey M, Lewis ET, et al. Appropriateness of intensive care treatments near the end of life during the COVID-19 pandemic. Breathe (Sheff). 2020;16(2):200062. PMID: 33304408; PMCID: PMC7714540. https://doi.org/10.1183/20734735.0062-2020 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/20734735.0062-2020</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudore RL, Lum HD, You JJ, et al. Defining advance care planning for adults: a consensus definition from a multidisciplinary Delphi panel. J Pain Symptom Manag. 2017;53(5):821&#x2013;32.e1.</Citation></Reference><Reference><Citation>Fan R. Self-determination vs. family&#x2010;determination: two incommensurable principles of autonomy. Bioethics. 1997;11(3&#x2013;4):309&#x2013;22.</Citation></Reference><Reference><Citation>Lim MYH. Patient autonomy in an East-Asian cultural milieu: a critique of the individualism-collectivism model. J Med Ethics. 2024;50(9):640&#x2013;42. PMID: 35672134. https://doi.org/10.1136/medethics-2022-108123 .</Citation></Reference><Reference><Citation>Mobeireek AF, Al-Kassimi F, Al-Zahrani K, et al. Information disclosure and decision-making: the Middle East versus the far East and the West. J Med Ethics. 2008;34(4):225&#x2013;9.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40713725</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1537-6613</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Jul</Month><Day>26</Day></PubDate></JournalIssue><Title>The Journal of infectious diseases</Title><ISOAbbreviation>J Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Robust COVID-19 Mortality Risk Assessment: Validation of a Two-Step Algorithm from the National COVID Cohort Collaborative.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">jiaf393</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/infdis/jiaf393</ELocationID><Abstract><AbstractText>This study introduces and validates a Two-Step algorithm for assessing COVID-19 mortality risk, leveraging data from over 7 million COVID-19 cases in the National COVID Cohort Collaborative (N3C). The original algorithm stratifies patients into risk categories based on routine clinical metrics and was initially tested across diverse cohorts from multiple institutions, demonstrating strong predictive performance. Further validation of this algorithm on 2.4 million valid N3C COVID-19 records, including a subset of 768,957 with complete data, yielded a C-statistic exceeding 0.85. The algorithm adapts effectively to evolving mortality trends, particularly during the Omicron variant surge. Comparative analyses of full and imputed datasets underscore the algorithm's robustness across varied clinical settings. Our work offers a scalable tool for pandemic management, highlighting the critical role of data-informed approaches in public health.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2025. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site&#x2014;for further information please contact journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Bingnan</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-7131-9428</Identifier><AffiliationInfo><Affiliation>Department of Statistics, University of Georgia, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ke</LastName><ForeName>Yuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Statistics, University of Georgia, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Xianyan</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0002-1806-0883</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology and Statistics, College of Public Health, University of Georgia, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinez</LastName><ForeName>Leonardo</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-0954-8489</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology, School of Public Health, Boston University, Boston, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Ye</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-6662-0048</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology and Statistics, College of Public Health, University of Georgia, Georgia, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Infect Dis</MedlineTA><NlmUniqueID>0413675</NlmUniqueID><ISSNLinking>0022-1899</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Missing Data Imputation</Keyword><Keyword MajorTopicYN="N">Model Validation</Keyword><Keyword MajorTopicYN="N">Mortality Risk Prediction</Keyword><Keyword MajorTopicYN="N">N3C</Keyword><Keyword MajorTopicYN="N">Risk Stratification</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>2</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>27</Day><Hour>1</Hour><Minute>5</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40713725</ArticleId><ArticleId IdType="doi">10.1093/infdis/jiaf393</ArticleId><ArticleId IdType="pii">8214006</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40713715</PMID><DateCompleted><Year>2025</Year><Month>07</Month><Day>27</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1479-5868</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>25</Day></PubDate></JournalIssue><Title>The international journal of behavioral nutrition and physical activity</Title><ISOAbbreviation>Int J Behav Nutr Phys Act</ISOAbbreviation></Journal><ArticleTitle>Effects of a school-based physical activity intervention on children with intellectual disability: a cluster randomized trial.</ArticleTitle><Pagination><StartPage>103</StartPage><MedlinePgn>103</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12966-025-01798-5</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Children living with disability have poorer health outcomes than their typically developing peers. They are less physically active and at increased risk of chronic disease. Teacher-led, whole-of-school physical activity interventions are promising levers for population-level change, but are seldom tested among children with disability. We aimed to evaluate the effect of a blended teacher-professional learning program (online and in-person) on fundamental movement skills (FMS) and physical activity among children with intellectual disability.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this cluster randomized clinical trial, we randomized 20 government-funded primary schools, including 238 consenting students (Grades 2-5; aged 8-11 years at baseline). Ten schools received the blended teacher-professional learning intervention and 10 were assigned as waitlist controls. The professional learning was designed to support teachers as they implemented a whole-of-school intervention designed to enhance FMS and increase physical activity levels. The school-based intervention was mostly online learning, followed by lesson observations and site visits from project staff. Blinded assessors measured FMS competency using the Test of Gross Motor Development-3. Secondary outcomes were self-concept, enjoyment, wellbeing, 300-yard run time, and accelerometer-measured physical activity.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We found no significant group-by-time effects for the primary outcome (FMS competency: b&#x2009;=&#x2009;1.07 [95% CI -3.70, 5.84], p&#x2009;=.658) or any secondary outcomes.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">A school-based intervention did not improve FMS competency or physical activity in children with intellectual disability. Results may be attenuated by the COVID-19 pandemic. Alternatively, low intensity teacher-professional learning interventions may not be enough to improve FMS or physical activity among children with intellectual disability.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">Australian New Zealand Clinical Trials Registry registration number: ACTRN12620000405910, registered: 25/03/2020.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Noetel</LastName><ForeName>Michael</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-6563-8203</Identifier><AffiliationInfo><Affiliation>School of Psychology, the University of Queensland, St Lucia, 4072, Australia. m.noetel@uq.edu.au.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanders</LastName><ForeName>Taren</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-4504-6008</Identifier><AffiliationInfo><Affiliation>Institute for Positive Psychology and Education, Australian Catholic University, North Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tracey</LastName><ForeName>Danielle</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-9590-9812</Identifier><AffiliationInfo><Affiliation>School of Education, Translational Health Research Institute, Western Sydney University, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lubans</LastName><ForeName>David R</ForeName><Initials>DR</Initials><Identifier Source="ORCID">0000-0002-0204-8257</Identifier><AffiliationInfo><Affiliation>Centre for Active Living and Learning, University of Newcastle, Callaghan, Newcastle, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Temple</LastName><ForeName>Viviene A</ForeName><Initials>VA</Initials><Identifier Source="ORCID">0000-0003-2213-1629</Identifier><AffiliationInfo><Affiliation>School of Exercise Science, Physical and Health Education, University of Victoria, Victoria, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennie</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-9151-4821</Identifier><AffiliationInfo><Affiliation>Darug Country, School of Health Sciences, Western Sydney University, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Conigrave</LastName><ForeName>James</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-8816-6229</Identifier><AffiliationInfo><Affiliation>Centre for Alcohol Policy Research, La Trobe University, Bundoora, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Babic</LastName><ForeName>Mark</ForeName><Initials>M</Initials><Identifier Source="ORCID">0009-0002-4635-4405</Identifier><AffiliationInfo><Affiliation>School of Education, College of Human and Social Futures, University of Newcastle, Callaghan, Newcastle, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Booker</LastName><ForeName>Bridget</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-8815-7314</Identifier><AffiliationInfo><Affiliation>School of Psychology, the University of Queensland, St Lucia, 4072, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pagano</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-9305-3184</Identifier><AffiliationInfo><Affiliation>School of Education, Australian Catholic University, Strathfield, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boyer</LastName><ForeName>James</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-0585-4238</Identifier><AffiliationInfo><Affiliation>Department of Education, Turrella, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lonsdale</LastName><ForeName>Chris</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-2523-5565</Identifier><AffiliationInfo><Affiliation>Australian Catholic University, North Sydney, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>PAR006502018</GrantID><Agency>Australian Sports Commission</Agency><Country/></Grant><Grant><GrantID>PAR006502018</GrantID><Agency>Australian Sports Commission</Agency><Country/></Grant><Grant><GrantID>PAR006502018</GrantID><Agency>Australian Sports Commission</Agency><Country/></Grant><Grant><GrantID>PAR006502018</GrantID><Agency>Australian Sports Commission</Agency><Country/></Grant><Grant><GrantID>PAR006502018</GrantID><Agency>Australian Sports Commission</Agency><Country/></Grant><Grant><GrantID>PAR006502018</GrantID><Agency>Australian Sports Commission</Agency><Country/></Grant><Grant><GrantID>PAR006502018</GrantID><Agency>Australian Sports Commission</Agency><Country/></Grant><Grant><GrantID>PAR006502018</GrantID><Agency>Australian Sports Commission</Agency><Country/></Grant><Grant><GrantID>PAR006502018</GrantID><Agency>Australian Sports Commission</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Behav Nutr Phys Act</MedlineTA><NlmUniqueID>101217089</NlmUniqueID><ISSNLinking>1479-5868</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008607" MajorTopicYN="Y">Intellectual Disability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015444" MajorTopicYN="Y">Exercise</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012574" MajorTopicYN="N">Schools</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012572" MajorTopicYN="Y">School Health Services</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006293" MajorTopicYN="Y">Health Promotion</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000070777" MajorTopicYN="N">School Teachers</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Fundamental movement skill</Keyword><Keyword MajorTopicYN="N">Inclusive education</Keyword><Keyword MajorTopicYN="N">Intellectual disability</Keyword><Keyword MajorTopicYN="N">Physical activity</Keyword><Keyword MajorTopicYN="N">Whole-of-school intervention</Keyword></KeywordList><CoiStatement>Declarations. Ethics approval and consent to participate: We received ethical approval from both the Australian Catholic University Human Research Ethics Committee (approval 2019&#x2013;106&#xa0;H) and the NSW Department of Education (State Education Research and Partnerships number 2019289). Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>1</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>27</Day><Hour>1</Hour><Minute>4</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40713715</ArticleId><ArticleId IdType="doi">10.1186/s12966-025-01798-5</ArticleId><ArticleId IdType="pii">10.1186/s12966-025-01798-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Olusanya BO, Kancherla V, Shaheen A, Ogbo FA, Davis AC. Global and regional prevalence of disabilities among children and adolescents: Analysis of findings from global health databases. Front Public Health. 2022 Sep 23 [cited 2025 Mar 10];10:977453. Available from: https://pubmed.ncbi.nlm.nih.gov/36249226/</Citation></Reference><Reference><Citation>Australian Institute of Health and Welfare. People with disability in Australia. Australian Government; 2024 [cited 2025 Mar 11]. Available from: https://www.aihw.gov.au/reports/disability/people-with-disability-in-australia/contents/education-and-skills/engagement-in-education</Citation></Reference><Reference><Citation>Thompson JR, Shogren K, Wehmeyer M. Supports and support needs in strengths-based models of intellectual disability. 2016 Nov 11 [cited 2024 Dec 10];39&#x2013;57. Available from: https://www.taylorfrancis.com/chapters/edit/10.4324/9781315736198-7/supports-support-needs-strengths-based-models-intellectual-disability-james-thompson-karrie-shogren-michael-wehmeyer</Citation></Reference><Reference><Citation>World Health Organisation. World Report on Disability. World Health Organisation. 2011 [cited 2024 Feb 7]. Available from: https://www.who.int/teams/noncommunicable-diseases/sensory-functions-disability-and-rehabilitation/world-report-on-disability</Citation></Reference><Reference><Citation>O&#x2019;Leary L, Cooper SA, Hughes-McCormack L. Early death and causes of death of people with intellectual disabilities: A systematic review. J Appl Res Intellect Disabil. 2018;31(3):325&#x2013;42. Available from: https://doi.org/10.1111/jar.12417</Citation></Reference><Reference><Citation>World Health Organisation. Global report on health equity for persons with disabilities. World Health Organisation; 2022 [cited 2024 Feb 7]. Available from: https://www.who.int/teams/noncommunicable-diseases/sensory-functions-disability-and-rehabilitation/global-report-on-health-equity-for-persons-with-disabilities</Citation></Reference><Reference><Citation>World Health Organisation. WHO guidelines on physical activity and sedentary behaviour. World Health Organisation; 2020 Nov [cited 2024 Feb 7]. Available from: https://www.who.int/publications/i/item/9789240015128</Citation></Reference><Reference><Citation>Aubert S, Barnes JD, Demchenko I, Hawthorne M, Abdeta C, Abi Nader P et al. Global Matrix 4.0 Physical Activity Report Card grades for children and adolescents: Results and analyses from 57 countries. J Phys Act Health. 2022;19(11):700&#x2013;28. Available from: https://doi.org/10.1123/jpah.2022-0456</Citation></Reference><Reference><Citation>Ross SM, Smit E, Yun J, Bogart K, Hatfield B, Logan SW. Updated National Estimates of Disparities in Physical Activity and Sports Participation Experienced by Children and Adolescents With Disabilities: NSCH 2016&#x2013;2017. J Phys Act Health. 2020;17(4):443&#x2013;55. Available from: https://doi.org/10.1123/jpah.2019-0421</Citation></Reference><Reference><Citation>Martin Ginis KA, van der Ploeg HP, Foster C, Lai B, McBride CB, Ng K et al. Participation of people living with disabilities in physical activity: a global perspective. Lancet. 2021;398(10298):443&#x2013;55. Available from: https://doi.org/10.1016/S0140-6736(21)01164-8</Citation></Reference><Reference><Citation>Kapsal NJ, Dicke T, Morin AJS, Vasconcellos D, Ma&#xef;ano C, Lee J et al. Effects of Physical Activity on the Physical and Psychosocial Health of Youth With Intellectual Disabilities: A Systematic Review and Meta-Analysis. J Phys Act Health. 2019;16(12):1187&#x2013;95. Available from: https://doi.org/10.1123/jpah.2018-0675</Citation></Reference><Reference><Citation>World Health Organisation. Promoting physical activity through schools: a toolkit. World Health Organisation; 2021 Dec [cited 2024 Feb 7]. Available from: https://www.who.int/publications/i/item/9789240035928</Citation></Reference><Reference><Citation>McGarty AM, Downs SJ, Melville CA, Harris L. A systematic review and meta-analysis of interventions to increase physical activity in children and adolescents with intellectual disabilities: Effect of interventions on physical activity. J Intellect Disabil Res. 2018;62(4):312&#x2013;29. Available from: https://doi.org/10.1111/jir.12467</Citation></Reference><Reference><Citation>Bloemen M, Van Wely L, Mollema J, Dallmeijer A, de Groot J. Evidence for increasing physical activity in children with physical disabilities: a systematic review. Dev Med Child Neurol. 2017;59(10):1004&#x2013;10. Available from: https://doi.org/10.1111/dmcn.13422</Citation></Reference><Reference><Citation>Hinckson EA, Dickinson A, Water T, Sands M, Penman L. Physical activity, dietary habits and overall health in overweight and obese children and youth with intellectual disability or autism. Res Dev Disabil. 2013;34(4):1170&#x2013;8. Available from: https://doi.org/10.1016/j.ridd.2012.12.006</Citation></Reference><Reference><Citation>Sun Y, Yu S, Wang A, Chan HCK, Ou AX, Zhang D et al. Effectiveness of an adapted physical activity intervention on health-related physical fitness in adolescents with intellectual disability: a randomized controlled trial. Sci Rep. 2022;12(1):22583. Available from: https://doi.org/10.1038/s41598-022-26024-1</Citation></Reference><Reference><Citation>Cohen KE, Morgan PJ, Plotnikoff RC, Callister R, Lubans DR. Physical activity and skills intervention: SCORES cluster randomized controlled trial. Med Sci Sports Exerc. 2015;47(4):765&#x2013;74. Available from: https://doi.org/10.1249/MSS.0000000000000452</Citation></Reference><Reference><Citation>Lonsdale C, Sanders T, Parker P, Noetel M, Hartwig T, Vasconcellos D et al. Effect of a Scalable School-Based Intervention on Cardiorespiratory Fitness in Children: A Cluster Randomized Clinical Trial. JAMA Pediatr. 2021;175(7):680&#x2013;8. Available from: https://doi.org/10.1001/jamapediatrics.2021.0417</Citation></Reference><Reference><Citation>Lubans DR, Sanders T, Noetel M, Parker P, McKay H, Morgan PJ et al. Scale-up of the Internet-based Professional Learning to help teachers promote Activity in Youth (iPLAY) intervention: a hybrid type 3 implementation-effectiveness trial. Int J Behav Nutr Phys Act. 2022;19(1):141. Available from: https://doi.org/10.1186/s12966-022-01371-4</Citation></Reference><Reference><Citation>Syed Yahya SMN, Jamaludin KA, Mazalan NS. Challenges faced by non-optional teachers in physical education: A comprehensive review. Int J Acad Res Progress Educ Dev. 2024;13(1). Available from: https://hrmars.com/papers_submitted/21211/challenges-faced-by-non-optional-teachers-in-physical-education-a-comprehensive-review.pdf</Citation></Reference><Reference><Citation>Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. Implement Sci. 2009;4(1):50. Available from: https://doi.org/10.1186/1748-5908-4-50</Citation></Reference><Reference><Citation>Morgan PJ, Barnett LM, Cliff DP, Okely AD, Scott HA, Cohen KE et al. Fundamental movement skill interventions in youth: a systematic review and meta-analysis. Pediatrics. 2013;132(5):e1361&#x2013;83. Available from: https://doi.org/10.1542/peds.2013-1167</Citation></Reference><Reference><Citation>Cornish K, Fox G, Fyfe T, Koopmans E, Pousette A, Pelletier CA. Understanding physical literacy in the context of health: a rapid scoping review. BMC Public Health. 2020 Oct 19 [cited 2024 May 30];20(1):1&#x2013;19. Available from: https://bmcpublichealth.biomedcentral.com/articles/ https://doi.org/10.1186/s12889-020-09583-8</Citation></Reference><Reference><Citation>Lubans DR, Morgan PJ, Cliff DP, Barnett LM, Okely AD. Fundamental Movement Skills in Children and Adolescents. Sports Med. 2010 Dec 1 [cited 2020 Feb 6];40(12):1019&#x2013;35. Available from: https://link.springer.com/article/ https://doi.org/10.2165/11536850-000000000-00000</Citation></Reference><Reference><Citation>Holfelder B, Schott N. Relationship of fundamental movement skills and physical activity in children and adolescents: A systematic review. Psychol Sport Exerc. 2014;15(4):382&#x2013;91. Available from: http://www.sciencedirect.com/science/article/pii/S1469029214000429</Citation></Reference><Reference><Citation>Oppewal A, Hilgenkamp TIM, van Wijck R, Evenhuis HM. Cardiorespiratory fitness in individuals with intellectual disabilities&#x2013;a review. Res Dev Disabil. 2013;34(10):3301&#x2013;16. Available from: https://doi.org/10.1016/j.ridd.2013.07.005</Citation></Reference><Reference><Citation>Ma&#xef;ano C, Hue O, April J. Fundamental movement skills in children and adolescents with intellectual disabilities: A systematic review. J Appl Res Intellect Disabil. 2019; Available from: https://doi.org/10.1111/jar.12606</Citation></Reference><Reference><Citation>McDermott MM, Newman AB. Preserving Clinical Trial Integrity During the Coronavirus Pandemic. JAMA. 2020;323(21):2135. Available from: https://jamanetwork.com/journals/jama/fullarticle/2763819</Citation></Reference><Reference><Citation>Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39(2):175&#x2013;91. Available from: https://www.ncbi.nlm.nih.gov/pubmed/17695343</Citation></Reference><Reference><Citation>Bland JM. Cluster randomised trials in the medical literature: two bibliometric surveys. BMC Med Res Methodol. 2004;4:21. Available from: https://doi.org/10.1186/1471-2288-4-21</Citation></Reference><Reference><Citation>Moore RT, Schnakenberg K, Block. Assign, and Diagnose Potential Interference in Randomized Experiments. 2016. Available from: https://cran.r-project.org/web/packages/blockTools/blockTools.pdf</Citation></Reference><Reference><Citation>Noetel M, Lonsdale C, Australian New Zealand Clinical Trials Registry. 2020. Internet-Based Professional Learning to Help Teachers Promote Activity in Youth with Intellectual Disability. The iPLAY For Inclusion Project: iPLAY4i. Available from: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=379417&amp;isReview=true</Citation></Reference><Reference><Citation>Lonsdale C, Sanders T, Cohen KE, Parker P, Noetel M, Hartwig T et al. Scaling-up an efficacious school-based physical activity intervention: Study protocol for the Internet-based Professional Learning to help teachers support Activity in Youth (iPLAY) cluster randomized controlled trial and scale-up implementation evaluation. BMC Public Health. 2016;16(1):873. Available from: https://doi.org/10.1186/s12889-016-3243-2</Citation></Reference><Reference><Citation>MacDonald A, McGill P. Outcomes of Staff Training in Positive Behaviour Support: A Systematic Review. J Dev Phys Disabil. 2013;25(1):17&#x2013;33. Available from: https://doi.org/10.1007/s10882-012-9327-8</Citation></Reference><Reference><Citation>Ok MW, Rao K, Bryant BR, McDougall D. Universal Design for Learning in Pre-K to Grade 12 Classrooms: A Systematic Review of Research. Exceptionality. 2017;25(2):116&#x2013;38. Available from: https://doi.org/10.1080/09362835.2016.1196450</Citation></Reference><Reference><Citation>Australian Sports Commission. Sports Ability. 2019 [cited 2024 May 28]. Using TREE. Available from: https://www.sportaus.gov.au/sports_ability/using_tree</Citation></Reference><Reference><Citation>Lubans DR, Lonsdale C, Cohen K, Eather N, Beauchamp MR, Morgan PJ et al. Framework for the design and delivery of organized physical activity sessions for children and adolescents: rationale and description of the `SAAFE&#x2019; teaching principles. Int J Behav Nutr Phys Act. 2017;14(1):24. Available from: https://doi.org/10.1186/s12966-017-0479-x</Citation></Reference><Reference><Citation>Webster EK, Ulrich DA. Evaluation of the psychometric properties of the Test of Gross Motor Development&#x2014;third edition. Journal of Motor Learning and Development. 2017;5(1):45&#x2013;58. Available from: https://journals.humankinetics.com/view/journals/jmld/5/1/article-p45.xml</Citation></Reference><Reference><Citation>Allen KA, Bredero B, Van Damme T, Ulrich DA, Simons J. Test of Gross Motor Development-3 (TGMD-3) with the Use of Visual Supports for Children with Autism Spectrum Disorder: Validity and Reliability. J Autism Dev Disord. 2017;47(3):813&#x2013;33. Available from: https://doi.org/10.1007/s10803-016-3005-0</Citation></Reference><Reference><Citation>Simons J, Eyitayo G. Aspects of reliability and validity of the TGMD-3 in 7&#x2013;10 year old children with intellectual disability in Belgium. European Psychomotricity Journal. 2016;8(1):3&#x2013;16. Available from: https://lirias.kuleuven.be/1689672?limo=0</Citation></Reference><Reference><Citation>Magistro D, Piumatti G, Carlevaro F, Sherar LB, Esliger DW, Bardaglio G et al. Measurement invariance of TGMD-3 in children with and without mental and behavioral disorders. Psychol Assess. 2018;30(11):1421&#x2013;9. Available from: https://doi.org/10.1037/pas0000587</Citation></Reference><Reference><Citation>Simons J, Daly D, Theodorou F, Caron C, Simons J, Andoniadou E. Validity and reliability of the TGMD-2 in 7-10-year-old Flemish children with intellectual disability. Adapt Phys Activ Q. 2008;25(1):71&#x2013;82. Available from: https://doi.org/10.1123/apaq.25.1.71</Citation></Reference><Reference><Citation>Baumgartner T, Horvat M. Reliability of Field Based Cardiovascular Fitness Running Tests for Individuals with Mental Retardation. Adapt Phys Activ Q. 1991 Apr 1 [cited 2019 Dec 17];8(2):107&#x2013;14. Available from: https://journals.humankinetics.com/view/journals/apaq/8/2/article-p107.xml</Citation></Reference><Reference><Citation>Aufsesser PM. Effects of repeated testing on the reliability of fitness scores of institutionalized mentally retarded individuals. Am J Ment Defic. 1979;84(3):313&#x2013;5. Available from: https://www.ncbi.nlm.nih.gov/pubmed/525662</Citation></Reference><Reference><Citation>Leung W, Siebert EA, Yun J. Measuring physical activity with accelerometers for individuals with intellectual disability: A systematic review. Res Dev Disabil. 2017;67:60&#x2013;70. Available from: https://doi.org/10.1016/j.ridd.2017.06.001</Citation></Reference><Reference><Citation>van Hees V, Migueles J, Fang Z, Zhao J, Heywood J, Mirkes E et al. GGIR: Raw Accelerometer Data Analysis. 2020. Available from: https://CRAN.R-project.org/package=GGIR</Citation></Reference><Reference><Citation>Hurter L, Fairclough SJ, Knowles ZR, Porcellato LA, Cooper-Ryan AM, Boddy LM. Establishing raw acceleration thresholds to classify sedentary and stationary behaviour in children. Children (Basel). 2018;5(12). Available from: https://doi.org/10.3390/children5120172</Citation></Reference><Reference><Citation>Hildebrand M, VAN Hees VT, Hansen BH, Ekelund U. Age group comparability of raw accelerometer output from wrist- and hip-worn monitors. Med Sci Sports Exerc. 2014;46(9):1816&#x2013;24. Available from: https://doi.org/10.1249/MSS.0000000000000289</Citation></Reference><Reference><Citation>Motl RW, Dishman RK, Saunders R, Dowda M, Felton G, Pate RR. Measuring enjoyment of physical activity in adolescent girls. Am J Prev Med. 2001;21(2):110&#x2013;7. Available from: https://doi.org/10.1016/s0749-3797(01)00326-9</Citation></Reference><Reference><Citation>Tracey DK, Marsh HW. Self-concepts of primary students with mild intellectual disabilities: Issues of measurement and educational placement. Self-concept theory, research and practice: Advances for the new millennium. 2000;419. Available from: http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.195.6552_rep=rep1_type=pdf#page=427</Citation></Reference><Reference><Citation>Marsh HW, Ellis LA, Parada RH, Richards G, Heubeck BG. A short version of the Self Description Questionnaire II: operationalizing criteria for short-form evaluation with new applications of confirmatory factor analyses. Psychol Assess. 2005;17(1):81&#x2013;102. Available from: https://doi.org/10.1037/1040-3590.17.1.81</Citation></Reference><Reference><Citation>Cheung F, Lucas RE. Assessing the validity of single-item life satisfaction measures: results from three large samples. Qual Life Res. 2014;23(10):2809&#x2013;18. Available from: https://doi.org/10.1007/s11136-014-0726-4</Citation></Reference><Reference><Citation>R Core Team. R: A language and environment for statistical computing, Vienna. Austria: R Foundation for Statistical Computing; 2024. Available from: https://www.R-project.org/</Citation></Reference><Reference><Citation>Twisk JW, Rijnhart JJ, Hoekstra T, Schuster NA, Ter Wee MM, Heymans MW. Intention-to-treat analysis when only a baseline value is available. Contemp Clin Trials Commun. 2020;20(100684):100684. Available from: https://www.sciencedirect.com/science/article/pii/S245186542030168X</Citation></Reference><Reference><Citation>van Buuren S, Groothuis-Oudshoorn K. mice: Multivariate Imputation by Chained Equations in R. J Stat Softw. 2011;45(3):1&#x2013;67. Available from: https://doi.org/10.18637/jss.v045.i03</Citation></Reference><Reference><Citation>Bates D, M&#xe4;chler M, Bolker B, Walker S. Fitting Linear Mixed-Effects Models Using lme4. Journal of Statistical Software, Articles. 2015;67(1):1&#x2013;48. Available from: https://www.jstatsoft.org/v067/i01</Citation></Reference><Reference><Citation>Hartwig TB, Sanders T, Vasconcellos D, Noetel M, Parker PD, Lubans DR et al. School-based interventions modestly increase physical activity and cardiorespiratory fitness but are least effective for youth who need them most: an individual participant pooled analysis of 20 controlled trials. Br J Sports Med. 2021; Available from: https://doi.org/10.1136/bjsports-2020-102740</Citation></Reference><Reference><Citation>Clark S, Parliment of A. 2022 [cited 2024 May 8]. COVID-19: chronology of state and territory announcements on schools and early childhood education in 2020. Available from: https://www.aph.gov.au/About_Parliament/Parliamentary_Departments/Parliamentary_Library/pubs/rp/rp2122/Chronologies/COVID-19-StateTerritoryAnnouncementsSchoolsEducation</Citation></Reference><Reference><Citation>Zhang D, Soh KG, Chan YM, Zaremohzzabieh Z. Effect of intervention programs to promote fundamental motor skills among typically developing children: A systematic review and meta-analysis. Child Youth Serv Rev. 2024;156(107320):107320. Available from: https://www.sciencedirect.com/science/article/pii/S0190740923005169</Citation></Reference><Reference><Citation>Zarei H, Norasteh AA, Dehghani N, Lieberman LJ, Ertel MW, Brian A. Effects of exercise training programs on motor skills of individuals with intellectual disabilities: a systematic review and meta-analysis. Disabil Rehabil. 2024;46(25):6001&#x2013;10. Available from: https://doi.org/10.1080/09638288.2024.2318486</Citation></Reference><Reference><Citation>Kilbourne AM, Neumann MS, Pincus HA, Bauer MS, Stall R. Implementing evidence-based interventions in health care: application of the replicating effective programs framework. Implement Sci. 2007;2(1):42. Available from: https://doi.org/10.1186/1748-5908-2-42</Citation></Reference><Reference><Citation>Lee J, Sanders T, Antczak D, Parker R, Noetel M, Parker P et al. Influences on user engagement in online professional learning: A narrative synthesis and meta-analysis. Rev Educ Res. 2021;0034654321997918. Available from: https://doi.org/10.3102/0034654321997918</Citation></Reference><Reference><Citation>Shields N, Synnot AJ, Barr M. Perceived barriers and facilitators to physical activity for children with disability: a systematic review. Br J Sports Med. 2012;46(14):989&#x2013;97. Available from: https://doi.org/10.1136/bjsports-2011-090236</Citation></Reference><Reference><Citation>Kable TJ, Leahy AA, Smith JJ, Eather N, Shields N, Noetel M et al. Time-efficient physical activity intervention for older adolescents with disability: rationale and study protocol for the Burn 2 Learn adapted (B2La) cluster randomised controlled trial. BMJ Open. 2022;12(8):e065321. Available from: https://doi.org/10.1136/bmjopen-2022-065321</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40713638</PMID><DateCompleted><Year>2025</Year><Month>07</Month><Day>27</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1756-0500</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>25</Day></PubDate></JournalIssue><Title>BMC research notes</Title><ISOAbbreviation>BMC Res Notes</ISOAbbreviation></Journal><ArticleTitle>General happiness index of a repeated cross-sectional survey among the general population from 2018 to 2024 in Hong Kong: A data note.</ArticleTitle><Pagination><StartPage>323</StartPage><MedlinePgn>323</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13104-025-07399-6</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The General Happiness Index is a vital indicator for reflecting the mental wellbeing of the community and monitoring the changes and trends in various factors that contribute to the index. This data was collected through a repeated cross-sectional survey from 2018 to 2024, which was deemed valuable because of its comprehensive record of the changes of the mental wellbeing of the general population in response to different traumatic events. Such data provided possibilities for policymakers, health and social care researchers and the Government to investigate the impact of those traumatic events and associated salient predictors on mental wellbeing.</AbstractText><AbstractText Label="DATA DESCRIPTION" NlmCategory="METHODS">The dataset encompassed 10,070 responses from the public between 2018 and 2024, who have been through several major sociopolitical and pandemic-related events in Hong Kong, namely social unrest in 2019, five waves of COVID-19 outbreaks from 2020 to 2022, and post-pandemic psychosocial issues in 2023 and 2024. The questionnaires comprised the demographics, individual happiness, the 4-item LIFE mental capital scale, personal values, social well-being, satisfaction with external environmental factors, physical and mental health status, and depressive symptoms. Data was collected through online and/or in-person interviews, subject to social conditions and infectious disease outbreaks. Data verification was performed, and additional computations (i.e., mean of mental capital and satisfaction with external environmental factors) were added to enhance interpretability.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Lam</LastName><ForeName>Simon Ching</ForeName><Initials>SC</Initials><Identifier Source="ORCID">0000-0002-2982-9192</Identifier><AffiliationInfo><Affiliation>School of Nursing, Tung Wah College, 31 Wylie Road, Homantin, Kowloon, Hong Kong SAR, China. simonlam@twc.edu.hk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Translational Research Centre for Digital Mental Health, Tung Wah College, 31 Wylie Road, Homantin, Kowloon, Hong Kong SAR, China. simonlam@twc.edu.hk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Chan</LastName><ForeName>Shun</ForeName><Initials>S</Initials><Identifier Source="ORCID">0009-0009-1536-250X</Identifier><AffiliationInfo><Affiliation>School of Nursing, Tung Wah College, 31 Wylie Road, Homantin, Kowloon, Hong Kong SAR, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsui</LastName><ForeName>Kwai Yu</ForeName><Initials>KY</Initials><Identifier Source="ORCID">0000-0001-5368-1901</Identifier><AffiliationInfo><Affiliation>School of Nursing, Tung Wah College, 31 Wylie Road, Homantin, Kowloon, Hong Kong SAR, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Odetayo</LastName><ForeName>Aderonke</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-8509-0460</Identifier><AffiliationInfo><Affiliation>School of Nursing, Tung Wah College, 31 Wylie Road, Homantin, Kowloon, Hong Kong SAR, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>ZH3U</GrantID><Agency>Wofoo Social Enterprise</Agency><Country/></Grant><Grant><GrantID>WOFOO21041</GrantID><Agency>Wofoo Foundation Limited</Agency><Country/></Grant><Grant><GrantID>WOFOO21041</GrantID><Agency>Research Grants Council, University Grants Committee</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Res Notes</MedlineTA><NlmUniqueID>101462768</NlmUniqueID><ISSNLinking>1756-0500</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006240" MajorTopicYN="Y">Happiness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006723" MajorTopicYN="N" Type="Geographic">Hong Kong</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008603" MajorTopicYN="Y">Mental Health</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010549" MajorTopicYN="N">Personal Satisfaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Community Mental Health</Keyword><Keyword MajorTopicYN="N">Cross-Sectional</Keyword><Keyword MajorTopicYN="N">Depression</Keyword><Keyword MajorTopicYN="N">General happiness index</Keyword><Keyword MajorTopicYN="N">Happiness</Keyword><Keyword MajorTopicYN="N">Public Health</Keyword><Keyword MajorTopicYN="N">Survey</Keyword></KeywordList><CoiStatement>Declarations. Ethics approval and consent to participate: This study was conducted in accordance with the principles outlined in the Helsinki Declaration. Ethical approval for the research involving human participants was obtained from the Ethics Sub-committee of the Hong Kong Polytechnic University (ref: HSEARS20201002002) and the Ethical Committee of Tung Wah College (ref: REC2022124). All participants provided informed consent prior to their inclusion in the study. The procedures followed ensured adherence to ethical standards, and participants were informed of their rights, including the right to withdraw from the study at any time without any consequences. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>4</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>27</Day><Hour>1</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40713638</ArticleId><ArticleId IdType="doi">10.1186/s13104-025-07399-6</ArticleId><ArticleId IdType="pii">10.1186/s13104-025-07399-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Helliwell JF, Layard R, Sachs JD, De Neve JE, Aknin LB, Wang S. World happiness report 2024. University of Oxford: Wellbeing Research Centre; 2024.</Citation></Reference><Reference><Citation>Waldinger R, Schulz M. The good life: lessons from the world&#x2019;s longest scientific study of happiness. Simon &amp; Schuster; 2023.</Citation></Reference><Reference><Citation>Exton C, Smith C, Vandendriessche D. Comparing happiness across the world: Does culture matter? [Internet]. OECD Statistics Working Papers, No. 2015/04. Paris: OECD Publishing; 2015 [cited 2025 Feb 12]. https://doi.org/10.1787/5jrqppzd9bs2-en</Citation></Reference><Reference><Citation>Oishi S, Graham J, Kesebir S, Galinha IC. Concepts of happiness across time and cultures. Pers Soc Psychol Bull. 2013;39(5):559&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">23599280</ArticleId></ArticleIdList></Reference><Reference><Citation>Baselmans BML, Bartels M. A genetic perspective on the relationship between Eudaimonic&#x2013;and hedonic well-being. Sci Rep. 2018;8(1):14610.</Citation><ArticleIdList><ArticleId IdType="pubmed">30279531</ArticleId><ArticleId IdType="pmc">6168466</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartels M, Boomsma DI. Born to be happy? The etiology of subjective well-being. Behav Genet. 2009;39(6):605&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">19728071</ArticleId><ArticleId IdType="pmc">2780680</ArticleId></ArticleIdList></Reference><Reference><Citation>Ni MY, Yao XI, Leung KSM, Yau C, Leung CMC, Lun P, et al. Depression and post-traumatic stress during major social unrest in Hong kong: a 10-year prospective cohort study. Lancet. 2020;395(10220):273&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">31928765</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung PHH, Chan CP, Jin DY. Lessons learned from the fifth wave of COVID-19 in Hong Kong in early 2022. Emerg Microbes Infections. 2022;11(1):1072&#x2013;8.</Citation></Reference><Reference><Citation>Flaskerud JH. Post-pandemic psychosocial issues. Issues Ment Health Nurs. 2023;44(2):130&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">35666683</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong B. 2024 Hong Kong General Happiness Index [Internet]. Wofoo Social Enterprise. 2024 [cited 2025 Feb 9]. Available from: https://wse.hk/news-room/2024-hong-kong-general-happiness-index/</Citation></Reference><Reference><Citation>Chen F. Over half of Hongkongers experience depression, highest level in 7 years: survey [Internet]. South China Morning Post. 2024 [cited 2025 Feb 12]. Available from: https://www.scmp.com/news/hong-kong/article/3291403/over-half-hongkongers-experience-depression-highest-level-7-years-survey</Citation></Reference><Reference><Citation>Choy G. Hong Kong happiness declines amid alarming mental health issues: survey [Internet]. South China Morning Post. 2019 [cited 2025 Feb 9]. Available from: https://www.scmp.com/news/hong-kong/health-environment/article/3032430/hong-kong-happiness-declines-survey-shows-quality</Citation></Reference><Reference><Citation>Lau A. Happiness falls to lowest level in 7 years - survey [Internet]. The Standard. 2024 [cited 2025 Feb 9]. Available from: https://www.thestandard.com.hk/section-news/section/47365910/268740/Happiness-falls-to-lowest-level-in-7-years---survey</Citation></Reference><Reference><Citation>Ho LS. The psychology and economics of happiness: love, life and positive living. 1st ed. Routledge; 2014.</Citation></Reference><Reference><Citation>Keyes CLM. Social well-being. Social Psychol Q. 1998;61(2):121&#x2013;40.</Citation></Reference><Reference><Citation>Kroenke K, Spitzer RL, Williams JBW. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">11556941</ArticleId><ArticleId IdType="pmc">1495268</ArticleId></ArticleIdList></Reference><Reference><Citation>Wofoo Social Enterprise. Happiness Index [Internet]. HK.WeCare. 2025 [cited 2025 Feb 12]. Available from: https://www.hkwecare.hk/happiness_index/</Citation></Reference><Reference><Citation>Raudensk&#xe1; P. Single-item measures of happiness and life satisfaction: the issue of cross-country invariance of popular general well-being measures. Humanit Social Sci Commun. 2023;10(1):1&#x2013;18.</Citation></Reference><Reference><Citation>Abdel-Khalek AM. Measuring happiness with a single-item scale. Social Behav Personality. 2006;34(2):139&#x2013;50.</Citation></Reference><Reference><Citation>Odetayo A, Shek DTL, Ho KHM, Cheung DSK, Siu SCN, Cheung J, et al. Predictors of family happiness in the COVID-19 pandemic: a cross-sectional study in Hong Kong. Applied Research in Quality of Life. 2025;20:833&#x2013;50.</Citation></Reference><Reference><Citation>Cheung F, Lucas RE. Assessing the validity of single-item life satisfaction measures: results from three large samples. Qual Life Res. 2014;23(10):2809&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">24890827</ArticleId><ArticleId IdType="pmc">4221492</ArticleId></ArticleIdList></Reference><Reference><Citation>Seligman M. PERMA and the Building blocks of well-being. J Posit Psychol. 2018;13(4):333&#x2013;5.</Citation></Reference><Reference><Citation>Nie YZ, Zhang X, Hong NW, Zhou C, Huang QQ, Cao SY, et al. Psychometric validation of the PERMA-profiler for well-being in Chinese adults. Acta Psychol. 2024;246:104248.</Citation></Reference><Reference><Citation>Wong MMC, Ma JLC, Wan PS, Xia LL, Fok MHT. The development and validation of a family wellbeing index for Hong Kong Chinese families. J Child Fam Stud. 2022;31:1683&#x2013;97.</Citation></Reference><Reference><Citation>Ho LS, Su JJ, Chong ACY, Cheung DSK, Ho KHM, Siu SCN et al. Validation of the love, insight, fortitude, and engagement (LIFE) scale in measuring mental capital for happiness in the Chinese community. BMC Psychol. 2025.</Citation></Reference><Reference><Citation>Li M, Yang D, Ding C, Kong F. Validation of the social well-being scale in a Chinese sample and invariance across gender. Soc Indic Res. 2014;121(2):607&#x2013;18.</Citation></Reference><Reference><Citation>Sun Y, Fu Z, Bo Q, Mao Z, Ma X, Wang C. The reliability and validity of PHQ-9 in patients with major depressive disorder in psychiatric hospital. BMC Psychiatry. 2020;20:474.</Citation><ArticleIdList><ArticleId IdType="pubmed">32993604</ArticleId><ArticleId IdType="pmc">7525967</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu X, Tam WWS, Wong PTK, Lam TH, Stewart SM. The patient health Questionnaire-9 for measuring depressive symptoms among the general population in Hong Kong. Compr Psychiatr. 2012;53(1):95&#x2013;102.</Citation></Reference><Reference><Citation>Chan S, Odetayo A, Tsui KY, Lam SC. General happiness index from 2018 to 2024 in Hong Kong SAR: dataset of repeated cross-sectional surveys. Mendeley Data. 2024. https://doi.org/10.17632/czxznncsv2.3 . V3.</Citation><ArticleIdList><ArticleId IdType="doi">10.17632/czxznncsv2.3</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">40713604</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1472-6963</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>26</Day></PubDate></JournalIssue><Title>BMC health services research</Title><ISOAbbreviation>BMC Health Serv Res</ISOAbbreviation></Journal><ArticleTitle>Challenges in delivering urban healthcare services during COVID-19 pandemic: a mixed-methods study in Ahmedabad, India.</ArticleTitle><Pagination><StartPage>979</StartPage><MedlinePgn>979</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12913-025-13147-0</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yasobant</LastName><ForeName>Sandul</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Public Health Science, Indian Institute of Public Health Gandhinagar (IIPHG), Gujarat, India. yasobant@iiphg.org.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for One Health Education, Research &amp; Development (COHERD), Indian Institute of Public Health Gandhinagar (IIPHG), Opp. Air Force Head Quarters, Nr. Lekawada, Gandhinagar, Gujarat, India. yasobant@iiphg.org.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Global Health, Institute for Hygiene &amp; Public Health, University Hospital Bonn, Bonn, Germany. yasobant@iiphg.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Krupali</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Jindal School of Public Health and Human Development, O.P. Jindal Global University, Sonipat, Haryana, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tadvi</LastName><ForeName>Ravina</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Centre for One Health Education, Research &amp; Development (COHERD), Indian Institute of Public Health Gandhinagar (IIPHG), Opp. Air Force Head Quarters, Nr. Lekawada, Gandhinagar, Gujarat, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thacker</LastName><ForeName>Hardi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Centre for One Health Education, Research &amp; Development (COHERD), Indian Institute of Public Health Gandhinagar (IIPHG), Opp. Air Force Head Quarters, Nr. Lekawada, Gandhinagar, Gujarat, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bruchhausen</LastName><ForeName>Walter</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Global Health, Institute for Hygiene &amp; Public Health, University Hospital Bonn, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saxena</LastName><ForeName>Deepak</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Public Health Science, Indian Institute of Public Health Gandhinagar (IIPHG), Gujarat, India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for One Health Education, Research &amp; Development (COHERD), Indian Institute of Public Health Gandhinagar (IIPHG), Opp. Air Force Head Quarters, Nr. Lekawada, Gandhinagar, Gujarat, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Health Serv Res</MedlineTA><NlmUniqueID>101088677</NlmUniqueID><ISSNLinking>1472-6963</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Community health workers</Keyword><Keyword MajorTopicYN="N">Community-based routine healthcare services</Keyword><Keyword MajorTopicYN="N">Pandemic preparedness</Keyword><Keyword MajorTopicYN="N">Urban health</Keyword></KeywordList><CoiStatement>Declarations. Ethics approval and consent to participate: Ethics approval for this study was obtained from the Indian Institute of Public Health Gandhinagar - Institutional Ethics Committee (TRC/2021022/17). Written consent was taken from each participant before the data collection. The identifiers in the data set were masked for confidentiality. Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>8</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>27</Day><Hour>0</Hour><Minute>59</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40713604</ArticleId><ArticleId IdType="doi">10.1186/s12913-025-13147-0</ArticleId><ArticleId IdType="pii">10.1186/s12913-025-13147-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization. (2020). Pulse survey on continuity of essential health services during the COVID-19 pandemic: interim report, 27 August 2020. https://www.who.int/publications/i/item/WHO-2019-nCoV-EHS_continuity-survey-2020.1</Citation></Reference><Reference><Citation>Scarpetta S, Dumont J-C, Socha-Dietrich K. Contribution of migrant doctors and nurses to tackling COVID-19 crisis in OECD countries. Tackling coronavirus (COVID-19). 2020:1&#x2013;10.</Citation></Reference><Reference><Citation>World Health Organization. Community-based health care, including outreach and campaigns, in the context of the COVID-19 pandemic. World Health Organization (WHO); 2020. May:3.</Citation></Reference><Reference><Citation>Can We Co-Opt the Fight Against COVID-19 With That of Tuberculosis?&#x2013; The Wire Science. Science The Wire. 2020. https://science.thewire.in/health/covid-19-tuberculosis-cases/ . Accessed 19 Jun 2025.</Citation></Reference><Reference><Citation>Paul P, Mondal D. Maternal and child healthcare in India during COVID-19 pandemic. Midwifery. 2021;92:102865.</Citation></Reference><Reference><Citation>Khatiwada AP, Shrestha N, Shrestha S. Will covid-19 lead to a resurgence of vaccine-preventable diseases? Infect Drug Resist. 2021;14:119&#x2013;24.</Citation></Reference><Reference><Citation>Akseer N, Kandru G, Keats EC, Bhutta ZA. COVID-19 pandemic and mitigation strategies: implications for maternal and child health and nutrition. Am J Clin Nutr. 2020;112:251&#x2013;6.</Citation></Reference><Reference><Citation>Dorji T. The gross National happiness framework and the health system response to the COVID-19 pandemic in Bhutan. Am J Trop Med Hyg. 2020;104:441&#x2013;5.</Citation></Reference><Reference><Citation>Chanda-Kapata P, Ntoumi F, Kapata N, Lungu P, Mucheleng&#x2019;anga LA, Chakaya J, et al. Tuberculosis, HIV/AIDS and malaria health services in sub-Saharan Africa - A situation analysis of the disruptions and impact of the COVID-19 pandemic. Int J Infect Dis. 2022. https://doi.org/10.1016/J.IJID.2022.03.033 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.IJID.2022.03.033</ArticleId></ArticleIdList></Reference><Reference><Citation>Jahan Y, Rahman A. COVID-19: challenges and viewpoints from low-and-middle-income Asian countries perspectives. J Saf Sci Resil. 2020;1:70&#x2013;2.</Citation></Reference><Reference><Citation>World Health Organization. Multisectoral preparedness coordination framework. 2020.</Citation></Reference><Reference><Citation>Takemoto MLS, McKay G, Amorim M, Gbomosa CN, Tengbeh AF, Wenham C. How can countries create outbreak response policies that are sensitive to maternal health? BMJ. 2021;373. https://doi.org/10.1136/BMJ.N1271 .</Citation></Reference><Reference><Citation>OMS. Relat&#xf3;rio de situa&#xe7;&#xe3;o do novo coronav&#xed;rus. Boi da OMS. 2020; January:8. Available at: https://bvsms.saude.gov.br/bvs/publicacoes/saude_brasil_2020-2021_analise_pandemia_covid-19.pdf . Accessed on July 2025.</Citation></Reference><Reference><Citation>Primary Health Care Performance Initiative. Maintaining Access to Routine and Essential Services. Available at: https://www.improvingphc.org/maintaining-access-routine-and-essential-services . Accessed on July 2025.</Citation></Reference><Reference><Citation>Ministry of Health &amp; Family Welfare, Govt. of India. AyushmaN Bharat: Comprehensive Primary Health Care through Health and Wellness Centers Operational Guidelines. 2017. Available at: https://www.nhm.gov.in/New_Updates_2018/NHM_Components/Health_System_Stregthening/Comprehensive_primary_health_care/letter/Operational_Guidelines_For_CPHC.pdf .</Citation></Reference><Reference><Citation>Kruk ME, Gage AD, Arsenault C, Jordan K, Leslie HH, Roder-DeWan S, et al. High-quality health systems in the sustainable development goals era: time for a revolution. Lancet Glob Health. 2018;6:e1196&#x2013;252.</Citation></Reference><Reference><Citation>Bisht R, Saharia R, Sarma J. COVID-19 and the burden of ill-health: a double crisis of disruptions and inequalities. J Soc Econ Dev. 2020;23(Suppl 2):342&#x2013;56.</Citation></Reference><Reference><Citation>Babalola OJ, Sesay HW, Blebo LS, Whesseh FK, Umeokonkwo CD, Adewuyi PA, et al. The influence of first wave of COVID-19 outbreak on routine healthcare services, liberia, August 2020: a mixed study approach. BMC Health Serv Res. 2022;22:684.</Citation></Reference><Reference><Citation>Kundapur R, Rashmi A, Velamala S, Aggarwal S, Shringarpure K, Gaitonde R, et al. Assessment of challenges and opportunities and identification of approaches and innovations in COVID-19 pandemic management by different States in india: A qualitative approach. J Epidemiol Glob Health. 2022;12:74&#x2013;84.</Citation></Reference><Reference><Citation>Tune SNBK, Islam BZ, Islam MR, Tasnim Z, Ahmed SM. Exploring the knowledge, attitudes, practices and lived experiences of frontline health workers in the times of COVID-19: A qualitative study from Bangladesh. BMJ Open. 2022;12:e051893.</Citation></Reference><Reference><Citation>Dhillon PK, Das S. Psychological resilience of frontline healthcare workers in india: A Mixed-Methods exploratory study during COVID-19 pandemic in India. Prev Medicine: Res Reviews. 2024;1:121&#x2013;4.</Citation></Reference><Reference><Citation>Revadi G, Baravakar J, Kumar A, Joshi A, Pakhare AP. Development of a tool for the assessment of job satisfaction amongst the community health workers. Preventive Medicine: Research &amp; Reviews; 2024. https://doi.org/10.4103/PMRR.PMRR_50_24 .</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/PMRR.PMRR_50_24</ArticleId></ArticleIdList></Reference><Reference><Citation>Laufs J, Waseem Z. Policing in pandemics: A systematic review and best practices for Police response to COVID-19. Int J Disaster Risk Reduct. 2020;51:101812.</Citation></Reference><Reference><Citation>.Pujolar G, Oliver-Angl&#xe8;s A, Vargas I, V&#xe1;zquez ML. Changes in Access to Health Services during the COVID-19 Pandemic: A Scoping Review. Int J Environ Res Public Health. 2022;19(3):1749. https://doi.org/10.3390/ijerph19031749 . PMID: 35162772; PMCID: PMC8834942.</Citation></Reference><Reference><Citation>Ali AA, Usman AM, Badebo FB, Tilahun SH. Exploring the patterns of multisectoral approach infighting COVID-19 Pandemic in SNNPR, Ethiopia: A qualitative case studyapproach. PLoS One. 2022;17:e0263667.</Citation></Reference><Reference><Citation>Causey K, Fullman N, Sorensen RJD, Galles NC, Zheng P, Aravkin A, et al. Estimating global andregional disruptions to routine childhood vaccine coverage during the COVID-19pandemic in 2020: a modelling study. Lancet. 2021;398:522&#x2013;34.</Citation></Reference><Reference><Citation>Gopalan HS, Misra A. COVID-19 pandemic and challenges for socio-economic issues, healthcare and National Health Programs in India. Diab Metabol Syndr Clin Res Rev. 2020 14:757&#x2013;9.</Citation></Reference><Reference><Citation>Olaniran A, Madaj B, Bar-Zev S, Van Den Broek N. The roles of community health workers who providematernal and newborn health services: case studies from Africa and Asia. BMJGlob Health. 2019;4:e001388.</Citation></Reference><Reference><Citation>Ferrinho P, Sidat M, Goma F, Dussault G. Task-shifting: experiences and opinions of health workers in Mozambique and Zambia. Hum Resour Health. 2012 10;34.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40713550</PMID><DateCompleted><Year>2025</Year><Month>07</Month><Day>27</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1478-4505</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>25</Day></PubDate></JournalIssue><Title>Health research policy and systems</Title><ISOAbbreviation>Health Res Policy Syst</ISOAbbreviation></Journal><ArticleTitle>Health research versus the virus: strengthening systems, saving lives.</ArticleTitle><Pagination><StartPage>95</StartPage><MedlinePgn>95</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12961-025-01354-4</ELocationID><Abstract><AbstractText>For this Commentary, we selected papers from those in this journal's Thematic Series on health research systems' pandemic response. The calling notice for papers suggested possible use of a WHO framework for analysing health research systems (HRSs). Whilst it was not widely used in the reported studies, it did provide the basis for the two main, overlapping, topics for analysis in this Commentary. These, in turn, informed the selection criteria for papers. First, we selected papers that described the contributions made towards meeting the needs for pandemic-related research in at least one area we could classify as being one of the nine components of a HRS, and did so in at least one jurisdiction. Second, we identified papers that could contribute to an analysis of how comprehensive HRSs facilitated progress in meeting the needs for pandemic-related research.Using the selection criteria, we included 13 papers in the Commentary covering research in 22 named countries, and many others unnamed. For the first topic, we found that for each of the nine components, we could identify at least two of the included papers, usually more, as having in some ways analysed the contributions made towards meeting the needs for pandemic-related research. Examples included, for coordination, the first HRS component, a paper describing a pandemic preparedness program in Australia. For other HRS components, some papers analysed prioritization systems in the United Kingdom and Iran, and another, research ethics governance across Central American countries. For the finance component, a US paper covered Operation Warp Speed's substantial funding. Papers showed existing capacity for conducting trials contributed to rapid progress on new drugs and vaccines in Brazil, the United Kingdom and the United States. Included papers showed how capacity was mobilized for knowledge production and how evidence, often locally produced, was used in many countries across the income range. Papers cited studies showing pandemic research had saved millions of lives through vaccines and repurposed drugs. For the second topic, evidence suggested that where there was a comprehensive HRS, especially with an overall strategy, considerable progress was made.The Commentary's added value lies in it extracting, collating and organizing data from the 13 papers to facilitate analysis of HRSs. Collectively, the papers provide evidence about the benefits of strengthening HRSs, and challenges (including resource waste) when HRSs were not well developed. This can justify a recommendation to give serious consideration to WHO's call in 2013 for a comprehensive approach to developing health research systems as fully as possible, in as many countries as possible. This could be particularly important before any future pandemics.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hanney</LastName><ForeName>Stephen Robert</ForeName><Initials>SR</Initials><Identifier Source="ORCID">0000-0002-7415-5932</Identifier><AffiliationInfo><Affiliation>Health Economics Research Group, Department of Health Sciences, Brunel University London, London, United Kingdom. stephen.hanney@brunel.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yazdizadeh</LastName><ForeName>Bahareh</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0003-4127-5986</Identifier><AffiliationInfo><Affiliation>Knowledge Utilization Research Center, Tehran University of Medical Science, Tehran, Iran. byazdizadeh@tums.ac.ir.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Health Res Policy Syst</MedlineTA><NlmUniqueID>101170481</NlmUniqueID><ISSNLinking>1478-4505</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="Y">Pandemics</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006302" MajorTopicYN="Y">Health Services Research</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="N">organization &amp; administration</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D035843" MajorTopicYN="Y">Biomedical Research</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014944" MajorTopicYN="N">World Health Organization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Ethics</Keyword><Keyword MajorTopicYN="N">Financing</Keyword><Keyword MajorTopicYN="N">Health research system (HRS)</Keyword><Keyword MajorTopicYN="N">Policymaking</Keyword><Keyword MajorTopicYN="N">Prioritization</Keyword><Keyword MajorTopicYN="N">Publications</Keyword><Keyword MajorTopicYN="N">Research coordination</Keyword><Keyword MajorTopicYN="N">Vaccines</Keyword><Keyword MajorTopicYN="N">World Health Organization</Keyword></KeywordList><CoiStatement>Declarations. Ethics approval and consent to participate: Not applicable. Consent for publication: Not applicable. Competing interests: The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>2</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>5</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>27</Day><Hour>0</Hour><Minute>57</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40713550</ArticleId><ArticleId IdType="doi">10.1186/s12961-025-01354-4</ArticleId><ArticleId IdType="pii">10.1186/s12961-025-01354-4</ArticleId></ArticleIdList><ReferenceList><Title>References:</Title><Reference><Citation>World Health Organization. The World Health Report 2013: research for universal health coverage. Geneva: WHO; 2013. https://apps.who.int/iris/bitstream/handle/10665/85761/9789240690837_eng.pdf?sequence=2 . Accessed 19 March 2025.</Citation></Reference><Reference><Citation>Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et&#xa0;al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579:265&#x2013;9. https://doi.org/10.1038/s41586-020-2008-3 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2008-3</ArticleId><ArticleId IdType="pubmed">32015508</ArticleId><ArticleId IdType="pmc">7094943</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrar J, Ahuja A. Spike&#x2014;The virus vs the people. The inside story. London: Profile Books; 2021.</Citation></Reference><Reference><Citation>National Health and Medical Research Council (NHMRC). Australian partnership for preparedness research on infectious disease emergencies. 2020.&#xa0; https://www.nhmrc.gov.au/about-us/news-centre/australian-partnership-preparedness-research-infectious-disease-emergencies . Accessed 19 March 2025.</Citation></Reference><Reference><Citation>Charit&#xe9;. Researchers develop first diagnostic test for novel coronavirus in China. Press release. Charit&#xe9; &#x2013;&#xa0;Universit&#xe4;tsmedizin Berlin. 2020. https://www.charite.de/en/service/press_reports/artikel/detail/researchers_develop_first_diagnostic_test_for_novel_coronavirus_in_china/ Accessed 19 March 2025.</Citation></Reference><Reference><Citation>Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DKW, et&#xa0;al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020. https://doi.org/10.2807/1560-7917.ES.2020.25.3.2000045 .</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2020.25.3.2000045</ArticleId><ArticleId IdType="pubmed">33243353</ArticleId><ArticleId IdType="pmc">7693167</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilbert S, Vaxxers GC. The inside story of the Oxford AstraZeneca vaccine and the race against the virus. London: Hodder and Stoughton; 2021.</Citation></Reference><Reference><Citation>Lane R. Sarah Gilbert: carving a path towards a COVID-19 vaccine. Lancet. 2020. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(2030796-0/fulltext .</Citation></Reference><Reference><Citation>Gallagher J. Oxford vaccine: how did they make it so quickly? BBC. 2020. https://www.bbc.com/news/health-55041371 . Accessed 19 March 2025.</Citation></Reference><Reference><Citation>Allen A. For billion-dollar COVID vaccines, basic government-funded science laid the groundwork. Kaiser Health Newsletter. 2020.&#xa0; https://www.scientificamerican.com/article/for-billion-dollar-covid-vaccines-basic-government-funded-science-laid-the-groundwork/ . Accessed 19 March 2025.</Citation></Reference><Reference><Citation>Dolgin E. The tangled history of mRNA vaccines. Nature. 2021. https://www.nature.com/articles/d41586-021-02483-w .</Citation></Reference><Reference><Citation>Roberts J. Q&amp;A: BioNTech vaccine is only &#x2018;mRNA 1.0&#x2019;. This is just the beginning, say co-founders https://ec.europa.eu/research-and-innovation/en/horizon-magazine/qa-biontech-vaccine-only-mrna-10-just-beginning-say-co-founders . Accessed 19 March 2025.</Citation></Reference><Reference><Citation>Hanney SR, Straus SE, Holmes BJ. Saving millions of lives but some resources squandered: emerging lessons from health research system pandemic achievements and challenges. Health Res Policy Sys. 2022;20:99. https://doi.org/10.1186/s12961-022-00883-6 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12961-022-00883-6</ArticleId></ArticleIdList></Reference><Reference><Citation>AbCellera. AbCellera is mobilizing a response to the novel coronavirus outbreak as part of its DARPA P3 program. AbCellera press release, 28 Jan 2020. https://investors.abcellera.com/news/news-releases/2020/AbCellera-is-mobilizing-a-response-to-the-novel-coronavirus-outbreak-as-part-of-its-DARPA-P3-program/default.aspx . Accessed 19 March 2025.</Citation></Reference><Reference><Citation>Kim K, Cho KT. A review of global collaboration on COVID-19 research during the pandemic in 2020. Sustainability. 2021. https://doi.org/10.3390/su13147618 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/su13147618</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner T, El-Jardali F. The crucible of COVID-19: what the pandemic is teaching us about health research systems. Health Res Policy Sys. 2020. https://doi.org/10.1186/s12961-020-00573-1 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12961-020-00573-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Yazdizadeh B (Ed.). Calling Notice: the role of the health research system during the COVID-19 epidemic: experiences, challenges and future vision. Health Res Policy Sys.2020. https://www.biomedcentral.com/collections/HRPSCovid . Accessed 19 March 2025.</Citation></Reference><Reference><Citation>Pang T, Sadana R, Hanney S, Bhutta ZA, Hyder AA, Simon J. Knowledge for better health: a conceptual framework and foundation for health research systems. Bull World Health Organ. 2003;81(11):815&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">14758408</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. World report on knowledge for better health: strengthening health systems. Geneva: WHO. 2004.&#xa0; https://apps.who.int/iris/bitstream/handle/10665/43058/9241562811.pdf?sequence=1&amp;isAllowed=y . Accessed 19 March 2025.</Citation></Reference><Reference><Citation>Hanney S, Kanya L, Pokhrel S, Jones T, Boaz A What is the evidence on policies, interventions and tools for establishing and/or strengthening national health research systems and their effectiveness? Copenhagen: WHO Regional Office for Europe. 2020. https://iris.who.int/handle/10665/331703 .</Citation></Reference><Reference><Citation>Yazdizadeh B, Majdzadeh R, Ahmadi A, Mesgarpour B. Health research system resilience: lesson learned from the COVID-19 crisis. Health Res Policy Sys. 2020. https://doi.org/10.1186/s12961-020-00667-w .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12961-020-00667-w</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleury Rosa MF, da Silva EN, Pacheco C, Millett C, Gadelha CAG, Santos LMP. Direct from the COVID-19 crisis: research and innovation sparks in Brazil. Health Res Policy Sys. 2021. https://doi.org/10.1186/s12961-020-00674-x .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12961-020-00674-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Roope LSJ, Candio P, Kiparoglou V, McShane H, Duch R, Clarke PM. Lessons from the pandemic on the value of research infrastructure. Health Res Policy Sys. 2021;19:54. https://doi.org/10.1186/s12961-021-00704-2 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12961-021-00704-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Henderson LR, McShane H, Kiparoglou V. Rapid research response to the COVID-19 pandemic: perspectives from a National Institute for Health Biomedical Research Centre. Health Res Policy Sys. 2022;20:24. https://doi.org/10.1186/s12961-022-00827-0 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12961-022-00827-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Yazdizadeh B, Ehsani-Chimeh E, Zendehdel K, et&#xa0;al. Knowledge gaps and national research priorities for COVID-19 in Iran. Health Res Policy Sys. 2022;20:25. https://doi.org/10.1186/s12961-021-00805-y .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12961-021-00805-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Faulkner-Gurstein R, Wyatt D, Cowan H, Hare N, Harris C, Wolfe C. The organization and impacts of clinical research delivery workforce redeployment during the COVID-19 pandemic: a qualitative case study of one research-intensive acute hospital trust. Health Res Policy Sys. 2022;20:68. https://doi.org/10.1186/s12961-022-00876-5 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12961-022-00876-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Koehlmoos TP, Korona-Bailey J, Janvri ML, et&#xa0;al. The collaborative research and service delivery partnership between the United States healthcare system and the U.S. Military Health System during the COVID-19 pandemic. Health Res Policy Sys. 2022;20:81. https://doi.org/10.1186/s12961-022-00885-4 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12961-022-00885-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Ananthakrishnan A, Luz ACG, Sarin KC, et&#xa0;al. How can health technology assessment support our response to public health emergencies? Health Res Policy Sys. 2022;20:124. https://doi.org/10.1186/s12961-022-00925-z .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12961-022-00925-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Canario Guzm&#xe1;n JA, Orlich J, Mendiz&#xe1;bal-Cabrera R, et&#xa0;al. Strengthening research ethics governance and regulatory oversight in Central America and the Dominican Republic in response to the COVID-19 pandemic: a qualitative study. Health Res Policy Sys. 2022;20:138. https://doi.org/10.1186/s12961-022-00933-z .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12961-022-00933-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Hennessey K, Pezzoli L, Mantel C. A framework for seroepidemiologic investigations in future pandemics: insights from an evaluation of WHO&#x2019;s Unity Studies initiative. Health Res Policy Sys. 2023;21:34. https://doi.org/10.1186/s12961-023-00973-z .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12961-023-00973-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Palese A, Chiappinotto S, Fonda F, et&#xa0;al. Lessons learnt while designing and conducting a longitudinal study from the first Italian COVID-19 pandemic wave up to 3 years. Health Res Policy Sys. 2023;21:111. https://doi.org/10.1186/s12961-023-01055-w .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12961-023-01055-w</ArticleId></ArticleIdList></Reference><Reference><Citation>Smits P, Cambourieu C, Ouimet M. Connections between health research systems and decision-making spaces: lessons from the COVID-19 pandemic in the province of Qu&#xe9;bec. Canada Health Res Policy Sys. 2023;21:116. https://doi.org/10.1186/s12961-023-01053-y .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12961-023-01053-y</ArticleId></ArticleIdList></Reference><Reference><Citation>APPRISE. Fast-tracked funding for the COVID-19 pandemic to support critical research areas. APPRISE. 2020.&#xa0; https://www.apprise.org.au/fast-tracked-funding-for-the-covid-19-pandemic-to-support-critical-research-areas/ . Accessed 19 March 2025.</Citation></Reference><Reference><Citation>Zimerman A, Lopes RD, D&#x2019;&#xc1;vila A, Rohde LE, Zimerman L. COVID-19 in Brazil: the headlines should be about science (letter). Lancet. 2020. https://doi.org/10.1016/S0140-6736(20)32375-8 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32375-8</ArticleId><ArticleId IdType="pubmed">33186532</ArticleId></ArticleIdList></Reference><Reference><Citation>Centre for Epidemiology and Evidence. Population Health Research Strategy 2018&#x2013;2022. Population and Public Health Division. Sydney: NSW Ministry of Health. 2019. https://www.health.nsw.gov.au/research/Publications/research-strategy-2018-2022.pdf . Accessed 19 March 2025.</Citation></Reference><Reference><Citation>Ministry of Business, Innovation and Employment (MBIE)/Ministry of Health. New Zealand health research strategy 2017&#x2013;2027. Wellington: Ministry of Business, Innovation and Employment/Ministry of Health. 2017. https://www.health.govt.nz/publication/new-zealand-health-research-strategy-2017-2027 . Accessed 19 March 2025.</Citation></Reference><Reference><Citation>Department of Health. Best research for best health: a new national health research strategy. The NHS contribution to health research in England. London: Department of Health. 2006. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/568772/dh_4127152_v2.pdf . Accessed 19 March 2025.</Citation></Reference><Reference><Citation>Michael Smith Foundation for Health Research. Directions for Health Research in British Columbia. Vancouver, BC, MSFHR; 2014 Directions for Health Research in BC by MSFHR (issuu.com). Accessed 18 March 2025.</Citation></Reference><Reference><Citation>Wyatt D, Faulkner-Gurstein R, Cowan H, Wolfe CDA. Impacts of COVID19 on clinical research in the UK: a multi-method qualitative case study. PLoS ONE. 2021. https://doi.org/10.1371/journal.pone.0256871 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0256871</ArticleId><ArticleId IdType="pubmed">34464430</ArticleId><ArticleId IdType="pmc">8407556</ArticleId></ArticleIdList></Reference><Reference><Citation>Horby P, Mullard A. RECOVERY 1 year on: a rare success in the COVID-19 clinical trial landscape. Nat Rev Drug Discov. 2021. https://doi.org/10.1038/d41573-021-00068-w .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41573-021-00068-w</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization, the Global Research Collaboration for Infectious Disease Preparedness and Response (GLOPID-R). A coordinated Global Research Roadmap. 2020. https://www.who.int/publications/m/item/a-coordinated-global-research-roadmap . Accessed 19 March2025.</Citation></Reference><Reference><Citation>RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with COVID-19. N Engl J Med. 2021. https://doi.org/10.1056/NEJMoa2021436 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2021436</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xc1;guas R, Mahdi A, Shretta R, Horby P, Landray M, White L, et&#xa0;al. Potential health and economic impacts of dexamethasone treatment for patients with COVID-19. Nat Commun. 2021. https://doi.org/10.1038/s41467-021-21134-2 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-21134-2</ArticleId><ArticleId IdType="pubmed">34737262</ArticleId><ArticleId IdType="pmc">8569205</ArticleId></ArticleIdList></Reference><Reference><Citation>Angus DC, Gordon AC, Bauchner H. Emerging lessons from COVID-19 for the US clinical research enterprise. JAMA. 2021. https://doi.org/10.1001/jama.2021.3284.101 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.3284.101</ArticleId><ArticleId IdType="pubmed">34905043</ArticleId><ArticleId IdType="pmc">8491132</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowen AC, Tong SYC, Davis JS. Australia needs a prioritized national research strategy for clinical trials in a pandemic: lessons learned from COVID-19. Med J Aust. 2021. https://doi.org/10.5694/mja2.51143 .</Citation><ArticleIdList><ArticleId IdType="doi">10.5694/mja2.51143</ArticleId><ArticleId IdType="pubmed">34689329</ArticleId><ArticleId IdType="pmc">8661691</ArticleId></ArticleIdList></Reference><Reference><Citation>Goossens H, Derde L, Horby P, Bonten M. The European clinical research response to optimise treatment of patients with COVID-19: lessons learned, future perspective, and recommendations. Lancet Infect Dis. 2021. https://doi.org/10.1016/S1473-3099(21)00705-2 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00705-2</ArticleId><ArticleId IdType="pubmed">34951954</ArticleId><ArticleId IdType="pmc">8691848</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamontagne F,&#xa0;Rowan KM, Guyatt G. Integrating research into clinical practice: challenges and solutions for Canada. CMAJ. 2021. https://doi.org/10.1503/cmaj.202397 .</Citation></Reference><Reference><Citation>World Health Organization. COVID 19 public health emergency of international concern (PHEIC). Global research and innovation forum: towards a research roadmap. 2020. https://www.who.int/docs/default-source/coronaviruse/global-research-and-innovation-forum-towards-a-research-roadmap.pdf . Accessed 19 March 2025.</Citation></Reference><Reference><Citation>Becerra-Posada F, Minayo M, Quental C, de Haan S. National research for health systems in Latin America and the Caribbean: moving towards the right direction? Health Res Policy Sys. 2014;12:13. https://doi.org/10.1186/1478-4505-12-13 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1478-4505-12-13</ArticleId></ArticleIdList></Reference><Reference><Citation>NHS England. COVID treatment developed in the NHS saves a million lives. News. 2021. https://www.england.nhs.uk/2021/03/covid-treatment-developed-in-the-nhs-saves-a-million-lives/#:~:text=Dexamethasone%2C%20an%20inexpensive%20and%20widely,clinical%20trial%20in%20the%20NHS . Accessed 19 March 2025.</Citation></Reference><Reference><Citation>Victora PC, Castro PMC, Gurzenda S, Medeiros AC, Franca GVA, Barros AJD. Estimating the early impact of vaccination against COVID-19 on deaths among elderly people in Brazil: analyses of routinely-collected data on vaccine coverage and mortality. EClinicalMedicine. 2021. https://doi.org/10.1016/j.eclinm.2021.101036 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101036</ArticleId><ArticleId IdType="pubmed">34927037</ArticleId><ArticleId IdType="pmc">8649218</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta S, Cantor J, Simon KI, Bento AI, Wing C, Whaley CM. Vaccinations against COVID-19 may have averted up to 140,000 deaths in the United States. Health Aff (Millwood). 2021. https://doi.org/10.1377/hlthaff.2021.00619 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1377/hlthaff.2021.00619</ArticleId><ArticleId IdType="pubmed">34406840</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider EC, Shah A, Sah P, Moghadas SM, Vilches T, Galvani A. The U.S. COVID-19 vaccination program at one year: how many deaths and hospitalizations were averted? Commonwealth Fund 2021. https://doi.org/10.26099/3542-5n54 . Accessed 25 Nov 2023.</Citation></Reference><Reference><Citation>Mesl&#xe9; MMI, Brown J, Mook P, Hagen J, Pastore R, Bundle N, et&#xa0;al. Estimated number of deaths directly averted in people 60 years and older as a result of COVID-19 vaccination in the WHO European Region, December 2020 to November 2021. Euro Surveill. 2021. https://doi.org/10.2807/1560-7917.ES.2021.26.47.2101021 .</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2021.26.47.2101021</ArticleId><ArticleId IdType="pubmed">34823641</ArticleId><ArticleId IdType="pmc">8619871</ArticleId></ArticleIdList></Reference><Reference><Citation>Slaoui M, Greene SE, Woodcock J. Bridging the gap at warp speed&#x2014;Delivering options for preventing and treating Covid-19. NEJM. 2020. https://doi.org/10.1056/NEJMp2028535 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMp2028535</ArticleId><ArticleId IdType="pubmed">32931679</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanney SR, Wooding S, Sussex J, Grant J. From COVID-19 research to vaccine application: why might it take 17&#xa0;months not 17&#xa0;years and what are the wider lessons? Health Res Policy Sys. 2020. https://doi.org/10.1186/s12961-020-00571-3 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12961-020-00571-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Lurie N, Saville M, Hatchett R, Halton J. Developing covid-19 vaccines at pandemic speed. N Engl J Med. 2020. https://doi.org/10.1056/NEJMp2005630 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMp2005630</ArticleId><ArticleId IdType="pubmed">32227757</ArticleId></ArticleIdList></Reference><Reference><Citation>Norton A, Bucher A, Antonio E, Advani N, Grund H, Mburu S, et&#xa0;al. A living mapping review for COVID-19 funded research projects: nine-month update [version 4; peer review: 2 approved]. Wellcome Open Research. 2021. https://doi.org/10.12688/wellcomeopenres.16259.4 .</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/wellcomeopenres.16259.4</ArticleId><ArticleId IdType="pubmed">35634533</ArticleId><ArticleId IdType="pmc">9120928</ArticleId></ArticleIdList></Reference><Reference><Citation>NIH. NIH to assess and expand COVID-19 testing for underserved communities (RADx-UP). NIH. 30 September 2020. https://www.nih.gov/news-events/news-releases/nih-assess-expand-covid-19-testing-underserved-communities . Accessed 19 March 2025</Citation></Reference><Reference><Citation>Prime Minister&#x2019;s Office. PM announces record funding to find a coronavirus vaccine. 2020. https://www.gov.uk/government/news/pm-announces-record-funding-to-find-a-coronavirus-vaccine . Accessed 19 March 2025</Citation></Reference><Reference><Citation>Ardern J. Opening Remarks. In: Mahi Tahi 2. Annual report 2020. Auckland, New Zealand: Office of the Prime Minister&#x2019;s Chief Scientific Advisor. 2020. https://cpb-ap-se2.wpmucdn.com/blogs.auckland.ac.nz/dist/f/688/files/2020/01/PMCSA-Annual-Report-2020-web-version_-to-upload-v4.pdf . Accessed 19 March 2025.</Citation></Reference><Reference><Citation>Baker MG, Wilson N, Anglemyer A. Successful elimination of COVID-19 transmission in New Zealand. N Engl J Med. 2020. https://doi.org/10.1056/NEJMc2025203 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2025203</ArticleId><ArticleId IdType="pubmed">33356051</ArticleId><ArticleId IdType="pmc">7449141</ArticleId></ArticleIdList></Reference><Reference><Citation>Geoghegan JL, Moreland NJ, Le Gros G, Ussher JE. New Zealand&#x2019;s science-led response to the SARS-CoV-2 pandemic. Nat Immunol. 2021. https://doi.org/10.1038/s41590-021-00872-x .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-00872-x</ArticleId><ArticleId IdType="pubmed">33627881</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell D, Edwards B, Milat A, Thackway S, Whittaker E, Goudswaard L, et&#xa0;al. NSW Health COVID-19 emergency response priority research program: a case study of rapid translation of research into health decision making. Public Health Res Pract. 2021;31(4):e3142124. https://doi.org/10.17061/phrp3142124 .</Citation><ArticleIdList><ArticleId IdType="doi">10.17061/phrp3142124</ArticleId></ArticleIdList></Reference><Reference><Citation>Centre for Epidemiology and Evidence. NSW Health COVID-19 research program impact evaluation report 2021. Sydney: NSW Ministry of Health. 2021. https://www.health.nsw.gov.au/research/Publications/covid-impact-evaluation-interim.pdf . Accessed 19 March 2025.</Citation></Reference><Reference><Citation>&#x15e;ahin U, Muik A, Derhovanessian E, Vogler I, Kranz ML, Vohrmehr M, et&#xa0;al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature. 2020. https://doi.org/10.1038/s41586-020-2814-7 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2814-7</ArticleId><ArticleId IdType="pubmed">32998157</ArticleId></ArticleIdList></Reference><Reference><Citation>Polark FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et&#xa0;al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020. https://doi.org/10.1056/NEJMoa2034577 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2034577</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et&#xa0;al. An mRNA vaccine against SARS-CoV-2&#x2014;Preliminary report. N Engl J Med. 2020;383:1920&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">32663912</ArticleId></ArticleIdList></Reference><Reference><Citation>Corbett KS, Flynn B, Foulds KE, Boyoglu-Barnum S, Werner AP, et&#xa0;al. Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. N Engl J Med. 2020;383:1544&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">32722908</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson EJ, Rouphael NG, Widge AT, Jackson LA, Roberts PC, Makhene M, et&#xa0;al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med. 2020;383:2427&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">32991794</ArticleId></ArticleIdList></Reference><Reference><Citation>Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et&#xa0;al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021. https://doi.org/10.1056/NEJMoa2035389 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2035389</ArticleId><ArticleId IdType="pubmed">34965346</ArticleId><ArticleId IdType="pmc">8609569</ArticleId></ArticleIdList></Reference><Reference><Citation>van Doremalen N, Lambe T, Spencer A, Belij-Rammerstorfer S, Purushotham JN, Port JR, et&#xa0;al. ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature. 2020. https://doi.org/10.1038/s41586-020-2608-y .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2608-y</ArticleId><ArticleId IdType="pubmed">32731258</ArticleId><ArticleId IdType="pmc">8436420</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramasamy M, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, et&#xa0;al. Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine administered in a primeboost regimen in older adults (COV002): a phase 2/3 single blind, randomised controlled trial. Lancet. 2020. https://doi.org/10.1016/S0140-6736(20)32466-1 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32466-1</ArticleId><ArticleId IdType="pubmed">33306989</ArticleId><ArticleId IdType="pmc">7674972</ArticleId></ArticleIdList></Reference><Reference><Citation>Voysey M, Clements SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et&#xa0;al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021. https://doi.org/10.1016/S0140-6736(20)32661-1 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32661-1</ArticleId><ArticleId IdType="pubmed">34688353</ArticleId><ArticleId IdType="pmc">8530465</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Jardali F, Bou-Karroum L, Fadlallah R. Amplifying the role of knowledge translation platforms in the COVID-19 pandemic response. Health Res Policy Syst. 2020;18(1):58. https://doi.org/10.1186/s12961-020-00576-y .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12961-020-00576-y</ArticleId><ArticleId IdType="pubmed">32493339</ArticleId><ArticleId IdType="pmc">7267748</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamontagne F, Agoritsas T, Macdonald H, Leo YS, Diaz J, Agarwal A. A living WHO guideline on drugs for covid-19. BMJ. 2020. https://doi.org/10.1136/bmj.m3379 .</Citation></Reference><Reference><Citation>Mazey S, Richardson J. Lesson-drawing from New Zealand and COVID-19: the need for anticipatory policy making. Polit Q. 2020;91:561&#x2013;70. https://doi.org/10.1111/1467-923X.12893 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1467-923X.12893</ArticleId><ArticleId IdType="pubmed">32836413</ArticleId><ArticleId IdType="pmc">7436465</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanney SR, Gonz&#xe1;lez-Block MA. Organising health research systems as a key to improving health: the World Health Report 2013 and how to make further progress. Health Res Policy Sys. 2013;11:47. https://doi.org/10.1186/1478-4505-11-47 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1478-4505-11-47</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Supporting the routine use of evidence during the policy-making process: a WHO checklist. Geneva: World Health Organization. 2023; Licence: CC BY-NC-SA 3.0 IGO https://iris.who.int/bitstream/handle/10665/366181/9789240056145-eng.pdf?sequence=1 . Accessed 19 March 2025.</Citation></Reference><Reference><Citation>Kuchenm&#xfc;ller T, Boeira L, Oliver S, et&#xa0;al. Domains and processes for institutionalizing evidence-informed health policy-making: a critical interpretive synthesis. Health Res Policy Sys. 2022;20:27. https://doi.org/10.1186/s12961-022-00820-7 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12961-022-00820-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Straus SE, Beckett R, Fahim C, et&#xa0;al. Royal Society of Canada working group on health research system recovery: strengthening Canada&#x2019;s health research system after the COVID-19 pandemic. FACETS. 2024;9:1&#x2013;44. https://doi.org/10.1139/facets-2023-0233 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1139/facets-2023-0233</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40713537</PMID><DateCompleted><Year>2025</Year><Month>07</Month><Day>27</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2334</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>25</Day></PubDate></JournalIssue><Title>BMC infectious diseases</Title><ISOAbbreviation>BMC Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Co-infections during SARS-CoV-2 infection in hematologic patients and cell therapy recipients in the omicron era: a Spanish hematopoietic stem cell transplantation and cell therapy group study.</ArticleTitle><Pagination><StartPage>944</StartPage><MedlinePgn>944</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12879-025-11302-w</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Although SARS-Cov-2 outcomes have improved in the Omicron era, the synergistic or additive effects between SARS-CoV-2 Omicron variants and other microbiological agents in adult hematologic patients have been little explored. We aimed to characterize co-infection types, identify risk factors for co-infection and determine co-infection-related mortality in hematologic patients and recipients of cellular therapy with a first episode of SARS-CoV-2 infection in the Omicron era.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Retrospective national Spanish registry analysis of 692 consecutive patients with hematological disease including receptors of cellular therapy from December 2021 to May 2023.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The co-infection rate was 9% (n&#x2009;=&#x2009;64), 30% of which were polymicrobial. Bacterial, viral, and fungal agents affected 64%, 30%, and 11% of patients, respectively. Among the microbiologically confirmed agents (n&#x2009;=&#x2009;82), the most common sites of identification were lower respiratory tract (33%), urinary tract (27%) and bloodstream (17%). Multivariable analysis identified cardiopathy (hazard ratio [HR] 1.69), CAR-T therapy (HR 3.42) and pneumonia (HR 5.54) as conditions associated with co-infection. Considering all-cause mortality at day 180 after SARS-CoV-2 detection, co-infection was associated with lower survival (71% versus 92%). Risk factors at COVID-19 diagnosis for non-relapse mortality (NRM) were co-infection (HR 4.28), age&#x2009;&#x2265;&#x2009;64&#xa0;years old (HR 2.55), active hematological treatment (HR 2.13) and under corticosteroid treatment (HR 3.21). In co-infected patients, the only identified factor increasing NRM was corticosteroid use (HR 3.33) at the time of SARS-CoV-2 detection.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">SARS-CoV-2 co-infection are relatively frequent in hematologic patients and cellular therapy recipients in the Omicron era. Patients with ischemic cardiopathy, those presenting with pneumonia and recipients of CAR-T are at a higher risk of developing a co-infection, while co-infection, age&#x2009;&#x2265;&#x2009;64&#xa0;years old, active hematological therapy and corticosteroid treatment showed higher NRM. Improvements in identifying and managing concurrent infections during SARS-CoV-2 are needed to further reduce morbimortality in hematologic patients.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chor&#xe3;o</LastName><ForeName>Pedro</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Hematology Department, Hospital Universitari I Polit&#xe8;cnic La Fe, Av. Fernando Abril Martorell, 106, 46026, Val&#xe8;ncia, Spain. pedro_chorao@iislafe.es.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hematology Research Group, Institut d'Investigaci&#xf3; Sanit&#xe0;ria La Fe, Val&#xe8;ncia, Spain. pedro_chorao@iislafe.es.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Avenda&#xf1;o</LastName><ForeName>Alex</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Hematology Department, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Cancer Research Institute of Salamanca-IBMCC (USAL-CSIC), Salamanca, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heras</LastName><ForeName>Inmaculada</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Hematology Division, Hospital Morales Meseguer, Murcia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aiello</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Infectious Disease Division, Hospital Clinic, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mic&#xf3;-Cerd&#xe1;</LastName><ForeName>Mireia</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Hematology Department, Hospital Cl&#xed;nico Universitario de Valencia, Valencia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>INCLIVA Biomedical Research Institute, Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arrufat Bel</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Hematology Division, Hospital de La Santa Creu I Sant Pau, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garcia-Gutierrez</LastName><ForeName>Valent&#xed;n</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Hematology Division, Hospital Ramon y Cajal, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olave</LastName><ForeName>Mar&#xed;a T</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Hematology Division, Hospital Cl&#xed;nico Universitario Lozano Blesa, IIS Aragon, Saragossa, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xf3;mez</LastName><ForeName>Marina Acera</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Hematology Department, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Cancer Research Institute of Salamanca-IBMCC (USAL-CSIC), Salamanca, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Espigado</LastName><ForeName>Ildefonso</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Hematology Division, Hospital Universitario Virgen Macarena- Hospital Universitario Virgen del Roc&#xed;o, IBiS-CSIC, Universidad de Sevilla, Seville, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cuesta-Casas</LastName><ForeName>Mar&#xed;a &#xc1;ngeles</ForeName><Initials>M&#xc1;</Initials><AffiliationInfo><Affiliation>Hematology Division, Hospital Regional Universitario Carlos Haya, Malaga, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonz&#xe1;lez-Santillana</LastName><ForeName>Clara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Hematology Division, Hospital de Fuenlabrada, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hern&#xe1;ndez-Rivas</LastName><ForeName>Jos&#xe9; &#xc1;ngel</ForeName><Initials>J&#xc1;</Initials><AffiliationInfo><Affiliation>Hematology Division, Hospital Universitario Infanta Leonor, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rold&#xe1;n-P&#xe9;rez</LastName><ForeName>Alicia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Hematology Division, Hospital Universitario Infanta Sofia, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Universidad Europea de Madrid, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Labrador</LastName><ForeName>Jorge</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Research Unit, Hospital Universitario de Burgos, Burgos, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hematology Department, Hospital Universitario de Burgos, Burgos, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villalba</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Hematology Department, Hospital Universitari I Polit&#xe8;cnic La Fe, Av. Fernando Abril Martorell, 106, 46026, Val&#xe8;ncia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hematology Research Group, Institut d'Investigaci&#xf3; Sanit&#xe0;ria La Fe, Val&#xe8;ncia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>V&#xe1;zquez</LastName><ForeName>Lourdes</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Hematology Department, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Cancer Research Institute of Salamanca-IBMCC (USAL-CSIC), Salamanca, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garcia Vidal</LastName><ForeName>Carolina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Infectious Disease Division, Hospital Clinic, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martino</LastName><ForeName>Rodrigo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Hematology Division, Hospital de La Santa Creu I Sant Pau, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xf3;pez-Jim&#xe9;nez</LastName><ForeName>Javier</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Hematology Division, Hospital Ramon y Cajal, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cedillo</LastName><ForeName>&#xc1;ngel</ForeName><Initials>&#xc1;</Initials><AffiliationInfo><Affiliation>Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH-TC) Office, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Solano</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Hematology Department, Hospital Cl&#xed;nico Universitario de Valencia, Valencia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>INCLIVA Biomedical Research Institute, Valencia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, School of Medicine, University of Valencia, Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a-Cadenas</LastName><ForeName>Irene</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Hematology Division, Hospital de La Santa Creu I Sant Pau, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pi&#xf1;ana</LastName><ForeName>Jos&#xe9; Lu&#xed;s</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Hematology Department, Hospital Cl&#xed;nico Universitario de Valencia, Valencia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>INCLIVA Biomedical Research Institute, Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Infectious Complications Subcommittee of the Spanish Hematopoietic Stem Cell Transplantation Cell Therapy Group (GETH-TC)</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Infect Dis</MedlineTA><NlmUniqueID>100968551</NlmUniqueID><ISSNLinking>1471-2334</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N" Type="Geographic">Spain</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060085" MajorTopicYN="Y">Coinfection</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018380" MajorTopicYN="Y">Hematopoietic Stem Cell Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006402" MajorTopicYN="Y">Hematologic Diseases</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Co-infections</Keyword><Keyword MajorTopicYN="N">Omicron</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList><CoiStatement>Declarations. Ethics approval and consent to participate: The local Research Ethics Committee of the Hospital Cl&#xed;nico Universitario de Valencia approved the study (reference code 35.21), which was carried out in accordance with the Declaration of Helsinki and its amendments, and applicable national regulatory requirements. The Research Ethics Committee of the Hospital Cl&#xed;nico Universitario de Valencia approved the waiver of informed consent for study inclusion. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>27</Day><Hour>0</Hour><Minute>57</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40713537</ArticleId><ArticleId IdType="doi">10.1186/s12879-025-11302-w</ArticleId><ArticleId IdType="pii">10.1186/s12879-025-11302-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pi&#xf1;ana JL, Heras I, Aiello TF, Garc&#xed;a-Cadenas I, Vazquez L, Lopez-Jimenez J, et al. Remdesivir or nirmatrelvir/ritonavir therapy for omicron SARS-CoV-2 infection in hematological patients and cell therapy recipients. Viruses. 2023;15(10):2066.</Citation><ArticleIdList><ArticleId IdType="pubmed">37896843</ArticleId><ArticleId IdType="pmc">10612015</ArticleId></ArticleIdList></Reference><Reference><Citation>Pi&#xf1;ana JL, Vazquez L, Heras I, Aiello TF, L&#xf3;pez-Corral L, Arroyo I, et al. Omicron SARS-CoV-2 infection management and outcomes in patients with hematologic disease and recipients of cell therapy. Front Oncol. 2024;19(14):1389345.</Citation></Reference><Reference><Citation>Pi&#xf1;ana JL, P&#xe9;rez A, Chor&#xe3;o P, Guerreiro M, Garc&#xed;a-Cadenas I, Solano C, et al. Respiratory virus infections after allogeneic stem cell transplantation: Current understanding, knowledge gaps, and recent advances. Transpl Infect Dis. 2023;25(S1):e14117.</Citation><ArticleIdList><ArticleId IdType="pubmed">37585370</ArticleId></ArticleIdList></Reference><Reference><Citation>Satyanarayana G, Enriquez KT, Sun T, Klein EJ, Abidi M, Advani SM, et al. Coinfections in patients with cancer and COVID-19: a COVID-19 and Cancer Consortium (CCC19) study. Open Forum Infect Dis. 2022;9(3):ofac037.</Citation><ArticleIdList><ArticleId IdType="pubmed">35198648</ArticleId><ArticleId IdType="pmc">8860152</ArticleId></ArticleIdList></Reference><Reference><Citation>Averbuch D, De La Camara R, Tridello G, Knelange NS, Bykova TA, Ifversen M, et al. Risk factors for a severe disease course in children with SARS-COV-2 infection following hematopoietic cell transplantation in the pre-Omicron period: a prospective multinational Infectious Disease Working Party from the European Society for Blood and Marrow Transplantation group (EBMT) and the Spanish Group of Hematopoietic Stem Cell Transplantation (GETH) study. Bone Marrow Transplant. 2023;58(5):558&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">36849806</ArticleId><ArticleId IdType="pmc">9969031</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes S, Troise O, Donaldson H, Mughal N, Moore LSP. Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting. Clin Microbiol Infect. 2020;26(10):1395&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">32603803</ArticleId><ArticleId IdType="pmc">7320692</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma L, Wang W, Le Grange JM, Wang X, Du S, Li C, et al. Coinfection of SARS-CoV-2 and Other Respiratory Pathogens. Infect Drug Resist. 2020;13:3045&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">32922049</ArticleId><ArticleId IdType="pmc">7457866</ArticleId></ArticleIdList></Reference><Reference><Citation>Ministerio de Sanidad, Centro de Coordinaci&#xf3;n de Alertas y Emergencias, Ministerio de Sanidad, Centro de Coordinaci&#xf3;n de Alertas y Emergencias Sanitarias. Actualizaci&#xf3;n de la situaci&#xf3;n epidemiol&#xf3;gica de las variantes de SARS-CoV-2 en Espa&#xf1;a. 2022. Available from: https://www.sanidad.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/documentos/COVID19_Actualizacion_variantes_20220523.pdf .</Citation></Reference><Reference><Citation>Centres for Diseases Control and Prevention. CDC/NHSN surveillance definitions for specific types of infections. 2024. Available from: https://www.cdc.gov/nhsn/pdfs/pscmanual/17pscnosinfdef_current.pdf .</Citation></Reference><Reference><Citation>Centres for Diseases Control and Prevention. Bloodstream Infection Event (Central Line-Associated Bloodstream Infection and Non-central Line Associated Bloodstream Infection). 2024. Available from: https://www.cdc.gov/nhsn/pdfs/pscmanual/4psc_clabscurrent.pdf .</Citation></Reference><Reference><Citation>Centres for Diseases Control and Prevention. Urinary Tract Infection (Catheter-Associated Urinary Tract Infection [CAUTI] and Non-Catheter-Associated Urinary Tract Infection [UTI]) Events. 2024. Available from: https://www.cdc.gov/nhsn/pdfs/pscmanual/7psccauticurrent.pdf .</Citation></Reference><Reference><Citation>Centres for Diseases Control and Prevention. Pneumonia (Ventilator-associated [VAP] and non-ventilatorassociated Pneumonia [PNEU]) Event. 2024. Available from: https://www.cdc.gov/nhsn/pdfs/pscmanual/6pscvapcurrent.pdf .</Citation></Reference><Reference><Citation>Donnelly JP, Chen SC, Kauffman CA, Steinbach WJ, Baddley JW, Verweij PE, et al. Revision and update of the consensus definitions of invasive fungal disease from the european organization for research and treatment of cancer and the mycoses study group education and research consortium. Clin Infect Dis. 2020;71(6):1367&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">31802125</ArticleId></ArticleIdList></Reference><Reference><Citation>Meersseman W, Lagrou K, Spriet I, Maertens J, Verbeken E, Peetermans WE, et al. Significance of the isolation of Candida species from airway samples in critically ill patients: a prospective, autopsy study. Intensive Care Med. 2009;35(9):1526&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">19357832</ArticleId></ArticleIdList></Reference><Reference><Citation>Ljungman P, Boeckh M, Hirsch HH, Josephson F, Lundgren J, Nichols G, et al. Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials: Table 1. Snydman DR, editor. Clin Infect Dis. 2017;64(1):87&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">27682069</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirsch HH, Martino R, Ward KN, Boeckh M, Einsele H, Ljungman P. Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis and treatment of human respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus, and coronavirus. Clin Infect Dis. 2013;56(2):258&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">23024295</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow O, Salmanton-Garc&#xed;a J, Nowak P, Itri F, Van Doesum J, L&#xf3;pez-Garc&#xed;a A, et al. Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: an EPICOVIDEHA survey report. Am J Hematol. 2022;97(8):E312&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">35702878</ArticleId><ArticleId IdType="pmc">9349555</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Vidal C, Sanjuan G, Moreno-Garc&#xed;a E, Puerta-Alcalde P, Garcia-Pouton N, Chumbita M, et al. Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study. Clin Microbiol Infect. 2021;27(1):83&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">32745596</ArticleId></ArticleIdList></Reference><Reference><Citation>Musuuza JS, Watson L, Parmasad V, Putman-Buehler N, Christensen L, Safdar N. Prevalence and outcomes of co-infection and superinfection with SARS-CoV-2 and other pathogens: a systematic review and meta-analysis. Huber VC, editor. PLoS One. 2021;16(5):e0251170.</Citation><ArticleIdList><ArticleId IdType="pubmed">33956882</ArticleId><ArticleId IdType="pmc">8101968</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai CC, Wang CY, Hsueh PR. Co-infections among patients with COVID-19: the need for combination therapy with non-anti-SARS-CoV-2 agents? J Microbiol Immunol Infect. 2020;53(4):505&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">32482366</ArticleId><ArticleId IdType="pmc">7245213</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldman C, Anderson R. The role of co-infections and secondary infections in patients with COVID-19. Pneumonia. 2021;13(1):5.</Citation><ArticleIdList><ArticleId IdType="pubmed">33894790</ArticleId><ArticleId IdType="pmc">8068564</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim D, Quinn J, Pinsky B, Shah NH, Brown I. Rates of Co-infection between SARS-CoV-2 and other respiratory pathogens. JAMA. 2020;323(20):2085.</Citation><ArticleIdList><ArticleId IdType="pubmed">32293646</ArticleId><ArticleId IdType="pmc">7160748</ArticleId></ArticleIdList></Reference><Reference><Citation>Saade A, Moratelli G, Azoulay E, Darmon M. Herpesvirus reactivation during severe COVID-19 and high rate of immune defect. Infect Dis Now. 2021;51(8):676&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">34332165</ArticleId><ArticleId IdType="pmc">8317452</ArticleId></ArticleIdList></Reference><Reference><Citation>Franklin A, John TM, Khawaja F, Jiang Y, Yepez E, Ahuja J, et al. Utility of bronchoalveolar lavage for the diagnosis and management of COVID-19 in patients with cancer. J Infect Dis. 2023;228(11):1549&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">37983000</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomassetti S, Ciani L, Luzzi V, Gori L, Trigiani M, Giuntoli L, et al. Utility of bronchoalveolar lavage for COVID-19: a perspective from the Dragon consortium. Front Med. 2024;2(11):1259570.</Citation></Reference><Reference><Citation>Jahn K, Karakioulaki M, Schumann DM, Hirsch HH, Leuzinger K, Grize L, et al. Impact of bronchoalveolar lavage on the management of immunocompromised hosts. Eur J Intern Med. 2024;120:52&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">37722932</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart AG, Henden AS. Infectious complications of CAR T-cell therapy: a clinical update. Ther Adv Infect Dis. 2021;8:204993612110367.</Citation></Reference><Reference><Citation>Pi&#xf1;ana JL, Martino R, Vazquez L, L&#xf3;pez-Corral L, P&#xe9;rez A, Chor&#xe3;o P, et al. SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination. Bone Marrow Transplant. 2023;58(5):567&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">36854892</ArticleId><ArticleId IdType="pmc">9974060</ArticleId></ArticleIdList></Reference><Reference><Citation>Dioverti V, Salto-Alejandre S, Haidar G. Immunocompromised patients with protracted COVID-19: a review of &#x201c;Long Persisters.&#x201d; Curr Transplant Rep. 2022;9(4):209&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">36407883</ArticleId><ArticleId IdType="pmc">9660019</ArticleId></ArticleIdList></Reference><Reference><Citation>Boeckh M. The challenge of respiratory virus infections in hematopoietic cell transplant recipients. Br J Haematol. 2008;143(4):455&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">18785968</ArticleId><ArticleId IdType="pmc">2735199</ArticleId></ArticleIdList></Reference><Reference><Citation>Alonso JM. Immunit&#xe9; et physiopathologie des infections de l&#x2019;arbre respiratoire. M&#xe9;decine Mal Infect. 2008;38(8):433&#x2013;7.</Citation></Reference><Reference><Citation>Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood. 2002;100(13):4358&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">12393425</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Vidal C, Upton A, Kirby KA, Marr KA. Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation. Clin Infect Dis. 2008;47(8):1041&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">18781877</ArticleId></ArticleIdList></Reference><Reference><Citation>Martino R, Pi&#xf1;ana JL, Parody R, Valcarcel D, Sureda A, Brunet S, et al. Lower respiratory tract respiratory virus infections increase the risk of invasive aspergillosis after a reduced-intensity allogeneic hematopoietic SCT. Bone Marrow Transplant. 2009;44(11):749&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">19398963</ArticleId><ArticleId IdType="pmc">7091792</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishiga M, Wang DW, Han Y, Lewis DB, Wu JC. COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. Nat Rev Cardiol. 2020;17(9):543&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">32690910</ArticleId><ArticleId IdType="pmc">7370876</ArticleId></ArticleIdList></Reference><Reference><Citation>He B, Quan LP, Cai CY, Yu DY, Yan W, Wei QJ, et al. Dysregulation and imbalance of innate and adaptive immunity are involved in the cardiomyopathy progression. Front Cardiovasc Med. 2022;6(9):973279.</Citation></Reference><Reference><Citation>McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure. N Engl J Med. 2014;371(11):993&#x2013;1004.</Citation><ArticleIdList><ArticleId IdType="pubmed">25176015</ArticleId></ArticleIdList></Reference><Reference><Citation>Langerbeins P, Hallek M. COVID-19 in patients with hematologic malignancy. Blood. 2022;140(3):236&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">35544585</ArticleId><ArticleId IdType="pmc">9098396</ArticleId></ArticleIdList></Reference><Reference><Citation>The RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021;384(8):693&#x2013;704.</Citation></Reference><Reference><Citation>Garcia-Vidal C, Puerta-Alcalde P, Mateu A, Cuesta-Chasco G, Meira F, Lopera C, et al. Prolonged viral replication in patients with hematologic malignancies hospitalized with COVID-19. Haematologica. 2022;107(7):1731&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">35295080</ArticleId><ArticleId IdType="pmc">9244835</ArticleId></ArticleIdList></Reference><Reference><Citation>Damlaj M, Bartoo G, Cartin-Ceba R, Gijima D, Alkhateeb HB, Merten J, et al. Corticosteroid use as adjunct therapy for respiratory syncytial virus infection in adult allogeneic stem cell transplant recipients. Transpl Infect Dis. 2016;18(2):216&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">26909896</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40713531</PMID><DateCompleted><Year>2025</Year><Month>07</Month><Day>27</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-244X</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>25</Day></PubDate></JournalIssue><Title>BMC psychiatry</Title><ISOAbbreviation>BMC Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Impact of COVID-19 on antidepressant prescription: a matched cohort study using the National insurance claims database in Japan.</ArticleTitle><Pagination><StartPage>725</StartPage><MedlinePgn>725</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12888-025-07172-w</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The COVID-19 pandemic has significantly affected global health, leading to an increased incidence of mental health disorders, particularly depression.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This matched cohort study aimed to assess the impact of COVID-19 on antidepressant prescriptions using data from Japan's National Insurance Claims Database. The primary outcome was new antidepressant prescriptions, with SARS-CoV-2 infection as exposure. Data were matched by age, sex, Charlson comorbidity index (CCI), and insurance enrollment date to compare SARS-CoV-2 infected individuals with matched uninfected controls. Follow-up was terminated upon new antidepressant prescriptions or at the end of the study. The incidence rate ratios (IRR) and differences were calculated and compared using survival analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In this study, 16&#xa0;million participants were analyzed, forming approximately 2.5&#xa0;million pairs. Over 34 months (median follow-up: 7 months, interquartile range 4-13), there were 54,352 and 33,101 antidepressant prescriptions in the COVID-19 and control groups, respectively, with a cumulative incidence difference of 841 events (95% confidence interval [CI]: 815-860) per 1,000,000 person-months and an IRR of 1.56 (95%CI 1.54-1.58). The largest increase was observed with serotonin antagonists and reuptake inhibitors (IRR:2.18, 95%CI 2.11-2.25). Subgroup analyses revealed higher prescription rates among older adults (65&#x2009;+&#x2009;years; IRR:2.02, 95%CI 1.98-2.07) and those with higher CCI scores (4+; IRR:1.82, 95%CI 1.77-1.88). Sensitivity analysis confirmed a persistent increase in risk 1-year post-exposure, with IRR of 1.65 (95%CI 1.63-1.68) and 1.23 (95%CI 1.19-1.27) before and after 1 year, respectively.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">COVID-19 is significantly associated with an increased risk of antidepressant prescriptions, underscoring the need for enhanced mental health support and resources. Addressing stigma and ensuring timely interventions are essential for managing mental health in this context.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Miyamori</LastName><ForeName>Daisuke</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of General Internal Medicine, Hiroshima University Hospital, 1-2-3, Kasumi Minami-ku, Hiroshima-Shi, Hiroshima, 734-8551, Japan. morimiya@hiroshima-u.ac.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoshida</LastName><ForeName>Shuhei</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of General Internal Medicine, Hiroshima University Hospital, 1-2-3, Kasumi Minami-ku, Hiroshima-Shi, Hiroshima, 734-8551, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Omori</LastName><ForeName>Wataru</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurosciences, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kashima</LastName><ForeName>Saori</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center for the Planetary Health and Innovation Science, The IDEC Institute, Hiroshima University, Hiroshima, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Environmental Health Sciences Laboratory, Graduate School of Advanced Science and Engineering, Hiroshima University, Hiroshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ito</LastName><ForeName>Masanori</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of General Internal Medicine, Hiroshima University Hospital, 1-2-3, Kasumi Minami-ku, Hiroshima-Shi, Hiroshima, 734-8551, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>21K17227</GrantID><Agency>Japan Society for the Promotion of Science</Agency><Country/></Grant><Grant><GrantID>JPSCIRS20220305</GrantID><Agency>Innovative Research Program on Suicide Countermeasures</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Psychiatry</MedlineTA><NlmUniqueID>100968559</NlmUniqueID><ISSNLinking>1471-244X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007564" MajorTopicYN="N" Type="Geographic">Japan</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="Y">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011307" MajorTopicYN="Y">Drug Prescriptions</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="Y">Depression</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antidepressants</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Depression</Keyword><Keyword MajorTopicYN="N">Matched cohort study</Keyword><Keyword MajorTopicYN="N">National insurance claims database</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList><CoiStatement>Declarations. Ethics approval and consent to participate: The study protocol was reviewed and approved by the Epidemiological Research Committee of Hiroshima University (approval number E2022-2025) and conducted in accordance with the Declaration of Helsinki. The data that support the findings of this study are available from the Ministry of Health, Labor, and Welfare and are subject to strict confidentiality and privacy regulations ( https://www.mhlw.go.jp/content/12400000/001158704.pdf , in Japanese). Informed consent to participate was waived since the data were obtained from an insurance claims database in an anonymous state. Consent for publication: Consent for publication of the findings based on this dataset was also obtained from the Ministry of Health, Labour, and Welfare in accordance with Guidelines for the use of National Insurance Claims Database (NDB) ( https://www.mhlw.go.jp/content/12400000/001158704.pdf , in Japanese). Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>10</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>27</Day><Hour>0</Hour><Minute>57</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40713531</ArticleId><ArticleId IdType="doi">10.1186/s12888-025-07172-w</ArticleId><ArticleId IdType="pii">10.1186/s12888-025-07172-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Estrela M, Silva TM, Gomes ER, Pineiro M, Figueiras A, Roque F, Herdeiro MT. Prescription of anxiolytics, sedatives, hypnotics and antidepressants in outpatient, universal care during the COVID-19 pandemic in portugal: a nationwide, interrupted time-series approach. J Epidemiol Community Health. 2022;76(4):335&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">34625519</ArticleId></ArticleIdList></Reference><Reference><Citation>Renaud-Charest O, Lui LMW, Eskander S, Ceban F, Ho R, Di Vincenzo JD, Rosenblat JD, Lee Y, Subramaniapillai M, McIntyre RS. Onset and frequency of depression in post-COVID-19 syndrome: A systematic review. J Psychiatr Res. 2021;144:129&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">34619491</ArticleId><ArticleId IdType="pmc">8482840</ArticleId></ArticleIdList></Reference><Reference><Citation>Bueno-Notivol J, Gracia-Garcia P, Olaya B, Lasheras I, Lopez-Anton R, Santabarbara J. Prevalence of depression during the COVID-19 outbreak: A meta-analysis of community-based studies. Int J Clin Health Psychol. 2021;21(1):100196.</Citation><ArticleIdList><ArticleId IdType="pubmed">32904715</ArticleId></ArticleIdList></Reference><Reference><Citation>Tiger M, Castelpietra G, Wesselhoeft R, Lundberg J, Reutfors J. Utilization of antidepressants, anxiolytics, and hypnotics during the COVID-19 pandemic. Transl Psychiatry. 2024;14(1):175.</Citation><ArticleIdList><ArticleId IdType="pubmed">38575574</ArticleId><ArticleId IdType="pmc">10995182</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitaker M, Elliott J, Chadeau-Hyam M, Riley S, Darzi A, Cooke G, Ward H, Elliott P. Persistent symptoms following SARS-CoV-2 infection in a random community sample of 606, 434 people. Nat Commun. 2022;13(1):1957. https://doi.org/10.1038/s41467-022-29521-z .</Citation></Reference><Reference><Citation>Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV. Condition WHOCCDWGoP-C-: A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022;22(4):e102&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y, Bitna H, Kim SW, Chang HH, Kwon KT, Bae S, Hwang S. Post-acute COVID-19 syndrome in patients after 12 months from COVID-19 infection in Korea. BMC Infect Dis. 2022;22(1):93.</Citation><ArticleIdList><ArticleId IdType="pubmed">35086489</ArticleId><ArticleId IdType="pmc">8793328</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazza MG, Palladini M, De Lorenzo R, Bravi B, Poletti S, Furlan R, Ciceri F, group Rovere-Querini C-BOCS, Benedetti P. One-year mental health outcomes in a cohort of COVID-19 survivors. J Psychiatr Res. 2021;145:118&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">34894521</ArticleId><ArticleId IdType="pmc">8607816</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng N, Zhao YM, Yan W, Li C, Lu QD, Liu L, Ni SY, Mei H, Yuan K, Shi L, et al. A systematic review and meta-analysis of long term physical and mental sequelae of COVID-19 pandemic: call for research priority and action. Mol Psychiatry. 2023;28(1):423&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">35668159</ArticleId></ArticleIdList></Reference><Reference><Citation>Caroppo E, Mazza M, Sannella A, Marano G, Avallone C, Claro AE, Janiri D, Moccia L, Janiri L, Sani G. Will nothing be the same again?? Changes in lifestyle during COVID-19 pandemic and consequences on mental health. Int J Environ Res Public Health. 2021;18(16):8433.</Citation><ArticleIdList><ArticleId IdType="pubmed">34444180</ArticleId><ArticleId IdType="pmc">8393535</ArticleId></ArticleIdList></Reference><Reference><Citation>Garrigues E, Janvier P, Kherabi Y, Le Bot A, Hamon A, Gouze H, Doucet L, Berkani S, Oliosi E, Mallart E, et al. Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. J Infect. 2020;81(6):e4&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">32853602</ArticleId><ArticleId IdType="pmc">7445491</ArticleId></ArticleIdList></Reference><Reference><Citation>Whiteside DM, Basso MR, Naini SM, Porter J, Holker E, Waldron EJ, Melnik TE, Niskanen N, Taylor SE. Outcomes in post-acute sequelae of COVID-19 (PASC) at 6 months post-infection part 1: cognitive functioning. Clin Neuropsychol. 2022;36(4):806&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">35130818</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Mental Health Gap Action Programme (mhGAP) guideline for mental, neurological and substance use disorders. https://www.who.int/publications/i/item/9789240084278 .</Citation></Reference><Reference><Citation>Sato K, Kondo N, Kondo K. Pre-pandemic individual- and community-level social capital and depressive symptoms during COVID-19: A longitudinal study of Japanese older adults in 2019-21. Health Place. 2022;74:102772.</Citation><ArticleIdList><ArticleId IdType="pubmed">35228058</ArticleId><ArticleId IdType="pmc">8872828</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsumoto K, Hamatani S, Shimizu E, Kall A, Andersson G. Impact of post-COVID conditions on mental health: a cross-sectional study in Japan and Sweden. BMC Psychiatry. 2022;22(1):237.</Citation><ArticleIdList><ArticleId IdType="pubmed">35379224</ArticleId><ArticleId IdType="pmc">8977559</ArticleId></ArticleIdList></Reference><Reference><Citation>Frontera JA, Simon NM. Bridging knowledge gaps in the diagnosis and management of neuropsychiatric sequelae of COVID-19. JAMA Psychiatry. 2022;79(8):811&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">35767287</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO COVID-19 dashboard. https://data.who.int/dashboards/covid19/deaths?n=o</Citation></Reference><Reference><Citation>Abe K, Suzuki K, Miyawaki A, Kawachi I. Impact of COVID-19 on medical utilization for psychiatric conditions in Japan. Soc Sci Med. 2025;367:117763.</Citation><ArticleIdList><ArticleId IdType="pubmed">39889382</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai M, Xie Y, Topol EJ, Al-Aly Z. Three-year outcomes of post-acute sequelae of COVID-19. Nat Med. 2024;30(6):1564&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">38816608</ArticleId><ArticleId IdType="pmc">11186764</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishikawa H, Kawakami N, Kessler RC, World Mental Health Japan Survey C. Lifetime and 12-month prevalence, severity and unmet need for treatment of common mental disorders in japan: results from the final dataset of world mental health Japan survey. Epidemiol Psychiatr Sci. 2016;25(3):217&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">26148821</ArticleId></ArticleIdList></Reference><Reference><Citation>Resonse to COVID-19. after the classification change [ https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000164708_00079.html ]</Citation></Reference><Reference><Citation>Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">3558716</ArticleId></ArticleIdList></Reference><Reference><Citation>Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, Saunders LD, Beck CA, Feasby TE, Ghali WA. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">16224307</ArticleId></ArticleIdList></Reference><Reference><Citation>Visualizing the data.: information on COVID-19 infections, number of confirmed cases (cumulative) [ https://covid19.mhlw.go.jp/public/opendata/confirmed_cases_cumulative_daily.csv ]</Citation></Reference><Reference><Citation>Kim S, Lee H, Lee J, Lee SW, Kwon R, Kim MS, Koyanagi A, Smith L, Fond G, Boyer L, et al. Short- and long-term neuropsychiatric outcomes in long COVID in South Korea and Japan. Nat Hum Behav. 2024;8(8):1530&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">38918517</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosolen V, Castriotta L, Driutti M, Albert U, Barbone F, Castelpietra G. Association between previous SARs-CoV-2 infection and new prescription of antidepressant drugs: a case-control study in Friuli Venezia Giulia region, Italy. Eur Arch Psychiatry Clin Neurosci. 2024;22(4):279&#x2013;87.</Citation></Reference><Reference><Citation>Velasquez EE, Kamdar NS, Rehkopf DH, Saydah S, Bull-Otterson L, Hao S, Vala A, Chu I, Bazemore AW, Phillips RL, et al. Post-COVID conditions in US primary care: A PRIME registry comparison of patients with COVID-19, Influenza-Like illness, and wellness visits. Ann Fam Med. 2024;22(4):279&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">39038980</ArticleId><ArticleId IdType="pmc">11268691</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohandas S, Jagannathan P, Henrich TJ, Sherif ZA, Bime C, Quinlan E, Portman MA, Gennaro M, Rehman J, Force RMPT. Immune mechanisms underlying COVID-19 pathology and post-acute sequelae of SARS-CoV-2 infection (PASC). eLife. 2023;12:e86014.</Citation></Reference><Reference><Citation>Brown LA, Ballentine E, Zhu Y, McGinley EL, Pezzin L, Abramoff B. The unique contribution of depression to cognitive impairment in Post-Acute sequelae of SARS-CoV-2 infection. Brain Behav Immun Health. 2022;22:100460.</Citation><ArticleIdList><ArticleId IdType="pubmed">35403066</ArticleId><ArticleId IdType="pmc">8983478</ArticleId></ArticleIdList></Reference><Reference><Citation>Vehar S, Boushra M, Ntiamoah P, Biehl M. Post-acute sequelae of SARS-CoV-2 infection: caring for the &#x2018;long-haulers&#x2019;. Cleve Clin J Med. 2021;88(5):267&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">33941600</ArticleId></ArticleIdList></Reference><Reference><Citation>Quan SF, Weaver MD, Czeisler ME, Barger LK, Booker LA, Howard ME, Jackson ML, Lane RI, McDonald CF, Ridgers A, et al. Association of obstructive sleep apnea with Post-Acute sequelae of SARS-CoV-2 infection. Am J Med. 2024;137(6):529&#x2013;37. e523.</Citation><ArticleIdList><ArticleId IdType="pubmed">38401674</ArticleId><ArticleId IdType="pmc">11144080</ArticleId></ArticleIdList></Reference><Reference><Citation>Cipriani G, Danti S, Nuti A, Carlesi C, Lucetti C, Di Fiorino M. A complication of coronavirus disease 2019: delirium. Acta Neurol Belgica. 2020;120(4):927&#x2013;32.</Citation></Reference><Reference><Citation>Garcia-Grimshaw M, Chiquete E, Jimenez-Ruiz A, Vidal-Mayo JJ, Grajeda-Gonzalez SL, Vargas-Martinez MLA, Toapanta-Yanchapaxi LN, Valdes-Ferrer SI, Chavez-Martinez OA, Marche-Fernandez OA, et al. Delirium and associated factors in a cohort of hospitalized patients with coronavirus disease 2019. J Acad Consult Liaison Psychiatry. 2022;63(1):3&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">34242847</ArticleId></ArticleIdList></Reference><Reference><Citation>Wada K, Morita Y, Iwamoto T, Mifune Y, Nojima S. First- and second-line Pharmacological treatment for delirium in general hospital setting-Retrospective analysis. Asian J Psychiatr. 2018;32:50&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">29216606</ArticleId></ArticleIdList></Reference><Reference><Citation>Baba H, Kito S, Nukariya K, Takeshima M, Fujise N, Iga J, Oshibuchi H, Kawano M, Kimura M, Mizukami K, et al. Guidelines for diagnosis and treatment of depression in older adults: A report from the Japanese society of mood disorders. J Neuropsychiatry Clin Neurosci. 2022;76(6):222&#x2013;34.</Citation></Reference><Reference><Citation>Xu X-m, Liu Y, Dong M-x. Zou D-z, Wei Y-d: tricyclic antidepressants for preventing migraine in adults. Medicine. 2017;96(22):e6989.</Citation><ArticleIdList><ArticleId IdType="pubmed">28562550</ArticleId><ArticleId IdType="pmc">5459715</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider J, Patterson M, Jimenez XF. Beyond depression: other uses for tricyclic antidepressants. Cleve Clin J Med. 2019;86(12):807&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">31821138</ArticleId></ArticleIdList></Reference><Reference><Citation>Bogowicz P, Curtis HJ, Walker AJ, Cowen P, Geddes J, Goldacre B. Trends and variation in antidepressant prescribing in english primary care: a retrospective longitudinal study. BJGP Open. 2021;5(4):BJGPO20210020.</Citation></Reference><Reference><Citation>Madeira L, Queiroz G, Henriques R. Prepandemic psychotropic drug status in portugal: a nationwide pharmacoepidemiological profile. Sci Rep. 2023;13(1):6912.</Citation><ArticleIdList><ArticleId IdType="pubmed">37106018</ArticleId><ArticleId IdType="pmc">10139661</ArticleId></ArticleIdList></Reference><Reference><Citation>Peano A, Calabrese F, Pechlivanidis K, Mimmo R, Politano G, Martella M, Gianino MM. International trends in antidepressant consumption: a 10-year comparative analysis (2010&#x2013;2020). Psychiatr Q. 2025;96(2):241&#x2013;55.</Citation></Reference><Reference><Citation>Nagappan A, Miller A, Jain S, Oakes AH. Stimulant, antidepressant, and opioid telehealth prescription trends between 2019 and 2022. JAMA Netw Open. 2024;7(9):e2433334&#x2013;2433334.</Citation><ArticleIdList><ArticleId IdType="pubmed">39269705</ArticleId><ArticleId IdType="pmc">11400214</ArticleId></ArticleIdList></Reference><Reference><Citation>Pierce M, Hope H, Ford T, Hatch S, Hotopf M, John A, Kontopantelis E, Webb R, Wessely S, McManus S, et al. Mental health before and during the COVID-19 pandemic: a longitudinal probability sample survey of the UK population. Lancet Psychiatry. 2020;7(10):883&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">32707037</ArticleId><ArticleId IdType="pmc">7373389</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe K, Sugiyama A, Ito N, Miwata K, Kitahara Y, Okimoto M, Mirzaev U, Kurisu A, Akita T, Ko K, et al. Variant-specific symptoms after COVID-19: A Hospital-based study in Hiroshima. J Epidemiol. 2023;34:238&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">37574270</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowe B, Xie Y, Al-Aly Z. Postacute sequelae of COVID-19 at 2 years. Nat Med. 2023;29(9):2347&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">37605079</ArticleId><ArticleId IdType="pmc">10504070</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MH, Perl DP, Nair G, Li W, Maric D, Murray H, Dodd SJ, Koretsky AP, Watts JA, Cheung V, et al. Microvascular injury in the brains of patients with Covid-19. N Engl J Med. 2021;384(5):481&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">33378608</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakamoto H, Ishikane M, Ghaznavi C, Ueda P. Assessment of suicide in Japan during the COVID-19 pandemic vs previous years. JAMA Netw Open. 2021;4(2):e2037378.</Citation><ArticleIdList><ArticleId IdType="pubmed">33528554</ArticleId><ArticleId IdType="pmc">7856546</ArticleId></ArticleIdList></Reference><Reference><Citation>Ando S, Yamaguchi S, Aoki Y, Thornicroft G. Review of mental-health-related stigma in J Apan. J Neuropsychiatry Clin Neurosci. 2013;67(7):471&#x2013;82.</Citation></Reference><Reference><Citation>Griffiths KM, Nakane Y, Christensen H, Yoshioka K, Jorm AF, Nakane H. Stigma in response to mental disorders: a comparison of Australia and Japan. BMC Psychiatry. 2006;6:21.</Citation><ArticleIdList><ArticleId IdType="pubmed">16716231</ArticleId><ArticleId IdType="pmc">1525161</ArticleId></ArticleIdList></Reference><Reference><Citation>Suka M, Yamauchi T, Sugimori H. Help-seeking intentions for early signs of mental illness and their associated factors: comparison across four kinds of health problems. BMC Public Health. 2016;16:301.</Citation><ArticleIdList><ArticleId IdType="pubmed">27056546</ArticleId><ArticleId IdType="pmc">4825081</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40713482</PMID><DateCompleted><Year>2025</Year><Month>07</Month><Day>27</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-227X</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>26</Day></PubDate></JournalIssue><Title>BMC emergency medicine</Title><ISOAbbreviation>BMC Emerg Med</ISOAbbreviation></Journal><ArticleTitle>Performance of dispatcher-assisted cardiopulmonary resuscitation integrating with mouth-and-nose covering instructions during the COVID-19 pandemic: a population-based retrospective study.</ArticleTitle><Pagination><StartPage>134</StartPage><MedlinePgn>134</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12873-025-01296-8</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The coronavirus disease 2019 (COVID-19) pandemic, which emerged in late 2019, compelled people to change their behavior globally. Due to concerns about potential aerosol transmission during chest compressions, a modified dispatcher-assisted cardiopulmonary resuscitation (DACPR) protocol incorporating mouth-and-nose covering instructions was introduced in Nara, Japan. This study examined its impact on DACPR performance during the COVID-19 pandemic.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This is a retrospective before-after study. DACPR performance data from the Nara Wide Area Fire Department were analyzed, comparing the non-pandemic period (March 2019 to February 2020) with the pandemic period (November 2020 to October 2021). The primary outcome was the time from emergency call acceptance to the first chest compression (T3). Secondary outcomes included the time to cardiac arrest recognition (T1), the time to start of DACPR instructions (T2), DACPR implementation rate, and adherence to infection prevention instructions.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The implementation of the modified protocol did not significantly alter the overall DACPR rate (406, 50.3% in the non-pandemic vs. 390, 47.2% in the pandemic; p&#x2009;=.214). Although the difference was relatively small, a statistically significant prolongation of T3 was observed during the pandemic period (246.0&#xa0;s vs. 261.5&#xa0;s, p&#x2009;&lt;.05). Compliance with mouth-and-nose covering instructions among dispatchers was relatively low (43.1%). Among cases where such instructions were provided, only 21.4% of bystanders fully adhered to the protocol (both the bystander and the patient covering their mouth and nose). However, dispatcher-provided instructions significantly increased the likelihood of bystanders wearing masks and covering the patient's mouth and nose. Multivariable analysis did not identify the protocol implementation as a significant factor influencing T3.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study demonstrated that the modified DACPR protocol incorporating infection prevention measures was associated with a statistically significant delay of approximately 15.0&#xa0;s in CPR initiation. However, given the low adherence rate, the overall impact of these measures on DACPR performance was limited. These findings highlight the need to increase adherence to infection prevention measures while minimizing delays in life-saving interventions, particularly during pandemics caused by airborne pathogens.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Asai</LastName><ForeName>Hideki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Emergency and Critical Care Medicine, Nara Medical University, Shijo-cho, 840, Kashihara City, Nara, 634-8522, Japan. asaih@naramed-u.ac.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fukushima</LastName><ForeName>Hidetada</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Emergency and Critical Care Medicine, Nara Medical University, Shijo-cho, 840, Kashihara City, Nara, 634-8522, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kawai</LastName><ForeName>Yasuyuki</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Emergency and Critical Care Medicine, Nara Medical University, Shijo-cho, 840, Kashihara City, Nara, 634-8522, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miyazaki</LastName><ForeName>Keita</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Emergency and Critical Care Medicine, Nara Medical University, Shijo-cho, 840, Kashihara City, Nara, 634-8522, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamamoto</LastName><ForeName>Kouji</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Emergency and Critical Care Medicine, Nara Medical University, Shijo-cho, 840, Kashihara City, Nara, 634-8522, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kinoshita</LastName><ForeName>Arisa</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Emergency and Critical Care Medicine, Nara Medical University, Shijo-cho, 840, Kashihara City, Nara, 634-8522, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okuda</LastName><ForeName>Hirozumi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Emergency and Critical Care Medicine, Nara Medical University, Shijo-cho, 840, Kashihara City, Nara, 634-8522, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Emerg Med</MedlineTA><NlmUniqueID>100968543</NlmUniqueID><ISSNLinking>1471-227X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016887" MajorTopicYN="Y">Cardiopulmonary Resuscitation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007564" MajorTopicYN="N" Type="Geographic">Japan</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071822" MajorTopicYN="Y">Emergency Medical Dispatcher</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Aerosol-borne infection</Keyword><Keyword MajorTopicYN="N">Emergency medical dispatch</Keyword><Keyword MajorTopicYN="N">Infection prevention</Keyword><Keyword MajorTopicYN="N">Out-of-hospital cardiac arrest</Keyword><Keyword MajorTopicYN="N">Pandemics</Keyword></KeywordList><CoiStatement>Declarations. Ethics approval and consent to participate: This study was approved by the Ethics Committee of Nara Medical University (No. 2322). The requirement for informed consent was waived by the ethics committee because this was a retrospective study using anonymized emergency call records. The study was conducted in accordance with the principles of the Declaration of Helsinki. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>27</Day><Hour>0</Hour><Minute>54</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40713482</ArticleId><ArticleId IdType="doi">10.1186/s12873-025-01296-8</ArticleId><ArticleId IdType="pii">10.1186/s12873-025-01296-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bobrow BJ, Spaite DW, Berg RA, Stolz U, Sanders AB, Kern KB, et al. Chest compression-only CPR by Lay rescuers and survival from out-of-hospital cardiac arrest. JAMA. 2010;304:1447&#x2013;54.</Citation></Reference><Reference><Citation>Iwami T, Kitamura T, Kiyohara K, Kawamura T. Dissemination of chest compression-only cardiopulmonary resuscitation and survival after out-of-hospital cardiac arrest. Circulation. 2015;132:415&#x2013;22.</Citation></Reference><Reference><Citation>Kitamura T, Kiyohara K, Nishiyama C, Kiguchi T, Kobayashi D, Kawamura T, et al. Chest compression-only versus conventional cardiopulmonary resuscitation for bystander-witnessed out-of-hospital cardiac arrest of medical origin: A propensity score-matched cohort from 143,500 patients. Resuscitation. 2018;126:29&#x2013;35.</Citation></Reference><Reference><Citation>Shibahashi K, Ishida T, Kuwahara Y, Sugiyama K, Hamabe Y. Effects of dispatcher-initiated telephone cardiopulmonary resuscitation after out-of-hospital cardiac arrest: A nationwide, population-based, cohort study. Resuscitation. 2019;144:6&#x2013;14.</Citation></Reference><Reference><Citation>Wu Z, Panczyk M, Spaite DW, Hu C, Fukushima H, Langlais B, et al. Telephone cardiopulmonary resuscitation is independently associated with improved survival and improved functional outcome after out-of-hospital cardiac arrest. Resuscitation. 2018;122:135&#x2013;40.</Citation></Reference><Reference><Citation>Rea TD, Eisenberg MS, Culley LL, Becker L. Dispatcher-assisted cardiopulmonary resuscitation and survival in cardiac arrest. Circulation. 2001;104:2513&#x2013;6.</Citation></Reference><Reference><Citation>Sasson C, Magid DJ, Chan P, Root ED, McNally BF, Kellermann AL, et al. Association of neighborhood characteristics with bystander-initiated CPR. N Engl J Med. 2012;367:1607&#x2013;15.</Citation></Reference><Reference><Citation>Bobrow BJ, Spaite DW, Vadeboncoeur TF, Hu C, Mullins T, Tormala W, et al. Implementation of a regional telephone cardiopulmonary resuscitation program and outcomes after out-of-hospital cardiac arrest. JAMA Cardiol. 2016;1:294&#x2013;302.</Citation></Reference><Reference><Citation>Baldi E, Sechi GM, Mare C, Canevari F, Brancaglione A, Primi R, et al. COVID-19 kills at home: the close relationship between the epidemic and the increase of out-of-hospital cardiac arrests. Eur Heart J. 2020;41:3045&#x2013;54.</Citation></Reference><Reference><Citation>Marijon E, Karam N, Jost D, Perrot D, Frattini B, Derkenne C, et al. Out-of-hospital cardiac arrest during the COVID-19 pandemic in paris, france: a population-based, observational study. Lancet Public Health. 2020;5:e437&#x2013;43.</Citation></Reference><Reference><Citation>Nishiyama C, Kiyohara K, Kitamura T, Hayashida S, Maeda T, Kiguchi T, et al. Impact of the COVID-19 pandemic on prehospital intervention and survival of patients with out-of-hospital cardiac arrest in Osaka city, Japan. Circ J. 2022;86:1579&#x2013;85.</Citation></Reference><Reference><Citation>Rosell Ortiz F, Del Fern&#xe1;ndez P, Knox EC, Jim&#xe9;nez F&#xe1;brega X, Navalpotro Pascual JM, Mateo Rodr&#xed;guez I, et al. Influence of the Covid-19 pandemic on out-of-hospital cardiac arrest. A Spanish nationwide prospective cohort study. Resuscitation. 2020;157:230&#x2013;40.</Citation></Reference><Reference><Citation>Grunau B, Bal J, Scheuermeyer F, Guh D, Dainty KN, Helmer J, et al. Bystanders are less willing to resuscitate out-of-hospital cardiac arrest victims during the COVID-19 pandemic. Resusc Plus. 2020;4:100034.</Citation></Reference><Reference><Citation>Simonds AK, Hanak A, Chatwin M, Morrell M, Hall A, Parker KH, et al. Evaluation of droplet dispersion during non-invasive ventilation, oxygen therapy, nebuliser treatment and chest physiotherapy in clinical practice: implications for management of pandemic influenza and other airborne infections. Health Technol Assess. 2010;14:131&#x2013;72.</Citation></Reference><Reference><Citation>Deakin CD, O&#x2019;Neill JF, Tabor T. Does compression-only cardiopulmonary resuscitation generate adequate passive ventilation during cardiac arrest? Resuscitation. 2007;75:53&#x2013;9.</Citation></Reference><Reference><Citation>Nolan JP, Monsieurs KG, Bossaert L, B&#xf6;ttiger BW, Greif R, Lott C, et al. European resuscitation Council COVID-19 guidelines executive summary. Resuscitation. 2020;153:45&#x2013;55.</Citation></Reference><Reference><Citation>Dameff C, Vadeboncoeur T, Tully J, Panczyk M, Dunham A, Murphy R, et al. A standardized template for measuring and reporting telephone pre-arrival cardiopulmonary resuscitation instructions. Resuscitation. 2014;85:869&#x2013;73.</Citation></Reference><Reference><Citation>Lerner EB, Rea TD, Bobrow BJ, Acker JE, Berg RA, Brooks SC, et al. Emergency medical service dispatch cardiopulmonary resuscitation prearrival instructions to improve survival from out-of-hospital cardiac arrest: a scientific statement from the American heart association. Circulation. 2012;125:648&#x2013;55.</Citation></Reference><Reference><Citation>Fukushima H, Imanishi M, Iwami T, Kitaoka H, Asai H, Seki T, et al. Implementation of a dispatch-instruction protocol for cardiopulmonary resuscitation according to various abnormal breathing patterns: a population-based study. Scand J Trauma Resusc Emerg Med. 2015;23:64.</Citation></Reference><Reference><Citation>Fukushima H, Kawai Y, Asai H, Seki T, Norimoto K, Urisono Y, et al. Performance review of regional emergency medical service pre-arrival cardiopulmonary resuscitation with or without dispatcher instruction: a population-based observational study. Acute Med Surg. 2017;4:293&#x2013;9.</Citation></Reference><Reference><Citation>Kanda Y. Investigation of the freely available easy-to-use software &#x2018;EZR&#x2019; for medical statistics. Bone Marrow Transpl. 2013;48:452&#x2013;8.</Citation></Reference><Reference><Citation>Tuffley RH, Folke F, Ersb&#xf8;ll AK, Blomberg SNF, Linderoth G. Is dispatcher-assisted cardiopulmonary resuscitation affected by a bystander&#x2019;s emotional stress state in out-of-hospital cardiac arrest? Scand J Trauma Resusc Emerg Med. 2023;31:82.</Citation></Reference><Reference><Citation>Tanaka Y, Maeda T, Kamikura T, Nishi T, Omi W, Hashimoto M, et al. Potential association of bystander-patient relationship with bystander response and patient survival in daytime out-of-hospital cardiac arrest. Resuscitation. 2015;86:74&#x2013;81.</Citation></Reference><Reference><Citation>Lim SL, Toh C, Fook-Chong S, Yazid M, Shahidah N, Ng QX, et al. Impact of COVID-19 on barriers to dispatcher-assisted cardiopulmonary resuscitation in adult out-of-hospital cardiac arrests in Singapore. Resuscitation. 2022;181:40&#x2013;7.</Citation></Reference><Reference><Citation>Fothergill RT, Smith AL, Wrigley F, Perkins GD. Out-of-Hospital cardiac arrest in London during the COVID-19 pandemic. Resusc Plus. 2021;5:100066.</Citation></Reference><Reference><Citation>Schumann H, B&#xf6;ckelmann I, Thielmann B. Relaxation and strain among emergency medical service personnel and emergency control center dispatchers during the first two waves of the SARS-CoV-2 pandemic. Med Pr. 2023;74:353&#x2013;62.</Citation></Reference><Reference><Citation>Langlais BT, Panczyk M, Sutter J. Barriers to patient positioning for telephone cardiopulmonary resuscitation in out-of-hospital cardiac arrest. Resuscitation. 2017;115:163&#x2013;8.</Citation></Reference><Reference><Citation>Lewis M, Stubbs BA, Eisenberg MS. Dispatcher-assisted cardiopulmonary resuscitation: time to identify cardiac arrest and deliver chest compression instructions. Circulation. 2013;128:1522&#x2013;30.</Citation></Reference><Reference><Citation>American Heart Association. Telecommunicator CPR recommendations and performance measures. American Heart Association, Dallas. 2025. https://cpr.heart.org/en/resuscitation-science/telecommunicator-cpr/telecommunicator-cpr-recommendations-and-performance-measures Accessed 20 Jun 2025.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40713365</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0929-6646</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Jul</Month><Day>25</Day></PubDate></JournalIssue><Title>Journal of the Formosan Medical Association = Taiwan yi zhi</Title><ISOAbbreviation>J Formos Med Assoc</ISOAbbreviation></Journal><ArticleTitle>Response to Letter to Editor "Advantage of the protein-subunit SARS-CoV-2 vaccines, MVC-CoV1901 and NVX-CoV2373".</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S0929-6646(25)00388-2</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jfma.2025.07.021</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lai</LastName><ForeName>Pei-Hsinq</ForeName><Initials>PH</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Taipei City Hospital Zhongxiao Branch, Taipei, Taiwan. Electronic address: hspeinqlai@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsieh</LastName><ForeName>Song-Chou</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; Department of Internal Medicine, National Taiwan University Hospital Cancer Center, Taipei, Taiwan. Electronic address: hsiehsc@ntu.edu.tw.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Singapore</Country><MedlineTA>J Formos Med Assoc</MedlineTA><NlmUniqueID>9214933</NlmUniqueID><ISSNLinking>0929-6646</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement>Declaration of competing interest The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>7</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>26</Day><Hour>23</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40713365</ArticleId><ArticleId IdType="doi">10.1016/j.jfma.2025.07.021</ArticleId><ArticleId IdType="pii">S0929-6646(25)00388-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40713033</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-2648</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Jul</Month><Day>25</Day></PubDate></JournalIssue><Title>Journal of advanced nursing</Title><ISOAbbreviation>J Adv Nurs</ISOAbbreviation></Journal><ArticleTitle>Evaluating the Effects of Organisational Environment on Patient-Perceived Hospital Discharge Readiness Among Patients With Acute Myocardial Infarction During Public Health Emergencies: An Observational Study.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1111/jan.70100</ELocationID><Abstract><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">To evaluate the effects of the organisational environment on hospital discharge readiness during public health emergencies.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">An observational study.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A regression-discontinuity design approach was employed to assess the impact of the organisational environment on hospital discharge readiness. Adult patients diagnosed with acute myocardial infarction and discharged from the Cardiac Critical Care Unit of a tertiary hospital in Shanghai, China, were recruited. Spearman correlation analysis was conducted to examine the associations between multiple factors at individual and organisational levels and hospital discharge readiness across three stages of pandemic policy changes.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 411 patients were included in the analysis. The regression-discontinuity analysis revealed a significant discontinuity at the cut-off, indicating that policy-driven changes in the organisational environment during public health emergencies were associated with a 21.61% reduction in hospital discharge readiness. Additionally, family functioning and the quality of nursing discharge education were significantly associated with discharge readiness across all three pandemic stages.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These findings demonstrate that patient-perceived hospital discharge readiness is significantly influenced by changes in the organisational environment during public health emergencies. Future research should focus on developing targeted discharge preparation programmes that allow for organisational adaptation in response to emergencies, such as pandemics or natural disasters.</AbstractText><AbstractText Label="IMPLICATIONS FOR PATIENT CARE" NlmCategory="CONCLUSIONS">Organisational responses to public health emergencies need to prioritise enhancing discharge preparedness. This includes bolstering family involvement and ensuring that nurses are adequately trained to provide effective discharge education, especially when healthcare resources are strained.</AbstractText><AbstractText Label="IMPACT" NlmCategory="CONCLUSIONS">The findings underscore the importance of adaptable and resilient discharge planning and transitional care, particularly in public health emergencies. Fostering an organisational environment that supports seamless discharge processes can significantly improve patient readiness for post-hospital care.</AbstractText><AbstractText Label="REPORTING METHODS" NlmCategory="UNASSIGNED">Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement.</AbstractText><AbstractText Label="PATIENT OR PUBLIC CONTRIBUTION" NlmCategory="UNASSIGNED">No patient or Public Contributions.</AbstractText><CopyrightInformation>&#xa9; 2025 John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wen</LastName><ForeName>Yuehui</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>School of Nursing, Shanghai Jiao Tong University, Shanghai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Shanghai Jiao Tong University School of Medicine, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Cardiology and Department of Nursing, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Geraldine</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-6385-8600</Identifier><AffiliationInfo><Affiliation>Catherine McAuley School of Nursing &amp; Midwifery, Brookfield Health Sciences Complex, University College Cork, Cork, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Mengyun</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Great Ormond Street Institute of Child Health, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xiyi</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0002-6470-8556</Identifier><AffiliationInfo><Affiliation>School of Nursing, Shanghai Jiao Tong University, Shanghai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Shanghai Jiao Tong University School of Medicine, Shanghai, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology and Department of Nursing, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>SJTUHLXK2024</GrantID><Agency>Shanghai Jiao Tong University School of Medicine: Nursing Development Program</Agency><Country/></Grant><Grant><GrantID>72304183</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>HLDC23-03</GrantID><Agency>the Medical Innovation Talent Cultivation Program of Shanghai High-level Local Universities</Agency><Country/></Grant><Grant><GrantID>25692114800</GrantID><Agency>Shanghai Science and Technology Foundation Soft Science Research Project</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Adv Nurs</MedlineTA><NlmUniqueID>7609811</NlmUniqueID><ISSNLinking>0309-2402</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID&#x2010;19</Keyword><Keyword MajorTopicYN="N">acute myocardial infarction</Keyword><Keyword MajorTopicYN="N">hospital discharge</Keyword><Keyword MajorTopicYN="N">organisational factors</Keyword><Keyword MajorTopicYN="N">public health emergencies</Keyword><Keyword MajorTopicYN="N">regression&#x2010;discontinuity design</Keyword><Keyword MajorTopicYN="N">transitional care</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>6</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>12</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>20</Hour><Minute>32</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40713033</ArticleId><ArticleId IdType="doi">10.1111/jan.70100</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>Aarons, G. A., C. Glisson, P. D. Green, et&#xa0;al. 2012. &#x201c;The Organizational Social Context of Mental Health Services and Clinician Attitudes Toward Evidence&#x2010;Based Practice: A United States National Study.&#x201d; Implementation Science 7, no. 1: 56. https://doi.org/10.1186/1748&#x2010;5908&#x2010;7&#x2010;56.</Citation></Reference><Reference><Citation>Bing&#x2010;Hua, W., W. Hui, and Y. Chun&#x2010;Zi. 2016. &#x201c;Reliability and Validity of the Chinese Version of the Quality of Discharge Teaching Scale.&#x201d; Chinese Journal of Nursing 51, no. 6: 752&#x2013;755. https://doi.org/10.3761/j.issn.0254&#x2010;1769.2016.06.025.</Citation></Reference><Reference><Citation>Blomstr&#xf6;m&#x2010;Lundqvist, C. 2020. &#x201c;Effects of COVID&#x2010;19 Lockdown Strategies on Management of Atrial Fibrillation.&#x201d; European Heart Journal 41, no. 32: 3080&#x2013;3082. https://doi.org/10.1093/eurheartj/ehaa538.</Citation></Reference><Reference><Citation>Braiteh, N., W. u. Rehman, M. Alom, et&#xa0;al. 2020. &#x201c;Decrease in Acute Coronary Syndrome Presentations During the COVID&#x2010;19 Pandemic in Upstate New York.&#x201d; American Heart Journal 226: 147&#x2013;151. https://doi.org/10.1016/j.ahj.2020.05.009.</Citation></Reference><Reference><Citation>Calonico, S., M. D. Cattaneo, M. Farrell, and R. o. Titiunik. 2017. &#x201c;Rdrobust: Software for Regression&#x2010;Discontinuity Designs.&#x201d; Stata Journal 17: 372&#x2013;404.</Citation></Reference><Reference><Citation>Calonico, S., N. Jawadekar, K. Kezios, and A. Zeki AlHazzouri. 2024. &#x201c;Regression Discontinuity Design Studies: A Guide for Health Researchers.&#x201d; British Medical Journal 384: e072254. https://doi.org/10.1136/bmj&#x2010;2022&#x2010;072254.</Citation></Reference><Reference><Citation>Carson, M. B., D. M. Scholtens, C. N. Frailey, et&#xa0;al. 2016. &#x201c;Characterizing Teamwork in Cardiovascular Care Outcomes: A Network Analytics Approach.&#x201d; Circulation. Cardiovascular Quality and Outcomes 9, no. 6: 670&#x2013;678. https://doi.org/10.1161/circoutcomes.116.003041.</Citation></Reference><Reference><Citation>Cattaneo, M., N. Idrobo, and R. Titiunik. 2023. &#x201c;A Practical Introduction to Regression Discontinuity Designs: Extensions.&#x201d; arXiv. Cambridge University Press. https://doi.org/10.48550/arXiv.2301.08958.</Citation></Reference><Reference><Citation>Cattaneo, M. D., M. Jansson, and X. Ma. 2018. &#x201c;Manipulation Testing Based on Density Discontinuity.&#x201d; Stata Journal 18: 234&#x2013;261. https://doi.org/10.1177/1536867X1801800115.</Citation></Reference><Reference><Citation>Chartrand, J., B. Shea, B. Hutton, et&#xa0;al. 2023. &#x201c;Patient&#x2010; and Family&#x2010;Centred Care Transition Interventions for Adults: A Systematic Review and Meta&#x2010;Analysis of RCTs.&#x201d; International Journal for Quality in Health Care 35, no. 4: mzad102. https://doi.org/10.1093/intqhc/mzad102.</Citation></Reference><Reference><Citation>Cherlin, E. J., L. A. Curry, J. W. Thompson, et&#xa0;al. 2013. &#x201c;Features of High Quality Discharge Planning for Patients Following Acute Myocardial Infarction.&#x201d; Journal of General Internal Medicine 28, no. 3: 436&#x2013;443. https://doi.org/10.1007/s11606&#x2010;012&#x2010;2234&#x2010;y.</Citation></Reference><Reference><Citation>Dang, H.&#x2010;A. H., and T.&#x2010;A. Trinh. 2021. &#x201c;Does the COVID&#x2010;19 Lockdown Improve Global Air Quality? New Cross&#x2010;National Evidence on Its Unintended Consequences.&#x201d; Journal of Environmental Economics and Management 105: 102401. https://doi.org/10.1016/j.jeem.2020.102401.</Citation></Reference><Reference><Citation>Dhuper, M., L. Ruttan, L. MacGillvray, et&#xa0;al. 2022. &#x201c;Future Public Health Emergencies and Disasters: Sustainability and Insights Into Support Programs for Healthcare Providers.&#x201d; BMC Psychiatry 22, no. 1: 664. https://doi.org/10.1186/s12888&#x2010;022&#x2010;04309&#x2010;z.</Citation></Reference><Reference><Citation>Donabedian, A. 2005. &#x201c;Evaluating the Quality of Medical Care. 1966.&#x201d; Milbank Quarterly 83, no. 4: 691&#x2013;729. https://doi.org/10.1111/j.1468&#x2010;0009.2005.00397.x.</Citation></Reference><Reference><Citation>Eskes, A. M., G. Tobiano, J. Carlini, C. Kuijpers, S. C. W. Musters, and W. Chaboyer. 2023. &#x201c;Fundamentally Shifting Discharge Planning and Post&#x2010;Hospital Care.&#x201d; International Journal of Nursing Studies 145: 104533. https://doi.org/10.1016/j.ijnurstu.2023.104533.</Citation></Reference><Reference><Citation>Glance, L. G., K. E. Joynt Maddox, J. Shang, et&#xa0;al. 2023. &#x201c;The COVID&#x2010;19 Pandemic and Associated Inequities in Acute Myocardial Infarction Treatment and Outcomes.&#x201d; JAMA Network Open 6, no. 8: e2330327. https://doi.org/10.1001/jamanetworkopen.2023.30327.</Citation></Reference><Reference><Citation>Goda, K., T. Kenzaka, S. Yahata, A. Kumabe, M. Katsurada, and H. Nishisaki. 2021. &#x201c;Concerns and Anxieties of Patients During Hospitalization for COVID&#x2010;19.&#x201d; Cureus 13, no. 9: e18202. https://doi.org/10.7759/cureus.18202.</Citation></Reference><Reference><Citation>Gramegna, M., L. Baldetti, A. Beneduce, et&#xa0;al. 2020. &#x201c;ST&#x2010;Segment&#x2010;Elevation Myocardial Infarction During COVID&#x2010;19 Pandemic: Insights From a Regional Public Service Healthcare Hub.&#x201d; Circulation. Cardiovascular Interventions 13, no. 8: e009413. https://doi.org/10.1161/circinterventions.120.009413.</Citation></Reference><Reference><Citation>Guo, X., J. Li, Y. Gao, F. Su, and B. Xue. 2021. &#x201c;Influence of Major Public Health Emergencies on Family Relationship and Humanistic Geographical Characteristics of China.&#x201d; International Journal of Environmental Research and Public Health 18, no. 8: 3879. https://doi.org/10.3390/ijerph18083879.</Citation></Reference><Reference><Citation>Hausman, C., and D. S. Rapson. 2018. &#x201c;Regression Discontinuity in Time: Considerations for Empirical Applications.&#x201d; Annual Review of Resource Economics 10, no. 1: 533&#x2013;552. https://doi.org/10.1146/annurev&#x2010;resource&#x2010;121517&#x2010;033306.</Citation></Reference><Reference><Citation>He, H., J. Wang, Z. Yuan, M. Teng, and S. Wang. 2024. &#x201c;Nurses' Mental Workload and Public Health Emergency Response Capacity in COVID&#x2010;19 Pandemic: A Cross&#x2010;Sectional Study.&#x201d; Journal of Advanced Nursing 80, no. 4: 1429&#x2013;1439. https://doi.org/10.1111/jan.15929.</Citation></Reference><Reference><Citation>Hendriks, J. M., and G. Lee. 2020. &#x201c;Shared Decision&#x2010;Making: The Patient on the Forefront of Care Coordination.&#x201d; European Heart Journal &#x2010; Quality of Care and Clinical Outcomes 6, no. 4: 231&#x2013;233. https://doi.org/10.1093/ehjqcco/qcaa039.</Citation></Reference><Reference><Citation>Hu, S. S. 2024. &#x201c;Epidemiology and Current Management of Cardiovascular Disease in China.&#x201d; Journal of Geriatric Cardiology 21, no. 4: 387&#x2013;406. https://doi.org/10.26599/1671&#x2010;5411.2024.04.001.</Citation></Reference><Reference><Citation>Hydzik, P., E. Kolarczyk, W. Kustrzycki, et&#xa0;al. 2021. &#x201c;Readiness for Discharge From Hospital After Myocardial Infarction: A Cross&#x2010;Sectional Study.&#x201d; International Journal of Environmental Research and Public Health 18, no. 13: 6397. https://doi.org/10.3390/ijerph18136937.</Citation></Reference><Reference><Citation>IBM Corp. 2019. IBM SPSS Statistics for Windows, Version 26.0. IBM Corp.</Citation></Reference><Reference><Citation>Kang, L., S. Ma, M. Chen, et&#xa0;al. 2020. &#x201c;Impact on Mental Health and Perceptions of Psychological Care Among Medical and Nursing Staff in Wuhan During the 2019 Novel Coronavirus Disease Outbreak: A Cross&#x2010;Sectional Study.&#x201d; Brain, Behavior, and Immunity 87: 11&#x2013;17. https://doi.org/10.1016/j.bbi.2020.03.028.</Citation></Reference><Reference><Citation>Kim, Y., K. Lee, S. Oh, and H. Park. 2022. &#x201c;Effectiveness of Emergent ad hoc Coordination Groups in Public Health Emergencies.&#x201d; Risk Analysis 42, no. 1: 5&#x2013;20. https://doi.org/10.1111/risa.13751.</Citation></Reference><Reference><Citation>Kolarczyk, E., A. Witkowska, M. Szymiczek, and A. M&#x142;ynarska. 2023. &#x201c;The Variables of the Readiness for Discharge From Hospital in Patients After Myocardial Infarction.&#x201d; International Journal of Environmental Research and Public Health 20, no. 2: 1582. https://doi.org/10.3390/ijerph20021582.</Citation></Reference><Reference><Citation>Kosobucka, A., P. Michalski, &#x141;. Pietrzykowski, et&#xa0;al. 2022. &#x201c;The Impact of Readiness to Discharge From Hospital on Adherence to Treatment in Patients After Myocardial Infarction.&#x201d; Cardiology Journal 29, no. 4: 582&#x2013;590. https://doi.org/10.5603/CJ.a2020.0005.</Citation></Reference><Reference><Citation>Lancet, T. 2023. &#x201c;The COVID&#x2010;19 Pandemic in 2023: Far From Over.&#x201d; Lancet 401, no. 10371: 79. https://doi.org/10.1016/S0140&#x2010;6736(23)00050&#x2010;8.</Citation></Reference><Reference><Citation>Lasater, K. B., M. D. McHugh, and L. H. Aiken. 2024. &#x201c;Hospital Nurse Staffing Variation and Covid&#x2010;19 Deaths: A Cross&#x2010;Sectional Study.&#x201d; International Journal of Nursing Studies 158: 104830. https://doi.org/10.1016/j.ijnurstu.2024.104830.</Citation></Reference><Reference><Citation>Lau, D., R. S. Padwal, S. R. Majumdar, et&#xa0;al. 2016. &#x201c;Patient&#x2010;Reported Discharge Readiness and 30&#x2010;Day Risk of Readmission or Death: A Prospective Cohort Study.&#x201d; American Journal of Medicine 129, no. 1: 89&#x2013;95. https://doi.org/10.1016/j.amjmed.2015.08.018.</Citation></Reference><Reference><Citation>Lavie, G., E. Battat, W. Saliba, and M. Y. Flugelman. 2022. &#x201c;Change in Hospitalizations and 30&#x2010;Day Mortality of Patients With Acute Myocardial Infarction During the First COVID&#x2010;19 Lockdown &#x2010; A Pure Social Isolation Effect?&#x201d; Cardiovascular Revascularization Medicine 38: 38&#x2013;42. https://doi.org/10.1016/j.carrev.2021.08.025.</Citation></Reference><Reference><Citation>Levoy, K., E. Rivera, M. McHugh, A. Hanlon, K. B. Hirschman, and M. D. Naylor. 2022. &#x201c;Caregiver Engagement Enhances Outcomes Among Randomized Control Trials of Transitional Care Interventions: A Systematic Review and Meta&#x2010;Analysis.&#x201d; Medical Care 60, no. 7: 519&#x2013;529. https://doi.org/10.1097/mlr.0000000000001728.</Citation></Reference><Reference><Citation>Lin, S., C. Wang, Q. Wang, et&#xa0;al. 2022. &#x201c;The Experience of Stroke Survivors and Caregivers During Hospital&#x2010;To&#x2010;Home Transitional Care: A Qualitative Longitudinal Study.&#x201d; International Journal of Nursing Studies 130: 104213. https://doi.org/10.1016/j.ijnurstu.2022.104213.</Citation></Reference><Reference><Citation>Lin, Y. H., C. C. Kao, A. M. Huang, M. T. Chi, and F. H. Chou. 2014. &#x201c;Psychometric Testing of the Chinese Version of the Readiness for Hospital Discharge Scale.&#x201d; Hu Li Za Zhi 61, no. 4: 56&#x2013;65. https://doi.org/10.6224/jn.61.4.56.</Citation></Reference><Reference><Citation>Mabire, C., S. Bachnick, D. Ausserhofer, and M. Simon. 2019. &#x201c;Patient Readiness for Hospital Discharge and Its Relationship to Discharge Preparation and Structural Factors: A Cross&#x2010;Sectional Study.&#x201d; International Journal of Nursing Studies 90: 13&#x2013;20. https://doi.org/10.1016/j.ijnurstu.2018.09.016.</Citation></Reference><Reference><Citation>Maciejewski, M. L., and A. Basu. 2020. &#x201c;Regression Discontinuity Design.&#x201d; JAMA 324, no. 4: 381&#x2013;382. https://doi.org/10.1001/jama.2020.3822.</Citation></Reference><Reference><Citation>Meleis, A. I., L. M. Sawyer, E.&#x2010;O. Im, D. K. Hilfinger Messias, and K. Schumacher. 2000. &#x201c;Experiencing Transitions: An Emerging Middle&#x2010;Range Theory.&#x201d; ANS. Advances in Nursing Science 23, no. 1: 12&#x2013;28. https://doi.org/10.1097/00012272&#x2010;200009000&#x2010;00006.</Citation></Reference><Reference><Citation>Mohtady Ali, H., J. Ranse, A. Roiko, and C. Desha. 2025. &#x201c;Health Care Workers' Perceptions of Hospital Disaster Planning and Preparedness for Building Resilient Healthcare Systems.&#x201d; Disaster Medicine and Public Health Preparedness 19: e77. https://doi.org/10.1017/dmp.2025.3.</Citation></Reference><Reference><Citation>Monfared, A., N. Javadi&#x2010;Pashaki, N. Dehghan Nayeri, and F. Jafaraghaee. 2024. &#x201c;Barriers and Facilitators of Readiness for Hospital Discharge in Patients With Myocardial Infarction: A Qualitative Study: Quality Improvement Study.&#x201d; Annals of Medicine and Surgery 86, no. 4: 1967&#x2013;1976. https://doi.org/10.1097/MS9.0000000000001706.</Citation></Reference><Reference><Citation>Poh, P.&#x2010;F., J. H. Lee, Y. J. Loh, T. H. Tan, and K. K. F. Cheng. 2020. &#x201c;Readiness for Hospital Discharge, Stress, and Coping in Mothers of Children Undergoing Cardiac Surgeries: A Single&#x2010;Center Prospective Study.&#x201d; Pediatric Critical Care Medicine 21, no. 5: e301&#x2013;e310. https://doi.org/10.1097/pcc.0000000000002276.</Citation></Reference><Reference><Citation>Presciutti, A. M., N. Enkhtsetseg, K. L. Flickinger, et&#xa0;al. 2024. &#x201c;Emotional Distress, Social Support, and Functional Dependence Predict Readiness for Hospital Discharge in a Prospective Sample of Cognitively Intact Cardiac Arrest Survivors.&#x201d; Resuscitation 198: 110166. https://doi.org/10.1016/j.resuscitation.2024.110166.</Citation></Reference><Reference><Citation>Qin, H., D. Bonderman, S. Brunner, T. Gro&#xdf;bichler, E. Scharinger, and H. Mayer. 2022. &#x201c;Exploring Patients' and Relatives' Needs Following Acute Myocardial Infarction&#x2014;A Qualitative Study.&#x201d; HeilberufeSCIENCE 13, no. 3: 110&#x2013;122. https://doi.org/10.1007/s16024&#x2010;022&#x2010;00373&#x2010;3.</Citation></Reference><Reference><Citation>Radaideh, A., J. A. Rababah, M. M. Al&#x2010;Hammouri, W. a. Ta'an, and M. Suliman. 2024. &#x201c;The Association of Health Literacy With the Quality of Discharge Planning and Readiness for Hospital Discharge in Jordanian Acute Myocardial Infarction Patients.&#x201d; Journal of Clinical Nursing 33: 17543. https://doi.org/10.1111/jocn.17543.</Citation></Reference><Reference><Citation>Raman, B., D. A. Bluemke, T. F. L&#xfc;scher, and S. Neubauer. 2022. &#x201c;Long COVID: Post&#x2010;Acute Sequelae of COVID&#x2010;19 With a Cardiovascular Focus.&#x201d; European Heart Journal 43, no. 11: 1157&#x2013;1172. https://doi.org/10.1093/eurheartj/ehac031.</Citation></Reference><Reference><Citation>Rattka, M., M. Baumhardt, J. Dreyhaupt, et&#xa0;al. 2020. &#x201c;31&#x2009;Days of COVID&#x2010;19&#x2010;Cardiac Events During Restriction of Public Life&#x2010;A Comparative Study.&#x201d; Clinical Research in Cardiology 109, no. 12: 1476&#x2013;1482. https://doi.org/10.1007/s00392&#x2010;020&#x2010;01681&#x2010;2.</Citation></Reference><Reference><Citation>Rodrigues, M. A., R. F. Santana, A. B. S. Hercules, P. F. A. Barros, and C. B. Lima. 2024. &#x201c;Telenursing With Elderly People in Home Care Service During the COVID&#x2010;19 Pandemic: Quasi&#x2010;Experimental Study.&#x201d; Revista Latino&#x2010;Americana de Enfermagem 32: e4320. https://doi.org/10.1590/1518&#x2010;8345.7138.4320.</Citation></Reference><Reference><Citation>Rohani, C., H. Jafarpoor, Y. Mortazavi, B. Esbakian, and H. Gholinia. 2022. &#x201c;Mortality in Patients With Myocardial Infarction and Potential Risk Factors: A Five&#x2010;Year Data Analysis.&#x201d; ARYA Atherosclerosis Journal 18, no. 3: 1&#x2013;8. https://doi.org/10.48305/arya.v18i0.2427.</Citation></Reference><Reference><Citation>Rotvig, C., A. V. Christensen, T. B. Rasmussen, et&#xa0;al. 2021. &#x201c;Unreadiness for Hospital Discharge Predicts Readmission Among Cardiac Patients: Results From the National DenHeart Survey.&#x201d; European Journal of Cardiovascular Nursing 20, no. 7: 667&#x2013;675. https://doi.org/10.1093/eurjcn/zvab017.</Citation></Reference><Reference><Citation>Ryan, B., M. Kako, R. Fink, et&#xa0;al. 2023. &#x201c;Strategies for Strengthening the Resilience of Public Health Systems for Pandemics, Disasters, and Other Emergencies.&#x201d; Disaster Medicine and Public Health Preparedness 17: e479. https://doi.org/10.1017/dmp.2023.136.</Citation></Reference><Reference><Citation>Santi, L., D. Golinelli, A. Tampieri, et&#xa0;al. 2021. &#x201c;Non&#x2010;COVID&#x2010;19 Patients in Times of Pandemic: Emergency Department Visits, Hospitalizations and Cause&#x2010;Specific Mortality in Northern Italy.&#x201d; PLoS One 16, no. 3: e0248995. https://doi.org/10.1371/journal.pone.0248995.</Citation></Reference><Reference><Citation>Schmitz, T., C. Meisinger, I. Kirchberger, et&#xa0;al. 2021. &#x201c;Impact of COVID&#x2010;19 Pandemic Lockdown on Myocardial Infarction Care.&#x201d; European Journal of Epidemiology 36, no. 6: 619&#x2013;627. https://doi.org/10.1007/s10654&#x2010;021&#x2010;00764&#x2010;2.</Citation></Reference><Reference><Citation>Shi, J., Y. Tao, C. Yan, et&#xa0;al. 2022. &#x201c;A Study on the Correlation Between Family Dynamic Factors and Depression in Adolescents.&#x201d; Frontiers in Psychiatry 13: 1025168. https://doi.org/10.3389/fpsyt.2022.1025168.</Citation></Reference><Reference><Citation>Solomon, M. D., E. J. McNulty, J. S. Rana, et&#xa0;al. 2020. &#x201c;The Covid&#x2010;19 Pandemic and the Incidence of Acute Myocardial Infarction.&#x201d; New England Journal of Medicine 383, no. 7: 691&#x2013;693. https://doi.org/10.1056/NEJMc2015630.</Citation></Reference><Reference><Citation>Song, J., K. Murugiah, S. Hu, et&#xa0;al. 2020. &#x201c;Incidence, Predictors, and Prognostic Impact of Recurrent Acute Myocardial Infarction in China.&#x201d; Heart 107, no. 4: 313&#x2013;318. https://doi.org/10.1136/heartjnl&#x2010;2020&#x2010;317165.</Citation></Reference><Reference><Citation>StataCorp. 2023. &#x201c;Stata Statistical Software: Release 18.&#x201d; College Station, TX: StataCorp LLC.</Citation></Reference><Reference><Citation>Tang, C., X. Chen, C. Guan, and P. Fang. 2022. &#x201c;Attitudes and Response Capacities for Public Health Emergencies of Healthcare Workers in Primary Healthcare Institutions: A Cross&#x2010;Sectional Investigation Conducted in Wuhan, China, in 2020.&#x201d; International Journal of Environmental Research and Public Health 19, no. 19: 12204. https://doi.org/10.3390/ijerph191912204.</Citation></Reference><Reference><Citation>Tangcharoensathien, V., O. Srisookwatana, P. Pinprateep, T. Posayanonda, and W. Patcharanarumol. 2017. &#x201c;Multisectoral Actions for Health: Challenges and Opportunities in Complex Policy Environments.&#x201d; International Journal of Health Policy and Management 6, no. 7: 359&#x2013;363. https://doi.org/10.15171/ijhpm.2017.61.</Citation></Reference><Reference><Citation>Titler, M. G., and D. M. Pettit. 1995. &#x201c;Discharge Readiness Assessment.&#x201d; Journal of Cardiovascular Nursing 9, no. 4: 64&#x2013;74. https://doi.org/10.1097/00005082&#x2010;199507000&#x2010;00007.</Citation></Reference><Reference><Citation>Tobiano, G., W. Chaboyer, T. Teasdale, J. Cussen, R. Raleigh, and E. Manias. 2021. &#x201c;Older Patient and Family Discharge Medication Communication: A Mixed&#x2010;Methods Study.&#x201d; Journal of Evaluation in Clinical Practice 27, no. 4: 898&#x2013;906. https://doi.org/10.1111/jep.13494.</Citation></Reference><Reference><Citation>Tomasoni, D., M. Adamo, L. Italia, et&#xa0;al. 2020. &#x201c;Impact of COVID&#x2010;2019 Outbreak on Prevalence, Clinical Presentation and Outcomes of ST&#x2010;Elevation Myocardial Infarction.&#x201d; Journal of Cardiovascular Medicine (Hagerstown, Md.) 21, no. 11: 874&#x2013;881. https://doi.org/10.2459/jcm.0000000000001098.</Citation></Reference><Reference><Citation>Wallace, A. S., A. A. Bristol, E. P. Johnson, et&#xa0;al. 2024. &#x201c;Impact of Social Risk Screening on Discharge Care Processes and Postdischarge Outcomes: A Pragmatic Mixed&#x2010;Methods Clinical Trial During the COVID&#x2010;19 Pandemic.&#x201d; Medical Care 62, no. 10: 639&#x2013;649. https://doi.org/10.1097/mlr.0000000000002048.</Citation></Reference><Reference><Citation>Wallace, A. S., S. E. Raaum, E. P. Johnson, et&#xa0;al. 2023. &#x201c;Impact of COVID&#x2010;19 Visitation Policies and Hospital Capacity on Discharge Readiness in Medicine Patients.&#x201d; Discover Health Systems 2, no. 1: 45. https://doi.org/10.1007/s44250&#x2010;023&#x2010;00060&#x2010;8.</Citation></Reference><Reference><Citation>Wang, X., J. Lian, M. Ji, G. Lee, and Y. Hu. 2024. &#x201c;Nurse Managers' Experiences in Organisational Adaptation During Public Health Emergencies: A Qualitative Study.&#x201d; Journal of Advanced Nursing 81: 4172&#x2013;4186. https://doi.org/10.1111/jan.16626.</Citation></Reference><Reference><Citation>Wang, X., J. Shao, J. Lian, et&#xa0;al. 2024. &#x201c;Measuring the Nursing Work Environment During Public Health Emergencies: Scale Adaptation and Validation.&#x201d; Journal of Nursing Management 2024: 9910079. https://doi.org/10.1155/2024/9910079.</Citation></Reference><Reference><Citation>Wang, X., L. Xu, G. Lee, et&#xa0;al. 2023. &#x201c;Development of an Integrated Cardiac Rehabilitation Program to Improve the Adaptation Level of Patients After Acute Myocardial Infarction.&#x201d; Frontiers in Public Health 11: 1121563. https://doi.org/10.3389/fpubh.2023.1121563.</Citation></Reference><Reference><Citation>Weiss, M. E., and L. B. Piacentine. 2006. &#x201c;Psychometric Properties of the Readiness for Hospital Discharge Scale.&#x201d; Journal of Nursing Measurement 14, no. 3: 163&#x2013;180. https://doi.org/10.1891/jnm&#x2010;v14i3a002.</Citation></Reference><Reference><Citation>Weiss, M. E., L. B. Piacentine, L. Lokken, et&#xa0;al. 2007. &#x201c;Perceived Readiness for Hospital Discharge in Adult Medical&#x2010;Surgical Patients.&#x201d; Clinical Nurse Specialist 21, no. 1: 31&#x2013;42. https://doi.org/10.1097/00002800&#x2010;200701000&#x2010;00008.</Citation></Reference><Reference><Citation>WHO. 2019. &#x201c;Health Emergency and Disaster Risk Management Framework.&#x201d; https://apps.who.int/iris/handle/10665/326106.</Citation></Reference><Reference><Citation>WHO. 2020. &#x201c;The Top 10 Causes of Death.&#x201d; HTTP://sfx&#x2010;86sjtu.hosted.exlibrisgroup.com.cn/86sjtu?url_ver=Z39.88&#x2010;2004&amp;rft.genre=other&amp;rfr_id=info%3Asid%2Fwiley&amp;rft.date=2020&amp;rft.title=%3FThe%20Top%2010%20Causes%20of%20Death.%3F.</Citation></Reference><Reference><Citation>Yang, Z., Y. Cui, Y. Yang, et&#xa0;al. 2021. &#x201c;The Relationship Between Mental Health Problems and Systemic Family Dynamics Among High School and University Students in Shaanxi Province, China.&#x201d; International Journal of Public Health 66: 1603988. https://doi.org/10.3389/ijph.2021.1603988.</Citation></Reference><Reference><Citation>Yu, J. C., J. P. Hl&#xe1;vka, E. Joe, F. J. Richmond, and D. N. Lakdawalla. 2022. &#x201c;Impact of Non&#x2010;Binding FDA Guidances on Primary Endpoint Selection in Alzheimer's Disease Trials.&#x201d; Alzheimer's &amp; Dementia 8, no. 1: e12280. https://doi.org/10.1002/trc2.12280.</Citation></Reference><Reference><Citation>Yu, L., X.&#x2009;. D. Zhao, W.&#x2009;. N. Zeng, et&#xa0;al. 2014. &#x201c;Reliability and Validity of the Chinese Revised Version of Self&#x2010;Rating Scale of Systemic Family Dynamics in Guangdong Students' Test.&#x201d; Chinese Journal of Health Statistics 31, no. 6: 979&#x2013;981.</Citation></Reference><Reference><Citation>Zhang, S. X., J. Liu, A. Afshar Jahanshahi, et&#xa0;al. 2021. &#x201c;Corrigendum to &#x201c;at the Height of the Storm: Healthcare Staff's Health Conditions and Job Satisfaction and Their Associated Predictors During the Epidemic Peak of COVID&#x2010;19&#x201d; [Brain Behav. Immun. 87 (2020) 144&#x2010;146].&#x201d; Brain, Behavior, and Immunity 92: 245&#x2013;246. https://doi.org/10.1016/j.bbi.2020.11.021.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40713025</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1557-8976</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Jul</Month><Day>25</Day></PubDate></JournalIssue><Title>Viral immunology</Title><ISOAbbreviation>Viral Immunol</ISOAbbreviation></Journal><ArticleTitle>Lower C3 and C4 Complement Serum Levels Are Associated with More Severe Forms of COVID-19 Disease.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1177/08828245251362439</ELocationID><Abstract><AbstractText><b><i>Background:</i></b> In a subgroup of patients, coronavirus disease (COVID)-19 is a severe illness with high mortality due to hyperinflammation, development of acute respiratory distress syndrome, and multiorgan dysfunction syndrome. Complement system activation plays a critical role in the pathogenesis and severity of COVID-19 disease. <b><i>Methods:</i></b> This cross-sectional, single-center study aimed to investigate the correlation between serum C3 and C4 levels and COVID-19 severity. We included 125 patients hospitalized between December 2020 and March 2021. Patients were stratified into three groups based on the level of respiratory support needed to maintain adequate oxygenation (PaO<sub>2</sub> &#x2265; 60 mmHg): 51 patients requiring oxygen supplementation up to 15 L/min, 51 patients requiring high-flow oxygen therapy, and 23 patients requiring mechanical ventilation (MV). We analyzed the blood counts and serum levels of C3, C4, C-reactive protein (CRP), IL-6, procalcitonin, d-dimers, high-sensitive troponin I (TnI), N-terminal pro-brain natriuretic peptide (NT-proBNP), IgA, IgG, IgM, C3, C4, rheumatoid factor, and anticitrullinated peptide antibodies. <b><i>Results:</i></b> Patients on MV had significantly lower levels of C3 and C4 (0.98 &#xb1; 0.24 g/L for C3 and 0.21 &#xb1; 013 g/L for C4) compared with patients with less severe disease (<i>p</i> &lt; 0.001 for C3, <i>p</i> &lt; 0.001 for C4). Serum C3 and C4 levels were lower in patients requiring high-flow oxygen therapy than in those requiring oxygen supplementation, however, the difference was not statistically significant. In addition, higher neutrophil counts were observed in patients on MV or high-flow oxygen therapy than in those on oxygen supplementation, and higher CRP, procalcitonin, and NT-proBNP levels were observed only in patients on MV. The levels of IL-6, d-dimers, and high-sensitive TnI were positively correlated with disease severity, whereas lymphocyte counts showed a negative correlation, and these differences were statistically significant among all three groups. <b><i>Conclusion:</i></b> The determination of serum levels of C3 and C4, along with other known laboratory risk factors, may contribute to the detection of patients at an increased risk for severe COVID-19.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>&#x10c;ulo</LastName><ForeName>Melanie-Ivana</ForeName><Initials>MI</Initials><Identifier Source="ORCID">0000-0002-5174-1226</Identifier><AffiliationInfo><Affiliation>Vuk Vrhovac University Clinic for Diabetes, Endocrinology and Metabolic Diseases, Merkur University Hospital, Zagreb, Croatia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Markovi&#x107;</LastName><ForeName>Ivan</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Special Hospital for Pulmonary Diseases, Zagreb, Croatia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#x160;avuk</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Nephrology and Dialysis, Dubrava University Hospital, Zagreb, Croatia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zagorec</LastName><ForeName>Nikola</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Nephrology and Dialysis, Dubrava University Hospital, Zagreb, Croatia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kere&#x161;</LastName><ForeName>Tatjana</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Emergency and Intensive Care Medicine, Dubrava University Hospital, Zagreb, Croatia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grizelj</LastName><ForeName>Danijela</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular disease, Dubrava University Hospital, Zagreb, Croatia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lisi&#x10d;i&#x107;</LastName><ForeName>Ante</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular disease, Dubrava University Hospital, Zagreb, Croatia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bu&#x161;i&#x107;</LastName><ForeName>Nik&#x161;a</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular disease, Dubrava University Hospital, Zagreb, Croatia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#x160;akota</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Emergency and Intensive Care Medicine, Dubrava University Hospital, Zagreb, Croatia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kmet</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Clinical Department of Laboratory Diagnostics, Dubrava University Hospital, Zagreb, Croatia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kelava</LastName><ForeName>Tomislav</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Physiology and Immunology, School of Medicine, University of Zagreb, Zagreb, Croatia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Livun</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Molecular Biology, Dubrava University Hospital, Zagreb, Croatia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Svagu&#x161;a</LastName><ForeName>Tomo</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular disease, Dubrava University Hospital, Zagreb, Croatia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Viral Immunol</MedlineTA><NlmUniqueID>8801552</NlmUniqueID><ISSNLinking>0882-8245</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">anticitrullinated peptide antibodies</Keyword><Keyword MajorTopicYN="N">complement system proteins</Keyword><Keyword MajorTopicYN="N">immunoglobulins</Keyword><Keyword MajorTopicYN="N">rheumatoid factor</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>19</Hour><Minute>52</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40713025</ArticleId><ArticleId IdType="doi">10.1177/08828245251362439</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40712931</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-2742</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Jul</Month><Day>23</Day></PubDate></JournalIssue><Title>The Journal of infection</Title><ISOAbbreviation>J Infect</ISOAbbreviation></Journal><ArticleTitle>Impact of distribution of facemasks on community incidence and outcomes of COVID-19: A cluster randomised trial in India.</ArticleTitle><Pagination><StartPage>106557</StartPage><MedlinePgn>106557</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jinf.2025.106557</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0163-4453(25)00151-3</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Randomised evidence on the effectiveness of delivering facemasks for reducing the health impact of COVID-19 remains limited.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a cluster randomised trial in Telangana, India, in August-November 2020 to investigate whether distribution and promotion of facemasks in villages reduces the incidence and adverse outcomes of COVID-19. We randomised 20 villages from the ongoing APCAPS surveillance study (1:1 ratio) to village-wide distribution of 3-layer cloth facemasks along with promotional messaging, or no intervention. Outcomes were incidence of notified COVID-19 (primary), hospitalised COVID-19 and all-cause mortality (secondary), collected through household surveillance by village health workers. Mask wearing was assessed through standardised observations in village centres. Data were analysed by multilevel Poisson regression.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">Use of the study facemasks and any face coverings in public spaces was higher in intervention villages (19% and 59%, respectively) than control villages (0% and 38%). In the 10 intervention (N=16,741 adults) and 10 control villages (N=15,278 adults), respectively, the crude incidence per thousand person months (number of events) of notified COVID-19 was 2.15 (n=144) and 2.45 (n=150), of hospitalised COVID-19 was 0.07 (n=5) and 0.21 (n=13), and of all-cause mortality was 0.91 (n=61) and 1.10 (n=67). In models accounting for age, sex and pre-intervention COVID-19 rate, rate ratios in intervention versus control villages were 0.96 (95% confidence interval 0.57 to 1.63) for COVID-19 cases, 0.36 (0.12 to 1.05) for COVID-19 hospitalisations, and 0.84 (0.55 to 1.29) for all-cause mortality. No adverse effects were reported.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">We are unable to draw firm conclusions about the effect of village-wide distribution and promotion of facemasks on COVID-19 incidence from these data due to a low number of events leading to imprecise effect estimates. Nonetheless, our findings are consistent with the modest protective effect on incident cases seen in previous randomised trials, extending these to adverse outcomes for the first time.</AbstractText><AbstractText Label="FUNDING" NlmCategory="BACKGROUND">Synergy India Foundation.</AbstractText><AbstractText Label="REGISTRATION" NlmCategory="BACKGROUND">The trial was pre-registered on the Clinical Trials Registry of India on 25/07/2020 (CTRI/2020/07/026796).</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 The Author(s). Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mallinson</LastName><ForeName>Poppy Ac</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Department of Non-Communicable Disease Epidemiology, London School of Hygiene &amp; Tropical Medicine, UK. Electronic address: poppy.mallinson1@lshtm.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dasi</LastName><ForeName>Teena</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Clinical Division, Indian Council of Medical Research-National Institute of Nutrition, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Banjara</LastName><ForeName>Santosh Kumar</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>Clinical Division, Indian Council of Medical Research-National Institute of Nutrition, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lieber</LastName><ForeName>Judith</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Medical Statistics, London School of Hygiene &amp; Tropical Medicine, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhogadi</LastName><ForeName>Santhi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Indian Institute of Public Health Hyderabad, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Addanki</LastName><ForeName>Srivalli</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Indian Institute of Public Health Hyderabad, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Undrajavarapu</LastName><ForeName>Prasad</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Clinical Division, Indian Council of Medical Research-National Institute of Nutrition, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masapeta</LastName><ForeName>Subhash</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Clinical Division, Indian Council of Medical Research-National Institute of Nutrition, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mahajan</LastName><ForeName>Hemant</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Clinical Division, Indian Council of Medical Research-National Institute of Nutrition, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kulkarni</LastName><ForeName>Bharati</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Clinical Division, Indian Council of Medical Research-National Institute of Nutrition, India; Reproductive and Child Health and Nutrition, Indian Council of Medical Research, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kinra</LastName><ForeName>Sanjay</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Non-Communicable Disease Epidemiology, London School of Hygiene &amp; Tropical Medicine, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Infect</MedlineTA><NlmUniqueID>7908424</NlmUniqueID><ISSNLinking>0163-4453</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Facemasks</Keyword><Keyword MajorTopicYN="N">India</Keyword><Keyword MajorTopicYN="N">Randomized Controlled Trial</Keyword><Keyword MajorTopicYN="N">infection prevention and control</Keyword><Keyword MajorTopicYN="N">respiratory viruses</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Declaration of interests The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>6</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>19</Hour><Minute>41</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40712931</ArticleId><ArticleId IdType="doi">10.1016/j.jinf.2025.106557</ArticleId><ArticleId IdType="pii">S0163-4453(25)00151-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40712752</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-5921</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Jul</Month><Day>23</Day></PubDate></JournalIssue><Title>Journal of clinical epidemiology</Title><ISOAbbreviation>J Clin Epidemiol</ISOAbbreviation></Journal><ArticleTitle>Capturing the influx of living systematic reviews: a systematic methodological survey.</ArticleTitle><Pagination><StartPage>111904</StartPage><MedlinePgn>111904</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jclinepi.2025.111904</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0895-4356(25)00237-9</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Living systematic reviews (LSRs) are an emerging type of review that continuously updates as new evidence becomes available. A previous methodological survey conducted in 2021 identified and studied all health-based LSRs. Since then, the landscape has changed, including the on-going accumulation of COVID-19 research and availability of automation tools. Furthermore, various methods and guidance exist for conducting LSRs and review authors are often encouraged to explore opportunities to maximise dissemination. We conducted a LSR survey update to describe LSRs in a 'post-COVID' era. Our objectives were to summarise the uptake of LSRs, describe their characteristics, including methodological and communicative characteristics, and identify patterns in LSR attributes.</AbstractText><AbstractText Label="STUDY DESIGN AND SETTING" NlmCategory="METHODS">We systematically searched for new LSRs and any updates - including updates from LSRs identified previously - published between May 2021 - March 2023 in any health field. Eligible articles were identified and data extracted and combined with data from the original survey. Outcomes broadly included LSR characteristics and uptake, and methodological and communicative characteristics. Analyses were descriptive and included visualisations to explore distributions, combinations, and any time effects of characteristics.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 549 records across 168 individual LSRs were identified (of which 92 LSRs were newly detected). Whilst the presence of COVID-19 LSRs dominated in later years, there was an increased uptake in non-COVID-19 LSRs; the former were found to search the evidence and update/publish results more frequently. Where reported, the approach to conducting updates varied considerably, including a wide range of pre-specified frequencies and/or triggers. Of the 337 updates, 25.5% reported on ongoing studies, and among LSRs with published results, 58.5% utilised the GRADE system. The proportion of LSRs with a centralised platform for sharing results was higher amongst i) those that included updates, ii) Cochrane reviews, iii) non-COVID-19 LSRs, and iv) funded LSRs. Few LSRs included interactive features.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The number of LSRs is growing at an accelerating rate, but this survey illustrates that there are still methodological limitations and challenges that carefully need addressing. Key areas for improvement include more explicit pre-specified updating strategies and better use of web-based platforms for disseminating results.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 The Author(s). Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nevill</LastName><ForeName>Clareece R</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>Biostatistics Research Group, Population Health Sciences, University of Leicester, Leicester, UK; Complex Reviews Synthesis Unit, Universities of Glasgow and Leicester, UK. Electronic address: clareece.nevill@leicester.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharifan</LastName><ForeName>Amin</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department for Evidence-based Medicine and Evaluation, University for Continuing Education Krems, Krems, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Mahony</LastName><ForeName>Aoife</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>School of Public Health, University College Cork, Cork, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tahir</LastName><ForeName>Hadiqa</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Biostatistics Research Group, Population Health Sciences, University of Leicester, Leicester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robinson</LastName><ForeName>Will</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Biostatistics Research Group, Population Health Sciences, University of Leicester, Leicester, UK; Complex Reviews Synthesis Unit, Universities of Glasgow and Leicester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Modha</LastName><ForeName>Urvi</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Biostatistics Research Group, Population Health Sciences, University of Leicester, Leicester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kahale</LastName><ForeName>Lara A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Infectious Disease Society of America, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khamis</LastName><ForeName>Assem M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Hull York Medical School, University of Hull, Hull, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akl</LastName><ForeName>Elie A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, American University of Beirut, Beirut, Lebanon.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Ellesha A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Biostatistics Research Group, Population Health Sciences, University of Leicester, Leicester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sutton</LastName><ForeName>Alex J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Biostatistics Research Group, Population Health Sciences, University of Leicester, Leicester, UK; Complex Reviews Synthesis Unit, Universities of Glasgow and Leicester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Freeman</LastName><ForeName>Suzanne C</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Biostatistics Research Group, Population Health Sciences, University of Leicester, Leicester, UK; Complex Reviews Synthesis Unit, Universities of Glasgow and Leicester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cooper</LastName><ForeName>Nicola J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>Biostatistics Research Group, Population Health Sciences, University of Leicester, Leicester, UK; Complex Reviews Synthesis Unit, Universities of Glasgow and Leicester, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Epidemiol</MedlineTA><NlmUniqueID>8801383</NlmUniqueID><ISSNLinking>0895-4356</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19 (1-7 keywords)</Keyword><Keyword MajorTopicYN="N">Dissemination</Keyword><Keyword MajorTopicYN="N">Living Systematic Reviews</Keyword><Keyword MajorTopicYN="N">Methodological Survey</Keyword><Keyword MajorTopicYN="N">Methods</Keyword><Keyword MajorTopicYN="N">Update</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>19</Hour><Minute>37</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40712752</ArticleId><ArticleId IdType="doi">10.1016/j.jclinepi.2025.111904</ArticleId><ArticleId IdType="pii">S0895-4356(25)00237-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40712743</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-6833</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Jul</Month><Day>23</Day></PubDate></JournalIssue><Title>The Journal of pediatrics</Title><ISOAbbreviation>J Pediatr</ISOAbbreviation></Journal><ArticleTitle>Maternal Mental Health and Emergency Department Visits for Infants Born Preterm and Enrolled in a Transition Home Program Before and During the COVID-19 Pandemic.</ArticleTitle><Pagination><StartPage>114753</StartPage><MedlinePgn>114753</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jpeds.2025.114753</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0022-3476(25)00294-X</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine the association between maternal mental health (MMH) disorders before and during COVID-19 and infant emergency department (ED) visits one- and three-months post-NICU discharge among infants in a transition home program (THP).</AbstractText><AbstractText Label="STUDY DESIGN" NlmCategory="METHODS">Retrospective analysis of a publicly insured neonatal intensive care unit (NICU) mother-infant dyad cohort enrolled in a THP. Groups were stratified to pre-COVID-19 pandemic (January 1, 2017-March 10, 2020) and COVID-19 pandemic (March 11, 2020-December 31, 2022). Contacts between THP families, social workers, and medical staff via phone and in-person visits were analyzed relative to ED visits and rehospitalizations. Regression models estimating effects of MMH on ED visit rates were examined.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Rates of MMH disorders trended upwards between time periods but did not reach significance. Maternal characteristics were similar between time periods, yet infant birth weight was higher during COVID-19. Overall, ED visits decreased during COVID-19 for the total cohort. THP in-person visits for the total cohort decreased during COVID-19 whereas phone contacts remained unchanged. However, for infants with an ED visit during COVID-19, phone and in-person THP visits increased. In regression models, MMH disorder was associated with higher odds of ED visits &#x2264; 1 month of discharge (OR 2.34, CI 1.11-4.91).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Over the entire study period, infants of mothers with MMH disorders had more ED visits &#x2264; 1 month of discharge compared with infants from women without a MMH disorder. THP staff responded with increased phone and in-person contacts to support mother-infant dyads for those who had an ED visit during both time periods.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mayne</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Neonatology, Department of Pediatrics, Women and Infants Hospital, Providence, Rhode Island; Warren Alpert Medical School of Brown University, Brown University, Providence, RI. Electronic address: jmayne@wihri.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hawes</LastName><ForeName>Katheleen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Neonatology, Department of Pediatrics, Women and Infants Hospital, Providence, Rhode Island; Warren Alpert Medical School of Brown University, Brown University, Providence, RI; College of Nursing, University of Rhode Island, Kingston, RI.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McGowan</LastName><ForeName>Elisabeth C</ForeName><Initials>EC</Initials><AffiliationInfo><Affiliation>Division of Neonatology, Department of Pediatrics, Women and Infants Hospital, Providence, Rhode Island; Warren Alpert Medical School of Brown University, Brown University, Providence, RI.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tucker</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of Neonatology, Department of Pediatrics, Women and Infants Hospital, Providence, Rhode Island.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vohr</LastName><ForeName>Betty R</ForeName><Initials>BR</Initials><AffiliationInfo><Affiliation>Division of Neonatology, Department of Pediatrics, Women and Infants Hospital, Providence, Rhode Island; Warren Alpert Medical School of Brown University, Brown University, Providence, RI. Electronic address: BVohr@wihri.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Pediatr</MedlineTA><NlmUniqueID>0375410</NlmUniqueID><ISSNLinking>0022-3476</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Maternal mental health</Keyword><Keyword MajorTopicYN="N">emergency department</Keyword><Keyword MajorTopicYN="N">neonate</Keyword><Keyword MajorTopicYN="N">preterm</Keyword></KeywordList><CoiStatement>Declaration of interests &#x2612; The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. &#x2610; The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>2</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>6</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>19</Hour><Minute>37</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40712743</ArticleId><ArticleId IdType="doi">10.1016/j.jpeds.2025.114753</ArticleId><ArticleId IdType="pii">S0022-3476(25)00294-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40712644</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1550-5103</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Jul</Month><Day>24</Day></PubDate></JournalIssue><Title>Nursing administration quarterly</Title><ISOAbbreviation>Nurs Adm Q</ISOAbbreviation></Journal><ArticleTitle>Tri-Council for Nursing: United Organizations Advancing the Profession.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1097/NAQ.0000000000000706</ELocationID><Abstract><AbstractText>For more than 45&#xa0;years, the Tri-Council for Nursing (Tri-Council), representing nursing regulation, education, and practice, has advanced common policy goals and addressed shared concerns of its members-the American Association of Colleges of Nursing, American Nurses Association, American Organization for Nursing Leadership, National Council of State Boards of Nursing, and National League for Nursing. The Tri-Council's tradition of influencing public policy and decision makers continues at a crucial time in health care. The Tri-Council produces a legislative agenda annually to advance federal policies throughout the year and continues to emphasize workforce issues. In response to crises resulting from the Covid-19 pandemic, the Tri-Council convened a summit on December 3, 2020, to identify critical lessons and future opportunities for transforming nursing and health care. The Tri-Council committed to identify implications, opportunities, and actions for its member organizations, while engaging nurses, educators, policymakers, and health care experts in new ways to inspire focused action that delivers innovations in nursing practice, education, and regulation. The Tri-Council will continue to use its united voice to advance the nursing profession.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 The Authors. Published by Wolters Kluwer Health, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Trautman</LastName><ForeName>Deborah</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Author Affiliations: American Association of Colleges of Nursing, President and Chief Executive Officer, Washington, DC (Dr Trautman); American Nurses Association, Chief Nursing Officer (retired), Maryland (Dr Dawson Hatmaker); American Organization for Nursing Leadership, Chief Executive Officer Emerita, Chicago, Illinois (Dr Begley); National Council of State Boards of Nursing, Chief Executive Officer, Chicago, Illinois (Dr Dickison); and National League for Nursing, President &amp; Chief Executive Officer, Washington, DC (Dr Malone).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dawson Hatmaker</LastName><ForeName>Debbie</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Begley</LastName><ForeName>Robyn</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Dickison</LastName><ForeName>Phil</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Malone</LastName><ForeName>Beverly</ForeName><Initials>B</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nurs Adm Q</MedlineTA><NlmUniqueID>7703976</NlmUniqueID><ISSNLinking>0363-9568</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">American Association of Colleges of Nursing</Keyword><Keyword MajorTopicYN="N">American Nurses Association</Keyword><Keyword MajorTopicYN="N">American Organization for Nursing Leadership</Keyword><Keyword MajorTopicYN="N">Covid-19 pandemic implications and opportunities</Keyword><Keyword MajorTopicYN="N">National Council of State Boards of Nursing</Keyword><Keyword MajorTopicYN="N">National League for Nursing</Keyword><Keyword MajorTopicYN="N">Tri-Council for Nursing</Keyword><Keyword MajorTopicYN="N">United Voice for Nursing</Keyword><Keyword MajorTopicYN="N">innovation in nursing</Keyword><Keyword MajorTopicYN="N">nursing education</Keyword><Keyword MajorTopicYN="N">nursing practice</Keyword><Keyword MajorTopicYN="N">nursing regulation</Keyword><Keyword MajorTopicYN="N">nursing workforce issues policy and advocacy</Keyword><Keyword MajorTopicYN="N">transforming nursing and health care</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>19</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40712644</ArticleId><ArticleId IdType="doi">10.1097/NAQ.0000000000000706</ArticleId><ArticleId IdType="pii">00006216-990000000-00025</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bednash GP. The tricouncil for nursing: an interorganizational collaboration for advancing the profession. Nurs Adm Q. 2015;39(3):218-228. doi:10.1097/NAQ.0000000000000105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NAQ.0000000000000105</ArticleId></ArticleIdList></Reference><Reference><Citation>Publications and Resources. Tri-council for nursing. Accessed November 19, 2024. https://tricouncilfornursing.org/publications-%26-resources</Citation></Reference><Reference><Citation>Statement from the tri-council for nursing the imperative need for diversity, equity, inclusion and belonging in nursing. Tri-Council for Nursing. July 19, 2024. Accessed November 19, 2024. Tri-Council-July-19-2024-DEIB-Statement.pdf</Citation></Reference><Reference><Citation>Transforming together: implications and opportunities from the COVID-19 pandemic for nursing education, practice, and regulation. January 2021. Accessed November 19, 2024. Tri-Council.COVID-19.Report-FINAL.pdf</Citation></Reference><Reference><Citation>Interstate practice, education, and licensure changing practice, evolving regulation. Tri-Council for Nursing. November 2014. Accessed November 19, 2024. https://img1.wsimg.com/blobby/go/3d8c2b58-0c32-4b54-adbd-efe8f931b2df/downloads/11-2014-Interstate-Practice-Educaiton-Licensur.pdf?ver=1555011040408</Citation></Reference><Reference><Citation>The essential role of the RN and integration of community health workers. Tri-Council for Nursing. January 2017. Accessed November 19, 2024. https://img1.wsimg.com/blobby/go/3d8c2b58-0c32-4b54-adbd-efe8f931b2df/downloads/1-2017-Community-Team-Based-Care-Statement.pdf?ver=1555011040408</Citation></Reference><Reference><Citation>Issues proclamation on nursing civility. Tri-Council for Nursing. September 26, 2017. Accessed November 19, 2024. aonl-statement-tri-council-nursing-civility.pdf</Citation></Reference><Reference><Citation>Tri-council for nursing. COVID-19 Virtual Summit. January 2021. Accessed November 19, 2024. https://tricouncilfornursing.org/videos</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40712614</PMID><DateCompleted><Year>2025</Year><Month>07</Month><Day>25</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2214-109X</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>8</Issue><PubDate><Year>2025</Year><Month>Aug</Month></PubDate></JournalIssue><Title>The Lancet. Global health</Title><ISOAbbreviation>Lancet Glob Health</ISOAbbreviation></Journal><ArticleTitle>Regional and type-specific variations in the global seasonality of human parainfluenza viruses and the influence of climatic factors: a systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>e1425</StartPage><EndPage>e1435</EndPage><MedlinePgn>e1425-e1435</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S2214-109X(25)00188-3</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2214-109X(25)00188-3</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Human parainfluenza viruses (hPIVs) are common viral causes of acute respiratory infections, resulting in substantial global disease burden. Seasonal patterns of hPIV epidemics can vary by geographical region and viral type, although these patterns are not well understood at a global level. We aimed to characterise regional and type-specific variations in hPIV seasonality and assess the potential role of climatic factors in explaining these variations.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this systematic review and meta-analysis, we collected monthly aggregated seasonal activity data for hPIV and its four types (hPIV-1, hPIV-2, hPIV-3, and hPIV-4) from various sources, including a systematic search of Embase, MEDLINE, and Ovid Global Health, for literature published between Jan 1, 2000, and Dec 31, 2024; unpublished data contributed by an established collaborative network; and public viral surveillance datasets from online platforms. We included studies that continuously tested hPIVs throughout their study period and reported seasonal activity in defined geographical locations on a monthly basis (or if monthly data could be derived from reports). We excluded published studies if they had fewer than 20 cases, focused on specific medical conditions, or contained duplicate data from published literature or publicly available datasets. A prespecified collection template was used to collect data from members in the collaborative network. We extracted site-specific monthly case counts of combined hPIVs and each viral type and used the annual average percentage approach to assess relative circulating strength, epidemic onset and peak month, and epidemic duration by virus type and latitude. We identified type-specific transmission zones of countries with similar circulating patterns with the k-means method. A local regression model (selected by leave-one-out cross-validation) was used to explore climatic factors associated with variations in hPIV monthly circulating activity. The study was registered with PROSPERO, CRD42023370261.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">We included 115 records in total: 103 studies identified from the published literature, five studies contributed by collaborators, and data from seven public surveillance datasets. We included 306&#x2008;719 cases from 141 sites in 64 countries. We found that hPIV-3 exhibited distinctive seasonal patterns compared with the other three hPIV types. In temperate regions, hPIV-3 seasons typically occurred in spring, summer, and winter, with a median onset in April (IQR April-May) in the northern temperate region and July (July-July) in the southern temperate region. hPIV-1, hPIV-2, and hPIV-4 seasons typically occurred in autumn, winter, and summer, with median onsets between August and October in the northern temperate region and between April and May in the southern temperate region. Both epidemic onset and peak timing for hPIV-1, hPIV-2, and hPIV-4 were less consistent in tropical and subtropical regions than in temperate regions, whereas the seasonality of hPIV-3 remained generally consistent across regions. Northern temperate and subtropical countries typically clustered in shared transmission zones for hPIV-1, hPIV-2, and hPIV-3 with a few exceptions, as did countries in the southern hemisphere. Nevertheless, hPIV-1 and hPIV-4 peak timings were delayed as latitude increased in the northern hemisphere (Pearson's r=0&#xb7;62 [p=0&#xb7;0012] for hPIV-1 and r=0&#xb7;53 [p=0&#xb7;049] for hPIV-4). Type-specific climate models yielded better fits (with greater area under the receiver operating characteristic curve values) than models for combined hPIVs. In temperate regions, higher hPIV-1, hPIV-2, and hPIV-4 activity correlated with declining temperature and increasing relative humidity (all p values &lt;0&#xb7;0001), whereas higher hPIV-3 activity was correlated with rising temperature (r<sub>s</sub>=0&#xb7;61; p&lt;0&#xb7;0001). In subtropical and tropical regions, the climate models showed suboptimal performance. Exploratory analyses showed differential timing shifts in hPIV epidemics across six included countries following the lifting of COVID-19 non-pharmacological interventions.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">Our results characterise both between-type and regional variations in hPIV seasonality and the differential effects of monthly temperature variability and relative humidity on the global seasonality of different hPIV types. These findings have important implications for development of global hPIV surveillance and epidemic prediction in diverse locations. Substantial gaps in hPIV type-specific seasonality data remain in many countries, highlighting the need to expand surveillance to improve characterisation and prediction of hPIV epidemics.</AbstractText><AbstractText Label="FUNDING" NlmCategory="BACKGROUND">National Natural Science Foundation of China.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Junru</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Key Laboratory of Public Health Safety and Emergency Prevention and Control Technology of Higher Education Institutions in Jiangsu Province, Nanjing Medical University, Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Shuyu</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, School of Public Health, Key Laboratory of Public Health Safety and Emergency Prevention and Control Technology of Higher Education Institutions in Jiangsu Province, Nanjing Medical University, Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Xiaoyu</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, School of Public Health, Key Laboratory of Public Health Safety and Emergency Prevention and Control Technology of Higher Education Institutions in Jiangsu Province, Nanjing Medical University, Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Shuting</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Key Laboratory of Public Health Safety and Emergency Prevention and Control Technology of Higher Education Institutions in Jiangsu Province, Nanjing Medical University, Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abo</LastName><ForeName>Yara-Natalie</ForeName><Initials>YN</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Infection Prevention and Control, Royal Children's Hospital Melbourne, Melbourne, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bassat</LastName><ForeName>Quique</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Pediatrics Department, Hospital Sant Joan de D&#xe9;u, Universitat de Barcelona, Barcelona, Spain; CIBER Epidemiology and Public Health, Madrid, Spain; ISGlobal, Hospital Cl&#xed;nic-Universitat de Barcelona, Barcelona, Spain; ICREA, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Jikui</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Infectious Diseases Department, Shenzhen Children's Hospital, Shenzhen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Komissarov</LastName><ForeName>Andrey B</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>Smorodintsev Research Institute of Influenza, Saint Petersburg, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Enmei</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing Key Laboratory of Child Rare Diseases in Infection and Immunity, Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mu&#xf1;oz-Almagro</LastName><ForeName>Carmen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>CIBER Epidemiology and Public Health, Madrid, Spain; Institut de Recerca Sant Joan de D&#xe9;u-Hospital Sant Joan de Deu, Barcelona, Spain; Medicine Department, Universitat Internacional de Catalunya, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ren</LastName><ForeName>Luo</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing Key Laboratory of Child Rare Diseases in Infection and Immunity, Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stolyarov</LastName><ForeName>Kirill</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Smorodintsev Research Institute of Influenza, Saint Petersburg, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tomlinson</LastName><ForeName>Jane</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Infection Prevention and Control, Royal Children's Hospital Melbourne, Melbourne, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cai</LastName><ForeName>Zhiqing</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Key Laboratory of Public Health Safety and Emergency Prevention and Control Technology of Higher Education Institutions in Jiangsu Province, Nanjing Medical University, Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qiao</LastName><ForeName>Mengling</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Disease Control and Prevention of Eastern Theater Command, Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>You</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, School of Public Health, Key Laboratory of Public Health Safety and Emergency Prevention and Control Technology of Higher Education Institutions in Jiangsu Province, Nanjing Medical University, Nanjing, China; Centre for Global Health, Usher Institute, University of Edinburgh, Edinburgh, UK. Electronic address: you.li@njmu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, National Vaccine Innovation Platform, School of Public Health, Nanjing Medical University, Nanjing, China; Key Laboratory of Public Health Safety and Emergency Prevention and Control Technology of Higher Education Institutions in Jiangsu Province, Nanjing Medical University, Nanjing, China; Centre for Global Health, Usher Institute, University of Edinburgh, Edinburgh, UK. Electronic address: xin.wang@njmu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Respiratory Virus Global Epidemiology Network</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Glob Health</MedlineTA><NlmUniqueID>101613665</NlmUniqueID><ISSNLinking>2214-109X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012621" MajorTopicYN="Y">Seasons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002980" MajorTopicYN="Y">Climate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014943" MajorTopicYN="Y">Global Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018184" MajorTopicYN="Y">Paramyxoviridae Infections</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Declaration of interests EL and LR report grants from MSD outside the submitted work. YL reports grants from GSK and WHO, and personal fees from Pfizer and WHO, outside the submitted work. XW reports grants from GSK, and personal fees from Pfizer, outside the submitted work. All other authors declare no competing interests.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Cisneros</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Daley</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Danilenko</LastName><ForeName>Daria</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Deng</LastName><ForeName>Guangcheng</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Deng</LastName><ForeName>Yu</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Launes</LastName><ForeName>Cristian</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lluansi</LastName><ForeName>Aleix</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mansour</LastName><ForeName>Oula</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tang</LastName><ForeName>Yuyi</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Waller</LastName><ForeName>Gregory</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zang</LastName><ForeName>Na</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zheng</LastName><ForeName>Jinjun</ForeName><Initials>J</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>11</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>4</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>4</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>18</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40712614</ArticleId><ArticleId IdType="doi">10.1016/S2214-109X(25)00188-3</ArticleId><ArticleId IdType="pii">S2214-109X(25)00188-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40712541</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-1026</ISSN><JournalIssue CitedMedium="Internet"><Volume>995</Volume><PubDate><Year>2025</Year><Month>Jul</Month><Day>24</Day></PubDate></JournalIssue><Title>The Science of the total environment</Title><ISOAbbreviation>Sci Total Environ</ISOAbbreviation></Journal><ArticleTitle>Long term assessment of SARS-CoV-2 in wastewater and the transition to evaluate additional viral targets.</ArticleTitle><Pagination><StartPage>180096</StartPage><MedlinePgn>180096</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.scitotenv.2025.180096</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0048-9697(25)01736-X</ELocationID><Abstract><AbstractText>The COVID-19 pandemic caused by the SARS-CoV-2 virus dramatically impacted society over five years ago and continues to have an impact today. Since the beginning of the pandemic there have responses and strategies implemented to maintain the public safety of communities affected by SARS-CoV-2. This study is a unique opportunity to analyze nearly four years of SARS-CoV-2 wastewater-based surveillance (WBS) data, obtained from five different laboratories, combined with four years of human health data from three adjacent regions of a large urban community (Miami-Dade County). The objective of this study was to analyze that data and evaluate longitudinal and geographic trends of SARS-CoV-2 levels in wastewater (WW) during the extensive time frame of this study. Additionally, WBS data were analyzed for multiple targets (influenza A/B, norovirus, RSV, HMPV, PMMoV) other than SARS-CoV-2 to assess the potential for expanding WBS to a wider range of targets. We found that SARS-CoV-2 levels correlated strongest with clinical positivity rates across all three geographic regions (Spearman r&#xa0;=&#xa0;0.81 for the entire period of record), with the most geographically restricted region showing higher correlations (South, r&#xa0;=&#xa0;0.86) than the region with populations with higher geographic mobility (North, r&#xa0;=&#xa0;0.69). Stronger correlations (0.80&#xa0;&lt;&#xa0;r&#xa0;&lt;&#xa0;0.97) were observed when correlations were established by variant waves rather than single or multiple year time frames (0.73&#xa0;&lt;&#xa0;r&#xa0;&lt;&#xa0;0.88). When analyzing the data for targets beyond SARS-CoV-2, results show promise as two laboratories detected norovirus, influenza A/B, RSV, and HMPV at statistically not different frequencies (Chi-squared&#x2265;0.6). Overall, results suggest that the clinical metrics used (e.g., positivity), geography, and the time frames of data analyses influence the ability of WBS to predict disease prevalence in a community. The consistency among the laboratories supports that the measurement of a wider range of viral targets can be disaggregated among different laboratories providing flexibility for building national-level WBS programs.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Amirali</LastName><ForeName>Ayaaz</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Chemical, Environmental, and Materials Engineering, University of Miami, Coral Gables, FL 33146, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharkey</LastName><ForeName>Mark E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Miami Miller School of Medicine, Miami 33136, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choudhary</LastName><ForeName>Shruti</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Chemical, Environmental, and Materials Engineering, University of Miami, Coral Gables, FL 33146, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Babler</LastName><ForeName>Kristina M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Department of Chemical, Environmental, and Materials Engineering, University of Miami, Coral Gables, FL 33146, USA; Currently with the Department of Human Genetics, University of Utah, Salt Lake City, UT 84112, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beaver</LastName><ForeName>Cynthia C</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL 33136, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Biswas</LastName><ForeName>Pratim</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Chemical, Environmental, and Materials Engineering, University of Miami, Coral Gables, FL 33146, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bowie</LastName><ForeName>Kate R</ForeName><Initials>KR</Initials><AffiliationInfo><Affiliation>Department of Chemical and Environmental Engineering, Yale University, New Haven, CT 06511, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burke</LastName><ForeName>Taylor</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Chemical and Environmental Engineering, Yale University, New Haven, CT 06511, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Currall</LastName><ForeName>Benjamin B</ForeName><Initials>BB</Initials><AffiliationInfo><Affiliation>Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL 33136, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grills</LastName><ForeName>George S</ForeName><Initials>GS</Initials><AffiliationInfo><Affiliation>Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL 33136, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Healy</LastName><ForeName>Hannah G</ForeName><Initials>HG</Initials><AffiliationInfo><Affiliation>Department of Environmental Health, T.H. Chan School of Public Health, Harvard University, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lucaci</LastName><ForeName>Alexander G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>Department of Physiology and Biophysics, Weill Cornell Medical College, New York City, NY 10021, USA; The HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsaud Institute for Computational Biomedicine, Weill Cornell Medicine, New York, NY 10021, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mason</LastName><ForeName>Christopher E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Department of Physiology and Biophysics, Weill Cornell Medical College, New York City, NY 10021, USA; The HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsaud Institute for Computational Biomedicine, Weill Cornell Medicine, New York, NY 10021, USA; The WorldQuant Initiative for Quantitative Prediction, Weill Cornell Medicine, New York, NY 10021, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McGuire</LastName><ForeName>Michaela</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Florida Department of Health, Tallahassee, FL 32399, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramos</LastName><ForeName>Rosemarie</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Florida Department of Health, Tallahassee, FL 32399, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruedaflores</LastName><ForeName>Madelena</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Chemical and Environmental Engineering, Yale University, New Haven, CT 06511, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Solle</LastName><ForeName>Natasha Schaefer</ForeName><Initials>NS</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Miami Miller School of Medicine, Miami 33136, FL, USA; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL 33136, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sch&#xfc;rer</LastName><ForeName>Stephan C</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL 33136, USA; Department of Molecular &amp; Cellular Pharmacology, University of Miami Miller School of Medicine, Miami, FL 33136, USA; Institute for Data Science &amp; Computing, University of Miami, Coral Gables, FL 33146, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shukla</LastName><ForeName>Bhavarth S</ForeName><Initials>BS</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Miami Miller School of Medicine, Miami 33136, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stevenson</LastName><ForeName>Mario</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Miami Miller School of Medicine, Miami 33136, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vidovi&#x107;</LastName><ForeName>Du&#x161;ica</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL 33136, USA; Department of Molecular &amp; Cellular Pharmacology, University of Miami Miller School of Medicine, Miami, FL 33136, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Sion L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL 33136, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Kongyang</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Chemical, Environmental, and Materials Engineering, University of Miami, Coral Gables, FL 33146, USA; Department of Industrial and Systems Engineering, University of Miami, Coral Gables, FL 33146, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zulli</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Chemical and Environmental Engineering, Yale University, New Haven, CT 06511, USA; Department of Civil and Environmental Engineering, Stanford University, Stanford, CA 94301, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peccia</LastName><ForeName>Jordan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Chemical and Environmental Engineering, Yale University, New Haven, CT 06511, USA. Electronic address: jordan.peccia@yale.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Solo-Gabriele</LastName><ForeName>Helena M</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Department of Chemical, Environmental, and Materials Engineering, University of Miami, Coral Gables, FL 33146, USA. Electronic address: hmsolo@miami.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Sci Total Environ</MedlineTA><NlmUniqueID>0330500</NlmUniqueID><ISSNLinking>0048-9697</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Clinical testing</Keyword><Keyword MajorTopicYN="N">Influenza a/B</Keyword><Keyword MajorTopicYN="N">RSV</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Wastewater</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>4</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>6</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>18</Hour><Minute>11</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40712541</ArticleId><ArticleId IdType="doi">10.1016/j.scitotenv.2025.180096</ArticleId><ArticleId IdType="pii">S0048-9697(25)01736-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40712415</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-1484</ISSN><JournalIssue CitedMedium="Internet"><Volume>408</Volume><PubDate><Year>2025</Year><Month>Jul</Month><Day>19</Day></PubDate></JournalIssue><Title>Atherosclerosis</Title><ISOAbbreviation>Atherosclerosis</ISOAbbreviation></Journal><ArticleTitle>Interplay of statin treatment and anti-SARS-CoV-2 antibody levels in the outcome of COVID-19: a prospective, propensity score matched cohort study.</ArticleTitle><Pagination><StartPage>120449</StartPage><MedlinePgn>120449</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.atherosclerosis.2025.120449</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0021-9150(25)01347-4</ELocationID><Abstract><AbstractText Label="BACKGROUND AND AIMS" NlmCategory="OBJECTIVE">Despite high global vaccination coverage and widespread statin use, it remains unclear how the interplay of anti-SARS-CoV-2-antibodies and statin treatment (ST) affect inflammation levels in COVID-19. It is further unclear whether the combination of ST and antibody levels affect COVID-19-related mortality risk.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a prospective, propensity-score-matched, multicenter-cohort study including 1144 COVID-19 patients hospitalized August 2021-April 2022. Anti-SARS-CoV-2-spike antibodies, interleukin-6, and CRP were measured on hospital admission. The pre-specified primary endpoint was all-cause in-hospital mortality.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Median follow-up was 90 days (IQR48-90). In matched patients, mortality risk increased incrementally from the lowest risk group of patients on ST exhibiting high antibody levels to the highest risk group of patients without ST and low antibody levels. The highest risk group also presented with the highest inflammation levels. After adjusting for potential confounders, matched patients not receiving statins with low antibody levels were approximately 7.9 times more likely to die than patients on ST with high antibody levels (aHR 7.922, 95 %CI 2.777-22.605, p&#xa0;&lt;&#xa0;0.001).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Hospitalized COVID-19 patients with low antibody levels and lack of statin treatment exhibited the highest mortality risks. The combination of ST and antibodies showed a stronger association with mortality risk than either factor individually.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mink</LastName><ForeName>Sylvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Central Medical Laboratories, Feldkirch, Austria; Private University in the Principality of Liechtenstein, Triesen, Principality of Liechtenstein. Electronic address: smink@mzl.at.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Drexel</LastName><ForeName>Heinz</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Private University in the Principality of Liechtenstein, Triesen, Principality of Liechtenstein; VIVIT Institute, Academic Teaching Hospital Feldkirch, Feldkirch, Austria; Drexel University College of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leiherer</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Central Medical Laboratories, Feldkirch, Austria; VIVIT Institute, Academic Teaching Hospital Feldkirch, Feldkirch, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cadamuro</LastName><ForeName>Janne</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, Paracelsus Medical University Salzburg, Salzburg, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hitzl</LastName><ForeName>Wolfgang</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Research and Innovation, Team Biostatistics and Publication of Clinical Trials, Paracelsus Medical University, Salzburg, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frick</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Academic Teaching Hospital Feldkirch, Feldkirch, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reimann</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Private University in the Principality of Liechtenstein, Triesen, Principality of Liechtenstein; Department of Internal Medicine, Academic Teaching Hospital Feldkirch, Feldkirch, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saely</LastName><ForeName>Christoph H</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Private University in the Principality of Liechtenstein, Triesen, Principality of Liechtenstein; VIVIT Institute, Academic Teaching Hospital Feldkirch, Feldkirch, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fraunberger</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Central Medical Laboratories, Feldkirch, Austria; Private University in the Principality of Liechtenstein, Triesen, Principality of Liechtenstein.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Atherosclerosis</MedlineTA><NlmUniqueID>0242543</NlmUniqueID><ISSNLinking>0021-9150</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Anti-SARS-CoV-2 spike antibodies</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Correlate of protection</Keyword><Keyword MajorTopicYN="N">Inflammation</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Statins</Keyword><Keyword MajorTopicYN="N">Vaccination</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>2</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>18</Hour><Minute>8</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40712415</ArticleId><ArticleId IdType="doi">10.1016/j.atherosclerosis.2025.120449</ArticleId><ArticleId IdType="pii">S0021-9150(25)01347-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40712405</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-8673</ISSN><JournalIssue CitedMedium="Internet"><Volume>313</Volume><PubDate><Year>2025</Year><Month>Jul</Month><Day>24</Day></PubDate></JournalIssue><Title>The Journal of surgical research</Title><ISOAbbreviation>J Surg Res</ISOAbbreviation></Journal><ArticleTitle>The Hidden Toll: Demographic Changes in Suicide Attempts During the Coronavirus Disease-19 Era.</ArticleTitle><Pagination><StartPage>509</StartPage><EndPage>515</EndPage><MedlinePgn>509-515</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jss.2025.06.053</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0022-4804(25)00390-7</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">The coronavirus disease-19 (COVID-19) pandemic, characterized by social isolation and economic disparity, has impacted mental health in the United States. While prior studies have linked the pandemic to increased rates of intentional penetrating trauma, the impact of self-inflicted injuries has not been thoroughly examined. We hypothesize an increased national rate of suicide attempts post-COVID-19 compared to previous years and aim to investigate shifts in demographics of trauma patients attempting suicide.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The Trauma Quality Improvement Program database was divided into prepandemic (2017-2019) and pandemic years (2020-2022). Bivariate analyses were performed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">From 73,967 patients, those presenting in the COVID era had a statistically decreased rate of suicide attempts (1.3% versus 1.4%, P &lt; 0.001) compared to prepandemic. Most suicide attempts occurred with knives in both groups (pandemic 50.9% versus prepandemic 50.2%, P = 0.06), who also had similar injury severity scores (median, 8). However, pandemic suicide attempts more commonly occurred in Blacks (13.3% versus 11.9%, P &lt; 0.001), Hispanics (13.4% versus 12.0%, P &lt; 0.001), young adults (age 20-39 y) (51.8% versus 49.9%, P &lt; 0.001), and individuals with mental health disorders (50.6% versus 48.2%, P &lt; 0.001). The mortality rate remained similar between cohorts (pandemic 19.8% versus prepandemic 19.5%, P = 0.26).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The pandemic was associated with a similar rate of suicide attempts among trauma patients but has led to a shift in demographics. Specifically, increased suicide attempts among Blacks, Hispanics, young adults, and those with mental health disorders. This highlights the pandemic's secondary impact and reinforces the need for targeted preventative measures for these populations during periods of increased stress.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 The Author(s). Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hunter</LastName><ForeName>Dylan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Trauma, Burns, and Surgical Critical Care, Department of Surgery, University of California, Irvine, Orange, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nahmias</LastName><ForeName>Jeffry</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Trauma, Burns, and Surgical Critical Care, Department of Surgery, University of California, Irvine, Orange, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aryan</LastName><ForeName>Negaar</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Division of Trauma, Burns, and Surgical Critical Care, Department of Surgery, University of California, Irvine, Orange, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dolich</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Trauma, Burns, and Surgical Critical Care, Department of Surgery, University of California, Irvine, Orange, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swentek</LastName><ForeName>Lourdes</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Trauma, Burns, and Surgical Critical Care, Department of Surgery, University of California, Irvine, Orange, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bagga</LastName><ForeName>Anushka</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Trauma, Burns, and Surgical Critical Care, Department of Surgery, University of California, Irvine, Orange, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grigorian</LastName><ForeName>Areg</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Trauma, Burns, and Surgical Critical Care, Department of Surgery, University of California, Irvine, Orange, California. Electronic address: agrigori@uci.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Surg Res</MedlineTA><NlmUniqueID>0376340</NlmUniqueID><ISSNLinking>0022-4804</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Demographic changes</Keyword><Keyword MajorTopicYN="N">Mental health</Keyword><Keyword MajorTopicYN="N">Suicide</Keyword><Keyword MajorTopicYN="N">Suicide attempts</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>2</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>5</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>18</Hour><Minute>8</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40712405</ArticleId><ArticleId IdType="doi">10.1016/j.jss.2025.06.053</ArticleId><ArticleId IdType="pii">S0022-4804(25)00390-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40712347</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-818X</ISSN><JournalIssue CitedMedium="Internet"><Volume>46</Volume><Issue>5</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>22</Day></PubDate></JournalIssue><Title>American journal of otolaryngology</Title><ISOAbbreviation>Am J Otolaryngol</ISOAbbreviation></Journal><ArticleTitle>The impact of COVID-19 and socio-economic crisis on primary hyperparathyroidism patients in Lebanon: A trend to operate more acute and advanced-stage cases.</ArticleTitle><Pagination><StartPage>104713</StartPage><MedlinePgn>104713</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.amjoto.2025.104713</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0196-0709(25)00116-4</ELocationID><Abstract><AbstractText Label="BACKGROUNDS" NlmCategory="BACKGROUND">Evaluate contribution of COVID-19 pandemic, the socio-economic crisis, and explosion of Beirut port to a concerning trend of operating on more advanced-stage in primary hyperparathyroism (PHPT).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We included all patients operated for PHPT between 1997 and 2024. Two groups were established: Group 1 between 1997 and 2018, and Group 2 after 2018.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Asymptomatic PHPT was statistically significantly more frequent in group 1. The rates of systemic manifestations were comparable but with a more advanced stage for some system in group 2. The rates of acute pancreatitis and acute hypercalcemia were significantly higher in group 2. The rate of parathyroid carcinoma was significantly higher in group 1. The hospital stay was statistically significantly longer in the group 2.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">COVID-19 pandemic and economic crisis has affected early intervention and comprehensive treatment for PHPT patients, resulting in a concerning rise in late-stage and acute cases requiring surgical intervention.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Abboud</LastName><ForeName>Bassam</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Division of General Surgery, Geitaoui Hospital, Faculty of Medicine, Lebanese University, Beirut, Lebanon. Electronic address: dbabboud@yahoo.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abboud</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Radiology, Hotel-Dieu Hospital, Faculty of Medicine, Saint-joseph University, Beirut, Lebanon.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Otolaryngol</MedlineTA><NlmUniqueID>8000029</NlmUniqueID><ISSNLinking>0196-0709</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Advanced stage disease</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Economic crisis</Keyword><Keyword MajorTopicYN="N">Primary hyperparathyroidism</Keyword><Keyword MajorTopicYN="N">Surgery</Keyword></KeywordList><CoiStatement>Declaration of competing interest All the authors have no conflicts of interests to declare. Conception and design, analysis and interpretation, data collection, writing the article, and critical revision of the article: Bassam Abboud, Christopher Abboud, All the authors contribute equally to make this paper and certifies that they made a direct and substantial contribution to the work reported in the manuscript by participating in each of the following three areas: (1) conceiving and designing the study; collecting the data; analyzing and interpreting the data; (2) writing the manuscript and providing critical revisions; and (3) approving the final version of the manuscript.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>6</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>18</Hour><Minute>6</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40712347</ArticleId><ArticleId IdType="doi">10.1016/j.amjoto.2025.104713</ArticleId><ArticleId IdType="pii">S0196-0709(25)00116-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40712320</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN><JournalIssue CitedMedium="Internet"><Volume>62</Volume><PubDate><Year>2025</Year><Month>Jul</Month><Day>24</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>2024-2025 BNT162b2 COVID-19 vaccine effectiveness in non-immunocompromised adults: mid-season estimates from vaccine registries in two states linked to administrative claims.</ArticleTitle><Pagination><StartPage>127534</StartPage><MedlinePgn>127534</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2025.127534</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0264-410X(25)00831-X</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Data are limited on 2024-2025 BNT162b2 COVID-19 vaccine effectiveness (VE).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Retrospective cohort study among non-immunocompromised adults from August 22, 2024 ("index") to December 31, 2024, among residents of California or Louisiana continuously enrolled in health insurance plans reporting to HealthVerity for &#x2265;1&#xa0;year prior to index. Receipt of 2024-2025 BNT162b2 COVID-19 vaccine was defined using state vaccine registries with health insurance claims, using a time-varying exposure definition. VE against COVID-19-associated hospital admissions was estimated as (1-hazard ratio), using adjusted Cox proportional hazards models with 95&#xa0;% confidence intervals (CI).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Overall, 6,900,361 individuals met selection criteria for the study. By the end of follow-up (median 4.4&#xa0;months), 325,362 (4.7&#xa0;%) had received a BNT162b2 2024-2025 COVID-19 vaccine dose. VE against COVID-19-associated hospital admission was 41&#xa0;% (95&#xa0;% CI 2-64).</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">The 2024-2025 formulation of BNT162b2 COVID-19 vaccine provided significant protection, particularly for older adults, in mid-season estimates. This study is registered on clinicaltrials.gov as NCT06923137.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 The Authors. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Andersen</LastName><ForeName>Kathleen M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Pfizer Inc., New York, NY, United States. Electronic address: Kathleen.andersen@pfizer.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahi</LastName><ForeName>Tara</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Pfizer Inc., New York, NY, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mateus</LastName><ForeName>Jazmine S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Genesis Research Group, Hoboken, NJ, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Tiange</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Genesis Research Group, Hoboken, NJ, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Anan</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Genesis Research Group, Hoboken, NJ, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopez</LastName><ForeName>Santiago M C</ForeName><Initials>SMC</Initials><AffiliationInfo><Affiliation>Pfizer Inc., Collegeville, PA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Puzniak</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Pfizer Inc., New York, NY, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT06923137</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">mRNA vaccines</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Dr. Andersen, Ms. Ahi, Dr. Lopez and Dr. Puzniak are employees of Pfizer Inc. and may hold stock and/or stock options. Ms. Mateus, Ms. Yu, and Ms. Zhou are employees of Genesis Research Group, which was a paid contractor to Pfizer in connection with the development of this manuscript.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>6</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>18</Hour><Minute>5</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40712320</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2025.127534</ArticleId><ArticleId IdType="pii">S0264-410X(25)00831-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40712319</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN><JournalIssue CitedMedium="Internet"><Volume>62</Volume><PubDate><Year>2025</Year><Month>Jul</Month><Day>24</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>Sociodemographic disparities in COVID-19 and RSV vaccine uptake among California adults &#x2265;60&#xa0;years old who received influenza vaccination.</ArticleTitle><Pagination><StartPage>127535</StartPage><MedlinePgn>127535</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2025.127535</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0264-410X(25)00832-1</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">In 2023, adults &#x2265;60&#xa0;years old were eligible to receive updated influenza and COVID-19 vaccines along with newly available respiratory syncytial virus (RSV) vaccines. Vaccine acceptance for influenza is typically high among this age cohort. We assessed COVID-19 and RSV vaccine uptake among influenza vaccine recipients to identify sociodemographic disparities among California adults &#x2265;60&#xa0;years old who did not receive all three vaccinations.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We used a cross-sectional design to assess the prevalence of COVID-19 and RSV vaccination among California adults &#x2265;60&#xa0;years old with an influenza vaccination reported to the California Immunization Registry during 08/01/2023-06/30/2024. We used log binomial regression to calculate prevalence ratios (PR) and 95&#xa0;% confidence intervals (95&#xa0;%CI) that measured associations between recipient sociodemographic characteristics and receipt of all three vaccines.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 4,471,042 adults included in this study, 901,815 (20&#xa0;%) received all three vaccinations during 2023-2024. The prevalence for receiving COVID-19 and RSV vaccines among Latino adults residing in the lowest resource communities was 80&#xa0;% less (PR: 0.20, 95&#xa0;%CI: 0.19, 0.20) than among white adults residing in the highest resource communities when the vaccination status of the comparison group was limited to influenza only vaccine recipients.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We identified concerning disparities in the uptake of COVID-19 and RSV vaccines among older adults during the 2023-2024 respiratory virus season in California. Provider awareness of these disparities may help improve vaccine uptake among older adult populations when patients seek their seasonal influenza vaccinations.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rizzo</LastName><ForeName>Kyle R</ForeName><Initials>KR</Initials><AffiliationInfo><Affiliation>Immunization Branch, California Department of Public Health, 850 Marina Bay Parkway, Building P, Second Floor, Richmond, CA 94804, United States of America. Electronic address: kyle.rizzo@cdph.ca.gov.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yen</LastName><ForeName>Cynthia Jean</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Immunization Branch, California Department of Public Health, 850 Marina Bay Parkway, Building P, Second Floor, Richmond, CA 94804, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quint</LastName><ForeName>Joshua</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Immunization Branch, California Department of Public Health, 850 Marina Bay Parkway, Building P, Second Floor, Richmond, CA 94804, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoover</LastName><ForeName>Cora</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Immunization Branch, California Department of Public Health, 850 Marina Bay Parkway, Building P, Second Floor, Richmond, CA 94804, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schechter</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Immunization Branch, California Department of Public Health, 850 Marina Bay Parkway, Building P, Second Floor, Richmond, CA 94804, United States of America.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID</Keyword><Keyword MajorTopicYN="N">Influenza</Keyword><Keyword MajorTopicYN="N">Older adults</Keyword><Keyword MajorTopicYN="N">RSV</Keyword><Keyword MajorTopicYN="N">Respiratory virus prevention</Keyword><Keyword MajorTopicYN="N">Vaccine acceptance</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>18</Hour><Minute>5</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40712319</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2025.127535</ArticleId><ArticleId IdType="pii">S0264-410X(25)00832-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40712311</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-6130</ISSN><JournalIssue CitedMedium="Internet"><Volume>58</Volume><PubDate><Year>2025</Year><Month>Jul</Month><Day>19</Day></PubDate></JournalIssue><Title>Economics and human biology</Title><ISOAbbreviation>Econ Hum Biol</ISOAbbreviation></Journal><ArticleTitle>Individualism and support for COVID-19 government interventions: The moderating role of perceived economic risk.</ArticleTitle><Pagination><StartPage>101513</StartPage><MedlinePgn>101513</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ehb.2025.101513</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1570-677X(25)00046-2</ELocationID><Abstract><AbstractText>Individualistic orientations in cultural worldviews significantly influence public attitudes toward government policies. We examine the impact and mechanisms of individualism on support for government interventions, focusing on the economic effects of COVID-19 containment measures. Utilizing data from the 10th and the latest 11th rounds of the European Social Survey (ESS), we find that individualism exerts a significant negative effect on public support for COVID-19 government interventions. Specifically, for each additional point increase in individualism corresponds to a 1.6&#x202f;% decrease in the probability of viewing border closures as extremely important and a 1.4&#x202f;% decrease for domestic movement restrictions. Our mechanism analysis reveals that individualism negatively affects intervention support by diminishing trust in government. Furthermore, higher perceived economic risk amplifies the negative impact of individualism on intervention support. Heterogeneity tests demonstrate that the negative influence of individualism is more pronounced among older individuals, those with lower income and education levels, employees in government and public sectors, and in non-post-socialist countries. We suggest that strategies to promote public policy support should be tailored to cultural and social contexts.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>School of Economics, Sichuan University, Chengdu 610065, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yin</LastName><ForeName>Guikun</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>School of Economics, Sichuan University, Chengdu 610065, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shao</LastName><ForeName>Qinglong</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>School of Ecology, Sun Yat-sen University - Shenzhen Campus, Shenzhen 518000, China. Electronic address: shaoqlong@mail.sysu.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Econ Hum Biol</MedlineTA><NlmUniqueID>101166135</NlmUniqueID><ISSNLinking>1570-677X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Government trust</Keyword><Keyword MajorTopicYN="N">Individualism</Keyword><Keyword MajorTopicYN="N">Perceived economic risks</Keyword><Keyword MajorTopicYN="N">Support for COVID-19 government interventions</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare no competing interests relevant to the content of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>5</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>18</Hour><Minute>5</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40712311</ArticleId><ArticleId IdType="doi">10.1016/j.ehb.2025.101513</ArticleId><ArticleId IdType="pii">S1570-677X(25)00046-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40712305</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1096-0341</ISSN><JournalIssue CitedMedium="Internet"><Volume>611</Volume><PubDate><Year>2025</Year><Month>Jul</Month><Day>21</Day></PubDate></JournalIssue><Title>Virology</Title><ISOAbbreviation>Virology</ISOAbbreviation></Journal><ArticleTitle>Murine antibody 4B1D3 exhibits broad cross-reactivity and neutralizing activity against SARS-CoV-2 variants.</ArticleTitle><Pagination><StartPage>110629</StartPage><MedlinePgn>110629</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.virol.2025.110629</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0042-6822(25)00242-9</ELocationID><Abstract><AbstractText>The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), identified in late 2019, spurred a global pandemic, prompting an unprecedented international mobilization in vaccination and public health strategies. Although the pandemic is now under greater control, the worldwide dissemination of variants of concern (VOCs) has led to resistance and decreased vaccine efficacy, highlighting the urgent need for broad-spectrum therapeutic and preventive solutions. In this study, we employed hybridoma technology to generate monoclonal antibodies (mAbs) from mice immunized with the SARS-CoV-2 Wuhan Spike protein trimer. We selected clones producing anti-Spike receptor-binding domain (RBD) mAbs and characterized a panel of four mAbs to assess their potential as antiviral agents and their utility as tools in research and diagnostics. Our results showed that all mAbs recognized the SARS-CoV-2 Wuhan strain in infected cells through immunofluorescence assay. Moreover, the binding profiles of these mAbs against the RBD protein from various SARS-CoV-2 variants revealed distinct reactivity and loss of binding as VOCs emerged. However, one mAb, named 4B1D3, showed the most promising features, exhibiting broad binding and neutralizing capacity across all tested SARS-CoV-2 variants, including Omicron BA.2, BA.4/5 and XBB.1.5 sublineages. Furthermore, a single prophylactic dose of the 4B1D3 mAb provided protection to K18-hACE2 mice against a lethal challenge with SARS-CoV-2 Wuhan strain. In conclusion, these mAbs represent valuable tools for research and diagnostics and have significant potential for the development of new therapeutic strategies against SARS-CoV-2 variants.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Silva</LastName><ForeName>Mari&#xe2;ngela de Oliveira</ForeName><Initials>MO</Initials><AffiliationInfo><Affiliation>Departamento de Parasitologia, Instituto Ci&#xea;ncias Biom&#xe9;dicas, Universidade de S&#xe3;o Paulo, S&#xe3;o Paulo, 05508-000, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daher</LastName><ForeName>Isabela Pazotti</ForeName><Initials>IP</Initials><AffiliationInfo><Affiliation>Instituto do Cora&#xe7;&#xe3;o, Hospital das Cl&#xed;nicas da Faculdade de Medicina, Universidade de S&#xe3;o Paulo, S&#xe3;o Paulo, 05403-000, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oda Ibrahim</LastName><ForeName>Catarina Harumi</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Departamento de Parasitologia, Instituto Ci&#xea;ncias Biom&#xe9;dicas, Universidade de S&#xe3;o Paulo, S&#xe3;o Paulo, 05508-000, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Souza</LastName><ForeName>Edmarcia Elisa</ForeName><Initials>EE</Initials><AffiliationInfo><Affiliation>Departamento de Parasitologia, Instituto Ci&#xea;ncias Biom&#xe9;dicas, Universidade de S&#xe3;o Paulo, S&#xe3;o Paulo, 05508-000, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Postol</LastName><ForeName>Edilberto</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Instituto do Cora&#xe7;&#xe3;o, Hospital das Cl&#xed;nicas da Faculdade de Medicina, Universidade de S&#xe3;o Paulo, S&#xe3;o Paulo, 05403-000, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Alencar</LastName><ForeName>Raquel Elaine</ForeName><Initials>RE</Initials><AffiliationInfo><Affiliation>Instituto do Cora&#xe7;&#xe3;o, Hospital das Cl&#xed;nicas da Faculdade de Medicina, Universidade de S&#xe3;o Paulo, S&#xe3;o Paulo, 05403-000, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Souza Silva</LastName><ForeName>Guilherme Ant&#xf4;nio</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>Departamento de Parasitologia, Instituto Ci&#xea;ncias Biom&#xe9;dicas, Universidade de S&#xe3;o Paulo, S&#xe3;o Paulo, 05508-000, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marques</LastName><ForeName>Rodolfo Ferreira</ForeName><Initials>RF</Initials><AffiliationInfo><Affiliation>Departamento de Parasitologia, Instituto Ci&#xea;ncias Biom&#xe9;dicas, Universidade de S&#xe3;o Paulo, S&#xe3;o Paulo, 05508-000, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adami</LastName><ForeName>Fl&#xe1;via Lopes</ForeName><Initials>FL</Initials><AffiliationInfo><Affiliation>Instituto do Cora&#xe7;&#xe3;o, Hospital das Cl&#xed;nicas da Faculdade de Medicina, Universidade de S&#xe3;o Paulo, S&#xe3;o Paulo, 05403-000, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuch</LastName><ForeName>Viviane</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Biochemistry, and Immunology, Morehouse School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamamoto</LastName><ForeName>Marcio Massao</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Departamento de Parasitologia, Instituto Ci&#xea;ncias Biom&#xe9;dicas, Universidade de S&#xe3;o Paulo, S&#xe3;o Paulo, 05508-000, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>da Silva Almeida</LastName><ForeName>Bianca</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Departamento de Parasitologia, Instituto Ci&#xea;ncias Biom&#xe9;dicas, Universidade de S&#xe3;o Paulo, S&#xe3;o Paulo, 05508-000, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koike</LastName><ForeName>Gabriela</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Departamento de Parasitologia, Instituto Ci&#xea;ncias Biom&#xe9;dicas, Universidade de S&#xe3;o Paulo, S&#xe3;o Paulo, 05508-000, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Azevedo</LastName><ForeName>Isabela Resende</ForeName><Initials>IR</Initials><AffiliationInfo><Affiliation>Departamento de Parasitologia, Instituto Ci&#xea;ncias Biom&#xe9;dicas, Universidade de S&#xe3;o Paulo, S&#xe3;o Paulo, 05508-000, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castro-Amarante</LastName><ForeName>Maria Fernanda</ForeName><Initials>MF</Initials><AffiliationInfo><Affiliation>Departamento de Microbiologia, Instituto Ci&#xea;ncias Biom&#xe9;dicas, Universidade de S&#xe3;o Paulo, S&#xe3;o Paulo, 05508-000, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosa</LastName><ForeName>Daniela Santoro</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>Departamento de Microbiologia, Imunologia e Parasitologia, Universidade Federal de S&#xe3;o Paulo, S&#xe3;o Paulo, 04023-062, Brazil; Instituto de Investiga&#xe7;&#xe3;o em Imunologia-Instituto Nacional de Ci&#xea;ncias e Tecnologia (iii-INCT), S&#xe3;o Paulo, 05403-000, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Durigon</LastName><ForeName>Edison Luiz</ForeName><Initials>EL</Initials><AffiliationInfo><Affiliation>Departamento de Microbiologia, Instituto Ci&#xea;ncias Biom&#xe9;dicas, Universidade de S&#xe3;o Paulo, S&#xe3;o Paulo, 05508-000, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wrenger</LastName><ForeName>Carsten</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Departamento de Parasitologia, Instituto Ci&#xea;ncias Biom&#xe9;dicas, Universidade de S&#xe3;o Paulo, S&#xe3;o Paulo, 05508-000, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cunha-Neto</LastName><ForeName>Edecio</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Instituto do Cora&#xe7;&#xe3;o, Hospital das Cl&#xed;nicas da Faculdade de Medicina, Universidade de S&#xe3;o Paulo, S&#xe3;o Paulo, 05403-000, Brazil; Instituto de Investiga&#xe7;&#xe3;o em Imunologia-Instituto Nacional de Ci&#xea;ncias e Tecnologia (iii-INCT), S&#xe3;o Paulo, 05403-000, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalil</LastName><ForeName>Jorge</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Instituto do Cora&#xe7;&#xe3;o, Hospital das Cl&#xed;nicas da Faculdade de Medicina, Universidade de S&#xe3;o Paulo, S&#xe3;o Paulo, 05403-000, Brazil; Instituto de Investiga&#xe7;&#xe3;o em Imunologia-Instituto Nacional de Ci&#xea;ncias e Tecnologia (iii-INCT), S&#xe3;o Paulo, 05403-000, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boscardin</LastName><ForeName>Silvia Beatriz</ForeName><Initials>SB</Initials><AffiliationInfo><Affiliation>Departamento de Parasitologia, Instituto Ci&#xea;ncias Biom&#xe9;dicas, Universidade de S&#xe3;o Paulo, S&#xe3;o Paulo, 05508-000, Brazil; Instituto de Investiga&#xe7;&#xe3;o em Imunologia-Instituto Nacional de Ci&#xea;ncias e Tecnologia (iii-INCT), S&#xe3;o Paulo, 05403-000, Brazil. Electronic address: sbboscardin@usp.br.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Virology</MedlineTA><NlmUniqueID>0110674</NlmUniqueID><ISSNLinking>0042-6822</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Hybridoma</Keyword><Keyword MajorTopicYN="N">Monoclonal antibody</Keyword><Keyword MajorTopicYN="N">Neutralization</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2 variants of concern</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>18</Hour><Minute>5</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40712305</ArticleId><ArticleId IdType="doi">10.1016/j.virol.2025.110629</ArticleId><ArticleId IdType="pii">S0042-6822(25)00242-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40712251</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1433-2981</ISSN><JournalIssue CitedMedium="Internet"><Volume>45</Volume><PubDate><Year>2025</Year><Month>Jun</Month><Day>27</Day></PubDate></JournalIssue><Title>Clinical oncology (Royal College of Radiologists (Great Britain))</Title><ISOAbbreviation>Clin Oncol (R Coll Radiol)</ISOAbbreviation></Journal><ArticleTitle>Real World Multi-centre UK Review of Nivolumab Monotherapy in Metastatic Endometrial Cancer With Mismatch Repair Deficiency During COVID-19.</ArticleTitle><Pagination><StartPage>103899</StartPage><MedlinePgn>103899</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.clon.2025.103899</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0936-6555(25)00154-2</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Immunotherapy checkpoint inhibition has shown improvement in efficacy and survival in patients with mismatch repair deficient (MMRd) advanced endometrial cancer (mEC) compared to chemotherapy. This is combined with chemotherapy in the first-line setting or as monotherapy in later lines of therapy.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To assess the efficacy, survival and toxicity of nivolumab monotherapy in metastatic endometrial cancer (mEC) in both first and later lines of therapy as used in the NICE COVID-19 systemic anti-cancer (SACT) guidelines.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A multi-centre retrospective review of mEC patients with associated MMRd who received nivolumab as per NICE COVID NG161 at 10 NHS cancer centres. Patient demographics, molecular classification and previous treatments were recorded in addition to treatment responses, duration of response, overall survival, progression-free survival and toxicities. Kaplan-Meier curves analyse the survival data.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">52 patients were identified. Median age was 67 (37-81) years. 87.5% of patients had endometrioid histology and 75% were oestrogen receptor (ER) positive. 10.4% patients were p53 mutated. 33.3% of mEC patients were stage IV at diagnosis. 30 (62.5%) patients received nivolumab as first-line mEC therapy. 33 (68.8%) patients received nivolumab 4-weekly. Treatment response was clinician-observed in 34 (70.8%) patients, with 7 (14.5%) more having stable disease. 52%, 45% and 36% of patients were progression-free at 12, 18 and 24months, respectively. 75%, 55% and 47% of patients were alive at 12, 18 and 24 months. There was no significant difference between survival or response whether nivolumab was given in the first line or subsequent lines. 29 (60.4%) patients have discontinued treatment with 23 (44.2%) being due to progressive disease or death. 18 (37.5%) patients developed G1-2 toxicity, and 3 (6.25%) patients discontinued due to G3 toxicity.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This retrospective cohort shows that nivolumab monotherapy has good real-world disease control of mEC patients with MMR deficiency. Toxicity rates were low, and checkpoint monotherapy may be a viable option for selected first-line MMRd mEC patients.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McGrane</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Royal Cornwall Hospital NHS Trust, Truro, UK. Electronic address: John.McGrane@nhs.net.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eastlake</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Royal Cornwall Hospital NHS Trust, Truro, UK. Electronic address: Leonie.Eastlake@nhs.net.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hadjiyiannakis</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Lancashire Teaching Hospitals NHS Trust, UK. Electronic address: Dennis.Hadjiyiannakis@lthtr.nhs.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lalondrelle</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Royal Marden Hospital NHS Trust, London, UK. Electronic address: Susan.Lalondrelle@rmh.nhs.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bowen</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Royal United Hospitals Bath NHS Foundation Trust, Bath, UK. Electronic address: Rebecca.bowen3@nhs.net.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trent</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Oxford University Hospitals, NHS Foundation Trust, Oxford, UK. Electronic address: Sally.Trent@ouh.nhs.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Obeid</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Lancashire Teaching Hospitals NHS Trust, UK. Electronic address: Mariam.Obeid@lthtr.nhs.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hudson</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Velindre Cancer Centre, Cardiff, UK. Electronic address: Emma.hudson@wales.nhs.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agarwal</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Northampton General Hospital NHS Trust, Northampton, UK. Electronic address: roshan.agarwal2@nhs.net.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gandhi</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Lancashire Teaching Hospitals NHS Trust, UK. Electronic address: Sarah.Gandhi@lthtr.nhs.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Young</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>The Royal Marsden Hospital, London, UK. Electronic address: thomas.young5@nhs.net.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kristeleit</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Guys and St Thomas's NHS Foundation Trust and King's College London, London, UK. Electronic address: Rebecca.Kristeleit@gstt.nhs.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohammed</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>University Hospitals of Derby and Burton NHS Foundation Trust, UK. Electronic address: rania.mohammed@nhs.net.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rowe</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Royal Cornwall Hospital NHS Trust, Truro, UK. Electronic address: Michael.rowe2@nhs.net.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dubey</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>University Hospital Plymouth, UK. Electronic address: SDubey@nhs.net.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Forrest</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Royal Devon University Healthcare NHS Foundation Trust, Exeter, UK. Electronic address: Jennifer.forrest1@nhs.net.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seneviratne</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>University Hospitals of Derby and Burton NHS Foundation Trust, UK. Electronic address: lalith.seneviratne@nhs.net.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hussain</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>University Hospitals of Northamptonshire, UK. Electronic address: mohammed.hussain52@nhs.net.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Melendez-Torres</LastName><ForeName>G J</ForeName><Initials>GJ</Initials><AffiliationInfo><Affiliation>University of Exeter, UK. Electronic address: G.J.Melendez-Torres@exeter.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>06</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Clin Oncol (R Coll Radiol)</MedlineTA><NlmUniqueID>9002902</NlmUniqueID><ISSNLinking>0936-6555</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Endometrial cancer</Keyword><Keyword MajorTopicYN="N">MMR deficiency</Keyword><Keyword MajorTopicYN="N">immunotherapy</Keyword><Keyword MajorTopicYN="N">nivolumab</Keyword></KeywordList><CoiStatement>Conflict of interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Rebecca Bowen reports a relationship with AstraZeneca PLC that includes: consulting or advisory, speaking and lecture fees, and travel reimbursement. Rebecca Bowen reports a relationship with pharma&amp; that includes: consulting or advisory, speaking and lecture fees, and travel reimbursement. Rebecca Bowen reports a relationship with Merck Sharp &amp; Dohme UK Ltd that includes: consulting or advisory. Rebecca Bowen reports a relationship with Pfizer that includes: speaking and lecture fees. John McGrane reports a relationship with Eisai Inc that includes: consulting or advisory and speaking and lecture fees. John McGrane reports a relationship with AstraZeneca PLC that includes: consulting or advisory. John McGrane reports a relationship with GlaxoSmithKline that includes: consulting or advisory and speaking and lecture fees. John McGrane reports a relationship with Bristol-Myers Squibb Co that includes: consulting or advisory and speaking and lecture fees. John McGrane reports a relationship with Merck Sharp &amp; Dohme UK Ltd that includes: consulting or advisory and speaking and lecture fees. Susan Lalondrelle reports a relationship with Merck Sharp &amp; Dohme UK Ltd that includes: consulting or advisory and speaking and lecture fees. Susan Lalondrelle reports a relationship with Regeneron Pharmaceuticals Inc that includes: consulting or advisory and speaking and lecture fees. Susan Lalondrelle reports a relationship with GlaxoSmithKline Inc that includes: consulting or advisory and speaking and lecture fees. Rebecca Kristeleit reports a relationship with Merck Sharp &amp; Dohme UK Ltd that includes: consulting or advisory and funding grants. Rebecca Kristeleit reports a relationship with GlaxoSmithKline Inc that includes: consulting or advisory, speaking and lecture fees, and travel reimbursement. Emma Hudson reports a relationship with AstraZeneca PLC that includes: consulting or advisory. Emma Hudson reports a relationship with Eisai Inc that includes: speaking and lecture fees. Rebecca Kristeleit reports a relationship with AstraZeneca PLC that includes: consulting or advisory, speaking and lecture fees, and travel reimbursement. Rebecca Kristeleit reports a relationship with Pharma&amp; that includes: consulting or advisory, speaking and lecture fees, and travel reimbursement. Rebecca Kristeleit reports a relationship with Merck Sharp &amp; Dohme UK Ltd that includes: consulting or advisory and speaking and lecture fees. Rebecca Kristeleit reports a relationship with Tubulis that includes: consulting or advisory and travel reimbursement. Rebecca Kristeleit reports a relationship with Incyte Corporation that includes: consulting or advisory. Rebecca Kristeleit reports a relationship with Epsilogen Ltd that includes: travel reimbursement. Rebecca Kristeleit reports a relationship with Duke St Bio that includes: consulting or advisory. Rebecca Kristeleit reports a relationship with Prokarium that includes: consulting or advisory. Rebecca Kristeleit reports a relationship with Clovis Oncology that includes: consulting or advisory. Rebecca Kristeleit reports a relationship with Celcuity, Inc. that includes: consulting or advisory. Rebecca Kristeleit reports a relationship with Leucid Bio Ltd that includes: consulting or advisory. Rebecca Kristeleit reports a relationship with Genmab US Inc that includes: consulting or advisory. Rebecca Kristeleit reports a relationship with ImmunoGen Inc that includes: consulting or advisory. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>28</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>12</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>6</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>18</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40712251</ArticleId><ArticleId IdType="doi">10.1016/j.clon.2025.103899</ArticleId><ArticleId IdType="pii">S0936-6555(25)00154-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40712141</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2198-3844</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Jul</Month><Day>25</Day></PubDate></JournalIssue><Title>Advanced science (Weinheim, Baden-Wurttemberg, Germany)</Title><ISOAbbreviation>Adv Sci (Weinh)</ISOAbbreviation></Journal><ArticleTitle>A Human Immuno-Lung Organoid Model to Study Macrophage-Mediated Lung Cell Senescence Upon SARS-CoV-2 Infection.</ArticleTitle><Pagination><StartPage>e03932</StartPage><MedlinePgn>e03932</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/advs.202503932</ELocationID><Abstract><AbstractText>While COVID-19 affects multiple organ systems, the human respiratory system is the primary viral target and main site for disease progression. In this study, spatial transcriptional assays (NanoString CosMx) are utilized to analyze both explant and autopsy samples from non-COVID and COVID-19 lungs, identifying the activation of proinflammatory macrophages in COVID-19 explants. It is further developed immuno-lung organoids comprising hPSC-derived alveolar and airway organoids co-cultured with macrophages to investigate the impact and underlying mechanisms of macrophage-mediated lung damage following SARS-CoV-2 infection. The findings demonstrate that proinflammatory macrophages induce lung cell senescence through the THBS1-(ITGA3+ITGB1) signaling axis, a mechanism further validated using spatial transcriptomics. This study not only establishes physiologically relevant immuno-lung organoid models for modeling macrophage-mediated tissue damage, but also identifies a previous unrecognized role of the THBS1-(ITGA3+ITGB1) pathway in driving lung cell senescence during infectious disease.</AbstractText><CopyrightInformation>&#xa9; 2025 The Author(s). Advanced Science published by Wiley&#x2010;VCH GmbH.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Yuling</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Surgery, Weill Cornell Medicine, 1300 York Ave, New York, NY, 10065, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Genomic Health, Weill Cornell Medicine, 1300 York Ave, New York, NY, 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leng</LastName><ForeName>Dongliang</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Surgery, Weill Cornell Medicine, 1300 York Ave, New York, NY, 10065, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Genomic Health, Weill Cornell Medicine, 1300 York Ave, New York, NY, 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Tuo</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Genomic Resource Core Facility, Weill Cornell Medicine, New York, NY, 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ge</LastName><ForeName>Jian</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Columbia Center for Human Development and Division of Digestive and Liver Disease, Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University IrvingMedical Center, New York, NY, 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fang</LastName><ForeName>Yinshan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Columbia Center for Human Development and Division of Digestive and Liver Disease, Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University IrvingMedical Center, New York, NY, 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Tiankun</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Surgery, Weill Cornell Medicine, 1300 York Ave, New York, NY, 10065, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Genomic Health, Weill Cornell Medicine, 1300 York Ave, New York, NY, 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dong</LastName><ForeName>Xue</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Surgery, Weill Cornell Medicine, 1300 York Ave, New York, NY, 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nair</LastName><ForeName>Manoj S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Silva</LastName><ForeName>Neranjan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Surgery, Weill Cornell Medicine, 1300 York Ave, New York, NY, 10065, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Genomic Health, Weill Cornell Medicine, 1300 York Ave, New York, NY, 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Zhaowei</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Gilbert S. Omenn Department of Computational Medicine &amp; Bioinformatics, University of Michigan, Ann Arbor, MI, 48109, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiao</LastName><ForeName>Tiancheng</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Gilbert S. Omenn Department of Computational Medicine &amp; Bioinformatics, University of Michigan, Ann Arbor, MI, 48109, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Yuanhao</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Gilbert S. Omenn Department of Computational Medicine &amp; Bioinformatics, University of Michigan, Ann Arbor, MI, 48109, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Meiqi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Gilbert S. Omenn Department of Computational Medicine &amp; Bioinformatics, University of Michigan, Ann Arbor, MI, 48109, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saqi</LastName><ForeName>Anjali</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY, 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hibshoosh</LastName><ForeName>Hanina</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY, 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meng</LastName><ForeName>Zihe</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Surgery, Weill Cornell Medicine, 1300 York Ave, New York, NY, 10065, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Genomic Health, Weill Cornell Medicine, 1300 York Ave, New York, NY, 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiang</LastName><ForeName>Jenny Z</ForeName><Initials>JZ</Initials><AffiliationInfo><Affiliation>Genomic Resource Core Facility, Weill Cornell Medicine, New York, NY, 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pan</LastName><ForeName>Chendong</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Genomic Resource Core Facility, Weill Cornell Medicine, New York, NY, 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Yanjie</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Genomic Resource Core Facility, Weill Cornell Medicine, New York, NY, 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ho</LastName><ForeName>David D</ForeName><Initials>DD</Initials><AffiliationInfo><Affiliation>Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Evans</LastName><ForeName>Todd</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Surgery, Weill Cornell Medicine, 1300 York Ave, New York, NY, 10065, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Genomic Health, Weill Cornell Medicine, 1300 York Ave, New York, NY, 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Gilbert S. Omenn Department of Computational Medicine &amp; Bioinformatics, University of Michigan, Ann Arbor, MI, 48109, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Liuliu</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Surgery, Weill Cornell Medicine, 1300 York Ave, New York, NY, 10065, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Genomic Health, Weill Cornell Medicine, 1300 York Ave, New York, NY, 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Que</LastName><ForeName>Jianwen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Columbia Center for Human Development and Division of Digestive and Liver Disease, Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University IrvingMedical Center, New York, NY, 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Shuibing</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-6294-5187</Identifier><AffiliationInfo><Affiliation>Department of Surgery, Weill Cornell Medicine, 1300 York Ave, New York, NY, 10065, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Genomic Health, Weill Cornell Medicine, 1300 York Ave, New York, NY, 10065, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Department of Surgery, Weill Cornell Medicine</Agency><Country/></Grant><Grant><GrantID>1R01HL152293</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01HL159675</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01HL179522</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>W81XWH-21-1-0196</GrantID><Agency>Department of Defense</Agency><Country/></Grant><Grant><GrantID>INV-037420</GrantID><Acronym>GATES</Acronym><Agency>Gates Foundation</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Adv Sci (Weinh)</MedlineTA><NlmUniqueID>101664569</NlmUniqueID><ISSNLinking>2198-3844</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">macrophage</Keyword><Keyword MajorTopicYN="N">organoid</Keyword><Keyword MajorTopicYN="N">spatial transcriptomics</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>6</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>18</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>18</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>17</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40712141</ArticleId><ArticleId IdType="doi">10.1002/advs.202503932</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>S. Upadhya, J. Rehman, A. B. Malik, S. Chen, Physiology (Bethesda) 2022, 37, 88.</Citation></Reference><Reference><Citation>A. F. Rendeiro, H. Ravichandran, Y. Bram, V. Chandar, J. Kim, C. Meydan, J. Park, J. Foox, T. Hether, S. Warren, Y. Kim, J. Reeves, S. Salvatore, C. E. Mason, E. C. Swanson, A. C. Borczuk, O. Elemento, R. E. Schwartz, Nature 2021, 593, 564.</Citation></Reference><Reference><Citation>A. Kulasinghe, C. W. Tan, A. F. R. S. Miggiolaro, J. Monkman, H. SadeghiRad, D. D. Bhuva, J. S. M. Junior, C. B. V. Paula, S. Nagashima, C. P. Baena, Eur. Respir. J. 2022, 59, 2101881.</Citation></Reference><Reference><Citation>A. R. Cross, C. E. de Andrea, M. Villalba&#x2010;Esparza, M. F. Landecho, L. Cerundolo, P. Weeratunga, R. E. Etherington, L. Denney, G. Ogg, L. P. Ho, I. S. Roberts, J. Hester, P. Klenerman, I. Melero, S. N. Sansom, F. Issa, JCI Insight 2023, 8, 157837.</Citation></Reference><Reference><Citation>S. Yamanaka, Cell Stem Cell 2020, 27, 523.</Citation></Reference><Reference><Citation>L. Yang, Y. Han, B. E. Nilsson&#x2010;Payant, V. Gupta, P. Wang, X. Duan, X. Tang, J. Zhu, Z. Zhao, F. Jaffre, T. Zhang, T. W. Kim, O. Harschnitz, D. Redmond, S. Houghton, C. Liu, A. Naji, G. Ciceri, S. Guttikonda, Y. Bram, D. T. Nguyen, M. Cioffi, V. Chandar, D. A. Hoagland, Y. Huang, J. Xiang, H. Wang, D. Lyden, A. Borczuk, H. J. Chen, et&#xa0;al., Cell Stem Cell 2020, 27, 125.</Citation></Reference><Reference><Citation>Y. Han, X. Duan, L. Yang, B. E. Nilsson&#x2010;Payant, P. Wang, F. Duan, X. Tang, T. M. Yaron, T. Zhang, S. Uhl, Y. Bram, C. Richardson, J. Zhu, Z. Zhao, D. Redmond, S. Houghton, D. T. Nguyen, D. Xu, X. Wang, J. Jessurun, A. Borczuk, Y. Huang, J. L. Johnson, Y. Liu, J. Xiang, H. Wang, L. C. Cantley, B. R. tenOever, D. D. Ho, F. C. Pan, et&#xa0;al., Nature 2021, 589, 270.</Citation></Reference><Reference><Citation>Y. Han, L. Tan, T. Zhou, L. Yang, L. Carrau, L. A. Lacko, M. Saeed, J. Zhu, Z. Zhao, B. E. Nilsson&#x2010;Payant, F. T. Lira Neto, C. Cahir, A. M. Giani, J. C. Chai, Y. Li, X. Dong, D. Moroziewicz, D. Paull, T. Zhang, S. Koo, C. Tan, R. Danziger, Q. Ba, L. Feng, Z. Chen, A. Zhong, G. J. Wise, J. Z. Xiang, H. Wang, R. E. Schwartz, et&#xa0;al., Cell Stem Cell 2022, 29, 1475.</Citation></Reference><Reference><Citation>C. C. Bain, C. D. Lucas, A. G. Rossi, Int. Rev. Cell. Mol. Biol. 2022, 367, 1.</Citation></Reference><Reference><Citation>L. Yang, Y. Han, F. Jaffr&#xe9;, B. E. Nilsson&#x2010;Payant, Y. Bram, P. Wang, J. Zhu, T. Zhang, D. Redmond, S. Houghton, S. Uhl, A. Borczuk, Y. Huang, C. Richardson, V. Chandar, J. A. Acklin, J. K. Lim, Z. Chen, J. Xiang, D. D. Ho, B. R. tenOever, R. E. Schwartz, T. Evans, S. Chen, Circ. Res. 2021, 129, 33.</Citation></Reference><Reference><Citation>L. Yang, Y. Han, T. Zhang, X. Dong, J. Ge, A. Roy, J. Zhu, T. Lu, J. Jeya Vandana, N. de Silva, C. C. Robertson, J. Z. Xiang, C. Pan, Y. Sun, J. Que, T. Evans, C. Liu, W. Wang, A. Naji, S. C. J. Parker, R. E. Schwartz, S. Chen, Cell Stem Cell 2024, 31, 1612.</Citation></Reference><Reference><Citation>D. Hassan, J. Chen, Nat. Commun. 2024, 15, 4148.</Citation></Reference><Reference><Citation>S. Kanagaki, S. Ikeo, T. Suezawa, Y. Yamamoto, M. Seki, T. Hirai, M. Hagiwara, Y. Suzuki, S. Gotoh, Stem Cells 2021, 39, 156.</Citation></Reference><Reference><Citation>J. Huang, A. J. Hume, K. M. Abo, R. B. Werder, C. Villacorta&#x2010;Martin, K. D. Alysandratos, M. L. Beermann, C. Simone&#x2010;Roach, J. Lindstrom&#x2010;Vautrin, J. Olejnik, E. L. Suder, E. Bullitt, A. Hinds, A. Sharma, M. Bosmann, R. Wang, F. Hawkins, E. J. Burks, M. Saeed, A. A. Wilson, E. Muhlberger, D. N. Kotton, Cell Stem Cell 2020, 27, 962.</Citation></Reference><Reference><Citation>R. Pei, J. Feng, Y. Zhang, H. Sun, L. Li, X. Yang, J. He, S. Xiao, J. Xiong, Y. Lin, K. Wen, H. Zhou, J. Chen, Z. Rong, X. Chen, Protein Cell 2021, 12, 717.</Citation></Reference><Reference><Citation>N. N. Alrajhi, Ann. Thorac. Med. 2023, 18, 173.</Citation></Reference><Reference><Citation>L. Vila Ellis, M. P. Cain, V. Hutchison, P. Flodby, E. D. Crandall, Z. Borok, B. Zhou, E. J. Ostrin, J. D. Wythe, J. Chen, Dev. Cell 2020, 52, 617.</Citation></Reference><Reference><Citation>A. C. Baege, G. L. Disbrow, R. Schlegel, J. Virol. 2004, 78, 5720.</Citation></Reference><Reference><Citation>V. Moiseeva, A. Cisneros, V. Sica, O. Deryagin, Y. Lai, S. Jung, E. Andres, J. An, J. Segales, L. Ortet, V. Lukesova, G. Volpe, A. Benguria, A. Dopazo, S. A. Benitah, Y. Urano, A. Del Sol, M. A. Esteban, Y. Ohkawa, A. L. Serrano, E. Perdiguero, P. Munoz&#x2010;Canoves, Nature 2023, 613, 169.</Citation></Reference><Reference><Citation>R. Mothes, A. Pascual&#x2010;Reguant, R. Koehler, J. Liebeskind, A. Liebheit, S. Bauherr, L. Philipsen, C. Dittmayer, M. Laue, R. von Manitius, S. Elezkurtaj, P. Durek, F. Heinrich, G. A. Heinz, G. M. Guerra, B. Obermayer, J. Meinhardt, J. Ihlow, J. Radke, F. L. Heppner, P. Enghard, H. Stockmann, T. Aschman, J. Schneider, V. M. Corman, L. E. Sander, M. F. Mashreghi, T. Conrad, A. C. Hocke, R. A. Niesner, et&#xa0;al., Nat. Commun. 2023, 14, 791.</Citation></Reference><Reference><Citation>Y. Pita&#x2010;Juarez, D. Karagkouni, N. Kalavros, J. C. Melms, S. Niezen, T. M. Delorey, A. L. Essene, O. R. Brook, D. Pant, D. Skelton&#x2010;Badlani, P. Naderi, P. Huang, L. Pan, T. Hether, T. S. Andrews, C. G. K. Ziegler, J. Reeves, A. Myloserdnyy, R. Chen, A. Nam, S. Phelan, Y. Liang, A. D. Amin, J. Biermann, H. Hibshoosh, M. Veregge, Z. Kramer, C. Jacobs, Y. Yalcin, D. Phillips, et&#xa0;al., bioRxiv 2022, 514070.</Citation></Reference><Reference><Citation>A. Kulasinghe, N. Liu, C. W. Tan, J. Monkman, J. E. Sinclair, D. D. Bhuva, D. Godbolt, L. Pan, A. Nam, H. Sadeghirad, K. Sato, G. L. Bassi, K. O'Byrne, C. Hartmann, A. F. R. Dos Santos Miggiolaro, G. L. Marques, L. Z. Moura, D. Richard, M. Adams, L. de Noronha, C. P. Baena, J. Y. Suen, R. Arora, G. T. Belz, K. R. Short, M. J. Davis, F. S. Guimaraes, J. F. Fraser, Immunology 2023, 168, 403.</Citation></Reference><Reference><Citation>E. R. Barrozo, M. D. Seferovic, E. C. C. Castro, A. M. Major, D. N. Moorshead, M. D. Jochum, R. F. Rojas, C. D. Shope, K. M. Aagaard, Med 2023, 4, 612.</Citation></Reference><Reference><Citation>N. Desai, A. Neyaz, A. Szabolcs, A. R. Shih, J. H. Chen, V. Thapar, L. T. Nieman, A. Solovyov, A. Mehta, D. J. Lieb, Nat. Commun. 2020, 11, 6319.</Citation></Reference><Reference><Citation>D. Wendisch, O. Dietrich, T. Mari, S. von Stillfried, I. L. Ibarra, M. Mittermaier, C. Mache, R. L. Chua, R. Knoll, S. Timm, S. Brumhard, T. Krammer, H. Zauber, A. L. Hiller, A. Pascual&#x2010;Reguant, R. Mothes, R. D. B&#xfc;low, J. Schulze, A. M. Leipold, S. Djudjaj, F. Erhard, R. Geffers, F. Pott, J. Kazmierski, J. Radke, P. Pergantis, K. Ba&#xdf;ler, C. Conrad, A. C. Aschenbrenner, B. Sawitzki, et&#xa0;al., Cell 2021, 184, 6243.</Citation></Reference><Reference><Citation>T. Recaldin, L. Steinacher, B. Gjeta, M. F. Harter, L. Adam, K. Kromer, M. P. Mendes, M. Bellavista, M. Nikolaev, G. Lazzaroni, R. Krese, U. Kilik, D. Popovic, B. Stoll, R. Gerard, M. Bscheider, M. Bickle, L. Cabon, J. Gray Camp, N. Gjorevski, Nature 2024, 633, 165.</Citation></Reference><Reference><Citation>A. J. M. Santos, V. van Unen, Z. Lin, S. M. Chirieleison, N. Ha, A. Batish, J. E. Chan, J. Cedano, E. T. Zhang, Q. Mu, A. Guh&#x2010;Siesel, M. Tomaske, D. Colburg, S. Varma, S. S. Choi, A. Christophersen, A. Baghdasaryan, K. E. Yost, K. Karlsson, A. Ha, J. Li, H. Dai, Z. M. Sellers, H. Y. Chang, J. C. Y. Dunn, B. M. Zhang, E. D. Mellins, L. M. Sollid, N. Q. Fernandez&#x2010;Becker, M. M. Davis, et&#xa0;al., Nature 2024, 632, 401.</Citation></Reference><Reference><Citation>A. I. Vazquez&#x2010;Armendariz, M. Heiner, E. El Agha, I. Salwig, A. Hoek, M. C. Hessler, I. Shalashova, A. Shrestha, G. Carraro, J. P. Mengel, A. G&#xfc;nther, R. E. Morty, I. Vad&#xe1;sz, M. Schwemmle, W. Kummer, T. Hain, A. Goesmann, S. Bellusci, W. Seeger, T. Braun, S. Herold, Embo J. 2020, 39, 103476.</Citation></Reference><Reference><Citation>X. Qin, J. Sufi, P. Vlckova, P. Kyriakidou, S. E. Acton, V. S. W. Li, M. Nitz, C. J. Tape, Nat. Methods 2020, 17, 335.</Citation></Reference><Reference><Citation>C. Bouffi, K. A. Wikenheiser&#x2010;Brokamp, P. Chaturvedi, N. Sundaram, G. R. Goddard, M. Wunderlich, N. E. Brown, J. F. Staab, R. Latanich, N. C. Zachos, E. M. Holloway, M. M. Mahe, H. M. Poling, S. Vales, G. W. Fisher, J. R. Spence, J. C. Mulloy, A. M. Zorn, J. M. Wells, M. A. Helmrath, Nat. Biotechnol. 2023, 41, 824.</Citation></Reference><Reference><Citation>J. O. M&#xfa;nera, D. O. Kechele, C. Bouffi, N. Qu, R. Jing, P. Maity, J. R. Enriquez, L. Han, I. Campbell, M. M. Mahe, H. A. McCauley, X. Zhang, N. Sundaram, J. R. Hudson, A. Zarsozo&#x2010;Lacoste, S. Pradhan, K. Tominaga, J. G. Sanchez, A. A. Weiss, P. Chatuvedi, J. R. Spence, M. Hachimi, T. North, G. Q. Daley, C. N. Mayhew, Y. C. Hu, T. Takebe, M. A. Helmrath, J. M. Wells, Cell Stem Cell 2023, 30, 1434.</Citation></Reference><Reference><Citation>S. Choi, J. Choi, S. Cheon, J. Song, S. Y. Kim, J. E. Kim, D. H. Nam, G. Manzar, S. M. Kim, H. S. Kang, K. K. Kim, S. H. Jeong, J. H. Lee, E. K. Park, M. Lee, H. A. Lee, K. S. Kim, H. J. Park, W. K. Oh, C. Park, C. H. Lee, E. M. Kim, Cell Biol. Toxicol. 2022, 38, 557.</Citation></Reference><Reference><Citation>S. Lee, Y. Yu, J. Trimpert, F. Benthani, M. Mairhofer, P. Richter&#x2010;Pechanska, E. Wyler, D. Belenki, S. Kaltenbrunner, M. Pammer, L. Kausche, T. C. Firsching, K. Dietert, M. Schotsaert, C. Mart&#xed;nez&#x2010;Romero, G. Singh, S. Kunz, D. Niemeyer, R. Ghanem, H. J. F. Salzer, C. Paar, M. M&#xfc;lleder, M. Uccellini, E. G. Michaelis, A. Khan, A. Lau, M. Sch&#xf6;nlein, A. Habringer, J. Tomasits, J. M. Adler, et&#xa0;al., Nature 2021, 599, 283.</Citation></Reference><Reference><Citation>K. Evangelou, D. Veroutis, K. Paschalaki, P. G. Foukas, N. Lagopati, M. Dimitriou, A. Papaspyropoulos, B. Konda, O. Hazapis, A. Polyzou, S. Havaki, A. Kotsinas, C. Kittas, A. G. Tzioufas, L. de Leval, D. Vassilakos, S. Tsiodras, B. R. Stripp, A. Papantonis, G. Blandino, I. Karakasiliotis, P. J. Barnes, V. G. Gorgoulis, Eur. Respir. J. 2022, 60, 2021.</Citation></Reference><Reference><Citation>L. Yang, T. W. Kim, Y. Han, M. S. Nair, O. Harschnitz, J. Zhu, P. Wang, S. Y. Koo, L. A. Lacko, V. Chandar, Y. Bram, T. Zhang, W. Zhang, F. He, C. Pan, J. Wu, Y. Huang, T. Evans, P. van der Valk, M. J. Titulaer, J. K. H. Spoor, R. L. Furler O'Brien, M. Bugiani, D. J. Van de Berg W, R. E. Schwartz, D. D. Ho, L. Studer, S. Chen, Cell Stem Cell 2024, 31, 196.</Citation></Reference><Reference><Citation>F. Merigo, A. Lagni, F. Boschi, P. Bernardi, A. Conti, R. Plebani, M. Romano, C. Sorio, V. Lotti, A. Sbarbati, Int. J. Mol. Sci. 2024, 25, 6185.</Citation></Reference><Reference><Citation>F. D'Agnillo, K. A. Walters, Y. Xiao, Z. M. Sheng, K. Scherler, J. Park, S. Gygli, L. A. Rosas, K. Sadtler, H. Kalish, C. A. Blatti III, R. Zhu, L. Gatzke, C. Bushell, M. J. Memoli, S. J. O'Day, T. D. Fischer, T. C. Hammond, R. C. Lee, J. C. Cash, M. E. Powers, G. E. O'Keefe, K. J. Butnor, A. V. Rapkiewicz, W. D. Travis, S. P. Layne, J. C. Kash, J. K. Taubenberger, Sci. Transl. Med. 2021, 13, abj7790.</Citation></Reference><Reference><Citation>E. Porpiglia, T. Mai, P. Kraft, C. A. Holbrook, A. de Morree, V. D. Gonzalez, K. I. Hilgendorf, L. Fresard, A. Trejo, S. Bhimaraju, P. K. Jackson, W. J. Fantl, H. M. Blau, Cell Stem Cell 2022, 29, 1653.</Citation></Reference><Reference><Citation>L. Schulz, F. Hornung, A. H&#xe4;der, L. Radosa, A. A. Brakhage, B. L&#xf6;ffler, S. Deinhardt&#x2010;Emmer, Aging Dis. 2023, 14, 1331.</Citation></Reference><Reference><Citation>V. Lara&#x2010;Aguilar, M. Llamas&#x2010;Ad&#xe1;n, &#xd3;. Brochado&#x2010;Kith, C. Crespo&#x2010;Bermejo, S. Grande&#x2010;Garc&#xed;a, S. Arca&#x2010;Lafuente, I. de los Santos, C. Prado, M. Al&#xed;a, C. Sainz&#x2010;Pin&#xf3;s, A. Fern&#xe1;ndez&#x2010;Rodr&#xed;guez, L. Mart&#xed;n&#x2010;Carbonero, R. Madrid, V. Briz, J. Biomed. Sci. 2024, 31, 80.</Citation></Reference><Reference><Citation>M. Naigeon, M. Roulleaux Dugage, F.&#x2010;X. Danlos, L. Boselli, J.&#x2010;M. Jouniaux, C. de Oliveira, R. Ferrara, B. Duchemann, C. Berthot, L. Girard, R. Flippot, L. Albiges, S. Farhane, P. Saulnier, L. Lacroix, F. Griscelli, G. Roman, T. Hulett, A. Marabelle, L. Cassard, B. Besse, N. Chaput, Sci. Adv. 2023, 9, adh0708.</Citation></Reference><Reference><Citation>Q. Lian, K. Zhang, Z. Zhang, F. Duan, L. Guo, W. Luo, B. W. Mok, A. Thakur, X. Ke, P. Motallebnejad, V. Nicolaescu, J. Chen, C. Y. Ma, X. Zhou, S. Han, T. Han, W. Zhang, A. Y. Tan, T. Zhang, X. Wang, D. Xu, J. Xiang, A. Xu, C. Liao, F. P. Huang, Y. W. Chen, J. Na, G. Randall, H. F. Tse, Z. Chen, et&#xa0;al., Nat. Commun. 2022, 13, 2028.</Citation></Reference><Reference><Citation>S. T. Chen, M. D. Park, D. M. Del Valle, M. Buckup, A. Tabachnikova, R. C. Thompson, N. W. Simons, K. Mouskas, B. Lee, D. Geanon, D. D'Souza, T. Dawson, R. Marvin, K. Nie, Z. Zhao, J. LeBerichel, C. Chang, H. Jamal, G. Akturk, U. Chaddha, K. Mathews, S. Acquah, S. A. Brown, M. Reiss, T. Harkin, M. Feldmann, C. A. Powell, J. L. Hook, S. Kim&#x2010;Schulze, A. H. Rahman, et&#xa0;al., Sci. Transl. Med. 2022, 14, abn5168.</Citation></Reference><Reference><Citation>Y. Hao, T. Stuart, M. H. Kowalski, S. Choudhary, P. Hoffman, A. Hartman, A. Srivastava, G. Molla, S. Madad, C. Fernandez&#x2010;Granda, R. Satija, Nat. Biotechnol. 2024, 42, 293.</Citation></Reference><Reference><Citation>C. Hafemeister, R. Satija, Genome Biol. 2019, 20, 296.</Citation></Reference><Reference><Citation>V. A. Traag, L. Waltman, N. J. van Eck, Sci. Rep. 2019, 9, 5233.</Citation></Reference><Reference><Citation>A. Ianevski, A. K. Giri, T. Aittokallio, Nat. Commun. 2022, 13, 1246.</Citation></Reference><Reference><Citation>N. Gaddis, J. Fortriede, M. Guo, E. E. Bardes, M. Kouril, S. Tabar, K. Burns, M. E. Ardini&#x2010;Poleske, S. Loos, D. Schnell, K. Jin, B. Iyer, Y. Du, B. X. Huo, A. Bhattacharjee, J. Korte, R. Munshi, V. Smith, A. Herbst, J. A. Kitzmiller, G. C. Clair, J. P. Carson, J. Adkins, E. E. Morrisey, G. S. Pryhuber, R. Misra, J. A. Whitsett, X. Sun, T. Heathorn, B. Paten, et&#xa0;al., Am. J. Respir. Cell Mol. Biol. 2024, 70, 129.</Citation></Reference><Reference><Citation>A. Jacob, M. Morley, F. Hawkins, K. B. McCauley, J. C. Jean, H. Heins, C. L. Na, T. E. Weaver, M. Vedaie, K. Hurley, A. Hinds, S. J. Russo, S. Kook, W. Zacharias, M. Ochs, K. Traber, L. J. Quinton, A. Crane, B. R. Davis, F. V. White, J. Wambach, J. A. Whitsett, F. S. Cole, E. E. Morrisey, S. H. Guttentag, M. F. Beers, D. N. Kotton, Cell Stem Cell 2017, 21, 472.</Citation></Reference><Reference><Citation>X. Cao, G. K. Yakala, F. E. van den Hil, A. Cochrane, C. L. Mummery, V. V. Orlova, Stem Cell Rep. 2019, 12, 1282.</Citation></Reference><Reference><Citation>L. Liu, P. Wang, M. S. Nair, J. Yu, M. Rapp, Q. Wang, Y. Luo, J. F. Chan, V. Sahi, A. Figueroa, X. V. Guo, G. Cerutti, J. Bimela, J. Gorman, T. Zhou, Z. Chen, K. Y. Yuen, P. D. Kwong, J. G. Sodroski, M. T. Yin, Z. Sheng, Y. Huang, L. Shapiro, D. D. Ho, Nature 2020, 584, 450.</Citation></Reference><Reference><Citation>C. S. McGinnis, L. M. Murrow, Z. J. Gartner, Cell Syst. 2019, 8, 329.</Citation></Reference><Reference><Citation>A. T. Lun, D. J. McCarthy, J. C. Marioni, F1000Res 2016, 5, 2122.</Citation></Reference><Reference><Citation>D. J. McCarthy, K. R. Campbell, A. T. Lun, Q. F. Wills, Bioinformatics 2017, 33, 1179.</Citation></Reference><Reference><Citation>L. Haghverdi, A. T. L. Lun, M. D. Morgan, J. C. Marioni, Nat. Biotechnol. 2018, 36, 421.</Citation></Reference><Reference><Citation>Y. Hao, S. Hao, E. Andersen&#x2010;Nissen, W. M. Mauck III, S. Zheng, A. Butler, M. J. Lee, A. J. Wilk, C. Darby, M. Zager, P. Hoffman, M. Stoeckius, E. Papalexi, E. P. Mimitou, J. Jain, A. Srivastava, T. Stuart, L. M. Fleming, B. Yeung, A. J. Rogers, J. M. McElrath, C. A. Blish, R. Gottardo, P. Smibert, R. Satija, Cell 2021, 184, 3573.</Citation></Reference><Reference><Citation>H. Wickham, Elegant Graphics for Data Analysis, Springer, Cham 2016.</Citation></Reference><Reference><Citation>K. J. Travaglini, A. N. Nabhan, L. Penland, R. Sinha, A. Gillich, R. V. Sit, S. Chang, S. D. Conley, Y. Mori, J. Seita, G. J. Berry, J. B. Shrager, R. J. Metzger, C. S. Kuo, N. Neff, I. L. Weissman, S. R. Quake, M. A. Krasnow, Nature 2020, 587, 619.</Citation></Reference><Reference><Citation>S. Xu, E. Hu, Y. Cai, Z. Xie, X. Luo, L. Zhan, W. Tang, Q. Wang, B. Liu, R. Wang, W. Xie, T. Wu, L. Xie, G. Yu, Nat. Protoc. 2024, 19, 3292.</Citation></Reference><Reference><Citation>T. Wu, E. Hu, S. Xu, M. Chen, P. Guo, Z. Dai, T. Feng, L. Zhou, W. Tang, L. Zhan, X. Fu, S. Liu, X. Bo, G. Yu, Innovation (Camb) 2021, 2, 100141.</Citation></Reference><Reference><Citation>S. Jin, M. V. Plikus, Q. Nie, Nat. Protoc. 2024, 20, 180.</Citation></Reference><Reference><Citation>T. Stuart, A. Srivastava, S. Madad, C. A. Lareau, R. Satija, Nat. Methods 2021, 18, 1333.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40712075</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1612-1880</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Jul</Month><Day>25</Day></PubDate></JournalIssue><Title>Chemistry &amp; biodiversity</Title><ISOAbbreviation>Chem Biodivers</ISOAbbreviation></Journal><ArticleTitle>Inhibition Potential of Quercetin Similar Compounds to SARS-CoV-2 Main Protease by High-Throughput Virtual Screening, Molecular Simulations, ADMET Analysis, and DFT Studies.</ArticleTitle><Pagination><StartPage>e01485</StartPage><MedlinePgn>e01485</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/cbdv.202501485</ELocationID><Abstract><AbstractText>This study focused on in silico investigation of SARS-CoV-2 Mpro inhibitors screened from 6663 quercetin similar compounds. Two promising compounds, blumeatin B (L<sub>1</sub>) and 3,5-dihydroxy-7,3',4',5'-tetramethoxyflavone (L<sub>2</sub>), were identified through machine learning based virtual screening and similarity analysis. They underwent molecular docking with Mpro and demonstrated strong interactions, with docking scores of -8.02 and -7.21&#xa0;kcal/mol, respectively. Various parameters (RMSD, RMSF, Rg, SASA, and the number of hydrogen bonds) observed during 200&#xa0;ns molecular dynamics (MD) simulation confirmed their stability. Principal component analysis (PCA) and dynamical cross-correlation matrix (DCCM) revealed minimal conformational changes and strongly correlated motions in the protein. End-state MM/GBSA free energy calculations for L<sub>1</sub> and L<sub>2</sub> with Mpro were -22.86 and -19.89&#xa0;kcal/mol. Density functional theory (DFT) studies at the B3LYP/6-311++G (d,p) level showed their polar nature, with electrophilicity index values exceeding 1.5&#xa0;eV. The HOMO-LUMO energy gaps of L<sub>1</sub> and L<sub>2</sub> were 4.04 and 3.57&#xa0;eV, aligning with the DOS spectra. Based on results from virtual screening, ADMET parameters, docking scores, hydrophobic interactions, hydrogen bonding, MD simulation, end-state free energy calculations, and DFT findings, L<sub>1</sub> and L<sub>2</sub> could be considered as promising SARS-CoV-2 Mpro inhibitors, requiring further experimental validation.</AbstractText><CopyrightInformation>&#xa9; 2025 Wiley&#x2010;VHCA AG, Zurich, Switzerland.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gyawali</LastName><ForeName>Kalpana</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Central Department of Physics, Tribhuvan University, Kathmandu, Nepal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tri-Chandra Multiple Campus, Tribhuvan University, Kathmandu, Nepal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chhetri</LastName><ForeName>Sandeep Poudel</ForeName><Initials>SP</Initials><AffiliationInfo><Affiliation>Central Department of Physics, Tribhuvan University, Kathmandu, Nepal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khanal</LastName><ForeName>Kamal</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Central Department of Physics, Tribhuvan University, Kathmandu, Nepal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Butwal Multiple Campus, Tribhuvan University, Butwal, Nepal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kshetri</LastName><ForeName>Mohan Bahadur</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>Central Department of Physics, Tribhuvan University, Kathmandu, Nepal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amrit Science Campus, Tribhuvan University, Lainchaur, Kathmandu, Nepal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maharjan</LastName><ForeName>Rajesh</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Central Department of Physics, Tribhuvan University, Kathmandu, Nepal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Acharya</LastName><ForeName>Arjun</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Central Department of Physics, Tribhuvan University, Kathmandu, Nepal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tri-Chandra Multiple Campus, Tribhuvan University, Kathmandu, Nepal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khanal</LastName><ForeName>Madan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Central Department of Physics, Tribhuvan University, Kathmandu, Nepal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Patan Multiple Campus, Tribhuvan University, Patandhoka, Lalitpur, Nepal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghimire</LastName><ForeName>Madhav Prasad</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Central Department of Physics, Tribhuvan University, Kathmandu, Nepal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lamichhane</LastName><ForeName>Tika Ram</ForeName><Initials>TR</Initials><AffiliationInfo><Affiliation>Central Department of Physics, Tribhuvan University, Kathmandu, Nepal.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Chem Biodivers</MedlineTA><NlmUniqueID>101197449</NlmUniqueID><ISSNLinking>1612-1872</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">MD simulations</Keyword><Keyword MajorTopicYN="N">ML&#x2010;based screening</Keyword><Keyword MajorTopicYN="N">PCA analysis</Keyword><Keyword MajorTopicYN="N">end&#x2010;state free energy and DFT study</Keyword><Keyword MajorTopicYN="N">natural inhibitors of SARS&#x2010;CoV&#x2010;2</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>4</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>18</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>18</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>14</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40712075</ArticleId><ArticleId IdType="doi">10.1002/cbdv.202501485</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>S. Keretsu, S. P. Bhujbal, and S. J. Cho, &#x201c;Rational Approach Toward COVID&#x2010;19 Main Protease Inhibitors via Molecular Docking, Molecular Dynamics Simulation and Free Energy Calculation,&#x201d; Scientific Reports 10 (2020): 17716.</Citation></Reference><Reference><Citation>&#x201c;COVID&#x2010;19 Cases, World,&#x201d; WHO, retrieved on February 9, 2025, https://data.who.int/dashboards/covid19/cases.</Citation></Reference><Reference><Citation>F. P. Esper, T. M. Adhikari, Z. J. Tu, et&#xa0;al., &#x201c;Alpha to Omicron: Disease Severity and Clinical Outcomes of Major SARS&#x2010;CoV&#x2010;2 Variants,&#x201d; Journal of Infectious Diseases 227 (2023): 344&#x2013;352.</Citation></Reference><Reference><Citation>R. Arya, S. Kumari, B. Pandey, et&#xa0;al., &#x201c;Structural Insights into SARS&#x2010;CoV&#x2010;2 Proteins,&#x201d; Journal of Molecular Biology 433 (2021): 166725.</Citation></Reference><Reference><Citation>J. P. Martinez, F. Sasse, M. Br&#xf6;nstrup, J. Diez, and A. Meyerhans, &#x201c;Antiviral Drug Discovery: Broad&#x2010;Spectrum Drugs From Nature,&#x201d; Natural Product Reports 32 (2015): 29&#x2013;48.</Citation></Reference><Reference><Citation>A. V. A. David, R. Arulmoli, and S. Parasuraman, &#x201c;Overviews of Biological Importance of Quercetin: A Bioactive Flavonoid,&#x201d; Pharmacognosy Reviews 10 (2016): 84.</Citation></Reference><Reference><Citation>A. Kakhar Umar, J. H. Zothantluanga, J. A. Luckanagul, P. Limpikirati, and S. Sriwidodo, &#x201c;Structure&#x2010;Based Computational Screening of 470 Natural Quercetin Derivatives for Identification of SARS&#x2010;CoV&#x2010;2 Mpro Inhibitor,&#x201d; PeerJ 11 (2023): e14915.</Citation></Reference><Reference><Citation>K. Gyawali, R. Maharjan, A. Acharya, M. Khanal, M. P. Ghimire, and T. R. Lamichhane, &#x201c;Identification of Catechin as Main Protease Inhibitor of SARS&#x2010;CoV&#x2010;2 Omicron Variant Using Molecular Docking, Molecular Dynamics, PCA, DCCM, MM/GBSA and ADMET Profiling,&#x201d; Natural Product Research (2024): 1&#x2013;8.</Citation></Reference><Reference><Citation>W. Y. Ho, Z. H. Shen, Y. Chen, T. H. Chen, X. Lu, and Y. S. Fu, &#x201c;Therapeutic Implications of Quercetin and Its Derived&#x2010;Products in COVID&#x2010;19 Protection and Prophylactic,&#x201d; Heliyon 10 (2024): e30080.</Citation></Reference><Reference><Citation>M. Nag, R. K. Paul, D. Dasgupta, et&#xa0;al., &#x201c;In&#x2010;Silico Screening of Natural Compound Library Against COVID&#x2010;19 Main Protease,&#x201d; Anti&#x2010;Infective Agents 23 (2025): E22113525310221.</Citation></Reference><Reference><Citation>R. Gupta, D. Srivastava, M. Sahu, S. Tiwari, R. K. Ambasta, and P. Kumar, &#x201c;Artificial Intelligence to Deep Learning: Machine Intelligence Approach for Drug Discovery,&#x201d; Molecular Diversity 25 (2021): 1315&#x2013;1360.</Citation></Reference><Reference><Citation>R. Maharjan, K. Gyawali, A. Acharya, et&#xa0;al., &#x201c;Machine Learning&#x2010;Based High&#x2010;Throughput Screening, Molecular Modeling and Quantum Chemical Analysis to Investigate Mycobacterium tuberculosis MetRS Inhibitors,&#x201d; ChemistryOpen 147 (2024): e202400460.</Citation></Reference><Reference><Citation>K. Gyawali, R. Maharjan, B. P. Sharma, et&#xa0;al., &#x201c;Synthesis, Characterization, and Antimicrobial Activity of Hydrazino Triazole&#x2010;Based Schiff Base Ligands and Their Oxovanadium (IV) Complexes and the Inhibitory Roles Against SARS&#x2010;CoV&#x2010;2 Using Molecular Docking, Dynamics, and ADMET Profiling,&#x201d; Applied Organometallic Chemistry 39 (2025): e70117.</Citation></Reference><Reference><Citation>S. Q. Huang, Y. J. Zhang, Z. H. Wang, and F. Xiong, &#x201c;Computational Discovery of SARS&#x2010;CoV&#x2010;2 Main Protease Inhibitors via a Virtual Screening, Molecular Docking, Molecular Dynamics and MM/PBSA Calculation&#x2010;Driven Approach,&#x201d; New Journal of Chemistry 48 (2024): 19650&#x2013;19660.</Citation></Reference><Reference><Citation>F. Xiong, Y. J. Zhang, H. Y. Jiang, and Z. H. Wang, &#x201c;Exploring the Efficacy of Noncovalent SARS&#x2010;CoV&#x2010;2 Main Protease Inhibitors: A Computational Simulation Analysis Study,&#x201d; Chemistry &amp; Biodiversity 21 (2024): e202302089.</Citation></Reference><Reference><Citation>H. Jiang, H. Xia, Z. Wang, and F. Xiong, &#x201c;Discovery of Severe Acute Respiratory Syndrome Coronavirus 2 Main Protease Inhibitors Through Rational Design of Novel Fluorinated 1,3,4&#x2010;Oxadiazole Amide Derivatives: An In&#x2010;Silico Study,&#x201d; Chemistry &amp; Biodiversity 22 (2025): e202403179.</Citation></Reference><Reference><Citation>T. H. Nguyen, Q. M. Thai, M. Q. Pham, P. T. H. Minh, and H. T. T. Phung, &#x201c;Machine Learning Combines Atomistic Simulations to Predict SARS&#x2010;CoV&#x2010;2 Mpro Inhibitors From Natural Compounds,&#x201d; Molecular Diversity 28 (2024): 553&#x2013;561.</Citation></Reference><Reference><Citation>N. T. H. Van, D. H. Nghi, P. C. Bach, et&#xa0;al., &#x201c;Triterpenoids From the Leaves of Camellia chrysantha Growing in Quang Ninh (Vietnam) and Their Activities on Main Protease (Mpro) and ACE2,&#x201d; Vietnam Journal of Chemistry 61 (2023): 140&#x2013;147.</Citation></Reference><Reference><Citation>N. M. Tam, T. H. Nguyen, M. Q. Pham, et&#xa0;al., &#x201c;Upgrading Nirmatrelvir to Inhibit SARS&#x2010;CoV&#x2010;2 Mpro via DeepFrag and Free Energy Calculations,&#x201d; Journal of Molecular Graphics and Modelling 124 (2023): 108535.</Citation></Reference><Reference><Citation>A. Salimi, J. H. Lim, J. H. Jang, and J. Y. Lee, &#x201c;The Use of Machine Learning Modeling, Virtual Screening, Molecular Docking, and Molecular Dynamics Simulations to Identify Potential VEGFR2 Kinase Inhibitors,&#x201d; Scientific Reports 12 (2022): 18825.</Citation></Reference><Reference><Citation>S. P. Chhetri, V. S. Bhandari, R. Maharjan, and T. R. Lamichhane, &#x201c;Identification of Lead Inhibitors for 3CLpro of SARS&#x2010;CoV&#x2010;2 Target Using Machine Learning Based Virtual Screening, ADMET Analysis, Molecular Docking and Molecular Dynamics Simulations,&#x201d; RSC Advances 14 (2024): 29683&#x2013;29692.</Citation></Reference><Reference><Citation>M. T. J. Quimque, K. I. R. Notarte, R. A. T. Fernandez, et&#xa0;al., &#x201c;Virtual Screening&#x2010;Driven Drug Discovery of SARS&#x2010;CoV2 Enzyme Inhibitors Targeting Viral Attachment, Replication, Post&#x2010;Translational Modification and Host Immunity Evasion Infection Mechanisms,&#x201d; Journal of Biomolecular Structure and Dynamics 39 (2021): 4316&#x2013;4333.</Citation></Reference><Reference><Citation>A. N. Lima, E. A. Philot, G. H. G. Trossini, L. P. B. Scott, V. G. Maltarollo, and K. M. Honorio, &#x201c;Use of Machine Learning Approaches for Novel Drug Discovery,&#x201d; Expert Opinion on Drug Discovery 11 (2016): 225&#x2013;239.</Citation></Reference><Reference><Citation>S. Kim, P. A. Thiessen, E. E. Bolton, et&#xa0;al., &#x201c;PubChem Substance and Compound Databases,&#x201d; Nucleic Acids Research 44 (2016): D1202&#x2013;D1213.</Citation></Reference><Reference><Citation>R. Sheridan, &#x201c;Why Do We Need So Many Chemical Similarity Search Methods?,&#x201d; Drug Discovery Today 7 (2002): 903&#x2013;911.</Citation></Reference><Reference><Citation>A. G. Maldonado, J. P. Doucet, M. Petitjean, and B. T. Fan, &#x201c;Molecular Similarity and Diversity in Chemoinformatics: From Theory to Applications,&#x201d; Molecular Diversity 10 (2006): 39&#x2013;79.</Citation></Reference><Reference><Citation>D. Bajusz, A. R&#xe1;cz, and K. H&#xe9;berger, &#x201c;Why Is Tanimoto Index an Appropriate Choice for Fingerprint&#x2010;Based Similarity Calculations?,&#x201d; Journal of Cheminformatics 7 (2015): 1&#x2013;13.</Citation></Reference><Reference><Citation>S. Riniker and G. A. Landrum, &#x201c;Similarity Maps&#x2014;A Visualization Strategy for Molecular Fingerprints and Machine&#x2010;Learning Methods,&#x201d; Journal of Cheminformatics 5 (2013): 43.</Citation></Reference><Reference><Citation>A. Daina, O. Michielin, and V. Zoete, &#x201c;SwissADME: A Free Web Tool to Evaluate Pharmacokinetics, Drug&#x2010;Likeness and Medicinal Chemistry Friendliness of Small Molecules,&#x201d; Scientific Reports 7 (2017): 42717.</Citation></Reference><Reference><Citation>D. E. Pires, T. L. Blundell, and D. B. Ascher, &#x201c;pkCSM: Predicting Small&#x2010;Molecule Pharmacokinetic and Toxicity Properties Using Graph&#x2010;Based Signatures,&#x201d; Journal of Medicinal Chemistry 58 (2015): 4066&#x2013;4072.</Citation></Reference><Reference><Citation>P. Banerjee, E. Kemmler, M. Dunkel, and R. Preissner, &#x201c;ProTox 3.0: A Webserver for the Prediction of Toxicity of Chemicals,&#x201d; Nucleic Acids Research 52 (2024): W513&#x2013;W520.</Citation></Reference><Reference><Citation>W. L. DeLano, &#x201c;PyMOL: An Open&#x2010;Source Molecular Graphics Tool,&#x201d; CCP4 Newsletter on Protein Crystallography 40 (2002): 82&#x2013;92.</Citation></Reference><Reference><Citation>F. Wan and W. Tang, &#x201c;Phosphorus Ligands from the Zhang Lab: Design, Asymmetric Hydrogenation, and Industrial Applications,&#x201d; Chinese Journal of Chemistry 39 (2021): 954&#x2013;968.</Citation></Reference><Reference><Citation>G. M. Morris, R. Huey, W. Lindstrom, et&#xa0;al., &#x201c;AutoDock4 and AutoDockTools4: Automated Docking with Selective Receptor Flexibility,&#x201d; Journal of Computational Chemistry 30 (2009): 2785&#x2013;2791.</Citation></Reference><Reference><Citation>D. S. Biovia, Discovery Studio, Version 21.1.0 (Dassault Syst&#xe8;mes, 2021).</Citation></Reference><Reference><Citation>D. Van Der Spoel, E. Lindahl, B. Hess, G. Groenhof, A. E. Mark, and H. J. Berendsen, &#x201c;GROMACS: Fast, Flexible, and Free,&#x201d; Journal of Computational Chemistry 26 (2005): 1701&#x2013;1718.</Citation></Reference><Reference><Citation>V. Zoete, M. A. Cuendet, A. Grosdidier, and O. Michielin, &#x201c;SwissParam: A Fast Force Field Generation Tool for Small Organic Molecules,&#x201d; Journal of Computational Chemistry 32 (2011): 2359&#x2013;2368.</Citation></Reference><Reference><Citation>J. Huang and A. D. MacKerell, &#x201c;CHARMM36 All&#x2010;Atom Additive Protein Force Field: Validation Based on Comparison to NMR Data,&#x201d; Journal of Computational Chemistry 34 (2013): 2135&#x2013;2145.</Citation></Reference><Reference><Citation>B. J. Grant, A. P. Rodrigues, K. M. ElSawy, J. A. McCammon, and L. S. Caves, &#x201c;Bio3D: An R Package for the Comparative Analysis of Protein Structures,&#x201d; Bioinformatics 22 (2006): 2695&#x2013;2696.</Citation></Reference><Reference><Citation>B. J. Grant, L. Skj&#xe6;rven, and X.&#x2010;Q. Yao, &#x201c;The Bio3D Packages for Structural Bioinformatics,&#x201d; Protein Science 30 (2021): 20&#x2013;30.</Citation></Reference><Reference><Citation>M. S. Vald&#xe9;s&#x2010;Tresanco, M. E. Vald&#xe9;s&#x2010;Tresanco, P. A. Valiente, and E. Moreno, &#x201c;gmx_MMPBSA: A New Tool to Perform End&#x2010;State Free Energy Calculations with GROMACS,&#x201d; Journal of Chemical Theory and Computation 17 (2021): 6281&#x2013;6291.</Citation></Reference><Reference><Citation>A. D. Becke, &#x201c;Density&#x2010;Functional Exchange&#x2010;Energy Approximation With Correct Asymptotic Behavior,&#x201d; Physical Review A 38 (1988): 3098&#x2013;3100.</Citation></Reference><Reference><Citation>C. Lee, W. Yang, and R. G. Parr, &#x201c;Development of the Colle&#x2010;Salvetti Correlation&#x2010;Energy Formula Into a Functional of the Electron Density,&#x201d; Physical Review B 37 (1988): 785&#x2013;789.</Citation></Reference><Reference><Citation>M. J. Frisch, G. W. Trucks, H. B. Schlegel, et&#xa0;al., Gaussian 16 Revision C.01 (Gaussian Inc., 2016).</Citation></Reference><Reference><Citation>R. D. I. I. Dennington, T. A. Keith, and J. M. Millam, GaussView, Version 6.0 (Semichem Inc., 2016).</Citation></Reference><Reference><Citation>N. M. O'Boyle, A. L. Tenderholt, and K. M. Langner, &#x201c;cclib: A Library for Package&#x2010;Independent Computational Chemistry Algorithms,&#x201d; Journal of Computational Chemistry 29 (2008): 839&#x2013;845.</Citation></Reference><Reference><Citation>A. Acharya, M. Khanal, R. Maharjan, et&#xa0;al., &#x201c;Quantum Chemical Calculations on Calcium Oxalate and Dolichin A and Their Binding Efficacy to Lactoferrin: An In Silico Study Using DFT, Molecular Docking, and Molecular Dynamics Simulations,&#x201d; AIMS Biophysics 11 (2024): 142&#x2013;165.</Citation></Reference><Reference><Citation>M. Khanal, A. Acharya, R. Maharjan, et&#xa0;al., &#x201c;Identification of Potent Inhibitors of HDAC2 from Herbal Products for the Treatment of Colon Cancer: Molecular Docking, Molecular Dynamics Simulation, MM/GBSA Calculations, DFT Studies, and Pharmacokinetic Analysis,&#x201d; PLoS One 19 (2024): e0307501.</Citation></Reference><Reference><Citation>R. S. Mulliken, &#x201c;Electronic Population Analysis on LCAO&#x2013;MO Molecular Wave Functions. I,&#x201d; Journal of Chemical Physics 23 (1955): 1833&#x2013;1840.</Citation></Reference><Reference><Citation>K. Fukui, &#x201c;Role of Frontier Orbitals in Chemical Reactions,&#x201d; Science 218 (1982): 747&#x2013;754.</Citation></Reference><Reference><Citation>R. G. Parr and R. G. Pearson, &#x201c;Absolute Hardness: Companion Parameter to Absolute Electronegativity,&#x201d; Journal of the American Chemical Society 105 (1983): 7512&#x2013;7516.</Citation></Reference><Reference><Citation>E. Runge and E. K. Gross, &#x201c;Density&#x2010;Functional Theory for Time&#x2010;Dependent Systems,&#x201d; Physical Review Letters 52 (1984): 997&#x2013;1000.</Citation></Reference><Reference><Citation>L. Breiman, &#x201c;Random Forests,&#x201d; Machine learning 45 (2001): 5&#x2013;32.</Citation></Reference><Reference><Citation>R. P. Sheridan, W. M. Wang, A. Liaw, J. Ma, and E. M. Gifford, &#x201c;Extreme Gradient Boosting as a Method for Quantitative Structure&#x2013;Activity Relationships,&#x201d; Journal of Chemical Information and Modeling 56 (2016): 2353&#x2013;2360.</Citation></Reference><Reference><Citation>L. Bottou, &#x201c;Large&#x2010;Scale Machine Learning with Stochastic Gradient Descent,&#x201d; in Proceedings of COMPSTAT'2010: 19th International Conference on Computational Statistics, Paris, France, August 22&#x2010;27, 2010: Keynote, Invited and Contributed Papers, Physica&#x2010;Verlag HD, 2010, pp. 177&#x2013;186.</Citation></Reference><Reference><Citation>C. A. Lipinski, F. Lombardo, B. W. Dominy, and P. J. Feeney, &#x201c;Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings,&#x201d; Advanced Drug Delivery Reviews 64 (2012): 4&#x2013;17.</Citation></Reference><Reference><Citation>A. A. Dawood, &#x201c;The Efficacy of Paxlovid Against COVID&#x2010;19 Is the Result of the Tight Molecular Docking Between Mpro and Antiviral Drugs (Nirmatrelvir and Ritonavir),&#x201d; Advances in Medical Sciences 68 (2023): 1&#x2013;9.</Citation></Reference><Reference><Citation>C. A. Ramos&#x2010;Guzm&#xe1;n, J. J. Ruiz&#x2010;Pern&#xed;a, and I. Tu&#xf1;&#xf3;n, &#x201c;Unraveling the SARS&#x2010;CoV&#x2010;2 Main Protease Mechanism Using Multiscale Methods,&#x201d; ACS Catalysis 10 (2020): 12544&#x2013;12554.</Citation></Reference><Reference><Citation>C. A. Ramos&#x2010;Guzm&#xe1;n, J. J. Ruiz&#x2010;Pern&#xed;a, and I. Tu&#xf1;&#xf3;n, &#x201c;A Microscopic Description of SARS&#x2010;CoV&#x2010;2 Main Protease Inhibition with Michael Acceptors. Strategies for Improving Inhibitor Design,&#x201d; Chemical Science 12 (2021): 3489&#x2013;3496.</Citation></Reference><Reference><Citation>S. T. Ngo, T. H. Nguyen, N. T. Tung, and B. K. Mai, &#x201c;Insights into the Binding and Covalent Inhibition Mechanism of PF&#x2010;07321332 to SARS&#x2010;CoV&#x2010;2 Mpro,&#x201d; RSC Advances 12 (2022): 3729&#x2013;3737.</Citation></Reference><Reference><Citation>T. R. Lamichhane and M. P. Ghimire, &#x201c;Evaluation of SARS&#x2010;CoV&#x2010;2 Main Protease and Inhibitor Interactions Using Dihedral Angle Distributions and Radial Distribution Function,&#x201d; Heliyon 7 (2021): e08220.</Citation></Reference><Reference><Citation>A. M. El&#x2010;Saghier, S. S. Enaili, A. Abdou, and A. M. Kadry, &#x201c;An Efficient Eco&#x2010;Friendly, Simple, and Green Synthesis of Some New Spiro&#x2010;N&#x2010;(4&#x2010;Sulfamoyl&#x2010;Phenyl)&#x2010;1,3,4&#x2010;Thiadiazole&#x2010;2&#x2010;Carboxamide Derivatives as Potential Inhibitors of SARS&#x2010;CoV&#x2010;2 Proteases: Drug&#x2010;Likeness, Pharmacophore, Molecular Docking, and DFT Exploration,&#x201d; Molecular Diversity 28 (2024): 249&#x2013;270.</Citation></Reference><Reference><Citation>Y. A. De Oliveira S&#xf3;, K. S. Bezerra, R. Gargano, et&#xa0;al., &#x201c;In Silico Comparative Analysis of Ivermectin and Nirmatrelvir Inhibitors Interacting With the SARS&#x2010;CoV&#x2010;2 Main Protease,&#x201d; Biomolecules 14 (2024): 755.</Citation></Reference><Reference><Citation>T. Koopmans, &#x201c;&#xdc;ber die Zuordnung von Wellenfunktionen und Eigenwerten zu den Einzelnen Elektronen Eines Atoms,&#x201d; Physica 1 (1934): 104&#x2013;113.</Citation></Reference><Reference><Citation>L. R. Domingo, M. R&#xed;os&#x2010;Guti&#xe9;rrez, and P. P&#xe9;rez, &#x201c;Applications of the Conceptual Density Functional Theory Indices to Organic Chemistry Reactivity,&#x201d; Molecules 21 (2016): 748.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40712053</PMID><DateCompleted><Year>2025</Year><Month>07</Month><Day>25</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1551-8930</ISSN><JournalIssue CitedMedium="Internet"><Issue>4</Issue><PubDate><Year>2025</Year><Month>Jun</Month><Day>10</Day></PubDate></JournalIssue><Title>National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System</Title><ISOAbbreviation>Natl Vital Stat Rep</ISOAbbreviation></Journal><ArticleTitle>National Vital Statistics Reports.</ArticleTitle><Pagination><StartPage>1</StartPage><MedlinePgn>1</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.15620/cdc/174588</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="UNASSIGNED">This report presents final 2022 data on U.S. deaths, death rates, life expectancy, infant and maternal mortality, and trends by selected characteristics such as age, sex, Hispanic origin and race, state of residence, and cause of death.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Information reported on death certificates is presented in descriptive tabulations. The original records are filed in state registration offices. Statistical information is compiled in a national database through the Vital Statistics Cooperative Program of the National Center for Health Statistics. Causes of death are processed according to the <i>International Classification of Diseases, 10th Revision</i> . Beginning in 2018, all states and the District of Columbia were using the 2003 revised certificate of death for the entire year, which includes the 1997 Office of Management and Budget revised standards for race. Data based on these revised standards are not completely comparable to previous years.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">In 2022, a total of 3,279,857 deaths were reported in the United States. The age-adjusted death rate was 798.8 deaths per 100,000 U.S. standard population, a decrease of 9.2% from the 2021 rate. Life expectancy at birth was 77.5 years, an increase of 1.1 years from 2021. Age-specific death rates decreased from 2021 to 2022 for age groups 15-24, 25-34, 35-44, 45-54, 55-64, 65-74, 75-84, and 85 and older and increased for age groups 1-4 and 5-14. In 2022, the 10 leading causes of death remained the same as in 2021, although four causes changed rank. Heart disease remained the top leading cause, followed by cancer. The infant mortality rate, 5.60 deaths per 1,000 live births in 2022, increased 2.9% from the rate in 2021 (5.44).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">In 2022, the age-adjusted death rate decreased and life expectancy at birth increased for the total, male, and female populations, primarily due to the decrease in deaths from COVID-19.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Jiaquan</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Murphy</LastName><ForeName>Sherry L</ForeName><Initials>SL</Initials></Author><Author ValidYN="Y"><LastName>Kochanek</LastName><ForeName>Kenneth D</ForeName><Initials>KD</Initials></Author><Author ValidYN="Y"><LastName>Arias</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Natl Vital Stat Rep</MedlineTA><NlmUniqueID>9814753</NlmUniqueID><ISSNLinking>1551-8922</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008017" MajorTopicYN="Y">Life Expectancy</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName><QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014798" MajorTopicYN="Y">Vital Statistics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002423" MajorTopicYN="N">Cause of Death</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009026" MajorTopicYN="Y">Mortality</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName><QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008428" MajorTopicYN="N">Maternal Mortality</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName><QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017677" MajorTopicYN="N">Age Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007226" MajorTopicYN="N">Infant Mortality</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017678" MajorTopicYN="N">Sex Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003644" MajorTopicYN="N">Death Certificates</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009309" MajorTopicYN="N">National Center for Health Statistics, U.S.</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>18</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>18</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>14</Hour><Minute>22</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40712053</ArticleId><ArticleId IdType="doi">10.15620/cdc/174588</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40711822</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2641-7650</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Jul</Month><Day>25</Day></PubDate></JournalIssue><Title>Kidney360</Title><ISOAbbreviation>Kidney360</ISOAbbreviation></Journal><ArticleTitle>Evaluation of a Protocol Managing the Cyclosporine and Nirmatrelvir/Ritonavir Interaction in Kidney Transplant Recipients.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.34067/KID.0000000861</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Nirmatrelvir/ritonavir has emerged as a crucial treatment for managing COVID-19 infections but interacts with calcineurin inhibitors. This study aims to assess the application of a standardized protocol managing this drug-drug interaction, specifically with cyclosporine, since current evidence is limited.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This retrospective study included recipients on cyclosporine undergoing therapy with nirmatrelvir/ritonavir between April 2022 and December 2023. As per protocol, cyclosporine doses were reduced by 80% and levels were measured two days after course completion. For subtherapeutic or therapeutic levels, cyclosporine dose was reinstated at 100%, with cyclosporine levels reassessed one week later. For supratherapeutic levels, the reduced dosage was maintained for an additional two days before being reinitiated at 100% of the baseline nirmatrelvir/ritonavir dose. Protocol adherence and clinical parameters such as cyclosporine levels, acute kidney injury episodes, hospitalization, and mortality were monitored up to 30-days after completion of nirmatrelvir/ritonavir therapy.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Thirty-five kidney transplant recipients met eligibility criteria. At baseline, 83% of recipients had therapeutic cyclosporine levels. At the first follow-up two days after completion of nirmatrelvir/ritonavir there was a greater proportion of recipients with subtherapeutic and supratherapeutic levels compared to baseline (20% vs 9% and 31% vs 9%), which had improved by the second follow-up at nine days after completion of nirmatrelvir/ritonavir (14% and 14%). Three recipients experienced acute kidney injury for reasons unrelated to COVID-19 treatment. There were 4 hospitalizations; none related to COVID-19 treatment. There was no graft rejection or death 30 days after completion of nirmatrelvir/ritonavir.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Though cyclosporine levels outside therapeutic range were common immediately after completion of nirmatrelvir/ritonavir treatment, levels were restored rapidly. No clinically relevant safety events occurred within the 30-days. Adherence to the protocol is crucial when using nirmatrelvir/ritonavir in kidney transplant recipients.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Society of Nephrology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Agtarap</LastName><ForeName>Kyla</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Ottawa Hospital.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gigu&#xe8;re</LastName><ForeName>Pierre</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-1174-8965</Identifier></Author><Author ValidYN="Y"><LastName>Desch&#xea;nes</LastName><ForeName>Marie-Jos&#xe9;e</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">0009-0007-4988-1514</Identifier></Author><Author ValidYN="Y"><LastName>DeVreese</LastName><ForeName>Lacey</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>McDougall</LastName><ForeName>Jessica</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-9459-0413</Identifier></Author><Author ValidYN="Y"><LastName>Hoar</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials><Identifier Source="ORCID">0009-0004-1938-1744</Identifier></Author><Author ValidYN="Y"><LastName>Hiremath</LastName><ForeName>Swapnil</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-0010-3416</Identifier></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Kidney360</MedlineTA><NlmUniqueID>101766381</NlmUniqueID><ISSNLinking>2641-7650</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>1</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>18</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>18</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>12</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40711822</ArticleId><ArticleId IdType="doi">10.34067/KID.0000000861</ArticleId><ArticleId IdType="pii">02200512-990000000-00719</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40711800</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1538-3598</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Jul</Month><Day>25</Day></PubDate></JournalIssue><Title>JAMA</Title><ISOAbbreviation>JAMA</ISOAbbreviation></Journal><ArticleTitle>WHO Report Suggests Likely Zoonotic Origin of COVID-19, Doesn't Rule Out Lab Leak.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1001/jama.2025.10976</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Lauren</ForeName><Initials>L</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA</MedlineTA><NlmUniqueID>7501160</NlmUniqueID><ISSNLinking>0098-7484</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>12</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>12</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>11</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40711800</ArticleId><ArticleId IdType="doi">10.1001/jama.2025.10976</ArticleId><ArticleId IdType="pii">2837028</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">40711780</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2689-0186</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>7</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>03</Day></PubDate></JournalIssue><Title>JAMA health forum</Title><ISOAbbreviation>JAMA Health Forum</ISOAbbreviation></Journal><ArticleTitle>COVID-19 Vaccination Saved Lives and This Matters in 2025.</ArticleTitle><Pagination><StartPage>e252237</StartPage><MedlinePgn>e252237</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamahealthforum.2025.2237</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gandhi</LastName><ForeName>Monica</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases and Global Medicine, Ward 86 HIV Clinic, Center for AIDS Research, University of California, San Francsico.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Health Forum</MedlineTA><NlmUniqueID>101769500</NlmUniqueID><ISSNLinking>2689-0186</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>12</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>12</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>11</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40711780</ArticleId><ArticleId IdType="doi">10.1001/jamahealthforum.2025.2237</ArticleId><ArticleId IdType="pii">2836436</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40711778</PMID><DateCompleted><Year>2025</Year><Month>07</Month><Day>25</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2689-0186</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>7</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>03</Day></PubDate></JournalIssue><Title>JAMA health forum</Title><ISOAbbreviation>JAMA Health Forum</ISOAbbreviation></Journal><ArticleTitle>Global Estimates of Lives and Life-Years Saved by COVID-19 Vaccination During 2020-2024.</ArticleTitle><Pagination><StartPage>e252223</StartPage><MedlinePgn>e252223</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamahealthforum.2025.2223</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="UNASSIGNED">Estimating global lives and life-years saved is important to put into perspective the benefits of COVID-19 vaccination. Prior studies have focused mainly on the pre-Omicron period or only on specific regions, and lack crucial life-year calculations and often depend on strong modeling assumptions with unaccounted uncertainty.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">To calculate the lives and life-years saved by COVID-19 vaccination worldwide from the onset of the vaccination campaigns and until October 1, 2024.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="UNASSIGNED">This comparative effectiveness study considered different strata of the worldwide population according to age, community-dwelling and long-term care residence status, pre-Omicron and Omicron periods, and vaccination before and after a SARS-CoV-2 infection.</AbstractText><AbstractText Label="EXPOSURES" NlmCategory="UNASSIGNED">Any COVID-19 vaccination in any schedule and number of doses.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURE" NlmCategory="UNASSIGNED">Death.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">In the main analysis, more than 2.5 million deaths were averted (1 death averted per 5400 vaccine doses administered). Eighty-two percent were among people vaccinated before any infection, 57% were during the Omicron period, and 90% pertained to people 60 years or older. Sensitivity analyses suggested 1.4 to 4.0 million lives were saved. Some sensitivity analyses showed a preponderance of the benefit during the pre-Omicron period. An estimated 14.8 million life-years were saved (1 life-year saved per 900 vaccine doses administered). The sensitivity range was 7.4 to 23.6 million life-years. Most life-years saved (76%) were among people 60 years or older, but long-term care residents contributed only 2% of the total. Children and adolescents (0.01% of lives saved and 0.1% of life-years saved) and young adults aged 20 through 29 years (0.07% of lives saved and 0.3% of life-years saved) had very small contributions to the total benefit.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="UNASSIGNED">Estimates in this study are substantially more conservative than previous calculations focusing mostly on the first year of vaccination, but they still clearly demonstrate a major overall benefit from COVID-19 vaccination during the years 2020-2024. Most benefits in lives and life-years saved was secured for a portion of older persons, a minority of the global population.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ioannidis</LastName><ForeName>John P A</ForeName><Initials>JPA</Initials><AffiliationInfo><Affiliation>Department of Medicine, Stanford University School of Medicine, Stanford, California.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology and Population Health, Stanford University School of Medicine, Stanford, California.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Meta-Research Innovation Center at Stanford (METRICS), Stanford University, Stanford, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pezzullo</LastName><ForeName>Angelo Maria</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Meta-Research Innovation Center at Stanford (METRICS), Stanford University, Stanford, California.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Section of Hygiene, Department of Life Sciences and Public Health, Universit&#xe0; Cattolica del Sacro Cuore, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cristiano</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Meta-Research Innovation Center at Stanford (METRICS), Stanford University, Stanford, California.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Section of Hygiene, Department of Life Sciences and Public Health, Universit&#xe0; Cattolica del Sacro Cuore, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boccia</LastName><ForeName>Stefania</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Section of Hygiene, Department of Life Sciences and Public Health, Universit&#xe0; Cattolica del Sacro Cuore, Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Health Forum</MedlineTA><NlmUniqueID>101769500</NlmUniqueID><ISSNLinking>2689-0186</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014943" MajorTopicYN="Y">Global Health</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="Y">Vaccination</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008017" MajorTopicYN="Y">Life Expectancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>12</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>12</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>11</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40711778</ArticleId><ArticleId IdType="doi">10.1001/jamahealthforum.2025.2223</ArticleId><ArticleId IdType="pii">2836434</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40711678</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-6628</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Jul</Month><Day>25</Day></PubDate></JournalIssue><Title>Maternal and child health journal</Title><ISOAbbreviation>Matern Child Health J</ISOAbbreviation></Journal><ArticleTitle>Hospital Breastfeeding Support during the Early Coronavirus Disease 2019 (COVID-19) Pandemic: Worsening Care for Black, Hispanic, and Asian Mothers.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10995-025-04123-5</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lazar Tucker</LastName><ForeName>Jane</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-7342-1461</Identifier><AffiliationInfo><Affiliation>College of Nursing, University of Rhode Island, 350 Eddy St, Providence, RI, 02903, USA. jlazartucker@uri.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arcoleo</LastName><ForeName>Kimberly</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>College of Nursing, University of Rhode Island, 350 Eddy St, Providence, RI, 02903, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DiTomasso</LastName><ForeName>Diane</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>College of Nursing, University of Rhode Island, 350 Eddy St, Providence, RI, 02903, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oaks</LastName><ForeName>Brietta M</ForeName><Initials>BM</Initials><AffiliationInfo><Affiliation>College of Health Sciences, University of Rhode Island, 55 Lower College Rd, Kingston, RI, 02881, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cabral</LastName><ForeName>Howard</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Boston University School of Public Health, 801 Massachusetts Ave, 3rd floor, Boston, MA, 02118, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#xe3;o-Jo&#xe3;o</LastName><ForeName>Tha&#xed;s</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>College of Nursing, University of Rhode Island, 350 Eddy St, Providence, RI, 02903, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Matern Child Health J</MedlineTA><NlmUniqueID>9715672</NlmUniqueID><ISSNLinking>1092-7875</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement>Declarations. Competing Interests: The authors declare that they have no conflict of interest. Consent To Participate: The manuscript is a secondary analysis of data collected by states for the CDC. The data was collected ethically and is de-identified. Ethical Approval: This study was designated exempt and informed consent was waived by the Institutional Review Board at the University of Rhode Island because the data were deidentified. Consent To Publish: Approval to publish from PRAMS/CDC was obtained prior to manuscript submission. Study Registration: osf.io/3rb7c [OSF link]. This statistical analysis plan is available online: osf.io/3rb7c [OSF link]</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>12</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>12</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>11</Hour><Minute>20</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40711678</ArticleId><ArticleId IdType="doi">10.1007/s10995-025-04123-5</ArticleId><ArticleId IdType="pii">10.1007/s10995-025-04123-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Barrera, C. M., Beauregard, J. L., Nelson, J. M., &amp; Perrine, C. G. (2019). Association of Maternity care practices and policies with in-hospital exclusive breastfeeding in the United States. Breastfeed Med, 14(4), 243&#x2013;248. https://doi.org/10.1089/bfm.2018.0196</Citation></Reference><Reference><Citation>Bigman, G., Wilkinson, A. V., Perez, A., &amp; Homedes, N. (2018). Acculturation and breastfeeding among Hispanic American women: A systematic review. Maternal and Child Health Journal, 22(9), 1260&#x2013;1277. https://doi.org/10.1007/s10995-018-2584-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10995-018-2584-0</ArticleId><ArticleId IdType="pubmed">30003522</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC (2022). PRAMS: Methodology. https://www.cdc.gov/prams/methodology.htm</Citation></Reference><Reference><Citation>Coelho, C. M., Suttiwan, P., Arato, N., &amp; Zsido, A. N. (2020). On the nature of fear and anxiety triggered by COVID-19. Frontiers in Psychology, 11, 581314. https://doi.org/10.3389/fpsyg.2020.581314</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpsyg.2020.581314</ArticleId><ArticleId IdType="pubmed">33240172</ArticleId><ArticleId IdType="pmc">7680724</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen, J., &amp; Rodgers, Y. V. M. (2020). Contributing factors to personal protective equipment shortages during the COVID-19 pandemic. Preventive Medicine, 141, 106263. https://doi.org/10.1016/j.ypmed.2020.106263</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ypmed.2020.106263</ArticleId><ArticleId IdType="pubmed">33017601</ArticleId><ArticleId IdType="pmc">7531934</ArticleId></ArticleIdList></Reference><Reference><Citation>Crenshaw, J. T., &amp; Budin, W. D. (2020). Hospital care practices associated with exclusive breastfeeding 3 and 6 months after discharge: A multisite study. J Perinat Educ, 29(3), 143&#x2013;151. https://doi.org/10.1891/J-PE-D-19-00033</Citation><ArticleIdList><ArticleId IdType="doi">10.1891/J-PE-D-19-00033</ArticleId><ArticleId IdType="pubmed">32760183</ArticleId><ArticleId IdType="pmc">7360129</ArticleId></ArticleIdList></Reference><Reference><Citation>Eilers, M. A., Hendrick, C. E., Perez-Escamilla, R., Powers, D. A., &amp; Potter, J. E. (2020). Breastfeeding initiation, duration, and supplementation among Mexican-Origin women in Texas. Pediatrics, 145(4). https://doi.org/10.1542/peds.2019-2742</Citation></Reference><Reference><Citation>Granada, S., Baumgart, Q., C., &amp; Rupley, D. (2022). Birthing experiences of Spanish speakers during the COVID-19 pandemic in NYC. Journal of Immigrant and Minority Health, 24(4), 1013&#x2013;1019. https://doi.org/10.1007/s10903-022-01331-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10903-022-01331-x</ArticleId><ArticleId IdType="pubmed">35133579</ArticleId><ArticleId IdType="pmc">8824325</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill, L., &amp; Artiga, S. (2022). COVID-19 Cases and Deaths by Race/Ethnicity: Current Data and Changes Over Time. Retrieved 10/10/2023 from https://www.kff.org/racial-equity-and-health-policy/issue-brief/covid-19-cases-and-deaths-by-race-ethnicity-current-data-and-changes-over-time/</Citation></Reference><Reference><Citation>Human Rights Watch (2020). Covid-19 Fueling Anti-Asian Racism and Xenophobia Worldwide. Retrieved November 13, 2023 from https://www.hrw.org/news/2020/05/12/covid-19-fueling-anti-asian-racism-and-xenophobia-worldwide</Citation></Reference><Reference><Citation>Kivlighan, K. T., Murray-Krezan, C., Schwartz, T., Shuster, G., &amp; Cox, K. (2020). Improved breastfeeding duration with baby friendly hospital initiative implementation in a diverse and underserved population. Birth, 47(1), 135&#x2013;143. https://doi.org/10.1111/birt.12468</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/birt.12468</ArticleId><ArticleId IdType="pubmed">31788842</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazar Tucker, J., Arcoleo, K., DiTomasso, D., Oaks, B. M., Cabral, H., &amp; S&#xe3;o-Jo&#xe3;o, T. (2025a). Baby friendly hospital initiative practices in U.S. hospitals mitigate Racial and ethnic disparities in breastfeeding continuation. Journal of Human Lactation: official Journal of International Lactation Consultant Association, 41(2), 283&#x2013;293. https://doi.org/10.1177/08903344251319362</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/08903344251319362</ArticleId><ArticleId IdType="pubmed">40110985</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazar Tucker, J., Arcoleo, K., DiTomasso, D., Oaks, B. M., Cabral, H., &amp; S&#xe3;o-Jo&#xe3;o, T. (2025b). Racial and ethnic disparities in hospital breastfeeding care in the US. Maternal and Child Health Journal, 29(2), 173&#x2013;182. https://doi.org/10.1007/s10995-025-04065-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10995-025-04065-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin, B. (2021). Report to the Nation: Anti-Asian Prejudice &amp; Hate Crime. https://www.csusb.edu/sites/default/files/Report%20to%20the%20Nation%20-%20Anti-Asian%20Hate%202020%20Final%20Draft%20-%20As%20of%20Apr%2030%202021%206%20PM%20corrected.pdf</Citation></Reference><Reference><Citation>Lubbe, W., Niela-Vilen, H., Thomson, G., &amp; Botha, E. (2022). Impact of the COVID-19 pandemic on breastfeeding support services and women's experiences of breastfeeding: A review. International Journal of Women's Health, 14, 1447&#x2013;1457. https://doi.org/10.2147/IJWH.S342754</Citation></Reference><Reference><Citation>Nelson, J. M., Perrine, C. G., Freedman, D. S., Williams, L., Morrow, B., Smith, R. A., &amp; Dee, D. L. (2018). Infant feeding-related maternity care practices and maternal report of breastfeeding outcomes. Birth, 45(4), 424&#x2013;431. https://doi.org/10.1111/birt.12337</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/birt.12337</ArticleId><ArticleId IdType="pubmed">29411887</ArticleId><ArticleId IdType="pmc">9462415</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Reilly, K. B. (2021). Bill targets anti-Asian hate crimes tied to COVID-19. American medical association. https://www.ama-assn.org/delivering-care/population-care/bill-targets-anti-asian-hate-crimes-tied-covid-19</Citation></Reference><Reference><Citation>Patterson, J. A., Keuler, N. S., &amp; Olson, B. H. (2019). The effect of maternity practices on exclusive breastfeeding rates in U.S. hospitals. Maternal &amp; Child Nutrition, 15(1), e12670. https://doi.org/10.1111/mcn.12670</Citation></Reference><Reference><Citation>Sebastian, R. A., Coronado, E., Otero, M. D., McKinney, C. R., &amp; Ramos, M. M. (2019). Associations between maternity care practices and 2-month breastfeeding duration vary by race, ethnicity, and acculturation. Maternal and Child Health Journal, 23(6), 858-867. https://doi.org/10.1007/s10995-018-02711-2</Citation></Reference><Reference><Citation>Shulman, H. B., D&#x2019;Angelo, D. V., Harrison, L., Smith, R. A., &amp; Warner, L. (2018). The pregnancy risk assessment monitoring system (PRAMS): Overview of design and methodology. American Journal of Public Health, 108(10), 1305&#x2013;1313. https://doi.org/10.2105/AJPH.2018.304563</Citation><ArticleIdList><ArticleId IdType="doi">10.2105/AJPH.2018.304563</ArticleId><ArticleId IdType="pubmed">30138070</ArticleId><ArticleId IdType="pmc">6137777</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas, E. V. (2018). Why even bother; they are not going to do it?? The structural roots of racism and discrimination in lactation care. Qualitative Health Research, 28(7), 1050&#x2013;1064. https://doi.org/10.1177/1049732318759491</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1049732318759491</ArticleId><ArticleId IdType="pubmed">29557297</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner, S., McGann, B., &amp; Brockway, M. (2022). A review of the disruption of breastfeeding supports in response to the COVID-19 pandemic in five Western countries and applications for clinical practice. International Breastfeeding Journal, 17(1), 38. https://doi.org/10.1186/s13006-022-00478-5</Citation></Reference><Reference><Citation>van Goudoever, J. B., Spatz, D. L., Hoban, R., Dumitriu, D., Gyamfi-Bannerman, C., Berns, M., McKechnie, L., &amp; Davanzo, R. (2022). Updating clinical practices to promote and protect human milk and breastfeeding in a COVID-19 era. Front Pediatr, 10, 867540. https://doi.org/10.3389/fped.2022.867540</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fped.2022.867540</ArticleId><ArticleId IdType="pubmed">35558372</ArticleId><ArticleId IdType="pmc">9086708</ArticleId></ArticleIdList></Reference><Reference><Citation>von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., G&#xf8;tzsche, P. C., &amp; Vandenbroucke, J. P. (2014). The strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies. International Journal of Surgery, 12(12), 1495&#x2013;1499. https://doi.org/10.1016/j.ijsu.2014.07.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijsu.2014.07.013</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40711664</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1865-3774</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Jul</Month><Day>25</Day></PubDate></JournalIssue><Title>International journal of hematology</Title><ISOAbbreviation>Int J Hematol</ISOAbbreviation></Journal><ArticleTitle>Humoral immunity after hematopoietic stem cell transplantation: evaluation by B-cell receptor repertoire analysis.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12185-025-04042-9</ELocationID><Abstract><AbstractText>Immunity acquired before hematopoietic stem cell transplantation (HSCT) may decrease or disappear following HSCT, and it is unclear whether the first vaccination after HSCT in patients with an antigen exposure history before HSCT elicits a primary or secondary immune response. The Quantification of Antigen-Specific Antibody Sequence (QASAS) method enables real-time assessment of responses to SARS-CoV-2 antigen exposure through B-cell receptor (BCR) repertoire analysis. Using this method, we evaluated the disappearance of immunological memory after HSCT. First, in individuals without hematologic disorders, primary SARS-CoV-2 antigen exposure elicited no immune response at 7&#xa0;days post-exposure but demonstrated activation between 14 to 21&#xa0;days. In contrast, repeated exposure elicited early responses (secondary immune responses) at 7&#xa0;days post-exposure. We then enrolled HSCT patients with pre-HSCT SARS-CoV-2 antigen exposure history and collected samples before and after vaccination. Despite prior exposure history, patients receiving their first vaccination after HSCT showed no response around 7&#xa0;days post-exposure but responded at 14&#xa0;days. In conclusion, even with pre-HSCT antigen exposure, the first vaccination after HSCT induced a primary immune response. This demonstrates that first vaccination after HSCT should be considered to induce a primary immune response, regardless of previous infection or vaccination history.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Matsumoto</LastName><ForeName>Sakuya</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Funakoshi</LastName><ForeName>Yohei</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-7793-5013</Identifier><AffiliationInfo><Affiliation>Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan. yohei@med.kobe-u.ac.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yakushijin</LastName><ForeName>Kimikazu</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsutani</LastName><ForeName>Takaji</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Translational Research Dept. Maruho Co., Ltd., Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okazoe-Hirakawa</LastName><ForeName>Yuri</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ohji</LastName><ForeName>Goh</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Infection Disease Therapeutics, Department of Microbiology and Infectious Diseases, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koyama</LastName><ForeName>Taiji</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nagatani</LastName><ForeName>Yoshiaki</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kurata</LastName><ForeName>Keiji</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kimbara</LastName><ForeName>Shiro</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kiyota</LastName><ForeName>Naomi</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cancer Center, Kobe University Hospital, Kobe, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Minami</LastName><ForeName>Hironobu</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cancer Center, Kobe University Hospital, Kobe, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>JP24K11560</GrantID><Agency>JSPS KAKENHI</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Int J Hematol</MedlineTA><NlmUniqueID>9111627</NlmUniqueID><ISSNLinking>0925-5710</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">B-cell receptor repertoire</Keyword><Keyword MajorTopicYN="N">Coronavirus Antibody Database</Keyword><Keyword MajorTopicYN="N">Hematopoietic stem cell transplantation</Keyword><Keyword MajorTopicYN="N">Quantification of antigen-specific antibody sequence</Keyword><Keyword MajorTopicYN="N">mRNA vaccine</Keyword></KeywordList><CoiStatement>Declarations. Conflict of interest: K.Y. has received research grants and honoraria from Pfizer, and is one of editors of International Journal of Hematology. T.M. was an employee of Repertoire Genesis Inc. H.M. has received research grants and honoraria from Daiichi-Sankyo. The other authors declare no potential conflicts of interest. Ethical approval: This study was conducted in accordance with the principles of the Declaration of Helsinki. Informed consent: All participants provided written informed consent for this research. Clinical trial registration number: The study protocol was approved by Kobe University Hospital Ethics Committee (No. B2356701 and 1481).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>12</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>12</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>11</Hour><Minute>19</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40711664</ArticleId><ArticleId IdType="doi">10.1007/s12185-025-04042-9</ArticleId><ArticleId IdType="pii">10.1007/s12185-025-04042-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006;354:1813&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">16641398</ArticleId></ArticleIdList></Reference><Reference><Citation>Niederwieser D, Baldomero H, Bazuaye N, Bupp C, Chaudhri N, Corbacioglu S, et al. One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors. Haematologica. 2022;107:1045&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">34382386</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogonek J, Kralj Juric M, Ghimire S, Varanasi PR, Holler E, Greinix H, et al. Immune reconstitution after allogeneic hematopoietic stem cell transplantation. Front Immunol. 2016;7: 507.</Citation><ArticleIdList><ArticleId IdType="pubmed">27909435</ArticleId><ArticleId IdType="pmc">5112259</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaudhry MS, Velardi E, Malard F, van den Brink MR. Immune reconstitution after allogeneic hematopoietic stem cell transplantation: time to T up the thymus. J Immunol. 2017;198:40&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">27994167</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamboj M, Bohlke K, Baptiste DM, Dunleavy K, Fueger A, Jones L, et al. Vaccination of adults with cancer: ASCO guideline. J Clin Oncol. 2024. https://doi.org/10.1200/JCO.24.00032 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.24.00032</ArticleId><ArticleId IdType="pubmed">38498792</ArticleId></ArticleIdList></Reference><Reference><Citation>Cordonnier C, Einarsdottir S, Cesaro S, Di Blasi R, Mikulska M, Rieger C, et al. Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis. 2019;19:e200&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">30744963</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe M, Yakushijin K, Funakoshi Y, Ohji G, Ichikawa H, Sakai H, et al. A third dose COVID-19 vaccination in allogeneic hematopoietic stem cell transplantation patients. Vaccines (Basel). 2022. https://doi.org/10.3390/vaccines10111830 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10111830</ArticleId><ArticleId IdType="pubmed">36366338</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe M, Yakushijin K, Funakoshi Y, Ohji G, Hojo W, Sakai H, et al. The safety and immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in Japanese patients after allogeneic stem cell transplantation. Vaccines. 2022. https://doi.org/10.3390/vaccines10020158 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10020158</ArticleId><ArticleId IdType="pubmed">36366338</ArticleId><ArticleId IdType="pmc">9695068</ArticleId></ArticleIdList></Reference><Reference><Citation>Park BG, Park CJ, Jang S, Chi HS, Kim DY, Lee JH, et al. Reconstitution of lymphocyte subpopulations after hematopoietic stem cell transplantation: comparison of hematologic malignancies and donor types in event-free patients. Leuk Res. 2015;39:1334&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">26422556</ArticleId></ArticleIdList></Reference><Reference><Citation>Marie-Cardine A, Divay F, Dutot I, Green A, Perdrix A, Boyer O, et al. Transitional B cells in humans: characterization and insight from B lymphocyte reconstitution after hematopoietic stem cell transplantation. Clin Immunol. 2008;127:14&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">18191619</ArticleId></ArticleIdList></Reference><Reference><Citation>Suryani S, Fulcher DA, Santner-Nanan B, Nanan R, Wong M, Shaw PJ, et al. Differential expression of CD21 identifies developmentally and functionally distinct subsets of human transitional B cells. Blood. 2010;115:519&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">19965666</ArticleId></ArticleIdList></Reference><Reference><Citation>Funakoshi Y, Yakushijin K, Ohji G, Matsutani T, Hojo W, Sakai H, et al. Response to mRNA SARS-CoV-2 vaccination evaluated by B-cell receptor repertoire after tixagevimab/cilgavimab administration. Br J Haematol. 2023;202:504&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">37349876</ArticleId></ArticleIdList></Reference><Reference><Citation>Funakoshi Y, Yakushijin K, Ohji G, Matsutani T, Doi K, Sakai H, et al. Analysis of B-cell receptor repertoire to evaluate immunogenicity of monovalent Omicron XBB.1.5 mRNA vaccines. EJHaem. 2024;5:661&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">39157599</ArticleId><ArticleId IdType="pmc">11327733</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohji G, Funakoshi Y, Yakushijin K, Matsutani T, Sasaki T, Kusakabe T, et al. Analysis of B-cell receptor repertoire to evaluate the immunogenicity of SARS-CoV-2 RBD mRNA vaccine: MAFB-7256a (DS-5670d). Front Immunol. 2024;15:1468760.</Citation><ArticleIdList><ArticleId IdType="pubmed">39434885</ArticleId><ArticleId IdType="pmc">11491357</ArticleId></ArticleIdList></Reference><Reference><Citation>Sethna Z, Elhanati Y, Callan CG, Walczak AM, Mora T. OLGA: fast computation of generation probabilities of B- and T-cell receptor amino acid sequences and motifs. Bioinformatics. 2019;35:2974&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">30657870</ArticleId><ArticleId IdType="pmc">6735909</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitaura K, Yamashita H, Ayabe H, Shini T, Matsutani T, Suzuki R. Different somatic hypermutation levels among antibody subclasses disclosed by a new next-generation sequencing-based antibody repertoire analysis. Front Immunol. 2017;8: 389.</Citation><ArticleIdList><ArticleId IdType="pubmed">28515723</ArticleId><ArticleId IdType="pmc">5413556</ArticleId></ArticleIdList></Reference><Reference><Citation>Sammut SJ, Galson JD, Minter R, Sun B, Chin SF, De Mattos-Arruda L, et al. Predictability of B cell clonal persistence and immunosurveillance in breast cancer. Nat Immunol. 2024;25:916&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">38698238</ArticleId><ArticleId IdType="pmc">11065701</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsoutsoukis M, Anthias C, Easdale S, Nicholson E. Re-vaccination against SARS-CoV-2 in allogeneic HSCT patients: repeated primary vaccine doses increase seroconversion rates. Br J Haematol. 2024;205:1720&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">39313909</ArticleId></ArticleIdList></Reference><Reference><Citation>Khawaja F, Papanicolaou G, Dadwal S, Pergam SA, Wingard JR, Boghdadly ZE, et al. Frequently asked questions on coronavirus disease 2019 vaccination for hematopoietic cell transplantation and chimeric antigen receptor T-cell recipients from the American Society for Transplantation and Cellular Therapy and the American Society of Hematology. Transplant Cell Ther. 2023;29:10&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">36273782</ArticleId></ArticleIdList></Reference><Reference><Citation>Moretta A, Maccario R, Fagioli F, Giraldi E, Busca A, Montagna D, et al. Analysis of immune reconstitution in children undergoing cord blood transplantation. Exp Hematol. 2001;29:371&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">11274766</ArticleId></ArticleIdList></Reference><Reference><Citation>Bae KW, Kim BE, Koh KN, Im HJ, Seo JJ. Factors influencing lymphocyte reconstitution after allogeneic hematopoietic stem cell transplantation in children. Korean J Hematol. 2012;47:44&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">22479277</ArticleId><ArticleId IdType="pmc">3317470</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakatani K, Imai K, Shigeno M, Sato H, Tezuka M, Okawa T, et al. Cord blood transplantation is associated with rapid B-cell neogenesis compared with BM transplantation. Bone Marrow Transplant. 2014;49:1155&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">24978139</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdel-Azim H, Elshoury A, Mahadeo KM, Parkman R, Kapoor N. Humoral immune reconstitution kinetics after allogeneic hematopoietic stem cell transplantation in children: a maturation block of IgM memory B cells may lead to impaired antibody immune reconstitution. Biol Blood Marrow Transplant. 2017;23:1437&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">28495643</ArticleId></ArticleIdList></Reference><Reference><Citation>Charrier E, Cordeiro P, Brito RM, Mezziani S, Herblot S, Le Deist F, et al. Reconstitution of maturating and regulatory lymphocyte subsets after cord blood and BMT in children. Bone Marrow Transplant. 2013;48:376&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">23064038</ArticleId></ArticleIdList></Reference><Reference><Citation>Yanir A, Schulz A, Lawitschka A, Nierkens S, Eyrich M. Immune reconstitution after allogeneic haematopoietic cell transplantation: from observational studies to targeted interventions. Front Pediatr. 2021;9: 786017.</Citation><ArticleIdList><ArticleId IdType="pubmed">35087775</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40711657</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1932-2267</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Jul</Month><Day>25</Day></PubDate></JournalIssue><Title>Journal of cancer survivorship : research and practice</Title><ISOAbbreviation>J Cancer Surviv</ISOAbbreviation></Journal><ArticleTitle>Differences in COVID-19 preventive behaviors among Black and White cancer survivors in North Carolina.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s11764-025-01871-9</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Engaging in COVID-19 preventive behaviors (e.g., wearing masks) can be particularly important for cancer survivors to avoid infectious disease. This cross-sectional study aimed to examine preventive behaviors of Black and White cancer survivors residing in North Carolina during the COVID-19 pandemic.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">From February through September 2022, we recruited 548 cancer survivors from the University of North Carolina Health Registry/Cancer Survivorship Cohort. Participants completed a retrospective survey about their COVID-preventive behaviors between March 2020 and December 2020 (Time 1) and within the last 30&#xa0;days (Time 2). We examined differences and changes over time in the prevalence of behaviors by race.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">At Time 1, Black cancer survivors had a higher prevalence of wearing gloves (adjusted prevalence ratio [aPR], 2.99; 95% CI 1.33-6.75), limiting visitors inside their homes (aPR, 1.22; 95% CI, 1.06-1.39), and avoiding public spaces, gatherings, and crowds (aPR, 1.13; 95% CI, 1.01-1.26) compared to White cancer survivors. While both Black and White cancer survivors decreased the prevalence of preventive behaviors at Time 2, White cancer survivors decreased their preventive behaviors at a greater rate than Black cancer survivors.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Black cancer survivors took more behavioral precautions and continued them over time at a higher rate than White cancer survivors. Despite the use of individual-level COVID-related preventive measures, inequities in COVID-related morbidity and mortality persist, underscoring the need for more multi-level interventions to address COVID-related inequities.</AbstractText><AbstractText Label="IMPLICATIONS FOR CANCER SURVIVORS" NlmCategory="CONCLUSIONS">State and local prioritization of equitable resource allocation to cancer survivors may improve&#xa0;long-term survivorship care and well-being.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kong</LastName><ForeName>Amanda Y</ForeName><Initials>AY</Initials><AffiliationInfo><Affiliation>Department of Social Sciences and Health Policy, Division of Public Health Sciences, Wake Forest University School of Medicine, 525 Vine St., Winston-Salem, NC, 27103, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deal</LastName><ForeName>Allison M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 101 Manning Drive, Chapel Hill, NC, 27514, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maaita</LastName><ForeName>Marah</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Health Policy and Management, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, #CB 7411, Chapel Hill, NC, 27599-7411, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gerstel</LastName><ForeName>Adrian</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cecil G. Sheps Health Services Research Center, University of North Carolina at Chapel Hill, CB# 7590, Chapel Hill, NC, 27599-7590, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Richmond</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Social Sciences and Health Policy, Division of Public Health Sciences, Wake Forest University School of Medicine, 525 Vine St., Winston-Salem, NC, 27103, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kent</LastName><ForeName>Erin E</ForeName><Initials>EE</Initials><AffiliationInfo><Affiliation>Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 101 Manning Drive, Chapel Hill, NC, 27514, USA. Erin.Kent@unc.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Health Policy and Management, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, #CB 7411, Chapel Hill, NC, 27599-7411, USA. Erin.Kent@unc.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cecil G. Sheps Health Services Research Center, University of North Carolina at Chapel Hill, CB# 7590, Chapel Hill, NC, 27599-7590, USA. Erin.Kent@unc.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R00CA277366</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Cancer Surviv</MedlineTA><NlmUniqueID>101307557</NlmUniqueID><ISSNLinking>1932-2259</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Preventive behaviors</Keyword><Keyword MajorTopicYN="N">Racial inequities</Keyword><Keyword MajorTopicYN="N">Survivorship</Keyword></KeywordList><CoiStatement>Declarations. Conflict of interest: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>11</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>12</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>12</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>11</Hour><Minute>19</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40711657</ArticleId><ArticleId IdType="doi">10.1007/s11764-025-01871-9</ArticleId><ArticleId IdType="pii">10.1007/s11764-025-01871-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12.</Citation><ArticleIdList><ArticleId IdType="pubmed">38230766</ArticleId></ArticleIdList></Reference><Reference><Citation>Fossa SD, Vassilopoulou-Sellin R, Dahl AA. Long term physical sequelae after adult-onset cancer. J Cancer Survivorship Res Pract. 2008;2(1):3&#x2013;11.</Citation></Reference><Reference><Citation>Kang DH, Weaver MT, Park NJ, Smith B, McArdle T, Carpenter J. Significant impairment in immune recovery after cancer treatment. Nurs Res. 2009;58(2):105&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">19289931</ArticleId><ArticleId IdType="pmc">2777669</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3):335&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">32066541</ArticleId><ArticleId IdType="pmc">7159000</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirby A, Drummond FJ, Lawlor A, Murphy A. Counting the social, psychological, and economic costs of COVID-19 for cancer patients. Support Care Cancer. 2022;30(11):8705&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">35690662</ArticleId><ArticleId IdType="pmc">9188420</ArticleId></ArticleIdList></Reference><Reference><Citation>Balzora S, Issaka RB, Anyane-Yeboa A, Gray DM 2nd, May FP. Impact of COVID-19 on colorectal cancer disparities and the way forward. Gastrointest Endosc. 2020. https://doi.org/10.1016/j.gie.2020.06.042 .</Citation></Reference><Reference><Citation>Webb Hooper M, Napoles AM, Perez-Stable EJ. COVID-19 and racial/ethnic disparities. JAMA. 2020;323(24):2466&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">32391864</ArticleId><ArticleId IdType="pmc">9310097</ArticleId></ArticleIdList></Reference><Reference><Citation>Guy GP Jr, Yabroff KR, Ekwueme DU, Virgo KS, Han X, Banegas MP, et al. Healthcare expenditure burden among non-elderly cancer survivors, 2008&#x2013;2012. Am J Prev Med. 2015;49(6 Suppl 5):S489&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">26590644</ArticleId><ArticleId IdType="pmc">6051701</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoehn RS, Zureikat AH. Cancer disparities in the COVID-19 era. J Surg Oncol. 2020;122(3):371&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pubmed">32452031</ArticleId><ArticleId IdType="pmc">7280588</ArticleId></ArticleIdList></Reference><Reference><Citation>Selden TM, Berdahl TA. COVID-19 and racial/ethnic disparities in health risk, employment, and household composition. Health Aff Millwood. 2020;39(9):1624&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">32663045</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee Smith J, Hall IJ. Advancing health equity in cancer survivorship: opportunities for public health. Am J Prev Med. 2015;49(6 Suppl 5):S477&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">26590642</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmer NR, Geiger AM, Lu L, Case LD, Weaver KE. Impact of rural residence on forgoing healthcare after cancer because of cost. Cancer Epidemiol Biomarkers Prev. 2013;22(10):1668&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">24097196</ArticleId></ArticleIdList></Reference><Reference><Citation>Czeisler ME, Lane RI, Petrosky E, Wiley JF, Christensen A, Njai R, et al. Mental health, substance use, and suicidal ideation during the COVID-19 pandemic - United States, June 24&#x2013;30, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(32):1049&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">32790653</ArticleId><ArticleId IdType="pmc">7440121</ArticleId></ArticleIdList></Reference><Reference><Citation>Ettman CK, Abdalla SM, Cohen GH, Sampson L, Vivier PM, Galea S. Prevalence of depression symptoms in US adults before and during the COVID-19 pandemic. JAMA Netw Open. 2020;3(9): e2019686.</Citation><ArticleIdList><ArticleId IdType="pubmed">32876685</ArticleId><ArticleId IdType="pmc">7489837</ArticleId></ArticleIdList></Reference><Reference><Citation>Richmond J, Sanderson M, Shrubsole MJ, Holowatyj AN, Schlundt DG, Aldrich MC. Psychosocial impact of COVID-19 among adults in the southeastern United States. Prev Med. 2022;163: 107191.</Citation><ArticleIdList><ArticleId IdType="pubmed">35964774</ArticleId><ArticleId IdType="pmc">9367170</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamlish T, Papautsky EL. Differences in emotional distress among Black and White breast cancer survivors during the Covid-19 pandemic: a national survey. J Racial Ethn Health Disparities. 2022;9(2):576&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">33620715</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinheiro LC, Wheeler SB, Chen RC, Mayer DK, Lyons JC, Reeve BB. The effects of cancer and racial disparities in health-related quality of life among older Americans: a case-control, population-based study. Cancer. 2015;121(8):1312&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">25522692</ArticleId></ArticleIdList></Reference><Reference><Citation>Slivjak Et MA, Fishbein Jn MA, Nealis MMPH, Schmiege Sj P, Arch JP. Cancer survivors&#x2019; perceived vulnerability to COVID-19 and impacts on cognitive, affective, and behavioral responses to the pandemic. J Psychosoc Oncol. 2021;39(3):366&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">33886442</ArticleId><ArticleId IdType="pmc">8788202</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong R, Lovier MA. Racial and ethnic disparities in COVID-19 diagnosis and adherence to mitigation behaviours in a national United States older adult sample. Epidemiol Infect. 2023;151: e175.</Citation><ArticleIdList><ArticleId IdType="pubmed">37799056</ArticleId><ArticleId IdType="pmc">10600897</ArticleId></ArticleIdList></Reference><Reference><Citation>Orom H, Allard NC, Kiviniemi MT, Hay JL, Waters EA, Schofield E, et al. Racial/ethnic differences in prosocial beliefs and prevention behavior during the COVID-19 pandemic. J Racial Ethn Health Disparities. 2022;9(5):1807&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">34462903</ArticleId></ArticleIdList></Reference><Reference><Citation>Hearne BN, Nino MD. Understanding how race, ethnicity, and gender shape mask-wearing adherence during the COVID-19 pandemic: evidence from the COVID impact survey. J Racial Ethn Health Disparities. 2022;9(1):176&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">33469866</ArticleId></ArticleIdList></Reference><Reference><Citation>Gwynn RC. Health inequity and the unfair impact of the COVID-19 pandemic on essential workers. Am J Public Health. 2021;111(8):1459&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">34464178</ArticleId><ArticleId IdType="pmc">8489649</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown JL. Addressing racial capitalism&#x2019;s impact on black essential workers during the COVID-19 pandemic: policy recommendations. J Racial Ethn Health Disparities. 2023;10(4):1597&#x2013;604.</Citation><ArticleIdList><ArticleId IdType="pubmed">35689156</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers TN, Rogers CR, VanSant-Webb E, Gu LY, Yan B, Qeadan F. Racial disparities in COVID-19 mortality among essential workers in the United States. World Med Health Policy. 2020;12(3):311&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">32837779</ArticleId><ArticleId IdType="pmc">7436547</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia MA, Homan PA, Garc&#xed;a C, Brown TH. The color of COVID-19: structural racism and the pandemic&#x2019;s disproportionate impact on older racial and ethnic minorities. J Gerontol Ser B Psychol Sci Soc Sci. 2020; gbaa114.&#xa0; https://doi.org/10.1093/geronb/gbaa114 .</Citation></Reference><Reference><Citation>Islam JY, Camacho-Rivera M, Vidot DC. Examining COVID-19 preventive behaviors among cancer survivors in the United States: an analysis of the COVID-19 impact survey. Cancer Epidemiol Biomarkers Prev. 2020. https://doi.org/10.1158/1055-9965.EPI-20-0801 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1055-9965.EPI-20-0801</ArticleId><ArticleId IdType="pubmed">32978173</ArticleId><ArticleId IdType="pmc">7871461</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin H, Sanders C, Prasetyo Y, Syukron M, Prentice E. Exploring the dynamic relationships between risk perception and behavior in response to the Coronavirus Disease 2019 (COVID-19) outbreak. Soc Sci Med. 2021;285: 114267.</Citation><ArticleIdList><ArticleId IdType="pubmed">34388619</ArticleId><ArticleId IdType="pmc">8305223</ArticleId></ArticleIdList></Reference><Reference><Citation>North Carolina Department of Health and Human Services. Cancer in North Carolina: data and resource guide. 2024. https://www.dph.ncdhhs.gov/chronic-disease-and-injury/cancer-prevention-and-control/state-cancer-burden-resourceguide/open . Accessed 15 Jan 2025.</Citation></Reference><Reference><Citation>Anderson C, Bensen JT, Allott EH, Basta PV, Irwin DE, Gerstel A, et al. The university of North Carolina cancer survivorship cohort: a resource for collaborative survivorship research. Cancer Epidemiol Biomarkers Prev. 2024. https://doi.org/10.1158/1055-9965.EPI-24-0794 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1055-9965.EPI-24-0794</ArticleId><ArticleId IdType="pubmed">39361354</ArticleId><ArticleId IdType="pmc">11609820</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett D, Bruine de Bruin W, Darling J, Jiang Q, Kapteyn A, Samek A. Understanding America Study, UAS230. 2021 [Available from: https://www.phenxtoolkit.org/toolkit_content/PDF/JHU_C4WARD_Perceived_Threat.pdf . Accessed 15 Jan 2021.</Citation></Reference><Reference><Citation>Glasner T, van der Vaart W. Applications of calendar instruments in social surveys: a review. Qual Quant. 2009;43(3):333&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">20046840</ArticleId></ArticleIdList></Reference><Reference><Citation>Worku F, Bennett F, Wheeler S, Siddiqi A, Papadakos J. Exploring the COVID-19 knowledge, attitudes, and practices (KAPs) in the Black community: a scoping review. J Racial Ethn Health Disparities. 2024;11(1):273&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">36757610</ArticleId></ArticleIdList></Reference><Reference><Citation>Soleman SR, Lyu Z, Okada T, Sassa MH, Fujii Y, Mahmoud MAM, et al. Efficacy of personal protective equipment to prevent environmental infection of COVID-19 among healthcare workers: a systematic review. Environ Health Prev Med. 2023;28:1.</Citation><ArticleIdList><ArticleId IdType="pubmed">36624079</ArticleId><ArticleId IdType="pmc">9845060</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y, Farkouh EK, Dunetz CA, Varanasi SL, Mathews S, Gollust SE, et al. Local TV news coverage of racial disparities in COVID-19 during the first wave of the pandemic, March-June 2020. Race Soc Probl. 2023;15(2):201&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">35855105</ArticleId></ArticleIdList></Reference><Reference><Citation>Turchi J, Melton-Fant C. Media framing of COVID-19 racial disparities: lessons from Memphis, Tennessee. Sociol Race Ethn. 2022;8(3):355&#x2013;69.</Citation></Reference><Reference><Citation>Golestaneh L, Neugarten J, Fisher M, Billett HH, Gil MR, Johns T, et al. The association of race and COVID-19 mortality. eClinicalMedicine. 2020;25.&#xa0; https://doi.org/10.1016/j.eclinm.2020.100455 .</Citation></Reference><Reference><Citation>Mackey K, Ayers CK, Kondo KK, Saha S, Advani SM, Young S, et al. Racial and ethnic disparities in COVID-19-related infections, hospitalizations, and deaths: a systematic review. Ann Intern Med. 2021;174(3):362&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">33253040</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubinelli S, Diviani N. The bases of targeting behavior in health promotion and disease prevention. Patient Educ Couns. 2020. https://doi.org/10.1016/j.pec.2020.08.043 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pec.2020.08.043</ArticleId><ArticleId IdType="pubmed">33419600</ArticleId><ArticleId IdType="pmc">7833684</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Elsaid MI, DeGraffinreid C, Champion VL, Paskett ED. Impact of C-oBatCCCiOg impact of the COVID-19 pandemic on cancer screening delays. J Clin Oncol. 2023;41(17):3194&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pubmed">36735899</ArticleId><ArticleId IdType="pmc">10256430</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Elsaid MI, DeGraffinreid C, Champion VL, Paskett ED. Impact of the COVID-19 pandemic on cancer screening delays. J Clin Oncol. 2023;41(17):3194&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pubmed">36735899</ArticleId><ArticleId IdType="pmc">10256430</ArticleId></ArticleIdList></Reference><Reference><Citation>Islam JY, Hathaway CA, Hume E, Turner K, Hallanger-Johnson J, Tworoger SS, et al. Racial and ethnic inequities in cancer care continuity during the COVID-19 pandemic among those with SARS-CoV-2. JAMA Netw Open. 2024;7(5): e2412050.</Citation><ArticleIdList><ArticleId IdType="pubmed">38767916</ArticleId><ArticleId IdType="pmc">11107297</ArticleId></ArticleIdList></Reference><Reference><Citation>Semprini J. How did states in the United States adapt their cancer control plan in response to the COVID-19 pandemic? Public Health Challenges. 2024;3(2): e179.</Citation><ArticleIdList><ArticleId IdType="pubmed">40496168</ArticleId><ArticleId IdType="pmc">12039613</ArticleId></ArticleIdList></Reference><Reference><Citation>North Carolina Advisory Committee on Cancer Coordination and Control. North Carolina Department of Health and Human Services, North Carolina Cancer Prevention and Control Branch. North Carolina comprehensive Cancer Control Action Plan. 2020&#x2013;2025; 2024. https://www.dph.ncdhhs.gov/chronic-disease-and-injury/cancer-prevention-and-control/nc-cancer-plan-2020-2025/open . Accessed 15 Jan 2015.</Citation></Reference><Reference><Citation>Biddell CB, Spees LP, Trogdon JG, Kent EE, Rosenstein DL, Angove RSM, et al. Economic evaluation of a nonmedical financial assistance program on missed treatment appointments among adults with cancer. J Clin Oncol. 2024;42(3):300&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">37897261</ArticleId></ArticleIdList></Reference><Reference><Citation>Wheeler SB, Birken SA, Wagi CR, Manning ML, Gellin M, Padilla N, et al. Core functions of a financial navigation intervention: an in-depth assessment of the Lessening the Impact of Financial Toxicity (LIFT) intervention to inform adaptation and scale-up in diverse oncology care settings. Front Health Serv. 2022;2:958831.</Citation><ArticleIdList><ArticleId IdType="pubmed">36925862</ArticleId><ArticleId IdType="pmc">10012722</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40711628</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1543-0154</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Jul</Month><Day>25</Day></PubDate></JournalIssue><Title>Journal of cancer education : the official journal of the American Association for Cancer Education</Title><ISOAbbreviation>J Cancer Educ</ISOAbbreviation></Journal><ArticleTitle>Utility of Virtual Program Information Sessions to Inform Medical Students About Radiation Oncology Residency Programs.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s13187-025-02689-w</ELocationID><Abstract><AbstractText>The COVID-19 pandemic led to widespread adoption of virtual program information sessions (VPIS) in Radiation Oncology (RO) to provide medical students (MS) with information about residency programs. We aimed to investigate whether students find VPIS useful and desire continuation. An anonymous survey utilizing 5-point Likert scales and descriptive feedback was developed to assess MS and residency program member (RPM) perspectives on VPIS. Surveys were distributed between September and December 2023 to MS who registered for RO VPIS during the 2022-2023 Canadian Resident Matching Service (CaRMS) cycle and RPMs who had attended VPIS. Quantitative data were interpreted with descriptive statistics. Eighteen MS (of 25 VPIS MS attendees) and 20 RPMs completed the survey. Overall, 100% of MS and RPMs agreed or strongly agreed that sessions were useful and should continue, though RPMs endorsed more strongly that sessions were useful (4.82 vs. 4.5, p&#x2009;=&#x2009;0.045) and should continue (5.00 vs. 4.67, p&#x2009;=&#x2009;0.008). MS reported sessions being cost-free and providing exposure to more programs as benefits (100% and 94% agree or strongly agree), as did RPMs (100% agree or strongly agree). Proposed improvements included having sessions for different time zones, increased resident interactions, and only having residents present. This is the first analysis of the utility of VPIS in RO and supports continuation. Responses suggest numerous benefits with limited detriments. We recommend integration of these results to optimize implementation.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s) under exclusive licence to American Association for Cancer Education.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kriegler</LastName><ForeName>Conley</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-9643-8976</Identifier><AffiliationInfo><Affiliation>Division of Radiation Oncology, Department of Oncology, University of Alberta, Edmonton, AB, Canada. kriegler@ualberta.ca.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cross Cancer Institute, 11560 University Ave, Edmonton, T6G 1Z2, AB, Canada. kriegler@ualberta.ca.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duimering</LastName><ForeName>Adele</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Radiation Oncology, Department of Oncology, University of Alberta, Edmonton, AB, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cross Cancer Institute, 11560 University Ave, Edmonton, T6G 1Z2, AB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Soobin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Radiation Oncology, Department of Oncology, University of Alberta, Edmonton, AB, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cross Cancer Institute, 11560 University Ave, Edmonton, T6G 1Z2, AB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Widomska</LastName><ForeName>Ania</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Faculty of Medicine &amp; Dentistry, University of Alberta, Edmonton, AB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Le</LastName><ForeName>Connie</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Radiation Oncology, Department of Oncology, University of Alberta, Edmonton, AB, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cross Cancer Institute, 11560 University Ave, Edmonton, T6G 1Z2, AB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al Balushi</LastName><ForeName>Mustafa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Sultan Qaboos Comprehensive Cancer Care and Research Center, University Medical City, Muscat, Oman.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ingledew</LastName><ForeName>Paris-Ann</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Division of Radiation Oncology, Department of Surgery, University of British Columbia, Vancouver, BC, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Cancer Educ</MedlineTA><NlmUniqueID>8610343</NlmUniqueID><ISSNLinking>0885-8195</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Medical student</Keyword><Keyword MajorTopicYN="N">Radiation oncology</Keyword><Keyword MajorTopicYN="N">Recruitment</Keyword></KeywordList><CoiStatement>Declarations. Ethics Approval and Consent to Participate: The study received ethics approval from the Health Research Ethics Board of Alberta. Informed consent was obtained from all participants. Competing Interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>12</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>12</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>11</Hour><Minute>18</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40711628</ArticleId><ArticleId IdType="doi">10.1007/s13187-025-02689-w</ArticleId><ArticleId IdType="pii">10.1007/s13187-025-02689-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>The Association of Faculties of Medicine of Canada (2022) 2020&#x2013;2021 annual report</Citation></Reference><Reference><Citation>Nham E, Kumar R, McAlpine K, Seabrook C, Valle M, Menard I, Watterson J, Roberts M (2022) Development, implementation, and uptake of a novel CaRMS residency recruitment committee strategy in the era of COVID-19. Can Urol Assoc J 16.&#xa0; https://doi.org/10.5489/cuaj.7676</Citation></Reference><Reference><Citation>Linehan V, Katlariwala P, Chahal BS, Khatchikian AD, Supersad A, Dobson JL (2021) The online cross-country tour: evaluation of a novel online series for Canadian radiology residency programs and future implications for the radiology CaRMS process. Acad Radiol 28:1313&#x2013;1320. https://doi.org/10.1016/j.acra.2021.03.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.acra.2021.03.009</ArticleId><ArticleId IdType="pubmed">33840599</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen AXL, Clark I, Damji KF, Hamel P, Belair ML, Goodyear E, Hardy I (2021) New virtual CaRMS: perspectives from residency programs. Can J Ophthalmol 56:273&#x2013;276</Citation><ArticleIdList><ArticleId IdType="pubmed">33421378</ArticleId><ArticleId IdType="pmc">9187507</ArticleId></ArticleIdList></Reference><Reference><Citation>The Association of Faculties of Medicine of Canada Canada&#x2019;s portal for residency program promotion.&#xa0; https://canprepp.ca/ .&#xa0;Accessed 1 Jun 2024.</Citation></Reference><Reference><Citation>Jiang J, Key P, Deibert CM (2020) Improving the residency program virtual open house experience: a survey of urology applicants. Urology 146:1&#x2013;3. https://doi.org/10.1016/j.urology.2020.08.077</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.urology.2020.08.077</ArticleId><ArticleId IdType="pubmed">33049230</ArticleId></ArticleIdList></Reference><Reference><Citation>Salah HT, Mirza KM (2021) Pathology residency open-house events: a novel marketing paradigm. Am J Clin Pathol 156:950&#x2013;953. https://doi.org/10.1093/ajcp/aqab065</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ajcp/aqab065</ArticleId><ArticleId IdType="pubmed">34125177</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng CF, Knewitz AP, Pasic TR, Glazer TA (2022) How we do it: otolaryngology applicant impressions of virtual meet and greets at a single institution. J Surg Educ 79:40&#x2013;45. https://doi.org/10.1016/j.jsurg.2021.07.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsurg.2021.07.016</ArticleId><ArticleId IdType="pubmed">34452854</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollom EL, Sandhu N, Deig CR, Obeid JP, Miller JA, Kahn JM. (2021) Networking and applying to radiation oncology during a pandemic: cross-sectional survey of medical student concerns. Adv Radiat Oncol 6. https://doi.org/10.1016/j.adro.2021.100643</Citation></Reference><Reference><Citation>Sandhu N, Frank J, von Eyben R, Miller JA, Obeid JP, Kastelowitz N, Panjwani N, Soltys S, Bagshaw HP, Donaldson SS, Horst K, Beadle BM, Chang DT, Gibbs IC, Pollom E (2020) Virtual radiation oncology clerkship during the COVID-19 pandemic and beyond. Int J Radiat Oncol Biol Phys 108:444&#x2013;451</Citation><ArticleIdList><ArticleId IdType="pubmed">32890529</ArticleId><ArticleId IdType="pmc">7462792</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahn JM, Fields EC, Pollom E, Wairiri L, Vapiwala N, Nabavizadeh N, Thomas CR, Jimenez RB, Chandra RA (2021) Increasing medical student engagement through virtual rotations in radiation oncology. Adv Radiat Oncol 6. https://doi.org/10.1016/j.adro.2020.07.015</Citation></Reference><Reference><Citation>Wang T, Wong B, Huang A, Khatri P, Ng C, Forgie M, Lanphear JH, O&#x2019;Neill PJ (2011) Factors affecting residency rank-listing: a Maxdiff survey of graduating Canadian medical students. BMC Med Educ 11:1&#x2013;7. https://doi.org/10.1186/1472-6920-11-61</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1472-6920-11-61</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaiser KA, Lench HC, Levine LJ (2022) Medical residency match applicants undervalue factors that predict stress and burnout. Med Educ Online 27(1):2109243. https://doi.org/10.1080/10872981.2022.2109243</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10872981.2022.2109243</ArticleId><ArticleId IdType="pubmed">35946069</ArticleId><ArticleId IdType="pmc">9373742</ArticleId></ArticleIdList></Reference><Reference><Citation>The Canadian Post-M.D. Education Registry (CAPER) annual census of Post-M.D. Training 2022&#x2013;2023.&#xa0; https://caper.ca/sites/default/files/pdf/annual-census/2022-23_CAPER_Census_EN.pdf . Accessed 1 Jun 2025</Citation></Reference><Reference><Citation>Winterton M, Ahn J, Bernstein J (2016) The prevalence and cost of medical student visiting rotations. BMC Med Educ 16:1&#x2013;7. https://doi.org/10.1186/s12909-016-0805-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12909-016-0805-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Jang S, Rosenberg SA, Hullet C, Bradley KA, Kimple RJ (2018) Value of elective radiation oncology rotations: how many is too many? Int J Radiat Oncol Biol Phys 100:558&#x2013;559. https://doi.org/10.1016/j.ijrobp.2017.10.052</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijrobp.2017.10.052</ArticleId><ArticleId IdType="pubmed">29413271</ArticleId></ArticleIdList></Reference><Reference><Citation>Sidiqi BU, Gillespie EF, Lapen K, Tsai CJ, Dawson M, Wu AJ (2020) Patterns and perceptions of &#x201c;away&#x201d; rotations among radiation oncology residency applicants. Int J Radiat Oncol Biol Phys 107:1007&#x2013;1011. https://doi.org/10.1016/j.ijrobp.2020.04.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijrobp.2020.04.024</ArticleId><ArticleId IdType="pubmed">32335186</ArticleId><ArticleId IdType="pmc">7381360</ArticleId></ArticleIdList></Reference><Reference><Citation>MacNevin W, Dow T, Rafiq R, Sun MMG, Bowes D (2020) The impact of a rotating elective on medical students&#x2019; perception of radiation oncology. Cureus. https://doi.org/10.7759/cureus.7931</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.7931</ArticleId><ArticleId IdType="pubmed">33527055</ArticleId><ArticleId IdType="pmc">7842240</ArticleId></ArticleIdList></Reference><Reference><Citation>Taparra K, Ebner DK, De La Cruz D, Holliday EB (2021) Away rotations, interviews, and rank lists: radiation oncology residency applicant perspectives on the 2020 match process. Adv Radiat Oncol 6. https://doi.org/10.1016/j.adro.2021.100696</Citation></Reference><Reference><Citation>Everett AS, Strickler S, Marcrom SR, McDonald AM (2021) Students&#x2019; perspectives and concerns for the 2020 to 2021 radiation oncology interview season. Adv Radiat Oncol 6. https://doi.org/10.1016/j.adro.2020.08.011</Citation></Reference><Reference><Citation>Dosani M, Chai B, Giuliani M, Golden DW, Jimenez RB, Hirsch AE, Caissie A, Malik N, Nguyen TK, Ingledew PA (2024) Perceived factors that enable resident entry to the specialty of radiation oncology. J Cancer Educ 7:1&#x2013;2. https://doi.org/10.1007/s13187-024-02515-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13187-024-02515-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Chai BS, Dosani M, Kong T, Ingledew PA (2024) Exploring motivating factors for pursuing radiation oncology: a comparative analysis of medical students and residents. Cureus 16(8):e67399. https://doi.org/10.7759/cureus.67399</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.67399</ArticleId><ArticleId IdType="pubmed">39310570</ArticleId><ArticleId IdType="pmc">11414726</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingledew PA, Lalani N, Daly M, Campbell SR (2023) Catalyzing the next generation: interventions to increase medical student interest in radiation oncology. Int J Radiat Oncol Biol Phys 115(5):1017&#x2013;1025. https://doi.org/10.1016/j.ijrobp.2022.11.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijrobp.2022.11.025</ArticleId><ArticleId IdType="pubmed">36922073</ArticleId></ArticleIdList></Reference><Reference><Citation>Canadian residency matching service applications by faculty and discipline. https://www.carms.ca/data-reports/r1-data-reports/applications-by-faculty-and-discipline/ .&#xa0;Accessed 1 Jun 2024</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40711525</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-0584</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Jul</Month><Day>25</Day></PubDate></JournalIssue><Title>Annals of hematology</Title><ISOAbbreviation>Ann Hematol</ISOAbbreviation></Journal><ArticleTitle>Infectious complications in CLL/SLL patients receiving Bruton's Tyrosine Kinase inhibitors - systematic review and meta-analysis of randomized controlled trials.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00277-025-06502-y</ELocationID><Abstract><AbstractText>The development of Bruton Tyrosine Kinase inhibitors (BTKis) has revolutionized the management of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). However, increased infection rates have been reported in patients receiving BTKis in multiple clinical trials. This study aimed to evaluate the risk of infections associated with BTKis compared to other therapeutic regimens in CLL/SLL patients. A systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted. We included trials comparing BTKi-containing regimens (e.g., BTKi alone or combined with anti-CD20 or venetoclax) to other therapeutic regimens, as well as studies comparing different BTKis or BTKi combinations. Primary outcomes were the risk of any infection and grade 3-4 infections. Secondary outcomes included pneumonia, sepsis, septic shock, COVID-19, fungal infections, fatal infections, bacteremia, and febrile neutropenia. Pooled risk ratios (RR) with 95% confidence intervals (CIs) were estimated using fixed or random effects models based on heterogeneity. Eighteen trials encompassing 8,324 patients were included. BTKi-containing regimens, either as monotherapy or combined with anti-CD20 or venetoclax, were not associated with a significantly increased risk of any infection compared to other regimens [BTKi&#x2009;+&#x2009;anti-CD20 or venetoclax: RR 0.93 (95% CI: 0.79-1.09, I<sup>2</sup>&#x2009;=&#x2009;46%), 3 trials; BTKi monotherapy: RR 1.12 (95% CI: 0.94-1.34, I<sup>2</sup>&#x2009;=&#x2009;73%), 3 trials]. Similarly, BTKi monotherapy was not associated with an increased risk of grade 3-4 infections [RR 1.05 (95% CI: 0.76-1.44, I<sup>2</sup>&#x2009;=&#x2009;61%), 5 trials]. The risk of sepsis was not significantly increased with BTKi regimens [BTKi&#x2009;+&#x2009;anti-CD20: RR 0.48 (95% CI: 0.12-1.84, I<sup>2</sup>&#x2009;=&#x2009;69%), 4 trials; BTKi monotherapy: RR 0.50 (95% CI: 0.25-1.01, I<sup>2</sup>&#x2009;=&#x2009;0%), 5 trials]. However, pneumonia risk was increased in the BTKi&#x2009;+&#x2009;anti-CD20 vs other regimens, [RR 2.18; 95% CI 1.29-3.70; I<sup>2</sup>&#x2009;=&#x2009;3%, 4 trials]. The risk of febrile neutropenia was reduced in trials comparing BTKi-containing regimens to other therapies. BTKi-containing regimens were not associated with an increased risk of overall infections or grade 3-4 infections compared to other regimens. However, an elevated risk of pneumonia was observed with BTKi combinations, highlighting the need for careful consideration when selecting treatment regimens for CLL/SLL patients.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Buchrits</LastName><ForeName>Shira</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Hematology, Davidoff Cancer Center, Beilinson Hospital, Rabin Medical Center, 39 Jabotinsky Road, 49100, Petah Tikva, Israel. shirab2805@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Internal Medicine Department A, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel. shirab2805@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medical and Health Sciences, Tel Aviv University, Tel-Aviv, Israel. shirab2805@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trieman</LastName><ForeName>Gal</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Internal Medicine Department A, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medical and Health Sciences, Tel Aviv University, Tel-Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giladi</LastName><ForeName>Odil</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Institute of Hematology, Davidoff Cancer Center, Beilinson Hospital, Rabin Medical Center, 39 Jabotinsky Road, 49100, Petah Tikva, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medical and Health Sciences, Tel Aviv University, Tel-Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hofstetter</LastName><ForeName>Liron</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute of Hematology, Davidoff Cancer Center, Beilinson Hospital, Rabin Medical Center, 39 Jabotinsky Road, 49100, Petah Tikva, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medical and Health Sciences, Tel Aviv University, Tel-Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gurion</LastName><ForeName>Ronit</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institute of Hematology, Davidoff Cancer Center, Beilinson Hospital, Rabin Medical Center, 39 Jabotinsky Road, 49100, Petah Tikva, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medical and Health Sciences, Tel Aviv University, Tel-Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Granot</LastName><ForeName>Galit</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Institute of Hematology, Davidoff Cancer Center, Beilinson Hospital, Rabin Medical Center, 39 Jabotinsky Road, 49100, Petah Tikva, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Felsenstein Medical Research Center, Rabin Medical Center, Petah Tikva, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medical and Health Sciences, Tel Aviv University, Tel-Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shacham-Abulafia</LastName><ForeName>Adi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Hematology, Davidoff Cancer Center, Beilinson Hospital, Rabin Medical Center, 39 Jabotinsky Road, 49100, Petah Tikva, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medical and Health Sciences, Tel Aviv University, Tel-Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raanani</LastName><ForeName>Pia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institute of Hematology, Davidoff Cancer Center, Beilinson Hospital, Rabin Medical Center, 39 Jabotinsky Road, 49100, Petah Tikva, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medical and Health Sciences, Tel Aviv University, Tel-Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gafter-Gvili</LastName><ForeName>Anat</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Hematology, Davidoff Cancer Center, Beilinson Hospital, Rabin Medical Center, 39 Jabotinsky Road, 49100, Petah Tikva, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Internal Medicine Department A, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medical and Health Sciences, Tel Aviv University, Tel-Aviv, Israel.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Ann Hematol</MedlineTA><NlmUniqueID>9107334</NlmUniqueID><ISSNLinking>0939-5555</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">BTK inhibitor toxicity</Keyword><Keyword MajorTopicYN="N">Bruton tyrosine kinase inhibitors</Keyword><Keyword MajorTopicYN="N">Chronic lymphocytic leukaemia (CLL)</Keyword></KeywordList><CoiStatement>Declarations. Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>12</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>12</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>11</Hour><Minute>12</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40711525</ArticleId><ArticleId IdType="doi">10.1007/s00277-025-06502-y</ArticleId><ArticleId IdType="pii">10.1007/s00277-025-06502-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, Xiao W (2022) The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia 36(7):1720&#x2013;1748. https://doi.org/10.1038/s41375-022-01620-2</Citation></Reference><Reference><Citation>Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, Hillmen P, Keating M, Montserrat E, Chiorazzi N et al (2018) iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive man-agement of CLL. Blood 131:2745&#x2013;2760</Citation><ArticleIdList><ArticleId IdType="pubmed">29540348</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen T, Wang J, Shi Y, Qian H, Liu P (2021) Inhibitors targeting Bruton&#x2019;s tyrosine kinase in cancers: Drug development advances. Leukemia 35:312&#x2013;332</Citation><ArticleIdList><ArticleId IdType="pubmed">33122850</ArticleId></ArticleIdList></Reference><Reference><Citation>Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, Bairey O, Hillmen P, Bartlett NL, Li J, Simpson D, Grosicki S, Devereux S, McCarthy H, Coutre S, Quach H, Gaidano G, Maslyak Z, Stevens DA, Janssens A, Offner F, Mayer J, O'Dwyer M, Hellmann A, Schuh A, Siddiqi T, Polliack A, Tam CS, Suri D, Cheng M, Clow F, Styles L, James DF, Kipps TJ; RESONATE-2 Investigators (2015) Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med 373(25):2425&#x2013;37. https://doi.org/10.1056/NEJMoa1509388</Citation></Reference><Reference><Citation>Byrd JC, Brown JR, O&#x2019;Brien S, Barrientos JC, Kay NE, Reddy NM, Coutre D, Tam CS, Mulligan SP, Jaeger U et al (2014) Ibrutinib versus ofa-tumumab in previously treated chronic lymphoid leukemia. N Engl J Med 371:213&#x2013;223</Citation><ArticleIdList><ArticleId IdType="pubmed">24881631</ArticleId><ArticleId IdType="pmc">4134521</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrd JC, Hillmen P, Ghia P, Kater AP, Chanan-Khan A, Furman RR, O&#x2019;Brien S, Yenerel MN, Ill&#xe9;s A, Kay N, Garcia-Marco JA, Mato A, Pinilla-Ibarz J, Seymour JF, Lepretre S, Stilgenbauer S, Robak T, Rothbaum W, Izumi R, Hamdy A, Patel P, Higgins K, Sohoni S, Jurczak W (2021) Acalabrutinib versus Ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial. J Clin Oncol 39(31):3441&#x2013;3452. https://doi.org/10.1200/JCO.21.01210</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.21.01210</ArticleId><ArticleId IdType="pubmed">34310172</ArticleId><ArticleId IdType="pmc">8547923</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown JR, Eichhorst B, Hillmen P, Jurczak W, Ka&#x17a;mierczak M, Lamanna N, O&#x2019;Brien SM, Tam CS, Qiu L, Zhou K, Simkovic M, Mayer J, Gillespie-Twardy A, Ferrajoli A, Ganly PS, Weinkove R, Grosicki S, Mital A, Robak T, Osterborg A, Yimer HA, Salmi T, Wang MD, Fu L, Li J, Wu K, Cohen A, Shadman M (2023) Zanubrutinib or Ibrutinib in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med 388(4):319&#x2013;332. https://doi.org/10.1056/NEJMoa2211582</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2211582</ArticleId><ArticleId IdType="pubmed">36511784</ArticleId></ArticleIdList></Reference><Reference><Citation>Mato AR, Davids MS, Fraser G et al (2024) Pirtobrutinib vs investigator&#x2019;s choice of idelalisib plus rituximab or bendamustine plus rituximab in relapsed/refractory CLL/SLL: primary analysis of the phase 3 BRUIN-CLL-321 trial. Presented at: 65th American Society of Hematology (ASH) Annual Meeting, San Diego, CA. Abstract #123456</Citation></Reference><Reference><Citation>O&#x2019;Brien S, Hillmen P, Coutre S, Barr PM, Fraser G, Tedeschi A, Burger JA, Dilhuydy MS, Hess G, Moreno C, Cramer P, Liu E, Chang S, Vermeulen J, Styles L, Howes A, James DF, Patel K, Graef T, Valentino R (2018) Safety analysis of four randomized controlled studies of Ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma or mantle cell lymphoma. Clin Lymphoma Myeloma Leuk 18(10):648-657.e15. https://doi.org/10.1016/j.clml.2018.06.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clml.2018.06.016</ArticleId><ArticleId IdType="pubmed">30061088</ArticleId></ArticleIdList></Reference><Reference><Citation>Maddocks KJ, Ruppert AS, Lozanski G, Heerema NA, Zhao W, Abruzzo L, Lozanski A, Davis M, Gordon A, Smith LL, Mantel R, Jones JA, Flynn JM, Jaglowski SM, Andritsos LA, Awan F, Blum KA, Grever MR, Johnson AJ, Byrd JC, Woyach JA (2015) Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia. JAMA Oncol 1(1):80&#x2013;87. https://doi.org/10.1001/jamaoncol.2014.218</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoncol.2014.218</ArticleId><ArticleId IdType="pubmed">26182309</ArticleId><ArticleId IdType="pmc">4520535</ArticleId></ArticleIdList></Reference><Reference><Citation>Tillman BF, Pauff JM, Satyanarayana G, Talbott M, Warner JL (2018) Systematic review of infectious events with the Bruton tyrosine kinase inhibitor ibrutinib in the treatment of hematologic malignancies. Eur J Haematol 100(4):325&#x2013;334. https://doi.org/10.1111/ejh.13020</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ejh.13020</ArticleId><ArticleId IdType="pubmed">29285806</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JPT, Green S (eds) (2011) Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. https://handbook-5-1.cochrane.org . Accessed 15 July 2025</Citation></Reference><Reference><Citation>Tam CS, Brown JR, Kahl BS, Ghia P, Giannopoulos K, Jurczak W, &#x160;imkovi&#x10d; M, Shadman M, &#xd6;sterborg A, Laurenti L, Walker P, Opat S, Chan H, Ciepluch H, Greil R, Tani M, Trn&#x11b;n&#xfd; M, Brander DM, Flinn IW, Grosicki S, Verner E, Tedeschi A, Li J, Tian T, Zhou L, Marimpietri C, Paik JC, Cohen A, Huang J, Robak T, Hillmen P (2022) Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. Lancet Oncol. 23(8):1031&#x2013;1043. https://doi.org/10.1016/S1470-2045(22)00293-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(22)00293-5</ArticleId><ArticleId IdType="pubmed">35810754</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, Kamdar M, Munir T, Walewska R, Corbett G et al (2020) Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): A randomised, controlled, phase 3 trial. Lancet 395:1278&#x2013;1291</Citation><ArticleIdList><ArticleId IdType="pubmed">32305093</ArticleId><ArticleId IdType="pmc">8151619</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghia P, Pluta A, Wach M, Lysak D, Kozak T, Simkovic M, Kaplan P, Kraychok I, Illes A, De La Serna J et al (2019) Acalabrutinib vs Rituximab plus Idelalisib (IdR) or Bendamustine (BR) by investigator choice in relapsed/refractory (RR) chronic lymphocytic leukemia: Phase 3 ASCEND study. Hematol Oncol 37:86&#x2013;87</Citation></Reference><Reference><Citation>Hillmen P, Pitchford A, Bloor A, Broom A, Young M, Kennedy B, Walewska R, Furtado M, Preston G, Neilson JR, Pemberton N, Sidra G, Morley N, Cwynarski K, Schuh A, Forconi F, Elmusharaf N, Paneesha S, Fox CP, Howard DR, Hockaday A, Brown JM, Cairns DA, Jackson S, Greatorex N, Webster N, Shingles J, Dalal S, Patten PEM, Allsup D, Rawstron A, Munir T (2023) Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 24(5):535&#x2013;552. https://doi.org/10.1016/S1470-2045(23)00144-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(23)00144-4</ArticleId><ArticleId IdType="pubmed">37142374</ArticleId></ArticleIdList></Reference><Reference><Citation>F&#xfc;rstenau M, Kater AP, Robrecht S, von Tresckow J, Zhang C, Gregor M, Thornton P, Staber PB, Tadmor T, Lindstr&#xf6;m V, Juliusson G, Janssens A, Levin MD, da Cunha-Bang C, Schneider C, Goldschmidt N, Vandenberghe E, Rossi D, Benz R, N&#xf6;sslinger T, Heintel D, Poulsen CB, Christiansen I, Frederiksen H, Enggaard L, Posthuma EFM, Issa DE, Visser HPJ, Bellido M, Kutsch N, D&#xfc;rig J, Stehle A, V&#xf6;hringer M, B&#xf6;ttcher S, Schulte C, Simon F, Fink AM, Fischer K, Holmes EE, Kreuzer KA, Ritgen M, Br&#xfc;ggemann M, Tausch E, Stilgenbauer S, Hallek M, Niemann CU, Eichhorst B (2024) First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 25(6):744&#x2013;759. https://doi.org/10.1016/S1470-2045(24)00196-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(24)00196-7</ArticleId><ArticleId IdType="pubmed">38821083</ArticleId></ArticleIdList></Reference><Reference><Citation>Niemann CU, Munir T, Moreno C, Owen C, Follows GA, Benjamini O, Janssens A, Levin MD, Robak T, Simkovic M, Voloshin S, Vorobyev V, Yagci M, Ysebaert L, Qi K, Qi Q, Sinet P, Parisi L, Srinivasan S, Schuier N, Baeten K, Howes A, Caces DB, Kater AP (2023) Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 24(12):1423&#x2013;1433. https://doi.org/10.1016/S1470-2045(23)00452-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(23)00452-7</ArticleId><ArticleId IdType="pubmed">37944541</ArticleId></ArticleIdList></Reference><Reference><Citation>Munir T, Cairns DA, Bloor A, Allsup D, Cwynarski K, Pettitt A, Paneesha S, Fox CP, Eyre TA, Forconi F, Elmusharaf N, Kennedy B, Gribben J, Pemberton N, Sheehy O, Preston G, Schuh A, Walewska R, Duley L, Howard D, Hockaday A, Jackson S, Greatorex N, Girvan S, Bell S, Brown JM, Webster N, Dalal S, de Tute R, Rawstron A, Patten PEM, Hillmen P, National Cancer Research Institute Chronic Lymphocytic Leukemia Subgroup (2024) Chronic lymphocytic leukemia therapy guided by measurable residual disease. N Engl J Med 390(4):326&#x2013;337. https://doi.org/10.1056/NEJMoa2310063</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2310063</ArticleId><ArticleId IdType="pubmed">38078508</ArticleId></ArticleIdList></Reference><Reference><Citation>Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, Bartlett NL, Brander DM, Barr PM, Rogers KA, Parikh SA, Coutre S, Hurria A, Brown JR, Lozanski G, Blachly JS, Ozer HG, Major-Elechi B, Fruth B, Nattam S, Larson RA, Erba H, Litzow M, Owen C, Kuzma C, Abramson JS, Little RF, Smith SE, Stone RM, Mandrekar SJ, Byrd JC (2018) Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med 379(26):2517&#x2013;2528. https://doi.org/10.1056/NEJMoa1812836</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1812836</ArticleId><ArticleId IdType="pubmed">30501481</ArticleId><ArticleId IdType="pmc">6325637</ArticleId></ArticleIdList></Reference><Reference><Citation>Burger JA, Sivina M, Jain N, Kim E, Kadia T, Estrov Z, Nogueras-Gonzalez GM, Huang X, Jorgensen J, Li J, Cheng M, Clow F, Ohanian M, Andreeff M, Mathew T, Thompson P, Kantarjian H, O&#x2019;Brien S, Wierda WG, Ferrajoli A, Keating MJ (2019) Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood 133(10):1011&#x2013;1019. https://doi.org/10.1182/blood-2018-10-879429</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2018-10-879429</ArticleId><ArticleId IdType="pubmed">30530801</ArticleId><ArticleId IdType="pmc">6405333</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharman JP, Brander DM, Mato AR, Ghosh N, Schuster SJ, Kambhampati S, Burke JM, Lansigan F, Schreeder MT, Lunin SD, Zweibach A, Shtivelband M, Travis PM, Chandler JC, Kolibaba KS, Sportelli P, Miskin HP, Weiss MS, Flinn IW (2021) Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial. Lancet Haematol. 8(4):e254&#x2013;e266. https://doi.org/10.1016/S2352-3026(20)30433-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-3026(20)30433-6</ArticleId><ArticleId IdType="pubmed">33631112</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno C, Greil R, Demirkan F, Tedeschi A, Anz B, Larratt L, Simkovic M, Novak J, Strugov V, Gill D et al (2022) First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: Final analysis of the randomized, phase 3 iLLUMINATE trial. Haematologica 107:2108</Citation><ArticleIdList><ArticleId IdType="pubmed">35021599</ArticleId><ArticleId IdType="pmc">9425310</ArticleId></ArticleIdList></Reference><Reference><Citation>Shanafelt TD, Wang XV, Kay NE, Hanson CA, O&#x2019;Brien S, Barrientos J, Jelinek DF, Braggio E, Leis JF, Zhang CC, Coutre SE, Barr PM, Cashen AF, Mato AR, Singh AK, Mullane MP, Little RF, Erba H, Stone RM, Litzow M, Tallman M (2019) Ibrutinib-Rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med 381(5):432&#x2013;443. https://doi.org/10.1056/NEJMoa1817073</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1817073</ArticleId><ArticleId IdType="pubmed">31365801</ArticleId><ArticleId IdType="pmc">6908306</ArticleId></ArticleIdList></Reference><Reference><Citation>Chanan-Khan A, Cramer P, Demirkan F, Fraser G, Silva RS, Grosicki S, Pristupa A, Janssens A, Mayer J, Bartlett NL, Dilhuydy MS, Pylypenko H, Loscertales J, Avigdor A, Rule S, Villa D, Samoilova O, Panagiotidis P, Goy A, Mato A, Pavlovsky MA, Karlsson C, Mahler M, Salman M, Sun S, Phelps C, Balasubramanian S, Howes A, Hallek M, HELIOS investigators (2016) Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol. 17(2):200&#x2013;211. https://doi.org/10.1016/S1470-2045(15)00465-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(15)00465-9</ArticleId><ArticleId IdType="pubmed">26655421</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohty M, Kharfan-Dabaja MA (2025) Fixed-duration acalabrutinib combinations in untreated chronic lymphocytic leukemia. N Engl J Med 392(21):2180&#x2013;2181. https://doi.org/10.1056/NEJMc2503839</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2503839</ArticleId><ArticleId IdType="pubmed">40466081</ArticleId></ArticleIdList></Reference><Reference><Citation>Eichhorst B, Fink AM, Bahlo J, Busch R, Kovacs G, Maurer C, Lange E, K&#xf6;ppler H, Kiehl M, S&#xf6;kler M, Schlag R, Vehling-Kaiser U, K&#xf6;chling G, Pl&#xf6;ger C, Gregor M, Plesner T, Trneny M, Fischer K, D&#xf6;hner H, Kneba M, Wendtner CM, Klapper W, Kreuzer KA, Stilgenbauer S, B&#xf6;ttcher S, Hallek M, International group of investigators, German CLL Study Group (GCLLSG) (2016) First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol 17(7):928&#x2013;942. https://doi.org/10.1016/S1470-2045(16)30051-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(16)30051-1</ArticleId><ArticleId IdType="pubmed">27216274</ArticleId></ArticleIdList></Reference><Reference><Citation>Mikulska M, Oltolini C, Zappulo E, Bartoletti M, Frustaci AM, Visentin A, Vitale C, Mauro FR (2024) Prevention and management of infectious complications in patients with chronic lymphocytic leukemia (CLL) treated with BTK and BCL-2 inhibitors, focus on current guidelines. Blood Rev 65:101180. https://doi.org/10.1016/j.blre.2024.101180</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.blre.2024.101180</ArticleId><ArticleId IdType="pubmed">38331696</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Brien SM, Furman RR, Coutre SE (2016) Five-year experience with single-agent ibrutinib in patients with previously untreated and relapsed/refractory chronic lymphocytic leukemia/small lymphocytic leukemia. Blood 128:233</Citation></Reference><Reference><Citation>de Weerdt I, Koopmans SM, Kater AP, van Gelder M (2017) Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach. Haematologica 102(10):1629&#x2013;1639. https://doi.org/10.3324/haematol.2017.164103</Citation><ArticleIdList><ArticleId IdType="doi">10.3324/haematol.2017.164103</ArticleId><ArticleId IdType="pubmed">28775119</ArticleId><ArticleId IdType="pmc">5622847</ArticleId></ArticleIdList></Reference><Reference><Citation>Eichhorst B, Robak T, Montserrat E, Ghia P, Niemann CU, Kater AP, Gregor M, Cymbalista F, Buske C, Hillmen P, Hallek M, Mey U; ESMO Guidelines Committee (2021) Electronic address: clinicalguidelines@esmo.org. Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 32(1):23&#x2013;33. https://doi.org/10.1016/j.annonc.2020.09.019</Citation></Reference><Reference><Citation>Ghosh N, Manzoor BS, Fakhri B, Emechebe N, Alhasani H, Skarbnik A, Jawaid D, Shadman M (2024) Real-world comparative effectiveness of venetoclax-obinutuzumab versus Bruton tyrosine kinase inhibitors for frontline chronic lymphocytic leukaemia. Br J Haematol. https://doi.org/10.1111/bjh.19613</Citation></Reference><Reference><Citation>Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D&#x2019;Rozario J, Assouline S, Owen C, Gerecitano J, Robak T, De la Serna J, Jaeger U, Cartron G, Montillo M, Humerickhouse R, Punnoose EA, Li Y, Boyer M, Humphrey K, Mobasher M, Kater AP (2018) Venetoclax-Rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med 378(12):1107&#x2013;1120. https://doi.org/10.1056/NEJMoa1713976</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1713976</ArticleId><ArticleId IdType="pubmed">29562156</ArticleId></ArticleIdList></Reference><Reference><Citation>ClinicalTrials.gov. Ibrutinib monotherapy versus fixed-duration venetoclax plus obinutuzumab versus fixed-duration ibrutinib plus venetoclax in patients with previously untreated chronic lymphocytic. leukaemia (CLL) (CLL17). [Cited 2023 Oct 2]. Available from: https://clinicaltrials.gov/ct2/show/NCT04608318</Citation></Reference><Reference><Citation>Ryan CE, Davids MS, Hermann R, Shahkarami M, Biondo J, Abhyankar S, Alhasani H, Sharman JP, Mato AR, Roeker LE (2022) MAJIC: a phase III trial of acalabrutinib&#xa0;+&#xa0;venetoclax versus venetoclax&#xa0;+&#xa0;obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. Future Oncol 18(33):3689&#x2013;3699. https://doi.org/10.2217/fon-2022-0456</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/fon-2022-0456</ArticleId><ArticleId IdType="pubmed">36102212</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40711443</PMID><DateCompleted><Year>2025</Year><Month>07</Month><Day>25</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1521-4141</ISSN><JournalIssue CitedMedium="Internet"><Volume>55</Volume><Issue>7</Issue><PubDate><Year>2025</Year><Month>Jul</Month></PubDate></JournalIssue><Title>European journal of immunology</Title><ISOAbbreviation>Eur J Immunol</ISOAbbreviation></Journal><ArticleTitle>Machine Learning Reassessment of Serum Immune Factors Shows No Unique Immune Profiles Linked to Disease Outcomes in SARS-CoV-2-infected Patients at Hospital Admittance.</ArticleTitle><Pagination><StartPage>e70001</StartPage><MedlinePgn>e70001</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/eji.70001</ELocationID><Abstract><AbstractText>The complex pathophysiology of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) involves a hyperinflammatory state with excessive cytokine production, leading to an influenza-like syndrome that may need emergency care. The severity of SARS-CoV-2 varies widely, and collective serum immune factors, evaluated in emergency care patients, have not been shown to correlate with disease progression. We applied a machine learning approach to reassess and define serum immune profiles that could align with clinical laboratory parameters and predict disease outcomes in patients with respiratory virus infections, including those with SARS-CoV-2, seeking emergency care. Sixty-two plasma immune molecules, in a cohort of 67 symptomatic SARS-CoV-2, were analyzed for correlation with antibodies (Abs) to spike (S) and nucleocapsid (N) proteins, as well as with clinical laboratory parameters, to identify early indicators of disease prognosis at hospital admission. This approach allowed us to analyze and cluster unlabeled datasets, delineating three distinct serum immune signatures. Two showed significant and opposite modulations, correlating with poorer disease outcomes, while most patients with moderate disease displayed modest immune factor dysregulation. This highlights the complexity of immune responses in the severity of diseases caused by highly respiratory pathogenic virus like SARS-CoV-2, emphasizing the importance of evaluating overall immune imbalance rather than focusing on a few dysregulated factors.</AbstractText><CopyrightInformation>&#xa9; 2025 The Author(s). European Journal of Immunology published by Wiley&#x2010;VCH GmbH.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rossi</LastName><ForeName>Stefania</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-8854-7072</Identifier><AffiliationInfo><Affiliation>Department of Oncology and Molecular Medicine, Istituto Superiore di Sanit&#xe0;, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Capone</LastName><ForeName>Imerio</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Oncology and Molecular Medicine, Istituto Superiore di Sanit&#xe0;, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cabri</LastName><ForeName>Enrico</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Istituto di Ricerche Farmacologiche "Mario Negri" IRCCS, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giabelli</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Istituto di Ricerche Farmacologiche "Mario Negri" IRCCS, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rossoni</LastName><ForeName>Ilaria</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Istituto di Ricerche Farmacologiche "Mario Negri" IRCCS, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Romagnoli</LastName><ForeName>Giulia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Oncology and Molecular Medicine, Istituto Superiore di Sanit&#xe0;, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santini</LastName><ForeName>Stefano M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Oncology and Molecular Medicine, Istituto Superiore di Sanit&#xe0;, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marcantonio</LastName><ForeName>Cinzia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Istituto Superiore di Sanit&#xe0;, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giuseppetti</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Istituto Superiore di Sanit&#xe0;, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villano</LastName><ForeName>Umbertina</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Istituto Superiore di Sanit&#xe0;, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bruni</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Istituto Superiore di Sanit&#xe0;, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ciccaglione</LastName><ForeName>Anna R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Istituto Superiore di Sanit&#xe0;, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frasca</LastName><ForeName>Federica</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine, Laboratory of Virology, Sapienza University of Rome, Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>d'Auria</LastName><ForeName>Alessandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine, Laboratory of Virology, Sapienza University of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bugani</LastName><ForeName>Ginevra</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>d'Ettorre</LastName><ForeName>Gabriella</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Antonelli</LastName><ForeName>Guido</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine, Laboratory of Virology, Sapienza University of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scagnolari</LastName><ForeName>Carolina</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-1044-1478</Identifier><AffiliationInfo><Affiliation>Department of Molecular Medicine, Laboratory of Virology, Sapienza University of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fratelli</LastName><ForeName>Maddalena</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Istituto di Ricerche Farmacologiche "Mario Negri" IRCCS, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gabriele</LastName><ForeName>Lucia</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-1483-866X</Identifier><AffiliationInfo><Affiliation>Department of Oncology and Molecular Medicine, Istituto Superiore di Sanit&#xe0;, Rome, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Fondo di Beneficenza di Intesa Sanpaolo 2020</Agency><Country/></Grant><Grant><Agency>European Union-NextGeneration EU</Agency><Country/></Grant><Grant><Agency>Italian Ministry of University and Research</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Eur J Immunol</MedlineTA><NlmUniqueID>1273201</NlmUniqueID><ISSNLinking>0014-2980</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086462">Coronavirus Nucleocapsid Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000705834">nucleocapsid phosphoprotein, SARS-CoV-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010750">Phosphoproteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069550" MajorTopicYN="Y">Machine Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086462" MajorTopicYN="N">Coronavirus Nucleocapsid Proteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010750" MajorTopicYN="N">Phosphoproteins</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID&#x2010;19</Keyword><Keyword MajorTopicYN="N">cytokines</Keyword><Keyword MajorTopicYN="N">infection</Keyword><Keyword MajorTopicYN="N">inflammation</Keyword><Keyword MajorTopicYN="N">machine learning</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>12</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>12</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>10</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40711443</ArticleId><ArticleId IdType="doi">10.1002/eji.70001</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>D. M. Altmann and R. J. Boyton, &#x201c;COVID&#x2010;19 Vaccination: The Road Ahead,&#x201d; Science 375, no. 6585 (2022): 1127&#x2013;1132.</Citation></Reference><Reference><Citation>R. Qin, L. He, Z. Yang, et&#xa0;al., &#x201c;Identification of Parameters Representative of Immune Dysfunction in Patients With Severe and Fatal COVID&#x2010;19 Infection: A Systematic Review and Meta&#x2010;analysis,&#x201d; Clinical Reviews in Allergy &amp; Immunology 64, no. 1 (2023): 33&#x2013;65.</Citation></Reference><Reference><Citation>M. Merad, C. A. Blish, F. Sallusto, and A. Iwasaki, &#x201c;The Immunology and Immunopathology of COVID&#x2010;19,&#x201d; Science 375, no. 6585 (2022): 1122&#x2013;1127.</Citation></Reference><Reference><Citation>J. M. Minkoff and B. tenOever, &#x201c;Innate Immune Evasion Strategies of SARS&#x2010;CoV&#x2010;2,&#x201d; Nature Reviews Microbiology 21, no. 3 (2023): 178&#x2013;194.</Citation></Reference><Reference><Citation>A. Bonaventura, A. Vecchie, L. Dagna, et&#xa0;al., &#x201c;Endothelial Dysfunction and Immunothrombosis as Key Pathogenic Mechanisms in COVID&#x2010;19,&#x201d; Nature Reviews Immunology 21, no. 5 (2021): 319&#x2013;329.</Citation></Reference><Reference><Citation>R. Karki and K. TD, &#x201c;Innate Immunity, Cytokine Storm, and Inflammatory Cell Death in COVID&#x2010;19,&#x201d; Journal of Translational Medicine 20, no. 1 (2022): 542.</Citation></Reference><Reference><Citation>J. S. Lee, S. Park, H. W. Jeong, et&#xa0;al., &#x201c;Immunophenotyping of COVID&#x2010;19 and Influenza Highlights the Role of Type I Interferons in Development of Severe COVID&#x2010;19,&#x201d; Science Immunology 5, no. 49 (2020): eabd1554.</Citation></Reference><Reference><Citation>S. Ramasamy and S. Subbian, &#x201c;Critical Determinants of Cytokine Storm and Type I Interferon Response in COVID&#x2010;19 Pathogenesis,&#x201d; Clinical Microbiology Reviews 34, no. 3 (2021): e00299&#x2013;20.</Citation></Reference><Reference><Citation>R. Savan and M. Gale, &#x201c;Innate Immunity and Interferon in SARS&#x2010;CoV&#x2010;2 Infection Outcome,&#x201d; Immunity 56, no. 7 (2023): 1443&#x2013;1450.</Citation></Reference><Reference><Citation>X. Li, M. Shao, X. Zeng, P. Qian, and H. Huang, &#x201c;Signaling Pathways in the Regulation of Cytokine Release Syndrome in Human Diseases and Intervention Therapy,&#x201d; Signal Transduction and Targeted Therapy 6, no. 1 (2021): 367.</Citation></Reference><Reference><Citation>X. Yongzhi, &#x201c;COVID&#x2010;19&#x2010;Associated Cytokine Storm Syndrome and Diagnostic Principles: An Old and New Issue,&#x201d; Emerging Microbes &amp; Infections 10, no. 1 (2021): 266&#x2013;276.</Citation></Reference><Reference><Citation>R. Q. Cron, &#x201c;No Perfect Therapy for the Imperfect COVID&#x2010;19 Cytokine Storm,&#x201d; Lancet Rheumatology 4, no. 5 (2022): e308.</Citation></Reference><Reference><Citation>V. A. Ryabkova, L. P. Churilov, and Y. Shoenfeld, &#x201c;Influenza Infection, SARS, MERS and COVID&#x2010;19: Cytokine Storm&#x2014;The Common Denominator and the Lessons to be Learned,&#x201d; Clinical Immunology 223 (2021): 108652.</Citation></Reference><Reference><Citation>N. Cheemalavagu, K. E. Shoger, Y. M. Cao, et&#xa0;al., &#x201c;Predicting Gene&#x2010;Level Sensitivity to JAK&#x2010;STAT Signaling Perturbation Using a Mechanistic&#x2010;to&#x2010;Machine Learning Framework,&#x201d; Cell Systems 15, no. 1 (2024): 37&#x2013;48.</Citation></Reference><Reference><Citation>A. Rahman, T. Debnath, D. Kundu, et&#xa0;al., &#x201c;Machine Learning and Deep Learning&#x2010;Based Approach in Smart Healthcare: Recent Advances, Applications, Challenges and Opportunities,&#x201d; AIMS Public Health 11 (2024): 58&#x2013;109.</Citation></Reference><Reference><Citation>D. C. Fajgenbaum and J CH. C Storm New England Journal of Medicine 383, no. 23 (2020): 2255&#x2013;2273.</Citation></Reference><Reference><Citation>Y. Gu, X. Zuo, S. Zhang, et&#xa0;al., &#x201c;The Mechanism Behind Influenza Virus Cytokine Storm,&#x201d; Viruses 13, no. 7 (2021): 1362.</Citation></Reference><Reference><Citation>C. Huang, Y. Wang, X. Li, et&#xa0;al., &#x201c;Clinical Features of Patients Infected With 2019 Novel Coronavirus in Wuhan,&#x201d; Lancet 395, no. 10223 (2020): 497&#x2013;506.</Citation></Reference><Reference><Citation>N. Mangalmurti and C. A. Hunter, &#x201c;Cytokine Storms: Understanding COVID&#x2010;19,&#x201d; Immunity 53, no. 1 (2020): 19&#x2013;25.</Citation></Reference><Reference><Citation>D. Martonik, A. Parfieniuk&#x2010;Kowerda, M. Rogalska, and R. Flisiak, &#x201c;The Role of Th17 Response in COVID&#x2010;19,&#x201d; Cells 10, no. 6 (2021): 1550.</Citation></Reference><Reference><Citation>R. Tang, M. Rangachari, and K. VK, &#x201c;Tim&#x2010;3: A Co&#x2010;receptor With Diverse Roles in T Cell Exhaustion and Tolerance,&#x201d; Seminars in Immunology 42 (2019): 101302.</Citation></Reference><Reference><Citation>T. Ueland, L. Heggelund, A. Lind, et&#xa0;al., &#x201c;Elevated Plasma sTIM&#x2010;3 Levels in Patients With Severe COVID&#x2010;19,&#x201d; Journal of Allergy and Clinical Immunology 147, no. 1 (2021): 92&#x2013;98.</Citation></Reference><Reference><Citation>J. W. Song, C. Zhang, X. Fan, et&#xa0;al., &#x201c;Immunological and Inflammatory Profiles in Mild and Severe Cases of COVID&#x2010;19,&#x201d; Nature Communications 11, no. 1 (2020): 3410.</Citation></Reference><Reference><Citation>WHO Working Group on the Clinical Characterisation and Management of COVID&#x2010;19 Infection, &#x201c;A Minimal Common Outcome Measure Set for COVID&#x2010;19 Clinical Research,&#x201d; Lancet Infectious Diseases 20, no. 8 (2020): e192.</Citation></Reference><Reference><Citation>S. Rossi, M. Cordella, C. Tabolacci, et&#xa0;al., &#x201c;TNF&#x2010;Alpha and Metalloproteases as Key Players in Melanoma Cells Aggressiveness,&#x201d; Journal of Experimental &amp; Clinical Cancer Research 37, no. 1 (2018): 326.</Citation></Reference><Reference><Citation>F. Nielsen, &#x201c;Hierarchical Clustering,&#x201d; Introduction to HPC With MPI for Data Science. Undergraduate Topics in Computer Science (Springer, 2016).</Citation></Reference><Reference><Citation>F. Yu, C. Wei, P. Deng, T. Peng, and X. Hu, &#x201c;Deep Exploration of Random Forest Model Boosts the Interpretability of Machine Learning Studies of Complicated Immune Responses and Lung Burden of Nanoparticles,&#x201d; Science Advances 7, no. 22 (2021): eabf4130.</Citation></Reference><Reference><Citation>J. Bergstra and Y. Bengio, &#x201c;Random Search for Hyper&#x2010;Parameter Optimization,&#x201d; Journal of Machine Learning Research 13 (2012): 281&#x2013;305.</Citation></Reference><Reference><Citation>S. M. Lundberg and S.&#x2010;I. Lee, &#x201c;A Unified Approach to Interpreting Model Predictions,&#x201d; Advances in Neural Information Processing Systems 30 (2017): 4765&#x2013;4774.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40711399</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2325-8179</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Jul</Month><Day>28</Day></PubDate></JournalIssue><Title>Ophthalmic surgery, lasers &amp; imaging retina</Title><ISOAbbreviation>Ophthalmic Surg Lasers Imaging Retina</ISOAbbreviation></Journal><ArticleTitle>Increasing Incidence of Retinal Vein Occlusion Among Young Adults Following the COVID-19 Pandemic.</ArticleTitle><Pagination><StartPage>1</StartPage><EndPage>5</EndPage><MedlinePgn>1-5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3928/23258160-20250701-01</ELocationID><Abstract><AbstractText Label="BACKGROUND AND OBJECTIVE" NlmCategory="OBJECTIVE">Retinal vein occlusion (RVO) incidence among adults under age 50 years before and during the coronavirus disease 2019 (COVID-19) pandemic was evaluated to clarify whether COVID-19 infection increases RVO risk.</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">This was a retrospective study of adult patients under age 50 years diagnosed with RVO between 2016 and 2023.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The study included 268 patients with RVO. Cases increased from 111 (41%) pre-pandemic (2016 to 2019) to 157 (59%) post-pandemic (2020 to 2023). Incidence rose from 2.7% to 4.2% of retina clinic diagnoses (<i>P</i> = 0.006). Age at diagnosis did not differ (median 40.4 vs 39.6 years, <i>P</i> &gt; 0.05). The youngest tertile (18 to 29 years) trended towards a greater proportion of cases post-pandemic (19.6% vs 10.6%, <i>P</i> = 0.20), while the oldest tertile (39 to 49 years) trended towards a smaller proportion (48.4% vs 56.1%, <i>P</i> = 0.42).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">An increase in RVO incidence during COVID-19 was observed, with a trend towards younger age groups.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Shah</LastName><ForeName>Shivesh H</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>From Harvard Retinal Imaging Lab.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Ophthalmology, Harvard Medical School.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Lu</LastName><ForeName>Edward S</ForeName><Initials>ES</Initials><AffiliationInfo><Affiliation>From Harvard Retinal Imaging Lab.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Ophthalmology, Harvard Medical School.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ploumi</LastName><ForeName>Ioanna</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>From Harvard Retinal Imaging Lab.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Ophthalmology, Harvard Medical School.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoyek</LastName><ForeName>Sandra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>From Harvard Retinal Imaging Lab.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Ophthalmology, Harvard Medical School.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nodecker</LastName><ForeName>Kayla</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>From Harvard Retinal Imaging Lab.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Ophthalmology, Harvard Medical School.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gumustop</LastName><ForeName>Selin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>From Harvard Retinal Imaging Lab.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Ophthalmology, Harvard Medical School.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wagner</LastName><ForeName>Sarah L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>From Harvard Retinal Imaging Lab.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Ophthalmology, Harvard Medical School.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ding</LastName><ForeName>Xinyi</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>From Harvard Retinal Imaging Lab.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Ophthalmology, Harvard Medical School.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>From Harvard Retinal Imaging Lab.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Ophthalmology, Harvard Medical School.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Chong</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>From Harvard Retinal Imaging Lab.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Ophthalmology, Harvard Medical School.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>A Kim</LastName><ForeName>Leo</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Harvard Medical School.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Retina Service, Massachusetts Eye and Ear, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vavvas</LastName><ForeName>Demetrios G</ForeName><Initials>DG</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Harvard Medical School.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Retina Service, Massachusetts Eye and Ear, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Joan W</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Harvard Medical School.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Retina Service, Massachusetts Eye and Ear, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Husain</LastName><ForeName>Deeba</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Harvard Medical School.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Retina Service, Massachusetts Eye and Ear, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Nimesh A</ForeName><Initials>NA</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Harvard Medical School.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Retina Service, Massachusetts Eye and Ear, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>John B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>From Harvard Retinal Imaging Lab.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Ophthalmology, Harvard Medical School.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Retina Service, Massachusetts Eye and Ear, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ophthalmic Surg Lasers Imaging Retina</MedlineTA><NlmUniqueID>101599215</NlmUniqueID><ISSNLinking>2325-8160</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>12</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>12</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>10</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40711399</ArticleId><ArticleId IdType="doi">10.3928/23258160-20250701-01</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40711352</PMID><DateCompleted><Year>2025</Year><Month>07</Month><Day>25</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1530-6860</ISSN><JournalIssue CitedMedium="Internet"><Volume>39</Volume><Issue>14</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>31</Day></PubDate></JournalIssue><Title>FASEB journal : official publication of the Federation of American Societies for Experimental Biology</Title><ISOAbbreviation>FASEB J</ISOAbbreviation></Journal><ArticleTitle>Omicron Impacts Olfaction in Hamsters.</ArticleTitle><Pagination><StartPage>e70879</StartPage><MedlinePgn>e70879</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1096/fj.202501431RR</ELocationID><Abstract><AbstractText>Olfactory disorders have been a hallmark of COVID-19. Since the emergence of Omicron, the prevalence of anosmia has dropped, reducing interest for Omicron pathophysiology in the nasal cavity. Using the hamster model, we show that despite a lower impact than early variants of SARS-CoV-2 (D614G), Omicron BA.1 infection leads to hyposmia as early as 2&#x2009;days postinfection (dpi). While the olfactory epithelium was mostly spared from Omicron infection at 2&#x2009;dpi, the respiratory epithelium was strongly infected with increased presence of inflammation markers, epithelial damage, and cellular debris in the lumen of the nasal cavity. The hyposmia caused by the early SARS-CoV-2 variant and Omicron BA.1 infection was similar at 4 and 8&#x2009;dpi. At 4&#x2009;dpi, Omicron successfully infected the olfactory epithelium although to a lesser extent than D614G. The BA.1 infection led to innate immune cell invasion and desquamation of the olfactory epithelium similarly as the D614G variant, with persistent inflammatory markers in the olfactory turbinates at 8&#x2009;dpi despite clearance of the virus. Overall, our results indicate that Omicron successfully infects the nasal epithelium including the olfactory epithelium, but with a delay and to a lesser extent than previous SARS-CoV-2 variants. These results are consistent with Omicron pathophysiology in humans showing a decreased olfactory threshold sensitivity that may be caused, as at the early stage in hamsters, by cellular debris filling the lumen of the olfactory cleft following epithelial damage.</AbstractText><CopyrightInformation>&#xa9; 2025 The Author(s). The FASEB Journal published by Wiley Periodicals LLC on behalf of Federation of American Societies for Experimental Biology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gu&#xe9;rin</LastName><ForeName>Virginie</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>UMR 1161 Virologie, INRAE-ENVA-ANSES, &#xc9;cole Nationale V&#xe9;t&#xe9;rinaire d'Alfort, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khan</LastName><ForeName>Mantasha</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Unit&#xe9; de Virologie et Immunologie Mol&#xe9;culaires (UR892), INRAE, Universit&#xe9; Paris-Saclay, Jouy-en-Josas, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Viral Genetics and Biosecurity Unit (GVB), French Agency for Food, Environmental and Occupational Health Safety (ANSES), Ploufragan, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bourgon</LastName><ForeName>Clara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Unit&#xe9; de Virologie et Immunologie Mol&#xe9;culaires (UR892), INRAE, Universit&#xe9; Paris-Saclay, Jouy-en-Josas, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boujedli</LastName><ForeName>Younes</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>UMR 1161 Virologie, INRAE-ENVA-ANSES, &#xc9;cole Nationale V&#xe9;t&#xe9;rinaire d'Alfort, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jacquelin</LastName><ForeName>Juliette</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Unit&#xe9; de Virologie et Immunologie Mol&#xe9;culaires (UR892), INRAE, Universit&#xe9; Paris-Saclay, Jouy-en-Josas, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>von Bartheld</LastName><ForeName>Christopher S</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>Department of Physiology and Cell Biology, University of Nevada, Reno School of Medicine, Reno, Nevada, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin-Latil</LastName><ForeName>Sandra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>UMR 1161 Virologie, INRAE-ENVA-ANSES, &#xc9;cole Nationale V&#xe9;t&#xe9;rinaire d'Alfort, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klonjkowski</LastName><ForeName>Bernard</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>UMR 1161 Virologie, INRAE-ENVA-ANSES, &#xc9;cole Nationale V&#xe9;t&#xe9;rinaire d'Alfort, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Le Poder</LastName><ForeName>Sophie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>UMR 1161 Virologie, INRAE-ENVA-ANSES, &#xc9;cole Nationale V&#xe9;t&#xe9;rinaire d'Alfort, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meunier</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-2769-647X</Identifier><AffiliationInfo><Affiliation>Unit&#xe9; de Virologie et Immunologie Mol&#xe9;culaires (UR892), INRAE, Universit&#xe9; Paris-Saclay, Jouy-en-Josas, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>22178</GrantID><Agency>Agence Nationale de Recherches sur le Sida et les Hepatites Virales (ANRS)</Agency><Country/></Grant><Grant><Agency>Agence Nationale de la Recherche (ANR)</Agency><Country/></Grant><Grant><GrantID>GM103554</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><Agency>DIM One Health</Agency><Country/></Grant><Grant><Agency>INRAe SA Department</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>FASEB J</MedlineTA><NlmUniqueID>8804484</NlmUniqueID><ISSNLinking>0892-6638</ISSNLinking></MedlineJournalInfo><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006224" MajorTopicYN="N">Cricetinae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009831" MajorTopicYN="N">Olfactory Mucosa</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008647" MajorTopicYN="N">Mesocricetus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012903" MajorTopicYN="Y">Smell</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086582" MajorTopicYN="Y">Anosmia</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="Y">Betacoronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">olfaction</Keyword><Keyword MajorTopicYN="N">olfactory behavior</Keyword><Keyword MajorTopicYN="N">respiratory viruses</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>4</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>12</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>12</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>9</Hour><Minute>44</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40711352</ArticleId><ArticleId IdType="doi">10.1096/fj.202501431RR</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>D. Planas, N. Saunders, P. Maes, et&#xa0;al., &#x201c;Considerable Escape of SARS&#x2010;CoV&#x2010;2 Omicron to Antibody Neutralization,&#x201d; Nature 602 (2022): 671&#x2013;675.</Citation></Reference><Reference><Citation>M. Chen, A. Pekosz, J. S. Villano, et&#xa0;al., &#x201c;Evolution of Nasal and Olfactory Infection Characteristics of SARS&#x2010;CoV&#x2010;2 Variants,&#x201d; Journal of Clinical Investigation 134, no. 8 (2024): e174439.</Citation></Reference><Reference><Citation>H. Shuai, J. F.&#x2010;W. Chan, B. Hu, et&#xa0;al., &#x201c;Attenuated Replication and Pathogenicity of SARS&#x2010;CoV&#x2010;2 B.1.1.529 Omicron,&#x201d; Nature 603 (2022): 693&#x2013;699.</Citation></Reference><Reference><Citation>P. J. Halfmann, S. Iida, K. Iwatsuki&#x2010;Horimoto, et&#xa0;al., &#x201c;SARS&#x2010;CoV&#x2010;2 Omicron Virus Causes Attenuated Disease in Mice and Hamsters,&#x201d; Nature 603 (2022): 687&#x2013;692.</Citation></Reference><Reference><Citation>C. S. von Bartheld and L. Wang, &#x201c;Prevalence of Olfactory Dysfunction With the Omicron Variant of SARS&#x2010;CoV&#x2010;2: A Systematic Review and Meta&#x2010;Analysis,&#x201d; Cells 12 (2023): 430.</Citation></Reference><Reference><Citation>L. A. Vaira, J. R. Lechien, G. Deiana, et&#xa0;al., &#x201c;Prevalence of Olfactory Dysfunction in D614G, Alpha, Delta and Omicron Waves: A Psychophysical Case&#x2010;Control Study,&#x201d; Rhinology 61 (2022): 32&#x2013;38.</Citation></Reference><Reference><Citation>C. Bourgon, A. S. Albin, O. Ando&#x2010;Grard, et&#xa0;al., &#x201c;Neutrophils Play a Major Role in the Destruction of the Olfactory Epithelium During SARS&#x2010;CoV&#x2010;2 Infection in Hamsters,&#x201d; Cellular and Molecular Life Sciences 79 (2022): 616.</Citation></Reference><Reference><Citation>T. Tsukahara, D. H. Brann, and S. R. Datta, &#x201c;Mechanisms of SARS&#x2010;CoV&#x2010;2 Associated Anosmia,&#x201d; Physiological Reviews 103 (2023): 2759&#x2013;2766.</Citation></Reference><Reference><Citation>S. Chen and S. Wang, &#x201c;The Immune Mechanism of the Nasal Epithelium in COVID&#x2010;19&#x2013;Related Olfactory Dysfunction,&#x201d; Frontiers in Immunology 14 (2023): 1045009.</Citation></Reference><Reference><Citation>F. Armando, G. Beythien, F. K. Kaiser, et&#xa0;al., &#x201c;SARS&#x2010;CoV&#x2010;2 Omicron Variant Causes Mild Pathology in the Upper and Lower Respiratory Tract of Hamsters,&#x201d; Nature Communications 13 (2022): 3519.</Citation></Reference><Reference><Citation>G. D. De Melo, V. Perraud, F. Alvarez, et&#xa0;al., &#x201c;Neuroinvasion and Anosmia Are Independent Phenomena Upon Infection With SARS&#x2010;CoV&#x2010;2 and Its Variants,&#x201d; Nature Communications 14 (2023): 4485.</Citation></Reference><Reference><Citation>L. Merle&#x2010;Nguyen, O. Ando&#x2010;Grard, C. Bourgon, et&#xa0;al., &#x201c;Early Corticosteroid Treatment Enhances Recovery From SARS&#x2010;CoV&#x2010;2 Induced Loss of Smell in Hamster,&#x201d; Brain, Behavior, and Immunity 118 (2024): 78&#x2013;89.</Citation></Reference><Reference><Citation>M. Fusade&#x2010;Boyer, A. Gambino, L. Merle&#x2010;Nguyen, et&#xa0;al., &#x201c;SARS&#x2010;CoV&#x2010;2 Delta Variant Induces Severe Damages in the Nasal Cavity From the First Day Post&#x2010;Infection in the Syrian Hamster Model,&#x201d; Virulence 16 (2025): 2519141.</Citation></Reference><Reference><Citation>B. Bryche, A. St Albin, S. Murri, et&#xa0;al., &#x201c;Massive Transient Damage of the Olfactory Epithelium Associated With Infection of Sustentacular Cells by SARS&#x2010;CoV&#x2010;2 in Golden Syrian Hamsters,&#x201d; Brain, Behavior, and Immunity 89 (2020): 579&#x2013;586.</Citation></Reference><Reference><Citation>R. A. Reyna, M. Kishimoto&#x2010;Urata, S. Urata, T. Makishima, S. Paessler, and J. Maruyama, &#x201c;Recovery of Anosmia in Hamsters Infected With SARS&#x2010;CoV&#x2010;2 Is Correlated With Repair of the Olfactory Epithelium,&#x201d; Scientific Reports 12 (2022): 628.</Citation></Reference><Reference><Citation>B. A. Rodriguez&#x2010;Rodriguez, G. O. Ciabattoni, R. Duerr, et&#xa0;al., &#x201c;A Neonatal Mouse Model Characterizes Transmissibility of SARS&#x2010;CoV&#x2010;2 Variants and Reveals a Role for ORF8,&#x201d; Nature Communications 14 (2023): 3026.</Citation></Reference><Reference><Citation>R. Butowt, K. Bilinska, and C. S. von Bartheld, &#x201c;Olfactory Dysfunction in COVID&#x2010;19: New Insights Into the Underlying Mechanisms,&#x201d; Trends in Neurosciences 46 (2023): 75&#x2013;90.</Citation></Reference><Reference><Citation>M. N. Ullah, N. R. Rowan, and A. P. Lane, &#x201c;Neuroimmune Interactions in the Olfactory Epithelium: Maintaining a Sensory Organ at an Immune Barrier Interface,&#x201d; Trends in Immunology 45 (2024): 987&#x2013;1000.</Citation></Reference><Reference><Citation>B. Meng, A. Abdullahi, I. A. T. M. Ferreira, et&#xa0;al., &#x201c;Altered TMPRSS2 Usage by SARS&#x2010;CoV&#x2010;2 Omicron Impacts Infectivity and Fusogenicity,&#x201d; Nature 603 (2022): 706&#x2013;714.</Citation></Reference><Reference><Citation>R. C. Challis, H. Tian, J. Wang, et&#xa0;al., &#x201c;An Olfactory Cilia Pattern in the Mammalian Nose Ensures High Sensitivity to Odors,&#x201d; Current Biology 25 (2015): 2503&#x2013;2512.</Citation></Reference><Reference><Citation>Y. Oka, Y. Takai, and K. Touhara, &#x201c;Nasal Airflow Rate Affects the Sensitivity and Pattern of Glomerular Odorant Responses in the Mouse Olfactory Bulb,&#x201d; Journal of Neuroscience 29 (2009): 12070&#x2013;12078.</Citation></Reference><Reference><Citation>B. Bryche, A. Dewaele, A. Saint&#x2010;Albin, C. Le Poupon Schlegel, P. Congar, and N. Meunier, &#x201c;IL&#x2010;17c Is Involved in Olfactory Mucosa Responses to Poly(I:C) Mimicking Virus Presence,&#x201d; Brain, Behavior, and Immunity 79 (2019): 274&#x2013;283.</Citation></Reference><Reference><Citation>J. W. Harding, T. V. Getchell, and F. L. Margolis, &#x201c;Denervation of the Primary Olfactory Pathway in Mice. V. Long&#x2010;Term Effect of Intranasal ZnSO4 Irrigation on Behavior, Biochemistry and Morphology,&#x201d; Brain Research 140 (1978): 271&#x2013;285.</Citation></Reference><Reference><Citation>K. L. Whitcroft, A. Altundag, P. Balungwe, et&#xa0;al., &#x201c;Position Paper on Olfactory Dysfunction: 2023,&#x201d; Rhinology 61 (2023): 1&#x2013;131.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40711294</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2306-7381</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>7</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>02</Day></PubDate></JournalIssue><Title>Veterinary sciences</Title><ISOAbbreviation>Vet Sci</ISOAbbreviation></Journal><ArticleTitle>In Vitro Antiviral Activity of the Fungal Metabolite 6-Pentyl-&#x3b1;-Pyrone Against Bovine Coronavirus: A Translational Study to SARS-CoV-2.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">634</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vetsci12070634</ELocationID><Abstract><AbstractText>The recent COVID-19 pandemic has prompted the scientific community to prioritize the discovery of preventive methods and new therapeutics, including the investigation of natural compounds with antiviral potential. Fungal secondary metabolites (SMs) represent a promising source of antiviral drugs due to their structural diversity and intrinsic biocompatibility. Herein, the antiviral activity of 6-pentyl-&#x3b1;-pyrone (6PP) against bovine coronavirus (BCoV) has been evaluated in vitro. Considering that BCoV and SARS-CoV-2 are both members of the <i>Betacoronavirus</i> genus and share several key features, BCoV represents a valuable reference model for human coronavirus research. A non-cytotoxic dose of 6PP was used on MDBK cells to evaluate its antiviral activity against BCoV. Different experimental conditions were employed to examine cell monolayer protection both pre- and post-infection, as well as the potential inhibition of viral internalization. Overall, post-infection 6PP treatment reduced viral load and decreased viral internalization. Results were analyzed using viral titration and quantitative PCR, while data interpretation was performed by statistical software tools. This study presents a novel fluorescence quantification approach with high confidence demonstrated by its significant concordance with RT-qPCR results. These data suggest that 6PP could be an effective antiviral agent for BCoV, warranting further investigation of its role in coronavirus inhibition.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vasinioti</LastName><ForeName>Violetta Iris</ForeName><Initials>VI</Initials><Identifier Source="ORCID">0000-0002-3798-0407</Identifier><AffiliationInfo><Affiliation>Department of Veterinary Medicine, University of Bari, 70010 Valenzano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Odigie</LastName><ForeName>Amienwanlen Eugene</ForeName><Initials>AE</Initials><Identifier Source="ORCID">0000-0002-8546-2997</Identifier><AffiliationInfo><Affiliation>Department of Veterinary Medicine, University of Bari, 70010 Valenzano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lucente</LastName><ForeName>Maria Stella</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Veterinary Medicine, University of Bari, 70010 Valenzano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Del Sorbo</LastName><ForeName>Luca</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Veterinary Medicine and Animal Production, University of Naples Federico II, 80137 Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Catella</LastName><ForeName>Cristiana</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-9594-5255</Identifier><AffiliationInfo><Affiliation>Department of Veterinary Medicine, University of Bari, 70010 Valenzano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Casalino</LastName><ForeName>Elisabetta</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-9330-350X</Identifier><AffiliationInfo><Affiliation>Department of Veterinary Medicine, University of Bari, 70010 Valenzano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salvatore</LastName><ForeName>Maria Michela</ForeName><Initials>MM</Initials><Identifier Source="ORCID">0000-0001-8318-3065</Identifier><AffiliationInfo><Affiliation>Department of Veterinary Medicine and Animal Production, University of Naples Federico II, 80137 Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Staropoli</LastName><ForeName>Alessia</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-8946-1609</Identifier><AffiliationInfo><Affiliation>Department of Agricultural Sciences, University of Naples Federico II, 80055 Portici, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Sustainable Plant Protection, National Research Council, 80055 Portici, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vinale</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-5090-8127</Identifier><AffiliationInfo><Affiliation>Department of Veterinary Medicine and Animal Production, University of Naples Federico II, 80137 Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tempesta</LastName><ForeName>Maria</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-4300-8822</Identifier><AffiliationInfo><Affiliation>Department of Veterinary Medicine, University of Bari, 70010 Valenzano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fiorito</LastName><ForeName>Filomena</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-6658-7807</Identifier><AffiliationInfo><Affiliation>Department of Veterinary Medicine and Animal Production, University of Naples Federico II, 80137 Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andolfi</LastName><ForeName>Anna</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-8949-3654</Identifier><AffiliationInfo><Affiliation>Department of Chemical Science, University of Naples Federico II, 80126 Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buonavoglia</LastName><ForeName>Alessio</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-1044-2027</Identifier><AffiliationInfo><Affiliation>Dental School, Department of Biomedical and Neuromotor Sciences, University of Bologna, 40126 Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pratelli</LastName><ForeName>Annamaria</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-6862-1792</Identifier><AffiliationInfo><Affiliation>Department of Veterinary Medicine, University of Bari, 70010 Valenzano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Capozza</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-5563-1131</Identifier><AffiliationInfo><Affiliation>Department of Veterinary Medicine, University of Bari, 70010 Valenzano, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Project PRIN Prot. 2022WTWB9R</GrantID><Agency>European Union-Next Generation EU</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vet Sci</MedlineTA><NlmUniqueID>101680127</NlmUniqueID><ISSNLinking>2306-7381</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">6-pentyl-&#x3b1;-pyrone</Keyword><Keyword MajorTopicYN="N">BCoV</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">antiviral activity</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>6</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>12</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>12</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>9</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40711294</ArticleId><ArticleId IdType="doi">10.3390/vetsci12070634</ArticleId><ArticleId IdType="pii">vetsci12070634</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40711237</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2079-4991</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>14</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>18</Day></PubDate></JournalIssue><Title>Nanomaterials (Basel, Switzerland)</Title><ISOAbbreviation>Nanomaterials (Basel)</ISOAbbreviation></Journal><ArticleTitle>Wafer-Level Fabrication of Radiofrequency Devices Featuring 2D Materials Integration.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1119</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/nano15141119</ELocationID><Abstract><AbstractText>Two-dimensional (2D) materials have been proposed for use in a multitude of applications, with graphene being one of the most well-known 2D materials. Despite their potential to contribute to innovative solutions, the fabrication of such devices still faces significant challenges. One of the key challenges is the fabrication at a wafer-level scale, a fundamental step for allowing reliable and reproducible fabrication of a large volume of devices with predictable properties. Overcoming this barrier will allow further integration with sensors and actuators, as well as enabling the fabrication of complex circuits based on 2D materials. This work presents the fabrication steps for a process that allows the on-wafer fabrication of active and passive radiofrequency (RF) devices enabled by graphene. Two fabrication processes are presented. In the first one, graphene is transferred to a back gate surface using critical point drying to prevent cracks in the graphene. In the second process, graphene is transferred to a flat surface planarized by ion milling, with the gate being buried beneath the graphene. The fabrication employs a damascene-like process, ensuring a flat surface that preserves the graphene lattice. RF transistors, passive RF components, and antennas designed for backscatter applications are fabricated and measured, illustrating the versatility and potential of the proposed method for 2D material-based RF devices. The integration of graphene on devices is also demonstrated in an antenna. This aimed to demonstrate that graphene can also be used as a passive device. Through this device, it is possible to measure different backscatter responses according to the applied graphene gating voltage, demonstrating the possibility of wireless sensor development. With the proposed fabrication processes, a flat graphene with good quality is achieved, leading to the fabrication of RF active devices (graphene transistors) with intrinsic f<sub>T</sub> and f<sub>max</sub> of 14 GHz and 80 GHz, respectively. Excellent yield and reproducibility are achieved through these methods. Furthermore, since the graphene membranes are grown by Chemical Vapor Deposition (CVD), it is expected that this process can also be applied to other 2D materials.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Silva</LastName><ForeName>Vitor</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>CMEMS-Center for Microelectromechanical Systems, University of Minho, Campus de Azur&#xe9;m, 4800-058 Guimar&#xe3;es, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>LABBELS-Associate Laboratory, 4710-057 Braga, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>INL-International Iberian Nanotechnology Laboratory, Av. Mestre Jos&#xe9; Veiga, 4715-330 Braga, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colmiais</LastName><ForeName>Ivo</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>CMEMS-Center for Microelectromechanical Systems, University of Minho, Campus de Azur&#xe9;m, 4800-058 Guimar&#xe3;es, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>LABBELS-Associate Laboratory, 4710-057 Braga, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>INL-International Iberian Nanotechnology Laboratory, Av. Mestre Jos&#xe9; Veiga, 4715-330 Braga, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dinis</LastName><ForeName>Hugo</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-2394-2119</Identifier><AffiliationInfo><Affiliation>CMEMS-Center for Microelectromechanical Systems, University of Minho, Campus de Azur&#xe9;m, 4800-058 Guimar&#xe3;es, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>LABBELS-Associate Laboratory, 4710-057 Braga, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borme</LastName><ForeName>J&#xe9;r&#xf4;me</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-5622-7760</Identifier><AffiliationInfo><Affiliation>INL-International Iberian Nanotechnology Laboratory, Av. Mestre Jos&#xe9; Veiga, 4715-330 Braga, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alpuim</LastName><ForeName>Pedro</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-9875-6188</Identifier><AffiliationInfo><Affiliation>INL-International Iberian Nanotechnology Laboratory, Av. Mestre Jos&#xe9; Veiga, 4715-330 Braga, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Physics, University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mendes</LastName><ForeName>Paulo M</ForeName><Initials>PM</Initials><Identifier Source="ORCID">0000-0003-2177-7321</Identifier><AffiliationInfo><Affiliation>CMEMS-Center for Microelectromechanical Systems, University of Minho, Campus de Azur&#xe9;m, 4800-058 Guimar&#xe3;es, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>LABBELS-Associate Laboratory, 4710-057 Braga, Portugal.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>SFRH/BD/141462/2018, COVID/BD/153002/2022, SFRH/BD/137529/2018, COVID/BD/153232/2023, UIDB/04436/2020, UIDP/04436/2020</GrantID><Agency>Funda&#xe7;&#xe3;o para a Ci&#xea;ncia e Tecnologia</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Nanomaterials (Basel)</MedlineTA><NlmUniqueID>101610216</NlmUniqueID><ISSNLinking>2079-4991</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">GFET</Keyword><Keyword MajorTopicYN="N">antennas</Keyword><Keyword MajorTopicYN="N">graphene</Keyword><Keyword MajorTopicYN="N">nanofabrication</Keyword><Keyword MajorTopicYN="N">radiofrequency</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>12</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>12</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>9</Hour><Minute>35</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40711237</ArticleId><ArticleId IdType="doi">10.3390/nano15141119</ArticleId><ArticleId IdType="pii">nano15141119</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40711118</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2075-4663</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>7</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>16</Day></PubDate></JournalIssue><Title>Sports (Basel, Switzerland)</Title><ISOAbbreviation>Sports (Basel)</ISOAbbreviation></Journal><ArticleTitle>Trends in Antidepressant, Anxiolytic, and Cannabinoid Use Among Italian Elite Athletes (2011-2023): A Longitudinal Anti-Doping Analysis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">233</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/sports13070233</ELocationID><Abstract><AbstractText>Mental health disorders, particularly depression and anxiety, have become increasingly prevalent among elite athletes, exacerbated by factors such as competitive pressure and the Coronavirus Disease 19 (COVID-19) pandemic. This study analyzes trends in the use of antidepressants, anxiolytics, and cannabinoids (delta-9-tetrahydrocannabinol (THC)/cannabidiol (CBD)) among Italian athletes from 2011 to the first half of 2023 (FH2023), referring to anti-doping reports published by the Italian Ministry of Health. Data from 13,079 athletes were examined, with a focus on non-prohibited medications, banned substances, and regulatory impacts, including threshold adjustments for THC since 2013 and the legalization of CBD. The results show fluctuating use of antidepressants/anxiolytics, with peaks in 2021 and the FH2023, coinciding with post-pandemic awareness. Positive THC cases rose following regulatory changes, reflecting socio-cultural trends. Gender disparities emerged, with THC use predominantly among males (e.g., nine males vs. one female in 2013), though female athletes were underrepresented in testing. This study highlights the need for personalized, evidence-based strategies that balance therapeutic efficacy and anti-doping compliance. Clinicians should carefully consider prescribing selective serotonin reuptake inhibitors (SSRIs) and benzodiazepines to address depression and anxiety and should monitor the risks of CBD contamination. Future research should adopt longitudinal, gender-sensitive approaches to refining guidelines and combating stigma in professional sports.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ruggiero</LastName><ForeName>Mario</ForeName><Initials>M</Initials><Identifier Source="ORCID">0009-0000-5359-6301</Identifier><AffiliationInfo><Affiliation>Department of Medical, Human Movement and Well-Being Sciences, University of Naples Parthenope, 80133 Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferrante</LastName><ForeName>Leopoldo</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Economics, Law, Cybersecurity and Sports Sciences, University of Naples Parthenope, 80035 Nola, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tafuri</LastName><ForeName>Domenico</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-5948-1414</Identifier><AffiliationInfo><Affiliation>Department of Medical, Human Movement and Well-Being Sciences, University of Naples Parthenope, 80133 Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meccariello</LastName><ForeName>Rosaria</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-2174-1118</Identifier><AffiliationInfo><Affiliation>Department of Medical, Human Movement and Well-Being Sciences, University of Naples Parthenope, 80133 Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mazzeo</LastName><ForeName>Filomena</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-5217-4710</Identifier><AffiliationInfo><Affiliation>Department of Economics, Law, Cybersecurity and Sports Sciences, University of Naples Parthenope, 80035 Nola, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Sports (Basel)</MedlineTA><NlmUniqueID>101722684</NlmUniqueID><ISSNLinking>2075-4663</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Coronavirus Disease 19 (COVID-19) impact</Keyword><Keyword MajorTopicYN="N">antidepressant</Keyword><Keyword MajorTopicYN="N">antidoping</Keyword><Keyword MajorTopicYN="N">anxiolytics</Keyword><Keyword MajorTopicYN="N">cannabidiol (CBD)</Keyword><Keyword MajorTopicYN="N">cannabinoids</Keyword><Keyword MajorTopicYN="N">delta-9-tetrahydrocannabinol (THC)</Keyword><Keyword MajorTopicYN="N">drugs</Keyword><Keyword MajorTopicYN="N">elite athletes</Keyword><Keyword MajorTopicYN="N">mental health</Keyword><Keyword MajorTopicYN="N">sport</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>12</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>12</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>9</Hour><Minute>34</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40711118</ArticleId><ArticleId IdType="doi">10.3390/sports13070233</ArticleId><ArticleId IdType="pii">sports13070233</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40711104</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2075-4663</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>7</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>07</Day></PubDate></JournalIssue><Title>Sports (Basel, Switzerland)</Title><ISOAbbreviation>Sports (Basel)</ISOAbbreviation></Journal><ArticleTitle>Police Fitness: An International Perspective on Current and Future Challenges.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">219</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/sports13070219</ELocationID><Abstract><AbstractText>Poor officer fitness can lead to decreased occupational task performance, injuries, increased absenteeism, and a variety of negative health sequalae further adding to the challenges of staffing law enforcement agencies. Optimizing the physical fitness for both serving officers and new recruits is critical as their loss is, and will increasingly be, difficult to replace. However, maintaining and recruiting a physically fit workforce faces several challenges. For serving officers, shiftwork is known to decrease motivation to exercise and negatively impact sleep and diet. Additional factors impacting their fitness includes age-related declines in fitness, increasing obesity, long periods of sedentarism, and negative COVID-19 effects. Concurrently, recruiting physically fit recruits is challenged by declining levels of fitness, reduced physical activity, and increasing obesity in community youth. Ability-based training (ABT), individualizing physical conditioning training based on the existing fitness levels of individuals within a group, offers a potential solution for delivering physical conditioning to groups of applicants, recruits, and officers with a range of physical fitness capabilities. Law enforcement agencies should consider implementing ABT during academy training and ongoing fitness maintenance to minimize injury risk and optimize task performance.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Orr</LastName><ForeName>Robin</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-8297-8288</Identifier><AffiliationInfo><Affiliation>Tactical Research Unit, Bond University, Gold Coast 4226, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Health Sciences and Medicine, Bond University, Gold Coast 4226, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Canetti</LastName><ForeName>Elisa F D</ForeName><Initials>EFD</Initials><Identifier Source="ORCID">0000-0002-8358-398X</Identifier><AffiliationInfo><Affiliation>Tactical Research Unit, Bond University, Gold Coast 4226, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Health Sciences and Medicine, Bond University, Gold Coast 4226, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gough</LastName><ForeName>Suzanne</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-1320-3558</Identifier><AffiliationInfo><Affiliation>Tactical Research Unit, Bond University, Gold Coast 4226, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Health Sciences and Medicine, Bond University, Gold Coast 4226, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Macdonald</LastName><ForeName>Kirstin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Tactical Research Unit, Bond University, Gold Coast 4226, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Health Sciences and Medicine, Bond University, Gold Coast 4226, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dulla</LastName><ForeName>Joe</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-0317-5319</Identifier><AffiliationInfo><Affiliation>Tactical Research Unit, Bond University, Gold Coast 4226, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Health Sciences and Medicine, Bond University, Gold Coast 4226, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tactical Athlete Project, Georgia Southern University, Statesboro, GA 30458, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lockie</LastName><ForeName>Robert G</ForeName><Initials>RG</Initials><Identifier Source="ORCID">0000-0002-7038-0294</Identifier><AffiliationInfo><Affiliation>Center for Sport Performance, Department of Kinesiology, California State University, Fullerton, CA 90840, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dawes</LastName><ForeName>J Jay</ForeName><Initials>JJ</Initials><Identifier Source="ORCID">0000-0002-2668-8873</Identifier><AffiliationInfo><Affiliation>Oklahoma State University Tactical Fitness and Nutrition Lab, Oklahoma State University, Stillwater, OK 74078, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blacker</LastName><ForeName>Sam D</ForeName><Initials>SD</Initials><Identifier Source="ORCID">0000-0003-3862-3572</Identifier><AffiliationInfo><Affiliation>Occupational Performance Research Group, Institute of Applied Sciences, University of Chichester, West Sussex PO19 6PE, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Milligan</LastName><ForeName>Gemma S</ForeName><Initials>GS</Initials><AffiliationInfo><Affiliation>School of Psychology, Sport and Health Science, University of Portsmouth, Portsmouth PO1 2ER, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schram</LastName><ForeName>Ben</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-1865-0488</Identifier><AffiliationInfo><Affiliation>Tactical Research Unit, Bond University, Gold Coast 4226, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Health Sciences and Medicine, Bond University, Gold Coast 4226, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Sports (Basel)</MedlineTA><NlmUniqueID>101722684</NlmUniqueID><ISSNLinking>2075-4663</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">capability</Keyword><Keyword MajorTopicYN="N">law enforcement</Keyword><Keyword MajorTopicYN="N">occupational fitness</Keyword><Keyword MajorTopicYN="N">physical fitness</Keyword><Keyword MajorTopicYN="N">recruitment</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>6</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>6</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>12</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>12</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>9</Hour><Minute>34</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40711104</ArticleId><ArticleId IdType="doi">10.3390/sports13070219</ArticleId><ArticleId IdType="pii">sports13070219</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40711073</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2414-6366</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>7</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>15</Day></PubDate></JournalIssue><Title>Tropical medicine and infectious disease</Title><ISOAbbreviation>Trop Med Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Is Ghana Prepared for Another Arboviral Outbreak? Evaluating the 2024 Dengue Fever Outbreak in the Context of Past Yellow Fever, Influenza, and COVID-19 Outbreaks.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">196</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/tropicalmed10070196</ELocationID><Abstract><AbstractText>Arboviruses are a growing concern in many nations. Several reports of arboviral outbreaks have been recorded globally in the past decade alone. Repeated arboviral outbreaks in developing countries have consistently highlighted vulnerabilities in disease surveillance and response systems, exposing critical gaps in early detection, contact tracing, and resource allocation. The 2024 Dengue fever outbreak in Ghana, which recorded 205 confirmed cases out of 1410 suspected cases, underscored the urgent need to evaluate the country's preparedness for arboviral outbreaks, given the detection of competent vectors in the country. A retrospective analysis of Ghana's 2009-2013 pandemic influenza response plan revealed significant deficiencies in emergency preparedness, raising concerns about the country's ability to manage emerging arboviral threats. This review assessed Ghana's current arboviral outbreak response and preparedness by examining (a) the effectiveness of vector control measures, (b) the role of early warning systems in mitigating outbreaks, (c) laboratory support and diagnostic capabilities, and (d) community engagement strategies. It highlights the successes made in previous outbreaks and sheds light on several gaps in Ghana's outbreak response efforts. This review also provides recommendations that can be implemented in many countries across Africa as they brace themselves for any arboviral outbreak.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Appiah</LastName><ForeName>Godfred Amoah</ForeName><Initials>GA</Initials><Identifier Source="ORCID">0009-0006-0118-5141</Identifier><AffiliationInfo><Affiliation>Department of Virology, Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana, Legon, Accra P.O. Box LG 581, Ghana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Babason</LastName><ForeName>Jerry John</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Department of Virology, Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana, Legon, Accra P.O. Box LG 581, Ghana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dziworshie</LastName><ForeName>Anthony Yaw</ForeName><Initials>AY</Initials><AffiliationInfo><Affiliation>Department of Virology, Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana, Legon, Accra P.O. Box LG 581, Ghana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abankwa</LastName><ForeName>Abigail</ForeName><Initials>A</Initials><Identifier Source="ORCID">0009-0003-1123-0135</Identifier><AffiliationInfo><Affiliation>Department of Virology, Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana, Legon, Accra P.O. Box LG 581, Ghana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonney</LastName><ForeName>Joseph Humphrey Kofi</ForeName><Initials>JHK</Initials><Identifier Source="ORCID">0000-0003-0301-8145</Identifier><AffiliationInfo><Affiliation>Department of Virology, Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana, Legon, Accra P.O. Box LG 581, Ghana.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Trop Med Infect Dis</MedlineTA><NlmUniqueID>101709042</NlmUniqueID><ISSNLinking>2414-6366</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Dengue fever virus</Keyword><Keyword MajorTopicYN="N">arbovirus</Keyword><Keyword MajorTopicYN="N">outbreak preparedness</Keyword><Keyword MajorTopicYN="N">outbreak response</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>6</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>12</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>12</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>9</Hour><Minute>34</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40711073</ArticleId><ArticleId IdType="doi">10.3390/tropicalmed10070196</ArticleId><ArticleId IdType="pii">tropicalmed10070196</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40711062</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2414-6366</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>7</Issue><PubDate><Year>2025</Year><Month>Jun</Month><Day>30</Day></PubDate></JournalIssue><Title>Tropical medicine and infectious disease</Title><ISOAbbreviation>Trop Med Infect Dis</ISOAbbreviation></Journal><ArticleTitle>The Factors Influencing the Incidence, Persistence, and Severity of Symptoms After SARS-CoV-2 Infection in Chinese Adults: A Case-Control Study.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">185</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/tropicalmed10070185</ELocationID><Abstract><AbstractText>Following the emergence of COVID-19, breakthrough SARS-CoV-2 infections have demonstrated substantial heterogeneity in both occurrence and clinical severity. This case-control study aimed to elucidate the factors associated with the incidence, duration, and severity of SARS-CoV-2 symptoms among Chinese adults during the Omicron wave. The analysis was based on data from a national COVID-19 surveillance program encompassing six provinces-Jiangsu, Chongqing, Shandong, Hunan, Anhui, and Yunnan-and included both laboratory-confirmed and clinically diagnosed cases. Data were systematically collected between February and April 2023. For each confirmed case, a matched control was selected through simple random sampling, matched on sex, age (&#xb1;5 years), and province of residence. Multivariate logistic regression analyses were employed to assess a range of potential determinants, including demographic characteristics, lifestyle behaviors, and pre-existing medical conditions, in relation to the risk of infection, as well as the persistence and severity of symptoms following SARS-CoV-2 breakthrough infection. A total of 10,426 cases and 10,426 matched controls were included in the final analysis. Among the infected individuals, 963 (9.24%) reported persistent symptoms, while 773 (7.41%) experienced moderate-to-severe clinical manifestations. Occasional alcohol consumption, presence of comorbidities, tea and coffee intake, overweight status, and a longer interval since the last vaccination dose were all significantly associated with increased odds of infection (OR &gt; 1, FDR &lt; 0.05). Conversely, weekly alcohol consumption and smoking were associated with a decreased risk (OR &lt; 1, FDR &lt; 0.05). Female sex was significantly associated with both persistent and moderate-to-severe symptoms. Additional risk factors for prolonged or severe symptoms included older age, being underweight or overweight, a history of immunotherapy, coffee consumption, and the presence of comorbidities. These findings underscore the multifactorial nature of SARS-CoV-2 infection outcomes and highlight the interplay between host characteristics and behavioral factors. The results support the development of personalized prevention strategies aimed at reducing the clinical burden and long-term impact of COVID-19.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Weixiao</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>National Vaccine Innovation Platform and Department of Epidemiology, School of Public Health, Nanjing Medical University, Nanjing 210009, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qi</LastName><ForeName>Runjie</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>National Vaccine Innovation Platform and Department of Epidemiology, School of Public Health, Nanjing Medical University, Nanjing 210009, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jia</LastName><ForeName>Siyue</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, 172 Jiangsu Rd., Nanjing 210009, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Zhihang</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0003-4372-2487</Identifier><AffiliationInfo><Affiliation>China Center for Disease Control and Prevention, Beijing 102206, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pan</LastName><ForeName>Hongxing</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, 172 Jiangsu Rd., Nanjing 210009, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Ming</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-8846-2880</Identifier><AffiliationInfo><Affiliation>NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, 172 Jiangsu Rd., Nanjing 210009, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yuanbao</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, 172 Jiangsu Rd., Nanjing 210009, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Xiaoqiang</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Yunnan Provincial Center for Disease Control and Prevention, Kunming 650022, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Qing</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Chongqing Provincial Center for Disease Control and Prevention, Chongqing 402100, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Shandong Provincial Center for Disease Control and Prevention, Jinan 250014, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Jihai</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-9776-6699</Identifier><AffiliationInfo><Affiliation>Anhui Provincial Center for Disease Control and Prevention, Hefei 230601, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Hao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Hunan Provincial Center for Disease Control and Prevention, Changsha 410153, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Pengfei</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, 172 Jiangsu Rd., Nanjing 210009, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Simin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>School of Public Health, Southeast University, Nanjing 210009, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jingxin</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-7033-5151</Identifier><AffiliationInfo><Affiliation>National Vaccine Innovation Platform and Department of Epidemiology, School of Public Health, Nanjing Medical University, Nanjing 210009, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, 172 Jiangsu Rd., Nanjing 210009, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Public Health, Southeast University, Nanjing 210009, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>82341031</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>82173584</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>82222062</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>BK20220064</GrantID><Agency>Science Fund for Distinguished Young Scholars of Jiangsu Province</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>06</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Trop Med Infect Dis</MedlineTA><NlmUniqueID>101709042</NlmUniqueID><ISSNLinking>2414-6366</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">influence factors</Keyword><Keyword MajorTopicYN="N">persistent symptoms</Keyword><Keyword MajorTopicYN="N">severity symptoms</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>6</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>12</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>12</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>9</Hour><Minute>34</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40711062</ArticleId><ArticleId IdType="doi">10.3390/tropicalmed10070185</ArticleId><ArticleId IdType="pii">tropicalmed10070185</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40711056</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2414-6366</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>7</Issue><PubDate><Year>2025</Year><Month>Jun</Month><Day>24</Day></PubDate></JournalIssue><Title>Tropical medicine and infectious disease</Title><ISOAbbreviation>Trop Med Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Occupational Syndemics in Farmworkers in the Cape Winelands, South Africa.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">179</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/tropicalmed10070179</ELocationID><Abstract><AbstractText>Occupational exposures in the agricultural industry globally have been associated with heightened risk for several diseases. Reports written in South Africa in the last decade have raised awareness of the harsh occupational conditions and human rights abuses suffered by farmworker communities in the wine industry. Despite receiving "fair trade" labels upon reentry into the global market in the 1990s, the working conditions on wine farms in South Africa have remained unchanged and exploitative for centuries. Farmworkers remain dependent on substandard farm housing, have insecure land tenure rights, are exposed to toxic pesticides, are denied access to benefits and unionization, and endure long working hours in harsh environmental conditions with low pay. These occupational conditions are linked to interacting disease clusters: metabolic syndrome, problematic drinking, and communicable diseases including tuberculosis, HIV, and COVID-19. This milieu of interacting diseases with deleterious outcomes is an under-considered occupational syndemic that will likely worsen given both the lasting impacts of COVID-19 and more recent shifts in global public health funding.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bulled</LastName><ForeName>Nicola</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-9699-3937</Identifier><AffiliationInfo><Affiliation>Institute for Collaboration on Health, Intervention, and Policy (InCHIP), University of Connecticut, 2006 Hillside Road, Storrs, CT 06269, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>06</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Trop Med Infect Dis</MedlineTA><NlmUniqueID>101709042</NlmUniqueID><ISSNLinking>2414-6366</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">HIV</Keyword><Keyword MajorTopicYN="N">South Africa</Keyword><Keyword MajorTopicYN="N">occupational health</Keyword><Keyword MajorTopicYN="N">syndemics</Keyword><Keyword MajorTopicYN="N">tuberculosis</Keyword><Keyword MajorTopicYN="N">wine farms</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>6</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>6</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>12</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>12</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>9</Hour><Minute>34</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40711056</ArticleId><ArticleId IdType="doi">10.3390/tropicalmed10070179</ArticleId><ArticleId IdType="pii">tropicalmed10070179</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40711028</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2305-6304</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>7</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>12</Day></PubDate></JournalIssue><Title>Toxics</Title><ISOAbbreviation>Toxics</ISOAbbreviation></Journal><ArticleTitle>Airborne SARS-CoV-2 Detection by ddPCR in Adequately Ventilated Hospital Corridors.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">583</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/toxics13070583</ELocationID><Abstract><AbstractText>Indoors, the infection risk of diseases transmitted through the airborne route is estimated from indoor carbon dioxide (CO<sub>2</sub>) levels. However, the approaches to assess this risk do not account for the airborne concentration of pathogens, among other limitations. In this study, we analyzed the relationship between airborne SARS-CoV-2 levels and environmental parameters. Bioaerosols were sampled (<i>n</i> = 40) in hospital corridors of two wards differing in the COVID-19 severity of the admitted patients. SARS-CoV-2 levels were quantified using droplet digital PCR. SARS-CoV-2 was detected in 60% of the total air samples. The ward where the mildly ill patients were admitted had a higher occupancy, transit of people in the corridor, and CO<sub>2</sub> levels, but there were no significant differences in SARS-CoV-2 detection between wards. The mean CO<sub>2</sub> concentration in the positive samples was 569 &#xb1; 35.6 ppm. Considering all samples, the CO<sub>2</sub> levels in the corridor were positively correlated with patient door openings but inversely correlated with SARS-CoV-2 levels. In conclusion, airborne SARS-CoV-2 can be detected indoors with optimal ventilation, and its levels do not scale with CO<sub>2</sub> concentration in hospital corridors. Therefore, CO<sub>2</sub> assessment should not be interpreted as a surrogate of airborne viral presence in all indoor spaces.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Truyols-Vives</LastName><ForeName>Joan</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-6146-8692</Identifier><AffiliationInfo><Affiliation>Molecular Biology, Health Geography, and One Health Research Group (MolONE), University of the Balearic Islands, 07122 Palma, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonz&#xe1;lez-L&#xf3;pez</LastName><ForeName>Marta</ForeName><Initials>M</Initials><Identifier Source="ORCID">0009-0003-0657-5542</Identifier><AffiliationInfo><Affiliation>Molecular Biology, Health Geography, and One Health Research Group (MolONE), University of the Balearic Islands, 07122 Palma, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colom-Fern&#xe1;ndez</LastName><ForeName>Antoni</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-5041-0778</Identifier><AffiliationInfo><Affiliation>Molecular Biology, Health Geography, and One Health Research Group (MolONE), University of the Balearic Islands, 07122 Palma, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Einsch&#xfc;tz-L&#xf3;pez</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><Identifier Source="ORCID">0009-0000-2390-414X</Identifier><AffiliationInfo><Affiliation>Institute of Biophysics, Department of Natural Sciences and Sustainable Resources, University of Natural Resources and Life Sciences, 1180 Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sala-Llin&#xe0;s</LastName><ForeName>Ernest</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Molecular Biology, Health Geography, and One Health Research Group (MolONE), University of the Balearic Islands, 07122 Palma, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>iRespire Research Group, Health Research Institute of the Balearic Islands, 07020 Palma, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre of Biomedical Research Network in Respiratory Diseases (CIBERES), 28029 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dom&#xe9;nech-S&#xe1;nchez</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-7892-8349</Identifier><AffiliationInfo><Affiliation>Molecular Biology, Health Geography, and One Health Research Group (MolONE), University of the Balearic Islands, 07122 Palma, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a-Baldov&#xed;</LastName><ForeName>Herme</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-8628-2605</Identifier><AffiliationInfo><Affiliation>Molecular Biology, Health Geography, and One Health Research Group (MolONE), University of the Balearic Islands, 07122 Palma, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Chemistry, Universitat Polit&#xe8;cnica de Val&#xe8;ncia, 46022 Val&#xe8;ncia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mercader-Barcel&#xf3;</LastName><ForeName>Josep</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-5293-2809</Identifier><AffiliationInfo><Affiliation>Molecular Biology, Health Geography, and One Health Research Group (MolONE), University of the Balearic Islands, 07122 Palma, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>iRespire Research Group, Health Research Institute of the Balearic Islands, 07020 Palma, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre of Biomedical Research Network in Respiratory Diseases (CIBERES), 28029 Madrid, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>COVID19-25</GrantID><Agency>Health Research Institute of the Balearic Islands</Agency><Country/></Grant><Grant><GrantID>AP_2021_032</GrantID><Agency>Regional Ministry of European funds, University and Culture of the Balearic Islands</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Toxics</MedlineTA><NlmUniqueID>101639637</NlmUniqueID><ISSNLinking>2305-6304</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">airborne transmission</Keyword><Keyword MajorTopicYN="N">bioaerosol</Keyword><Keyword MajorTopicYN="N">carbon dioxide</Keyword><Keyword MajorTopicYN="N">ddPCR</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>12</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>12</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>9</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40711028</ArticleId><ArticleId IdType="doi">10.3390/toxics13070583</ArticleId><ArticleId IdType="pii">toxics13070583</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40710986</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2305-6304</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>7</Issue><PubDate><Year>2025</Year><Month>Jun</Month><Day>27</Day></PubDate></JournalIssue><Title>Toxics</Title><ISOAbbreviation>Toxics</ISOAbbreviation></Journal><ArticleTitle>Application of a Dynamic Exposure Population Toxicokinetic Model for Perfluorooctane Sulfonic Acid (PFOS) and Extension to Perfluorodecanoic Acid (PFDA) at a North American Beef Cattle Farm with a History of Biosolids Land Application.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">541</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/toxics13070541</ELocationID><Abstract><AbstractText>Historical application of wastewater treatment sludge (biosolids) has introduced per- and polyfluoroalkyl substances (PFAS) into agricultural systems and led to contamination of crops and livestock. Previous work validated a dynamic exposure and population toxicokinetic (DE_PopTK) modeling approach for estimating perfluorooctane sulfonic acid (PFOS) and perfluorohexane sulfonic acid (PFHxS) concentrations in cattle tissues at sites primarily dominated by water contamination. This work expands the efforts to validate the DE_PopTK model at a self-contained beef farm in Maine with PFAS exposures from feed grown on site where soil is contaminated from historical biosolids applications. The model is also extended to estimate perfluorodecanoic acid (PFDA) exposure and tissue levels. Farm-specific data were obtained to consider farm management practices, spatial variation of PFAS in soil, animal growth, and seasonal and annual variability in estimating daily exposures based on water, feed, and soil intake. A dynamic exposure pattern was observed as cattle accumulated PFAS while consuming feed grown on contaminated land and eliminated it while grazing on non-contaminated pastures. Model-estimated PFOS and PFDA levels in serum and muscle were in good agreement with biomonitoring data collected at the farm over a four-year period to reflect periods of accumulation and depuration, with the percentage error ranging from 16% to 73% when comparing modeled and measured data. Our findings demonstrated that understanding farm exposures and collecting site-specific data were integral to model performance. The model was applied to simulate management strategies and complement economic analyses to demonstrate that, with modifications to management practices, it is feasible for the farm to achieve lower PFOS and PFDA levels in beef and maintain economic viability despite elevated PFAS soil levels.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Astmann</LastName><ForeName>Barbara A</ForeName><Initials>BA</Initials><Identifier Source="ORCID">0000-0002-5683-2215</Identifier><AffiliationInfo><Affiliation>Maine Center for Disease Control and Prevention, Augusta, ME 04333, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mikkonen</LastName><ForeName>Antti T</ForeName><Initials>AT</Initials><Identifier Source="ORCID">0000-0002-9941-0987</Identifier><AffiliationInfo><Affiliation>Environment Protection Authority (EPA) Victoria, Centre for Applied Sciences, Macleod, VIC 3085, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simones</LastName><ForeName>Thomas L</ForeName><Initials>TL</Initials><Identifier Source="ORCID">0009-0001-4400-4746</Identifier><AffiliationInfo><Affiliation>Maine Center for Disease Control and Prevention, Augusta, ME 04333, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flanagan</LastName><ForeName>Meghan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Agriculture, Conservation and Forestry, Augusta, ME 04333, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pfaehler</LastName><ForeName>Duncan</ForeName><Initials>D</Initials><Identifier Source="ORCID">0009-0002-6745-1343</Identifier><AffiliationInfo><Affiliation>Department of Agriculture, Conservation and Forestry, Augusta, ME 04333, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lenov</LastName><ForeName>Ivan</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0003-0752-4926</Identifier><AffiliationInfo><Affiliation>U.S. Department of Agriculture Food Safety and Inspection Service, Saint Louis, MO 63120, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Andrew E</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>Maine Center for Disease Control and Prevention, Augusta, ME 04333, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Public Health Infrastructure, Workforce and Data Systems Grant Award # NE11OE000003, and the Cooperative Agreement for Emergency Response: Public Health Crisis Response-2018, COVID Public Health Workforce Supplemental, Award # NU90TP922141.</GrantID><Agency>United States Center for Disease Control and Prevention</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>06</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Toxics</MedlineTA><NlmUniqueID>101639637</NlmUniqueID><ISSNLinking>2305-6304</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">biosolids</Keyword><Keyword MajorTopicYN="N">body burden</Keyword><Keyword MajorTopicYN="N">cattle</Keyword><Keyword MajorTopicYN="N">dynamic exposure</Keyword><Keyword MajorTopicYN="N">food safety</Keyword><Keyword MajorTopicYN="N">perfluorodecanoic acid (PFDA)</Keyword><Keyword MajorTopicYN="N">perfluorooctane sulfonic acid (PFOS)</Keyword><Keyword MajorTopicYN="N">risk management</Keyword><Keyword MajorTopicYN="N">toxicokinetics</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>6</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>12</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>12</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>9</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40710986</ArticleId><ArticleId IdType="doi">10.3390/toxics13070541</ArticleId><ArticleId IdType="pii">toxics13070541</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40710982</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2305-6304</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>7</Issue><PubDate><Year>2025</Year><Month>Jun</Month><Day>26</Day></PubDate></JournalIssue><Title>Toxics</Title><ISOAbbreviation>Toxics</ISOAbbreviation></Journal><ArticleTitle>Presence and Dermal Exposure to Benzene and Acetaldehyde in Hand Sanitizers Available in Taiwan.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">537</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/toxics13070537</ELocationID><Abstract><AbstractText>The widespread use of alcohol-based hand sanitizers (ABHS) during and after the COVID-19 pandemic has raised concerns about potential exposure to harmful volatile organic compounds (VOCs), such as benzene, acetaldehyde, and other impurities, which may pose health risks. This study investigated the concentrations of ethanol, isopropanol, and 12 impurities, including benzene, acetaldehyde, and methanol, in 85 commercially available ABHS products in Taiwan using gas chromatography-mass spectrometry (GC-MS). The results revealed that 12 samples contained alcohol concentrations below the recommended 60% (<i>v</i>/<i>v</i>) threshold. Benzene and acetaldehyde were identified as the primary impurities, with mean concentrations of 0.84 &#x3bc;g/g and 22.39 &#x3bc;g/g, respectively, exceeding the US FDA interim limits. For frequent ABHS users, the average dermal exposure doses (DEDs) to benzene ranged from 3.17 &#xd7; 10<sup>-2</sup> to 15.5 &#x3bc;g/kg-bw/day, with children aged 2-11 years showing the highest non-carcinogenic risk (Hazard Quotient &gt; 1) and cancer risk (6.37 &#xd7; 10<sup>-5</sup> to 9.33 &#xd7; 10<sup>-4</sup>). The findings emphasize the need for stringent quality control of ABHS products and caution in their selection and use. This study provides critical insights into the health risks associated with ABHS in Taiwan, underscoring the importance of regulatory oversight to ensure consumer safety.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Chieh-An</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Institute of Environmental and Occupational Health Sciences, College of Public Health, National Taiwan University, No. 17, Xuzhou Road, Taipei 100, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Shih-Wei</ForeName><Initials>SW</Initials><Identifier Source="ORCID">0000-0001-8963-2183</Identifier><AffiliationInfo><Affiliation>Institute of Environmental and Occupational Health Sciences, College of Public Health, National Taiwan University, No. 17, Xuzhou Road, Taipei 100, Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MOST 111-2314-B-002-096-MY3</GrantID><Agency>National Science and Technology Council</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>06</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Toxics</MedlineTA><NlmUniqueID>101639637</NlmUniqueID><ISSNLinking>2305-6304</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">alcohol-based hand sanitizers</Keyword><Keyword MajorTopicYN="N">health risk assessment</Keyword><Keyword MajorTopicYN="N">impurities</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>6</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>12</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>12</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>9</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40710982</ArticleId><ArticleId IdType="doi">10.3390/toxics13070537</ArticleId><ArticleId IdType="pii">toxics13070537</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40710948</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2039-4403</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>7</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>14</Day></PubDate></JournalIssue><Title>Nursing reports (Pavia, Italy)</Title><ISOAbbreviation>Nurs Rep</ISOAbbreviation></Journal><ArticleTitle>Nurse-Led Bereavement Support During the Time of Hospital Visiting Restrictions Imposed by the COVID-19 Pandemic-A Qualitative Study of Family Members' Experiences.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">254</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/nursrep15070254</ELocationID><Abstract><AbstractText><b>Objectives</b>: This study aims to explore the experiences of bereaved family members during and after the loss of a relative in an intensive care unit (ICU) during the COVID-19 pandemic-related visitation restrictions, as well as to assess their perceptions of a nurse-led bereavement support programme. <b>Methods</b>: Ten participants with a relative who had died in an ICU were recruited in September 2020 during a follow-up bereavement meeting at a tertiary cardiac centre in Switzerland. Descriptive qualitative research was conducted. Face-to-face nurse-led follow-up bereavement meetings, adapted to the pandemic circumstances and conducted as semi-structured interviews, were analysed by a thematic analysis. <b>Findings</b>: Fifteen sub-themes and three main categories were identified. The motivation behind the family members' participation in the meetings was to ask and learn about their experiences regarding the death of their relative during this abnormal time. The reactions to the meetings varied among the families. Many expressed that the experience of bereavement was particularly challenging and painful, and that the absence of a final farewell to their loved one, as well as the impossibility of having a formally held funeral, made the deaths harder to accept. The families appreciated the interview as it gave them clarification, information, and an awareness of the facts and the care provided, and for several of them it was also a chance to share their emotions and express any difficulties they might have encountered both during and after the patient's death. <b>Conclusion</b>: The COVID-19 pandemic's restrictions had a profound impact on families who lost a loved one in an ICU. The nurse-led bereavement support service responded to the needs of grieving families, providing valuable emotional and practical support and re-establishing a healthy relationship between the families and the caregivers that was hindered by pandemic restrictions. The study also shows that a nurse-led bereavement support service can be a valuable component of family-centred care.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Villa</LastName><ForeName>Michele</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-0898-8127</Identifier><AffiliationInfo><Affiliation>Department of Intensive Care, Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale, Via Tesserete 48, 6900 Lugano, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palermo</LastName><ForeName>Annunziata</ForeName><Initials>A</Initials><Identifier Source="ORCID">0009-0001-4548-3902</Identifier><AffiliationInfo><Affiliation>Department of Intensive Care, Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale, Via Tesserete 48, 6900 Lugano, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montemarano</LastName><ForeName>Dora Gallo</ForeName><Initials>DG</Initials><Identifier Source="ORCID">0009-0001-6877-0904</Identifier><AffiliationInfo><Affiliation>Department of Intensive Care, Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale, Via Tesserete 48, 6900 Lugano, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bottega</LastName><ForeName>Michela</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-5482-641X</Identifier><AffiliationInfo><Affiliation>Chief Nurse's Office, Department of Healthcare Professions, Azienda Unita Locale Socio Sanitaria (AULSS) 2 Marca Trevigiana, Via Sant'Ambrogio di Fiera 37, 31100 Treviso, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deelen</LastName><ForeName>Paula</ForeName><Initials>P</Initials><Identifier Source="ORCID">0009-0004-5092-3871</Identifier><AffiliationInfo><Affiliation>Department of Intensive Care, Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale, Via Tesserete 48, 6900 Lugano, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grassellini</LastName><ForeName>Paola Rusca</ForeName><Initials>PR</Initials><Identifier Source="ORCID">0009-0004-1007-5150</Identifier><AffiliationInfo><Affiliation>Department of Intensive Care, Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale, Via Tesserete 48, 6900 Lugano, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bernasconi</LastName><ForeName>Stefano</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-6048-5159</Identifier><AffiliationInfo><Affiliation>Chief Nurse's Office, Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale, Via Tesserete 48, 6900 Lugano, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cassina</LastName><ForeName>Tiziano</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-9700-1584</Identifier><AffiliationInfo><Affiliation>Department of Intensive Care, Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale, Via Tesserete 48, 6900 Lugano, Switzerland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Nurs Rep</MedlineTA><NlmUniqueID>101592662</NlmUniqueID><ISSNLinking>2039-439X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">bereaved</Keyword><Keyword MajorTopicYN="N">family</Keyword><Keyword MajorTopicYN="N">follow-up</Keyword><Keyword MajorTopicYN="N">intensive care unit</Keyword><Keyword MajorTopicYN="N">qualitative research</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>12</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>12</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>9</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40710948</ArticleId><ArticleId IdType="doi">10.3390/nursrep15070254</ArticleId><ArticleId IdType="pii">nursrep15070254</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40710934</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2039-4403</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>7</Issue><PubDate><Year>2025</Year><Month>Jun</Month><Day>29</Day></PubDate></JournalIssue><Title>Nursing reports (Pavia, Italy)</Title><ISOAbbreviation>Nurs Rep</ISOAbbreviation></Journal><ArticleTitle>Quiet Quitting Among Nurses: A Case Study in a Northern Italian Hospital.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">239</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/nursrep15070239</ELocationID><Abstract><AbstractText><b>Background/Objectives:</b> Quiet Quitting (QQ) describes a state of reduced workplace engagement characterized by a lack of motivation and initiative. Employees practicing QQ typically limit their efforts to fulfilling only their assigned tasks, expending the minimum necessary energy, while still ensuring the completion of their core responsibilities. QQ is an emerging phenomenon in healthcare settings following the COVID-19 pandemic and is still relatively unexplored in the literature. The aim of this study is to assess QQ among nurses in a northern Italian hospital. <b>Methods:</b> A cross-sectional study with a convenience sample of 91 nurses in a single-specialist orthopedic hospital was conducted. Data were collected in August 2024 using an online form of the Quiet Quitting Scale (QQS). Demographic data were collected, including gender, age, years of work experience and department. <b>Results:</b> A response rate of 83.50% was recorded. Data analysis revealed that 46.06% of the sample (35 nurses) was identified as quiet quitters. Fewer years of service and a younger age were associated with a higher probability of Quiet Quitting. The highest average score was observed for "Lack of motivation" subscale at 2.40 (SD = 1.14). <b>Conclusions:</b> The findings establish QQ as a significant issue requiring urgent attention in healthcare. To guarantee high-quality nursing care, healthcare organizations must prioritize interventions focused on enhancing employee support and work environment. Longitudinal research is necessary to explore the long-term effects of QQ on patient outcomes and to evaluate the success of targeted interventions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rinaldi</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>IRRCS Rizzoli Orthopaedic Institute, 40136 Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pomarolli</LastName><ForeName>Ester</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Hospital of Bolzano (SABES-ASDAA), 39100 Bolzano, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>06</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Nurs Rep</MedlineTA><NlmUniqueID>101592662</NlmUniqueID><ISSNLinking>2039-439X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">nurses</Keyword><Keyword MajorTopicYN="N">nursing</Keyword><Keyword MajorTopicYN="N">quiet quitting</Keyword><Keyword MajorTopicYN="N">satisfaction</Keyword><Keyword MajorTopicYN="N">workplace</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>5</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>5</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>12</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>12</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>9</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40710934</ArticleId><ArticleId IdType="doi">10.3390/nursrep15070239</ArticleId><ArticleId IdType="pii">nursrep15070239</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40710841</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2571-841X</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>2</Issue><PubDate><Year>2025</Year><Month>Apr</Month><Day>16</Day></PubDate></JournalIssue><Title>Reports (MDPI)</Title><ISOAbbreviation>Reports (MDPI)</ISOAbbreviation></Journal><ArticleTitle>A Rare Case of Cerebral Venous Sinus Thrombosis Following the Second Dose of BNT162b2 mRNA COVID-19 Vaccine-Just a Coincidence? A Case Report.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">50</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/reports8020050</ELocationID><Abstract><AbstractText><b>Background and Clinical Significance:</b> The occurrence of cerebral venous sinus thrombosis (CVST), both with or without thrombocytopenia, following COVID-19 vaccination, is well documented and more common in recipients of vector vaccines. Cases of CVST following immunization with the COVID-19 messenger RNA (mRNA) vaccine are rare; most of these cases occur within 28 days of the first dose of the vaccine. <b>Case Presentation:</b> We present the case of a 38-year-old male with a history of two episodes of deep vein thrombosis in the lower limbs, but without a specific thrombophilic condition, who developed CVST 13 days after the second dose of the Pfizer/BioNTech BNT162b2 vaccine. He suffered from diffuse tension-type headache of progressively increasing intensity, and his objective neurological findings were normal. Magnetic resonance venography showed thrombosis of the transverse and right sigmoid sinuses, and magnetic resonance imaging (MRI) of the brain revealed no cerebral infarction. Two months later, a follow-up MR venography showed partial recanalization of the affected sinuses, and a brain MRI showed no infarction. <b>Conclusions:</b> Given the temporal sequence and the absence of other possible causes, we speculate that the second dose of the COVID-19 BNT162b2 vaccine may have triggered the development of CVST.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Maty&#xe1;&#x161;</LastName><ForeName>David</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-6278-8057</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Comprehensive Stroke Centre, University Hospital Hradec Kr&#xe1;lov&#xe9;, CZ-500 05 Hradec Kr&#xe1;lov&#xe9;, Czech Republic.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Faculty of Medicine in Hradec Kr&#xe1;lov&#xe9;, Charles University, CZ-500 03 Hradec Kr&#xe1;lov&#xe9;, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herzig</LastName><ForeName>Roman</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-7238-7724</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Comprehensive Stroke Centre, University Hospital Hradec Kr&#xe1;lov&#xe9;, CZ-500 05 Hradec Kr&#xe1;lov&#xe9;, Czech Republic.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Faculty of Medicine in Hradec Kr&#xe1;lov&#xe9;, Charles University, CZ-500 03 Hradec Kr&#xe1;lov&#xe9;, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#x160;im&#x16f;nek</LastName><ForeName>Libor</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-2606-2686</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Comprehensive Stroke Centre, University Hospital Hradec Kr&#xe1;lov&#xe9;, CZ-500 05 Hradec Kr&#xe1;lov&#xe9;, Czech Republic.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Faculty of Medicine in Hradec Kr&#xe1;lov&#xe9;, Charles University, CZ-500 03 Hradec Kr&#xe1;lov&#xe9;, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abuhajar</LastName><ForeName>Mohamed</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Radiology, Comprehensive Stroke Centre, University Hospital Hradec Kr&#xe1;lov&#xe9;, CZ-500 05 Hradec Kr&#xe1;lov&#xe9;, Czech Republic.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology, Faculty of Medicine in Hradec Kr&#xe1;lov&#xe9;, Charles University, CZ-500 03 Hradec Kr&#xe1;lov&#xe9;, Czech Republic.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>DRO - UHHK 00179906</GrantID><Agency>Ministry of Health of the Czech Republic</Agency><Country/></Grant><Grant><GrantID>Cooperatio Program, research area NEUR</GrantID><Agency>Charles University</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>04</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Reports (MDPI)</MedlineTA><NlmUniqueID>101757880</NlmUniqueID><ISSNLinking>2571-841X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">case report</Keyword><Keyword MajorTopicYN="N">cerebral venous sinus thrombosis</Keyword><Keyword MajorTopicYN="N">mRNA vaccine</Keyword><Keyword MajorTopicYN="N">vaccination</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>2</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>4</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>12</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>12</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>9</Hour><Minute>32</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40710841</ArticleId><ArticleId IdType="doi">10.3390/reports8020050</ArticleId><ArticleId IdType="pii">reports8020050</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40710840</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2571-841X</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>2</Issue><PubDate><Year>2025</Year><Month>Apr</Month><Day>14</Day></PubDate></JournalIssue><Title>Reports (MDPI)</Title><ISOAbbreviation>Reports (MDPI)</ISOAbbreviation></Journal><ArticleTitle>Spontaneous Abdominal Wall Hematoma Following Violent Cough: A Rare but Severe Condition-Surgical Challenges and Outcomes Regarding Three Cases and a Literature Review.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">49</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/reports8020049</ELocationID><Abstract><AbstractText><b>Background and Clinical Significance:</b> Spontaneous abdominal wall hematoma following violent coughing is a rare condition that poses a sometimes difficult therapeutic challenge, with surgical intervention often necessary in severe cases. This report aims to shed light on this rare but severe affection and raise the medical community's interest by detailing the pathophysiology, management strategies, and outcome of spontaneous abdominal wall hematoma. <b>Case Presentation:</b> The basis for our paper was a comprehensive retrospective analysis of three cases treated in our surgical departments. We rigorously reviewed their clinical notes and imaging examinations to ensure the accuracy and reliability of our findings. <b>Conclusions:</b> These case reports underscore the challenging nature of such hematomas. Clinicians should be aware of this pathology, as it can be life-threatening. Our successful management of these cases shows that it is possible to effectively manage difficult clinical situations with timely intervention.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ungureanu</LastName><ForeName>Claudiu Octavian</ForeName><Initials>CO</Initials><AffiliationInfo><Affiliation>Faculty of Dental Medicine, "Carol Davila" University of Medicine and Pharmacy, 37 Dionisie Lupu Street, 020021 Bucharest, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>General Surgery Department, "Sf. Ioan" Clinical Emergency Hospital, 13 Vitan-B&#xe2;rze&#x15f;ti Road, 042122 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>St&#x103;nculea</LastName><ForeName>Floris Cristian</ForeName><Initials>FC</Initials><Identifier Source="ORCID">0009-0005-5366-5684</Identifier><AffiliationInfo><Affiliation>Faculty of Dental Medicine, "Carol Davila" University of Medicine and Pharmacy, 37 Dionisie Lupu Street, 020021 Bucharest, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>General Surgery Department, "Sf. Ioan" Clinical Emergency Hospital, 13 Vitan-B&#xe2;rze&#x15f;ti Road, 042122 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iordache</LastName><ForeName>Alexandru</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Faculty of Dental Medicine, "Carol Davila" University of Medicine and Pharmacy, 37 Dionisie Lupu Street, 020021 Bucharest, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>"Professor Doctor Theodor Burghele" Clinical Hospital, 20 Panduri Road, 050659 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burleanu</LastName><ForeName>Cosmin</ForeName><Initials>C</Initials><Identifier Source="ORCID">0009-0008-1294-7388</Identifier><AffiliationInfo><Affiliation>General Surgery Department, "Bagdasar-Arseni" Clinical Emergency Hospital, 12 Berceni Road, 041915 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grigorean</LastName><ForeName>Valentin Titus</ForeName><Initials>VT</Initials><AffiliationInfo><Affiliation>Faculty of Dental Medicine, "Carol Davila" University of Medicine and Pharmacy, 37 Dionisie Lupu Street, 020021 Bucharest, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>General Surgery Department, "Bagdasar-Arseni" Clinical Emergency Hospital, 12 Berceni Road, 041915 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ginghina</LastName><ForeName>Octav</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Faculty of Dental Medicine, "Carol Davila" University of Medicine and Pharmacy, 37 Dionisie Lupu Street, 020021 Bucharest, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery 3, "Prof. Dr. Al. Trestioreanu" Institute of Oncology Bucharest, 022328 Bucharest, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li&#x21b;escu</LastName><ForeName>Mircea</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-6022-2236</Identifier><AffiliationInfo><Affiliation>Faculty of Dental Medicine, "Carol Davila" University of Medicine and Pharmacy, 37 Dionisie Lupu Street, 020021 Bucharest, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>General Surgery Department, "Sf. Ioan" Clinical Emergency Hospital, 13 Vitan-B&#xe2;rze&#x15f;ti Road, 042122 Bucharest, Romania.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>04</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Reports (MDPI)</MedlineTA><NlmUniqueID>101757880</NlmUniqueID><ISSNLinking>2571-841X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">abdominal wall hematoma</Keyword><Keyword MajorTopicYN="N">computed tomography</Keyword><Keyword MajorTopicYN="N">cough</Keyword><Keyword MajorTopicYN="N">hematoma</Keyword><Keyword MajorTopicYN="N">surgery</Keyword><Keyword MajorTopicYN="N">ultrasonography</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>4</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>4</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>12</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>12</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>9</Hour><Minute>32</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40710840</ArticleId><ArticleId IdType="doi">10.3390/reports8020049</ArticleId><ArticleId IdType="pii">reports8020049</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40710798</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2308-3425</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>7</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>17</Day></PubDate></JournalIssue><Title>Journal of cardiovascular development and disease</Title><ISOAbbreviation>J Cardiovasc Dev Dis</ISOAbbreviation></Journal><ArticleTitle>Plasma Soluble ST2 as a Prognostic Biomarker for Cardiovascular Events and Mortality in COVID-19 Patients.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">273</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/jcdd12070273</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Coronavirus disease 2019 (COVID-19) is frequently complicated by cardiovascular involvement. Soluble growth stimulation-expressed gene 2 (sST2) is a promising cardiovascular biomarker, but its prognostic value in COVID-19 remains unclear.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This retrospective cohort study included 314 hospitalized COVID-19 patients classified into mild/moderate (<i>n</i> = 168) and severe/critical (<i>n</i> = 146). Plasma sST2 were measured using an enzyme-linked immunosorbent assay. Correlation analyses evaluated associations between sST2 and clinical parameters. Cox regression assessed the independent predictive value for cardiovascular events and all-cause mortality.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">sST2 levels were significantly higher in severe/critical patients (16.877 ng/mL) than in mild/moderate cases (6.189 ng/mL) and healthy controls (4.003 ng/mL). sST2 positively correlated with cardiac injury markers (cTnI, CK-Mb, NT-proBNP), inflammatory indices (IL-1&#x3b2;, hsCRP), D-dimer, and inversely correlated with a left ventricular ejection fraction (r = -0.86). Elevated sST2 independently predicted cardiovascular events (HR = 2.972) and mortality (HR = 4.681). The Kaplan-Meier survival analysis demonstrated higher cardiovascular event rates and lower survival probabilities in patients with elevated sST2. The ROC curve indicated sST2 outperformed cTnI and NT-proBNP in predicting cardiovascular events (AUC = 0.898) and mortality (AUC = 0.871).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Elevated sST2 is associated with myocardial injury, inflammation, and poor prognosis in COVID-19, supporting its value for risk stratification.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Yongcui</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-0705-2087</Identifier><AffiliationInfo><Affiliation>Division of Cardiology and Hubei Key Laboratory of Genetics and Molecular Mechanisms of Cardiological Disorders, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhuang</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0009-0004-1962-0530</Identifier><AffiliationInfo><Affiliation>Division of Cardiology and Hubei Key Laboratory of Genetics and Molecular Mechanisms of Cardiological Disorders, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Huihui</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Cardiology and Hubei Key Laboratory of Genetics and Molecular Mechanisms of Cardiological Disorders, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Dao Wen</ForeName><Initials>DW</Initials><AffiliationInfo><Affiliation>Division of Cardiology and Hubei Key Laboratory of Genetics and Molecular Mechanisms of Cardiological Disorders, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2022YFC3400700</GrantID><Agency>National Key Research and Development Program of China</Agency><Country/></Grant><Grant><GrantID>82241034</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>82370397</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>31971358</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>U22A20266</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>C-0052</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>J Cardiovasc Dev Dis</MedlineTA><NlmUniqueID>101651414</NlmUniqueID><ISSNLinking>2308-3425</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">cardiovascular events</Keyword><Keyword MajorTopicYN="N">prognosis</Keyword><Keyword MajorTopicYN="N">soluble ST2</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>12</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>12</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>9</Hour><Minute>25</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40710798</ArticleId><ArticleId IdType="doi">10.3390/jcdd12070273</ArticleId><ArticleId IdType="pii">jcdd12070273</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40710380</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2075-4426</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>7</Issue><PubDate><Year>2025</Year><Month>Jun</Month><Day>20</Day></PubDate></JournalIssue><Title>Journal of personalized medicine</Title><ISOAbbreviation>J Pers Med</ISOAbbreviation></Journal><ArticleTitle>Pleural Empyema in Spain (2016-2022): A Nationwide Study on Trends in Hospitalizations, Mortality, and Impact of Comorbidities.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">263</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/jpm15070263</ELocationID><Abstract><AbstractText><b>Background</b>: Pleural empyema (PE) is a major cause of morbidity and mortality worldwide. This study aimed to analyze the epidemiological characteristics of patients hospitalized for PE in Spain between 2016 and 2022. <b>Methods</b>: This retrospective observational study of PE cases was based on the hospital discharge records from the National Health System between 2016 and 2022. The variables analyzed were sex, age, comorbidities, discharge diagnoses and procedures, overall severity, whether empyema was a primary or secondary diagnosis, admission to the intensive care unit (ICU), length of stay (LOS), in-hospital mortality, and healthcare costs. <b>Results</b>: Between 2016 and 2022, 19864 PE cases were diagnosed in Spain, revealing an overall rate of 0.64 per 1000 hospitalizations, with the exception of a slight decline in 2021. The mean age of the patients with PE was 61 years, and 73.85% were men. Most patients had low comorbidities, with a median Charlson comorbidity index (CCI) of 1.7. Most cases (63%) involved secondary diagnoses (pneumonia, pneumococcal pneumonia, sepsis, COVID, or lung cancer). The in-hospital mortality rate was higher in the secondary diagnosis group than in the primary diagnosis group (13.4% vs. 6.2%, respectively, <i>p</i> &lt; 0.001). The factors associated with increased mortality included older age (&#x2265;66 years), higher CCI scores, ICU admission, and shorter LOS (&lt;10 days). Conversely, pleural drainage and pneumonia as secondary diagnoses were protective factors. <b>Conclusions</b>: PE is an increasingly common pathology in clinical practice, especially in older and frail patients. It is associated with high morbidity and mortality, and its prognosis worsens with age and comorbidities. Therefore, early and appropriate diagnosis and standardized management strategies are required to mitigate the mortality and healthcare costs.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Perez-de-Paz</LastName><ForeName>Bego&#xf1;a</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Pneumology, Hospital Universitario de Mostoles, 28935 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fernandez-Cotarelo</LastName><ForeName>Maria-Jose</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">0000-0002-8072-6965</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Hospital Universitario de Mostoles, 28935 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Specialties and Public Health, Faculty of Health Sciences, Universidad Rey Juan Carlos, 28922 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodriguez-Romero</LastName><ForeName>Lydia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Pneumology, Hospital Universitario de Mostoles, 28935 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ribeiro-Neves-Pinto</LastName><ForeName>Carolina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Medical Specialties and Public Health, Faculty of Health Sciences, Universidad Rey Juan Carlos, 28922 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quilez-Ruiz-Rico</LastName><ForeName>Natividad</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Pneumology, Hospital Universitario de Mostoles, 28935 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#xc1;lvaro-&#xc1;lvarez</LastName><ForeName>Dolores</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Pneumology, Hospital Universitario de Mostoles, 28935 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moreno-Cuerda</LastName><ForeName>Victor</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Hospital Universitario de Mostoles, 28935 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, Universidad Francisco de Vitoria, 28223 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henriquez-Camacho</LastName><ForeName>Cesar</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-6714-5840</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Hospital Universitario de Mostoles, 28935 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Specialties and Public Health, Faculty of Health Sciences, Universidad Rey Juan Carlos, 28922 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, Universidad Francisco de Vitoria, 28223 Madrid, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>06</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>J Pers Med</MedlineTA><NlmUniqueID>101602269</NlmUniqueID><ISSNLinking>2075-4426</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Spain</Keyword><Keyword MajorTopicYN="N">comorbidity pneumonia</Keyword><Keyword MajorTopicYN="N">mortality</Keyword><Keyword MajorTopicYN="N">pleural drainage</Keyword><Keyword MajorTopicYN="N">pleural empyema</Keyword><Keyword MajorTopicYN="N">prognosis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>4</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>5</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>12</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>12</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>9</Hour><Minute>22</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40710380</ArticleId><ArticleId IdType="doi">10.3390/jpm15070263</ArticleId><ArticleId IdType="pii">jpm15070263</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40710346</PMID><DateCompleted><Year>2025</Year><Month>07</Month><Day>25</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2073-4409</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>14</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>17</Day></PubDate></JournalIssue><Title>Cells</Title><ISOAbbreviation>Cells</ISOAbbreviation></Journal><ArticleTitle>Evolution of Blood Innate Immune Cell Phenotypes Following SARS-CoV-2 Infection in Hospitalized Patients with COVID-19.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1093</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/cells14141093</ELocationID><Abstract><AbstractText>Innate immune cells appear to have an important implication in the resolution and/or the aggravation of the COVID-19 pathogenesis after infection with SARS-CoV-2. To better appreciate the role of these cells during COVID-19, changes in blood eosinophil, the neutrophil and monocyte count, and levels of surface protein markers have been reported. However, analyses at several timepoints of multiple surface markers on granulocytes and monocytes over a period of one month after a SARS-CoV-2 infection are missing. Therefore, in this study, we performed blood eosinophil, neutrophil, and monocyte phenotyping using a list of surface proteins and flow cytometry during a period of 30 days after the hospitalization of patients with severe SARS-CoV-2 infections. Blood cell counts were reported at seven different timepoints over the 30-day period as well as measures of multiple mediators in serum using a targeted multiplex assay approach. Our results indicate a 95% drop in the blood eosinophil count by D1, with eosinophils displaying a phenotype defined as CD69/CD63/CD125<sup>high</sup> and CCR3/CD44<sup>low</sup> during the early phases of hospitalization. Conversely, by D7 the neutrophil count increased significantly and displayed an immature, activated, and immunosuppressive phenotype (i.e., 3% of CD10/CD16<sup>low</sup> and CD10<sup>low</sup>CD177<sup>high</sup>, 6.7% of CD11b<sup>high</sup>CD62L<sup>low</sup>, and 1.6% of CD16<sup>high</sup>CD62L<sup>low</sup>), corroborated by enhanced serum proteins that are markers of neutrophil activation. Finally, our results suggest a rapid recruitment of non-classical monocytes leaving CD163/CD64<sup>high</sup> and CD32<sup>low</sup> monocytes in circulation during the very early phase. In conclusion, our study reveals potential very early roles for eosinophils and monocytes in the pathogenesis of COVID-19 with a likely reprogramming of eosinophils in the bone marrow. The exact roles of the pro-inflammatory neutrophils and the functions of the eosinophils and the monocytes, as well as these innate immune cell types, interplays need to be further investigated.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dendooven</LastName><ForeName>Arnaud</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Univ. Lille, INSERM, CHU Lille, U1286-INFINITE-Institute for Translational Research in Inflammation, F-59000 Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CHU Lille, Institut d'Immunologie, F-59000 Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Esnault</LastName><ForeName>Stephane</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-7238-8671</Identifier><AffiliationInfo><Affiliation>Univ. Lille, INSERM, CHU Lille, U1286-INFINITE-Institute for Translational Research in Inflammation, F-59000 Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CHU Lille, Institut d'Immunologie, F-59000 Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI 53705, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jacob</LastName><ForeName>Marie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Univ. Lille, INSERM, CHU Lille, U1286-INFINITE-Institute for Translational Research in Inflammation, F-59000 Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CHU Lille, Institut d'Immunologie, F-59000 Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trauet</LastName><ForeName>Jacques</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Univ. Lille, INSERM, CHU Lille, U1286-INFINITE-Institute for Translational Research in Inflammation, F-59000 Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CHU Lille, Institut d'Immunologie, F-59000 Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delaunay</LastName><ForeName>Emeline</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Univ. Lille, INSERM, CHU Lille, U1286-INFINITE-Institute for Translational Research in Inflammation, F-59000 Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CHU Lille, Institut d'Immunologie, F-59000 Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guerrier</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Univ. Lille, INSERM, CHU Lille, U1286-INFINITE-Institute for Translational Research in Inflammation, F-59000 Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Samarasinghe</LastName><ForeName>Amali E</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI 53705, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mirgot</LastName><ForeName>Floriane</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>CHU Lille, Institut d'Immunologie, F-59000 Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vuotto</LastName><ForeName>Fanny</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>CHU Lille, Service Universitaire de Maladies Infectieuses, F-59000 Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Faure</LastName><ForeName>Karine</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>CHU Lille, Service Universitaire de Maladies Infectieuses, F-59000 Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Univ. Lille, U1019-UMR 9017-CIIL-Center for Infection and Immunity of Lille, F-59000 Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poissy</LastName><ForeName>Julien</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>CHU Lille, P&#xf4;le de R&#xe9;animation CNRS Inserm U1285-UMR 8576-UGSF-Unit&#xe9; de Glycobiologie, Structurale et Fonctionnelle Univ. Lille, F-59000 Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lambert</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>CHU Lille, Service de M&#xe9;decine Interne et Immunologie Clinique, F-59000 Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CHU Lille, D&#xe9;partement de M&#xe9;decine Polyvalente Post-Urgences, F-59000 Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Labalette</LastName><ForeName>Myriam</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Univ. Lille, INSERM, CHU Lille, U1286-INFINITE-Institute for Translational Research in Inflammation, F-59000 Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CHU Lille, Institut d'Immunologie, F-59000 Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lef&#xe8;vre</LastName><ForeName>Guillaume</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Univ. Lille, INSERM, CHU Lille, U1286-INFINITE-Institute for Translational Research in Inflammation, F-59000 Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CHU Lille, Institut d'Immunologie, F-59000 Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CHU Lille, Service de M&#xe9;decine Interne et Immunologie Clinique, F-59000 Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CEREO, National Reference Center for Hypereosinophilic Syndromes, F-59000 Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Demaret</LastName><ForeName>Julie</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-6960-4521</Identifier><AffiliationInfo><Affiliation>Univ. Lille, INSERM, CHU Lille, U1286-INFINITE-Institute for Translational Research in Inflammation, F-59000 Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CHU Lille, Institut d'Immunologie, F-59000 Lille, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>I-SITE ULNE/ANR-16-IDEX-0004 ULNE</GrantID><Agency>French Government _Programme Investissement d'Avenir</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Cells</MedlineTA><NlmUniqueID>101600052</NlmUniqueID><ISSNLinking>2073-4409</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007113" MajorTopicYN="Y">Immunity, Innate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009000" MajorTopicYN="N">Monocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009504" MajorTopicYN="N">Neutrophils</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004804" MajorTopicYN="N">Eosinophils</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">cytokines</Keyword><Keyword MajorTopicYN="N">eosinophils</Keyword><Keyword MajorTopicYN="N">flow cytometry</Keyword><Keyword MajorTopicYN="N">monocytes</Keyword><Keyword MajorTopicYN="N">multiplex assay</Keyword><Keyword MajorTopicYN="N">neutrophils</Keyword><Keyword MajorTopicYN="N">phenotype</Keyword><Keyword MajorTopicYN="N">serum</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>6</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>12</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>12</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>9</Hour><Minute>15</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40710346</ArticleId><ArticleId IdType="doi">10.3390/cells14141093</ArticleId><ArticleId IdType="pii">cells14141093</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40710333</PMID><DateCompleted><Year>2025</Year><Month>07</Month><Day>25</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2073-4409</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>14</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>15</Day></PubDate></JournalIssue><Title>Cells</Title><ISOAbbreviation>Cells</ISOAbbreviation></Journal><ArticleTitle>Pathogenesis of Autoimmunity/Systemic Lupus Erythematosus (SLE).</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1080</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/cells14141080</ELocationID><Abstract><AbstractText>SLE is characterized by the generation of a variety of autoantibodies including anti-dsDNA autoantibodies, causing damage in various organs. If autoimmunity is defined by the generation of a variety of autoantibodies against the self, SLE is the only disease to qualify. Identification of the SLE-causing factor must fulfill the following criteria: (i) the factor induces SLE, (ii) the factor is operating in active SLE and (iii) SLE heals after removal of the factor. All candidate factors are reviewed from this viewpoint in this review. As to the cause of SLE, high levels of interferon &#x3b1; can induce SLE; however, interferon &#x3b1; in most patients did not reach this high level. BAFF (B cell activating factor of the TNF family) is increased in SLE. BAFF itself induced some manifestation of SLE, whereas removal of interferon &#x3b1; or BAFF by an antibody (Ab) did not heal SLE. BXSB male mice with a duplicated <i>TLR7</i> gene develop SLE; however, the gene <i>Sle1</i> is also required for the development of SLE. In addition, <i>sanroque</i> mice develop a variety of autoantibodies and SLE; the <i>sanroque</i> mutation, which disrupts one of the repressors of ICOS, results in increased CCR7<sup>lo</sup> CXCR5<sup>+</sup>Tfh cells, IL-21 and SLE. ICOS<sup>+</sup>T follicular helper (Tfh) cells increase in SLE and SLE-model (NZBxNZW)F1 mice, and the blockade of Tfh development ameliorated SLE, indicating the importance of Tfh cells in the pathogenesis of SLE. Self-organized criticality theory shows that SLE is caused by repeated infection, wherein SLE-inducing pathogens can vary individually depending on one's HLA; however, the pathogen presented on HLA stimulates the T cell receptor (TCR) strongly beyond self-organized criticality. This stimulation generates TCR-revised, autoreactive DOCK8<sup>+</sup>Tfh cells, which induced a variety of autoantibodies and SLE. The SARS-CoV-2 virus is an example pathogen because SLE occurs after SARS-CoV-2 infection and vaccination. DOCK8<sup>+</sup>Tfh cells and SLE decreased after conventional or anti-DOCK Ab therapies. Thus, DOCK8<sup>+</sup>Tfh cells newly generated after repeated infection fulfill the criteria (i), (ii) and (iii) as the cause of SLE.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shiozawa</LastName><ForeName>Shunichi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute for Rheumatic Diseases, 60-14 Okuikeminamicho, Ashiya 659-0004, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Matsubara Mayflower Hospital, 944-25 Fujita, Katoshi 673-1462, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Rheumatology, Graduate School of Medicine and Health Sciences, Kobe University, 7-10-2 Tomogaoka, Sumaku, Kobe 654-0142, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Grant-in-aid 25515003, 17659301, 13204059, 11557026, 12204074 and 0003 of Center of Excellence (CEO)</GrantID><Agency>Institute for Rheumatic Diseases, Ministry of Education, Culture, Sports, Science and Technology of Japan, and Japan Science and Technology Agency</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Cells</MedlineTA><NlmUniqueID>101600052</NlmUniqueID><ISSNLinking>2073-4409</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053264">B-Cell Activating Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015551" MajorTopicYN="Y">Autoimmunity</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053264" MajorTopicYN="N">B-Cell Activating Factor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">T follicular helper cells (Tfh cells)</Keyword><Keyword MajorTopicYN="N">autoimmunity</Keyword><Keyword MajorTopicYN="N">pathogenesis</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus (SLE)</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>4</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>12</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>12</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>9</Hour><Minute>15</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40710333</ArticleId><ArticleId IdType="doi">10.3390/cells14141080</ArticleId><ArticleId IdType="pii">cells14141080</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40710127</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2304-6767</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>7</Issue><PubDate><Year>2025</Year><Month>Jun</Month><Day>23</Day></PubDate></JournalIssue><Title>Dentistry journal</Title><ISOAbbreviation>Dent J (Basel)</ISOAbbreviation></Journal><ArticleTitle>Mortality Associated with Orofacial Clefts in Brazil.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">282</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/dj13070282</ELocationID><Abstract><AbstractText><b>Background/Objectives:</b> Orofacial clefts are congenital anomalies that cause substantial morbidity and mortality. This study aimed to investigate temporal and geographic trends in mortality among Brazilian individuals with orofacial clefts listed as the underlying cause of death on death certificates. <b>Methods:</b> A retrospective cross-sectional study was conducted using data from the Department of Informatics of the Brazilian Unified Health System (DATASUS) from 1996 to 2023. <b>Results:</b> The mortality information system registered 987 deaths related to orofacial clefts, with 880 patients under 1 year of age. There was a downward trend in annual mortality rates from 1996 to 2019, followed by an increase from 2020 to 2023. The main associated cause of death was respiratory and cardiovascular disorders. The mortality rate for infants under 1 year with orofacial clefts showed greater variation than did the mortality rate of children who died of other causes. The reduction in mortality rates from 1996 to 2019 occurred during the expansion and strengthening of DATASUS and its coordination with other levels of healthcare. The rise in mortality between 2020 and 2023 coincided with a reduction in surgical procedures due to the COVID-19 pandemic. <b>Conclusions:</b> This study revealed a decline in deaths from orofacial clefts in Brazil over several decades. These findings emphasize the importance of addressing preventable causes of death, including respiratory infections and malnutrition. High mortality within the first year of life-particularly among newborns under 28 days-highlights a critical shortage of pediatricians and its impact on care for individuals with craniofacial anomalies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Costa</LastName><ForeName>Amanda de Andrade</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Primary Care/Health Sciences Postgraduate Program, State University of Montes Claros Claros (UNIMONTES), Montes Claros 39401-089, MG, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farias</LastName><ForeName>Hildeth Maisa Torres</ForeName><Initials>HMT</Initials><AffiliationInfo><Affiliation>Epidemiological Surveillance and Occupational Health Center, Regional Health Superintendency of Montes Claros, Montes Claros 39408-111, MG, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martelli</LastName><ForeName>Daniella Reis B</ForeName><Initials>DRB</Initials><AffiliationInfo><Affiliation>Primary Care/Health Sciences Postgraduate Program, State University of Montes Claros Claros (UNIMONTES), Montes Claros 39401-089, MG, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dias</LastName><ForeName>Ver&#xf4;nica Oliveira</ForeName><Initials>VO</Initials><Identifier Source="ORCID">0000-0003-1989-7797</Identifier><AffiliationInfo><Affiliation>Primary Care/Health Sciences Postgraduate Program, State University of Montes Claros Claros (UNIMONTES), Montes Claros 39401-089, MG, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brazilian Oral Cleft Group</LastName></Author><Author ValidYN="Y"><LastName>Coletta</LastName><ForeName>Ricardo D</ForeName><Initials>RD</Initials><Identifier Source="ORCID">0000-0001-5285-3046</Identifier><AffiliationInfo><Affiliation>Department of Oral Diagnosis and Graduate Program in Oral Biology, School of Dentistry, University of Campinas, Piracicaba 13414-018, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martelli Junior</LastName><ForeName>Herc&#xed;lio</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Oral Pathology and Oral Medicine, School of Dentistry, State University of Montes Claros (UNIMONTES), Montes Claros 39400-000, MG, Brazil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>06</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Dent J (Basel)</MedlineTA><NlmUniqueID>101716125</NlmUniqueID><ISSNLinking>2304-6767</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">mortality</Keyword><Keyword MajorTopicYN="N">orofacial cleft</Keyword><Keyword MajorTopicYN="N">unified health system</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>6</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>12</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>12</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>9</Hour><Minute>14</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40710127</ArticleId><ArticleId IdType="doi">10.3390/dj13070282</ArticleId><ArticleId IdType="pii">dj13070282</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40710108</PMID><DateCompleted><Year>2025</Year><Month>07</Month><Day>25</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2079-6374</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>7</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>16</Day></PubDate></JournalIssue><Title>Biosensors</Title><ISOAbbreviation>Biosensors (Basel)</ISOAbbreviation></Journal><ArticleTitle>AI-Driven Comprehensive SERS-LFIA System: Improving Virus Automated Diagnostics Through SERS Image Recognition and Deep Learning.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">458</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/bios15070458</ELocationID><Abstract><AbstractText>Highly infectious and pathogenic viruses seriously threaten global public health, underscoring the need for rapid and accurate diagnostic methods to effectively manage and control outbreaks. In this study, we developed a comprehensive Surface-Enhanced Raman Scattering-Lateral Flow Immunoassay (SERS-LFIA) detection system that integrates SERS scanning imaging with artificial intelligence (AI)-based result discrimination. This system was based on an ultra-sensitive SERS-LFIA strip with SiO<sub>2</sub>-Au NSs as the immunoprobe (with a theoretical limit of detection (LOD) of 1.8 pg/mL). On this basis, a negative-positive discrimination method combining SERS scanning imaging with a deep learning model (ResNet-18) was developed to analyze probe distribution patterns near the T line. The proposed machine learning method significantly reduced the interference of abnormal signals and achieved reliable detection at concentrations as low as 2.5 pg/mL, which was close to the theoretical Raman LOD. The accuracy of the proposed ResNet-18 image recognition model was 100% for the training set and 94.52% for the testing set, respectively. In summary, the proposed SERS-LFIA detection system that integrates detection, scanning, imaging, and AI automated result determination can achieve the simplification of detection process, elimination of the need for specialized personnel, reduction in test time, and improvement of diagnostic reliability, which exhibits great clinical potential and offers a robust technical foundation for detecting other highly pathogenic viruses, providing a versatile and highly sensitive detection method adaptable for future pandemic prevention.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Shuai</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>State Key Laboratory of High Performance Ceramics, Shanghai Institute of Ceramics, Chinese Academy of Sciences, 1295 Dingxi Road, Shanghai 200050, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Materials Science and Optoelectronics Engineering, University of Chinese Academy of Sciences, Beijing 100049, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate School of the Chinese Academy of Sciences, No.19 (A) Yuquan Road, Beijing 100049, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Meimei</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>State Key Laboratory of High Performance Ceramics, Shanghai Institute of Ceramics, Chinese Academy of Sciences, 1295 Dingxi Road, Shanghai 200050, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Materials Science and Optoelectronics Engineering, University of Chinese Academy of Sciences, Beijing 100049, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate School of the Chinese Academy of Sciences, No.19 (A) Yuquan Road, Beijing 100049, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Chenglong</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>State Key Laboratory of High Performance Ceramics, Shanghai Institute of Ceramics, Chinese Academy of Sciences, 1295 Dingxi Road, Shanghai 200050, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Materials Science and Optoelectronics Engineering, University of Chinese Academy of Sciences, Beijing 100049, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate School of the Chinese Academy of Sciences, No.19 (A) Yuquan Road, Beijing 100049, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Weida</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>State Key Laboratory of High Performance Ceramics, Shanghai Institute of Ceramics, Chinese Academy of Sciences, 1295 Dingxi Road, Shanghai 200050, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Materials Science and Optoelectronics Engineering, University of Chinese Academy of Sciences, Beijing 100049, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate School of the Chinese Academy of Sciences, No.19 (A) Yuquan Road, Beijing 100049, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Dan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>State Key Laboratory of High Performance Ceramics, Shanghai Institute of Ceramics, Chinese Academy of Sciences, 1295 Dingxi Road, Shanghai 200050, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Materials Science and Optoelectronics Engineering, University of Chinese Academy of Sciences, Beijing 100049, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate School of the Chinese Academy of Sciences, No.19 (A) Yuquan Road, Beijing 100049, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Yusi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>State Key Laboratory of High Performance Ceramics, Shanghai Institute of Ceramics, Chinese Academy of Sciences, 1295 Dingxi Road, Shanghai 200050, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Materials Science and Optoelectronics Engineering, University of Chinese Academy of Sciences, Beijing 100049, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanemura</LastName><ForeName>Masaki</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-8771-7888</Identifier><AffiliationInfo><Affiliation>Department of Frontier Materials, Nagoya Institute of Technology, Nagoya 466 8555, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Yong</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-8996-2182</Identifier><AffiliationInfo><Affiliation>State Key Laboratory of High Performance Ceramics, Shanghai Institute of Ceramics, Chinese Academy of Sciences, 1295 Dingxi Road, Shanghai 200050, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Materials Science and Optoelectronics Engineering, University of Chinese Academy of Sciences, Beijing 100049, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>No. 2022YFE0110100 &amp; 2023YFC3041100</GrantID><Agency>National Key Research and Development Program</Agency><Country/></Grant><Grant><GrantID>No. 52172167</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>No. 2022000272</GrantID><Agency>China Postdoctoral Science Foundation</Agency><Country/></Grant><Grant><GrantID>No. 23YF1454600</GrantID><Agency>Shanghai Sailing Program</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Biosensors (Basel)</MedlineTA><NlmUniqueID>101609191</NlmUniqueID><ISSNLinking>2079-6374</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>7440-57-5</RegistryNumber><NameOfSubstance UI="D006046">Gold</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D013059" MajorTopicYN="Y">Spectrum Analysis, Raman</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077321" MajorTopicYN="Y">Deep Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007118" MajorTopicYN="N">Immunoassay</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001185" MajorTopicYN="Y">Artificial Intelligence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006046" MajorTopicYN="N">Gold</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057230" MajorTopicYN="N">Limit of Detection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015374" MajorTopicYN="Y">Biosensing Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053768" MajorTopicYN="N">Metal Nanoparticles</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014780" MajorTopicYN="Y">Viruses</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">SERS-LFIA</Keyword><Keyword MajorTopicYN="N">automated detection system</Keyword><Keyword MajorTopicYN="N">deep learning</Keyword><Keyword MajorTopicYN="N">machine learning</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>6</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>12</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>12</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>9</Hour><Minute>14</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40710108</ArticleId><ArticleId IdType="doi">10.3390/bios15070458</ArticleId><ArticleId IdType="pii">bios15070458</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40710086</PMID><DateCompleted><Year>2025</Year><Month>07</Month><Day>25</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2079-6374</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>7</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>07</Day></PubDate></JournalIssue><Title>Biosensors</Title><ISOAbbreviation>Biosensors (Basel)</ISOAbbreviation></Journal><ArticleTitle>Democratization of Point-of-Care Viral Biosensors: Bridging the Gap from Academia to the Clinic.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">436</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/bios15070436</ELocationID><Abstract><AbstractText>The COVID-19 pandemic and recent viral outbreaks have highlighted the need for viral diagnostics that balance accuracy with accessibility. While traditional laboratory methods remain essential, point-of-care solutions are critical for decentralized testing at the population level. However, a gap persists between academic proof-of-concept studies and clinically viable tools, with novel technologies remaining inaccessible to clinics due to cost, complexity, training, and logistical constraints. Recent advances in surface functionalization, assay simplification, multiplexing, and performance in complex media have improved the feasibility of both optical and non-optical sensing techniques. These innovations, coupled with scalable manufacturing methods such as 3D printing and streamlined hardware production, pave the way for practical deployment in real-world settings. Additionally, software-assisted data interpretation, through simplified readouts, smartphone integration, and machine learning, enables the broader use of diagnostics once limited to experts. This review explores improvements in viral diagnostic approaches, including colorimetric, optical, and electrochemical assays, showcasing their potential for democratization efforts targeting the clinic. We also examine trends such as open-source hardware, modular assay design, and standardized reporting, which collectively reduce barriers to clinical adoption and the public dissemination of information. By analyzing these interdisciplinary advances, we demonstrate how emerging technologies can mature into accessible, low-cost diagnostic tools for widespread testing.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Van Zant</LastName><ForeName>Westley</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0002-4123-3551</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ray</LastName><ForeName>Partha</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-7075-5463</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego, CA 92093, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Biosensors (Basel)</MedlineTA><NlmUniqueID>101609191</NlmUniqueID><ISSNLinking>2079-6374</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015374" MajorTopicYN="Y">Biosensing Techniques</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019095" MajorTopicYN="Y">Point-of-Care Systems</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000097788" MajorTopicYN="N">Academia</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">accessible diagnostics</Keyword><Keyword MajorTopicYN="N">biosensors</Keyword><Keyword MajorTopicYN="N">democratization</Keyword><Keyword MajorTopicYN="N">point-of-care (POC) testing</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>4</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>6</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>12</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>12</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>9</Hour><Minute>14</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40710086</ArticleId><ArticleId IdType="doi">10.3390/bios15070436</ArticleId><ArticleId IdType="pii">bios15070436</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40710045</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1520-6882</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Jul</Month><Day>25</Day></PubDate></JournalIssue><Title>Analytical chemistry</Title><ISOAbbreviation>Anal Chem</ISOAbbreviation></Journal><ArticleTitle>Evaluation of Simultaneous Production Strategies for Adenoviral Vector-Based SARS-CoV-2 Multivalent Vaccines via an Expanded Allele-specific Competitive Blocker PCR Quantification Method.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1021/acs.analchem.5c01281</ELocationID><Abstract><AbstractText>As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to evolve, developing multivalent vaccines becomes crucial to ensure broader immunogenicity against the emerging variants. Traditional multivalent vaccines are produced by combining separately formulated monovalent vaccines in equal proportions, which necessitates precisely quantifying each component. However, the minimal differences in SARS-CoV-2 spike protein sequences among variants pose challenges for immunological quantification methods. In this study, we established an allele-specific competitive blocker polymerase chain reaction (ACB-PCR)-based quantification method to accurately determine the composition of a multivalent adenoviral vector-based SARS-CoV-2 vaccine. By designing primers tailored to each variant and integrating a blocker for target-specific amplification, we achieved high accuracy in distinguishing closely related spike protein variants. Additionally, we explored coinfection and cotransfection strategies as alternative approaches for the simultaneous production of multivalent vaccines. Our results indicated that both these methods maintained antigen composition within a percentage error of approximately 10%, thereby supporting their feasibility for large-scale vaccine manufacturing. This study provides a robust molecular quantification tool for multivalent vaccine analysis and highlights efficient coproduction strategies that could enhance vaccine manufacturing scalability and responsiveness to emerging SARS-CoV-2 variants.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Soojeong</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-1961-6687</Identifier><AffiliationInfo><Affiliation>Research &amp; Development Center, Cellid Co., Ltd., Seoul 08826, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Hyemin</ForeName><Initials>H</Initials><Identifier Source="ORCID">0009-0007-5351-3722</Identifier><AffiliationInfo><Affiliation>Research &amp; Development Center, Cellid Co., Ltd., Seoul 08826, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shin</LastName><ForeName>Jieun</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-7020-2140</Identifier><AffiliationInfo><Affiliation>Research &amp; Development Center, Cellid Co., Ltd., Seoul 08826, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Seowoo</ForeName><Initials>S</Initials><Identifier Source="ORCID">0009-0002-7055-1417</Identifier><AffiliationInfo><Affiliation>Research &amp; Development Center, Cellid Co., Ltd., Seoul 08826, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Bongju</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0001-7897-4540</Identifier><AffiliationInfo><Affiliation>Research &amp; Development Center, Cellid Co., Ltd., Seoul 08826, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Chang-Yuil</ForeName><Initials>CY</Initials><Identifier Source="ORCID">0000-0002-1843-6967</Identifier><AffiliationInfo><Affiliation>Research &amp; Development Center, Cellid Co., Ltd., Seoul 08826, Republic of Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Anal Chem</MedlineTA><NlmUniqueID>0370536</NlmUniqueID><ISSNLinking>0003-2700</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>12</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>12</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>9</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40710045</ArticleId><ArticleId IdType="doi">10.1021/acs.analchem.5c01281</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40710029</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2039-7275</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>7</Issue><PubDate><Year>2025</Year><Month>Jun</Month><Day>25</Day></PubDate></JournalIssue><Title>Clinics and practice</Title><ISOAbbreviation>Clin Pract</ISOAbbreviation></Journal><ArticleTitle>The Association Between COVID-19-Related Persistent Symptoms, Psychological Flexibility, and General Mental Health Among People With and Without Persistent Pain in the UK.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">119</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/clinpract15070119</ELocationID><Abstract><AbstractText><b>Objectives:</b> Persistent symptoms following COVID-19 may adversely impact the general mental health of people with chronic pain, and psychological flexibility may buffer these impacts. However, it remains unclear whether such lasting implications of COVID-19 differ between people with and without chronic pain. This study investigated the relationships between persistent symptoms post-COVID-19, psychological flexibility, and general mental health among people with and without persistent pain during the COVID-19 pandemic in the UK. <b>Methods:</b> A total of 204 adults living in the UK were recruited via social media and completed an online survey, including measures of persistent symptoms, depression (Patient Health Questionnaire-9), anxiety (General Anxiety Disorder-7), insomnia (the Insomnia Severity Index), and psychological flexibility (the Multidimensional Psychological Flexibility Inventory), and were included in the analyses. <b>Results:</b> Participants with persistent pain (n = 70) experienced more-persistent symptoms, poorer general mental health, and a higher level of psychological inflexibility compared with participants without persistent pain (n = 133). Overall, the relationships between persistent physical symptoms, general mental health, and psychological (in)flexibility showed similar patterns in the two groups. Participants with more-persistent physical symptoms experienced significantly poorer general mental health. Furthermore, people with higher levels of psychological inflexibility reported worse general mental health. There was little evidence that psychological (in)flexibility could "buffer" the association between persistent physical symptoms and general mental health. <b>Conclusions:</b> People with chronic pain appear more vulnerable to persistent symptoms and reduced general mental health compared with people without pain. Treatments that reduce psychological inflexibility, such as ACT, may improve outcomes for people with persistent symptoms post-COVID-19.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Lin</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-0038-9266</Identifier><AffiliationInfo><Affiliation>Department of Psychology, Middlesex University, London NW4 4BT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCracken</LastName><ForeName>Lance M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Department of Psychology, Uppsala University, 752 37 Uppsala, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>06</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Clin Pract</MedlineTA><NlmUniqueID>101563282</NlmUniqueID><ISSNLinking>2039-7275</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">mental health</Keyword><Keyword MajorTopicYN="N">pain</Keyword><Keyword MajorTopicYN="N">persistent symptoms</Keyword><Keyword MajorTopicYN="N">psychological flexibility</Keyword><Keyword MajorTopicYN="N">&#x201c;long COVID&#x201d;</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>4</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>5</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>12</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>12</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>9</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40710029</ArticleId><ArticleId IdType="doi">10.3390/clinpract15070119</ArticleId><ArticleId IdType="pii">clinpract15070119</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40709999</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2079-9721</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>7</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>03</Day></PubDate></JournalIssue><Title>Diseases (Basel, Switzerland)</Title><ISOAbbreviation>Diseases</ISOAbbreviation></Journal><ArticleTitle>Persistent Changes in Hormones and Growth Factors Involved in Ageing in Patients That Recovered from Severe COVID-19.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">209</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/diseases13070209</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The coronavirus disease-19 pandemic affected millions of people and its long-term impact on the health of survivors is under evaluation.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">In this study, we hypothesized that severe coronavirus disease-19 could promote long-term changes in the blood levels of hormones and growth factors known to be involved in the regulation of ageing.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We evaluated 49 patients that recovered from severe COVID-19 and compared them with matched controls that were never infected by the virus. The blood levels of growth hormone, insulin-like growth factor-1, insulin, brain-derived neurotrophic factor, nerve growth factor, oxytocin, ghrelin, platelet-derived growth factor, fibroblast growth factor-1, and transforming growth factor-beta were determined using enzyme-linked immunosorbent assays.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">After six months of recovery, patients presented reduced blood levels of growth hormone, insulin-like growth factor-1, brain-derived neurotrophic factor, and platelet-derived growth factor. Fifteen months after, the reductions in the blood levels of all four hormones/growth factors persisted.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our study advances the field by identifying hormones and growth factors involved in ageing that undergo persistent changes in patients that recover from severe COVID-19. Further studies could explore the potential of the identified hormones/growth factors as therapeutic targets for the late complications and accelerated ageing that may affect patients recovering from severe COVID-19.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cuchi-Cabral</LastName><ForeName>Alice</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>School of Nursing, University of Campinas, Campinas 13083-970, SP, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Cell Signalling, Obesity and Comorbidities Research Center (OCRC), University of Campinas, Campinas 13083-970, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palma</LastName><ForeName>Andr&#xe9; C</ForeName><Initials>AC</Initials><Identifier Source="ORCID">0000-0001-6823-0847</Identifier><AffiliationInfo><Affiliation>Faculty of Medical Sciences, University of Campinas, Campinas 13083-970, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nogueira</LastName><ForeName>Guilherme A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>Laboratory of Cell Signalling, Obesity and Comorbidities Research Center (OCRC), University of Campinas, Campinas 13083-970, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oliveira</LastName><ForeName>Henrique Ceretta</ForeName><Initials>HC</Initials><Identifier Source="ORCID">0000-0002-8190-0718</Identifier><AffiliationInfo><Affiliation>School of Nursing, University of Campinas, Campinas 13083-970, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fusco</LastName><ForeName>Suzimar F Benato</ForeName><Initials>SFB</Initials><Identifier Source="ORCID">0000-0001-8356-0705</Identifier><AffiliationInfo><Affiliation>School of Nursing, University of Campinas, Campinas 13083-970, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moretti</LastName><ForeName>Maria L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Faculty of Medical Sciences, University of Campinas, Campinas 13083-970, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Velloso</LastName><ForeName>Licio A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Laboratory of Cell Signalling, Obesity and Comorbidities Research Center (OCRC), University of Campinas, Campinas 13083-970, SP, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medical Sciences, University of Campinas, Campinas 13083-970, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Araujo</LastName><ForeName>Eliana P</ForeName><Initials>EP</Initials><AffiliationInfo><Affiliation>School of Nursing, University of Campinas, Campinas 13083-970, SP, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Cell Signalling, Obesity and Comorbidities Research Center (OCRC), University of Campinas, Campinas 13083-970, SP, Brazil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>0001</GrantID><Agency>National Council for Scientific and Technological Research and Development (CNPq)</Agency><Country/></Grant><Grant><GrantID>2013/07607-8</GrantID><Agency>S&#xe3;o Paulo Research Foundation</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Diseases</MedlineTA><NlmUniqueID>101636232</NlmUniqueID><ISSNLinking>2079-9721</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">BDNF</Keyword><Keyword MajorTopicYN="N">FGF-1</Keyword><Keyword MajorTopicYN="N">GH</Keyword><Keyword MajorTopicYN="N">IGF-1</Keyword><Keyword MajorTopicYN="N">PDGF</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>6</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>12</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>12</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>9</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40709999</ArticleId><ArticleId IdType="doi">10.3390/diseases13070209</ArticleId><ArticleId IdType="pii">diseases13070209</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>